<SEC-DOCUMENT>0001590750-17-000010.txt : 20171109
<SEC-HEADER>0001590750-17-000010.hdr.sgml : 20171109
<ACCEPTANCE-DATETIME>20171108180019
ACCESSION NUMBER:		0001590750-17-000010
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		74
CONFORMED PERIOD OF REPORT:	20170930
FILED AS OF DATE:		20171109
DATE AS OF CHANGE:		20171108

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			MIRAGEN THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001590750
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				471187261
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36483
		FILM NUMBER:		171187742

	BUSINESS ADDRESS:	
		STREET 1:		6200 LOOKOUT ROAD
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301
		BUSINESS PHONE:		303-531-5952

	MAIL ADDRESS:	
		STREET 1:		6200 LOOKOUT ROAD
		CITY:			BOULDER
		STATE:			CO
		ZIP:			80301

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	MIRAGEN THERAPEUDICS, INC.
		DATE OF NAME CHANGE:	20170213

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SIGNAL GENETICS, INC.
		DATE OF NAME CHANGE:	20140710

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SIGNAL GENETICS LLC
		DATE OF NAME CHANGE:	20131031
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>mgen-9302017x10q.htm
<DESCRIPTION>10-Q
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s928B8BFCCED15C16BB6FCC71BC12E946"></a></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Washington, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;____________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:18pt;font-weight:bold;">FORM&#160;10-Q</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________________________________</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:36px;text-indent:-19px;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;font-weight:bold;">x</font><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:9pt;">&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">QUARTERLY REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the quarterly period ended </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">or</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;padding-left:36px;text-indent:-19px;font-size:12pt;"><font style="font-family:Wingdings;font-size:12pt;font-weight:bold;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font><font style="font-family:inherit;font-size:8pt;">&#160;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d)&#160;OF THE SECURITIES EXCHANGE ACT OF&#160;1934</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commission File No.&#160;001-36483</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;____________________________________________&#160;</font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font><font style="font-family:inherit;font-size:18pt;font-weight:bold;">MIRAGEN THERAPEUTICS, INC.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;____________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:49%;"></td><td style="width:2%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Delaware</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">incorporation or organization)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">47-1187261</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identification No.)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6200 Lookout Road, Boulder, CO 80301</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address, including zip code, of registrant&#8217;s principal executive offices)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(720)&#160;643-5200</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Registrant&#8217;s telephone number, including area code)</font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;____________________________________________</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#32;x</font><font style="font-family:inherit;font-size:10pt;">&#32;&#160;&#160; No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#32;o</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files).&#160;Yes&#160;&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#32;x</font><font style="font-family:inherit;font-size:10pt;">&#32;&#160;&#160; No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">&#32;o</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#ff0000;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:57%;"></td><td style="width:1%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Large accelerated filer&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accelerated filer&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Non-accelerated filer&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;(do not check if a smaller reporting company)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Smaller reporting company </font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Emerging growth company&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div><hr style="page-break-after:always"><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </font><font style="font-family:Wingdings;font-size:10pt;">o</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Indicate by check mark whether the registrant is shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;Yes&#160;</font><font style="font-family:Wingdings;font-size:10pt;">o</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160; No&#160;</font><font style="font-family:Wingdings;font-size:10pt;">x</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">November&#160;2, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">22,309,419</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the registrant&#8217;s Common Stock outstanding.</font></div><div style="line-height:120%;text-align:left;font-size:1pt;"><font style="font-family:inherit;font-size:1pt;">&#160;</font></div><div><br></div><hr style="page-break-after:always"><div><a name="s6C95F9186C8257CA88AF1907B0CB34BC"></a></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Miragen Therapeutics, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Table of Contents</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:96%;"></td><td style="width:4%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;" href="#s41D8077381BB5233841A91F29B94925F"><font style="font-family:inherit;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;">PART I. FINANCIAL INFORMATION</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sE37923EC0F4E5FCF945DE79C644EDB7A"><font style="font-family:inherit;font-size:10pt;">Item&#160;1. Financial Statements</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFB827A6D66B6599D9CD818545998E70A"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Balance Sheets as of September 30, 2017 and December&#160;31, 2016 (Unaudited)</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFB827A6D66B6599D9CD818545998E70A">4</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD0CE05F75FB15D7A8098666487CADCEC"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2017 and 2016 (Unaudited)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sD0CE05F75FB15D7A8098666487CADCEC">5</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1523C4F1DE335596A0367DE2FE14FEF8"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Preferred Stock and Stockholders&#8217; Equity (Deficit) for the nine months ended September 30, 2017 (Unaudited)</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s1523C4F1DE335596A0367DE2FE14FEF8">6</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA8F01721960F534CB4E834A3BFF78EF6"><font style="font-family:inherit;font-size:10pt;">Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2017 and 2016 (Unaudited)</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sA8F01721960F534CB4E834A3BFF78EF6">7</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2CF7BF44A72C53999B42DA7D5462CC26"><font style="font-family:inherit;font-size:10pt;">Notes to Condensed Consolidated Financial Statements (Unaudited)</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s2CF7BF44A72C53999B42DA7D5462CC26">8</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0DDA80A3ABB35015BD5090862621EB87"><font style="font-family:inherit;font-size:10pt;">Item&#160;2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s0DDA80A3ABB35015BD5090862621EB87">29</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAC34E1706F75566A87D7C8FD02BFF26B"><font style="font-family:inherit;font-size:10pt;">Item&#160;3. Quantitative and Qualitative Disclosures about Market Risk</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAC34E1706F75566A87D7C8FD02BFF26B">37</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9A29995D65C75EB8941EACDA702486FF"><font style="font-family:inherit;font-size:10pt;">Item&#160;4. Controls and Procedures</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s9A29995D65C75EB8941EACDA702486FF">37</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;" href="#sBE1BCE32C4AC513D9BBB738E346178C2"><font style="font-family:inherit;font-size:10pt;font-weight:bold;color:#000000;text-decoration:none;">PART II. OTHER INFORMATION</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBA0F3902369C5D379C9D3349FF99087D"><font style="font-family:inherit;font-size:10pt;">Item&#160;1. Legal Proceedings</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sBA0F3902369C5D379C9D3349FF99087D">38</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFDE4F33EE3095BABB204A4463724069A"><font style="font-family:inherit;font-size:10pt;">Item&#160;1A. Risk Factors</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sFDE4F33EE3095BABB204A4463724069A">38</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s498C0187EEF25978B81E11B310EED25F"><font style="font-family:inherit;font-size:10pt;">Item&#160;2. Unregistered Sales of Equity Securities and Use of Proceeds</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s498C0187EEF25978B81E11B310EED25F">68</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3774814DB26B58A3B6AC6CB154C80477"><font style="font-family:inherit;font-size:10pt;">Item&#160;3. Defaults Upon Senior Securities</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s3774814DB26B58A3B6AC6CB154C80477">68</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC753B4D05CF952B1A591FE6C4D196AB2"><font style="font-family:inherit;font-size:10pt;">Item&#160;4. Mine Safety Disclosures</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC753B4D05CF952B1A591FE6C4D196AB2">68</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAF06CC58C9DD50CD875969C54A6244BB"><font style="font-family:inherit;font-size:10pt;">Item&#160;5. Other Information</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sAF06CC58C9DD50CD875969C54A6244BB">68</a></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC38F8F2A95655B6DB78967EC99B4F7F8"><font style="font-family:inherit;font-size:10pt;">Item&#160;6. Exhibits</font></a></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#sC38F8F2A95655B6DB78967EC99B4F7F8">69</a></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3</font></div></div><hr style="page-break-after:always"><div><a name="s41D8077381BB5233841A91F29B94925F"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART I. FINANCIAL INFORMATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE37923EC0F4E5FCF945DE79C644EDB7A"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 1. FINANCIAL STATEMENTS</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFB827A6D66B6599D9CD818545998E70A"></a></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Miragen Therapeutics, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Balance Sheets</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">September&#160;30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">December&#160;31, <br>2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Assets</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current assets:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42,805</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,104</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">635</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid expenses and other current assets</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,981</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,753</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current assets</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46,421</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,877</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">610</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other assets</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">258</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total assets</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,081</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,760</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liabilities, Preferred Stock, and Stockholders&#8217; Equity (Deficit)</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accounts payable</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">409</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,007</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,142</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,909</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Current portion of notes payable</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,983</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total current liabilities</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,534</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6,885</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Notes payable, less current portion</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,391</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,820</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other liabilities</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">171</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,096</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,705</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Commitments and contingencies</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series A redeemable convertible preferred stock, $0.001 par value; 7,169,176 shares authorized; 7,149,176 shares issued and outstanding and liquidation preference of $21,448 at December 31, 2016</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series B redeemable convertible preferred stock, $0.001 par value; 2,183,318 shares authorized; 2,166,651 shares issued and outstanding and liquidation preference of $13,000 at December 31, 2016; stated at accreted redemption value</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12,975</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Series C redeemable convertible preferred stock, $0.001 par value; 9,303,000 shares authorized; 9,268,563 shares issued and outstanding and liquidation preference of $41,060 at December 31, 2016; stated at accreted redemption value</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stockholders&#8217; equity (deficit):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Common stock, $0.01 par value; 100,000,000 shares authorized; 21,886,568 and 833,744 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additional paid-in capital</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">125,973</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,147</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accumulated deficit</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(87,207</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(67,076</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total stockholders&#8217; equity (deficit)</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,985</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(61,921</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total liabilities, preferred stock, and stockholders&#8217; equity (deficit)</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47,081</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,760</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes to these condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4</font></div></div><hr style="page-break-after:always"><div><a name="sD0CE05F75FB15D7A8098666487CADCEC"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Miragen Therapeutics, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statements of Operations</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share and per share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended<br>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Collaboration revenue</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,493</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">715</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,991</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,479</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Grant revenue</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">138</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">820</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">489</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total revenue</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,631</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">936</font></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,811</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,968</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Operating expenses:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,018</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,965</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,625</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9,786</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,502</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,053</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8,364</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,255</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total operating expenses</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,520</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5,018</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,989</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14,041</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Loss from operations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,889</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,082</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,178</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,073</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense):</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other income</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">113</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">245</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest and other related expense</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(58</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(78</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(193</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(250</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,834</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,153</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,126</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,300</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accretion of redeemable convertible preferred stock to redemption value</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(13</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(37</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss available to common stockholders</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,834</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,166</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,131</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,337</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss per share, basic and diluted</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.27</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6.92</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1.11</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(18.84</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted-average shares used to compute basic and diluted net loss per share</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21,572,498</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">601,667</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18,215,857</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">601,667</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes to these condensed consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></div><hr style="page-break-after:always"><div><a name="s1523C4F1DE335596A0367DE2FE14FEF8"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Miragen Therapeutics, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statements of Preferred Stock and Stockholders&#8217; Equity (Deficit)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands, except share data)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="26"></td></tr><tr><td style="width:24%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Redeemable Convertible<br>Preferred Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Additional<br>Paid-in<br>Capital</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Accumulated<br>Deficit</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Total<br>Stockholders&#8217; Equity (Deficit)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18,584,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">76,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">833,744</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">8</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5,147</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(67,076</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(61,921</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock to investors, net of issuance cost - private financing</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">6,359,628</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">64</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">39,092</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">39,156</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock to investors, net of issuance cost - at the market </font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">297,653</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,619</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,622</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accretion of redeemable convertible preferred stock to redemption value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(5</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Conversion of preferred stock to common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(18,584,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(76,981</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13,066,666</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">131</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">76,850</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">76,981</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock upon reverse merger</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,024,960</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">10</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">194</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">204</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Reclassification of preferred stock warrant to common stock warrant</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">51</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Issuance of common stock upon cashless exercise of warrant</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">16,387</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Exercises of stock options and issuance of restricted stock awards</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">274,337</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">217</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">220</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Shares issued for cash under employee share purchase plan</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">13,193</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">110</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">110</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Share-based compensation expense</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(20,126</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(20,126</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">21,886,568</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">219</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">125,973</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(87,207</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">38,985</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes to these condensed consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6</font></div></div><hr style="page-break-after:always"><div><a name="sA8F01721960F534CB4E834A3BFF78EF6"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Miragen Therapeutics, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Condensed Consolidated Statements of Cash Flows</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(in thousands)</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><font style="font-family:inherit;font-size:7pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash flows from operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net loss</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(20,126</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(11,300</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Adjustments to reconcile net loss to net cash used in operating activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">227</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">253</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Share-based compensation expense</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,693</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">129</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Non-cash interest expense</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">85</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">125</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Change in fair value of preferred stock warrants</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unrealized gain on short term investments</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Changes in operating assets and liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accounts receivable</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(615</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(9</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Prepaid expenses and other assets</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(719</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(545</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Deferred revenue</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(439</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accounts payable</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(598</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(586</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:60px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(871</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">893</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net cash used in operating activities</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(20,924</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(11,468</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash flows from investing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash acquired in reverse merger</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Purchases of property and equipment</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(212</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(240</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Purchases of short-term investments</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,010</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net cash provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,068</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,250</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash flows from financing activities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from the sale of common stock - private financing</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">40,703</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Payment of issuance costs associated with the sale of common stock - private financing</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,216</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from issuance of redeemable convertible preferred stock</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">16,091</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Redeemable convertible preferred stock issuance costs</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(10</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from the sale of common stock - at the market</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,711</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Payment of issuance costs associated with the sale of common stock - at the market</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(172</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Payment of issuance costs associated with the shelf registration</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(299</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Payments of principal on notes payable</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(1,500</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from the exercise of stock options</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">220</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Proceeds from employee stock purchases</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">110</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">40,557</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">16,081</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:84px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Net increase in cash and cash equivalents</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">20,701</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3,363</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash and cash equivalents at beginning of period</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">22,104</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">21,235</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Cash and cash equivalents at end of period</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">42,805</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">24,598</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:17px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Supplemental disclosure of cash flow information</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Interest paid</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">112</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">124</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Supplemental disclosure of non-cash investing and financing activities</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Conversion of preferred stock to common stock</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">76,981</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Liabilities assumed, net of non-cash assets received in reverse merger</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1,076</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Transfer of common stock issuance costs from prepaid expenses and other current assets to equity (private financing and at the market sales)</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">339</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Reclassification of preferred stock warrant (accrued liability) to common stock warrant (equity)</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">51</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accretion of redeemable convertible preferred stock to redemption value</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">37</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Unpaid common stock issuance costs included in prepaid expenses and other assets, accounts payable, and accrued liabilities</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">See accompanying notes to these condensed consolidated financial statements.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></div><hr style="page-break-after:always"><div><a name="s2CF7BF44A72C53999B42DA7D5462CC26"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Miragen Therapeutics, Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Notes to Condensed Consolidated Financial Statements</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">(unaudited)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8F8E1601D10F55CEA07EFB59A37912CE"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">1. DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Miragen Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221; or &#8220;Miragen&#8221;), is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapeutics with a specific focus on microRNAs and their roles in diseases where there is a high unmet medical need. microRNAs are short RNA molecules, or oligonucleotides, that regulate gene expression or activity and play vital roles in influencing the pathways responsible for many disease processes. The Company&#8217;s two lead product candidates, MRG-106 and MRG-201, are currently in clinical development. MRG-106 is an inhibitor of microRNA-155, which is found at abnormally high levels in malignant cells of several blood cancers. MRG-201 is a replacement for microRNA-29 (&#8220;miR-29&#8221;), which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary, and ocular fibrosis, as well as in systemic sclerosis. Miragen is also developing MRG-110, an inhibitor of microRNA-92, under a License and Collaboration Agreement (the &#8220;Servier Collaboration Agreement&#8221;) with Les Laboratoires Servier and Institut de Recherches Servier (collectively, &#8220;Servier&#8221;). MRG-110 is being developed for the treatment of heart failure and other ischemic disease. In addition to these programs, the Company continues to develop a pipeline of wholly-owned preclinical product candidates. The goal of the Company&#8217;s translational medicine strategy is to progress rapidly to first-in-human trials once it has adequately established the pharmacokinetics (the movement of drug into, through, and out of the body), pharmacodynamics (the effect and mechanism of action of a drug), safety, and manufacturability of the product candidate in preclinical studies.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Miragen Therapeutics Europe Limited (&#8220;Miragen Europe&#8221;), the Company&#8217;s wholly-owned subsidiary, was formed in January 2011 for the sole purpose of submitting regulatory filings in Europe. Miragen Europe has no employees or operations. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 13, 2017, the Company, then known as Signal Genetics, Inc. (&#8220;Signal&#8221;), completed its merger with Miragen Therapeutics, Inc., a then privately-held Delaware corporation (&#8220;Private Miragen&#8221;). Pursuant to the Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) by and among the Company, Private Miragen, and Signal Merger Sub, Inc., a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), Merger Sub merged with and into Private Miragen, with Private Miragen surviving as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;). Immediately, following the Merger, Private Miragen merged with and into the Company, with the Company as the surviving corporation (the &#8220;Short-Form Merger&#8221; and, together with the Merger, the &#8220;Mergers&#8221;). In connection with the Short-Form Merger, the Company changed its corporate name to &#8220;Miragen Therapeutics, Inc.&#8221; </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of shares of Private Miragen common stock outstanding immediately prior to the Merger received approximately </font><font style="font-family:inherit;font-size:10pt;">0.7031</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company&#8217;s common stock in exchange for each share of Private Miragen common stock in the Merger. Following the Merger on February 13, 2017, the combined company had </font><font style="font-family:inherit;font-size:10pt;">21,309,440</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of common stock outstanding at a par value of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;">&#32;per share (the &#8220;Common Stock&#8221;) as compared to the par value of Private Miragen&#8217;s common stock of </font><font style="font-family:inherit;font-size:10pt;">$0.001</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. The accompanying unaudited condensed consolidated financial statements and notes to the unaudited condensed consolidated financial statements give retroactive effect to the exchange ratio and change in par value for all periods presented.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has incurred annual net operating losses since its inception. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$87.2</font><font style="font-family:inherit;font-size:10pt;">&#32;million and net losses of </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$20.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. On February 13, 2017, the date of the Merger, Private Miragen received </font><font style="font-family:inherit;font-size:10pt;">$40.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash, before offering expenses, from the issuance of common stock to investors. Additionally, on March 31, 2017, the Company entered into an at the market issuance Common Stock Sales Agreement (the &#8220;ATM Agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;) under which the Company may offer and sell, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$50,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;through Cowen, as its sales agent. As of September 30, 2017, the Company has sold, pursuant to the terms of such ATM Agreement, an aggregate of </font><font style="font-family:inherit;font-size:10pt;">297,653</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of its Common Stock, at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$9.11</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, for aggregate gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">. Net proceeds received during the nine months ended September 30, 2017 were approximately </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, including initial expenses for executing the &#8220;at the market offering&#8221; and commissions to Cowen as sales agent. The Company&#8217;s management believes that the </font><font style="font-family:inherit;font-size:10pt;">$42.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of cash and cash equivalents on hand at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;will be sufficient to fund its operations in the normal course of business and allow the Company to meet its liquidity needs through the end of 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">8</font></div></div><hr style="page-break-after:always"><div><a name="s57AED94E5F795DFC88C0295B94680A30"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Miragen Europe. The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and follow the requirements of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#8217;s financial information. These interim results are not necessarily indicative of the results to be expected for the year ending December 31, 2017, or for any other interim period, or for any other future year. The balance sheet as of December 31, 2016 has been derived from audited consolidated financial statements at that date but does not include all the information required by U.S. GAAP for complete financial statements. All intercompany balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements of the Company and the notes thereto contained in the Company&#8217;s Form 8-K/A for the year ended December 31, 2016, filed with the SEC on March 31, 2017. The Company&#8217;s management performed an evaluation of its activities through the date of filing of these financial statements and concluded that there are no subsequent events requiring disclosure, other than as disclosed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s consolidated financial statements are prepared in accordance with U.S.&#160;GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue principally from its strategic alliance and collaboration agreement. Revenue is recognized from upfront payments for licenses and milestone payments that are generated from defined research or development events, as well as from the reimbursement of amounts for research and development services under its strategic alliance and collaboration agreement. The Company recognizes revenue when all four of the following criteria are met: (1)&#160;persuasive evidence of an arrangement exists; (2)&#160;products have been delivered or services rendered; (3)&#160;the selling price is fixed or determinable; and (4)&#160;collectability is reasonably assured.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple-element arrangements are examined to determine whether the deliverables can be separated or must be accounted for as a single unit of accounting. The Servier Collaboration Agreement with Servier, for example, includes a combination of upfront license fees, payments for research and development activities, and milestone payments that are evaluated to determine whether each deliverable under the agreement has value to the customer on a stand-alone basis and whether reliable evidence of fair value for the deliverable exists. Deliverables in an arrangement that do not meet this separation criteria are treated as a single unit of accounting, generally applying applicable revenue recognition guidance for the final deliverable to the combined unit of accounting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue from non-refundable upfront license fees over the term of performance under the Servier Collaboration Agreement. When the performance period is not specified, the Company estimates the performance period based upon provisions contained within the agreement, such as the duration of the research or development term, the existence, or likelihood, of achievement of development commitments, and any other significant commitments. These advance payments are deferred and recorded as deferred revenue upon receipt, pending recognition, and are classified as a short-term or long-term liability in the accompanying condensed consolidated balance sheets. Expected performance periods are reviewed periodically and, if applicable, the amortization period is adjusted, which may accelerate or decelerate revenue recognition. The timing of revenue recognition, specifically as it relates to the amortization of upfront license fees, is significantly influenced by the Company&#8217;s estimates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">9</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for share-based compensation expense related to stock options granted to employees and members of its board of directors under its 2008 Equity Incentive Plan (the &#8220;2008 Plan&#8221;) and under its 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;) by estimating the fair value of each stock option or award on the date of grant using the Black-Scholes option pricing model. The Company recognizes share-based compensation expense on a straight-line basis over the vesting term. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for stock options issued to non-employees by valuing the award using an option pricing model and remeasuring such awards to the current fair value until the awards are vested or a performance commitment has otherwise been reached.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred in performing research and development activities. The costs include employee-related expense including salaries, benefits, share-based compensation, fees for acquiring and maintaining licenses under third party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#8217;s behalf, laboratory supplies, depreciation, and facilities and overhead costs. The Company defers and capitalizes non-refundable advance payments for research and development activities until the related goods are received or services performed. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records upfront and milestone payments to acquire contractual rights to licensed technology as research and development expenses when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. The Company considers future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved by the U.S. Food and Drug Administration or when other significant risk factors are abated.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Trial and Preclinical Study Accruals</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company makes estimates of accrued expenses as of each balance sheet date in its condensed consolidated financial statements based on certain facts and circumstances at that time. The Company&#8217;s accrued expenses for clinical trials and preclinical studies are based on estimates of costs incurred for services provided by clinical research organizations, manufacturing organizations, and other providers. Payments under the Company&#8217;s agreements with external service providers depend on a number of factors, such as site initiation, patient screening, enrollment, delivery of reports, and other events. In accruing for these activities, the Company obtains information from various sources and estimates the level of effort or expense allocated to each period. Adjustments to the Company&#8217;s research and development expenses may be necessary in future periods as its estimates change.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All highly-liquid investments that have maturities of 90 days or less at the date of purchase are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value due to the short maturities of these instruments.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present information about the Company&#8217;s financial assets and liabilities that have been measured at fair value and indicate the fair value of the hierarchy of the valuation inputs utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair value determined by Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">10</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">for the asset or liability.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,<br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,<br>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds (included in cash and cash equivalents)</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,112</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;text-indent:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;text-indent:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred and common stock warrants (included in accrued and other liabilities)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">______________________</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)  Amounts presented for each period above differ from cash and cash equivalents reported in the condensed consolidated balance sheets due to outstanding disbursements and deposits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balances of the Company&#8217;s liabilities measured at fair value using significant unobservable, or Level 3, inputs are as follows for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;(in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance of liability as of December 31, 2016</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassification of preferred stock warrant to common stock warrant</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance of liability as of September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to the short-term nature of their maturities, such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses. The carrying amount of the Company&#8217;s note payable approximates its fair value (a Level 2 fair value measurement), reflecting interest rates currently available to the Company. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for its warrants to purchase common and preferred stock pursuant to ASC Topic&#160;480,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Distinguishing Liabilities from Equity</font><font style="font-family:inherit;font-size:10pt;">, and classifies warrants for redeemable preferred stock and certain warrants for common stock as liabilities. The warrants are reported at their estimated fair value and any changes in fair value are reflected in interest expense and other related expenses.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with two financial institutions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company carries its property and equipment at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">. Leasehold improvements are amortized over the shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets. Construction in progress is not depreciated until placed in service. Repairs and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;impairment charges were recorded during the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Share</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of Common Stock outstanding during the period without consideration of Common Stock equivalents. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Loss</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources. If the Company had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity (deficit). There were no elements of comprehensive loss during the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes by using an asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s significant deferred tax assets are for net operating loss carryforwards, tax credits, and capitalized start-up costs. The Company has provided a valuation allowance for its entire net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that its deferred tax assets will not be realized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has no unrecognized tax benefits. The Company classifies interest and penalties arising from the underpayment of income taxes in the condensed consolidated statements of operations as general and administrative expenses. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;such expenses have been recognized during the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in&#160;</font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#160;operating segment and, accordingly, no segment disclosures have been presented herein. All equipment, leasehold improvements, and other fixed assets are physically located within the United States and all agreements with the Company&#8217;s partners are denominated in U.S. dollars, except where noted.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements &#8211; Not Yet Adopted</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;(&#8220;</font><font style="font-family:inherit;font-size:10pt;">ASU&#8221;) No. 2014-09</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that &#8220;an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&#8221; The standard provides enhancements to the quality and consistency of how revenue is reported by companies, while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or U.S. GAAP.&#160;The new standard also will require enhanced revenue disclosures, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. This accounting standard becomes effective for the Company for reporting periods beginning after December 15, 2018, and interim reporting periods thereafter. Early adoption is permitted for annual reporting periods (including interim periods) beginning after December 15, 2016. This new standard permits the use of either the retrospective or cumulative effect transition method. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-08</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations</font><font style="font-family:inherit;font-size:10pt;">. The purpose of this standard is to clarify the implementation of guidance on principal versus agent </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">12</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">considerations related to ASU 2014-09. The standard has the same effective date as ASU 2014-09 described above.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2016, the FASB issued</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;</font><font style="font-family:inherit;font-size:10pt;">ASU No. 2016-10,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;Revenue from Contracts with Customer, </font><font style="font-family:inherit;font-size:10pt;">which provides clarity related to ASU 2014-09 regarding identifying performance obligations and licensing implementation. The standard has the same effective date as ASU 2014-09 described above. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May&#160;2016, the FASB issued ASU 2016-12:</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:inherit;font-size:10pt;">, which provides narrow scope improvements and practical expedients related to ASU 2014-09. The purpose of&#160;this standard&#160;is to clarify certain narrow aspects of ASU 2014-09, such as assessing the collectability criterion, presentation of sales taxes, and other similar taxes collected from customers, noncash consideration, contract modifications at transition, completed contracts at transition, and technical correction. The standard has the same effective date as ASU 2014-09 described above. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2016, the FASB issued ASU 2016-20:</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#32;Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">. The amendments in this standard affect narrow aspects of guidance issued in ASU 2014-09. The standard has the same effective date as ASU 2014-09 described above. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company plans to adopt these new standards in the first quarter of 2019. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were limited contracts that will be in effect (actively) as of the transition date and, accordingly, the Company has not yet determined the effect of the standard on its condensed consolidated financial statements. The Company&#8217;s selected implementation transition method will be dependent upon contracts that are in place closer to the transition date. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred Taxes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Balance Sheet Classification of Deferred Taxes</font><font style="font-family:inherit;font-size:10pt;">. ASU No. 2015-17 requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. This standard is effective for the Company for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods thereafter. The Company does not believe the adoption of this standard will have a material impact on its condensed consolidated financial statements due to the full valuation allowance on all net deferred tax assets. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Leases (Topic 842), which supersedes FASB ASC Topic 840, Leases (Topic 840),</font><font style="font-family:inherit;font-size:10pt;">&#32;and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. In September 2017, the FASB issued ASU 2017-13,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842),&#160;</font><font style="font-family:inherit;font-size:10pt;">which provides additional implementation guidance on the previously issued ASU 2016-02&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">. ASU 2016-02 requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for the Company for fiscal years beginning after December 15, 2019, and interim periods thereafter, with early adoption permitted. At adoption, this update will be applied using a modified retrospective approach. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share-based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, which is intended to simplify accounting for equity share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This standard is effective for the Company for annual periods beginning after December 15, 2017, and interim periods thereafter. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendments related to the timing of when excess tax benefits are recognized, minimum statutory withholding requirements, forfeitures, and intrinsic value should be applied using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of the beginning of the period in which the guidance is adopted. Amendments related to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement should be applied retrospectively. Amendments requiring recognition of excess tax benefits </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and tax deficiencies in the income statement and the practical expedient for estimating the expected term should be applied prospectively. An entity may elect to apply the amendments related to the presentation of excess tax benefits on the statement of cash flows using either a prospective transition method or a retrospective transition method. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other new pronouncements issued but not effective as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;are not expected to have a material impact on the Company&#8217;s condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sECEBA36EE5A356C09E526E7463043582"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">3. STRATEGIC ALLIANCE AND COLLABORATION WITH SERVIER</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2011, the Company entered into the Servier Collaboration Agreement with Servier for the research, development, and commercialization of RNA-targeting therapeutics in cardiovascular disease, which was subsequently amended. Under the Servier Collaboration Agreement, the Company granted Servier an exclusive license to research, develop, and commercialize RNA-targeting therapeutics for three targets in the cardiovascular field. In 2017, the Company and Servier agreed to amend the Servier Collaboration Agreement to remove three existing targets, add one named target, and provide Servier with the right to add one additional target through September 2019. Under the terms of the amended agreement, the term of the Research Collaboration has been extended through September 2019. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Servier&#8217;s rights to each named target is limited to therapeutics in the cardiovascular field in their territory, which is worldwide except for the United States and Japan. The Company retains all rights in the United States and Japan.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is eligible to receive development milestone payments of </font><font style="font-family:inherit;font-size:10pt;">&#8364;5.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">&#8364;13.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$16.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">) and regulatory milestone payments of </font><font style="font-family:inherit;font-size:10pt;">&#8364;10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">&#8364;40.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">$11.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;to </font><font style="font-family:inherit;font-size:10pt;">$47.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">) for each target. Additionally, the Company may receive up to </font><font style="font-family:inherit;font-size:10pt;">&#8364;175 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">$206.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">) in commercialization milestones, as well as quarterly royalty payments expressed in percentages ranging from the low-double digits to the mid-teens (subject to reductions for patent expiration, generic competition, third-party royalty, and costs of goods) on the net sales of any licensed product commercialized by Servier. Servier is obligated to make royalty payments for a period specified under the Servier Collaboration Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the Servier Collaboration Agreement, the Company established a multiple-year research collaboration, under which it jointly performs agreed upon research activities directed to the identification and characterization of named targets and oligonucleotides in the cardiovascular field, which is referred to as the Research Collaboration. The current term of the Research Collaboration extends through September 2019. Servier is responsible for funding the costs of the Research Collaboration, as defined under the Servier Collaboration Agreement. During the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized as revenue amounts reimbursable under the Servier Collaboration Agreement of </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized as revenue amounts reimbursable under the Servier Collaboration Agreement of </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The development of each product candidate (commencing with registration enabling toxicology studies) under the Servier Collaboration Agreement is performed pursuant to a mutually agreed upon development plan to be conducted by the parties as necessary to generate data useful for both parties to obtain regulatory approval of such product candidates. Servier is responsible for a specified percentage of the cost of research and development activities under the development plan through the completion of one or more Phase 2 clinical trials and will reimburse the Company for a specified portion of such costs it incurs. The costs of Phase 3 clinical trials for each product candidate will be allocated between the parties at a specified percentage of costs. The applicable percentage for each product candidate will be based upon whether certain events under the Servier Collaboration Agreement occur, including if the Company enters into a third-party agreement for the development and/or commercialization of a product in the United States at least 180 days before the initiation of the first Phase 3 clinical trial, or&#160;if the Company subsequently enters into a U.S. partner agreement, or if it does not enter into a U.S. partner agreement but files for approval in the United States using data from the Phase 3 clinical trial.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Servier Collaboration Agreement, the Company also granted Servier a royalty-free, non-exclusive license to develop a companion diagnostic in its territory for any therapeutic product that may be developed by Servier under the Servier Collaboration Agreement. The Company also granted Servier an exclusive, royalty-free license to commercialize such a companion diagnostic in its territory for use in connection with the development and commercialization of such therapeutic product in its territory.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Servier Collaboration Agreement will expire as to each underlying product candidate when Servier&#8217;s royalty obligations as to such product candidate have expired. Servier may also terminate the Servier Collaboration Agreement for (i) convenience upon a specified number of days&#8217; prior notice to the Company or (ii) upon determination of a safety issue relating to </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">14</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">development under the agreement upon a specified number of days&#8217; prior notice to the Company. Either party may terminate the Servier Collaboration Agreement upon a material breach by the other party which is not cured within a specified number of days. The Company may also terminate the agreement if Servier challenges any of the patents licensed by the Company to Servier.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the elements within the Servier Collaboration Agreement should be treated as a single unit of accounting because the delivered elements, the licenses, did not have stand-alone value to Servier at the time the license was granted. As such, the Company recognized license fees earned under the Servier Collaboration Agreement as revenue on a proportional performance basis over the estimated period to complete the activities under the Research Collaboration. The total period of performance is equal to the estimated term of the Research Collaboration. The Company measures its progress under the proportional performance method based on actual and estimated full-time equivalents. The Company received a total of </font><font style="font-family:inherit;font-size:10pt;">$12.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">&#8364;9.0 million</font><font style="font-family:inherit;font-size:10pt;">) in non-refundable license fees under the Servier Collaboration Agreement. Based on earlier estimates of the term of the Research Collaboration, these license fees had been fully recognized as revenue during the period from October 2011 through December 2016. Accordingly, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;amounts were recognized as revenue during the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">. During the three months and </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized license revenue of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In total, for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, as revenue under the Servier Collaboration Agreement. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, as revenue under the Servier Collaboration Agreement. Amounts incurred but not billed to Servier for research and related intellectual property activities totaled </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. These amounts are included in prepaid expenses and other current assets in the Company&#8217;s condensed consolidated balance sheets. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, accounts receivable for Servier research and related intellectual property activities totaled </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;">&#32;amounts billed to Servier included in accounts receivable.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s889831208D345762A9BD7286827714FF"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">4. REVERSE MERGER</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 13, 2017, Private Miragen completed the Merger as discussed in Note 1.&#160;For accounting purposes, Private Miragen is considered to be acquiring Signal in the Merger. Private Miragen was determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i) the Private Miragen security holders own approximately </font><font style="font-family:inherit;font-size:10pt;">95.2%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the combined company&#8217;s outstanding common stock immediately following the closing of the Merger; (ii) former Private Miragen directors hold all of the board seats in the combined company; and (iii) Private Miragen management holds key management positions of the combined company. The Merger has been accounted for as an asset acquisition rather than business combination because the assets acquired and liabilities assumed by Private Miragen do not meet the definition of a business as defined by U.S. GAAP. The net assets acquired in connection with this transaction were recorded at their estimated acquisition date fair values as of February 13, 2017, the date the Mergers were completed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Immediately prior to the effective date of the Merger, all shares of preferred stock of Private Miragen converted into shares of common stock of Private Miragen on a </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-for-one basis. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the effective date of the Merger, the Company issued shares of its Common Stock to Private Miragen stockholders, at an exchange rate of approximately </font><font style="font-family:inherit;font-size:10pt;">0.7031</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Signal Common Stock in exchange for each share of Private Miragen common stock outstanding immediately prior to the Merger. The exchange rate was calculated by a formula that was determined through arms-length negotiations between the Company and Private Miragen. The combined company assumed all of the outstanding options, whether or not vested, under the 2008 Plan with such options representing the right to purchase a number of shares of Common Stock equal to approximately </font><font style="font-family:inherit;font-size:10pt;">0.7031</font><font style="font-family:inherit;font-size:10pt;">&#32;multiplied by the number of shares of Private Miragen common stock previously represented by such options.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Immediately after the Merger on February 13, 2017, there were </font><font style="font-family:inherit;font-size:10pt;">21,309,440</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Common Stock outstanding. In addition, immediately after the Merger, Private Miragen stockholders, warrant holders, and option holders owned approximately </font><font style="font-family:inherit;font-size:10pt;">95.9%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the aggregate number of shares of Common Stock, and the stockholders of the Company immediately prior to the Merger owned approximately </font><font style="font-family:inherit;font-size:10pt;">4.1%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the aggregate number of shares of Common Stock (each on a fully diluted basis).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 13, 2017, prior to the effectiveness of the Merger, Signal had </font><font style="font-family:inherit;font-size:10pt;">1,024,960</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Common Stock outstanding and a market capitalization of </font><font style="font-family:inherit;font-size:10pt;">$12.6 million</font><font style="font-family:inherit;font-size:10pt;">. The estimated fair value of the net assets of Signal on February 13, 2017, prior to the Merger, was </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value of Common Stock on the Merger closing date, prior to the Merger, was above the fair value of the Company&#8217;s net assets. As the Company&#8217;s net assets were predominantly comprised of cash offset by current </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">liabilities, the fair value of the Company&#8217;s net assets as of February 13, 2017, prior to the Merger, is considered to be the best indicator of the fair value and, therefore, the estimated preliminary purchase consideration.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the net assets acquired based on their estimated fair values as of February 13, 2017, prior to the Merger (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">248</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net acquired tangible assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sE5244BE62ED85860A319C4421FDABC7D"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">5. PROPERTY AND EQUIPMENT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net, consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">729</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">688</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,183</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,776</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,558</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">610</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, depreciation and amortization expense was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for each period. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, depreciation and amortization expense was </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Depreciation and amortization expense is recorded primarily in research and development expense on the condensed consolidated statements of operations. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s7F138B8B241D577784488FBB128E4272"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">6. ACCRUED LIABILITIES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued outsourced clinical and preclinical studies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued employee compensation and related taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,061</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">928</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued legal fees and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">607</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued other professional service fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">457</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued equipment and lab materials</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Value of liability-classified stock purchase warrants </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred and accrued facility lease obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accrued liabilities</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,909</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2A05B75952625B719D9351448D0DC331"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">7. NOTES PAYABLE</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2015 Silicon Valley Bank Loan Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, Private Miragen entered into a loan and security agreement with Silicon Valley Bank (the &#8220;2015 SVB Loan Agreement&#8221;) to borrow up to </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;separate tranches. The first tranche of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was funded in May 2015 </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">and had a </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-month payment period following an </font><font style="font-family:inherit;font-size:10pt;">18</font><font style="font-family:inherit;font-size:10pt;">-month interest-only payment period that ended in November 2016.&#160;Amounts outstanding bear interest at the prime rate minus </font><font style="font-family:inherit;font-size:10pt;">0.25%</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">4.00%</font><font style="font-family:inherit;font-size:10pt;">&#32;at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">), with a final payment fee equal to </font><font style="font-family:inherit;font-size:10pt;">5.50%</font><font style="font-family:inherit;font-size:10pt;">&#32;of amounts borrowed. Borrowings are secured by a priority security interest, right, and title in all business assets, excluding the Company&#8217;s intellectual property, which is subject to a negative pledge.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the first tranche, in April 2015, Private Miragen issued detachable warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;">11,718</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Private Miragen preferred stock at an adjusted exercise price of </font><font style="font-family:inherit;font-size:10pt;">$8.53</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. At issuance, the warrants were classified as a liability subject to remeasurement at each balance sheet date. Immediately prior to the Merger, these warrants became exercisable for Private Miragen common stock, which was immediately exchanged for the right to purchase the Company&#8217;s Common Stock. The Company determined that although the warrants were no longer exercisable for redeemable preferred stock, the warrants continued to be classified as a liability after the Merger due to the right of the holder to require the Company to repurchase the warrants for </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;under certain circumstances. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company estimated the fair value of the warrants to be </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;using a probability adjusted present value method with the following assumptions: term of </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;">&#32;years, discount rate of </font><font style="font-family:inherit;font-size:10pt;">6.8%</font><font style="font-family:inherit;font-size:10pt;">, and probability of </font><font style="font-family:inherit;font-size:10pt;">90.0%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2016, the 2015 SVB Loan Agreement was amended to extend the end of the draw period from December 31, 2016 to July 31, 2017. The Company chose not to draw the second </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;tranche prior to the expiration of the draw period in July 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts outstanding under notes payable are as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount outstanding</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt discount</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accreted final payment fee</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total notes payable</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,374</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: current maturities</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,983</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,969</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term notes payable, net of current portion</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,391</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,820</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future annual minimum principal payments of notes payable are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017 (remainder of year)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,167</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17</font></div></div><hr style="page-break-after:always"><div><a name="s0E048CC417015AA5B060710FA2C7D40F"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">8. COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Indemnification Agreements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has entered into indemnification agreements with each of its directors and officers whereby it has agreed to indemnify such persons for certain events or occurrences while the individual is, or was, serving as a director, officer, employee, or other agent of the Company. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employment Agreements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has entered into agreements with its executives that provide for base salary, severance, eligibility for bonuses, and other generally available benefits. The agreements provide that the Company may terminate the employment of its executives at any time, with or without cause. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an executive is terminated without cause, as defined in the employment agreements, or an executive resigns for good reason, as defined in the employment agreements, then the executive is entitled to receive, upon the execution of a release agreement, a severance package consisting of: (i)&#160;the equivalent of 12 months of the executive&#8217;s base salary in effect immediately prior to date of termination, (ii)&#160;acceleration of vesting of the equivalent of 12 months of vesting of the executive&#8217;s outstanding unvested stock options or other equity awards that were outstanding as of the effective date of the executive&#8217;s employment agreement, and (iii)&#160;12 months of continued health coverage. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an executive is terminated without cause or resigns for good reason within one month prior to or 12 months following a change of control, as defined in the employment agreements, the executive is entitled to receive, upon the execution of a release agreement, a severance package consisting of: (i)&#160;the equivalent of 12 months of the executive&#8217;s base salary in effect immediately prior to date of termination, (ii)&#160;the vesting in full of the executive&#8217;s then-outstanding stock options or other equity awards subject to time-based vesting, and (iii)&#160;12 months of continued health coverage. Solely in the case of the Company&#8217;s Chief Executive Officer, if such termination occurs one month before or 12 months following a change of control, then, upon the execution of a release agreement, the executive is entitled to: (i)&#160;the equivalent of 24 months of the executive&#8217;s base salary in effect immediately prior to the date of termination, (ii)&#160;the vesting in full of the executive&#8217;s outstanding stock options or other equity awards subject to time-based vesting, and (iii)&#160;12 months of continued health coverage.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreements with the University of Texas</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;">&#32;exclusive patent license agreements (the &#8220;UT License Agreements&#8221;) with the Board of Regents of The University of Texas System (the &#8220;University of Texas&#8221;). Under each of the UT License Agreements, the University of Texas granted the Company exclusive and nonexclusive licenses to certain patent and technology rights. The University of Texas is a minority stockholder of the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In consideration of rights granted by the University of Texas, the Company is required to: (i) pay a nonrefundable upfront license documentation fee in the amount of </font><font style="font-family:inherit;font-size:10pt;">$10 thousand</font><font style="font-family:inherit;font-size:10pt;">&#32;per license; (ii) pay an annual license maintenance fee in the amount of </font><font style="font-family:inherit;font-size:10pt;">$10 thousand</font><font style="font-family:inherit;font-size:10pt;">&#32;per license starting one year from the date of each agreement; (iii) reimburse the University of Texas for actual costs incurred in conjunction with the filing, prosecution, enforcement, and maintenance of patent rights prior to the effective date; and (iv) bear all future costs of and manage the filing, prosecution, enforcement, and maintenance of patent rights. During the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2016, the Company incurred immaterial upfront and maintenance fees, which were recorded as research and development expense. All costs related to the filing, prosecution, and maintenance of patent and technology rights are recorded as general and administrative expense when incurred.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the UT License Agreements, the Company may be obligated to make the following future milestone payments for each licensed product candidate: (i) up to approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the initiation of defined clinical trials; (ii) </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon regulatory approval in the United States; and (iii) </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;per region upon regulatory approval in other specified regions. Additionally, if the Company or its sublicensees successfully commercializes any product candidate subject to the UT License Agreements, it is responsible for royalty payments in the low-single digits based upon net sales of such licensed products and payments at a percentage in the mid-teens of any sublicense income, subject to specified exceptions. The University of Texas&#8217;s right to these royalty payments will expire as to each license agreement upon the expiration of the last patent claim subject to the applicable UT License Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The license term extends on a product by product and country by country basis until the expiration of the last to expire of the licensed patents that covers such product in such country. Upon expiration of the royalty payment obligation, the Company will </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">18</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">have a fully paid license in such country. The Company may also terminate each UT License Agreement for convenience upon a specified number of days&#8217; prior notice to the University of Texas. The University of Texas also has the right to earlier terminate the UT License Agreements after a defined date under specified circumstances where the Company has effectively abandoned its research and development efforts or has no sales. The UT License Agreements will terminate under customary termination provisions including automatic termination upon the Company&#8217;s bankruptcy or insolvency, upon notice of an uncured material breach, and upon mutual written consent. All charges incurred under the UT License Agreements have been expensed to date due to the uncertainty as to future economic benefit from the acquired rights.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreement with Roche Innovation Center Copenhagen A/S (formerly Santaris Pharma A/S)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2010, Private Miragen entered into a license agreement with the Santaris Pharma A/S, which was acquired by F. Hoffmann-La Roche Ltd (&#8220;Roche&#8221;) in 2014 and subsequently changed its name to Roche Innovation Center Copenhagen A/S (&#8220;RICC&#8221;). The agreement was amended in October 2011 and amended and restated in December 2012 (the &#8220;RICC License Agreement&#8221;).&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the RICC License Agreement, the Company has received exclusive and nonexclusive licenses from RICC to use specified technology of RICC (the &#8220;RICC Technology&#8221;) for specified uses including research, development, and commercialization of pharmaceutical products using this technology worldwide. Under the RICC License Agreement, the Company has the right to develop and commercialize the RICC Technology directed to four specified targets and the option to obtain exclusive product licenses for up to six additional targets. The acquisition of Santaris Pharma A/S by Roche was considered a change-of-control under the RICC License Agreement, and as such, certain terms and conditions of the RICC License Agreement changed, as contemplated and in accordance with the RICC License Agreement. These changes primarily relate to milestone payments reflected in the disclosures below. As consideration for the grant of the license and option, Private Miragen previously paid RICC </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and issued RICC </font><font style="font-family:inherit;font-size:10pt;">856,806</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Private Miragen&#8217;s Series A convertible preferred stock, which subsequently converted to </font><font style="font-family:inherit;font-size:10pt;">602,420</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Common Stock. If the Company exercises its option to obtain additional product licenses or to replace the target families, it will be required to make additional payments to RICC.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the RICC License Agreement, milestone payments were previously decreased by a specified percentage as a result of the change of control by RICC referenced above. The Company is obligated to make future milestone payments for each licensed product for up to </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;">, which is inclusive of a potential product license option fee. Certain of these milestones will be increased by a specified percentage if the Company undergoes a change in control during the term of the RICC License Agreement. If the Company grants a third party a sublicense to the RICC Technology, it is required to remit to Roche up to a specified percentage of the upfront and milestone and other specified payments it receives under its sublicense, and if such sublicense covers use of the RICC Technology in the United States or the entire European Union, the Company will not have any further obligation to pay the fixed milestone payments noted above.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company or its sublicensee successfully commercializes any product candidate subject to the RICC License Agreements, then RICC is entitled to royalty payments in the mid-single digits on the net sales of such product, provided that if such net sales are made by a sublicensee under the RICC License Agreement, RICC is entitled to royalty payments equal to the lesser of a percentage in the mid-single digits on the net sales of such product or a specified percentage of the royalties paid to the Company by such sublicensee, subject to specified restrictions. The Company is obligated to make any such royalty payments until the later of: (i) a specified anniversary of the first commercial sale of the applicable product or (ii) the expiration of the last valid patent claim licensed by RICC under the RICC License Agreement underlying such product. Upon the occurrence of specified events, the royalty owed to RICC will be decreased by a specified percentage.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The RICC License Agreement will terminate upon the latest of the expiration of all of RICC&#8217;s royalty rights, the termination of the last Miragen target, or the expiration of its right to obtain a product license for a new target under the RICC License Agreement. The Company may also terminate the RICC License Agreement for convenience upon a specified number of days&#8217; prior notice to RICC, subject to specified terms and conditions. Either party may terminate the RICC License Agreement upon an uncured material breach by the other party and RICC may terminate the RICC License Agreement upon the occurrence of other specified events immediately or after such event is not cured within a specified number of days, as applicable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All charges incurred under the RICC License Agreement have been expensed to date due to the uncertainty as to future economic benefit from the acquired rights. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and 2016, the Company paid </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, to Roche for raw materials to be used in its drug manufacturing process. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">19</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Subcontract Agreement with Yale University</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, Private Miragen and Yale University (&#8220;Yale&#8221;) entered into a subcontract agreement and into a subaward agreement in March 2015 (the &#8220;Yale Agreements&#8221;), which was subsequently amended. Under the Yale Agreements, the Company is providing specified services regarding the development of a proprietary compound that targets miR-29 in the indication of idiopathic pulmonary fibrosis. Yale entered into the Yale Agreements in connection with a grant that Yale received from the National Institutes of Health (&#8220;NIH&#8221;) for the development of a miR-29 mimic as a potential therapy for pulmonary fibrosis.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In consideration of the Company&#8217;s services under the Yale Agreements, Yale has agreed to pay the Company up to </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;over </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">, subject to the availably of funds under the grant and continued eligibility. Under the terms of the Yale Agreements, the Company retains all rights to any and all intellectual property developed solely by the Company in connection with the Yale Agreements. Yale has also agreed to provide the Company with an exclusive option to negotiate in good faith for an exclusive, royalty-bearing license from Yale for any intellectual property developed by Yale or jointly by the parties under the Yale Agreements. Yale is responsible for filing, prosecuting, and maintaining foreign and domestic patent applications and patents on all inventions jointly developed by the parties under the Yale Agreements. Through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has received </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;under the Yale Agreements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Yale Agreements terminate automatically on the date that Yale delivers its final research report to the NIH under the terms of the grant underlying the Yale Agreements. Each party may also terminate the Yale Agreements upon a specified number of days&#8217; notice in the event that the NIH&#8217;s grant funding is reduced or terminated or upon material breach by the other party.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreements with the t2cure GmbH</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2010, Private Miragen entered into a license and collaboration agreement (the &#8220;t2cure Agreement&#8221;) with t2cure GmbH (&#8220;t2cure&#8221;), which was subsequently amended. Under the t2cure Agreement, the Company has received a worldwide, royalty-bearing, and exclusive license to specified patent and technology rights relating to miR-92.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In consideration of rights granted by t2cure, Private Miragen paid an upfront fee of </font><font style="font-family:inherit;font-size:10pt;">$46 thousand</font><font style="font-family:inherit;font-size:10pt;">&#32;and agreed to: (i) pay an annual license maintenance fee in the amount of </font><font style="font-family:inherit;font-size:10pt;">&#8364;3 thousand</font><font style="font-family:inherit;font-size:10pt;">&#32;(</font><font style="font-family:inherit;font-size:10pt;">$3 thousand</font><font style="font-family:inherit;font-size:10pt;">&#32;as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">); and (ii) reimburse t2cure for costs incurred in conjunction with the filing, prosecution, enforcement, and maintenance of patent rights. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the t2cure Agreement, the Company is obligated to make the following future milestone payments for each licensed product: (i) up to approximately </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon the initiation of certain defined clinical trials; (ii) </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;upon regulatory approval in the United States; and (iii) up to </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;per region upon regulatory approval in the European Union or Japan. Additionally, if the Company or its sublicensees successfully commercialize any product candidate subject to the t2cure Agreement, it is responsible for royalty payments equal to percentages in the low-single digits upon net sales of licensed products and sublicense fees equal to a percentage in the low-twenties of sublicense income received by it. The Company is obligated to make any such royalty payment until the later of (i) the tenth anniversary of the first commercial sale of the applicable product or (ii) the expiration of the last valid claim to a patent licensed by t2cure under the t2cure Agreement covering such product. If such patent claims expire prior to the end of the </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">-year term, then the royalty owed to t2cure will be decreased by a specified percentage. The Company also has the right to decrease its royalty payments by a specified percentage for royalties paid to third parties for licenses to certain third-party intellectual property.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The license term extends on a country by country basis until the later of: (i) the tenth anniversary of the first commercial sale of a licensed product in a country and (ii) the expiration of the last to expire valid claim that claims such licensed product in such country. Upon expiration of the royalty payment obligation, the Company will have a fully paid license in such country. The Company has the right to terminate the t2cure Agreement at will, on a country-by-country basis, after </font><font style="font-family:inherit;font-size:10pt;">60</font><font style="font-family:inherit;font-size:10pt;">&#32;days&#8217; written notice. The t2cure Agreement will also automatically terminate upon the Company&#8217;s bankruptcy or insolvency or upon notice of an uncured material breach.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has expensed all charges incurred under the t2cure Agreement to date, due to the uncertainty as to future economic benefit from the acquired rights.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreement with The Brigham and Women&#8217;s Hospital</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016, Private Miragen and The Brigham and Women&#8217;s Hospital (&#8220;BWH&#8221;) entered into an exclusive patent license agreement (the &#8220;BWH License Agreement&#8221;). Under the BWH License Agreement, the Company has an exclusive, worldwide license, including a right to sublicense, to specified patent rights and a nonexclusive, worldwide license, including a right to </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sublicense, to specified technology rights of BWH, each related to certain microRNAs believed to be involved in various neurodegenerative disorders. As consideration for these rights, the Company is obligated to pay a specified annual license fee. BWH is also entitled to milestone payments of up to approximately </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for each of the Company&#8217;s product candidates developed based on the patent rights subject to the BWH License Agreement plus a one-time sales milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for all product candidates developed based on the patent rights subject to the BWH License Agreement. If the Company were to successfully commercialize any product candidate subject to the BWH License Agreement, then BWH is entitled to royalty payments in the low-single digits on the net sales of such product. BWH&#8217;s right to these royalty payments will expire on a product by product and country by country basis upon the expiration of the last patent claim in such country that is subject to the BWH License Agreement and covers the product, and the Company&#8217;s license to such product in such country will become fully paid at such time. BWH is also entitled to a percentage in the low-double digits of any sublicense income from such product, subject to specified exceptions. The Company is also responsible for all costs associated with the preparation, filing, prosecution, and maintenance of the patent rights subject to the BWH License Agreement. Additionally, the Company is obligated to use commercially reasonable efforts to develop a product under the BWH License Agreement and to meet specified diligence milestones thereunder. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The BWH License Agreement will terminate upon the expiration of all issued patents and patent applications subject to the patent rights under the agreement. The Company may also terminate the BWH License Agreement for convenience upon a specified number of days&#8217; prior notice to BWH. BWH may terminate the BWH License Agreement upon a breach by the Company of its payment obligations and upon the occurrence of other specified events that are not cured within a specified number of days, provided that such termination is automatic upon the Company&#8217;s bankruptcy or insolvency.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company paid the first annual license fee, which was immaterial. To date, the Company has not met any milestones that have required milestone payments.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Facility Lease</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2010, Private Miragen entered into a multi-year lease agreement for its current office and lab space. The agreement was subsequently amended to extend the term through August 2020. This lease is noncancelable. Minimum base lease payments, including the impact of tenant improvement allowances, under the operating lease are recognized on a straight-line basis over the full term of the lease. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, rent expense was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for each period. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, rent expense was </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also required to pay for operating expenses. During the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, operating expenses were </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for each period. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, operating expenses related to the leased space were </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for each period.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future annual minimum payments under the lease are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:87%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,<br>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017 (remainder of year)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,167</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">21</font></div></div><hr style="page-break-after:always"><div><a name="s312E8327524B5FCC9DED12E297A77D49"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">9. CAPITAL STOCK</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is authorized to issue </font><font style="font-family:inherit;font-size:10pt;">105,000,000</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of its stock, of which </font><font style="font-family:inherit;font-size:10pt;">100,000,000</font><font style="font-family:inherit;font-size:10pt;">&#160;shares have been designated as Common Stock and </font><font style="font-family:inherit;font-size:10pt;">5,000,000</font><font style="font-family:inherit;font-size:10pt;">&#32;shares have been designated as preferred stock with a par value of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;">&#32;per&#160;share. The number of authorized shares of Common Stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#8217;s stock who are entitled to vote. Each share of Common Stock is entitled to one vote. The holders of Common Stock are entitled to receive dividends when and as declared or paid by its board of directors. At the effective date of the Merger, each outstanding share of Private Miragen common stock was converted into the right to receive approximately </font><font style="font-family:inherit;font-size:10pt;">0.7031</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of the Company&#8217;s Common Stock. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 13, 2017, immediately prior to the Merger and in accordance with subscription agreements entered into with certain investors in October 2016, Private Miragen issued and sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;">9,045,126</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Private Miragen&#8217;s common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$4.50</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">6,359,628</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Common Stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$6.40</font><font style="font-family:inherit;font-size:10pt;">&#32;as adjusted for the exchange ratio in the Merger, for aggregate consideration of </font><font style="font-family:inherit;font-size:10pt;">$40.7 million</font><font style="font-family:inherit;font-size:10pt;">, offset by associated financing fees of </font><font style="font-family:inherit;font-size:10pt;">$1.5&#160;million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Series Preferred</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February&#160;2017, in conjunction with the Merger, all of the outstanding redeemable convertible preferred stock of Private Miragen converted into Private Miragen common stock at a ratio of </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;">:1 and was immediately exchanged for the Company&#8217;s Common Stock at an exchange ratio of </font><font style="font-family:inherit;font-size:10pt;">0.7031</font><font style="font-family:inherit;font-size:10pt;">&#32;as a result of the Merger. A summary of the conversion by class of preferred stock is summarized as follows (in thousands, except share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28"></td></tr><tr><td style="width:19%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Series A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Series B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Series C</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,149,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,166,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,268,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">40,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18,584,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">76,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accretion of redeemable convertible preferred stock to redemption value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Conversion of preferred stock to common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(7,149,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(23,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,166,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(12,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(9,268,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(40,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(18,584,390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(76,981</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at February 13, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had no shares of preferred stock outstanding and had not designated the rights, preferences, or privileges of any class or series of preferred stock. Although the Company&#8217;s board of directors has the authority to issue preferred stock at its discretion in one or more classes or series and to fix the designations, powers, preferences and rights, and the qualifications, limitations, or restrictions thereof, including dividend rights, conversion right, voting rights, terms of redemption, liquidation preferences, and the number of shares constituting any class or series of preferred stock, without further vote or action by the stockholders.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Sales Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 31,&#160;2017, the Company entered into an ATM Agreement with Cowen, under which the Company may offer and sell, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;through Cowen as its sales agent.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cowen may sell the Common Stock by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 of the Securities Act of 1933, as amended, including without limitation sales made by means of ordinary brokers&#8217; transactions on The NASDAQ Capital Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise directed by the Company. Cowen will use commercially reasonable efforts to sell the Common Stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay Cowen a commission equal to </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;of the gross sales proceeds of any Common Stock sold through Cowen under the ATM Agreement, and also has provided Cowen with customary indemnification rights.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is not obligated to make any sales of Common Stock under the ATM Agreement. The offering of shares of Common Stock pursuant to the ATM Agreement will terminate upon the earlier of: (i) the sale of all Common Stock subject to the ATM Agreement or (ii) termination of the ATM Agreement in accordance with its terms.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has sold, pursuant to the terms of the ATM Agreement, </font><font style="font-family:inherit;font-size:10pt;">297,653</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Common Stock, at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$9.11</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, for aggregate gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">. Net proceeds received during the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were approximately </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, including initial expenses for executing the &#8220;at the market offering&#8221; and commissions to Cowen as sales agent. See Note 13 for a discussion of sales of Common Stock made under the ATM Agreement after </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has incurred approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in offering costs for the ATM Agreement, including costs for the related shelf filing, but excluding the commissions paid to Cowen as sales agent.&#160;The costs incurred are initially included in prepaid expenses and other current assets and are being amortized to a reduction of offering costs as shares are sold under the ATM Agreement.&#160;The costs reflected in the condensed consolidated statement of cash flows include the </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;">&#32;commission paid to Cowen on shares sold (</font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">) along with </font><font style="font-family:inherit;font-size:10pt;">$8 thousand</font><font style="font-family:inherit;font-size:10pt;">&#32;of amortized offering costs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s8377A1228FB456DC810B688D37042C71"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">10. WARRANTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock purchase warrant activity is as follows for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:37%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred Stock Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants acquired in Merger</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,534</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.70</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock warrants converted into Common Stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercises</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,092</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.04</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of outstanding Common Stock purchase warrants as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:30%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Underlying Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration Date</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$80.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 &amp; 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,718</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.53</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2025</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, Private Miragen assumed </font><font style="font-family:inherit;font-size:10pt;">13,534</font><font style="font-family:inherit;font-size:10pt;">&#32;outstanding warrants to purchase shares of the Company&#8217;s Common Stock at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$80.70</font><font style="font-family:inherit;font-size:10pt;">&#32;per share. The assumed warrants expire on various dates in 2019 and 2020.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sAF52FFE9B2125BD4BBFC5BAAFBF540CD"></a></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">11. SHARE-BASED COMPENSATION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Incentive Plans</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2017, the Company&#8217;s 2014 Stock Incentive Plan (the &#8220;2014 Plan&#8221;) was terminated as a result of the Merger. There are no awards outstanding under the 2014 Plan and no future awards will be issued under the 2014 Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">2,060,993</font><font style="font-family:inherit;font-size:10pt;">&#32;options outstanding and no remaining equity awards available for future issuances under the 2008 Plan. All awards granted under the 2008 Plan that, after February 13, 2017, expire or terminate for any reason prior to exercise or settlement, are forfeited, or are reacquired, withheld, or not issued to satisfy a tax withholding obligation or to satisfy the exercise price of a stock award, will become available for grant under the 2016 Plan in accordance with its terms. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, other stock awards, and performance awards that may be settled in cash, stock, or other property. All employees and non-employee directors are eligible to participate in the 2016 Plan and may receive all types </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">23</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of awards other than incentive stock options. Incentive stock options may be granted under the 2016 Plan only to employees (including officers) and employees of the Company&#8217;s affiliates. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate number of shares of Common Stock that may be issued under the 2016 Plan will not exceed </font><font style="font-family:inherit;font-size:10pt;">4,182,404</font><font style="font-family:inherit;font-size:10pt;">&#32;shares, which number is the sum of: (i) </font><font style="font-family:inherit;font-size:10pt;">1,681,294</font><font style="font-family:inherit;font-size:10pt;">&#32;shares, plus (ii) the number of shares subject to outstanding stock awards that were granted under the 2008 Plan, that, from and after the closing date of the Merger, expire or terminate for any reason prior to exercise or settlement, are forfeited because of the failure to meet a contingency or condition required to vest such shares, or are reacquired, withheld, or not issued to satisfy a tax withholding obligation in connection with an award or to satisfy the purchase price or exercise price of a stock award, if any, as such shares become available from time to time. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">908,227</font><font style="font-family:inherit;font-size:10pt;">&#32;equity awards outstanding and </font><font style="font-family:inherit;font-size:10pt;">773,067</font><font style="font-family:inherit;font-size:10pt;">&#32;remaining equity awards available for future issuances under the 2016 Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted under the 2008 Plan and 2016 Plan have an exercise price equal to the market value of the Common Stock at the date of grant and expire </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">&#32;years from the date of grant. Generally, options vest </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;">&#32;on the first anniversary of the vesting commencement date and </font><font style="font-family:inherit;font-size:10pt;">75%</font><font style="font-family:inherit;font-size:10pt;">&#32;ratably in equal monthly installments over the remaining </font><font style="font-family:inherit;font-size:10pt;">36 months</font><font style="font-family:inherit;font-size:10pt;">. The Company has also granted options that vest in equal monthly or quarterly amounts over periods up to </font><font style="font-family:inherit;font-size:10pt;">48 months</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of Common Stock option activity is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:75%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Options <br>(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">956</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.48</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11.40</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,969</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Assumptions</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options granted. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility, and expected lives of the options. Because the Company has a limited history of stock purchase and sale activity, expected volatility is based on historical data from public companies similar to the Company in size and nature of operations. The Company will continue to use similar entity volatility information until its historical volatility is relevant to measure expected volatility for option grants. The Company has not applied a forfeiture rate to its assumptions as the impact would not be material to the consolidated financial statements. The risk-free rate for periods within the contractual life of each option is based on the U.S.&#160;Treasury yield curve in effect at the time of the grant for a period commensurate with the expected term of the grant. The expected term (without regard to forfeitures) for options granted represents the period of time that options granted are expected to be outstanding and is derived from the contractual terms of the options granted and expected option exercise behaviors. Prior to the Merger, Private Miragen estimated the fair value of underlying shares of common stock using a third-party valuation report that derived the fair value using the probability-weighted expected return method. After the Merger, the fair value of the underlying Common Stock is based on the closing price of the Common Stock on the NASDAQ Capital Market at the date of grant. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options Granted to Employees</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average fair value of options granted during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;was </font><font style="font-family:inherit;font-size:10pt;">$8.32</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$0.70</font><font style="font-family:inherit;font-size:10pt;">, respectively. The fair value was determined by the Black-Scholes option pricing model using the following assumptions:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term, in years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average grant date fair value of underlying Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options Granted to Non-Employees</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determines the value of Common Stock options issued to non-employees using the Black-Scholes option pricing model and adjusting the value of such awards to current fair value each reporting period until the awards are vested or a performance commitment has otherwise been reached. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;">&#32;Common Stock options were issued to non-employees during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;">&#32;months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) allows qualified employees to purchase shares of the Company's Common Stock at a price equal to&#160;85%&#160;of the lower of: (i) the closing price at the beginning of the offering period or (ii) the closing price at the end of the offering period. The Company expects that a new 6-month offering period will begin each August&#160;22 and February&#160;22. As of&#160;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had&#160;</font><font style="font-family:inherit;font-size:10pt;">0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#160;shares available for issuance and </font><font style="font-family:inherit;font-size:10pt;">13 thousand</font><font style="font-family:inherit;font-size:10pt;">&#32;shares had been issued under the ESPP.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation Expense</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation related to all equity awards issued pursuant to the 2008 Plan and 2016 Plan and for estimated shares to be issued under the ESPP for the current purchase period is included in the condensed consolidated statements of operations as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16"></td></tr><tr><td style="width:53%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">416</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,050</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share-based compensation expense</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,693</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:53%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$7.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of total unrecognized employee share-based compensation costs, which the Company expects to recognize over a weighted-average remaining period of </font><font style="font-family:inherit;font-size:10pt;">3.2</font><font style="font-family:inherit;font-size:10pt;">&#160;years. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, based on the current estimate of fair value, the Company estimates that the remaining unrecognized share-based compensation expense related to non-employees of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;will be recorded to expense over a weighted-average remaining period of </font><font style="font-family:inherit;font-size:10pt;">0.9</font><font style="font-family:inherit;font-size:10pt;">&#160;years. </font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sECDBFB0E5CA2541585D3920CE4D38EEF"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">12. NET LOSS PER SHARE</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of Common Stock outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional shares of Common Stock that would have been outstanding if the potential shares of Common Stock had been issued and if the additional shares of Common Stock were dilutive. Diluted net loss per share is the same as basic net loss per share of Common Stock, since the effects of potentially dilutive securities are antidilutive.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Potentially dilutive securities include the following:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6"></td></tr><tr><td style="width:77%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options to purchase Common Stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,067</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,994</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,365</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s27e30389a2e04ff8852f01b7784991d8"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">13. SUBSEQUENT EVENTS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, and through </font><font style="font-family:inherit;font-size:10pt;">November 7, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company sold, pursuant to the terms of the ATM Agreement, an aggregate of </font><font style="font-family:inherit;font-size:10pt;">403,306</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of Common Stock, at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$9.65</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, for aggregate gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;Net proceeds were approximately </font><font style="font-family:inherit;font-size:10pt;">$3.8 million</font><font style="font-family:inherit;font-size:10pt;">, including commissions to Cowen, as sales agent.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></div><hr style="page-break-after:always"><div><a name="s51C9281852B05C1386DA4D93227D338A"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">FORWARD-LOOKING STATEMENTS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This quarterly report on Form 10-Q, or this Quarterly Report, contains forward-looking statements that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements contained in this Quarterly Report other than statements of historical fact, including statements regarding our strategy, future operations, future financial position, future revenue, projected expenses, prospects, plans, and objectives of management are forward-looking statements. The words &#8220;believe,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;continue,&#8221; &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;expect,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;opportunity,&#8221; &#8220;goals,&#8221; or &#8220;should,&#8221; and similar expressions are intended to identify forward-looking statements. Unless otherwise mentioned or unless the context requires otherwise, all references in this Quarterly Report to &#8220;Miragen,&#8221; &#8220;company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; or similar references refer to Miragen Therapeutics, Inc., and our consolidated subsidiaries.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Such statements are based on management&#8217;s current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have incurred losses since our inception, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have never generated any revenue from product sales and may never be profitable.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be unsuccessful in maintaining orphan drug marketing exclusivity after regulatory</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;</font><font style="font-family:inherit;font-size:10pt;">approval of our product candidates, because the U.S. Food and Drug Administration, or FDA, can subsequently approve the same drug for the same indication from a different sponsor if it concludes that the later drug is clinically superior in that it is shown to be safer, more effective, or makes a major contribution to patient care.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be unsuccessful in gaining the benefits of orphan medicinal product designation after approval by the European Commission because, at the time of a marketing application, we may be unable to establish that our product candidate continues to meet the criteria of the European Commission for orphan-drug designation.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials are costly, time consuming, and inherently risky, and we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The approach we are taking to discover and develop novel therapeutics that target microRNAs is unproven and may never lead to marketable products.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our microRNA-targeted therapeutic product candidates are based on a relatively novel technology, which makes it unusually difficult to predict the time and cost of development, and the time and cost, or likelihood, of obtaining regulatory approval. To date, no microRNA-targeted therapeutics have been approved for marketing in the United States.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may not be able to develop or identify technology that can effectively deliver MRG-106, MRG-201, or any other of our microRNA-targeted product candidates to the intended diseased cells or tissues, and any failure in such delivery technology could adversely affect and delay the development of MRG-106, MRG-201, and our other product candidates. </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent regulatory approval, limit the commercial viability of an approved label, or result in significant negative consequences following marketing approval, if any.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are heavily dependent on the success of our product candidates, which are in the early stages of clinical development. Some of our product candidates have produced results only in&#160;preclinical&#160;settings, or for other indications than those for which we contemplate conducting development and seeking approval from the FDA, and we cannot give any assurance that we will generate data for any of our product candidates sufficiently supportive to receive regulatory approval in our planned indications, which will be required before they can be commercialized.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">27</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We face substantial competition, and our competitors may discover, develop, or commercialize products faster or more successfully than us.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be unable to realize the potential benefits of any collaboration.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may attempt to form collaborations in the future with respect to our product candidates, but we may not be able to do so, which may cause us to alter our development and commercialization plans.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business, or our market, our stock price and trading volume could decline.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives, and financial needs. These forward-looking statements are subject to a number of risks, uncertainties, and assumptions, including those described in Part II, Item 1A, &#8220;Risk Factors,&#8221; in this Quarterly Report and under a similar heading in any other periodic or current report we may file with the Securities and Exchange Commission, or the SEC, in the future. Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties, and assumptions, the future events and trends discussed in this Quarterly Report may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We undertake no obligation to revise or publicly release the results of any revision to these forward-looking statements, except as required by law. Given these risks and uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">28</font></div></div><hr style="page-break-after:always"><div><a name="s0DDA80A3ABB35015BD5090862621EB87"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 2. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our condensed consolidated financial statements and related notes thereto included in Part I, Item 1 of this Quarterly Report, our consolidated financial statements and related notes thereto for the year ended December 31, 2016, included in our Annual Report on Form 10-K filed with the SEC on March 24, 2017, and the consolidated financial statement and pro forma financial statements of then privately-held Miragen Therapeutics, Inc., or Private Miragen, included in our Form 8-K/A filed with the SEC on March 31, 2017. This discussion and other parts of this report contain forward-looking statements that involve risks and uncertainties, such as our plans, objectives, expectations, intentions, and beliefs. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section entitled &#8220;Risk Factors&#8221; included elsewhere in this report.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Overview</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapeutics with a specific focus on microRNAs and their roles in diseases where there is a high unmet medical need. microRNAs are short RNA molecules, or oligonucleotides, that regulate gene expression or activity and play vital roles in influencing the pathways responsible for many disease processes. Our two lead product candidates, MRG-106 and MRG-201, are currently in clinical development. MRG-106 is an inhibitor of microRNA-155, which is found at abnormally high levels in several blood cancers. MRG-201 is a replacement for microRNA-29, which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary, and ocular fibrosis, as well as in systemic sclerosis. We are also developing MRG-110, an inhibitor of microRNA-92, under a License and Collaboration Agreement, or the Servier Collaboration Agreement, with Les Laboratoires Servier and Institut de Recherches Servier, or Servier. MRG-110 is being developed for the treatment of heart failure and other ischemic disease. In addition to these programs, we continue to develop a pipeline of wholly-owned preclinical product candidates. The goal of our translational medicine strategy is to progress rapidly to first-in-human trials once we have adequately established the pharmacokinetics (the movement of drug into, through, and out of the body), pharmacodynamics (the effect and mechanism of action of a drug), safety, and manufacturability of the product candidate in preclinical studies.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, we administered MRG-106 to the first subject in a multi-site, open-label, dose-ranging Phase&#160;1 clinical trial that seeks to enroll up to approximately 50 subjects with a confirmed diagnosis of mycosis fungoides, or MF. MF is a subtype of cutaneous T&#8209;cell lymphoma, or CTCL, in which malignant T-cells move to the skin and form patches (palpable flat lesions) or plaques and tumors. As of </font><font style="font-family:inherit;font-size:10pt;">October&#160;11, 2017</font><font style="font-family:inherit;font-size:10pt;">, 27 subjects have been on study for up to approximately one year. MRG-106 has been generally safe and well tolerated. One subject developed a worsening in itching compared to their baseline level on two occasions, once after the initial systemic treatment and again after retreatment at a lower dose. These events were deemed to be dose limiting toxicities. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In 2017, we expanded the Phase 1 clinical trial for MRG-106 to include three additional hematological malignancies including adult T-cell leukemia/lymphoma, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia. In each of these expansion indications, the disease process appears to correlate with an increase in microRNA-155 levels, the direct target of MRG-106. In all cases, treated subjects will have failed at least one or two prior therapies depending on the indication. We began dosing subjects in these expanded indications in the second half of 2017 and plan to initially enroll up to 25 subjects.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the second half of 2018, we intend to initiate a Phase&#160;2 clinical trial with MRG-106 to treat MF patients. Dosing regimen and the duration of treatment in the trial will be determined from data presently being collected from our Phase&#160;1 trial.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recently completed a single-center Phase 1, double-blind, placebo-controlled, single and multiple dose-escalation clinical trial studying MRG-201. Fifty-four volunteers participated in the clinical trial, 47 of whom were administered MRG-201 and seven of whom were enrolled and underwent study procedures without receiving a dose of MRG-201. MRG-201 was generally safe and well-tolerated with injection site reactions of mild or moderate severity being the most common adverse events. The trial was completed in the second quarter of 2017, and we presented complete results at the American Society for Dermatologic Surgery Annual Meeting on October 5, 2017. In the first half of 2018, we intend to initiate a Phase 2a, double-blind randomized trial to evaluate MRG-201 in subjects with a predisposition for keloid formation, a pathological fibrotic disease.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The primary product candidate under our amended Servier Collaboration Agreement is MRG-110. MRG-110 inhibits the activity of microRNA-92a, which has been shown in our preclinical studies and reported in multiple peer reviewed scientific publications to be a negative regulator of new blood vessel creation. During the first half of 2018, we intend to initiate two </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">29</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Phase 1 clinical trials evaluating MRG-110 delivered both systemically and intradermally. As part of the Phase 1 clinical trials, in addition to safety and pharmacokinetics, we intend to analyze biomarkers that may provide mechanistic proof of concept and support further study of MRG-110 in the treatment of cardiovascular disease and certain other conditions where vascular flow is compromised.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to MRG-106, MRG-201, and MRG-110, we have a pipeline of wholly-owned, preclinical product candidates that target individual microRNAs thought to be at abnormally high or low levels in particular diseases. We believe our experience in microRNA biology and chemistry, drug discovery, bioinformatics, and translational medicine allows us to identify and develop RNA-targeted drugs that are designed to regulate gene pathways to return diseased tissues to a healthy state. We believe that our drug discovery and development strategy will enable us to progress our product candidates from preclinical discovery to confirmation of mechanism of action in humans quickly and efficiently. The elements of this strategy include identification of biomarkers that may predict clinical benefit and monitoring outcomes in early-stage clinical trials to help guide later clinical development.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Recent Developments</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Mergers</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February&#160;13, 2017, we, then named Signal Genetics, Inc., completed our merger with Private Miragen. Pursuant to the terms of the Agreement and Plan of Merger and Reorganization, or the Merger Agreement, Signal Merger Sub, Inc., our wholly-owned subsidiary, merged with and into Private Miragen, with Private Miragen surviving as our wholly-owned subsidiary, or the Merger. Immediately following the Merger, Private Miragen merged with and into us, with us as the surviving corporation, or the Short-Form Merger and, together with the Merger, or the Mergers. In connection with the Short-Form Merger, we changed our corporate name to &#8220;Miragen Therapeutics, Inc.&#8221; Our common stock, par value $0.01 per share, or our common stock, began trading on The NASDAQ Capital Market under the ticker symbol &#8220;MGEN&#8221; on February&#160;14, 2017. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unless otherwise noted, the discussion herein gives retroactive effect to the Mergers.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financing</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, we entered into a Common Stock Sales Agreement, or the ATM&#160;Agreement, with Cowen and Company, LLC, or Cowen, under which we may offer and sell, from time to time, at our sole discretion, shares of our common stock having an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;through Cowen as our sales agent. As of </font><font style="font-family:inherit;font-size:10pt;">November 7, 2017</font><font style="font-family:inherit;font-size:10pt;">, we have sold, pursuant to the terms of the ATM Agreement, </font><font style="font-family:inherit;font-size:10pt;">700,959</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock, at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$9.42</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, for aggregate gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$6.6 million</font><font style="font-family:inherit;font-size:10pt;">. Net proceeds as of </font><font style="font-family:inherit;font-size:10pt;">November 7, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were approximately </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;">, including initial expenses for executing the &#8220;at the market offering&#8221; and commissions to Cowen as sales agent.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2017, immediately prior to the closing of the Merger, Private Miragen issued and sold an aggregate of approximately </font><font style="font-family:inherit;font-size:10pt;">$40.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of shares of Private Miragen&#8217;s common stock to certain stockholders of Private Miragen and certain new investors at a per share price of $4.50 (not adjusted to reflect the exchange ratio of Private Miragen&#8217;s capital stock effective as of the Merger), or the Concurrent Financing.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Orphan-Drug Designation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 31, 2017, we announced that the FDA granted orphan-drug designation to our product candidate, MRG-106, for the treatment of MF. Additionally, on May 24, 2017, we announced that the European Commission granted orphan medicinal product designation to our product candidate, MRG-106, for the treatment of CTCL. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Amendment of Collaboration Agreement with Servier</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We amended the Servier Collaboration Agreement in May and September 2017, or the 2017 Amendments. The 2017 Amendments removed the three existing targets and added a new target, microRNA-92, providing Servier with: (i) an exclusive license to research, develop, and commercialize MRG-110, our product candidate that targets microRNA-92 for the treatment of diseases through revascularization, in all countries other than the United States and Japan where we retain all rights, as if microRNA-92 were an original target under the Servier Collaboration Agreement, and (ii) the right to obtain such an exclusive license for another target to be named by Servier no later than September 30, 2019. The 2017 Amendments also provided for other modifications to our agreement including to extend the term of the research collaboration between us and Servier until September 30, 2019 or the date of completion of the agreed upon research activities, whichever is later. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">30</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the 2017 Amendments, Servier&#8217;s rights to the three removed targets and product candidates directed to such removed targets were terminated and returned to us.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Financial Operations Overview</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenues</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our revenue consists primarily of upfront payments for licenses, milestone payments, and payments for other research services earned under our strategic alliance and collaboration agreement. We also recognize revenue for amounts received or receivable under certain grants we have been awarded.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the future, we may generate revenue from a combination of license fees and other upfront payments, payments for research and development services, milestone payments, product sales, and royalties in connection with strategic alliances. We expect that any revenue we generate will fluctuate from quarter to quarter as a result of the timing of our achievement of preclinical, clinical, regulatory, and commercialization milestones, the timing and amount of payments relating to such milestones, and the extent to which any of our products are approved and successfully commercialized by us or our strategic alliance partners. If our strategic alliance partners do not elect or otherwise agree to fund our development costs pursuant to our strategic alliance agreements, or we or our strategic alliance partners fail to develop product candidates in a timely manner or to obtain regulatory approval for them, then our ability to generate future revenues, and our results of operations and financial position would be adversely affected.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and development expenses</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred and include compensation and related benefits, share-based compensation, license fees, laboratory supplies, facilities, and overhead costs. We occasionally make non-refundable advance payments for goods and services that will be used in future research and development activities. These payments are capitalized and recorded as expense in the period in which we receive the goods or when the services are performed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record upfront and milestone payments to acquire contractual rights to licensed technology as research and development expenses when incurred if there is uncertainty in our receiving future economic benefit from the acquired contractual rights. We consider future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved by the FDA or when other significant risk factors are abated.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expense consists of costs associated with our research activities, drug discovery efforts, and development of our therapeutic programs, which includes:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">employee-related expenses, including salaries, benefits, travel, and share-based compensation expense;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">external research and development expenses incurred under arrangements with third parties, such as contract research organizations, or CROs, contract manufacturing organizations, or CMOs, other clinical trial-related vendors, consultants, and our scientific advisors;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">license fees; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">facilities, depreciation, and other allocated expenses, which include direct and allocated expenses for rent and maintenance of facilities, depreciation of leasehold improvements and equipment, and laboratory and other supplies.</font></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect our research and development expenses to increase for the foreseeable future as we continue to conduct our ongoing clinical trials, initiate additional clinical trials, and advance our preclinical research programs. The process of conducting clinical trials and preclinical studies necessary to obtain regulatory approval is costly and time consuming. We, or our strategic alliance partners, may never succeed in achieving marketing approval for any of our product candidates. The probability of success for each product candidate may be affected by numerous factors, including clinical data, preclinical data, competition, manufacturing capability, and commercial viability. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Successful development of future product candidates is highly uncertain and may not result in approved products. Completion dates and completion costs can vary significantly for each future product candidate and are difficult to predict. We anticipate we will make determinations as to which programs to pursue and how much funding to direct to each program on an ongoing basis in response to our ability to maintain or enter into new strategic alliances with respect to each program or potential product candidate, the scientific and clinical success of each future product candidate, and ongoing assessments as to each future </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">31</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product candidate&#8217;s commercial potential. We will need to raise additional capital and may seek additional strategic alliances in the future in order to advance our various programs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and administrative expenses</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses consist primarily of salaries and related benefits, including share-based compensation, related to our executive, finance, legal, business development and support functions. Other general and administrative expenses include allocated facility-related costs and professional fees for auditing, tax, and legal services. Leading up to the Merger, we incurred incremental expenses related to both the Merger and the result of becoming a public company following completion of the Merger. This included expenses related to our compliance with the rules and regulations of the SEC and The NASDAQ Stock Market, LLC, or NASDAQ, additional insurance, professional services, investor relations, and other administrative expenses. </font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other income (expense), net</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense) consists primarily of interest income and expense, and various income or expense items of a non-recurring nature. We earn interest income from interest-bearing accounts and money market funds. Interest expense is comprised of interest incurred under notes payable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Critical Accounting Policies and Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This discussion and analysis of financial condition and results of operations is based on our condensed consolidated financial statements, which have been prepared in accordance with U.S. generally accepted accounting principles, or U.S. GAAP. The preparation of financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, and expenses. On an ongoing basis, we evaluate these estimates and judgments. We base our estimates on historical experience and on various assumptions that we believe to be reasonable under the circumstances. These estimates and assumptions form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results may differ materially from these estimates. We believe that the accounting policies discussed below are critical to understanding our historical and future performance, as these policies relate to the more significant areas involving our judgments and estimates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue from upfront payments for licenses or options to obtain licenses in the future and milestone payments that are generated from defined research or development events, as well as from amounts for other research and development services under strategic alliance and collaboration agreements. We recognize revenue when all four of the following criteria are met: (i)&#160;persuasive evidence of an arrangement exists; (ii)&#160;products have been delivered or services rendered; (iii)&#160;the selling price is fixed or determinable; and (iv)&#160;collectability is reasonably assured.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple-element arrangements are examined to determine whether the deliverables can be separated or must be accounted for as a single unit of accounting. The Servier Collaboration Agreement, for example, includes a combination of upfront license fees, payments for research and development activities, and milestone payments that are evaluated to determine whether each deliverable under the agreement has value to the customer on a stand-alone basis and whether reliable evidence of fair value for the deliverable exists. Deliverables in an arrangement that do not meet these separation criteria are treated as a single unit of accounting, generally applying applicable revenue recognition guidance for the final deliverable to the combined unit of accounting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We recognize revenue from nonrefundable upfront license fees over the term of performance under the collaboration agreement. When the performance period is not specified, we estimate the performance period based upon provisions contained within the agreement, such as the duration of the research or development term, the existence or likelihood of achievement of development commitments, and any other significant commitments. These advance payments are deferred and recorded as deferred revenue upon receipt, pending recognition, and are classified as a short-term or long-term liability in the condensed consolidated balance sheets. Expected performance periods are reviewed periodically and, if applicable, the amortization period is adjusted, which may accelerate or decelerate revenue recognition. The timing of revenue recognition, specifically as it relates to the amortization of upfront license fees, is significantly influenced by our estimates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">32</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for share-based compensation expense related to stock options granted to employees and members of our board of directors under our 2008 Equity Incentive Plan, or the 2008 Plan, and our 2016 Equity Incentive Plan, or the 2016 Plan, by estimating the fair value of each stock option or award on the date of grant using the Black-Scholes model. We recognize share-based compensation expense on a straight-line basis over the vesting term.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We account for stock options issued to non-employees by estimating the fair value of each award using an option pricing model and remeasuring such awards to the current fair value until the awards are vested or a performance commitment has otherwise been reached.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred in performing research and development activities. The costs include employee-related expenses including salaries, benefits, share-based compensation, fees for acquiring and maintaining license under third party licensing agreements, consulting fees, costs of research and development activities conducted by third parties on our behalf, laboratory supplies, depreciation, and facilities and overhead costs. We defer and capitalize non-refundable advance payments for research and development activities until the related goods are received or services performed. In circumstances where amounts have been paid in excess of costs incurred, we record a prepaid expense. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record upfront and milestone payments to acquire contractual rights to licensed technology as research and development expenses when incurred if there is uncertainty in our receiving future economic benefit from the acquired contractual rights. We consider future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved by the FDA or when other significant risk factors are abated.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Trial and Preclinical Study Accruals</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We make estimates of our accrued expenses as of each balance sheet date in our condensed consolidated financial statements based on certain facts and circumstances at that time. Our accrued expenses for preclinical studies and clinical trials are based on estimates of costs incurred for services provided by CROs and manufacturing organizations and for other trial-related activities. Payments under our agreements with external service providers depend on a number of factors, such as site initiation, patient screening, enrollment, delivery of reports, and other events. In accruing for these activities, we obtain information from various sources and estimate the level of effort or expense allocated to each period. Adjustments to our research and development expenses may be necessary in future periods as our estimates change. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s0CF378B6AD0454DE92773E105305C16B"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Results of Operations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Comparison of the </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Three Months Ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Three Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,631</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">936</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,018</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,965</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,502</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,053</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other income (expense), net</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(71</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(5,834</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,153</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue was </font><font style="font-family:inherit;font-size:10pt;">$1.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$0.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">. The </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;was due primarily to a $0.8 million increase in research and development activity reimbursable by Servier under the Servier Collaboration Agreement. This increase was partially offset by a $0.1 million decrease in grant revenue recognized in the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">33</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses increased to </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">. The </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;was due primarily to:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased personnel costs of </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">, including share-based compensation, primarily as the result of an increase in research and development headcount to support our research and development activities; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased outsourced manufacturing expense related to our development stage programs of </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased clinical trial expense of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;as our programs advance further into clinical development.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expenses</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses were </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$2.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">.&#160;The </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;in general and administrative expenses was due primarily to:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased consulting and professional fees of </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, primarily related to costs associated with operating as a public company, which included accounting and financial support, board compensation, and investor relation activities;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">decreased legal expense of </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;primarily driven by higher merger related activities in the third quarter of 2016, offset by higher patent filing, prosecution, and enforcement expenses; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased share-based compensation of </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other income (expense), net</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net other income (expense) was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;net income during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;net expense during the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">.&#160;The change in net other income (expense) was due primarily to an increase in interest income earned in 2017 on higher cash and cash equivalent balances.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Comparison of the </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Nine Months Ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-weight:bold;">2016</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,811</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,968</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14,625</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,786</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(8,364</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(4,255</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other expense, net</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(227</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:52px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net loss</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,126</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,300</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Revenue decreased to </font><font style="font-family:inherit;font-size:10pt;">$2.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$3.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;recognized during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">. The </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily due to a </font><font style="font-family:inherit;font-size:10pt;">decrease</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in license revenue recognized under the Servier Collaboration Agreement as prior license payments were fully amortized to revenue in 2016. This decrease in revenue was partially offset by an </font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in grant revenue, which was driven by an increase in grant funded research and development activities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">34</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development Expenses</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development expenses were </font><font style="font-family:inherit;font-size:10pt;">$14.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$9.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">.&#160;The </font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;in research and development expense of </font><font style="font-family:inherit;font-size:10pt;">$4.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was driven primarily by:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased outsourced manufacturing expense of </font><font style="font-family:inherit;font-size:10pt;">$2.4 million</font><font style="font-family:inherit;font-size:10pt;">, primarily related to an increase in outsourced manufacturing activities under our lead program, MRG-106; </font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased personnel costs of </font><font style="font-family:inherit;font-size:10pt;">$2.2 million</font><font style="font-family:inherit;font-size:10pt;">, due primarily to an increase in research and development headcount to support and expand and our research and development capabilities, as well as increased share-based compensation expense; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased other research and development costs of $0.2 million.</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">General and Administrative Expenses</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative expenses were </font><font style="font-family:inherit;font-size:10pt;">$8.4 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$4.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">.&#160;The </font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;in general and administrative expenses of </font><font style="font-family:inherit;font-size:10pt;">$4.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was driven primarily by:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased consulting, professional fees, and board of director compensation charges of $1.8 million, primarily related to costs associated with becoming a public company, which included accounting and financial support, investor relation activities, recruiting, and increased board compensation;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased personnel costs of </font><font style="font-family:inherit;font-size:10pt;">$1.0 million</font><font style="font-family:inherit;font-size:10pt;">, due to an increase in general and administrative headcount as well as an increase in share-based compensation; </font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">increased legal expense of </font><font style="font-family:inherit;font-size:10pt;">$0.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;primarily related to costs associated with and following the Merger, as well as increased costs related to patent filing, prosecution, and enforcement; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">net increase in other general and administrative expenses of $0.5 million.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Other income (expense), net</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net other income (expense) was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;income during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#32;net expense during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">.&#160;The change in net other income (expense) was due primarily to an increase in interest income earned in 2017 on higher cash and cash equivalent balances. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s090F8CC637D15C6B8EC41221FD431689"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Liquidity and Capital Resources</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have no products approved for commercial sale and have not generated any revenue from product sales. We have funded our operations to date principally through proceeds from equity financings of </font><font style="font-family:inherit;font-size:10pt;">$115.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;(including notes payable that previously converted to equity) and proceeds received under the Servier Collaboration Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2017, we entered into the ATM&#160;Agreement with Cowen, under which we may offer and sell, from time to time, at our sole discretion, shares of our common stock having an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;through Cowen as our sales agent. Our&#160;registration statement on Form S-3 (No. 333-217084), as filed on March 31, 2017 and declared effective by the SEC on April 25, 2017, included a prospectus covering the offering of up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;">&#32;of shares of our common stock in accordance with the ATM Agreement. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, we sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;">297,653</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock, at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$9.11</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, for aggregate gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">. Net proceeds received during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were approximately </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, including initial expenses for executing the &#8220;at the market offering&#8221; and commissions to Cowen as sales agent.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since our inception and through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, we have generated cumulative losses of </font><font style="font-family:inherit;font-size:10pt;">$87.2 million</font><font style="font-family:inherit;font-size:10pt;">. Substantially all of our operating losses resulted from expenses incurred in connection with our research and development programs and from general and administrative costs associated with our operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will continue to require substantial additional capital to continue our clinical development and potential commercialization </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">35</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">activities. Accordingly, we will need to raise substantial additional capital to continue to fund our operations. The amount and timing of future funding requirements will depend on many factors, including the pace and results of our clinical development efforts, continued performance under our Servier Collaboration Agreement, securing additional partnerships and collaborations, and issuing debt or other financing vehicles. Our ability to secure capital is dependent upon a number of factors, including success in developing our technology and drug product candidates. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to incur significant expenses and increasing operating losses for at least the next several years as we continue the clinical development of, and seek regulatory approval for, our product candidates and add personnel necessary to operate as a public company with an advanced clinical candidate pipeline of product candidates. In addition, operating as a publicly-traded company involves the hiring of additional financial and other personnel, upgrading financial information systems, and incurring costs associated with operating as a public company. We expect that our operating losses will fluctuate significantly from quarter to quarter and year to year due to timing of clinical development programs and efforts to achieve regulatory approval.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we raise additional funds through the incurrence of indebtedness, the obligations related to such indebtedness could be senior to rights of holders of our capital stock and could contain covenants that may restrict our operations. Should additional capital not be available to us in the near term, or not be available on acceptable terms, we may be unable to realize value from our assets and discharge our liabilities in the normal course of business, which may, among other alternatives, cause us to further delay, substantially reduce, or discontinue operational activities to conserve our cash resources.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;">$42.8 million</font><font style="font-family:inherit;font-size:10pt;">. We believe our current resources will be sufficient to fund our operations in the normal course of business and allow us to meet our liquidity needs through the end of 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Summarized cash flows for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">&#32;are as follows:</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Nine Months Ended<br>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">Change</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="11" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(20,924</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11,468</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(9,456</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by (used in) investing activities</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,068</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,250</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,318</font></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40,557</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">16,081</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">24,476</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net increase in cash and cash equivalents</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">20,701</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,363</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">17,338</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Operating Activities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash used in operating activities was </font><font style="font-family:inherit;font-size:10pt;">$20.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$11.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">.&#160;The </font><font style="font-family:inherit;font-size:10pt;">$9.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;in cash used in operating activities was primarily the result of an </font><font style="font-family:inherit;font-size:10pt;">$8.9 million</font><font style="font-family:inherit;font-size:10pt;">&#32;</font><font style="font-family:inherit;font-size:10pt;">increase</font><font style="font-family:inherit;font-size:10pt;">&#32;in operating expenses during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">. The increase in operating expenses was largely driven by increased research and development expenses as we advanced our programs further into clinical development, increases in legal expense and other professional fees related to the Merger and operating as a public company, and increased personnel costs incurred as we grew our workforce.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Investing Activities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by investing activities was </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;compared to net cash used by investing activities of </font><font style="font-family:inherit;font-size:10pt;">$1.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">.&#160;The </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;">&#32;increase in cash provided by investing activities was primarily the result of the cash acquired in the Merger during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, along with purchases of short-term investments during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">&#32;that did not recur in 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">36</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Financing Activities</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net cash provided by financing activities was </font><font style="font-family:inherit;font-size:10pt;">$40.6 million</font><font style="font-family:inherit;font-size:10pt;">&#32;for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, compared to </font><font style="font-family:inherit;font-size:10pt;">$16.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;during the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">. The increase of </font><font style="font-family:inherit;font-size:10pt;">$24.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;was primarily due to </font><font style="font-family:inherit;font-size:10pt;">$39.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net proceeds received in our Concurrent Financing together with </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net proceeds for sales of our common stock under our ATM Agreement with Cowen, as compared to </font><font style="font-family:inherit;font-size:10pt;">$16.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in net proceeds received in 2016 related to the follow-on sale of Private Miragen&#8217;s Series C preferred stock. This increase was partially offset by </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;">&#32;in principal payments on our notes payable in 2017 that began in the fourth quarter of 2016.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s2D3834D821EF5135A905806653AF23F0"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Commitments and Contingencies</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:2px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had no material commitments other than the liabilities reflected and commitments disclosed in our condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Off-Balance Sheet Arrangements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have not entered into any off-balance sheet arrangements and do not have any holdings in variable interest entities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">The JOBS Act</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2012, the Jumpstart Our Business Startups Act, or the JOBS Act, was enacted. Section 107 of the JOBS Act provides that an emerging growth company can take advantage of an extended transition period for complying with new or revised accounting standards. Thus, an emerging growth company can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies. We have elected to avail ourselves of the extended transition period for adopting new or revised accounting standards. As a result of this election, our financial statements may not be comparable to companies that comply with public company effective dates.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sAC34E1706F75566A87D7C8FD02BFF26B"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s9A29995D65C75EB8941EACDA702486FF"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;4. CONTROLS AND PROCEDURES</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Evaluation of Disclosure Controls and Procedures</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file under the Securities Exchange Act of 1934, as amended, or the Exchange Act, is recorded, processed, summarized, and reported within the time periods specified in the rules and forms of the SEC, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing and evaluating the disclosure controls and procedures, management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management is required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As required by Rule 13a-15(b) and Rule 15d-15(b) of the Exchange Act, an evaluation was carried out under the supervision and with the participation of management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures as of the end of the quarter covered by this report. Based on the foregoing, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at a reasonable level of assurance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Changes in Internal Control Over Financial Reporting</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially effect, our internal control over financial reporting. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37</font></div></div><hr style="page-break-after:always"><div><a name="sBE1BCE32C4AC513D9BBB738E346178C2"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PART II. OTHER INFORMATION</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sBA0F3902369C5D379C9D3349FF99087D"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1. LEGAL PROCEEDINGS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sFDE4F33EE3095BABB204A4463724069A"></a></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;1A. RISK FACTORS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Our business, financial condition, and operating results may be affected by a number of factors, whether currently known or unknown, including but not limited to those described below. Any one or more of such factors could directly or indirectly cause our actual results of operations and financial condition to vary materially from past or anticipated future results of operations and financial condition. Any of these factors, in whole or in part, could materially and adversely affect our business, financial condition, results of operations, and stock price. The following information should be read in conjunction with Part I, Item 2 &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and the condensed consolidated financial statements and related notes in Part I, Item 1, &#8220;Financial Information&#8221; of this Quarterly Report.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Financial Condition and Capital Requirements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have incurred losses since our inception, have a limited operating history on which to assess our business, and anticipate that we will continue to incur significant losses for the foreseeable future.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a clinical development-stage biopharmaceutical company with a limited operating history. We have incurred net losses in each year since Private Miragen&#8217;s inception in 2006.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, net loss was </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$4.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, net loss was </font><font style="font-family:inherit;font-size:10pt;">$20.1 million</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;">$11.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$87.2 million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;">$42.8 million</font><font style="font-family:inherit;font-size:10pt;">. In September 2016, we received $16.1 million in financing through a follow-on sale of Private Miragen&#8217;s Series C preferred stock. Additionally, in February 2017, we received $40.7 million in financing through the Concurrent Financing. As of </font><font style="font-family:inherit;font-size:10pt;">November 7, 2017</font><font style="font-family:inherit;font-size:10pt;">, we have sold, pursuant to the terms of the ATM Agreement, </font><font style="font-family:inherit;font-size:10pt;">700,959</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock, at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$9.42</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, for aggregate gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$6.6 million</font><font style="font-family:inherit;font-size:10pt;">. Net proceeds as of </font><font style="font-family:inherit;font-size:10pt;">November 7, 2017</font><font style="font-family:inherit;font-size:10pt;">&#32;were approximately </font><font style="font-family:inherit;font-size:10pt;">$6.3 million</font><font style="font-family:inherit;font-size:10pt;">, including initial expenses for executing the &#8220;at the market offering&#8221; and commissions to Cowen as sales agent. We believe that we have sufficient capital to fund our operations in the normal course of business and to meet our liquidity needs through the end of 2018.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We will continue to require substantial additional capital to continue our clinical development and potential commercialization activities. Accordingly, we will need to raise substantial additional capital to continue to fund our operations. The amount and timing of our future funding requirements will depend on many factors, including the pace and results of our clinical development efforts. Failure to raise capital as and when needed, on favorable terms or at all, would have a negative impact on our financial condition and our ability to develop our product candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have devoted substantially all of our financial resources to identify, acquire, and develop our product candidates, including conducting clinical trials and providing general and administrative support for our operations. To date, we have financed our operations primarily through the sale of equity securities and convertible promissory notes. The amount of our future net losses will depend, in part, on the rate of our future expenditures and our ability to obtain funding through equity or debt financings, strategic collaborations, or grants. Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We expect our losses to increase as we complete Phase 1 development and advance into Phase 2 development of our lead product candidates. We have not yet commenced pivotal clinical trials for any product candidate and it may be several years, if ever, before we complete pivotal clinical trials or have a product candidate approved for commercialization. We expect to invest significant funds into the research and development of our current product candidates to determine the potential to advance these product candidates to regulatory approval.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we obtain regulatory approval to market a product candidate, our future revenue will depend upon the size of any markets in which our product candidates may receive approval, and our ability to achieve sufficient market acceptance, pricing, reimbursement from third-party payors, and adequate market share for our product candidates in those markets. Even if we obtain adequate market share for our product candidates, because the potential markets in which our product candidates </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">may ultimately receive regulatory approval could be very small, we may never become profitable despite obtaining such market share and acceptance of our products.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future and our expenses will increase substantially if and as we:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue the clinical development of our product candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">continue efforts to discover new product candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">undertake the manufacturing of our product candidates or increase volumes manufactured by third parties;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">advance our programs into larger, more expensive clinical trials;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">initiate additional preclinical, clinical, or other trials or studies for our product candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">seek regulatory and marketing approvals and reimbursement for our product candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:42px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">establish a sales, marketing, and distribution infrastructure to commercialize any products for which we may obtain marketing approval and market for ourselves;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">seek to identify, assess, acquire, and/or develop other product candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">make milestone, royalty, or other payments under third-party license agreements;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">seek to maintain, protect, and expand our intellectual property portfolio;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">seek to attract and retain skilled personnel; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">experience any delays or encounter issues with the development and potential for regulatory approval of our clinical candidates such as safety issues, manufacturing delays, clinical trial accrual delays, longer follow-up for planned studies, additional major studies, or supportive studies necessary to support marketing approval.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, the net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have never generated any revenue from product sales and may never be profitable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have no products approved for commercialization and have never generated any revenue from product sales. Our ability to generate revenue and achieve profitability depends on our ability, alone or with strategic collaborators, to successfully complete the development of, and obtain the regulatory and marketing approvals necessary to commercialize one or more of our product candidates. We do not anticipate generating revenue from product sales for the foreseeable future. Our ability to generate future revenue from product sales depends heavily on our success in many areas, including but not limited to:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">completing research and development of our product candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtaining regulatory and marketing approvals for our product candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">manufacturing product candidates and establishing and maintaining supply and manufacturing relationships with third parties that are commercially feasible, meet regulatory requirements and our supply needs in sufficient quantities to meet market demand for our product candidates, if approved;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">marketing, launching, and commercializing product candidates for which we obtain regulatory and marketing approval, either directly or with a collaborator or distributor;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">gaining market acceptance of our product candidates as treatment options;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">addressing any competing products;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">39</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">protecting and enforcing our intellectual property rights, including patents, trade secrets, and know-how;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">negotiating favorable terms in any collaboration, licensing, or other arrangements into which we may enter;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">obtaining reimbursement or pricing for our product candidates that supports profitability; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">attracting, hiring, and retaining qualified personnel.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if one or more of the product candidates that we develop is approved for commercial sale, we anticipate incurring significant costs associated with commercializing any approved product candidate. Portions of our current pipeline of product candidates have been in-licensed from third parties, which make the commercial sale of such in-licensed products potentially subject to additional royalty and milestone payments to such third parties. We will also have to develop or acquire manufacturing capabilities or continue to contract with contract manufacturers in order to continue development and potential commercialization of our product candidates. For instance, our current costs of manufacturing our drug product are not commercially feasible and we will need to develop or procure our drug product in a commercially feasible manner in order to successfully commercialize any future approved product, if any. Additionally, if we are not able to generate revenue from the sale of any approved products, we may never become profitable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">To the extent that we raise additional capital through the sale of equity, including pursuant to any sales under the ATM Agreement, convertible debt or other securities convertible into equity, the ownership interest of our stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect rights of our stockholders. For instance, as of </font><font style="font-family:inherit;font-size:10pt;">November 7, 2017</font><font style="font-family:inherit;font-size:10pt;">, we have sold, pursuant to the terms of the ATM Agreement, </font><font style="font-family:inherit;font-size:10pt;">700,959</font><font style="font-family:inherit;font-size:10pt;">&#32;shares of our common stock, at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$9.42</font><font style="font-family:inherit;font-size:10pt;">&#32;per share, for aggregate gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$6.6 million</font><font style="font-family:inherit;font-size:10pt;">. We anticipate that we will continue to make sales of our common stock under the ATM Agreement from time to time into the foreseeable future, and we may sell shares of our common stock of up to $50.0 million in aggregate value under the ATM Agreement. Sales under the ATM Agreement dilute the ownership interest of our stockholders and may cause the price per share of our common stock to decrease. Debt financing, if available, would likely involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, making additional product acquisitions, or declaring dividends. For instance, our loan and security agreement with Silicon Valley Bank limits our ability to enter into an asset sale, enter into any change of control, incur additional indebtedness, pay any dividends, or enter into specified transactions with our affiliates. If we raise additional funds through strategic collaborations or licensing arrangements with third parties, we may have to relinquish valuable rights to our product candidates or future revenue streams or grant licenses on terms that are not favorable to us. We cannot be assured that we will be able to obtain additional funding if and when necessary to fund our entire portfolio of product candidates to meet our projected plans. If we are unable to obtain funding on a timely basis, we may be required to delay or discontinue one or more of our development programs or the commercialization of any product candidates or be unable to expand our operations or otherwise capitalize on potential business opportunities, which could materially harm our business, financial condition, and results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have also historically received funds from state and federal government grants for research and development. The grants have been, and any future government grants and contracts we may receive may be, subject to the risks and contingencies set forth below under the risk factor titled &#8220;Reliance on government funding for our programs may add uncertainty to our research and commercialization efforts with respect to those programs that are tied to such funding and may impose requirements that limit our ability to take specified actions, increase the costs of commercialization and production of product candidates developed under those programs and subject us to potential financial penalties, which could materially and adversely affect our business, financial condition, and results of operations.&#8221; Although we might apply for government contracts and grants in the future, we cannot be certain that we will be successful in obtaining additional grants for any product candidates or programs.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to the Development of Our Product Candidates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical trials are costly, time consuming, and inherently risky, and we may fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical development is expensive, time consuming, and involves significant risk. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of development. Events that may prevent successful or timely completion of clinical development include but are not limited to:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">inability to generate satisfactory preclinical, toxicology, or other in vivo or in vitro data or diagnostics to support the initiation or continuation of clinical trials;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in reaching agreement on acceptable terms with CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical trial sites;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in obtaining required institutional review board approval at each clinical trial site;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to permit the conduct of a clinical trial by regulatory authorities, after review of an investigational new drug or equivalent foreign application or amendment;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in recruiting qualified patients in our clinical trials;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure by clinical sites or CROs or other third parties to adhere to clinical trial requirements;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure by our clinical sites, CROs or other third parties to perform in accordance with the good clinical practices requirements of the FDA or applicable foreign regulatory guidelines;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">patients dropping out of our clinical trials;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse events or tolerability or animal toxicology issues significant enough for the FDA or other regulatory agencies to put any or all clinical trials on hold;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">occurrence of adverse events associated with our product candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of clinical trials of our product candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">negative or inconclusive results from our clinical trials, which may result in our deciding, or regulators requiring us, to conduct additional clinical trials or abandon development programs in other ongoing or planned indications for a product candidate; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">delays in reaching agreement on acceptable terms with third-party manufacturers and the time for manufacture of sufficient quantities of our product candidates for use in clinical trials.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any inability to successfully complete clinical development and obtain regulatory approval for our product candidates could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional preclinical trials and the results obtained from such new formulation may not be consistent with previous results obtained. Clinical trial delays could also shorten any periods during which our products have patent protection and may allow competitors to develop and bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">41</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The approach we are taking to discover and develop novel therapeutics that target microRNAs is unproven and may never lead to marketable products.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The scientific discoveries that form the basis for our efforts to discover and develop our product candidates are relatively recent. To date, neither we nor any other company has received regulatory approval to market therapeutics utilizing microRNA-targeted molecules. The scientific evidence to support the feasibility of developing drugs based on these discoveries is both preliminary and limited. Successful development of microRNA-targeted therapeutic products by us will require solving a number of issues, including providing suitable methods of stabilizing the therapeutic product and delivering it into target cells in the human body. In addition, any product candidates that we develop may not demonstrate in patients the chemical and pharmacological properties ascribed to them in laboratory and preclinical trials, and they may interact with human biological systems in unforeseen, ineffective, or even harmful ways. For instance, our clinical and preclinical data to date has not been fully validated and we have no way of knowing if, after validation, our clinical trial data will be complete and consistent. If we do not successfully develop and commercialize product candidates based upon this technological approach, we may not become profitable and the value of our capital stock may decline.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Further, our focus on microRNA technology for developing product candidates as opposed to multiple, more proven technologies for drug development, increases the risk associated with our business. If we are not successful in developing an approved product using microRNA technology, we may not be able to identify and successfully implement an alternative product development strategy. In addition, work by other companies pursuing similar technologies may encounter setbacks and difficulties that regulators and investors may attribute to our product candidates, whether appropriately or not.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our microRNA-targeted therapeutic product candidates are based on a relatively novel technology, which makes it unusually difficult to predict the time and cost of development and the time and cost, or likelihood, of subsequently obtaining regulatory approval. To date, no microRNA-targeted therapeutics have been approved for marketing in the United States.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have concentrated our research and development efforts to date on a limited number of product candidates based on our microRNA-targeted therapeutic platform and identifying our initial targeted disease indications. Our future success depends on our successful development of viable product candidates. Only two of our product candidates, MRG-106 and MRG-201, are in clinical development, and the remainder of our product candidates are in preclinical development. There can be no assurance that we will not experience problems or delays in developing our product candidates and that such problems or delays will not cause unanticipated costs, or that any such development problems can be solved.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, the FDA, the European Medicines Agency, and other regulatory authorities, have relatively limited experience with microRNA-targeted therapeutics. No regulatory authority has granted approval to any person or entity, including us, to market or commercialize microRNA-targeted therapeutics, which may increase the complexity, uncertainty, and length of the regulatory approval process for our product candidates. If our product candidates fail to prove to be safe, effective, or commercially viable, our product candidate pipeline would have little, if any, value, which would have a material adverse effect on our business, financial condition, or results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The clinical trial and manufacturing requirements of the FDA, the European Medicines Agency, and other regulatory authorities, and the criteria these regulators use to determine the safety and efficacy of a product candidate, vary substantially according to the type, complexity, novelty, intended use, and market of the product candidate. The regulatory approval process for novel product candidates such as microRNA-targeted therapeutics can be more expensive and take longer than for other, better known or more extensively studied product candidates. It is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates in either the United States or the European Union or from other agencies, or how long it will take to commercialize our product candidates, even if approved for marketing. Approvals by one regulatory agency may not be indicative of the approval requirements of other regulatory bodies. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product candidate to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations, and prospects may be harmed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">42</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to develop or identify a technology that can effectively deliver MRG-106, MRG-201, or any other of our microRNA-targeted product candidates to the intended diseased cells or tissues, and any failure in such delivery technology could adversely affect and delay the development of MRG-106, MRG-201, and our other product candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with our Phase 1 clinical trials of MRG-106 and MRG-201, we have used intravenous, intralesional, subcutaneous, and intradermal injections as the route of administration. We cannot be certain that these routes of administration will be capable of delivering adequate levels of MRG-106, MRG-201, or our other product candidates to produce a therapeutic response for all indications. While we are continuing to evaluate the use of subcutaneous, intravenous, and intradermal injections in different indications, and additional delivery technologies and routes of administration that might enable us to target specific cells with our product candidates, we cannot be certain whether we will be successful in developing effective delivery mechanisms. Our failure to effectively deliver any of our product candidates to the intended diseased cells or tissues could adversely affect and delay the development of our product candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial viability of an approved label, or result in significant negative consequences following marketing approval, if any.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Undesirable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay, or terminate clinical trials. They additionally may result in a delay of regulatory approval by the FDA or comparable foreign authorities, or, even in the instance that an affected product candidate is approved, may result in a restrictive drug label.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our MRG-106 and MRG-201 product candidates have been studied in only a limited number of patients with a confirmed diagnosis of MF and healthy volunteers, respectively, and the most common adverse events of any grade were injection site reactions, including pain, itchiness, redness, and swelling when compounds were delivered intradermally or subcutaneiously. We have not yet begun any clinical trials of MRG-110 in humans. We may experience a higher rate or severity of adverse events and comparable or higher rates of discontinuation of trial participants in our future clinical trials. There is no guarantee that additional or more severe side effects will not be identified during ongoing or future clinical trials of our product candidates for current and other indications. Undesirable side effects and negative results for other indications may negatively impact the development and potential for approval of our product candidates for their proposed indications.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, even if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, potentially significant negative consequences could result, including but not limited to:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may withdraw approvals of such products;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">regulatory authorities may require additional warnings on the drug label;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may be required to create a Risk Evaluation and Mitigation Strategy, which could include a medication guide outlining the risks of such side effects for distribution to patients, a communication plan for healthcare providers, and/or other elements to assure safe use;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we could be sued and held liable for harm caused to patients; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our reputation may suffer.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, even if approved, and could significantly harm our business, results of operations, and prospects.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our product development program may not uncover all possible adverse events that patients who take MRG-106, MRG-201, or our other product candidates may experience. The number of subjects exposed to MRG-106, MRG-201, or our other product candidates and the average exposure time in the clinical development program may be inadequate to detect rare adverse events that may only be detected once the product is administered to more patients and for greater periods of time.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">43</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical trials by their nature utilize a sample of the potential patient population. However, with a limited number of subjects and limited duration of exposure, we cannot be fully assured that rare and severe side effects of MRG-106, MRG-201, or our other product candidates will be uncovered. Such rare and severe side effects may only be uncovered with a significantly larger number of patients exposed to the drug. If such safety problems occur or are identified after MRG-106, MRG-201, or another product candidate reaches the market, the FDA may require that we amend the labeling of the product or recall the product or may even withdraw approval for the product.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our microRNA-targeted therapeutic approach is novel. Negative public opinion and increased regulatory scrutiny of microRNA or other nucleic acid-based therapies may damage public perception of the safety of our product candidates and adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">MicroRNA therapy remains a novel technology, with no microRNA-targeted therapeutic product approved to date in the United States. Public perception may be influenced by claims that microRNA therapy is unsafe, and microRNA therapy may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians who specialize in the treatment of the diseases targeted by our product candidates, prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are familiar and for which greater clinical data may be available. More restrictive government regulations or negative public opinion regarding microRNA or other nucleic acid-based therapeutics could have an adverse effect on our business, financial condition, or results of operations and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. Serious adverse events in microRNA clinical trials for our competitors&#8217; products, even if not ultimately attributable to the relevant product candidates, and the resulting publicity, could result in increased government regulation, unfavorable public perception, potential regulatory delays in the testing or approval of our product candidates, stricter labeling requirements for those product candidates that are approved, and a decrease in demand for any such product candidates. For instance, in June 2016, the FDA placed a regulatory hold on the clinical trial of a microRNA- or nucleic acid-focused biopharmaceutical company with a microRNA-targeted product candidate for the treatment of hepatitis C virus due to serious adverse events in that trial. Another microRNA-focused biopharmaceutical company also voluntarily halted an ongoing Phase 1 clinical trial for a microRNA-targeted therapy for multiple cancers in September 2016 due to multiple immune-related severe adverse events. We cannot predict what effect, if any, these clinical holds will have on the government and public perception of our product candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We are heavily dependent on the success of our product candidates, which are in the early stages of clinical development. Some of our product candidates have produced results only in preclinical settings, or for other indications than those for which we contemplate conducting development and seeking FDA approval, and we cannot give any assurance that we will generate data for any of our product candidates sufficiently supportive to receive regulatory approval in our planned indications, which will be required before they can be commercialized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have invested substantially all of our effort and financial resources to identify, acquire, and develop our portfolio of product candidates. Our future success is dependent on our ability to successfully further develop, obtain regulatory approval for, and commercialize one or more product candidates. We currently generate no revenue from sales of any products, and we may never be able to develop or commercialize a product candidate.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have two product candidates in Phase 1 clinical trials. Of these product candidates, MRG-106 has been predominantly administered in patients with MF. This is only one of the multiple indications for which we plan to develop this product candidate. Additionally, our clinical and preclinical data to date is not validated, and we have no way of knowing if after validation our clinical trial data will be complete and consistent. There can be no assurance that the data that we develop for our product candidates in our planned indications will be sufficiently supportive to obtain regulatory approval.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, none of our product candidates have advanced into a pivotal clinical trial for our proposed indications, and it may be years before any such clinical trial is initiated and completed, if at all. We are not permitted to market or promote any of our product candidates before we receive regulatory approval from the FDA or comparable foreign regulatory authorities, and we may never receive such regulatory approval for any of our product candidates. We cannot be certain that any of our product candidates will be successful in clinical trials or receive regulatory approval. Further, our product candidates may not receive regulatory approval even if they are successful in clinical trials. If we do not receive regulatory approvals for our product candidates, we may not be able to continue our operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Product development involves a lengthy and expensive process with an uncertain outcome, and results of earlier preclinical and clinical trials may not be predictive of future clinical trial results.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Clinical testing is expensive and generally takes many years to complete, and the outcome is inherently uncertain. Failure can </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">occur at any time during the clinical trial process. Additionally, microRNAs are a new class of drug target and as such may have some potentially unknown risks from both an efficacy and safety perspective. The results of preclinical trials and early clinical trials of our product candidates may not be predictive of the results of larger, later-stage controlled clinical trials. Product candidates that have shown promising results in early-stage clinical trials may still suffer significant setbacks in subsequent clinical trials. Our clinical trials to date have been conducted on a small number of patients or healthy volunteers in limited numbers of clinical sites for a limited number of indications. We will have to conduct larger, well-controlled trials in our proposed indications to verify the results obtained to date and to support any regulatory submissions for further clinical development. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles despite promising results in earlier, smaller clinical trials. For instance, in June 2016, the FDA placed a regulatory hold on the clinical trial of a microRNA-focused biopharmaceutical company with a microRNA product candidate for the treatment of hepatitis C virus due to serious adverse events in that trial. Another microRNA-focused biopharmaceutical company also voluntarily halted an ongoing Phase 1 clinical trial for a microRNA therapy for multiple cancers in September 2016 due to multiple immune-related severe adverse events. Moreover, clinical data are often susceptible to varying interpretations and analyses. We do not know whether any Phase 2, Phase 3, or other clinical trials we may conduct will demonstrate consistent or adequate efficacy and safety with respect to the proposed indication for use sufficient to receive regulatory approval or market our drug candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may use our financial and human resources to pursue a particular research program or product candidate and fail to capitalize on programs or product candidates that may be more profitable or for which there is a greater likelihood of success.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because we have limited financial and human resources, we may forego or delay pursuit of opportunities with some programs or product candidates or for other indications that later prove to have greater commercial potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or more profitable market opportunities. Our spending on current and future research and development programs and future product candidates for specific indications may not yield any commercially viable products. We may also enter into additional strategic collaboration agreements to develop and commercialize some of our programs and potential product candidates in indications with potentially large commercial markets. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through strategic collaborations, licensing, or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate, or we may allocate internal resources to a product candidate in a therapeutic area in which it would have been more advantageous to enter into a partnering arrangement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may find it difficult to enroll patients in our clinical trials given the limited number of patients who have the diseases for which our product candidates are being studied. Difficulty in enrolling patients could delay or prevent clinical trials of our product candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Identifying and qualifying patients to participate in clinical trials of our product candidates is essential to our success. The timing of our clinical trials depends in part on the rate at which we can recruit patients to participate in clinical trials of our product candidates, and we may experience delays in our clinical trials if we encounter difficulties in enrollment.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The eligibility criteria of our planned clinical trials may further limit the available eligible trial participants as we expect to require that patients have specific characteristics that we can measure or meet the criteria to assure their conditions are appropriate for inclusion in our clinical trials. For instance, our Phase 1 clinical trial of MRG-106 includes patients with MF. The estimated prevalence of MF is 16,000 to 20,000 cases in the United States and only a subset of this group satisfies the enrollment criteria for our MRG-106 clinical trial. We may not be able to identify, recruit, and enroll a sufficient number of patients to complete our clinical trials in a timely manner because of the perceived risks and benefits of the product candidate under study, the availability and efficacy of competing therapies and clinical trials, and the willingness of physicians to participate in our planned clinical trials. If patients are unwilling to participate in our clinical trials for any reason, the timeline for conducting trials and obtaining regulatory approval of our product candidates may be delayed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we experience delays in the completion of, or termination of, any clinical trials of our product candidates, the commercial prospects of our product candidates could be harmed, and our ability to generate product revenue from any of these product candidates could be delayed or prevented. In addition, any delays in completing our clinical trials would likely increase our overall costs, impair product candidate development, and jeopardize our ability to obtain regulatory approval relative to our current plans. Any of these occurrences may harm our business, financial condition, and prospects significantly.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may face potential product liability, and, if successful claims are brought against us, we may incur substantial liability and costs. If the use or misuse of our approved products, if any, or product candidates harms patients, or is perceived to </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">harm patients even when such harm is unrelated to our approved products, if any, or product candidates, our regulatory approvals, if any, could be revoked or otherwise negatively impacted, and we could be subject to costly and damaging product liability claims. If we are unable to obtain adequate insurance or are required to pay for liabilities resulting from a claim excluded from, or beyond the limits of, our insurance coverage, a material liability claim could adversely affect our financial condition.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The use or misuse of our product candidates in clinical trials and the sale of any products for which we may obtain marketing approval exposes us to the risk of potential product liability claims. Product liability claims might be brought against us by consumers, healthcare providers, pharmaceutical companies, or others selling or otherwise coming into contact with our product candidates and approved products, if any. There is a risk that our product candidates may induce adverse events. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs. Some of our microRNA-targeted therapeutics have shown adverse events in clinical trials, including injection site reactions and pain at the injection site, erythema, nausea, diarrhea, decreased white blood cell and platelet counts, neutropenia, elevated aspartate aminotransferase, alanine aminotransferase, uric acid, and creatine kinase levels, prolonged partial thromboplastin time, blurred vision, itchiness, fatigue, headache, and microscopic hematuria, among others. In almost all cases, these events were mild to moderate and self-limited. There is a risk that our future product candidates may induce similar or more severe adverse events. Patients with the diseases targeted by our product candidates may already be in severe and advanced stages of disease and have both known and unknown significant preexisting and potentially life-threatening health risks. During the course of treatment, patients may suffer adverse events, including death, for reasons that may be related to our product candidates. Such events could subject us to costly litigation, require us to pay substantial amounts of money to injured patients, delay, negatively impact, or end our opportunity to receive or maintain regulatory approval to market our products, or require us to suspend or abandon our commercialization efforts. Even in a circumstance in which an adverse event is unrelated to our product candidates, the investigation into the circumstance may be time-consuming or inconclusive. These investigations may delay our regulatory approval process or impact and limit the type of regulatory approvals our product candidates receive or maintain.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of these factors, a product liability claim, even if successfully defended, could have a material adverse effect on our business, financial condition, or results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we have product liability insurance, which covers our clinical trials in the United States, for up to $5.0 million per occurrence, up to an aggregate limit of $5.0 million, our insurance may be insufficient to reimburse us for any expenses or losses we may suffer. We will also likely be required to increase our product liability insurance coverage for the advanced clinical trials that we plan to initiate. If we obtain marketing approval for any of our product candidates, we will need to expand our insurance coverage to include the sale of commercial products. There is no way to know if we will be able to continue to obtain product liability coverage and obtain expanded coverage, if we require it, in sufficient amounts to protect us against losses due to liability, on acceptable terms, or at all. We may not have sufficient resources to pay for any liabilities resulting from a claim excluded from, or beyond the limits of, our insurance coverage. Where we have provided indemnities in favor of third parties under our agreements with them, there is also a risk that these third parties could incur liability and bring a claim under such indemnities. An individual may bring a product liability claim against us alleging that one of our product candidates causes, or is claimed to have caused, an injury or is found to be unsuitable for consumer use. Any such product liability claims may include allegations of defects in manufacturing, defects in design, failure to warn of dangers inherent in the product, negligence, strict liability, and a breach of warranties. Claims could also be asserted under state consumer protection acts. Any product liability claim brought against us, with or without merit, could result in:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">withdrawal of clinical trial volunteers, investigators, patients or trial sites, or limitations on approved indications;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the inability to commercialize, or if commercialized, decreased demand for, our product candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if commercialized, product recalls, labeling, marketing or promotional restrictions, or the need for product modification;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">initiation of investigations by regulators;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">loss of revenues;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">substantial costs of litigation, including monetary awards to patients or other claimants;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">liabilities that substantially exceed our product liability insurance, which we would then be required to pay ourselves;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">46</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">an increase in our product liability insurance rates or the inability to maintain insurance coverage in the future on acceptable terms, if at all;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the diversion of management&#8217;s attention from our business; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">damage to our reputation and the reputation of our products and our technology.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product liability claims may subject us to the foregoing and other risks, which could have a material adverse effect on our business, financial condition, or results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Regulatory Approval of Our Product Candidates and Other Legal Compliance Matters</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">A potential breakthrough therapy designation by the FDA for our product candidates may not lead to a faster development or regulatory review or approval process, and it does not increase the likelihood that our product candidates will receive marketing approval.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may seek a breakthrough therapy designation from the FDA for some of our product candidates. A breakthrough therapy is defined as a drug or biological product that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug or biological product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs or biological products that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA could also be eligible for accelerated approval.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Designation as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe one of our product candidates meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a faster development process, review, or approval compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify and are designated as breakthrough therapies, the FDA may later decide that the drugs or biological products no longer meet the conditions for designation and the designation may be rescinded.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may seek Fast Track designation for one or more of our product candidates, but we might not receive such designation, and even if we do, such designation may not actually lead to a faster development or regulatory review or approval process.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a product candidate is intended for the treatment of a serious condition and nonclinical or clinical data demonstrate the potential to address unmet medical need for this condition, a product sponsor may apply for FDA Fast Track designation. If we seek Fast Track designation for a product candidate, we may not receive it from the FDA. However, even if we receive Fast Track designation, Fast Track designation does not ensure that we will receive marketing approval or that approval will be granted within any particular timeframe. We may not experience a faster development or regulatory review or approval process with Fast Track designation compared to conventional FDA procedures. In addition, the FDA may withdraw Fast Track designation if it believes that the designation is no longer supported by data from our clinical development program. Fast Track designation alone does not guarantee qualification for the FDA&#8217;s priority review procedures.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Even if we obtain regulatory approval for a product, we will remain subject to ongoing regulatory requirements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of our product candidates are approved, we will be subject to ongoing regulatory requirements with respect to manufacturing, labeling, packaging, storage, advertising, promotion, sampling, record-keeping, conduct of post-marketing clinical trials, and submission of safety, efficacy, and other post-approval information, including both federal and state requirements in the United States, and requirements of comparable foreign regulatory authorities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturers and manufacturers&#8217; facilities are required to continuously comply with FDA and comparable foreign regulatory authority requirements, including ensuring that quality control and manufacturing procedures conform to current Good Manufacturing Practices, or cGMP, regulations and corresponding foreign regulatory manufacturing requirements. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMP and adherence to commitments made in any new drug application or marketing authorization application.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any regulatory approvals that we receive for our product candidates may be subject to limitations on the approved indicated uses for which the product candidate may be marketed or to the conditions of approval, or contain requirements for potentially costly post-marketing testing, including Phase 4 clinical trials, and surveillance to monitor the safety and efficacy of the product candidate. We will be required to report adverse reactions and production problems, if any, to the FDA and comparable foreign regulatory authorities. Any new legislation addressing drug safety issues could result in delays in product development or commercialization, or increased costs to assure compliance. If our original marketing approval for a product candidate was obtained through an accelerated approval pathway, we could be required to conduct a successful post-marketing clinical trial in order to confirm the clinical benefit for our products. An unsuccessful post-marketing clinical trial or failure to complete such a trial could result in the withdrawal of marketing approval.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or disagrees with the promotion, marketing or labeling of a product, the regulatory agency may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If we fail to comply with applicable regulatory requirements, a regulatory agency or enforcement authority may, among other things:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">issue warning letters;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">impose civil or criminal penalties;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspend or withdraw regulatory approval;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspend any of our ongoing clinical trials;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">refuse to approve pending applications or supplements to approved applications submitted by us;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">impose restrictions on our operations, including closing our contract manufacturers&#8217; facilities; or</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">require a product recall.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any government investigation of alleged violations of law would be expected to require us to expend significant time and resources in response and could generate adverse publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to develop and commercialize our products, and the value of the company and our operating results would be adversely affected.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Healthcare legislative reform measures may have a material adverse effect on our business, financial condition, or results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. For example, in March 2010, the Affordable Care Act was passed, which substantially changes the way healthcare is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The Affordable Care Act, among other things, addresses a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected, increases the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program and extends the rebate program to individuals enrolled in Medicaid managed care organizations, establishes annual fees and taxes on manufacturers of specified branded prescription drugs, and promotes a new Medicare Part D coverage gap discount program.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Since its enactment, certain aspects of the Affordable Care Act have faced Congressional and Judicial challenges. On January 20, 2017, President Trump signed an Executive Order directing federal agencies with authorities and responsibilities under the Affordable Care Act to waive, defer, grant exemptions from, or delay the implementation of any provision of the Affordable Care Act that would impose a fiscal or regulatory burden on states, individuals, healthcare providers, health insurers, or manufacturers of pharmaceuticals or medical devices. Congress is currently considering, and could consider in the future, legislation to replace the Affordable Care Act or elements thereof. We cannot predict how the Affordable Care Act, its possible repeal, or any legislation Congress passes to replace the Affordable Care Act will affect our business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted, and we expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand or lower pricing for our product candidates or additional pricing pressures.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">48</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and health information privacy and security laws. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we obtain FDA approval for any of our product candidates and begin commercializing those products in the United States, our operations may be subject to various federal and state fraud and abuse laws, including, without limitation, the federal Anti-Kickback Statute, the federal False Claims Act, and Physician Payments Sunshine Act, and regulations. These laws may impact, among other things, our relationships with principal investigators and consultants and our proposed sales, marketing, and education programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our ability to operate include:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal Anti-Kickback Statute, which prohibits, among other things, persons from knowingly and willfully soliciting, receiving, offering, or paying remuneration, directly or indirectly, to induce, or in return for, the purchase or recommendation of an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">federal civil and criminal false claims laws and civil monetary penalties law, which prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, claims for payment from Medicare, Medicaid, or other third-party payors that are false or fraudulent;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created new federal criminal statutes that prohibit, among other things, executing a scheme to defraud any healthcare benefit program and making false statements relating to healthcare matters;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and their implementing regulations, which imposes specified obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security, and transmission of individually identifiable health information without the appropriate authorization, on entities subject to the law, such as healthcare providers, health plans, and healthcare clearinghouses and their respective business associates that perform services for them that involve the creation, use, maintenance, or disclosure of individually identifiable health information;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the federal Physician Payment Sunshine Act under the Affordable Care Act requires manufacturers of drugs, devices, biologics, and medical supplies to report annually to the U.S. Department of Health and Human Services information related to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers, as well as their immediate family members and applicable group purchasing organizations; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws that may apply to items or services reimbursed by any third-party payor, including governmental and private payors, to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws that require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures, and state laws governing the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of our business activities could be subject to challenge under one or more of such laws. In addition, recent healthcare reform legislation has strengthened these laws. For example, the Affordable Care Act, among other things, amends the intent requirement of the federal Anti-Kickback Statute and criminal healthcare fraud statutes, such that a person or entity no longer needs to have actual knowledge of the statute or specific intent to violate the law. Moreover, the Affordable Care Act provides that the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the False Claims Act.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our operations are found to be in violation of any of the laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including civil and criminal penalties, disgorgement, damages, fines, contractual damages, reputational harm, diminished profits and future earnings, exclusion from participation in government healthcare programs, such as Medicare and Medicaid, including imprisonment, additional reporting requirements and/or oversight if we </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">49</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Reliance on government funding for our programs may add uncertainty to our research and commercialization efforts with respect to those programs that are tied to such funding and may impose requirements that limit our ability to take specified actions, increase the costs of commercialization and production of product candidates developed under those programs and subject us to potential financial penalties, which could materially and adversely affect our business, financial condition, and results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the course of our development of our product candidates, we have been funded in part through federal and state grants, including but not limited to the funding we received from Yale pursuant to a subcontract agreement with Yale. In addition to the funding we have received to date, we have applied and intend to continue to apply for federal and state grants to receive additional funding in the future. Contracts and grants funded by the U.S. government, state governments and their related agencies include provisions that reflect the government&#8217;s substantial rights and remedies, many of which are not typically found in commercial contracts, including powers of the government to:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">require repayment of all or a portion of the grant proceeds, in specified cases with interest, in the event we violate specified covenants pertaining to various matters that include a failure to achieve;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">specify milestones or terms relating to use of grant proceeds, or to comply with specified laws;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">terminate agreements, in whole or in part, for any reason or no reason;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">reduce or modify the government&#8217;s obligations under such agreements without the consent of the other party;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">claim rights, including intellectual property rights, in products and data developed under such agreements;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">audit contract related costs and fees, including allocated indirect costs;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspend the contractor or grantee from receiving new contracts pending resolution of alleged violations of procurement laws or regulations;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">impose U.S. manufacturing requirements for products that embody inventions conceived or first reduced to practice under such agreements;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">impose qualifications for the engagement of manufacturers, suppliers, and other contractors as well as other criteria for reimbursements;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">suspend or debar the contractor or grantee from doing future business with the government;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">control and potentially prohibit the export of products;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">pursue criminal or civil remedies under the False Claims Act, False Statements Act, and similar remedy provisions specific to government agreements; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">limit the government&#8217;s financial liability to amounts appropriated by the U.S. Congress on a fiscal year basis, thereby leaving some uncertainty about the future availability of funding for a program even after we have been funded for an initial period.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to those powers set forth above, the government funding we may receive could also impose requirements to make payments based upon sales of our products, if any, in the future.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may not have the right to prohibit the U.S. government from using specified technologies developed by it, and we may not be able to prohibit third-party companies, including our competitors, from using those technologies in providing products and services to the U.S. government. The U.S. government generally takes the position that we have the right to royalty-free use of technologies that are developed under U.S. government contracts. These and other provisions of government grants may also apply to intellectual property we license now or in the future.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">50</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, government contracts and grants normally contain additional requirements that may increase our costs of doing business, reduce our profits, and expose us to liability for failure to comply with these terms and conditions. These requirements include, for example:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">specialized accounting systems unique to government contracts and grants;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">mandatory financial audits and potential liability for price adjustments or recoupment of government funds after such funds have been spent;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">public disclosures of some contract and grant information, which may enable competitors to gain insights into our research program; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">mandatory socioeconomic compliance requirements, including labor standards, non-discrimination and affirmative action programs, and environmental compliance requirements.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we fail to maintain compliance with any such requirements that may apply to us now or in the future, we may be subject to potential liability and to termination of our contracts.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business, financial condition, or results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our research and development activities and our third-party manufacturers&#8217; and suppliers&#8217; activities involve the controlled storage, use, and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds. We and our manufacturers and suppliers are subject to laws and regulations governing the use, manufacture, storage, handling, and disposal of these hazardous materials. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#8217; facilities pending their use and disposal. We cannot eliminate the risk of contamination, which could cause an interruption of our commercialization efforts, research and development efforts, and business operations, and cause environmental damage resulting in costly clean-up and liabilities under applicable laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products. Although we believe that the safety procedures utilized by us and our third-party manufacturers for handling and disposing of these materials generally comply with the standards prescribed by these laws and regulations, we cannot guarantee that this is the case or eliminate the risk of accidental contamination or injury from these materials. In such an event, we may be held liable for any resulting damages and such liability could exceed our resources, and state or federal or other applicable authorities may curtail our use of specified materials and/or interrupt our business operations. Furthermore, environmental laws and regulations are complex, change frequently, and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. We do not currently carry biological or hazardous waste insurance coverage.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Intellectual Property</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be successful in obtaining or maintaining necessary rights to microRNA targets, product compounds and processes for our development pipeline through acquisitions and in-licenses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Presently, we have rights to the intellectual property, through licenses from third parties and under patents and patent applications that we own, to modulate only a subset of the known microRNA targets. Because our programs may involve a range of microRNA targets, including targets that require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license, or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For example, we have previously collaborated and may continue to collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide an option to negotiate a license to any of the institution&#8217;s rights in technology resulting from the collaboration. Regardless of such right of first negotiation for intellectual property, we may be unable to negotiate a license </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">within the specified time frame or under terms that are acceptable to it. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment. If we are unable to successfully obtain rights to third-party intellectual property rights, our business, financial condition, and prospects for growth could suffer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We intend to rely on patent rights for our product candidates and any future product candidates. If we are unable to obtain or maintain exclusivity from the combination of these approaches, we may not be able to compete effectively in our markets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We rely or will rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect the intellectual property related to our technologies and product candidates. Our success depends in large part on our and our licensors&#8217; ability to obtain regulatory exclusivity and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary technology and products.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates that are important to our business. This process is expensive and time consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain unsolved. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our product candidates, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found unenforceable, or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We, independently or together with our licensors, have filed several patent applications covering various aspects of our product candidates. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent, or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we cannot obtain and maintain effective protection of exclusivity from our regulatory efforts and intellectual property rights, including patent protection or data exclusivity, for our product candidates, we may not be able to compete effectively and our business and results of operations would be harmed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not have sufficient patent term protections for our product candidates to effectively protect our business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patents have a limited term. In the United States, the statutory expiration of a patent is generally 20 years after it is filed. Additional patent terms may be available through a patent term adjustment process, resulting from the United States Patent and Trademark Office, or USPTO, delays during prosecution. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product candidate, we may be open to competition from generic medications.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Patent term extensions under the Hatch-Waxman Act in the United States and under supplementary protection certificates in Europe may be available to extend the patent or data exclusivity terms of our product candidates. We will likely rely on patent term extensions, and we cannot provide any assurances that any such patent term extensions will be obtained and, if so, for how long. As a result, we may not be able to maintain exclusivity for our product candidates for an extended period after regulatory approval, if any, which would negatively impact our business, financial condition, results of operations, and </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">52</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">prospects. If we do not have sufficient patent terms or regulatory exclusivity to protect our product candidates, our business and results of operations will be adversely affected.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products, and recent patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As is the case with other biotechnology companies, our success is heavily dependent on patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and is therefore costly, time-consuming, and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in specified circumstances and weakened the rights of patent owners in specified situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The USPTO has issued subject matter eligibility guidance to patent examiners instructing USPTO examiners on the ramifications of the Supreme Court rulings in </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Mayo Collaborative Services v. Prometheus Laboratories, Inc.</font><font style="font-family:inherit;font-size:10pt;">&#32;and </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Association for Molecular Pathology v. Myriad Genetics, Inc., </font><font style="font-family:inherit;font-size:10pt;">and applied the Myriad ruling to natural products and principles including all naturally occurring nucleic acids. In addition, the USPTO continues to provide updates to its guidance and this is a developing area. The USPTO guidance may make it impossible for us to pursue similar patent claims in patent applications we may prosecute in the future.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our patent portfolio contains claims of various types and scope, including chemically modified mimics, inhibitors, as well as methods of medical treatment. The presence of varying claims in our patent portfolio significantly reduces, but may not eliminate, our exposure to potential validity challenges.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For our U.S. patent applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law. These include provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The USPTO has promulgated regulations and developed procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, did not come into effect until March 16, 2013. Accordingly, it is not yet clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, or results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">An important change introduced by the Leahy-Smith Act is that, as of March 16, 2013, the United States transitioned to a &#8220;first-to-file&#8221; system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. This will require us to be cognizant going forward of the time from invention to filing of a patent application. Furthermore, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our technology and the prior art allow our technology to be patentable over the prior art. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that we were the first to either (i) file any patent application related to our product candidates or (ii) invent any of the inventions claimed in our patents or patent applications.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Among some of the other changes introduced by the Leahy-Smith Act are changes that limit where a patentee may file a patent infringement suit and new procedures providing opportunities for third parties to challenge any issued patent in the USPTO. Included in these new procedures is a process known as Inter Partes Review, or IPR, which has been generally used by many third parties over the past four years to invalidate patents. The IPR process is not limited to patents filed after the Leahy-Smith Act was enacted, and would therefore be available to a third party seeking to invalidate any of our U.S. patents, even those issued before March 16, 2013. Because of a lower evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal court necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action. Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. Additionally, the rights of review and appeal for IPR decisions is an area of law that is </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">53</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">still developing.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we are unable to maintain effective proprietary rights for our product candidates or any future product candidates, we may not be able to compete effectively in our proposed markets.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information, or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations, and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors, and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed, or that our trade secrets and other confidential proprietary information will not be disclosed, or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business, financial condition, or results of operations. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our commercial success depends in part on our ability to develop, manufacture, market, and sell our product candidates and use our proprietary technology without infringing the patent rights of third parties. Numerous third-party U.S. and non-U.S. issued patents and pending applications exist in the area of microRNA. We are aware of U.S. and foreign patents and pending patent applications owned by third parties that cover therapeutic uses of microRNA replacements and inhibitors. From time to time, we may also monitor these patents and patent applications. We may in the future pursue available proceedings in the U.S. and foreign patent offices to challenge the validity of these patents and patent applications. In addition, or alternatively, we may consider whether to seek to negotiate a license of rights to technology covered by one or more of such patents and patent applications. If any patents or patent applications cover our product candidates or technologies, we may not be free to manufacture or market our product candidates, including MRG-106 or MRG-201, as planned, absent such a license, which may not be available to us on commercially reasonable terms, or at all.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">It is also possible that we have failed to identify relevant third-party patents or applications. For example, applications filed before November 29, 2000 and applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Moreover, it is difficult for industry participants, including us, to identify all third-party patent rights that may be relevant to our product candidates and technologies because patent searching is imperfect due to differences in terminology among patents, incomplete databases, and the difficulty in assessing the meaning of patent claims. We may fail to identify relevant patents or patent applications or may identify pending patent applications of potential interest but incorrectly predict the likelihood that such patent applications may issue with claims of relevance to our technology. In addition, we may be unaware of one or more issued patents that would be infringed by the manufacture, sale, or use of a current or future product candidate, or we may incorrectly conclude that a third-party patent is invalid, unenforceable, or not infringed by our activities. Additionally, pending patent applications that have been published can, subject to specified limitations, be later amended in a manner that could cover our technologies, our product candidates, or the use of our product candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits in federal courts, and interferences, oppositions, inter partes reviews, post-grant reviews, and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign-issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">54</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">infringement of the patent rights of third parties.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#8217; fees for willful infringement, pay royalties, redesign our infringing products, or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be successful in meeting our obligations under our existing license agreements necessary to maintain our product candidate licenses in effect. In addition, if required in order to commercialize our product candidates, we may be unsuccessful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We currently have rights to the intellectual property, through licenses from third parties and under patents that we do not own, to develop and commercialize our product candidates. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to maintain in effect these proprietary rights. Any termination of license agreements with third parties with respect to our product candidates would be expected to negatively impact our business prospects.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for our product candidates. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. Even if we are able to license or acquire third-party intellectual property rights that are necessary for our product candidates, there can be no assurance that they will be available on favorable terms.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We collaborate with U.S. and foreign academic institutions to identify product candidates, accelerate our research, and conduct development. Typically, these institutions have provided us with an option to negotiate an exclusive license to any of the institution&#8217;s rights in the patents or other intellectual property resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue a program of interest to us.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are unable to successfully obtain and maintain rights to required third-party intellectual property, we may have to abandon development of that product candidate or pay additional amounts to the third party, and our business and financial condition could suffer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The patent protection and patent prosecution for some of our product candidates is dependent on third parties.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">While we normally seek and gain the right to fully prosecute the patents relating to our product candidates, there may be times when patents relating to our product candidates are controlled by our licensors. For instance, this is the case with our agreement with Santaris Pharma A/S, which subsequently changed its name to Roche Innovation Center Copenhagen A/S, or RICC, who is primarily responsible for the prosecution of patents and patent applications licensed to us under the applicable agreement. If RICC or any of our future licensors fail to appropriately and broadly prosecute and maintain patent protection for patents covering any of our product candidates, our ability to develop and commercialize those product candidates may be adversely affected, and we may not be able to prevent competitors from making, using, importing, and selling competing products. In addition, even where we now have the right to control patent prosecution of patents and patent applications we have licensed from third parties, we may still be adversely affected or prejudiced by actions or inactions of our licensors in effect from actions prior to us assuming control over patent prosecution.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to comply with obligations in the agreements under which we license intellectual property and other rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are a party to a number of intellectual property license and supply agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing agreements impose, and we expect that future </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">55</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">license agreements will impose, various diligence, milestone payments, royalties, purchasing, and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, our agreements may be subject to termination by the licensor, in which event we would not be able to develop, manufacture, or market products covered by the license or subject to supply commitments.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Competitors may infringe our patents or the patents of our licensors. If we or one of our licensing partners were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description, clarity, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to us from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring our product candidates to market.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we have written agreements and make every effort to ensure that our employees, consultants, and independent contractors do not use the proprietary information or intellectual property rights of others in their work for us, we may in the future be subject to any claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be able to protect our intellectual property rights throughout the world.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop our own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">56</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of some countries, particularly some developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally.</font></div><div style="line-height:120%;text-align:left;padding-left:9px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Reliance on Third Parties</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely on third parties to conduct our clinical trials, manufacture our product candidates, and perform other services. If these third parties do not successfully perform and comply with regulatory requirements, we may not be able to successfully complete clinical development, obtain regulatory approval, or commercialize our product candidates and our business could be substantially harmed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We have relied upon and plan to continue to rely upon third-party CROs to conduct, monitor, and manage our ongoing clinical programs. We rely on these parties for execution of clinical trials, and we manage and control only some aspects of their activities. We remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol, legal, regulatory, and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities. We and our CROs and other vendors are required to comply with all applicable laws, regulations, and guidelines, including those required by the FDA and comparable foreign regulatory authorities for all of our product candidates in clinical development. If we or any of our CROs or vendors fail to comply with applicable laws, regulations, and guidelines, the results generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot be assured that our CROs and other vendors will meet these requirements, or that upon inspection by any regulatory authority, such regulatory authority will determine that efforts, including any of our clinical trials, comply with applicable requirements. Our failure to comply with these laws, regulations, and guidelines may require us to repeat clinical trials, which would be costly and delay the regulatory approval process.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of our relationships with these third-party CROs terminate, we may not be able to enter into arrangements with alternative CROs in a timely manner or do so on commercially reasonable terms. In addition, our CROs may not prioritize our clinical trials relative to those of other customers, and any turnover in personnel or delays in the allocation of CRO employees by the CRO may negatively affect our clinical trials. If CROs do not successfully carry out their contractual duties or obligations or meet expected deadlines, our clinical trials may be delayed or terminated, and we may not be able to meet our current plans with respect to our product candidates. CROs may also involve higher costs than anticipated, which could negatively affect our financial condition and operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, we do not currently have, nor do we currently plan to establish, the capability to manufacture product candidates for use in the conduct of our clinical trials, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale without the use of third-party manufacturers. We plan to rely on third-party manufacturers and their responsibilities will include purchasing from third-party suppliers the materials necessary to produce our product candidates for our clinical trials and regulatory approval. There are expected to be a limited number of suppliers for the active ingredients and other materials that we expect to use to manufacture our product candidates, and we may not be able to identify alternative suppliers to prevent a possible disruption of the manufacture of our product candidates for our clinical trials, and, if approved, ultimately for commercial sale. Although we generally do not expect to begin a clinical trial unless we believe we have a sufficient supply of a product candidate to complete the trial, any significant delay or discontinuity in the supply of a product candidate, or the active ingredient or other material components in the manufacture of the product candidate, could delay completion of our clinical trials and potential timing for regulatory approval of our product candidates, which would harm our business and results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We rely and expect to continue to rely on third parties to manufacture our clinical product supplies, and we intend to rely on third parties to produce and process our product candidates, if approved, and our commercialization of any of our product candidates could be stopped, delayed, or made less profitable if those third parties fail to obtain approval of government regulators, fail to provide us with sufficient quantities of drug product, or fail to do so at acceptable quality </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">57</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">levels or prices.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not currently have nor do we currently plan to develop the infrastructure or capability internally to manufacture our clinical supplies for use in the conduct of our clinical trials, and we lack the resources and the capability to manufacture any of our product candidates on a clinical or commercial scale. We currently rely on outside vendors to manufacture our clinical supplies of our product candidates and plan to continue relying on third parties to manufacture our product candidates on a commercial scale, if approved.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing of our product candidates and our current cost to manufacture our drug products is not commercially feasible. Additionally, the actual cost to manufacture our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, our reliance on third-party manufacturers exposes us to the following additional risks:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may be unable to identify manufacturers on acceptable terms or at all.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Contract manufacturers may not be able to execute our manufacturing procedures appropriately.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our future third-party manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store, and distribute our products.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with cGMPs and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#8217; compliance with these regulations and standards.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our third-party manufacturers could breach or terminate their agreement with us.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each of these risks could delay our clinical trials, as well as the approval, if any, of our product candidates by the FDA, or the commercialization of our product candidates, or could result in higher costs, or could deprive us of potential product revenue. In addition, we rely on third parties to perform release testing on our product candidates prior to delivery to patients. If these tests are not appropriately conducted and test data are not reliable, patients could be put at risk of serious harm and could result in product liability suits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The manufacture of medical products is complex and requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of medical products often encounter difficulties in production, particularly in scaling up and validating initial production and absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of our product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot be assured that any stability or other issues relating to the manufacture of our product candidates will not occur in the future. Additionally, our manufacturers may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our manufacturers were to encounter any of these difficulties, or otherwise fail to comply with their contractual obligations, our ability to provide our product candidates to patients in clinical trials would be jeopardized. Any delay or interruption in the supply of clinical trial supplies could delay the completion of clinical trials, increase the costs associated with maintaining clinical trial programs and, depending upon the period of delay, require us to commence new clinical trials at additional expense or terminate clinical trials completely.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may be unable to realize the potential benefits of any collaboration.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">58</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if we are successful in entering into a collaboration with respect to the development and/or commercialization of one or more product candidates, there is no guarantee that the collaboration will be successful. Collaborations may pose a number of risks, including:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators often have significant discretion in determining the efforts and resources that they will apply to the collaboration and may not commit sufficient resources to the development, marketing, or commercialization of the product or products that are subject to the collaboration;</font></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators may not perform their obligations as expected;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any such collaboration may significantly limit our share of potential future profits from the associated program and may require us to relinquish potentially valuable rights to our current product candidates, potential products, proprietary technologies, or grant licenses on terms that are not favorable to us;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators may cease to devote resources to the development or commercialization of our product candidates if the collaborators view our product candidates as competitive with their own products or product candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation, or the course of development, might cause delays or termination of the development or commercialization of product candidates, and might result in legal proceedings, which would be time consuming, distracting, and expensive;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators may be impacted by changes in their strategic focus or available funding, or business combinations involving them, which could cause them to divert resources away from the collaboration;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the collaborations may not result in us achieving revenues to justify such transactions; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">collaborations may be terminated and, if terminated, may result in a need for us to raise additional capital to pursue further development or commercialization of the applicable product candidate.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result, a collaboration may not result in the successful development or commercialization of our product candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For instance, in October 2011, we entered into the Servier Collaboration Agreement with Servier for the research, development, and commercialization of RNA-targeting therapeutics in cardiovascular disease, which was subsequently amended. Under the Servier Collaboration Agreement, we have granted Servier an exclusive license to research, develop, and commercialize RNA-targeting therapeutics for one target in the cardiovascular field and the right to obtain such an exclusive license for one additional target through September 2019. Servier&#8217;s rights to this target are limited to therapeutics in the cardiovascular field in their territory, which is worldwide except for the United States and Japan. We retain all rights for the named target in the United States and Japan and for any products or product candidates outside of the cardiovascular field. We cannot guarantee that any product candidate will ever be successfully commercialized under the Servier Collaboration Agreement. If no product candidate subject to the Servier Collaboration Agreement is successfully commercialized, we may never receive additional milestone or any royalty payments under the Servier Collaboration Agreement. Also, due to restrictions contained in the Servier Collaboration Agreement, we may not be able to effectively develop, market, or commercialize any such product candidate in the United States and Japan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We enter into various contracts in the normal course of our business in which we indemnify the other party to the contract. In the event we have to perform under these indemnification provisions, we could have a material adverse effect on our business, financial condition, and results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the normal course of business, we periodically enter into academic, commercial, service, collaboration, licensing, consulting, and other agreements that contain indemnification provisions. With respect to our academic and other research agreements, we typically indemnify the institution and related parties from losses arising from claims relating to the products, processes, or services made, used, sold, or performed pursuant to the agreements for which we have secured licenses, and from claims arising from our or our sublicensees&#8217; exercise of rights under the agreement. With respect to our collaboration agreements, we indemnify our collaborators from any third-party product liability claims that could result from the production, use, or consumption of the product, as well as for alleged infringements of any patent or other intellectual property right by a third party. With respect to consultants, we indemnify them from claims arising from the good faith </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">59</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">performance of their services.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Should our obligation under an indemnification provision exceed applicable insurance coverage or if we were denied insurance coverage, our business, financial condition, and results of operations could be adversely affected. Similarly, if we are relying on a collaborator to indemnify us and the collaborator is denied insurance coverage or the indemnification obligation exceeds the applicable insurance coverage, and if the collaborator does not have other assets available to indemnify us, our business, financial condition, and results of operations could be adversely affected.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Commercialization of Our Product Candidates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We currently have limited marketing and sales experience. If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although some of our employees may have marketed, launched, and sold other pharmaceutical products in the past while employed at other companies, we have no experience selling and marketing our product candidates and we currently have no marketing or sales organization. To successfully commercialize any products that may result from our development programs, we will need to find one or more collaborators to commercialize our products or invest in and develop these capabilities, either on our own or with others, which would be expensive, difficult, and time consuming. Any failure or delay in the timely development of our internal commercialization capabilities could adversely impact the potential for success of our products.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If commercialization collaborators do not commit sufficient resources to commercialize our future products and we are unable to develop the necessary marketing and sales capabilities on our own, we will be unable to generate sufficient product revenue to sustain or grow our business. We may be competing with companies that currently have extensive and well-funded marketing and sales operations, particularly in the markets our product candidates are intended to address. Without appropriate capabilities, whether directly or through third-party collaborators, we may be unable to compete successfully against these more established companies.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may attempt to form collaborations in the future with respect to our product candidates, but we may not be able to do so, which may cause us to alter our development and commercialization plans.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may attempt to form strategic collaborations, create joint ventures, or enter into licensing arrangements with third parties with respect to our programs that we believe will complement or augment our existing business. We may face significant competition in seeking appropriate strategic collaborators, and the negotiation process to secure appropriate terms is time consuming and complex. We may not be successful in our efforts to establish such a strategic collaboration for any product candidates and programs on terms that are acceptable to us, or at all. This may be because our product candidates and programs may be deemed to be at too early of a stage of development for collaborative effort, our research and development pipeline may be viewed as insufficient, the competitive or intellectual property landscape may be viewed as too intense or risky, and/or third parties may not view our product candidates and programs as having sufficient potential for commercialization, including the likelihood of an adequate safety and efficacy profile.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Any delays in identifying suitable collaborators and entering into agreements to develop and/or commercialize our product candidates could delay the development or commercialization of our product candidates, which may reduce their competitiveness even if they reach the market. Absent a strategic collaborator, we would need to undertake development and/or commercialization activities at our own expense. If we elect to fund and undertake development and/or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we are unable to do so, we may not be able to develop our product candidates or bring them to market and our business may be materially and adversely affected.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If the market opportunities for our product candidates are smaller than we believe they are, we may not meet our revenue expectations and, assuming approval of a product candidate, our business may suffer. Because the patient populations in the market for our product candidates may be small, we must be able to successfully identify patients and acquire a significant market share to achieve profitability and growth.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Given the small number of patients who have the diseases that we are targeting, our eligible patient population and pricing estimates may differ significantly from the actual market addressable by our product candidates. For instance, our Phase 1 clinical trial in MRG-106 is focused on MF. The estimated prevalence of MF is 16,000 to 20,000 cases in the United States, only a subset of which may benefit from treatment with MRG-106. Our projections of both the number of people who have this disease, as well as the subset of people with this disease who have the potential to benefit from treatment with our </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including the scientific literature, patient foundations, or market research, and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these diseases. The number of patients may turn out to be lower than expected. Additionally, while we believe that the data in our Phase 1 clinical trials for MRG-106 and MRG-201 are supportive of application to other indications, there can be no assurance that our clinical trials will successfully address any additional indications. Likewise, the potentially addressable patient population for each of our product candidates may be limited or may not be amenable to treatment with our product candidates, and new patients may become increasingly difficult to identify or gain access to, which would adversely affect our business, financial condition, results of operations and prospects.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We face substantial competition and our competitors may discover, develop, or commercialize products faster or more successfully than us.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The development and commercialization of new drug products is highly competitive. We face competition from major pharmaceutical companies, specialty pharmaceutical companies, biotechnology companies, universities, and other research institutions worldwide with respect to MRG-106, MRG-201, and the other product candidates that we may seek to develop or commercialize in the future. We are aware that the following companies have therapeutics marketed or in development for CTCL: Actelion Ltd, Bristol-Myers Squibb Company, Celgene Corporation, Merck &amp; Co., Inc., Mylan Pharmaceuticals Inc., Novartis International AG, Spectrum Pharmaceuticals, Inc., Seattle Genetics, Inc., Takeda Pharmaceutical Company Ltd, and Valeant Pharmaceuticals International, Inc. We are also aware that the several companies have marketed therapeutics for pulmonary fibrosis, including Boehringer Ingelheim GmbH and F. Hoffmann-La Roche Ltd. Our competitors may succeed in developing, acquiring, or licensing technologies and drug products that are more effective or less costly than MRG-106, MRG-201, or any other product candidates that we are currently developing or that we may develop, which could render our product candidates obsolete and noncompetitive.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition to the competition we face from alternative therapies for the diseases we intend to target with our product candidates, we are also aware of several companies that are also working specifically to develop microRNA-targeted therapeutics, including Mirna Therapeutics, Inc., Regulus Therapeutics, Inc., Microlin Bio, Inc., and InteRNA Technologies. Further, there are several companies working to develop other types of oligonucleotide therapeutic products, including Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Dicerna Pharmaceuticals, Inc., RaNa Therapeutics, Inc., RXi Pharmaceuticals Corporation, and Silence Therapeutics AG. Many of our competitors have substantially greater financial, technical, and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations. Third-party payors, including governmental and private insurers, may also encourage the use of generic products. For example, if MRG-106 or MRG-201 is approved, it may be priced at a significant premium over other competitive products. This may make it difficult for MRG-106, MRG-201, or any other future products to compete with these products.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our competitors obtain marketing approval from the FDA or comparable foreign regulatory authorities for their product candidates more rapidly than us, it could result in our competitors establishing a strong market position before we are able to enter the market.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Many of our competitors have materially greater name recognition and financial, manufacturing, marketing, research, and drug development resources than we do. Additional mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Large pharmaceutical companies in particular have extensive expertise in preclinical and clinical testing and in obtaining regulatory approvals for drugs. In addition, academic institutions, government agencies, and other public and private organizations conducting research may seek patent protection with respect to potentially competitive products or technologies. These organizations may also establish exclusive collaborative or licensing relationships with our competitors. Failure of MRG-106, MRG-201, or other product candidates to effectively compete against established treatment options or in the future with new products currently in development would harm our business, financial condition, results of operations, and prospects.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The commercial success of any of our current or future product candidates will depend upon the degree of market acceptance by physicians, patients, third-party payors, and others in the medical community.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even with the approvals from the FDA and comparable foreign regulatory authorities, the commercial success of our products will depend in part on the healthcare providers, patients, and third-party payors accepting our product candidates as medically useful, cost-effective, and safe. Any product that we bring to the market may not gain market acceptance by physicians, patients, and third-party payors. The degree of market acceptance of any of our products will depend on a number of factors, including but not limited to:</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">61</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the efficacy of the product as demonstrated in clinical trials and potential advantages over competing treatments;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the prevalence and severity of the disease and any side effects;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the clinical indications for which approval is granted, including any limitations or warnings contained in a product&#8217;s approved labeling;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the convenience and ease of administration;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the cost of treatment;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the willingness of the patients and physicians to accept these therapies;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the perceived ratio of risk and benefit of these therapies by physicians and the willingness of physicians to recommend these therapies to patients based on such risks and benefits;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the marketing, sales, and distribution support for the product;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the publicity concerning our products or competing products and treatments; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the pricing and availability of third-party insurance coverage and reimbursement.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Even if a product displays a favorable efficacy and safety profile upon approval, market acceptance of the product remains uncertain. Efforts to educate the medical community and third-party payors on the benefits of the products may require significant investment and resources and may never be successful. If our products fail to achieve an adequate level of acceptance by physicians, patients, third-party payors, and other healthcare providers, we will not be able to generate sufficient revenue to become or remain profitable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We may not be successful in any efforts to identify, license, discover, develop, or commercialize additional product candidates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Although a substantial amount of our effort will focus on the continued clinical testing, potential approval, and commercialization of our existing product candidates, the success of our business is also expected to depend in part upon our ability to identify, license, discover, develop, or commercialize additional product candidates. Research programs to identify new product candidates require substantial technical, financial, and human resources. We may focus our efforts and resources on potential programs or product candidates that ultimately prove to be unsuccessful. Our research programs or licensing efforts may fail to yield additional product candidates for clinical development and commercialization for a number of reasons, including but not limited to the following:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our research or business development methodology or search criteria and process may be unsuccessful in identifying potential product candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">we may not be able or willing to assemble sufficient resources to acquire or discover additional product candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our product candidates may not succeed in preclinical or clinical testing;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our potential product candidates may be shown to have harmful side effects or may have other characteristics that may make the products unmarketable or unlikely to receive marketing approval;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">competitors may develop alternatives that render our product candidates obsolete or less attractive;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">product candidates we develop may be covered by third parties&#8217; patents or other exclusive rights;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the market for a product candidate may change during our program so that such a product may become unreasonable to continue to develop;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">62</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">a product candidate may not be accepted as safe and effective by patients, the medical community, or third-party payors.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If any of these events occur, we may be forced to abandon our development efforts for a program or programs, or we may not be able to identify, license, discover, develop, or commercialize additional product candidates, which would have a material adverse effect on our business, financial condition, or results of operations and could potentially cause us to cease operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Failure to obtain or maintain adequate reimbursement or insurance coverage for products, if any, could limit our ability to market those products and decrease our ability to generate revenue.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The pricing, coverage, and reimbursement of our approved products, if any, must be sufficient to support our commercial efforts and other development programs, and the availability and adequacy of coverage and reimbursement by third-party payors, including governmental and private insurers, are essential for most patients to be able to afford expensive treatments. Sales of our approved products, if any, will depend substantially, both domestically and abroad, on the extent to which the costs of our approved products, if any, will be paid for or reimbursed by health maintenance, managed care, pharmacy benefit, and similar healthcare management organizations, or government payors and private payors. If coverage and reimbursement are not available, or are available only in limited amounts, we may have to subsidize or provide products for free, or we may not be able to successfully commercialize our products.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In addition, there is significant uncertainty related to the insurance coverage and reimbursement for newly-approved products. In the United States, the principal decisions about coverage and reimbursement for new drugs are typically made by CMS, an agency within the U.S. Department of Health and Human Services, that decides whether and to what extent a new drug will be covered and reimbursed under Medicare. Private payors tend to follow the coverage reimbursement policies established by CMS to a substantial degree. It is difficult to predict what CMS will decide with respect to reimbursement for novel product candidates such as our and what reimbursement codes our product candidates may receive if approved.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outside the United States, international operations are generally subject to extensive governmental price controls and other price-restrictive regulations, and we believe the increasing emphasis on cost-containment initiatives in Europe, Canada, and other countries has and will continue to put pressure on the pricing and usage of products. In many countries, the prices of products are subject to varying price control mechanisms as part of national health systems. Price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our products, if any. Accordingly, in markets outside the United States, the potential revenue may be insufficient to generate commercially reasonable revenue and profits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moreover, increasing efforts by governmental and private payors in the United States and abroad to limit or reduce healthcare costs may result in restrictions on coverage and the level of reimbursement for new products and, as a result, they may not cover or provide adequate payment for our products. Further, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, reduce the cost of drugs under Medicare, and reform government program reimbursement methodologies for drugs. We expect to experience pricing pressures in connection with products due to the increasing trend toward managed healthcare, including the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs, has increased and is expected to continue to increase in the future. As a result, profitability of our products, if any, may be more difficult to achieve even if they receive regulatory approval.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Our Business Operations</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our future success depends in part on our ability to retain our president and chief executive officer and to attract, retain, and motivate other qualified personnel.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are highly dependent on William S. Marshall, Ph.D., our president and chief executive officer, the loss of whose services may adversely impact the achievement of our objectives. Dr. Marshall could leave our employment at any time, as he is an &#8220;at will&#8221; employee. Recruiting and retaining other qualified employees, consultants, and advisors for our business, including scientific and technical personnel, will also be critical to our success. There is currently a shortage of highly qualified personnel in our industry, which is likely to continue. Additionally, this shortage of highly qualified personnel is particularly acute in the area where we are located. As a result, competition for personnel is intense and the turnover rate can be high. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for individuals with similar skill sets. In addition, failure to succeed in development and </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">63</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">commercialization of our product candidates may make it more challenging to recruit and retain qualified personnel. The inability to recruit and retain qualified personnel, or the loss of the services of Dr. Marshall, may impede the progress of our research, development, and commercialization objectives and would negatively impact our ability to succeed in our product development strategy.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We will need to expand our organization and we may experience difficulties in managing this growth, which could disrupt our operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, we had 59 full-time employees. As our development and commercialization plans and strategies develop, we expect to need additional managerial, operational, sales, marketing, financial, legal, and other resources. Our management may need to divert a disproportionate amount of our attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees, and reduced productivity among remaining employees. Our expected growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to generate and/or grow revenue could be reduced and we may not be able to implement our business strategy. Our future financial performance and our ability to commercialize product candidates and compete effectively will depend, in part, on our ability to effectively manage any future growth.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Failure in our information technology and storage systems could significantly disrupt the operation of our business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our ability to execute our business plan and maintain operations depends on the continued and uninterrupted performance of our information technology, or IT, systems. IT systems are vulnerable to risks and damages from a variety of sources, including telecommunications or network failures, malicious human acts, and natural disasters. Moreover, despite network security and back-up measures, some of our and our vendors&#8217; servers are potentially vulnerable to physical or electronic break-ins, including cyber-attacks, computer viruses, and similar disruptive problems. These events could lead to the unauthorized access, disclosure, and use of non-public information. The techniques used by criminal elements to attack computer systems are sophisticated, change frequently, and may originate from less regulated and remote areas of the world. As a result, we may not be able to address these techniques proactively or implement adequate preventative measures. If our computer systems are compromised, we could be subject to fines, damages, litigation, and enforcement actions, and we could lose trade secrets, the occurrence of which could harm our business. Despite precautionary measures to prevent unanticipated problems that could affect our IT systems, sustained or repeated system failures that interrupt our ability to generate and maintain data could adversely affect our ability to operate our business.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our principal stockholders own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our directors, officers, 5% stockholders, and their affiliates currently beneficially own a majority of our outstanding voting stock. Therefore, these stockholders have the ability and may continue to have the ability to influence us through this ownership position. These stockholders may be able to determine some or all matters requiring stockholder approval. For example, these stockholders, acting together, may be able to control elections of directors, amendments of organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may believe are in your best interest as one of our stockholders.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Risks Related to Ownership of our Common Stock</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">The market price of our common stock is expected to be volatile, and the market price of our common stock may drop in the future.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The market price of our common stock following the Merger could be subject to significant fluctuations. Market prices for securities of early-stage pharmaceutical, biotechnology, and other life sciences companies have historically been particularly volatile. Some of the factors that may cause the market price of our common stock to fluctuate include:</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">our ability to obtain regulatory approvals for MRG-106, MRG-201, or other product candidates, and delays or failures to obtain such approvals;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure of any of our product candidates, if approved, to achieve commercial success;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">64</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to maintain our existing third-party license and supply agreements;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in laws or regulations applicable to our product candidates;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">any inability to obtain adequate supply of our product candidates or the inability to do so at acceptable prices;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse regulatory authority decisions;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">introduction of new products, services, or technologies by our competitors;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to meet or exceed financial and development projections we may provide to the public;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">failure to meet or exceed the financial and development projections of the investment community;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the perception of the pharmaceutical industry by the public, legislatures, regulators, and the investment community;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">announcements of significant acquisitions, strategic collaborations, joint ventures, or capital commitments by us or our competitors;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">disputes or other developments relating to proprietary rights, including patents, litigation matters, and our ability to obtain patent protection for our technologies;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">additions or departures of key personnel;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">significant lawsuits, including patent or stockholder litigation;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">if securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinions regarding our business and stock;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the market valuations of similar companies;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">general market or macroeconomic conditions;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">sales of our common stock by us our stockholders in the future;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">trading volume of our common stock;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">announcements by commercial partners or competitors of new commercial products, clinical progress or the lack thereof, significant contracts, commercial relationships, or capital commitments;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">adverse publicity relating to microRNA-targeted therapeutics generally, including with respect to other products and potential products in such markets;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">the introduction of technological innovations or new therapies that compete with our potential products;</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">changes in the structure of health care payment systems; and</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:10pt;padding-left:25px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">period-to-period fluctuations in our financial results.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Moreover, the stock markets in general have experienced substantial volatility that has often been unrelated to the operating performance of individual companies. These broad market fluctuations may also adversely affect the trading price of our common stock.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In the past, following periods of volatility in the market price of a company&#8217;s securities, stockholders have often instituted class action securities litigation against those companies. Such litigation, if instituted, could result in substantial costs and diversion of management attention and resources, which could significantly harm our profitability and reputation.</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additionally, a decrease in our stock price may cause our common stock to no longer satisfy the continued listing standards </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">65</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">of The NASDAQ Capital Market. If we are not able to maintain the requirements for listing on The NASDAQ Capital Market, we could be delisted, which could have a materially adverse effect on our ability to raise additional funds as well as the price and liquidity of our common stock.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As a result of the Mergers, we will incur significant legal, accounting, and other expenses that Private Miragen did not incur as a private company, including costs associated with public company reporting requirements. We will also incur costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act, as well as new rules implemented by the SEC and NASDAQ. These rules and regulations are expected to increase our legal and financial compliance costs and to make some activities more time-consuming and costly. For example, our management team consists of the executive officers of Private Miragen prior to the Merger, some of whom have not previously managed and operated a public company. These executive officers and other personnel will need to devote substantial time to gaining expertise regarding operations as a public company and compliance with applicable laws and regulations. These rules and regulations may also make it difficult and expensive for us to obtain directors&#8217; and officers&#8217; liability insurance. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as our executive officers, which may adversely affect investor confidence and could cause our business or stock price to suffer.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our management.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Provisions in our certificate of incorporation and bylaws may delay or prevent an acquisition or a change in management. These provisions include a prohibition on actions by written consent of our stockholders and the ability of our board of directors to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which prohibits stockholders owning in excess of 15% of our outstanding voting stock from merging or combining with us. Although we believe these provisions collectively will provide for an opportunity to receive higher bids by requiring potential acquirers to negotiate with our board of directors, they would apply even if the offer may be considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove then current management by making it more difficult for stockholders to replace members of the board of directors, which is responsible for appointing the members of management.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Our bylaws provide that the Court of Chancery of the State of Delaware is the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or other employees.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Our bylaws provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty owed by any of our directors, officers, or other employees to us or our stockholders, any action asserting a claim against us arising pursuant to any provisions of the Delaware General Corporation Law, our certificate of incorporation or our bylaws, or any action asserting a claim against us that is governed by the internal affairs doctrine. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage such lawsuits against our and our directors, officers, and other employees. If a court were to find the choice of forum provision contained in the bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We do not anticipate that we will pay any cash dividends in the foreseeable future.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The current expectation is that we will retain our future earnings, if any, to fund the development and growth of our business. As a result, capital appreciation, if any, of our common stock will be your sole source of gain, if any, for the foreseeable future.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">An active trading market for our common stock may not develop and our stockholders may not be able to resell their shares of common stock for a profit, if at all.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prior to the Merger, there had been no public market for Private Miragen&#8217;s common stock. An active trading market for our shares of common stock may never develop or be sustained. If an active market for our common stock does not develop or is not sustained, it may be difficult for our stockholders to sell their shares at an attractive price or at all.</font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">66</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Future sales of shares by existing stockholders could cause our stock price to decline.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If our stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market after legal restrictions on resale lapse, the trading price of our common stock could decline. In addition, shares of common stock that are subject to our outstanding options will become eligible for sale in the public market to the extent permitted by the provisions of various vesting agreements and Rules 144 and 701 under the Securities Act. If these shares are sold, the trading price of our common stock could decline.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If equity research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business, or our market, our stock price and trading volume could decline.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The trading market for our common stock will be influenced by the research and reports that equity research analysts publish about us and our business. Equity research analysts may elect not to provide research coverage of our common stock and such lack of research coverage may adversely affect the market price of our common stock. In the event we do have equity research analyst coverage, we will not have any control over the analysts or the content and opinions included in their reports. The price of our common stock could decline if one or more equity research analysts downgrade our stock or issue other unfavorable commentary or research. If one or more equity research analysts ceases coverage of us or fails to publish reports on us regularly, demand for our common stock could decrease, which in turn could cause our stock price or trading volume to decline.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">We have experienced in the past, and may experience in the future, ownership changes under Section 382 of the Code which limit or eliminate net operating loss carryforwards and certain other tax attributes available to us. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If a corporation undergoes an &#8220;ownership change&#8221; within the meaning of Section 382 of the Code, or Section 382, the corporation&#8217;s net operating loss carryforwards and certain other tax attributes arising from before the ownership change are subject to limitations on use after the ownership change. In general, an ownership change occurs if there is a cumulative change in the corporation&#8217;s equity ownership by certain stockholders that exceeds fifty percentage points by value over a rolling three-year period. Similar rules may apply under state tax laws. Our most recent analysis of possible ownership changes was completed for certain tax periods ending through the date of the Merger. The Merger resulted in an ownership change for us and, accordingly, our net operating loss carryforwards and certain other tax attributes are subject to limitation. Additional ownership changes in the future could result in additional limitations on our net operating loss carryforwards and certain other tax attributes. Consequently, even if we achieve profitability, we may not be able to utilize a material portion of our net operating loss carryforwards and certain other tax attributes, which could have a material adverse effect on cash flow and results of operations.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">If we fail to maintain proper and effective internal controls, our ability to produce accurate financial statements on a timely basis could be impaired.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We are subject to the reporting requirements of the Exchange Act, the Sarbanes-Oxley Act, and the rules and regulations of NASDAQ. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. We must perform system and process evaluation and testing of our internal control over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting in our Annual Report filing for that year, as required by Section 404 of the Sarbanes-Oxley Act. As a private company, Private Miragen had never been required to test its internal controls within a specified period. This will require that we incur substantial professional fees and internal costs to expand our accounting and finance functions and that we expend significant management efforts. We may experience difficulty in meeting these reporting requirements in a timely manner for each period.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We may discover weaknesses in our system of internal financial and accounting controls and procedures that could result in a material misstatement of our financial statements. Our internal control over financial reporting will not prevent or detect all errors and all fraud. A control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control system&#8217;s objectives will be met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that misstatements due to error or fraud will not occur or that all control issues and instances of fraud will be detected.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If we are not able to comply with the requirements of Section 404 of the Sarbanes-Oxley Act, or if we are unable to maintain proper and effective internal controls, we may not be able to produce timely and accurate financial statements. If that were to happen, the market price of our common stock could decline, and it could be subject to sanctions or investigations by </font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">67</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">NASDAQ, the SEC, or other regulatory authorities.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s498C0187EEF25978B81E11B310EED25F"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="s3774814DB26B58A3B6AC6CB154C80477"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;3. DEFAULTS UPON SENIOR SECURITIES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sC753B4D05CF952B1A591FE6C4D196AB2"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;4. MINE SAFETY DISCLOSURES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><a name="sAF06CC58C9DD50CD875969C54A6244BB"></a></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;5. OTHER INFORMATION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not applicable.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">68</font></div></div><hr style="page-break-after:always"><div><a name="sC38F8F2A95655B6DB78967EC99B4F7F8"></a></div><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;text-align:left;-sec-extract:summary;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ITEM&#160;6. EXHIBITS</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.89806320081549%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit</font></div><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Description of Exhibit</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1590750/000117184314003982/exh_31.htm"><font style="font-family:inherit;font-size:10pt;">3.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1590750/000117184314003982/exh_31.htm"><font style="font-family:inherit;font-size:10pt;">Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (No. 001-36483), as filed with the SEC on August 14, 2014).</font></a></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312516784004/d238687dex33.htm"><font style="font-family:inherit;font-size:10pt;">3.2</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312516784004/d238687dex33.htm"><font style="font-family:inherit;font-size:10pt;">Certificate of Amendment of Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.3 to the Registrant&#8217;s Registration Statement on Form S-4 (File No. 333-214893), as filed with the SEC on December 2, 2016, as amended).</font></a></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312517040701/d342434dex31.htm"><font style="font-family:inherit;font-size:10pt;">3.3</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312517040701/d342434dex31.htm"><font style="font-family:inherit;font-size:10pt;">Certificate of Amendment of Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-36483), as filed with the SEC on February 13, 2017).</font></a></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312517040701/d342434dex32.htm"><font style="font-family:inherit;font-size:10pt;">3.4</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312517040701/d342434dex32.htm"><font style="font-family:inherit;font-size:10pt;">Certificate of Amendment of Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-36483), as filed with the SEC on February 13, 2017).</font></a></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1590750/000117184316011777/exh_31.htm"><font style="font-family:inherit;font-size:10pt;">3.5</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1590750/000117184316011777/exh_31.htm"><font style="font-family:inherit;font-size:10pt;">Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (No. 001-36483), as filed with the SEC on August 15, 2016).</font></a></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312517040701/d342434dex33.htm"><font style="font-family:inherit;font-size:10pt;">3.6</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312517040701/d342434dex33.htm"><font style="font-family:inherit;font-size:10pt;">Amendment to the Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.3 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-36483), as filed with the SEC on February 13, 2017).</font></a></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312517040701/d342434dex34.htm"><font style="font-family:inherit;font-size:10pt;">3.7</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1590750/000119312517040701/d342434dex34.htm"><font style="font-family:inherit;font-size:10pt;">Certificate of Ownership and Merger of the Registrant (incorporated by reference to Exhibit 3.4 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-36483), as filed with the SEC on February 13, 2017).</font></a></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1590750/000114420414016510/v369400_ex4-1.htm"><font style="font-family:inherit;font-size:10pt;">4.1</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/1590750/000114420414016510/v369400_ex4-1.htm"><font style="font-family:inherit;font-size:10pt;">Specimen Common Stock Certificate (incorporated by reference to Exhibit 4.1 to the Registration Statement on Form S-1 (No. 333-194668), as filed with the SEC on March 19, 2014).</font></a></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="mgen-9302017xex102servier.htm"><font style="font-family:inherit;font-size:10pt;">10.1&#8224;*</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="mgen-9302017xex102servier.htm"><font style="font-family:inherit;font-size:10pt;">Sixth Amendment of the License and Collaboration Agreement, effective as September 27, 2017, by and between Registrant and Les Laboratoires Servier, on the first part, and Institut de Recherches Servier, on the second part.</font></a></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a102yaletouploadctr.htm"><font style="font-family:inherit;font-size:10pt;">10.2&#8224;*</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="a102yaletouploadctr.htm"><font style="font-family:inherit;font-size:10pt;">Research Subaward Agreement, effective as of July 1, 2017, by and between Registrant and Yale University, as amended.</font></a></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="mgen-9302017xex311.htm"><font style="font-family:inherit;font-size:10pt;">31.1*</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="mgen-9302017xex311.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.</font></a></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="mgen-9302017xex312.htm"><font style="font-family:inherit;font-size:10pt;">31.2*</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="mgen-9302017xex312.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Financial Officer pursuant to Rule13a-14(a) and Rule 15d-14(a) of the Securities and Exchange Act, as amended.</font></a></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="mgen-9302017xex321.htm"><font style="font-family:inherit;font-size:10pt;">32.1*</font></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="mgen-9302017xex321.htm"><font style="font-family:inherit;font-size:10pt;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. (1)</font></a></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.INS^</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Instance Document</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.SCH^</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Schema Document</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.CAL^</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Calculation Linkbase Document</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.DEF^</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Definition Linkbase Document</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.LAB^</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Label Linkbase Document</font></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">101.PRE^</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">XBRL Taxonomy Extension Presentation Linkbase Document</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">________________________</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.89806320081549%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:7%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">*</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Filed herewith.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">This certification is being furnished pursuant to 18 U.S.C. Section 1350, and is not being filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, and is not to be incorporated by reference into any filing of the Registrant, whether made before or after the date hereof.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">^</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In accordance with Rule 406T of Regulation S-T, the Interactive Data Files in Exhibit 101 are deemed not filed or part of a registration statement or prospectus for purposes of Sections 11 or 12 of the Securities Act of 1933, as amended, are deemed not filed for purposes of Section 18 of the Exchange Act of 1934, as amended, and otherwise are not subject to liability under these sections.</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8224;</font></div><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Confidential treatment has been requested as to portions of the exhibit. Confidential materials omitted and filed separately with the SEC.</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">69</font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><a style="font-family:inherit;font-size:10pt;" href="#s6C95F9186C8257CA88AF1907B0CB34BC"><font style="font-family:inherit;font-size:10pt;">Table of Contents</font></a></div></div><div><br></div><div style="line-height:120%;padding-top:35px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;padding-top:17px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.89806320081549%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:29%;"></td><td style="width:17%;"></td><td style="width:5%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Miragen&#160;Therapeutics,&#160;Inc.</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: November&#160;9, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ William S. Marshall</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William S. Marshall, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Jason A. Leverone</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jason A. Leverone</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer; Principal Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>mgen-9302017xex102servier.htm
<DESCRIPTION>EXHIBIT 10.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s95208916c3094e8199f882babd1fdc27"></a></div><div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Exhibit 10.1</font></div></div><div><br></div><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">SIXTH AMENDMENT OF</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">THE LICENSE AND COLLABORATION AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;padding-top:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;">This </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sixth Amendment of the License and Collaboration Agreement </font><font style="font-family:inherit;font-size:12pt;">(this &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sixth Amendment</font><font style="font-family:inherit;font-size:12pt;">&#8221;) is made and effective as of September 27th, 2017 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Sixth Amendment</font><font style="font-family:inherit;font-size:12pt;">&#32;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Effective Date</font><font style="font-family:inherit;font-size:12pt;">&#8221;) by and between </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Miragen Therapeutics, Inc.</font><font style="font-family:inherit;font-size:12pt;">, a corporation organized and existing under the laws of Delaware, having its principal place of business at 6200 Lookout Rd., Boulder, CO 80301, USA (&#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Miragen</font><font style="font-family:inherit;font-size:12pt;">&#8221;) on the first part, and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Les Laboratoires Servier</font><font style="font-family:inherit;font-size:12pt;">, a corporation organized and existing under the laws of France, having offices at 50 rue Carnot, 92284 Suresnes cedex France and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Institut de Recherches Servier, </font><font style="font-family:inherit;font-size:12pt;">a corporation organized and existing under the laws of France, having offices at 3 rue de la R&#233;publique, 92150 Suresnes, France (these two entities jointly referred to as &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Servier</font><font style="font-family:inherit;font-size:12pt;">&#8221;) on the second part.  Servier and Miragen are referred to in this Agreement individually as a &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Party</font><font style="font-family:inherit;font-size:12pt;">&#8221; and collectively as the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Parties</font><font style="font-family:inherit;font-size:12pt;">.&#8221;  </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WHEREAS, </font><font style="font-family:inherit;font-size:12pt;">Miragen and Servier are parties to that certain License and Collaboration Agreement, dated October 13, 2011 as amended by First Amendment dated May 13, 2013, Second Amendment dated May 13, 2014, Third Amendment dated May 28, 2015, Fourth Amendment dated September 22, 2016, and Fifth Amendment dated May 2, 2017 (the &#8220;</font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Collaboration Agreement</font><font style="font-family:inherit;font-size:12pt;">&#8221;), pursuant to which the Parties established a collaboration for the research, development and commercialization of products directed at miRNA targets for the treatment of cardiovascular diseases; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">WHEREAS</font><font style="font-family:inherit;font-size:12pt;">, the Parties also wish to amend certain other terms and condition of the Collaboration Agreement, all as set forth below. </font></div><div style="line-height:120%;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;"></font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">NOW THEREFORE,</font><font style="font-family:inherit;font-size:12pt;">&#32;in consideration of the foregoing premises and the mutual promises, covenants and conditions contained in this Sixth Amendment, the Parties agree as follows:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">1.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Unless otherwise indicated, capitalized terms used but not defined herein shall have the meanings set forth in the Collaboration Agreement.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">2.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The last sentence of Section 9.3(a) of the Collaboration Agreement, which was added pursuant to the Fifth Amendment, is hereby deleted and replaced in its entirety with the following:</font></div></td></tr></table><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Notwithstanding the foregoing, miRagen agrees to invoice Servier for [*] costs associated with the manufacture of MRG-110 drug substance that commenced in [*], which are currently estimated to be approximately [*] (&#8220;Provisional Budget&#8221;). Such costs include [*] and [*].   The drug substance is expected to be delivered and ready for use [*] (&#8220;Provisional Completion Date&#8221;). If necessary, the estimated Provisional Budget and the Provisional Completion Date may be adjusted through a decision of the JEC in accordance with the provisions of Sections 3.4 and 3.9 of the Collaboration Agreement.  Following the Sixth </font></div><div><br></div><div></div><hr style="page-break-after:always"><div><a name="s1d1c8e57444f4fc6bd6dde874ed82298"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:justify;padding-left:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Amendment Effective Date, miRagen will submit an invoice to Servier for [*] costs associated with the manufacture and production of MRG-110 drug substance incurred by miRagen prior to [*] and through [*] (estimated to be [*]) that had been deferred under the terms of the Fifth Amendment. [*] subsequent costs associated with the manufacture and production of MRG-110 drug product incurred after [*] will be invoiced to Servier as incurred on the standard quarterly invoice schedule.&#8221; </font></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">3.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The last sentence of Section 5.4(a) of the Collaboration Agreement, which was added pursuant to the Fifth Amendment, is hereby deleted in its entirety.  For clarity, miRagen will no longer be responsible for [*] of Pre-Phase 3 Costs incurred by miRagen during the third calendar quarter of 2017. Servier [*] for such Pre-Phase 3 Costs [*].  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">4.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Section 9.4(e) of the Collaboration Agreement, which was added pursuant to the Fifth Amendment, is hereby deleted in its entirety. </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">5.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Sixth Amendment amends the terms of the Collaboration Agreement as expressly provided above, and the Collaboration Agreement, as so amended and including all of its other terms and provisions that are not amended, remains in full force and effect and sets forth the complete, final and exclusive agreement and all the covenants, promises, agreements, warranties, representations, conditions and understandings between the Parties hereto with respect to the subject matter of the Collaboration Agreement and supersedes, as of the Sixth Amendment Effective Date, all prior and contemporaneous agreements and understandings between the Parties with respect to the subject matter of the Collaboration Agreement.  There are no covenants, promises, agreements, warranties, representations, conditions or understandings, either oral or written, between the Parties other than as set forth in the Collaboration Agreement (as further amended by this Sixth Amendment).</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">6.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">The validity, performance, construction, and effect of this Sixth Amendment shall be governed by and construed under the laws of Germany, without giving effect to any choice of law principles that would require the application of the laws of a different state.  </font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:12pt;padding-left:0px;"><font style="font-family:inherit;font-size:12pt;">7.</font></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This Sixth Amendment may be executed in two (2) or more counterparts, each of which shall be deemed an original, but all of which shall constitute one and the same instrument.  </font></div></td></tr></table><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">{Signature page follows}</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><a name="sc42bce4ba8e04da2ade1445659f59154"></a></div><div></div><div><br></div><div style="line-height:120%;padding-bottom:13px;text-align:justify;text-indent:48px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">IN WITNESS WHEREOF, the Parties intending to be bound have caused this Sixth Amendment to be executed by their duly authorized representatives as of the Sixth Amendment Effective Date.</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:8%;"></td><td style="width:45%;"></td><td style="width:47%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Miragen Therapeutics, Inc.</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:&#160;&#160;&#160;&#160;/s/ William S. Marshall</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:&#160;&#160;&#160;&#160;William S. MARSHALL</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:&#160;&#160;&#160;&#160;President and CEO</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Les Laboratoires Servier</font></div><div style="padding-bottom:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-bottom:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:&#160;&#160;&#160;&#160;/s/ Christian Bazantay</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:&#160;&#160;&#160;&#160;Christian BAZANTAY</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:&#160;&#160;&#160;&#160;Proxy</font></div><div style="padding-top:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="padding-top:16px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Institut de Recherches Servier</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">By:&#160;&#160;&#160;&#160;/s/ Emmanuel Canet</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Name:&#160;&#160;&#160;&#160;Emmanuel CANET</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Title:&#160;&#160;&#160;&#160;President Research and Development</font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">[Signature Page of the Sixth Amendment of the License and Collaboration Agreement by and between Miragen Therapeutics, Inc. and Les Laboratoires Servier]</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>a102yaletouploadctr.htm
<DESCRIPTION>EXHIBIT 10.2
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc --><TITLE>a102yaletouploadctr</TITLE></HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:799;">
<!-- Slide 0001 -->
<DIV style="padding-top:2em;">
<IMG src="a102yaletouploadctr001.jpg" title="Page 1" width="799" height="1034">
<DIV><FONT size="1" style="font-size:1pt;color:white">Exhibit 10.2 &#13;&#10; &#13;&#10;[*] = Certain confidential information contained in this document, marked by brackets, is filed with the Securities and &#13;&#10;Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. &#13;&#10; &#13;&#10;Research Subaward Agreement &#13;&#10;Amendment &#13;&#10;Pass-Through Entity (PTE) Subrecipient &#13;&#10; Yale University Entity Name Miragen Therapeutics, Inc. &#13;&#10; &#13;&#10;Office of Sponsored Projects &#13;&#10;25 Science Park, 3rd Floor &#13;&#10;150 Munson Street, PO Box 208327 &#13;&#10;New Haven, CT 06520-8327 &#13;&#10;Address &#13;&#10;including City, State, Zip+4 &#13;&#10;(Country, if non-US) &#13;&#10;6200 Lookout Road &#13;&#10;Boulder, CO 80301 &#13;&#10;[*], MD Principal Investigator Rusty Montgomery, MD &#13;&#10; PTE Federal Award No: Amendment No: Federal Awarding Agency: &#13;&#10;National Heart, Lung, and Blood Institute 5UH3HL123886-04   4  &#13;&#10;Project Title: Mir-29 mimicry as a therapy for pulmonary fibrosis &#13;&#10;Subaward Period of Performance: Amount Funded This Action: Subaward No: &#13;&#10;Start Date: Jul 1, 2017 End Date: Jun 30, 2018   $ [*]   GR100301  (CON-80000904) &#13;&#10;Effective Date of Amendment: Total Amount of Federal Funds Obligated to Date: &#13;&#10;$ [*] &#13;&#10;Subject to FFATA: &#13;&#10;&#10004; Yes No Jul 1, 2017  &#13;&#10; Amendment(s) to Original Terms and Conditions &#13;&#10;This Amendment revises the above-referenced Research Subaward Agreement as follows: &#13;&#10;Action: &#13;&#10;&#8226; Subaward Period of Performance extended to June 30, 2018. &#13;&#10; &#13;&#10;&#8226; Authorized Funding for Budget Period: [*] &#13;&#10; &#13;&#10;&#8226; Carry over is not automatic and requires prior approval. &#13;&#10; &#13;&#10;&#8226; Subaward No. revised to GR100301 (CON-80000904). Invoices that do not reference the &#13;&#10;revised Subaward No. will be returned to Subrecipient. Questions concerning invoices should be &#13;&#10;directed to Dennis Titley at dennis.titley@yale.edu. &#13;&#10;All other terms and conditions of this Subaward Agreement remain in full force and effect. &#13;&#10;By an Authorized Official of PTE: &#13;&#10;           /s/ Andrea Lozano &#13;&#10;  _ &#13;&#10;Name: Andrea Lozano                   Date 10/5 / 17 &#13;&#10;Title: Award Manager &#13;&#10;By an Authorized Official of &#13;&#10;Subrecipient: &#13;&#10; /s/ Jason Leverone  &#13;&#10; &#13;&#10; 9/29/2017 | 10:18 AM MDT  &#13;&#10;Name: &#13;&#10;Title: &#13;&#10;Jason Leverone  Date &#13;&#10;Chief Financial Officer &#13;&#10; &#13;&#10;&#13;&#10;</FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>

</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>mgen-9302017xex311.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sDB4D3D15995D5D3FB0F94576626E2B34"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, William S. Marshall, certify that:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.&#160;&#160;&#160; I have reviewed this Quarterly Report on Form 10-Q of Miragen Therapeutics, Inc., a Delaware corporation;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.&#160;&#160;&#160; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160; Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.&#160;&#160;&#160; The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.&#160;&#160;&#160; The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.703125%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:29%;"></td><td style="width:17%;"></td><td style="width:5%;"></td><td style="width:49%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: November&#160;9, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ William S. Marshall</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William S. Marshall, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>mgen-9302017xex312.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s2723446E0107513FAEE8F4D1EE6803AD"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 31.2</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">I, Jason A. Leverone, certify that:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.&#160;&#160;&#160; I have reviewed this Quarterly Report on Form 10-Q of Miragen Therapeutics, Inc., a Delaware corporation;</font></div><div style="line-height:120%;text-align:justify;text-indent:6px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.&#160;&#160;&#160; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.&#160;&#160;&#160; Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.&#160;&#160;&#160; The registrant's other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a&#8211;15(e) and 15d&#8211;15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.&#160;&#160;&#160; The registrant's other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:justify;text-indent:72px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:26%;"></td><td style="width:17%;"></td><td style="width:5%;"></td><td style="width:52%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: November&#160;9, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">By:</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Jason A. Leverone</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jason A. Leverone</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer; Principal Accounting Officer)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>mgen-9302017xex321.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s89297EF7135158039A082AFCA76687BE"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Exhibit 32.1</font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SECTION 1350 CERTIFICATION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Each of the undersigned, William S. Marshall, Chief Executive Officer of Miragen Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221;), and Jason A. Leverone, Chief Financial Officer of the Company, do hereby certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that, to the best of his knowledge (1) the Quarterly Report on Form 10-Q of the Company for the quarterly period ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended, and (2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:25%;"></td><td style="width:25%;"></td><td style="width:17%;"></td><td style="width:33%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ William S. Marshall</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">William S. Marshall, Ph.D.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Executive Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Executive Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: November&#160;9, 2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">/s/ Jason A. Leverone</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Jason A. Leverone</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Principal Financial Officer; Principal Accounting Officer)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date: November&#160;9, 2017</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">This certification accompanies and is being &#8220;furnished&#8221; with this Report, shall not be deemed &#8220;filed&#8221; by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Report, irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement required by Section 906, has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div style="text-align:center;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>mgen-20170930.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:5A323D08C651555D86832F8DB846B904,x:0486ef935ce1479e8af6052f13c904a1-->
<xbrli:xbrl xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgen="http://www.miragentherapeutics.com/20170930" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
	<link:schemaRef xlink:href="mgen-20170930.xsd" xlink:type="simple" />
	<xbrli:context id="FD2017Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q3nov2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesBRedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgen:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementClassOfStockAxis_mgen_SeriesBRedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgen:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementClassOfStockAxis_mgen_SeriesCRedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgen:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesCRedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgen:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgen:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgen:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_PrivateFinancingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgen:PrivateFinancingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_PrivateFinancingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgen:PrivateFinancingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgen:AtthemarketOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgen:AtthemarketOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_PrivateFinancingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgen:PrivateFinancingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgen:AtthemarketOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_PrivateFinancingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgen:PrivateFinancingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q3">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgen:AtthemarketOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_ShelfRegistrationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgen:ShelfRegistrationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_ShelfRegistrationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgen:ShelfRegistrationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_ConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2015Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3SinceOffering_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgen:AtthemarketOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-14</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb13_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mgen:SignalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgen:AtthemarketOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb13_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember_us-gaap_ConversionOfStockByUniqueDescriptionAxis_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mgen:SignalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mgen:SignalSharesIssuedToMiragenCommonShareholdersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb12_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mgen:SignalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgen:AtthemarketOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2016Q4Oct1Dec31_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2011-10-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb13_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember_us-gaap_OwnershipAxis_mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mgen:SignalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OwnershipAxis">mgen:PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb12_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb13_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember_us-gaap_OwnershipAxis_mgen_SignalShareholdersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mgen:SignalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OwnershipAxis">mgen:SignalShareholdersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb13_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember_us-gaap_OwnershipAxis_mgen_MiragenShareholdersMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">mgen:SignalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:OwnershipAxis">mgen:MiragenShareholdersMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q2Apr_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mgen:TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-04-01</xbrli:startDate>
			<xbrli:endDate>2015-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_ClassOfWarrantOrRightAxis_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mgen:DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mgen:TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q2Apr_us-gaap_DebtInstrumentAxis_mgen_SiliconValleyBankAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mgen:SiliconValleyBankAgreementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_us-gaap_ShareholdersEquityClassAxis_us-gaap_WarrantsNotSettleableInCashMember_us-gaap_ValuationTechniqueAxis_us-gaap_IncomeApproachValuationTechniqueMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mgen:DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShareholdersEquityClassAxis">us-gaap:WarrantsNotSettleableInCashMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ValuationTechniqueAxis">us-gaap:IncomeApproachValuationTechniqueMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q2Apr_us-gaap_ClassOfWarrantOrRightAxis_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mgen:DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mgen:TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q2May31_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mgen:TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q2May31_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mgen:TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mgen:TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2015Q2May_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mgen:TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-05-01</xbrli:startDate>
			<xbrli:endDate>2015-05-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2015Q2May31_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">mgen:TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:NotesPayableToBanksMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-05-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_mgen_UniversityofTexasMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgen:UniversityofTexasMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_CounterpartyNameAxis_mgen_RocheInnovationCenterCopenhagenASMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgen:RocheInnovationCenterCopenhagenASMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_CounterpartyNameAxis_mgen_UniversityofTexasMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgen:UniversityofTexasMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_mgen_RocheInnovationCenterCopenhagenASMember_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgen:RocheInnovationCenterCopenhagenASMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgen:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_mgen_T2cureGmbHMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgen:T2cureGmbHMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_MajorCustomersAxis_mgen_YaleUniversityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgen:YaleUniversityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_mgen_RocheInnovationCenterCopenhagenASMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgen:RocheInnovationCenterCopenhagenASMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_CounterpartyNameAxis_mgen_UniversityofTexasMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgen:UniversityofTexasMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_CounterpartyNameAxis_mgen_T2cureGmbHMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgen:T2cureGmbHMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2010Q4Oct_us-gaap_CounterpartyNameAxis_mgen_T2cureGmbHMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgen:T2cureGmbHMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2010-10-01</xbrli:startDate>
			<xbrli:endDate>2010-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_mgen_TheBrighamandWomensHospitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgen:TheBrighamandWomensHospitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_CounterpartyNameAxis_mgen_T2cureGmbHMember_us-gaap_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgen:T2cureGmbHMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_mgen_RocheInnovationCenterCopenhagenASMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgen:RocheInnovationCenterCopenhagenASMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_CounterpartyNameAxis_mgen_T2cureGmbHMember_us-gaap_StatementGeographicalAxis_mgen_EuropeanUnionorJapanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgen:T2cureGmbHMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">mgen:EuropeanUnionorJapanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_MajorCustomersAxis_mgen_YaleUniversityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgen:YaleUniversityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q3YaleAgreement_us-gaap_MajorCustomersAxis_mgen_YaleUniversityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:MajorCustomersAxis">mgen:YaleUniversityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-10-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_CounterpartyNameAxis_mgen_UniversityofTexasMember_us-gaap_StatementGeographicalAxis_us-gaap_NonUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">mgen:UniversityofTexasMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">us-gaap:NonUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Jan1Feb13_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-02-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Jan1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesCRedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgen:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-02-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesBRedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgen:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesCRedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgen:SeriesCRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Jan1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgen:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-02-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb13_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Jan1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesBRedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgen:SeriesBRedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-02-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">mgen:SeriesARedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb13">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-13</xbrli:startDate>
			<xbrli:endDate>2017-02-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb13_us-gaap_ConversionOfStockByUniqueDescriptionAxis_mgen_PostMergerSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mgen:PostMergerSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-13</xbrli:startDate>
			<xbrli:endDate>2017-02-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgen:AtthemarketOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb13_us-gaap_ConversionOfStockByUniqueDescriptionAxis_mgen_PreMergerSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mgen:PreMergerSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1Feb13_us-gaap_ConversionOfStockByUniqueDescriptionAxis_mgen_PreMergerSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mgen:PreMergerSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-13</xbrli:startDate>
			<xbrli:endDate>2017-02-13</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q1March31_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgen:AtthemarketOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-31</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb13_us-gaap_ConversionOfStockByUniqueDescriptionAxis_mgen_PostMergerSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ConversionOfStockByUniqueDescriptionAxis">mgen:PostMergerSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-13</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q1Feb28_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mgen:CommonStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsExpiring2019and2020Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mgen:CommonStockWarrantsExpiring2019and2020Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_PreferredStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mgen:PreferredStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_ClassOfWarrantOrRightAxis_mgen_PreferredStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mgen:PreferredStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_mgen_PreferredStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mgen:PreferredStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mgen:CommonStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mgen:CommonStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsExpiring2025Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">mgen:CommonStockWarrantsExpiring2025Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_PlanNameAxis_mgen_EquityPlan2008Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgen:EquityPlan2008Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_mgen_NonemployeeStockOptionMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_mgen_NonemployeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mgen:NonemployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">mgen:NonemployeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_AwardTypeAxis_mgen_NonemployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mgen:NonemployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_mgen_NonemployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mgen:NonemployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_PlanNameAxis_mgen_EquityPlan2016Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">mgen:EquityPlan2016Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_RangeAxis_us-gaap_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-07-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-07-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2017Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AwardTypeAxis_mgen_NonemployeeStockOptionMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_mgen_NonemployeesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">mgen:NonemployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis">mgen:NonemployeesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mgen_PreferredStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgen:PreferredStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mgen_CommonStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgen:CommonStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mgen_CommonStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgen:CommonStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mgen_PreferredStockWarrantsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">mgen:PreferredStockWarrantsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="I2017Q4Nov7_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgen:AtthemarketOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context>
	<xbrli:context id="D2017Q4Oct1Nov7_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0001590750</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">mgen:AtthemarketOfferingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-11-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context>
	<xbrli:unit id="segment">
		<xbrli:measure>mgen:segment</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="eur">
		<xbrli:measure>iso4217:EUR</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="tranche">
		<xbrli:measure>mgen:tranche</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit>
	<xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit>
	<xbrli:unit id="arrangement">
		<xbrli:measure>mgen:arrangement</xbrli:measure>
	</xbrli:unit>
	<dei:AmendmentFlag contextRef="FD2017Q3YTD" id="Fact-2D15A22A6C9A5648D0850825E9182554">false</dei:AmendmentFlag>
	<dei:CurrentFiscalYearEndDate contextRef="FD2017Q3YTD" id="Fact-AF841D1FD69B64D70DA90825E9181B57">--12-31</dei:CurrentFiscalYearEndDate>
	<dei:DocumentFiscalPeriodFocus contextRef="FD2017Q3YTD" id="Fact-C2BF2C6B95A1DC3417F90825E918B581">Q3</dei:DocumentFiscalPeriodFocus>
	<dei:DocumentFiscalYearFocus contextRef="FD2017Q3YTD" id="Fact-AD542D940CCE2CD677EF0825E9199824">2017</dei:DocumentFiscalYearFocus>
	<dei:DocumentPeriodEndDate contextRef="FD2017Q3YTD" id="Fact-F8778BF5C48C73B806950825E91803C1">2017-09-30</dei:DocumentPeriodEndDate>
	<dei:DocumentType contextRef="FD2017Q3YTD" id="Fact-4906261D2E540108591A0825E91944A2">10-Q</dei:DocumentType>
	<dei:EntityCentralIndexKey contextRef="FD2017Q3YTD" id="Fact-523286323D93810A83420825E9187236">0001590750</dei:EntityCentralIndexKey>
	<dei:EntityCommonStockSharesOutstanding contextRef="I2017Q3nov2" decimals="INF" id="Fact-F67A1E4A2F0692D0C3CE0825E9199F5B" unitRef="shares">22309419</dei:EntityCommonStockSharesOutstanding>
	<dei:EntityFilerCategory contextRef="FD2017Q3YTD" id="Fact-53C42242AD8434BE5C3C0825E918AD26">Smaller Reporting Company</dei:EntityFilerCategory>
	<dei:EntityRegistrantName contextRef="FD2017Q3YTD" id="Fact-3DDE29A856373B32138A0825E9192FFC">MIRAGEN THERAPEUTICS, INC.</dei:EntityRegistrantName>
	<mgen:AccretionofOfferingCosts contextRef="FD2016Q3YTD" decimals="-3" id="Fact-35021338F9DF755FCDD70825E91ADE55" unitRef="usd">37000</mgen:AccretionofOfferingCosts>
	<mgen:AccretionofOfferingCosts contextRef="FD2017Q3YTD" decimals="-3" id="Fact-AB6AFD3941FCF62B38130825E917E404" unitRef="usd">5000</mgen:AccretionofOfferingCosts>
	<mgen:AccruedLegalFeesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-27E3C8EDAAED68887F330825E92296F2" unitRef="usd">759000</mgen:AccruedLegalFeesCurrent>
	<mgen:AccruedLegalFeesCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-292C05851221C10222C40825E921FBC9" unitRef="usd">607000</mgen:AccruedLegalFeesCurrent>
	<mgen:AccruedLiabilitiesEquipmentandLabMaterials contextRef="FI2016Q4" decimals="-3" id="Fact-F3160488B87EB130C2240825E922F8C6" unitRef="usd">0</mgen:AccruedLiabilitiesEquipmentandLabMaterials>
	<mgen:AccruedLiabilitiesEquipmentandLabMaterials contextRef="FI2017Q3" decimals="-3" id="Fact-8D5F517C5F835EEDDBC10825E91DD7E8" unitRef="usd">156000</mgen:AccruedLiabilitiesEquipmentandLabMaterials>
	<mgen:AccruedLiabilityofWarrantsonTemporaryEquity contextRef="FI2016Q4" decimals="-3" id="Fact-9073E99082F4E471AB6B0825E91E3BD1" unitRef="usd">133000</mgen:AccruedLiabilityofWarrantsonTemporaryEquity>
	<mgen:AccruedLiabilityofWarrantsonTemporaryEquity contextRef="FI2017Q3" decimals="-3" id="Fact-30A692F7C3B49C9C2BC30825E9140755" unitRef="usd">82000</mgen:AccruedLiabilityofWarrantsonTemporaryEquity>
	<mgen:AccruedOutsourcingClinicalandPreclinicalStudies contextRef="FI2016Q4" decimals="-3" id="Fact-F494AED38A7B5258A7510825E91E9A9F" unitRef="usd">1684000</mgen:AccruedOutsourcingClinicalandPreclinicalStudies>
	<mgen:AccruedOutsourcingClinicalandPreclinicalStudies contextRef="FI2017Q3" decimals="-3" id="Fact-585F23ED8279502CFC160825E9226380" unitRef="usd">1635000</mgen:AccruedOutsourcingClinicalandPreclinicalStudies>
	<mgen:AccumulatedAmortizationDeferredCosts contextRef="FI2017Q3" decimals="-3" id="Fact-09965C615DFB3EED678E784955F711D7" unitRef="usd">8000</mgen:AccumulatedAmortizationDeferredCosts>
	<mgen:AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability contextRef="FD2017Q3YTD" decimals="-3" id="Fact-B992961223E165E475A50825E919350E" unitRef="usd">51000</mgen:AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability>
	<mgen:AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-CB0323BEFFFCC0F411180825E91A45FD" unitRef="usd">51000</mgen:AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability>
	<mgen:CapitalStockSharesAuthorized contextRef="FI2017Q3" decimals="INF" id="Fact-91884E4BF3B3BAE35AE60825E916C763" unitRef="shares">105000000</mgen:CapitalStockSharesAuthorized>
	<mgen:ClassofWarrantorRightAcquiredinAcquisition contextRef="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsMember" decimals="INF" id="Fact-96A0CC3637635177F95D0825E91DBE1B" unitRef="shares">13534</mgen:ClassofWarrantorRightAcquiredinAcquisition>
	<mgen:ClassofWarrantorRightAcquiredinAcquisition contextRef="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_PreferredStockWarrantsMember" decimals="INF" id="Fact-AE8FCD8DF98D32B6A6EF0825E9147099" unitRef="shares">0</mgen:ClassofWarrantorRightAcquiredinAcquisition>
	<mgen:ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice contextRef="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsMember" decimals="2" id="Fact-E91833F9DA333A4D71120825E91C254D" unitRef="usdPerShare">80.70</mgen:ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice>
	<mgen:ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice contextRef="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_PreferredStockWarrantsMember" decimals="2" id="Fact-A47F25E4D0C8C22D85AD0825E91CB6B9" unitRef="usdPerShare">0.00</mgen:ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice>
	<mgen:ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice contextRef="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsMember" decimals="2" id="Fact-5327E3A419FC41F3EB3B0825E91EED29" unitRef="usdPerShare">6.21</mgen:ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice>
	<mgen:ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice contextRef="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_PreferredStockWarrantsMember" decimals="2" id="Fact-BA0DD74FC2174CFB9DD20825E91F92B2" unitRef="usdPerShare">6.21</mgen:ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice>
	<mgen:ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice contextRef="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsMember" decimals="2" id="Fact-58A3595BB25F653DE34E0825E91C1F5C" unitRef="usdPerShare">3.04</mgen:ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice>
	<mgen:ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice contextRef="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_PreferredStockWarrantsMember" decimals="2" id="Fact-2D322A517F13457BBAEA0825E91C084E" unitRef="usdPerShare">0.00</mgen:ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice>
	<mgen:ClassofWarrantorRightWarrantsConverted contextRef="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsMember" decimals="INF" id="Fact-40F22BFE57A327FF1E8A0825E91CF312" unitRef="shares">25779</mgen:ClassofWarrantorRightWarrantsConverted>
	<mgen:ClassofWarrantorRightWarrantsConverted contextRef="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_PreferredStockWarrantsMember" decimals="INF" id="Fact-0B947A2B1496A1B95D750825E91FE2AA" unitRef="shares">-25779.000</mgen:ClassofWarrantorRightWarrantsConverted>
	<mgen:ClassofWarrantorRightWarrantsExercised contextRef="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsMember" decimals="INF" id="Fact-740418C8A163AFAA8E860825E91C58B3" unitRef="shares">21092.000</mgen:ClassofWarrantorRightWarrantsExercised>
	<mgen:ClassofWarrantorRightWarrantsExercised contextRef="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_PreferredStockWarrantsMember" decimals="INF" id="Fact-7795791896EB7EBD29B30825E91C0D68" unitRef="shares">0</mgen:ClassofWarrantorRightWarrantsExercised>
	<mgen:CollaborationArrangementPotentialCashProceedsforServices contextRef="FI2017Q3_us-gaap_MajorCustomersAxis_mgen_YaleUniversityMember" decimals="-5" id="Fact-04C6F9F748AFA3C228830825E91C5BAD" unitRef="usd">1100000</mgen:CollaborationArrangementPotentialCashProceedsforServices>
	<mgen:CollaborationArrangementTermOfAgreement contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_mgen_T2cureGmbHMember" id="Fact-2F1B4C39D69391684EC70825E9179428">P10Y</mgen:CollaborationArrangementTermOfAgreement>
	<mgen:CollaborationArrangementTermOfAgreement contextRef="FD2017Q3YTD_us-gaap_MajorCustomersAxis_mgen_YaleUniversityMember" id="Fact-DAA9162C5838681623D80825E91C0924">P5Y</mgen:CollaborationArrangementTermOfAgreement>
	<mgen:CollaborationArrangementTermofAgreementTerminationPeriod contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_mgen_T2cureGmbHMember" id="Fact-EFD5A6250ECE0302D7800825E91B1B51">P60D</mgen:CollaborationArrangementTermofAgreementTerminationPeriod>
	<mgen:CollaborativeArrangementNumberofArrangements contextRef="FI2017Q3_us-gaap_CounterpartyNameAxis_mgen_UniversityofTexasMember" decimals="INF" id="Fact-7441F63E7E874D2E1ACC0825E916821C" unitRef="arrangement">5</mgen:CollaborativeArrangementNumberofArrangements>
	<mgen:CollaborativeArrangementPotentialCommercializationMilestonePayments contextRef="FI2017Q3_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-6" id="Fact-3B684F9D90E0DCA119CD0825E91AD1DF" unitRef="eur">175000000</mgen:CollaborativeArrangementPotentialCommercializationMilestonePayments>
	<mgen:CollaborativeArrangementPotentialCommercializationMilestonePayments contextRef="FI2017Q3_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-A154490FA50651E277AB0825E915B741" unitRef="usd">206700000</mgen:CollaborativeArrangementPotentialCommercializationMilestonePayments>
	<mgen:CollaborativeArrangementPotentialDevelopmentMilestonePayments contextRef="FI2017Q3_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-F24C0B3159AEA3AAE9DB0825E91ABBA6" unitRef="eur">13800000</mgen:CollaborativeArrangementPotentialDevelopmentMilestonePayments>
	<mgen:CollaborativeArrangementPotentialDevelopmentMilestonePayments contextRef="FI2017Q3_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-6743B0F29BF6106461020825E91B3BF2" unitRef="usd">16300000</mgen:CollaborativeArrangementPotentialDevelopmentMilestonePayments>
	<mgen:CollaborativeArrangementPotentialDevelopmentMilestonePayments contextRef="FI2017Q3_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-C536AB0C93C3D196F98B0825E91B9894" unitRef="eur">5800000</mgen:CollaborativeArrangementPotentialDevelopmentMilestonePayments>
	<mgen:CollaborativeArrangementPotentialDevelopmentMilestonePayments contextRef="FI2017Q3_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-8FDD6CE89D9509A31C9A0825E9153227" unitRef="usd">6900000</mgen:CollaborativeArrangementPotentialDevelopmentMilestonePayments>
	<mgen:CollaborativeArrangementPotentialRegulatoryMilestonePayments contextRef="FI2017Q3_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-22C724B2FDDE8D1EB27D0825E9152AC4" unitRef="eur">40000000</mgen:CollaborativeArrangementPotentialRegulatoryMilestonePayments>
	<mgen:CollaborativeArrangementPotentialRegulatoryMilestonePayments contextRef="FI2017Q3_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-A484BDA8B53AE5C308680825E9159DE5" unitRef="usd">47300000</mgen:CollaborativeArrangementPotentialRegulatoryMilestonePayments>
	<mgen:CollaborativeArrangementPotentialRegulatoryMilestonePayments contextRef="FI2017Q3_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-5FCFE5302F73DA5DA6DB0825E9152690" unitRef="eur">10000000</mgen:CollaborativeArrangementPotentialRegulatoryMilestonePayments>
	<mgen:CollaborativeArrangementPotentialRegulatoryMilestonePayments contextRef="FI2017Q3_us-gaap_RangeAxis_us-gaap_MinimumMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-D38E7095DB00F70D91D40825E91AEC55" unitRef="usd">11800000</mgen:CollaborativeArrangementPotentialRegulatoryMilestonePayments>
	<mgen:ConversionOfStockSharesIssuedConversionRate contextRef="I2017Q1Feb12_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-2E73E74FCA23BE97B6280825E91B009A" unitRef="number">1</mgen:ConversionOfStockSharesIssuedConversionRate>
	<mgen:ConversionOfStockSharesIssuedConversionRate contextRef="I2017Q1Feb13_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember_us-gaap_ConversionOfStockByUniqueDescriptionAxis_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember" decimals="INF" id="Fact-682A343CB30BFA2F815D0825E91F03A2" unitRef="number">0.7031</mgen:ConversionOfStockSharesIssuedConversionRate>
	<mgen:ConversionOfStockSharesIssuedConversionRate contextRef="I2017Q1Feb28_us-gaap_StatementClassOfStockAxis_us-gaap_PreferredStockMember" decimals="INF" id="Fact-ECA0CFC438BA1591A26C0825E91EC02B" unitRef="number">1</mgen:ConversionOfStockSharesIssuedConversionRate>
	<mgen:ConversionofWarrantstoPermanentEquity contextRef="FD2016Q3YTD" decimals="-3" id="Fact-C6E99CF0DDB49541C8A20825E916042F" unitRef="usd">0</mgen:ConversionofWarrantstoPermanentEquity>
	<mgen:ConversionofWarrantstoPermanentEquity contextRef="FD2017Q3YTD" decimals="-3" id="Fact-957DF7063BB677ACCCC60825E917A83E" unitRef="usd">51000</mgen:ConversionofWarrantstoPermanentEquity>
	<mgen:DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed contextRef="I2015Q2May31_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember" decimals="INF" id="Fact-24E4D38086CBB3A5E0E00825E915B140" unitRef="number">0.055</mgen:DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed>
	<mgen:DebtInstrumentNumberOfTranches contextRef="I2015Q2Apr_us-gaap_DebtInstrumentAxis_mgen_SiliconValleyBankAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember" decimals="INF" id="Fact-E6734A69DA2F806D7C9E0825E91AACAA" unitRef="tranche">2</mgen:DebtInstrumentNumberOfTranches>
	<mgen:DebtInstrumentTermInterestOnlyPayments contextRef="D2015Q2May_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember" id="Fact-A5136CFA52AA7A45D33D0825E91AB1A3">P18M</mgen:DebtInstrumentTermInterestOnlyPayments>
	<mgen:FairValueInputsProbabilityofExercise contextRef="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_us-gaap_ShareholdersEquityClassAxis_us-gaap_WarrantsNotSettleableInCashMember_us-gaap_ValuationTechniqueAxis_us-gaap_IncomeApproachValuationTechniqueMember" decimals="3" id="Fact-7BB09E8366E45403AD390825E9220658" unitRef="number">0.900</mgen:FairValueInputsProbabilityofExercise>
	<mgen:LicenseCostAnnualMaintenanceFeePerLicense contextRef="D2010Q4Oct_us-gaap_CounterpartyNameAxis_mgen_T2cureGmbHMember" decimals="-3" id="Fact-A5350D1EF18C487D0AA70825E91712A8" unitRef="eur">3000</mgen:LicenseCostAnnualMaintenanceFeePerLicense>
	<mgen:LicenseCostAnnualMaintenanceFeePerLicense contextRef="D2010Q4Oct_us-gaap_CounterpartyNameAxis_mgen_T2cureGmbHMember" decimals="-3" id="Fact-FEFBFB4A9C81B6614E570825E9177CBD" unitRef="usd">3000</mgen:LicenseCostAnnualMaintenanceFeePerLicense>
	<mgen:LicenseCostAnnualMaintenanceFeePerLicense contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_mgen_UniversityofTexasMember" decimals="-3" id="Fact-3104D1C38574112A66100825E91D980A" unitRef="usd">10000</mgen:LicenseCostAnnualMaintenanceFeePerLicense>
	<mgen:LicenseCostPotentialMilestonePaymentRegulatoryApproval contextRef="FI2017Q3_us-gaap_CounterpartyNameAxis_mgen_T2cureGmbHMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-89B14AA3716DEA2D353D0825E9176CD4" unitRef="usd">2500000</mgen:LicenseCostPotentialMilestonePaymentRegulatoryApproval>
	<mgen:LicenseCostPotentialMilestonePaymentRegulatoryApproval contextRef="FI2017Q3_us-gaap_CounterpartyNameAxis_mgen_T2cureGmbHMember_us-gaap_StatementGeographicalAxis_mgen_EuropeanUnionorJapanMember" decimals="INF" id="Fact-2520F4B5A627C014FD910825E91B2FB8" unitRef="usd">1500000.0</mgen:LicenseCostPotentialMilestonePaymentRegulatoryApproval>
	<mgen:LicenseCostPotentialMilestonePaymentRegulatoryApproval contextRef="FI2017Q3_us-gaap_CounterpartyNameAxis_mgen_UniversityofTexasMember_us-gaap_StatementGeographicalAxis_country_US" decimals="-5" id="Fact-2B7B26C0FF3E4248783E0825E9188A36" unitRef="usd">2000000</mgen:LicenseCostPotentialMilestonePaymentRegulatoryApproval>
	<mgen:LicenseCostPotentialMilestonePaymentRegulatoryApproval contextRef="FI2017Q3_us-gaap_CounterpartyNameAxis_mgen_UniversityofTexasMember_us-gaap_StatementGeographicalAxis_us-gaap_NonUsMember" decimals="-5" id="Fact-A9265E1424B4D9693C6E0825E91C2852" unitRef="usd">500000</mgen:LicenseCostPotentialMilestonePaymentRegulatoryApproval>
	<mgen:LicenseCostsOnetimeSalesMilestonePayment contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_mgen_TheBrighamandWomensHospitalMember" decimals="-5" id="Fact-1114FBE7E858F99D8A600825E91C5D70" unitRef="usd">300000</mgen:LicenseCostsOnetimeSalesMilestonePayment>
	<mgen:LicenseCostsPotentialMilestonePayment contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_mgen_TheBrighamandWomensHospitalMember" decimals="-5" id="Fact-A7178978E1C028A2F1CA0825E91C057D" unitRef="usd">2600000</mgen:LicenseCostsPotentialMilestonePayment>
	<mgen:LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials contextRef="FI2017Q3_us-gaap_CounterpartyNameAxis_mgen_T2cureGmbHMember" decimals="-5" id="Fact-AADEC473C1C5203549AF0825E91C2A32" unitRef="usd">700000</mgen:LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials>
	<mgen:LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials contextRef="FI2017Q3_us-gaap_CounterpartyNameAxis_mgen_UniversityofTexasMember" decimals="-5" id="Fact-B4DB750AB9197864790F0825E9150FE5" unitRef="usd">600000</mgen:LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials>
	<mgen:LicenseCostsPotentialMilestonePaymentPerLicensedProduct contextRef="FI2017Q3_us-gaap_CounterpartyNameAxis_mgen_RocheInnovationCenterCopenhagenASMember" decimals="INF" id="Fact-E5BA573A76EF04B1DEAF0825E91DF900" unitRef="usd">5200000.0</mgen:LicenseCostsPotentialMilestonePaymentPerLicensedProduct>
	<mgen:LicenseCostsUpfrontLicensingFeePerLicense contextRef="D2010Q4Oct_us-gaap_CounterpartyNameAxis_mgen_T2cureGmbHMember" decimals="-3" id="Fact-FD35ACFC433ADE7D6A470825E9177AA2" unitRef="usd">46000</mgen:LicenseCostsUpfrontLicensingFeePerLicense>
	<mgen:LicenseCostsUpfrontLicensingFeePerLicense contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_mgen_UniversityofTexasMember" decimals="-3" id="Fact-877241C0E3BA8579A8160825E915DA09" unitRef="usd">10000</mgen:LicenseCostsUpfrontLicensingFeePerLicense>
	<mgen:LongTermDebtAccumulatedAccretionOfFinalPaymentFee contextRef="FI2016Q4" decimals="-3" id="Fact-293620346CF4068E9CBA0825E91AE0AC" unitRef="usd">167000</mgen:LongTermDebtAccumulatedAccretionOfFinalPaymentFee>
	<mgen:LongTermDebtAccumulatedAccretionOfFinalPaymentFee contextRef="FI2017Q3" decimals="-3" id="Fact-6C959D00A578DC3A4C320825E9155985" unitRef="usd">227000</mgen:LongTermDebtAccumulatedAccretionOfFinalPaymentFee>
	<mgen:MarketCapitalization contextRef="I2017Q1Feb12_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember" decimals="-5" id="Fact-92717046E7E68FCDEA9D0825E919581F" unitRef="usd">12600000</mgen:MarketCapitalization>
	<mgen:OperatingLeasesOperatingExpense contextRef="FD2016Q3QTD" decimals="-5" id="Fact-2E1CB81D108097ED50190825E920365A" unitRef="usd">100000</mgen:OperatingLeasesOperatingExpense>
	<mgen:OperatingLeasesOperatingExpense contextRef="FD2016Q3YTD" decimals="-5" id="Fact-C5DDB425382893FAB1A10825E920D93E" unitRef="usd">200000</mgen:OperatingLeasesOperatingExpense>
	<mgen:OperatingLeasesOperatingExpense contextRef="FD2017Q3QTD" decimals="-5" id="Fact-9F8D361B9ACE8CCD95FD0825E9203DDA" unitRef="usd">100000</mgen:OperatingLeasesOperatingExpense>
	<mgen:OperatingLeasesOperatingExpense contextRef="FD2017Q3YTD" decimals="-5" id="Fact-902955016A1CB0A6C7C80825E91A48AF" unitRef="usd">200000</mgen:OperatingLeasesOperatingExpense>
	<mgen:PaymentsForLicensingAgreement contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_mgen_RocheInnovationCenterCopenhagenASMember" decimals="-5" id="Fact-2CE3AB71646ADCD6B69B0825E91C5DF3" unitRef="usd">2300000</mgen:PaymentsForLicensingAgreement>
	<mgen:PaymentstoAcquireRawMaterials contextRef="FD2016Q3YTD_us-gaap_CounterpartyNameAxis_mgen_RocheInnovationCenterCopenhagenASMember" decimals="-5" id="Fact-28A1D2CF4D57D1B80F4E0825E91CCCCC" unitRef="usd">200000</mgen:PaymentstoAcquireRawMaterials>
	<mgen:PaymentstoAcquireRawMaterials contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_mgen_RocheInnovationCenterCopenhagenASMember" decimals="-5" id="Fact-8ED2AFF66702904A3D8E0825E921398D" unitRef="usd">500000</mgen:PaymentstoAcquireRawMaterials>
	<mgen:SaleofStockAdditionalAuthorizedTransactionAmount contextRef="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="INF" id="Fact-8C0AE46746008082D529782C5E6BDC41" unitRef="usd">50000000</mgen:SaleofStockAdditionalAuthorizedTransactionAmount>
	<mgen:SaleofStockCommissionFeePercentageofGrossSaleProceeds contextRef="D2017Q1March31_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="INF" id="Fact-783C01DBBDCA46EB50BA0825E91F961A" unitRef="number">0.03</mgen:SaleofStockCommissionFeePercentageofGrossSaleProceeds>
	<mgen:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding contextRef="FI2017Q3" decimals="INF" id="Fact-FDDDBAB5089F2E7F85F30825E91E29E5" unitRef="shares">908227</mgen:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding>
	<mgen:SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_mgen_NonemployeeStockOptionMember" id="Fact-F58DA708BC3E089036360825E91EDF1E">P0Y11M12D</mgen:SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition>
	<mgen:SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions contextRef="FI2017Q3_us-gaap_AwardTypeAxis_mgen_NonemployeeStockOptionMember" decimals="-5" id="Fact-9F4931B24BE44CDBA1540825E919E1B2" unitRef="usd">100000</mgen:SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions>
	<mgen:StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction contextRef="FD2016Q3YTD" decimals="-3" id="Fact-5AE467AFB86DBB4452E10825E9168D04" unitRef="usd">0</mgen:StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction>
	<mgen:StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction contextRef="FD2017Q3YTD" decimals="-3" id="Fact-3D4F18E42FC9D9750F640825E9155541" unitRef="usd">3000</mgen:StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction>
	<mgen:StockIssuedDuringPeriodSharesExerciseofWarrants contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-FCE1EE8E2D76B7D27A6D0825E91BB054" unitRef="shares">16387</mgen:StockIssuedDuringPeriodSharesExerciseofWarrants>
	<mgen:TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction contextRef="FD2016Q3YTD" decimals="-3" id="Fact-ED9C16961EAA0828DEDE5589CAC2D1CD" unitRef="usd">0</mgen:TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction>
	<mgen:TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction contextRef="FD2017Q3YTD" decimals="-3" id="Fact-B54540D991C8B700FEC95589CAAD187C" unitRef="usd">339000</mgen:TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction>
	<us-gaap:AccountsPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-9CDDB846AC8F928872240825E918EF36" unitRef="usd">1007000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsPayableCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-595A247C8169830F17280825E91700FA" unitRef="usd">409000</us-gaap:AccountsPayableCurrent>
	<us-gaap:AccountsReceivableNet contextRef="FI2016Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-3" id="Fact-679404CC24D6B6AE70C178339256E321" unitRef="usd">0</us-gaap:AccountsReceivableNet>
	<us-gaap:AccountsReceivableNet contextRef="FI2017Q3_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-D7263B817D58C65F7C937833924E48AC" unitRef="usd">500000</us-gaap:AccountsReceivableNet>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-6336985B9F0BA73925010825E91F4B95" unitRef="usd">20000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccountsReceivableNetCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-A84C838861D374A873400825E92136C0" unitRef="usd">635000</us-gaap:AccountsReceivableNetCurrent>
	<us-gaap:AccretionExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-5ADFB27F1C1CA65733840825E9161A6D" unitRef="usd">125000</us-gaap:AccretionExpense>
	<us-gaap:AccretionExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-6F5DFC488070D1E26E460825E91AA577" unitRef="usd">85000</us-gaap:AccretionExpense>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-DF7E03B5C3AC0D62DCA50825E9195B9E" unitRef="usd">3909000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-F0AD892B5F08B2EA91A80825E918B8EA" unitRef="usd">4142000</us-gaap:AccruedLiabilitiesCurrent>
	<us-gaap:AccruedLiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-BF53C6B3250863CF2BA60825E918D7C7" unitRef="usd">0</us-gaap:AccruedLiabilitiesFairValueDisclosure>
	<us-gaap:AccruedLiabilitiesFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-EE7611AC8A8126D848DE0825E916B47D" unitRef="usd">133000</us-gaap:AccruedLiabilitiesFairValueDisclosure>
	<us-gaap:AccruedLiabilitiesFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-0E94AE9755FD96A7C68A0825E9154620" unitRef="usd">0</us-gaap:AccruedLiabilitiesFairValueDisclosure>
	<us-gaap:AccruedLiabilitiesFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-84F2D3194CE890D1C4A90825E916AE6F" unitRef="usd">82000</us-gaap:AccruedLiabilitiesFairValueDisclosure>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-8E35E4FC6BB6082A77580825E91D4992" unitRef="usd">124000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedProfessionalFeesCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-BCBAD0D0497620281F8C0825E91D572C" unitRef="usd">457000</us-gaap:AccruedProfessionalFeesCurrent>
	<us-gaap:AccruedRentCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-3BAB5B143EFA6BBD9DDF0825E9199703" unitRef="usd">221000</us-gaap:AccruedRentCurrent>
	<us-gaap:AccruedRentCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-1CE9D6300D272AA50DFE0825E9227D14" unitRef="usd">70000</us-gaap:AccruedRentCurrent>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2016Q4" decimals="-3" id="Fact-A9BD4ACA8FF03A7DBFEC0825E91A9A35" unitRef="usd">2558000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="FI2017Q3" decimals="-3" id="Fact-4698DD5EC0996010A3230825E918663A" unitRef="usd">2776000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2016Q4" decimals="-3" id="Fact-6B8EEDB00590DB5E27590825E9218FB7" unitRef="usd">5147000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdditionalPaidInCapital contextRef="FI2017Q3" decimals="-3" id="Fact-1A3DF06152926E0639C00825E9141279" unitRef="usd">125973000</us-gaap:AdditionalPaidInCapital>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q3YTD" decimals="-3" id="Fact-1815B298B5AA81C64BAC0825E918C761" unitRef="usd">1693000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-33C9D7147836BECF2CC90825E9174745" unitRef="usd">1693000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
	<us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="FD2017Q3YTD" decimals="-5" id="Fact-FEE3266EE77AFBC24A047846E2B957F2" unitRef="usd">400000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-E4E212E52A26BDBFFD610825E921534E" unitRef="usd">45000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-D1D3CE7E62F8715D054B5594E832B1CF" unitRef="usd">40000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-70278B7D13520DD86BE25594E83A932D" unitRef="usd">5000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-E942F164200D679203FA0825E920465D" unitRef="usd">129000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-39A34DA8BB83F35BBE6A0825E920C4C7" unitRef="usd">107000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2016Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-586178B20AE691D872CF0825E9205763" unitRef="usd">22000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-58CE37D938B97DB95AD60825E9206F71" unitRef="usd">679000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-B7D461E5AA68D124FFA45594E849161C" unitRef="usd">416000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3QTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-DA3808EE507E661221935594E84185F6" unitRef="usd">263000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-4889CDDEE5430955B3650825E920FF07" unitRef="usd">1693000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember" decimals="-3" id="Fact-3223399E076553DB62BD0825E920FDC5" unitRef="usd">1050000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AllocatedShareBasedCompensationExpense contextRef="FD2017Q3YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" decimals="-3" id="Fact-53519D2FDCEC2AB186A70825E9202A56" unitRef="usd">643000</us-gaap:AllocatedShareBasedCompensationExpense>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q3YTD" decimals="-3" id="Fact-0865EDBC299AA4AB0BDD0825E9205DD1" unitRef="shares">15365000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mgen_CommonStockWarrantsMember" decimals="-3" id="Fact-AE1720B40E67F81BCDF90825E91FC1C0" unitRef="shares">7000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mgen_PreferredStockWarrantsMember" decimals="-3" id="Fact-BD079B1CB7327BAD27CD0825E9207AEA" unitRef="shares">26000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" decimals="-3" id="Fact-D98418D09924AD5E0C8755A24420A049" unitRef="shares">13067000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2016Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-8DAF414959AE6F2FA0DB0825E9200BA1" unitRef="shares">2265000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3YTD" decimals="-3" id="Fact-46CE8AC9BB5E5C3830F80825E920D4FE" unitRef="shares">2994000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mgen_CommonStockWarrantsMember" decimals="-3" id="Fact-1F96E0865ECFC8B3AA3F0825E9213E4D" unitRef="shares">25000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_mgen_PreferredStockWarrantsMember" decimals="-3" id="Fact-6FF28ACB2CF6342C3A710825E91F32DE" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_ConvertibleDebtSecuritiesMember" decimals="-3" id="Fact-9B5FDF6FE0EB6B26BF3F0825E9204349" unitRef="shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="FD2017Q3YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-AEE507A181F6B22D56800825E9218A94" unitRef="shares">2969000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
	<us-gaap:Assets contextRef="FI2016Q4" decimals="-3" id="Fact-7FB092923B8D43782EBF0825E9216363" unitRef="usd">24760000</us-gaap:Assets>
	<us-gaap:Assets contextRef="FI2017Q3" decimals="-3" id="Fact-7F8EF90B759DEE4502EC0825E9198D3B" unitRef="usd">47081000</us-gaap:Assets>
	<us-gaap:AssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-8EC74F55ED6C0FF29F5E0825E921B01D" unitRef="usd">23877000</us-gaap:AssetsCurrent>
	<us-gaap:AssetsCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-CA93375B0925807644FF0825E9167910" unitRef="usd">46421000</us-gaap:AssetsCurrent>
	<us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired contextRef="I2017Q1Feb13_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember_us-gaap_OwnershipAxis_mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember" decimals="INF" id="Fact-58E8B356A76BA088C8310825E920DA37" unitRef="number">0.952</us-gaap:BusinessAcquisitionPercentageOfVotingInterestsAcquired>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents contextRef="I2017Q1Feb13_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember" decimals="-3" id="Fact-505575F846C4EDBB4E7D0825E917AA20" unitRef="usd">1280000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets contextRef="I2017Q1Feb13_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember" decimals="-3" id="Fact-E114235A9CD072247C5E0825E91BCB9F" unitRef="usd">248000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="I2017Q1Feb13_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember" decimals="-3" id="Fact-21EDA44BE6ABE8CDAD7B0825E91BD04C" unitRef="usd">204000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet contextRef="I2017Q1Feb13_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember" decimals="-5" id="Fact-F99E6B778934F23123260825E91B8DF6" unitRef="usd">200000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet>
	<us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities contextRef="I2017Q1Feb13_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember" decimals="-3" id="Fact-2CD50A853028138C16A10825E91C95A5" unitRef="usd">1324000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities>
	<us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="I2017Q1Feb13_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember_us-gaap_OwnershipAxis_mgen_MiragenShareholdersMember" decimals="3" id="Fact-52F25A0DCA32AFF443EF0825E91A6681" unitRef="number">0.041</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
	<us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage contextRef="I2017Q1Feb13_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember_us-gaap_OwnershipAxis_mgen_SignalShareholdersMember" decimals="3" id="Fact-F27342A750A82A7042B50825E91BE79E" unitRef="number">0.959</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
	<us-gaap:CashAcquiredFromAcquisition contextRef="FD2016Q3YTD" decimals="-3" id="Fact-187C83A63DE7FAA1906F0825E9159543" unitRef="usd">0</us-gaap:CashAcquiredFromAcquisition>
	<us-gaap:CashAcquiredFromAcquisition contextRef="FD2017Q3YTD" decimals="-3" id="Fact-FCFEF4418C75AFED202A0825E91BF388" unitRef="usd">1280000</us-gaap:CashAcquiredFromAcquisition>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2015Q4" decimals="-3" id="Fact-F8DF56E2614FF0A769A10825E91727BE" unitRef="usd">21235000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q3" decimals="-3" id="Fact-CEA7C38975B02945BC290825E9163221" unitRef="usd">24598000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2016Q4" decimals="-3" id="Fact-5467963469D1C71C4DBE0825E9213683" unitRef="usd">22104000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="FI2017Q3" decimals="-3" id="Fact-217E4308228697E385490825E918900D" unitRef="usd">42805000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-9E765977A2F7A6E54DD60825E9168297" unitRef="usd">22189000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2016Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-E00BB6C8932E0FA278A30825E916B083" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" decimals="-3" id="Fact-18AE9F4A56FDD55CA6380825E916594C" unitRef="usd">44112000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashAndCashEquivalentsFairValueDisclosure contextRef="FI2017Q3_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" decimals="-3" id="Fact-B86505CD3641B46CFC8B0825E9164334" unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
	<us-gaap:CashPeriodIncreaseDecrease contextRef="FD2016Q3YTD" decimals="-3" id="Fact-B5CC0DDB246EAF6B9C8A0825E9151E05" unitRef="usd">3363000</us-gaap:CashPeriodIncreaseDecrease>
	<us-gaap:CashPeriodIncreaseDecrease contextRef="FD2017Q3YTD" decimals="-3" id="Fact-5C52C6E58C32031CDA0F0825E91A6BA7" unitRef="usd">20701000</us-gaap:CashPeriodIncreaseDecrease>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsMember" decimals="2" id="Fact-ED94A3A9C630E4B668C30825E91D195A" unitRef="usdPerShare">0.57</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_mgen_PreferredStockWarrantsMember" decimals="2" id="Fact-80AAFB63CB0FF1AE453D0825E91CD6C9" unitRef="usdPerShare">6.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q3_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsExpiring2019and2020Member" decimals="2" id="Fact-A5F7E2E3163C371DC82B0825E91DDA8C" unitRef="usdPerShare">80.70</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q3_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsExpiring2025Member" decimals="2" id="Fact-6DD4BED4D8F81F52ECC40825E91DFD40" unitRef="usdPerShare">8.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q3_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsMember" decimals="2" id="Fact-7A0BEBEDA980B8A94C2A0825E91D8CF7" unitRef="usdPerShare">47.21</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="FI2017Q3_us-gaap_ClassOfWarrantOrRightAxis_mgen_PreferredStockWarrantsMember" decimals="2" id="Fact-6A483C1F2D8FF60896980825E920987B" unitRef="usdPerShare">0.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="I2015Q2Apr_us-gaap_ClassOfWarrantOrRightAxis_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember" decimals="2" id="Fact-E316E07C0EB65F387D310825E918D393" unitRef="usdPerShare">8.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q3_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsExpiring2019and2020Member" decimals="INF" id="Fact-FD90B7B82657F5A867E10825E91F5EF3" unitRef="shares">13534</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q3_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsExpiring2025Member" decimals="INF" id="Fact-78A2D064BABA83D842880825E91C30EF" unitRef="shares">11718</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="FI2017Q3_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsMember" decimals="INF" id="Fact-767B766E6055904AEB580825E91AAF04" unitRef="shares">25252</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="I2015Q2Apr_us-gaap_ClassOfWarrantOrRightAxis_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember" decimals="INF" id="Fact-D942DA606F861AA283CF0825E91C0A07" unitRef="shares">11718</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsMember" decimals="INF" id="Fact-35543CD5CCC409B555C10825E91D9D92" unitRef="shares">7031</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2016Q4_us-gaap_ClassOfWarrantOrRightAxis_mgen_PreferredStockWarrantsMember" decimals="INF" id="Fact-91013185812AECBACDB90825E91C4179" unitRef="shares">25779</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q3_us-gaap_ClassOfWarrantOrRightAxis_mgen_CommonStockWarrantsMember" decimals="INF" id="Fact-84AB62867A22C47D6FCD0825E92038EE" unitRef="shares">25252</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:ClassOfWarrantOrRightOutstanding contextRef="FI2017Q3_us-gaap_ClassOfWarrantOrRightAxis_mgen_PreferredStockWarrantsMember" decimals="INF" id="Fact-32BAF54FA93FD740D3130825E91DD244" unitRef="shares">0</us-gaap:ClassOfWarrantOrRightOutstanding>
	<us-gaap:CommitmentsAndContingencies contextRef="FI2016Q4" id="Fact-1767D74A5E12EA00B20C0825E9175901" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommitmentsAndContingencies contextRef="FI2017Q3" id="Fact-DC43BF40DF5F9A25CA440825E91E8F9B" unitRef="usd" xsi:nil="true" />
	<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="FI2017Q3" decimals="INF" id="Fact-5F9517FCC8A2FCCF4ECB0825E91DA34A" unitRef="shares">773067</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2016Q4" decimals="INF" id="Fact-AAC75272B57C9C8C00950825E91D7169" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="FI2017Q3" decimals="INF" id="Fact-6E34A4EAA73E31E826A30825E91AFB08" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="I2017Q1Feb12_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember" decimals="INF" id="Fact-7CA5C506E565EE467C010825E91FC71D" unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockParOrStatedValuePerShare contextRef="I2017Q1Feb13_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember" decimals="INF" id="Fact-59E3BDCCB986C72F5F5C0825E91F9644" unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2016Q4" decimals="INF" id="Fact-FF8DFA076118573A5D000825E914906F" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesAuthorized contextRef="FI2017Q3" decimals="INF" id="Fact-CBC550401BD8D04AA9CA0825E91F03A2" unitRef="shares">100000000</us-gaap:CommonStockSharesAuthorized>
	<us-gaap:CommonStockSharesIssued contextRef="FI2016Q4" decimals="INF" id="Fact-BE65E36B9B93C72A72DE0825E91FEDD4" unitRef="shares">833744</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesIssued contextRef="FI2017Q3" decimals="INF" id="Fact-B70FEB2D715C6CD2811A0825E92172FD" unitRef="shares">21886568</us-gaap:CommonStockSharesIssued>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4" decimals="INF" id="Fact-9397EC43E0464E25DD050825E916DE62" unitRef="shares">833744</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A56E1068A4F748735F3E0825E9192D60" unitRef="shares">833744</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q3" decimals="INF" id="Fact-6E34F8D7EF1AB869EA600825E9156054" unitRef="shares">21886568</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-F175D140CB42C6850E2D0825E91B6E55" unitRef="shares">21886568</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2017Q1Feb12_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember" decimals="INF" id="Fact-F83B0CEC95444DED35220825E91C6AE2" unitRef="shares">1024960.00</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockSharesOutstanding contextRef="I2017Q1Feb13_us-gaap_BusinessAcquisitionAxis_mgen_SignalMember" decimals="INF" id="Fact-52A84B6C156237E8E08B0825E91FCE41" unitRef="shares">21309440.00</us-gaap:CommonStockSharesOutstanding>
	<us-gaap:CommonStockValue contextRef="FI2016Q4" decimals="-3" id="Fact-1EEB3C1828ADBA9025790825E922AD81" unitRef="usd">8000</us-gaap:CommonStockValue>
	<us-gaap:CommonStockValue contextRef="FI2017Q3" decimals="-3" id="Fact-502C893C4A4B13E494E30825E915D49C" unitRef="usd">219000</us-gaap:CommonStockValue>
	<us-gaap:ConversionOfStockSharesIssued1 contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_mgen_RocheInnovationCenterCopenhagenASMember_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-4882DE3F31BB73A261920825E918B047" unitRef="shares">602420</us-gaap:ConversionOfStockSharesIssued1>
	<us-gaap:CostsInExcessOfBillingsOnUncompletedContractsOrPrograms contextRef="FI2016Q4_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-FFE2BD5660B193F6FC5B0825E9148A68" unitRef="usd">300000</us-gaap:CostsInExcessOfBillingsOnUncompletedContractsOrPrograms>
	<us-gaap:CostsInExcessOfBillingsOnUncompletedContractsOrPrograms contextRef="FI2017Q3_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="INF" id="Fact-C1EA9EC8B842E11A3F520825E91640DA" unitRef="usd">1439871.000</us-gaap:CostsInExcessOfBillingsOnUncompletedContractsOrPrograms>
	<us-gaap:DebtInstrumentBasisSpreadOnVariableRate1 contextRef="D2015Q2Apr_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember" decimals="INF" id="Fact-D4F6042F110991AF74850825E91A2D39" unitRef="number">0.0025</us-gaap:DebtInstrumentBasisSpreadOnVariableRate1>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="FI2016Q4" decimals="-3" id="Fact-3D48C106B35F09B9EB7B0825E91C1709" unitRef="usd">4667000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentCarryingAmount contextRef="FI2017Q3" decimals="-3" id="Fact-F7CFA2BF73E01DE5A2FF0825E9190723" unitRef="usd">3167000</us-gaap:DebtInstrumentCarryingAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2015Q2Apr_us-gaap_DebtInstrumentAxis_mgen_SiliconValleyBankAgreementMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember" decimals="-5" id="Fact-3D31368FCE7F0FB76DF10825E9183E97" unitRef="usd">10000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2015Q2May31_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember" decimals="-5" id="Fact-7F65DDFF57C95260DC920825E9169C54" unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentFaceAmount contextRef="I2015Q2May31_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember" decimals="-5" id="Fact-66AB98934A6C426E60FD0825E91E9D85" unitRef="usd">5000000</us-gaap:DebtInstrumentFaceAmount>
	<us-gaap:DebtInstrumentTerm contextRef="D2015Q2May_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember" id="Fact-12B43E5DA357CE492CD40825E91CA368">P30M</us-gaap:DebtInstrumentTerm>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2016Q4" decimals="-3" id="Fact-5BD61467BEF305E227CD0825E91B3D88" unitRef="usd">14000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DebtInstrumentUnamortizedDiscount contextRef="FI2017Q3" decimals="-3" id="Fact-4D06E04B28C2F77059BB0825E91FB67A" unitRef="usd">6000</us-gaap:DebtInstrumentUnamortizedDiscount>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2016Q4" decimals="-3" id="Fact-45E90D67ECC5EE2AE4230825E9200B10" unitRef="usd">31000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredFinanceCostsNet contextRef="FI2017Q3" decimals="-3" id="Fact-5BC32C03F421043F33830825E91A83A2" unitRef="usd">14000</us-gaap:DeferredFinanceCostsNet>
	<us-gaap:DeferredOfferingCosts contextRef="FI2017Q3" decimals="-5" id="Fact-AE2DD0B57B8B1C392BF37844FE8BFD68" unitRef="usd">100000</us-gaap:DeferredOfferingCosts>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q3QTD" decimals="-5" id="Fact-0897EA75033F4B24BEBE9D2B9A07EEBC" unitRef="usd">100000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q3YTD" decimals="-3" id="Fact-CACE768151E28A6C9ACF0825E9171D73" unitRef="usd">253000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2016Q3YTD" decimals="-5" id="Fact-9E3BAE70AB50CD6A3DE60825E922C93F" unitRef="usd">300000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q3QTD" decimals="-5" id="Fact-C5AA2405CE97C0B861430825E918BAF9" unitRef="usd">100000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q3YTD" decimals="-5" id="Fact-B4769D9EB06B2926503755924EBD0FA4" unitRef="usd">200000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:DepreciationDepletionAndAmortization contextRef="FD2017Q3YTD" decimals="-3" id="Fact-FEB54782E22D3C7A306C0825E9164CFA" unitRef="usd">227000</us-gaap:DepreciationDepletionAndAmortization>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q3QTD" decimals="2" id="Fact-5F9ACD5DDABEF5400B5A0825E917876D" unitRef="usdPerShare">-6.92</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2016Q3YTD" decimals="2" id="Fact-2FDAAAA1F4A3E47881640825E91CDC9C" unitRef="usdPerShare">-18.84</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q3QTD" decimals="2" id="Fact-EEE3E42AE7FAA89F3F9D0825E922862B" unitRef="usdPerShare">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EarningsPerShareBasicAndDiluted contextRef="FD2017Q3YTD" decimals="2" id="Fact-7C28272E08F407215A3D0825E9205D80" unitRef="usdPerShare">-1.11</us-gaap:EarningsPerShareBasicAndDiluted>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-2136794555EA588EBB840825E915EC01" unitRef="usd">928000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-8CE36C06284180A61F030825E91E2F5C" unitRef="usd">1061000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="FI2017Q3" decimals="-5" id="Fact-01CFCD5CE2D6FE5503DC0825E91D087C" unitRef="usd">7400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
	<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="FD2017Q3YTD" id="Fact-AFEBF7A94AB6854F07920825E91E489B">P3Y2M11D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
	<us-gaap:EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-5" id="Fact-F0C5C43C772E5EC06864559BAB0AB531" unitRef="shares">200000</us-gaap:EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2016Q3YTD" decimals="-3" id="Fact-12DF953E81CD90BF061F0825E9175379" unitRef="usd">2000</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAdjustmentOfWarrants contextRef="FD2017Q3YTD" decimals="-3" id="Fact-61992051417DCD484F690825E9173E1E" unitRef="usd">0</us-gaap:FairValueAdjustmentOfWarrants>
	<us-gaap:FairValueAssumptionsExpectedTerm contextRef="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_us-gaap_ShareholdersEquityClassAxis_us-gaap_WarrantsNotSettleableInCashMember_us-gaap_ValuationTechniqueAxis_us-gaap_IncomeApproachValuationTechniqueMember" id="Fact-62E4C98E4205E947C8D20825E917DA03">P2Y</us-gaap:FairValueAssumptionsExpectedTerm>
	<us-gaap:FairValueInputsDiscountRate contextRef="FD2017Q3YTD_us-gaap_ClassOfWarrantOrRightAxis_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_us-gaap_ShareholdersEquityClassAxis_us-gaap_WarrantsNotSettleableInCashMember_us-gaap_ValuationTechniqueAxis_us-gaap_IncomeApproachValuationTechniqueMember" decimals="3" id="Fact-89869DD93D91BA81A6FB0825E91C7943" unitRef="number">0.068</us-gaap:FairValueInputsDiscountRate>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet contextRef="FD2017Q3YTD" decimals="-3" id="Fact-0867E1623EEA6AB45EF90825E91BA48A" unitRef="usd">51000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2016Q4" decimals="-3" id="Fact-8B321D8D2199DFD2BBC00825E91691E4" unitRef="usd">133000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue contextRef="FI2017Q3" decimals="-3" id="Fact-00508D78CE742D4A2A0E0825E91C5053" unitRef="usd">82000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-3CFDF339A8CEAD96BA230825E91B174F" unitRef="usd">2053000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-6E467969FE51D33997170825E91BF3FD" unitRef="usd">4255000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-B16EA69F227EDFB34CC10825E91BF256" unitRef="usd">2502000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:GeneralAndAdministrativeExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-68B6ACC0402296ACEFAE0825E922FCA8" unitRef="usd">8364000</us-gaap:GeneralAndAdministrativeExpense>
	<us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="FD2016Q3QTD" decimals="-3" id="Fact-674F588BCA84F093FA0E0825E92107F9" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
	<us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="FD2016Q3YTD" decimals="-3" id="Fact-AB1697811BE862E28BD30825E921BB7A" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
	<us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="FD2017Q3QTD" decimals="-3" id="Fact-5888B6635B2642A328310825E9212DB7" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
	<us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="FD2017Q3YTD" decimals="INF" id="Fact-EA148EB63E75E4ABC1C10825E915F70A" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
	<us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="FD2016Q3QTD" decimals="INF" id="Fact-D8D97834DDDFD3BB48B90825E92259FC" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
	<us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="FD2016Q3YTD" decimals="INF" id="Fact-A1D6ACD697B91A061A890825E9225FB7" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
	<us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="FD2017Q3QTD" decimals="INF" id="Fact-7003B22B50F84EEA784E0825E921F0D3" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
	<us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense contextRef="FD2017Q3YTD" decimals="INF" id="Fact-68FAB6E1A87B97B44D270825E91E75C6" unitRef="usd">0</us-gaap:IncomeTaxExaminationPenaltiesAndInterestExpense>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2016Q3YTD" decimals="-3" id="Fact-8FF44DDE21C00A0091FB0825E91677E4" unitRef="usd">-586000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsPayable contextRef="FD2017Q3YTD" decimals="-3" id="Fact-336F8D3A9451733C57B00825E91B5E76" unitRef="usd">-598000</us-gaap:IncreaseDecreaseInAccountsPayable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2016Q3YTD" decimals="-3" id="Fact-718F9C5D492BEA7912F20825E915A68D" unitRef="usd">9000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="FD2017Q3YTD" decimals="-3" id="Fact-EEFAADD08D013E0CF58B0825E91669E7" unitRef="usd">615000</us-gaap:IncreaseDecreaseInAccountsReceivable>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-3D785E4A23E73EC624F10825E916B5A9" unitRef="usd">893000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-1571C13248BFB9997E250825E917AD0F" unitRef="usd">-871000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2016Q3YTD" decimals="-3" id="Fact-D9CA23A58CAB6ECEA4AB0825E917F3C3" unitRef="usd">-439000</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInDeferredRevenue contextRef="FD2017Q3YTD" decimals="-3" id="Fact-8C5532782F88E81241540825E91A9C61" unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredRevenue>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2016Q3YTD" decimals="-3" id="Fact-B9EDCD73BBC4A40A83800825E915B29D" unitRef="usd">545000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="FD2017Q3YTD" decimals="-3" id="Fact-15DD105E6FA86647D4830825E91A4BE3" unitRef="usd">719000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
	<us-gaap:InterestAndDebtExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-36AF541ADB48B74FDCA90825E91B3284" unitRef="usd">78000</us-gaap:InterestAndDebtExpense>
	<us-gaap:InterestAndDebtExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-ECAB9D8B28C49C25CC8B0825E922E233" unitRef="usd">250000</us-gaap:InterestAndDebtExpense>
	<us-gaap:InterestAndDebtExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-5958D329C155C51B91B30825E921A903" unitRef="usd">58000</us-gaap:InterestAndDebtExpense>
	<us-gaap:InterestAndDebtExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-74747967E1BC4EA4A7F00825E9156EB7" unitRef="usd">193000</us-gaap:InterestAndDebtExpense>
	<us-gaap:InterestPaid contextRef="FD2016Q3YTD" decimals="-3" id="Fact-29B277B79CBEA79EDAF80825E9170F50" unitRef="usd">124000</us-gaap:InterestPaid>
	<us-gaap:InterestPaid contextRef="FD2017Q3YTD" decimals="-3" id="Fact-9DC37358DF760E7CC2C20825E91B9C3C" unitRef="usd">112000</us-gaap:InterestPaid>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2016Q3QTD" decimals="-5" id="Fact-48DEC70CA239E875615C0825E920D8AC" unitRef="usd">100000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2016Q3YTD" decimals="-5" id="Fact-8EF9CA99E2B0B93CC24C0825E91A8DEF" unitRef="usd">300000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2017Q3QTD" decimals="-5" id="Fact-673940424F4B482428550825E91CC467" unitRef="usd">100000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:LeaseAndRentalExpense contextRef="FD2017Q3YTD" decimals="-5" id="Fact-8B571D1181397F9D30A431C8AB940111" unitRef="usd">200000</us-gaap:LeaseAndRentalExpense>
	<us-gaap:Liabilities contextRef="FI2016Q4" decimals="-3" id="Fact-5584BC0D171C301BAFF20825E922AE4A" unitRef="usd">9705000</us-gaap:Liabilities>
	<us-gaap:Liabilities contextRef="FI2017Q3" decimals="-3" id="Fact-C12D338750600AA19D210825E91A6A30" unitRef="usd">8096000</us-gaap:Liabilities>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-0B41042E437937BEDBB00825E91A7070" unitRef="usd">24760000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesAndStockholdersEquity contextRef="FI2017Q3" decimals="-3" id="Fact-51BAEC5C1D6B4648774A0825E91BF48B" unitRef="usd">47081000</us-gaap:LiabilitiesAndStockholdersEquity>
	<us-gaap:LiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-337B82486AD821155CE40825E9211433" unitRef="usd">6885000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LiabilitiesCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-F07C4FCAA43E198000780825E9172BC5" unitRef="usd">6534000</us-gaap:LiabilitiesCurrent>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2016Q3QTD" decimals="-3" id="Fact-80B5F1EBEB469E2556830825E9163627" unitRef="usd">715000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2016Q3QTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-404E6479C44A81FF0A6F0825E91A5BF2" unitRef="usd">700000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2016Q3YTD" decimals="-3" id="Fact-2DB0BDA5632D4A01CB970825E91E496A" unitRef="usd">2479000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-8BFC2DF503341FF30CC00825E915FD10" unitRef="usd">2500000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2017Q3QTD" decimals="-3" id="Fact-AEE1402136A615F1C9D00825E92066C7" unitRef="usd">1493000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2017Q3QTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-915FBA1A21026FB91B340825E91B4F44" unitRef="usd">1500000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2017Q3YTD" decimals="-3" id="Fact-BA7B182392963841C4AF0825E921D02A" unitRef="usd">1991000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicenseAndServicesRevenue contextRef="FD2017Q3YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-18DD9535D9D7691B6FC90825E9177678" unitRef="usd">2000000</us-gaap:LicenseAndServicesRevenue>
	<us-gaap:LicensesRevenue contextRef="D2016Q4Oct1Dec31_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-CC2C091D81618054ABAE0825E91B6BFC" unitRef="eur">9000000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="D2016Q4Oct1Dec31_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-0A3A2B2F1A9FAC08C99D0825E915A814" unitRef="usd">12400000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q3QTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-7A4715D8256F8409F1610825E915FDA6" unitRef="usd">100000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-8DB110C096DAF0D9A7600825E91B769C" unitRef="usd">500000</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2017Q3QTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="INF" id="Fact-610639154C8C08F9424F0825E92250DD" unitRef="usd">0</us-gaap:LicensesRevenue>
	<us-gaap:LicensesRevenue contextRef="FD2017Q3YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="INF" id="Fact-3C252EC93E16226E27790825E91B297E" unitRef="usd">0</us-gaap:LicensesRevenue>
	<us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd contextRef="FI2017Q3_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_us-gaap_LongtermDebtTypeAxis_us-gaap_NotesPayableToBanksMember_us-gaap_VariableRateAxis_us-gaap_PrimeRateMember" decimals="4" id="Fact-E412140E90B70D5B1EFA0825E91AD13D" unitRef="number">0.0400</us-gaap:LineOfCreditFacilityInterestRateAtPeriodEnd>
	<us-gaap:LongTermDebt contextRef="FI2017Q3" decimals="-3" id="Fact-47DE04C2537EF6C05BBF0825E9190044" unitRef="usd">3167000</us-gaap:LongTermDebt>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="FI2017Q3" decimals="-3" id="Fact-1FC29396AA4A7AA76DD50825E9219F3C" unitRef="usd">667000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="FI2017Q3" decimals="-3" id="Fact-4ACED0478C2EEFA89B4C0825E919B3EC" unitRef="usd">2000000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
	<us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear contextRef="FI2017Q3" decimals="-3" id="Fact-857981D387B1B9E675A30825E91B48BB" unitRef="usd">500000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear>
	<us-gaap:LongTermNotesPayable contextRef="FI2016Q4" decimals="-3" id="Fact-3AC37D6923D55817EE190825E91BF794" unitRef="usd">2820000</us-gaap:LongTermNotesPayable>
	<us-gaap:LongTermNotesPayable contextRef="FI2017Q3" decimals="-3" id="Fact-287C65D2A6E563E48A780825E91D504F" unitRef="usd">1391000</us-gaap:LongTermNotesPayable>
	<us-gaap:MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments contextRef="FD2016Q3YTD" decimals="-3" id="Fact-1E816EBAE0CCE30E88490825E91666FB" unitRef="usd">-9000</us-gaap:MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments>
	<us-gaap:MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments contextRef="FD2017Q3YTD" decimals="-3" id="Fact-012C1D93230C061054C60825E9167A71" unitRef="usd">0</us-gaap:MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-027798BF7A5E6F91CF640825E9176D08" unitRef="usd">16081000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-AB566E679973BF95F3820825E9154D1E" unitRef="usd">40557000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-24F6733080215A4143F00825E91AEC2A" unitRef="usd">-1250000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-0385F6BCD8174FA7F3750825E9150260" unitRef="usd">1068000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-E3C34FFA87086457B1D60825E91B2A87" unitRef="usd">-11468000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-203D3708543944D837F70825E91BC4B4" unitRef="usd">-20924000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-998368CE8FBAF0E501000825E91F41D9" unitRef="usd">-4153000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2016Q3YTD" decimals="-3" id="Fact-9B62C85C47405C7B176E0825E91D43DF" unitRef="usd">-11300000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3QTD" decimals="-3" id="Fact-F262F6E58B17BEEC250D0825E918EAAF" unitRef="usd">-5834000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3YTD" decimals="-3" id="Fact-003F71628D85DA930FA60825E91D8ACB" unitRef="usd">-20126000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLoss contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-1B87E15D1860803323EA0825E9226DC4" unitRef="usd">-20126000</us-gaap:NetIncomeLoss>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2016Q3QTD" decimals="-3" id="Fact-D0504AE3F2D05E7A12D30825E922EBDE" unitRef="usd">-4166000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2016Q3YTD" decimals="-3" id="Fact-2761F1BE2B3FF624FAE30825E9195051" unitRef="usd">-11337000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2017Q3QTD" decimals="-3" id="Fact-4536098A16822425D1360825E91BF4D6" unitRef="usd">-5834000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic contextRef="FD2017Q3YTD" decimals="-3" id="Fact-56A1EE568A023AD3C8A80825E9170E18" unitRef="usd">-20131000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
	<us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1 contextRef="FD2016Q3YTD" decimals="-3" id="Fact-65801500C1DBACB5B1E90825E9158B09" unitRef="usd">0</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
	<us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1 contextRef="FD2017Q3YTD" decimals="-3" id="Fact-4DFC92140697E41110D20825E91A155C" unitRef="usd">1076000</us-gaap:NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-DE7AAAE0151C7DB81DF80825E916880C" unitRef="usd">7000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-EE9244D37EEADE9F8DE90825E9206D0D" unitRef="usd">23000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-FC6B9CD905F11D0611E10825E9167329" unitRef="usd">113000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NonoperatingIncomeExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-F34F63BFB64FB44E82140825E916DE3F" unitRef="usd">245000</us-gaap:NonoperatingIncomeExpense>
	<us-gaap:NotesPayable contextRef="FI2016Q4" decimals="-3" id="Fact-ACCBA67BBF109DC9C5490825E919D89F" unitRef="usd">4789000</us-gaap:NotesPayable>
	<us-gaap:NotesPayable contextRef="FI2017Q3" decimals="-3" id="Fact-E33966CA33CBB51BB39A0825E9196919" unitRef="usd">3374000</us-gaap:NotesPayable>
	<us-gaap:NotesPayableCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-9CFB055CA552B34908B70825E921E39C" unitRef="usd">1969000</us-gaap:NotesPayableCurrent>
	<us-gaap:NotesPayableCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-4F77D9050154312EF8E10825E919172B" unitRef="usd">1983000</us-gaap:NotesPayableCurrent>
	<us-gaap:NumberOfOperatingSegments contextRef="FD2017Q3YTD" decimals="INF" id="Fact-68AFA6C2FC5FD3AE618E0825E920828F" unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
	<us-gaap:OperatingExpenses contextRef="FD2016Q3QTD" decimals="-3" id="Fact-48A4172E65DB335C20580825E91E1A34" unitRef="usd">5018000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2016Q3YTD" decimals="-3" id="Fact-CB5B660D2E8FCFA120FB0825E921B2E1" unitRef="usd">14041000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q3QTD" decimals="-3" id="Fact-22C0EDF601FD9A6897120825E91C309B" unitRef="usd">7520000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingExpenses contextRef="FD2017Q3YTD" decimals="-3" id="Fact-3FB8BF7BAC29888660320825E921D595" unitRef="usd">22989000</us-gaap:OperatingExpenses>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q3QTD" decimals="-3" id="Fact-D6EF93B5780C24EA3E5A0825E91EE467" unitRef="usd">-4082000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2016Q3YTD" decimals="-3" id="Fact-7F13BF55241FD451E6610825E916E22B" unitRef="usd">-11073000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q3QTD" decimals="-3" id="Fact-40AFE1F54CC4AC10699A0825E921F648" unitRef="usd">-5889000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingIncomeLoss contextRef="FD2017Q3YTD" decimals="-3" id="Fact-5CE959D0962EDDB033030825E922CC38" unitRef="usd">-20178000</us-gaap:OperatingIncomeLoss>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="FI2017Q3" decimals="-3" id="Fact-8105373437174880BD5D0825E91B150D" unitRef="usd">1167000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="FI2017Q3" decimals="-3" id="Fact-36B054948024FB33E3760825E91B3A7C" unitRef="usd">277000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="FI2017Q3" decimals="-3" id="Fact-E356754D478612EA7AA40825E91B13C7" unitRef="usd">404000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="FI2017Q3" decimals="-3" id="Fact-969F759F67042E7D71700825E91B21EC" unitRef="usd">391000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
	<us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear contextRef="FI2017Q3" decimals="-3" id="Fact-D4BFEEFD802A5EB47E8D0825E91CB7A9" unitRef="usd">95000</us-gaap:OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-A7D3A80B7271C68282C90825E9187671" unitRef="usd">60000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-15A97FAC0BBF51FBB6840825E921C22C" unitRef="usd">74000</us-gaap:OtherAccruedLiabilitiesCurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-6B569E8D7970742ED7850825E91D3228" unitRef="usd">258000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherAssetsNoncurrent contextRef="FI2017Q3" decimals="-3" id="Fact-17B564BEE2F608B4EEB50825E91A384B" unitRef="usd">50000</us-gaap:OtherAssetsNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2016Q4" decimals="-3" id="Fact-E2657770264A5A78C02B0825E91A2519" unitRef="usd">0</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:OtherLiabilitiesNoncurrent contextRef="FI2017Q3" decimals="-3" id="Fact-4D1C868D93B4E660EF700825E9143BE0" unitRef="usd">171000</us-gaap:OtherLiabilitiesNoncurrent>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="D2017Q1Feb13" decimals="-5" id="Fact-83DE6F47CCB1804515960825E9213A2E" unitRef="usd">1500000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2016Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="-3" id="Fact-4492A267699842ABBBE331C1011C621A" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2016Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_PrivateFinancingMember" decimals="-3" id="Fact-E490D19DA302DB2090F90825E914176E" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2016Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_ShelfRegistrationMember" decimals="-3" id="Fact-C9B7E51B3AF656E01413558BB4C986C1" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2016Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="-3" id="Fact-860355477766743C3FD80825E9229C0B" unitRef="usd">10000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2017Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="-3" id="Fact-ECC15EE5FE424C1587FC31C0FF8AB356" unitRef="usd">172000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2017Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_PrivateFinancingMember" decimals="-3" id="Fact-6E2AE9FEC9BDBC804C810825E917F5E1" unitRef="usd">1216000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2017Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_ShelfRegistrationMember" decimals="-3" id="Fact-24A85A369E214E5E1A94558BB1574E31" unitRef="usd">299000</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsOfStockIssuanceCosts contextRef="FD2017Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_ConvertiblePreferredStockMember" decimals="-3" id="Fact-9FEE3A205BAF2F7876A30825E9171430" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
	<us-gaap:PaymentsToAcquireMarketableSecurities contextRef="FD2016Q3YTD" decimals="-3" id="Fact-54FE3C67B42019A43FB10825E915D165" unitRef="usd">1010000</us-gaap:PaymentsToAcquireMarketableSecurities>
	<us-gaap:PaymentsToAcquireMarketableSecurities contextRef="FD2017Q3YTD" decimals="-3" id="Fact-B77510433D5FD7F51B990825E917E8F1" unitRef="usd">0</us-gaap:PaymentsToAcquireMarketableSecurities>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2016Q3YTD" decimals="-3" id="Fact-18CA581970B2A2FB5EF40825E918C614" unitRef="usd">240000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="FD2017Q3YTD" decimals="-3" id="Fact-1690F47160924A2CF3F80825E9183F05" unitRef="usd">212000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
	<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="FD2017Q3YTD" decimals="-3" id="Fact-FD517CF2629FAEB2D4E50825E9200E15" unitRef="usd">5000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
	<us-gaap:PreferredStockAccretionOfRedemptionDiscount contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-C29D34F620E0D680FD1E0825E9170757" unitRef="usd">5000</us-gaap:PreferredStockAccretionOfRedemptionDiscount>
	<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="FI2017Q3" decimals="INF" id="Fact-CE1AD5C4732A7406BCD40825E91DE9A0" unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
	<us-gaap:PreferredStockSharesAuthorized contextRef="FI2017Q3" decimals="INF" id="Fact-6199F62729DD68AE805D0825E9171EC5" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2016Q4" decimals="-3" id="Fact-8D18385C46267FAF764B0825E91EA428" unitRef="usd">1753000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="FI2017Q3" decimals="-3" id="Fact-88D7201AEE555C0935960825E91EDCFD" unitRef="usd">2981000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
	<us-gaap:ProceedsFromCollaborators contextRef="D2017Q3YaleAgreement_us-gaap_MajorCustomersAxis_mgen_YaleUniversityMember" decimals="-5" id="Fact-67AF89C06F47DEB066D57837927E89E6" unitRef="usd">100000</us-gaap:ProceedsFromCollaborators>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2017Q1Feb13" decimals="-5" id="Fact-3D16AEF702EA2BE31FA5783C5FB83048" unitRef="usd">40700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="D2017Q4Oct1Nov7_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="-5" id="Fact-7D18652ABFA91870C25F92949F1CBFCB" unitRef="usd">3900000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2016Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="-3" id="Fact-B4BF6F243878FA8DC8F631C0E51D20BC" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2016Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_PrivateFinancingMember" decimals="-3" id="Fact-221A62D331A74823C1810825E91AB306" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2017Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="-3" id="Fact-4B718568C5C081FA89C031C0E3827B38" unitRef="usd">2711000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="FD2017Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_PrivateFinancingMember" decimals="-3" id="Fact-825B66E09380678CB3BF0825E91FF4D1" unitRef="usd">40703000</us-gaap:ProceedsFromIssuanceOfCommonStock>
	<us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock contextRef="FD2016Q3YTD" decimals="-3" id="Fact-4D2F1BEE7C3609E36FFD0825E921BD8F" unitRef="usd">16091000</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
	<us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock contextRef="FD2017Q3YTD" decimals="-3" id="Fact-08398AC74F4A9AD164030825E9217FC4" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock>
	<us-gaap:ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans contextRef="FD2016Q3YTD" decimals="-3" id="Fact-0395306B08DD5A17D8E631C41FF2BADE" unitRef="usd">0</us-gaap:ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans>
	<us-gaap:ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans contextRef="FD2017Q3YTD" decimals="-3" id="Fact-5D350700CEBEE7FE436131C41FF91F46" unitRef="usd">110000</us-gaap:ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2016Q3YTD" decimals="-3" id="Fact-68571D906DA660C803FC0825E9176A87" unitRef="usd">0</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:ProceedsFromStockOptionsExercised contextRef="FD2017Q3YTD" decimals="-3" id="Fact-87B242D70345B5CD1F390825E91853EE" unitRef="usd">220000</us-gaap:ProceedsFromStockOptionsExercised>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4" decimals="-3" id="Fact-844D31A715F2EDDD62940825E919340B" unitRef="usd">3183000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-9A734DEC5FB0C2155DEF0825E919D59C" unitRef="usd">281000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" decimals="-3" id="Fact-467A572394F424AD00DC0825E91914B3" unitRef="usd">2163000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-91D6915848CA58F9FA260825E91F3F0D" unitRef="usd">51000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2016Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-69C049831676B59C9F000825E915F9CD" unitRef="usd">688000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q3" decimals="-3" id="Fact-C86E966F1DBBF11E151D0825E9228243" unitRef="usd">3386000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember" decimals="-3" id="Fact-7C16D2437F5E80B08C9D0825E91762A4" unitRef="usd">361000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember" decimals="-3" id="Fact-C35F504D1971F94F6BD30825E9180666" unitRef="usd">2219000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" decimals="-3" id="Fact-B3BB4E006DB2203A878D0825E91ADC45" unitRef="usd">77000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentGross contextRef="FI2017Q3_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember" decimals="-3" id="Fact-75EEDEA121191FEB8F120825E91B2165" unitRef="usd">729000</us-gaap:PropertyPlantAndEquipmentGross>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2016Q4" decimals="-3" id="Fact-761A742BA5F2DC885D0C0825E921EDB5" unitRef="usd">625000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentNet contextRef="FI2017Q3" decimals="-3" id="Fact-4B24241AA8C1C0F0AB0A0825E9190142" unitRef="usd">610000</us-gaap:PropertyPlantAndEquipmentNet>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-56631F2C784545B169860825E91573D0">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MinimumMember" id="Fact-F74F79B8F8A79D1D7BBE0825E91DE674">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
	<us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="D2017Q1Jan1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-74B87716F86039017B050825E91AF7E6" unitRef="usd">-23125000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
	<us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="D2017Q1Jan1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesBRedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-CD6217863BF52C774DA80825E917F22A" unitRef="usd">-12976000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
	<us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="D2017Q1Jan1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesCRedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-9C6EEA49A22DB646E6510825E917BE7F" unitRef="usd">-40880000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
	<us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="D2017Q1Jan1Feb13_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-71539C0635B9F7A44F9692908C67037D" unitRef="usd">-76981000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
	<us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="FD2016Q3YTD" decimals="-3" id="Fact-E0DF72FC3225A3E699C10825E9178134" unitRef="usd">0</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
	<us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="FD2017Q3YTD" decimals="-3" id="Fact-85882BFB65852E1329BD0825E920A768" unitRef="usd">76981000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
	<us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="FD2017Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-263CBD016721921D64880825E918421E" unitRef="usd">-76981000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
	<us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-EE288434EAF988C834C40825E919C1F5" unitRef="usd">76850000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
	<us-gaap:ReclassificationsOfTemporaryToPermanentEquity contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-ACF197ACF186DA1010790825E91F1BB8" unitRef="usd">131000</us-gaap:ReclassificationsOfTemporaryToPermanentEquity>
	<us-gaap:ReimbursementRevenue contextRef="FD2016Q3QTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-0FC3FE6FDA722CFB5A460825E91A349C" unitRef="usd">600000</us-gaap:ReimbursementRevenue>
	<us-gaap:ReimbursementRevenue contextRef="FD2016Q3YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-C41D74EFFE28209FE31A0825E91BABDB" unitRef="usd">2000000</us-gaap:ReimbursementRevenue>
	<us-gaap:ReimbursementRevenue contextRef="FD2017Q3QTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-57EF610A8E44C3E3E5EE0825E91ADC79" unitRef="usd">1500000</us-gaap:ReimbursementRevenue>
	<us-gaap:ReimbursementRevenue contextRef="FD2017Q3YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" decimals="-5" id="Fact-9DD489BD5F9467EDE72C0825E91AD035" unitRef="usd">2000000</us-gaap:ReimbursementRevenue>
	<us-gaap:RepaymentsOfNotesPayable contextRef="FD2016Q3YTD" decimals="-3" id="Fact-20DEB3DC781710A4AE710825E9199753" unitRef="usd">0</us-gaap:RepaymentsOfNotesPayable>
	<us-gaap:RepaymentsOfNotesPayable contextRef="FD2017Q3YTD" decimals="-3" id="Fact-A00F9B4F2D0352BDF6670825E9187C0F" unitRef="usd">1500000</us-gaap:RepaymentsOfNotesPayable>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q3QTD" decimals="-3" id="Fact-0A69924F179AF55BBDBC0825E91C61BC" unitRef="usd">2965000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2016Q3YTD" decimals="-3" id="Fact-FE4E2A94404824993CD30825E91D6D94" unitRef="usd">9786000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q3QTD" decimals="-3" id="Fact-9A56F354E05E6D33F6070825E91ABCC0" unitRef="usd">5018000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:ResearchAndDevelopmentExpense contextRef="FD2017Q3YTD" decimals="-3" id="Fact-60E6C5BF49EBB9068E3B0825E9199CC5" unitRef="usd">14625000</us-gaap:ResearchAndDevelopmentExpense>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2016Q4" decimals="-3" id="Fact-B84E3D2A0D16451E30F20825E91E6E25" unitRef="usd">-67076000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="FI2017Q3" decimals="-3" id="Fact-553AD3654083A761EF4E0825E916AA4A" unitRef="usd">-87207000</us-gaap:RetainedEarningsAccumulatedDeficit>
	<us-gaap:RevenueFromGrants contextRef="FD2016Q3QTD" decimals="-3" id="Fact-F22BB6C13385478835580825E91F08B7" unitRef="usd">221000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="FD2016Q3YTD" decimals="-3" id="Fact-54EFB4B81FC8676DDF9C0825E917E392" unitRef="usd">489000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="FD2017Q3QTD" decimals="-3" id="Fact-075D9A289DCB43DCC7E70825E921D101" unitRef="usd">138000</us-gaap:RevenueFromGrants>
	<us-gaap:RevenueFromGrants contextRef="FD2017Q3YTD" decimals="-3" id="Fact-DCA762FD9330AA5A02500825E91BD94E" unitRef="usd">820000</us-gaap:RevenueFromGrants>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2017Q3SinceOffering_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="-5" id="Fact-3B6DFD063BAD721A5357782CE7309AD1" unitRef="usd">2700000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="D2017Q4Oct1Nov7_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="-5" id="Fact-73C5C6983B67FAAED93392954F29B78B" unitRef="usd">3800000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="FD2017Q3YTD_us-gaap_RangeAxis_us-gaap_MaximumMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="-5" id="Fact-A46AC42F3961C4BE9A900825E91587AC" unitRef="usd">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="FD2017Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="-5" id="Fact-13BE31D27E6D2DC0E85B31CB34DF5FCE" unitRef="usd">2500000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2017Q3SinceOffering_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="INF" id="Fact-DC3CCC2D5F767B688B13782E0FFB5051" unitRef="shares">297653</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="D2017Q4Oct1Nov7_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="INF" id="Fact-F325B465669B39622F1C9294EA2B9291" unitRef="shares">403306</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
	<us-gaap:SaleOfStockPricePerShare contextRef="FI2017Q3_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="2" id="Fact-0A1E3B7F7A01B0664CBD0825E91D9E2F" unitRef="usdPerShare">9.11</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2017Q1Feb13_us-gaap_ConversionOfStockByUniqueDescriptionAxis_mgen_PostMergerSharesMember" decimals="2" id="Fact-5C87A4489595DEFF517A0825E91E020B" unitRef="usdPerShare">6.40</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2017Q1Feb13_us-gaap_ConversionOfStockByUniqueDescriptionAxis_mgen_PreMergerSharesMember" decimals="2" id="Fact-DFB7D69A6776B9ED7A880825E922B1D3" unitRef="usdPerShare">4.50</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SaleOfStockPricePerShare contextRef="I2017Q4Nov7_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="2" id="Fact-BE91A2FE5650F487D010929424DA62EF" unitRef="usdPerShare">9.65</us-gaap:SaleOfStockPricePerShare>
	<us-gaap:SalesRevenueNet contextRef="FD2016Q3QTD" decimals="-3" id="Fact-93DBE61BECB90D0F23610825E91F71EF" unitRef="usd">936000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2016Q3YTD" decimals="-3" id="Fact-585F9A7A0B41AF4378000825E91CB576" unitRef="usd">2968000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2017Q3QTD" decimals="-3" id="Fact-D892EACDD0119A6C55780825E91A06D1" unitRef="usd">1631000</us-gaap:SalesRevenueNet>
	<us-gaap:SalesRevenueNet contextRef="FD2017Q3YTD" decimals="-3" id="Fact-6CBA0B7111FE56A31A040825E918C86C" unitRef="usd">2811000</us-gaap:SalesRevenueNet>
	<us-gaap:ShareBasedCompensation contextRef="FD2016Q3YTD" decimals="-3" id="Fact-63281BFBC428899E59150825E9153176" unitRef="usd">129000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensation contextRef="FD2017Q3YTD" decimals="-3" id="Fact-78A1174A393A000B9B9B0825E918EFEA" unitRef="usd">1693000</us-gaap:ShareBasedCompensation>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_RangeAxis_us-gaap_MaximumMember" id="Fact-F61E67C8DF2C4E5FF5040825E91E62BB">P48M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" id="Fact-26CAA35C9559B10DC9C40825E91DC49D">P36M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-E52B109FE47CDE24FBB50825E91D5EB1" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="0" id="Fact-ED9FA253BFEE862D58140825E9204C2A" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="3" id="Fact-B813B7BEBD88F045C4590825E91FB1D7" unitRef="number">0.840</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="3" id="Fact-9B40E2682D41BB53FEF60825E91FB4D9" unitRef="number">0.838</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="3" id="Fact-BC93C1D054B868E3DDE90825E91D5B7E" unitRef="number">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="3" id="Fact-C8DEC6C5DD69427F24170825E91F7B3D" unitRef="number">0.021</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="FI2017Q3_us-gaap_PlanNameAxis_mgen_EquityPlan2016Member" decimals="INF" id="Fact-9E9C573528D013F4E2E90825E91D7D3F" unitRef="shares">4182404</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="FI2017Q3_us-gaap_PlanNameAxis_mgen_EquityPlan2016Member" decimals="INF" id="Fact-F5306418011D9C7F98270825E91FA7F6" unitRef="shares">1681294</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-6AE7EBDD0A167A9797420825E91FF019" unitRef="shares">34000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_mgen_NonemployeeStockOptionMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_mgen_NonemployeesMember" decimals="-3" id="Fact-8B18256049DA85AD188D0825E91E747E" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_mgen_NonemployeeStockOptionMember_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_mgen_NonemployeesMember" decimals="INF" id="Fact-0D078037B2E62EC0CF720825E91E51B6" unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-F389CD9225EC283426900825E9201997" unitRef="shares">956000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-088B90154848F2A96D170825E91C4181" unitRef="usdPerShare">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-258D891C8611A753D8130825E91D4A6F" unitRef="usdPerShare">8.32</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-B2DDF014D963F81A21F40825E91F4D9C" unitRef="shares">2321000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-75D8EC5F29779D59A2D70825E9218FA3" unitRef="shares">2969000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="FI2017Q3_us-gaap_PlanNameAxis_mgen_EquityPlan2008Member" decimals="INF" id="Fact-6C4B91EC26B66D4B58750825E91D9889" unitRef="shares">2060993</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2016Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-D4657F92F94EB33B8ECE0825E9210631" unitRef="usdPerShare">1.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="FI2017Q3_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-73E3B1592D038ABF838B0825E920EF75" unitRef="usdPerShare">4.62</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-FD13B35C2FBCB059C5200825E91E6181" unitRef="usdPerShare">0.80</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-91FF2CA99E0F13845C390825E9206882" unitRef="usdPerShare">11.40</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-EC19CDB7820A39D66B150825E91FDFAD" unitRef="usdPerShare">1.05</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="2" id="Fact-A4944A2FB39E9A63803C0825E9200626" unitRef="usdPerShare">11.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheOneMember" decimals="INF" id="Fact-CC073E7E257CA9D2A78F0825E91DC70B" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_VestingAxis_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" decimals="INF" id="Fact-79B0CFF308CAC7E9AC340825E91E54A3" unitRef="number">0.75</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-9237DB8CAA51419579370825E91DDBE7">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2016Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-7ECAF0A166B0374DAD950825E91E7177">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" id="Fact-B5532B20E5EA409AACB20825E921A928">P6Y5M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
	<us-gaap:StockIssuedDuringPeriodSharesAcquisitions contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-A4BD9EBEAC85ADA1AD240825E91CC21E" unitRef="shares">1024960</us-gaap:StockIssuedDuringPeriodSharesAcquisitions>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="D2017Q1Jan1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-7D3E8A43B5225FC10AD00825E9182432" unitRef="shares">-7149176</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="D2017Q1Jan1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesBRedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-45BDDF930826884E9F400825E91EF4A6" unitRef="shares">-2166651</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="D2017Q1Jan1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesCRedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-7EB1D4695AF649609E100825E914ACE7" unitRef="shares">-9268563</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="D2017Q1Jan1Feb13_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-5129FB14333596F99F0992908C6CCD24" unitRef="shares">-18584390.00</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2017Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-3AFA4D4079D9A591250E0825E91E535C" unitRef="shares">-18584390</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-C83595F297C7DDCF04D40825E922222F" unitRef="shares">13066666</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
	<us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-E0F9C18A222737431D4331BFF162B4B9" unitRef="shares">13193</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
	<us-gaap:StockIssuedDuringPeriodSharesIssuedForServices contextRef="FD2017Q3YTD_us-gaap_CounterpartyNameAxis_mgen_RocheInnovationCenterCopenhagenASMember_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-8E3B5F15D741956E19C60825E91C1819" unitRef="shares">856806</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2017Q1Feb13_us-gaap_ConversionOfStockByUniqueDescriptionAxis_mgen_PostMergerSharesMember" decimals="INF" id="Fact-CC6302F9782E601D83F00825E9217996" unitRef="shares">6359628</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="D2017Q1Feb13_us-gaap_ConversionOfStockByUniqueDescriptionAxis_mgen_PreMergerSharesMember" decimals="INF" id="Fact-9231F6AA7359914EB55D0825E922E474" unitRef="shares">9045126</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2017Q3QTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="INF" id="Fact-374E72D605AF639BD84D0825E91DC475" unitRef="shares">297653</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="INF" id="Fact-2DD9B2FBB9E1894754AE31BD4DD051D5" unitRef="shares">297653</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_PrivateFinancingMember" decimals="INF" id="Fact-A11B2A864681D6C237FC0825E916395C" unitRef="shares">6359628</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
	<us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="INF" id="Fact-9E46D91462FB1C44C9860825E91C6F25" unitRef="shares">274337</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="FD2017Q3YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" decimals="-3" id="Fact-45428A79BFC90FE829BE0825E91713A2" unitRef="shares">274000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2017Q3YTD" decimals="-3" id="Fact-5C7AF8E98706BD569C250825E9207475" unitRef="usd">204000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-76066C939127BD88A61A0825E9227296" unitRef="usd">194000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueAcquisitions contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-2628A14F6243B7A7CC130825E91AC024" unitRef="usd">10000</us-gaap:StockIssuedDuringPeriodValueAcquisitions>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2017Q3YTD" decimals="-3" id="Fact-9E18FD4BC1552624DF5331BFAE52F543" unitRef="usd">110000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-2F4961F71C809553111831BFAE60B3B4" unitRef="usd">110000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="-3" id="Fact-41B51A4F8B9C2A11F9D031BD52575FD7" unitRef="usd">2619000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_PrivateFinancingMember" decimals="-3" id="Fact-6343A8DAA0901874EBA60825E91670E9" unitRef="usd">39092000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="-3" id="Fact-2E7C550CBAEDD7C22D6F31BD504B46EB" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_us-gaap_SubsidiarySaleOfStockAxis_mgen_PrivateFinancingMember" decimals="-3" id="Fact-7F6B8524120B2474B4320825E91441E7" unitRef="usd">64000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_AtthemarketOfferingMember" decimals="-3" id="Fact-810BD62A532D960D9B8931BD56938936" unitRef="usd">2622000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="FD2017Q3YTD_us-gaap_SubsidiarySaleOfStockAxis_mgen_PrivateFinancingMember" decimals="-3" id="Fact-4F29519F16D82311DB120825E917D1AB" unitRef="usd">39156000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2017Q3YTD" decimals="-3" id="Fact-E7F5F146AE667D3693340825E921C9DF" unitRef="usd">220000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-8F7D73C5C197A3C0BEFC0825E91EF6BD" unitRef="usd">217000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="FD2017Q3YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-4C1A723C80DFD7CB21A30825E919B885" unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4" decimals="-3" id="Fact-687ECA66F0831144CC630825E91AB6C2" unitRef="usd">-61921000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-B2DBD00C55DC785F2B4F0825E91AA9F0" unitRef="usd">5147000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-64DE7BE210EB2267B0710825E91B6533" unitRef="usd">8000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-2FF945FE45D714777EB60825E91E8AD8" unitRef="usd">-67076000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3" decimals="-3" id="Fact-65C5909694A3F2E423700825E914A820" unitRef="usd">38985000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" decimals="-3" id="Fact-D71D228E6F3608464BC70825E918F4B7" unitRef="usd">125973000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" decimals="-3" id="Fact-0BCADA9C23B83EEAF6EA0825E91A9337" unitRef="usd">219000</us-gaap:StockholdersEquity>
	<us-gaap:StockholdersEquity contextRef="FI2017Q3_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" decimals="-3" id="Fact-AE898687783807FF01140825E91543C0" unitRef="usd">-87207000</us-gaap:StockholdersEquity>
	<us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="D2017Q1Jan1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-BC3ACDC58EE86C4BAEF00825E91676D1" unitRef="usd">1000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
	<us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="D2017Q1Jan1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesBRedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-C1BF92803EEBBE34F79F0825E919385D" unitRef="usd">1000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
	<us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="D2017Q1Jan1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesCRedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-6D86EB8E5001EBCD40070825E91F1C27" unitRef="usd">3000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
	<us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="D2017Q1Jan1Feb13_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-D767112884B91171A4DA92908C64C5AA" unitRef="usd">5000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
	<us-gaap:TemporaryEquityAccretionToRedemptionValue contextRef="FD2017Q3YTD_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-8CEE797E8D8CC068BF680825E9167006" unitRef="usd">5000</us-gaap:TemporaryEquityAccretionToRedemptionValue>
	<us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="FD2016Q3QTD" decimals="-3" id="Fact-EB39D1BA893C99564DAA0825E9181389" unitRef="usd">13000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
	<us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="FD2016Q3YTD" decimals="-3" id="Fact-238B7698B9E1B42555060825E915E456" unitRef="usd">37000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
	<us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="FD2017Q3QTD" decimals="-3" id="Fact-2DC1558B2F80FFBF75D60825E91F1753" unitRef="usd">0</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
	<us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment contextRef="FD2017Q3YTD" decimals="-3" id="Fact-C8198E28831F8EA4876F0825E91A4D33" unitRef="usd">5000</us-gaap:TemporaryEquityAccretionToRedemptionValueAdjustment>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-C887A3A76BCD19D10D6D0825E9163308" unitRef="usd">23124000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesBRedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-CABDD68D7EEB21588F770825E917932E" unitRef="usd">12975000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesCRedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-16AD1F590D0C698771FC0825E9225143" unitRef="usd">40877000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-43008829BBEB46996F5E0825E918F048" unitRef="usd">76976000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-6C50FFF9C5154E7567E70825E920AEAD" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_mgen_SeriesBRedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-7A035CEA0E9250F2E6AA0825E91B95C7" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_mgen_SeriesCRedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-4EF26CC989C8B728B6E40825E91CA9C3" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-CF009014E6D9A5D981EC0825E9193D53" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="I2017Q1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-1781700CC35085BED07F0825E918F7F4" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="I2017Q1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesBRedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-3FEB55169FE7F9ABE43D0825E91646E3" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="I2017Q1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesCRedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-42179A7FEA4D94AF3C930825E9182282" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityCarryingAmountAttributableToParent contextRef="I2017Q1Feb13_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" decimals="-3" id="Fact-24104B3B5FB09991C10E92908C5A816C" unitRef="usd">0</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-C889731C55B4E630A8640825E9208055" unitRef="usd">21448</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesBRedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-410EB265A18A83A109A30825E91FCC10" unitRef="usd">13000</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityLiquidationPreference contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesCRedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-E90F6B357A0DB4E3A1DB0825E919BEC8" unitRef="usd">41060</us-gaap:TemporaryEquityLiquidationPreference>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-B5EFCC12664BFBCB1FA40825E916968B" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesBRedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-2FDC80340D94857EB5DD0825E91B66DD" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquityParOrStatedValuePerShare contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesCRedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-86C5C7F5C66FC4BACC5C0825E91B6220" unitRef="usdPerShare">0.001</us-gaap:TemporaryEquityParOrStatedValuePerShare>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-39E053C35A1F3064A92B0825E91599E1" unitRef="shares">7169176</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesBRedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-78215CA581F81C16A3A40825E920A8DB" unitRef="shares">2183318</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesAuthorized contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesCRedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-2E6BD542C1CA86D50E9F0825E91B6C53" unitRef="shares">9303000</us-gaap:TemporaryEquitySharesAuthorized>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-ECF29952841E6F57CDBE0825E91944CD" unitRef="shares">7149176</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesBRedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-77EAF1121A134768D7260825E9216F81" unitRef="shares">2166651</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesIssued contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesCRedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-807985D20C78BC0ADD070825E9159F17" unitRef="shares">9268563</us-gaap:TemporaryEquitySharesIssued>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-2EB5DAF9D449A4D7EADA0825E91CE3D0" unitRef="shares">7149176</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesBRedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-1E43C14DB0BC3DF018780825E9172F67" unitRef="shares">2166651</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_mgen_SeriesCRedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-F23980A7CD818B48AB2B0825E918B7E8" unitRef="shares">9268563</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-FC8ED892B6D2DE00E0DB92908C69A41C" unitRef="shares">18584390.00</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2016Q4_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-CE376F0BCD18BFE06B2D0825E91C2812" unitRef="shares">18584390</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="FI2017Q3_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-80F059DFFE6EFE0AF2660825E91961F1" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="I2017Q1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesARedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-553959E080C12D8DD7D00825E918AD9A" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="I2017Q1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesBRedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-D61D14762E85C9AAC4930825E91E214F" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="I2017Q1Feb13_us-gaap_StatementClassOfStockAxis_mgen_SeriesCRedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-D5E64D9D921A51DDD29E0825E91841A3" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:TemporaryEquitySharesOutstanding contextRef="I2017Q1Feb13_us-gaap_StatementClassOfStockAxis_us-gaap_RedeemableConvertiblePreferredStockMember" decimals="INF" id="Fact-F199E19E0FF785D4335492908C6E2A85" unitRef="shares">0</us-gaap:TemporaryEquitySharesOutstanding>
	<us-gaap:WarrantsAndRightsOutstanding contextRef="FI2017Q3_us-gaap_ClassOfWarrantOrRightAxis_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_us-gaap_DebtInstrumentAxis_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember" decimals="-5" id="Fact-6850D0DC2277CAEB0FC10825E916C6C9" unitRef="usd">100000</us-gaap:WarrantsAndRightsOutstanding>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q3QTD" decimals="0" id="Fact-3926154DFA65124BBA5C0825E922DBEF" unitRef="shares">601667</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2016Q3YTD" decimals="0" id="Fact-95F77970ADA2E52988ED0825E919056C" unitRef="shares">601667</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q3QTD" decimals="0" id="Fact-C3871B7BFBC3092219D40825E9196357" unitRef="shares">21572498</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="FD2017Q3YTD" decimals="0" id="Fact-F907CA0E6C95FDD5EB5F0825E919E158" unitRef="shares">18215857</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
	<mgen:ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-77204D4CED9E325607E10825E91FE35B">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Clinical Trial and Preclinical Study Accruals&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company makes estimates of accrued expenses as of each balance sheet date in its condensed consolidated financial statements based on certain facts and circumstances at that time. The Company&amp;#8217;s accrued expenses for clinical trials and preclinical studies are based on estimates of costs incurred for services provided by clinical research organizations, manufacturing organizations, and other providers. Payments under the Company&amp;#8217;s agreements with external service providers depend on a number of factors, such as site initiation, patient screening, enrollment, delivery of reports, and other events. In accruing for these activities, the Company obtains information from various sources and estimates the level of effort or expense allocated to each period. Adjustments to the Company&amp;#8217;s research and development expenses may be necessary in future periods as its estimates change.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</mgen:ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock>
	<us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="FD2017Q3YTD" id="Fact-135D9B6A37126D61E0190825E91B67FD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;ACCRUED LIABILITIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued outsourced clinical and preclinical studies&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued employee compensation and related taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued legal fees and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;607&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued other professional service fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued equipment and lab materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Value of liability-classified stock purchase warrants &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred and accrued facility lease obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,909&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
	<us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-46704BA4E90780FD5FC80825E91F8DF9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Miragen Europe. The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&amp;#8220;U.S. GAAP&amp;#8221;) and follow the requirements of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company&amp;#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&amp;#8217;s financial information. These interim results are not necessarily indicative of the results to be expected for the year ending December 31, 2017, or for any other interim period, or for any other future year. The balance sheet as of December 31, 2016 has been derived from audited consolidated financial statements at that date but does not include all the information required by U.S. GAAP for complete financial statements. All intercompany balances and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements of the Company and the notes thereto contained in the Company&amp;#8217;s Form 8-K/A for the year ended December 31, 2016, filed with the SEC on March 31, 2017. The Company&amp;#8217;s management performed an evaluation of its activities through the date of filing of these financial statements and concluded that there are no subsequent events requiring disclosure, other than as disclosed.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
	<us-gaap:BusinessCombinationDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-EC1129EBD6B72EC98D630825E91932D0">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt; REVERSE MERGER&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 13, 2017, Private Miragen completed the Merger as discussed in Note 1.&amp;#160;For accounting purposes, Private Miragen is considered to be acquiring Signal in the Merger. Private Miragen was determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i) the Private Miragen security holders own approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;95.2%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the combined company&amp;#8217;s outstanding common stock immediately following the closing of the Merger; (ii) former Private Miragen directors hold all of the board seats in the combined company; and (iii) Private Miragen management holds key management positions of the combined company. The Merger has been accounted for as an asset acquisition rather than business combination because the assets acquired and liabilities assumed by Private Miragen do not meet the definition of a business as defined by U.S. GAAP. The net assets acquired in connection with this transaction were recorded at their estimated acquisition date fair values as of February 13, 2017, the date the Mergers were completed.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Immediately prior to the effective date of the Merger, all shares of preferred stock of Private Miragen converted into shares of common stock of Private Miragen on a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-for-one basis. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;At the effective date of the Merger, the Company issued shares of its Common Stock to Private Miragen stockholders, at an exchange rate of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.7031&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Signal Common Stock in exchange for each share of Private Miragen common stock outstanding immediately prior to the Merger. The exchange rate was calculated by a formula that was determined through arms-length negotiations between the Company and Private Miragen. The combined company assumed all of the outstanding options, whether or not vested, under the 2008 Plan with such options representing the right to purchase a number of shares of Common Stock equal to approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.7031&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; multiplied by the number of shares of Private Miragen common stock previously represented by such options.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Immediately after the Merger on February 13, 2017, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,309,440&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Common Stock outstanding. In addition, immediately after the Merger, Private Miragen stockholders, warrant holders, and option holders owned approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;95.9%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the aggregate number of shares of Common Stock, and the stockholders of the Company immediately prior to the Merger owned approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.1%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the aggregate number of shares of Common Stock (each on a fully diluted basis).&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 13, 2017, prior to the effectiveness of the Merger, Signal had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,024,960&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Common Stock outstanding and a market capitalization of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The estimated fair value of the net assets of Signal on February 13, 2017, prior to the Merger, was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The fair value of Common Stock on the Merger closing date, prior to the Merger, was above the fair value of the Company&amp;#8217;s net assets. As the Company&amp;#8217;s net assets were predominantly comprised of cash offset by current liabilities, the fair value of the Company&amp;#8217;s net assets as of February 13, 2017, prior to the Merger, is considered to be the best indicator of the fair value and, therefore, the estimated preliminary purchase consideration.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the net assets acquired based on their estimated fair values as of February 13, 2017, prior to the Merger (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,280&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net acquired tangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;204&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
	<us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="FD2017Q3YTD" id="Fact-1C75A54D1D2E30380F470825E91FBBD4">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;DESCRIPTION OF BUSINESS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Miragen Therapeutics, Inc., a Delaware corporation (the &amp;#8220;Company&amp;#8221; or &amp;#8220;Miragen&amp;#8221;), is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapeutics with a specific focus on microRNAs and their roles in diseases where there is a high unmet medical need. microRNAs are short RNA molecules, or oligonucleotides, that regulate gene expression or activity and play vital roles in influencing the pathways responsible for many disease processes. The Company&amp;#8217;s two lead product candidates, MRG-106 and MRG-201, are currently in clinical development. MRG-106 is an inhibitor of microRNA-155, which is found at abnormally high levels in malignant cells of several blood cancers. MRG-201 is a replacement for microRNA-29 (&amp;#8220;miR-29&amp;#8221;), which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary, and ocular fibrosis, as well as in systemic sclerosis. Miragen is also developing MRG-110, an inhibitor of microRNA-92, under a License and Collaboration Agreement (the &amp;#8220;Servier Collaboration Agreement&amp;#8221;) with Les Laboratoires Servier and Institut de Recherches Servier (collectively, &amp;#8220;Servier&amp;#8221;). MRG-110 is being developed for the treatment of heart failure and other ischemic disease. In addition to these programs, the Company continues to develop a pipeline of wholly-owned preclinical product candidates. The goal of the Company&amp;#8217;s translational medicine strategy is to progress rapidly to first-in-human trials once it has adequately established the pharmacokinetics (the movement of drug into, through, and out of the body), pharmacodynamics (the effect and mechanism of action of a drug), safety, and manufacturability of the product candidate in preclinical studies.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Miragen Therapeutics Europe Limited (&amp;#8220;Miragen Europe&amp;#8221;), the Company&amp;#8217;s wholly-owned subsidiary, was formed in January 2011 for the sole purpose of submitting regulatory filings in Europe. Miragen Europe has no employees or operations. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 13, 2017, the Company, then known as Signal Genetics, Inc. (&amp;#8220;Signal&amp;#8221;), completed its merger with Miragen Therapeutics, Inc., a then privately-held Delaware corporation (&amp;#8220;Private Miragen&amp;#8221;). Pursuant to the Agreement and Plan of Merger and Reorganization (the &amp;#8220;Merger Agreement&amp;#8221;) by and among the Company, Private Miragen, and Signal Merger Sub, Inc., a wholly-owned subsidiary of the Company (&amp;#8220;Merger Sub&amp;#8221;), Merger Sub merged with and into Private Miragen, with Private Miragen surviving as a wholly-owned subsidiary of the Company (the &amp;#8220;Merger&amp;#8221;). Immediately, following the Merger, Private Miragen merged with and into the Company, with the Company as the surviving corporation (the &amp;#8220;Short-Form Merger&amp;#8221; and, together with the Merger, the &amp;#8220;Mergers&amp;#8221;). In connection with the Short-Form Merger, the Company changed its corporate name to &amp;#8220;Miragen Therapeutics, Inc.&amp;#8221; &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The holders of shares of Private Miragen common stock outstanding immediately prior to the Merger received approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.7031&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&amp;#8217;s common stock in exchange for each share of Private Miragen common stock in the Merger. Following the Merger on February 13, 2017, the combined company had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;21,309,440&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of common stock outstanding at a par value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.01&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share (the &amp;#8220;Common Stock&amp;#8221;) as compared to the par value of Private Miragen&amp;#8217;s common stock of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.001&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. The accompanying unaudited condensed consolidated financial statements and notes to the unaudited condensed consolidated financial statements give retroactive effect to the exchange ratio and change in par value for all periods presented.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Liquidity&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has incurred annual net operating losses since its inception. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had an accumulated deficit of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$87.2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; million and net losses of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$20.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for the three and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. On February 13, 2017, the date of the Merger, Private Miragen received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$40.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in cash, before offering expenses, from the issuance of common stock to investors. Additionally, on March 31, 2017, the Company entered into an at the market issuance Common Stock Sales Agreement (the &amp;#8220;ATM Agreement&amp;#8221;) with Cowen and Company, LLC (&amp;#8220;Cowen&amp;#8221;) under which the Company may offer and sell, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through Cowen, as its sales agent. As of September 30, 2017, the Company has sold, pursuant to the terms of such ATM Agreement, an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;297,653&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of its Common Stock, at a weighted average price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.11&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, for aggregate gross proceeds of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Net proceeds received during the nine months ended September 30, 2017 were approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, including initial expenses for executing the &amp;#8220;at the market offering&amp;#8221; and commissions to Cowen as sales agent. The Company&amp;#8217;s management believes that the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$42.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of cash and cash equivalents on hand at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; will be sufficient to fund its operations in the normal course of business and allow the Company to meet its liquidity needs through the end of 2018.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
	<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-E981B63EBA2885D08F4C0825E9217C13">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All highly-liquid investments that have maturities of 90 days or less at the date of purchase are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value due to the short maturities of these instruments.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
	<us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-51B2721D35B9F2BBE4E90825E917F614">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;STRATEGIC ALLIANCE AND COLLABORATION WITH SERVIER&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2011, the Company entered into the Servier Collaboration Agreement with Servier for the research, development, and commercialization of RNA-targeting therapeutics in cardiovascular disease, which was subsequently amended. Under the Servier Collaboration Agreement, the Company granted Servier an exclusive license to research, develop, and commercialize RNA-targeting therapeutics for three targets in the cardiovascular field. In 2017, the Company and Servier agreed to amend the Servier Collaboration Agreement to remove three existing targets, add one named target, and provide Servier with the right to add one additional target through September 2019. Under the terms of the amended agreement, the term of the Research Collaboration has been extended through September 2019. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Servier&amp;#8217;s rights to each named target is limited to therapeutics in the cardiovascular field in their territory, which is worldwide except for the United States and Japan. The Company retains all rights in the United States and Japan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is eligible to receive development milestone payments of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8364;5.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8364;13.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$16.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) and regulatory milestone payments of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8364;10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8364;40.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$11.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$47.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) for each target. Additionally, the Company may receive up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8364;175 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$206.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) in commercialization milestones, as well as quarterly royalty payments expressed in percentages ranging from the low-double digits to the mid-teens (subject to reductions for patent expiration, generic competition, third-party royalty, and costs of goods) on the net sales of any licensed product commercialized by Servier. Servier is obligated to make royalty payments for a period specified under the Servier Collaboration Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As part of the Servier Collaboration Agreement, the Company established a multiple-year research collaboration, under which it jointly performs agreed upon research activities directed to the identification and characterization of named targets and oligonucleotides in the cardiovascular field, which is referred to as the Research Collaboration. The current term of the Research Collaboration extends through September 2019. Servier is responsible for funding the costs of the Research Collaboration, as defined under the Servier Collaboration Agreement. During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized as revenue amounts reimbursable under the Servier Collaboration Agreement of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized as revenue amounts reimbursable under the Servier Collaboration Agreement of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The development of each product candidate (commencing with registration enabling toxicology studies) under the Servier Collaboration Agreement is performed pursuant to a mutually agreed upon development plan to be conducted by the parties as necessary to generate data useful for both parties to obtain regulatory approval of such product candidates. Servier is responsible for a specified percentage of the cost of research and development activities under the development plan through the completion of one or more Phase 2 clinical trials and will reimburse the Company for a specified portion of such costs it incurs. The costs of Phase 3 clinical trials for each product candidate will be allocated between the parties at a specified percentage of costs. The applicable percentage for each product candidate will be based upon whether certain events under the Servier Collaboration Agreement occur, including if the Company enters into a third-party agreement for the development and/or commercialization of a product in the United States at least 180 days before the initiation of the first Phase 3 clinical trial, or&amp;#160;if the Company subsequently enters into a U.S. partner agreement, or if it does not enter into a U.S. partner agreement but files for approval in the United States using data from the Phase 3 clinical trial.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the Servier Collaboration Agreement, the Company also granted Servier a royalty-free, non-exclusive license to develop a companion diagnostic in its territory for any therapeutic product that may be developed by Servier under the Servier Collaboration Agreement. The Company also granted Servier an exclusive, royalty-free license to commercialize such a companion diagnostic in its territory for use in connection with the development and commercialization of such therapeutic product in its territory.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Servier Collaboration Agreement will expire as to each underlying product candidate when Servier&amp;#8217;s royalty obligations as to such product candidate have expired. Servier may also terminate the Servier Collaboration Agreement for (i) convenience upon a specified number of days&amp;#8217; prior notice to the Company or (ii) upon determination of a safety issue relating to development under the agreement upon a specified number of days&amp;#8217; prior notice to the Company. Either party may terminate the Servier Collaboration Agreement upon a material breach by the other party which is not cured within a specified number of days. The Company may also terminate the agreement if Servier challenges any of the patents licensed by the Company to Servier.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determined that the elements within the Servier Collaboration Agreement should be treated as a single unit of accounting because the delivered elements, the licenses, did not have stand-alone value to Servier at the time the license was granted. As such, the Company recognized license fees earned under the Servier Collaboration Agreement as revenue on a proportional performance basis over the estimated period to complete the activities under the Research Collaboration. The total period of performance is equal to the estimated term of the Research Collaboration. The Company measures its progress under the proportional performance method based on actual and estimated full-time equivalents. The Company received a total of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$12.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8364;9.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) in non-refundable license fees under the Servier Collaboration Agreement. Based on earlier estimates of the term of the Research Collaboration, these license fees had been fully recognized as revenue during the period from October 2011 through December 2016. Accordingly, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; amounts were recognized as revenue during the three and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. During the three months and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized license revenue of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In total, for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, as revenue under the Servier Collaboration Agreement. For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company recognized &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, as revenue under the Servier Collaboration Agreement. Amounts incurred but not billed to Servier for research and related intellectual property activities totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. These amounts are included in prepaid expenses and other current assets in the Company&amp;#8217;s condensed consolidated balance sheets. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, accounts receivable for Servier research and related intellectual property activities totaled &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. At &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;December&amp;#160;31, 2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;no&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; amounts billed to Servier included in accounts receivable.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
	<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-F5AFD7871906158D2F2B0825E917B085">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;COMMITMENTS AND CONTINGENCIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Indemnification Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has entered into indemnification agreements with each of its directors and officers whereby it has agreed to indemnify such persons for certain events or occurrences while the individual is, or was, serving as a director, officer, employee, or other agent of the Company. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Employment Agreements&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has entered into agreements with its executives that provide for base salary, severance, eligibility for bonuses, and other generally available benefits. The agreements provide that the Company may terminate the employment of its executives at any time, with or without cause. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If an executive is terminated without cause, as defined in the employment agreements, or an executive resigns for good reason, as defined in the employment agreements, then the executive is entitled to receive, upon the execution of a release agreement, a severance package consisting of: (i)&amp;#160;the equivalent of 12 months of the executive&amp;#8217;s base salary in effect immediately prior to date of termination, (ii)&amp;#160;acceleration of vesting of the equivalent of 12 months of vesting of the executive&amp;#8217;s outstanding unvested stock options or other equity awards that were outstanding as of the effective date of the executive&amp;#8217;s employment agreement, and (iii)&amp;#160;12 months of continued health coverage. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If an executive is terminated without cause or resigns for good reason within one month prior to or 12 months following a change of control, as defined in the employment agreements, the executive is entitled to receive, upon the execution of a release agreement, a severance package consisting of: (i)&amp;#160;the equivalent of 12 months of the executive&amp;#8217;s base salary in effect immediately prior to date of termination, (ii)&amp;#160;the vesting in full of the executive&amp;#8217;s then-outstanding stock options or other equity awards subject to time-based vesting, and (iii)&amp;#160;12 months of continued health coverage. Solely in the case of the Company&amp;#8217;s Chief Executive Officer, if such termination occurs one month before or 12 months following a change of control, then, upon the execution of a release agreement, the executive is entitled to: (i)&amp;#160;the equivalent of 24 months of the executive&amp;#8217;s base salary in effect immediately prior to the date of termination, (ii)&amp;#160;the vesting in full of the executive&amp;#8217;s outstanding stock options or other equity awards subject to time-based vesting, and (iii)&amp;#160;12 months of continued health coverage.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;License Agreements with the University of Texas&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; exclusive patent license agreements (the &amp;#8220;UT License Agreements&amp;#8221;) with the Board of Regents of The University of Texas System (the &amp;#8220;University of Texas&amp;#8221;). Under each of the UT License Agreements, the University of Texas granted the Company exclusive and nonexclusive licenses to certain patent and technology rights. The University of Texas is a minority stockholder of the Company.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In consideration of rights granted by the University of Texas, the Company is required to: (i) pay a nonrefundable upfront license documentation fee in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10 thousand&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per license; (ii) pay an annual license maintenance fee in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10 thousand&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per license starting one year from the date of each agreement; (iii) reimburse the University of Texas for actual costs incurred in conjunction with the filing, prosecution, enforcement, and maintenance of patent rights prior to the effective date; and (iv) bear all future costs of and manage the filing, prosecution, enforcement, and maintenance of patent rights. During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and 2016, the Company incurred immaterial upfront and maintenance fees, which were recorded as research and development expense. All costs related to the filing, prosecution, and maintenance of patent and technology rights are recorded as general and administrative expense when incurred.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the UT License Agreements, the Company may be obligated to make the following future milestone payments for each licensed product candidate: (i) up to approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon the initiation of defined clinical trials; (ii) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon regulatory approval in the United States; and (iii) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per region upon regulatory approval in other specified regions. Additionally, if the Company or its sublicensees successfully commercializes any product candidate subject to the UT License Agreements, it is responsible for royalty payments in the low-single digits based upon net sales of such licensed products and payments at a percentage in the mid-teens of any sublicense income, subject to specified exceptions. The University of Texas&amp;#8217;s right to these royalty payments will expire as to each license agreement upon the expiration of the last patent claim subject to the applicable UT License Agreement.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The license term extends on a product by product and country by country basis until the expiration of the last to expire of the licensed patents that covers such product in such country. Upon expiration of the royalty payment obligation, the Company will have a fully paid license in such country. The Company may also terminate each UT License Agreement for convenience upon a specified number of days&amp;#8217; prior notice to the University of Texas. The University of Texas also has the right to earlier terminate the UT License Agreements after a defined date under specified circumstances where the Company has effectively abandoned its research and development efforts or has no sales. The UT License Agreements will terminate under customary termination provisions including automatic termination upon the Company&amp;#8217;s bankruptcy or insolvency, upon notice of an uncured material breach, and upon mutual written consent. All charges incurred under the UT License Agreements have been expensed to date due to the uncertainty as to future economic benefit from the acquired rights.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;License Agreement with Roche Innovation Center Copenhagen A/S (formerly Santaris Pharma A/S)&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In June 2010, Private Miragen entered into a license agreement with the Santaris Pharma A/S, which was acquired by F. Hoffmann-La Roche Ltd (&amp;#8220;Roche&amp;#8221;) in 2014 and subsequently changed its name to Roche Innovation Center Copenhagen A/S (&amp;#8220;RICC&amp;#8221;). The agreement was amended in October 2011 and amended and restated in December 2012 (the &amp;#8220;RICC License Agreement&amp;#8221;).&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the RICC License Agreement, the Company has received exclusive and nonexclusive licenses from RICC to use specified technology of RICC (the &amp;#8220;RICC Technology&amp;#8221;) for specified uses including research, development, and commercialization of pharmaceutical products using this technology worldwide. Under the RICC License Agreement, the Company has the right to develop and commercialize the RICC Technology directed to four specified targets and the option to obtain exclusive product licenses for up to six additional targets. The acquisition of Santaris Pharma A/S by Roche was considered a change-of-control under the RICC License Agreement, and as such, certain terms and conditions of the RICC License Agreement changed, as contemplated and in accordance with the RICC License Agreement. These changes primarily relate to milestone payments reflected in the disclosures below. As consideration for the grant of the license and option, Private Miragen previously paid RICC &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and issued RICC &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;856,806&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Private Miragen&amp;#8217;s Series A convertible preferred stock, which subsequently converted to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;602,420&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Common Stock. If the Company exercises its option to obtain additional product licenses or to replace the target families, it will be required to make additional payments to RICC.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the RICC License Agreement, milestone payments were previously decreased by a specified percentage as a result of the change of control by RICC referenced above. The Company is obligated to make future milestone payments for each licensed product for up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which is inclusive of a potential product license option fee. Certain of these milestones will be increased by a specified percentage if the Company undergoes a change in control during the term of the RICC License Agreement. If the Company grants a third party a sublicense to the RICC Technology, it is required to remit to Roche up to a specified percentage of the upfront and milestone and other specified payments it receives under its sublicense, and if such sublicense covers use of the RICC Technology in the United States or the entire European Union, the Company will not have any further obligation to pay the fixed milestone payments noted above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;If the Company or its sublicensee successfully commercializes any product candidate subject to the RICC License Agreements, then RICC is entitled to royalty payments in the mid-single digits on the net sales of such product, provided that if such net sales are made by a sublicensee under the RICC License Agreement, RICC is entitled to royalty payments equal to the lesser of a percentage in the mid-single digits on the net sales of such product or a specified percentage of the royalties paid to the Company by such sublicensee, subject to specified restrictions. The Company is obligated to make any such royalty payments until the later of: (i) a specified anniversary of the first commercial sale of the applicable product or (ii) the expiration of the last valid patent claim licensed by RICC under the RICC License Agreement underlying such product. Upon the occurrence of specified events, the royalty owed to RICC will be decreased by a specified percentage.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The RICC License Agreement will terminate upon the latest of the expiration of all of RICC&amp;#8217;s royalty rights, the termination of the last Miragen target, or the expiration of its right to obtain a product license for a new target under the RICC License Agreement. The Company may also terminate the RICC License Agreement for convenience upon a specified number of days&amp;#8217; prior notice to RICC, subject to specified terms and conditions. Either party may terminate the RICC License Agreement upon an uncured material breach by the other party and RICC may terminate the RICC License Agreement upon the occurrence of other specified events immediately or after such event is not cured within a specified number of days, as applicable.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All charges incurred under the RICC License Agreement have been expensed to date due to the uncertainty as to future economic benefit from the acquired rights. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;For the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and 2016, the Company paid &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively, to Roche for raw materials to be used in its drug manufacturing process. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Subcontract Agreement with Yale University&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2014, Private Miragen and Yale University (&amp;#8220;Yale&amp;#8221;) entered into a subcontract agreement and into a subaward agreement in March 2015 (the &amp;#8220;Yale Agreements&amp;#8221;), which was subsequently amended. Under the Yale Agreements, the Company is providing specified services regarding the development of a proprietary compound that targets miR-29 in the indication of idiopathic pulmonary fibrosis. Yale entered into the Yale Agreements in connection with a grant that Yale received from the National Institutes of Health (&amp;#8220;NIH&amp;#8221;) for the development of a miR-29 mimic as a potential therapy for pulmonary fibrosis.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In consideration of the Company&amp;#8217;s services under the Yale Agreements, Yale has agreed to pay the Company up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; over &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, subject to the availably of funds under the grant and continued eligibility. Under the terms of the Yale Agreements, the Company retains all rights to any and all intellectual property developed solely by the Company in connection with the Yale Agreements. Yale has also agreed to provide the Company with an exclusive option to negotiate in good faith for an exclusive, royalty-bearing license from Yale for any intellectual property developed by Yale or jointly by the parties under the Yale Agreements. Yale is responsible for filing, prosecuting, and maintaining foreign and domestic patent applications and patents on all inventions jointly developed by the parties under the Yale Agreements. Through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has received &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; under the Yale Agreements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Yale Agreements terminate automatically on the date that Yale delivers its final research report to the NIH under the terms of the grant underlying the Yale Agreements. Each party may also terminate the Yale Agreements upon a specified number of days&amp;#8217; notice in the event that the NIH&amp;#8217;s grant funding is reduced or terminated or upon material breach by the other party.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;License Agreements with the t2cure GmbH&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In October 2010, Private Miragen entered into a license and collaboration agreement (the &amp;#8220;t2cure Agreement&amp;#8221;) with t2cure GmbH (&amp;#8220;t2cure&amp;#8221;), which was subsequently amended. Under the t2cure Agreement, the Company has received a worldwide, royalty-bearing, and exclusive license to specified patent and technology rights relating to miR-92.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In consideration of rights granted by t2cure, Private Miragen paid an upfront fee of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$46 thousand&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and agreed to: (i) pay an annual license maintenance fee in the amount of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8364;3 thousand&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3 thousand&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;); and (ii) reimburse t2cure for costs incurred in conjunction with the filing, prosecution, enforcement, and maintenance of patent rights. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Under the terms of the t2cure Agreement, the Company is obligated to make the following future milestone payments for each licensed product: (i) up to approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon the initiation of certain defined clinical trials; (ii) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; upon regulatory approval in the United States; and (iii) up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per region upon regulatory approval in the European Union or Japan. Additionally, if the Company or its sublicensees successfully commercialize any product candidate subject to the t2cure Agreement, it is responsible for royalty payments equal to percentages in the low-single digits upon net sales of licensed products and sublicense fees equal to a percentage in the low-twenties of sublicense income received by it. The Company is obligated to make any such royalty payment until the later of (i) the tenth anniversary of the first commercial sale of the applicable product or (ii) the expiration of the last valid claim to a patent licensed by t2cure under the t2cure Agreement covering such product. If such patent claims expire prior to the end of the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-year term, then the royalty owed to t2cure will be decreased by a specified percentage. The Company also has the right to decrease its royalty payments by a specified percentage for royalties paid to third parties for licenses to certain third-party intellectual property.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The license term extends on a country by country basis until the later of: (i) the tenth anniversary of the first commercial sale of a licensed product in a country and (ii) the expiration of the last to expire valid claim that claims such licensed product in such country. Upon expiration of the royalty payment obligation, the Company will have a fully paid license in such country. The Company has the right to terminate the t2cure Agreement at will, on a country-by-country basis, after &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; days&amp;#8217; written notice. The t2cure Agreement will also automatically terminate upon the Company&amp;#8217;s bankruptcy or insolvency or upon notice of an uncured material breach.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has expensed all charges incurred under the t2cure Agreement to date, due to the uncertainty as to future economic benefit from the acquired rights.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;License Agreement with The Brigham and Women&amp;#8217;s Hospital&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2016, Private Miragen and The Brigham and Women&amp;#8217;s Hospital (&amp;#8220;BWH&amp;#8221;) entered into an exclusive patent license agreement (the &amp;#8220;BWH License Agreement&amp;#8221;). Under the BWH License Agreement, the Company has an exclusive, worldwide license, including a right to sublicense, to specified patent rights and a nonexclusive, worldwide license, including a right to sublicense, to specified technology rights of BWH, each related to certain microRNAs believed to be involved in various neurodegenerative disorders. As consideration for these rights, the Company is obligated to pay a specified annual license fee. BWH is also entitled to milestone payments of up to approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.6 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for each of the Company&amp;#8217;s product candidates developed based on the patent rights subject to the BWH License Agreement plus a one-time sales milestone payment of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for all product candidates developed based on the patent rights subject to the BWH License Agreement. If the Company were to successfully commercialize any product candidate subject to the BWH License Agreement, then BWH is entitled to royalty payments in the low-single digits on the net sales of such product. BWH&amp;#8217;s right to these royalty payments will expire on a product by product and country by country basis upon the expiration of the last patent claim in such country that is subject to the BWH License Agreement and covers the product, and the Company&amp;#8217;s license to such product in such country will become fully paid at such time. BWH is also entitled to a percentage in the low-double digits of any sublicense income from such product, subject to specified exceptions. The Company is also responsible for all costs associated with the preparation, filing, prosecution, and maintenance of the patent rights subject to the BWH License Agreement. Additionally, the Company is obligated to use commercially reasonable efforts to develop a product under the BWH License Agreement and to meet specified diligence milestones thereunder. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The BWH License Agreement will terminate upon the expiration of all issued patents and patent applications subject to the patent rights under the agreement. The Company may also terminate the BWH License Agreement for convenience upon a specified number of days&amp;#8217; prior notice to BWH. BWH may terminate the BWH License Agreement upon a breach by the Company of its payment obligations and upon the occurrence of other specified events that are not cured within a specified number of days, provided that such termination is automatic upon the Company&amp;#8217;s bankruptcy or insolvency.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company paid the first annual license fee, which was immaterial. To date, the Company has not met any milestones that have required milestone payments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Facility Lease&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December 2010, Private Miragen entered into a multi-year lease agreement for its current office and lab space. The agreement was subsequently amended to extend the term through August 2020. This lease is noncancelable. Minimum base lease payments, including the impact of tenant improvement allowances, under the operating lease are recognized on a straight-line basis over the full term of the lease. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, rent expense was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for each period. During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, rent expense was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is also required to pay for operating expenses. During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, operating expenses were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for each period. During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, operating expenses related to the leased space were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for each period.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future annual minimum payments under the lease are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017 (remainder of year)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;391&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;277&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
	<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-29B48E6F7DFD1F7080820825E91F1CE7">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources. If the Company had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&amp;#8217; equity (deficit).&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
	<us-gaap:ConcentrationRiskCreditRisk contextRef="FD2017Q3YTD" id="Fact-FE69D70BCF229203FCE70825E92121E9">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with two financial institutions.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConcentrationRiskCreditRisk>
	<us-gaap:DebtDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-1D19C7ADDE4D6805CA8C0825E919C398">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;NOTES PAYABLE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;2015 Silicon Valley Bank Loan Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2015, Private Miragen entered into a loan and security agreement with Silicon Valley Bank (the &amp;#8220;2015 SVB Loan Agreement&amp;#8221;) to borrow up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$10.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; separate tranches. The first tranche of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was funded in May 2015 and had a &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;30&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month payment period following an &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;18&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;-month interest-only payment period that ended in November 2016.&amp;#160;Amounts outstanding bear interest at the prime rate minus &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.00%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; at &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;), with a final payment fee equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.50%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of amounts borrowed. Borrowings are secured by a priority security interest, right, and title in all business assets, excluding the Company&amp;#8217;s intellectual property, which is subject to a negative pledge.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the first tranche, in April 2015, Private Miragen issued detachable warrants to purchase up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,718&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Private Miragen preferred stock at an adjusted exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.53&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. At issuance, the warrants were classified as a liability subject to remeasurement at each balance sheet date. Immediately prior to the Merger, these warrants became exercisable for Private Miragen common stock, which was immediately exchanged for the right to purchase the Company&amp;#8217;s Common Stock. The Company determined that although the warrants were no longer exercisable for redeemable preferred stock, the warrants continued to be classified as a liability after the Merger due to the right of the holder to require the Company to repurchase the warrants for &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; under certain circumstances. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company estimated the fair value of the warrants to be &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; using a probability adjusted present value method with the following assumptions: term of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;two&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years, discount rate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.8%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and probability of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;90.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December 2016, the 2015 SVB Loan Agreement was amended to extend the end of the draw period from December 31, 2016 to July 31, 2017. The Company chose not to draw the second &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$5.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; tranche prior to the expiration of the draw period in July 2017.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amounts outstanding under notes payable are as follows:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal amount outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accreted final payment fee&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total notes payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,374&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,789&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: current maturities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,983&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term notes payable, net of current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,391&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,820&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future annual minimum principal payments of notes payable are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017 (remainder of year)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
	<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="FD2017Q3YTD" id="Fact-C9849D4AFA2FDA090BDE0825E91CBF6C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;SHARE-BASED COMPENSATION&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Equity Incentive Plans&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2017, the Company&amp;#8217;s 2014 Stock Incentive Plan (the &amp;#8220;2014 Plan&amp;#8221;) was terminated as a result of the Merger. There are no awards outstanding under the 2014 Plan and no future awards will be issued under the 2014 Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,060,993&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; options outstanding and no remaining equity awards available for future issuances under the 2008 Plan. All awards granted under the 2008 Plan that, after February 13, 2017, expire or terminate for any reason prior to exercise or settlement, are forfeited, or are reacquired, withheld, or not issued to satisfy a tax withholding obligation or to satisfy the exercise price of a stock award, will become available for grant under the 2016 Plan in accordance with its terms. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The 2016 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, other stock awards, and performance awards that may be settled in cash, stock, or other property. All employees and non-employee directors are eligible to participate in the 2016 Plan and may receive all types of awards other than incentive stock options. Incentive stock options may be granted under the 2016 Plan only to employees (including officers) and employees of the Company&amp;#8217;s affiliates. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The aggregate number of shares of Common Stock that may be issued under the 2016 Plan will not exceed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,182,404&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares, which number is the sum of: (i) &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,681,294&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares, plus (ii) the number of shares subject to outstanding stock awards that were granted under the 2008 Plan, that, from and after the closing date of the Merger, expire or terminate for any reason prior to exercise or settlement, are forfeited because of the failure to meet a contingency or condition required to vest such shares, or are reacquired, withheld, or not issued to satisfy a tax withholding obligation in connection with an award or to satisfy the purchase price or exercise price of a stock award, if any, as such shares become available from time to time. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there were &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;908,227&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; equity awards outstanding and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;773,067&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; remaining equity awards available for future issuances under the 2016 Plan.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options granted under the 2008 Plan and 2016 Plan have an exercise price equal to the market value of the Common Stock at the date of grant and expire &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ten&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; years from the date of grant. Generally, options vest &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; on the first anniversary of the vesting commencement date and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;75%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; ratably in equal monthly installments over the remaining &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;36 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The Company has also granted options that vest in equal monthly or quarterly amounts over periods up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;48 months&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A summary of Common Stock option activity is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of Options &lt;br clear="none"/&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,321&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;956&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value Assumptions&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options granted. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility, and expected lives of the options. Because the Company has a limited history of stock purchase and sale activity, expected volatility is based on historical data from public companies similar to the Company in size and nature of operations. The Company will continue to use similar entity volatility information until its historical volatility is relevant to measure expected volatility for option grants. The Company has not applied a forfeiture rate to its assumptions as the impact would not be material to the consolidated financial statements. The risk-free rate for periods within the contractual life of each option is based on the U.S.&amp;#160;Treasury yield curve in effect at the time of the grant for a period commensurate with the expected term of the grant. The expected term (without regard to forfeitures) for options granted represents the period of time that options granted are expected to be outstanding and is derived from the contractual terms of the options granted and expected option exercise behaviors. Prior to the Merger, Private Miragen estimated the fair value of underlying shares of common stock using a third-party valuation report that derived the fair value using the probability-weighted expected return method. After the Merger, the fair value of the underlying Common Stock is based on the closing price of the Common Stock on the NASDAQ Capital Market at the date of grant. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock Options Granted to Employees&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The weighted-average fair value of options granted during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.32&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.70&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. The fair value was determined by the Black-Scholes option pricing model using the following assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term, in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;84.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average grant date fair value of underlying Common Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Stock Options Granted to Non-Employees&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company determines the value of Common Stock options issued to non-employees using the Black-Scholes option pricing model and adjusting the value of such awards to current fair value each reporting period until the awards are vested or a performance commitment has otherwise been reached. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; Common Stock options were issued to non-employees during the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Employee Stock Purchase Plan&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The 2016 Employee Stock Purchase Plan (&amp;#8220;ESPP&amp;#8221;) allows qualified employees to purchase shares of the Company's Common Stock at a price equal to&amp;#160;85%&amp;#160;of the lower of: (i) the closing price at the beginning of the offering period or (ii) the closing price at the end of the offering period. The Company expects that a new 6-month offering period will begin each August&amp;#160;22 and February&amp;#160;22. As of&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;shares available for issuance and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13 thousand&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares had been issued under the ESPP.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Share-Based Compensation Expense&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share-based compensation related to all equity awards issued pursuant to the 2008 Plan and 2016 Plan and for estimated shares to be issued under the ESPP for the current purchase period is included in the condensed consolidated statements of operations as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;416&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,050&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total share-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,693&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$7.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of total unrecognized employee share-based compensation costs, which the Company expects to recognize over a weighted-average remaining period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.2&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;years. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, based on the current estimate of fair value, the Company estimates that the remaining unrecognized share-based compensation expense related to non-employees of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; will be recorded to expense over a weighted-average remaining period of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.9&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;years.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
	<us-gaap:EarningsPerSharePolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-1A7246AF1F8F2B2771150825E91524CA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of Common Stock outstanding during the period without consideration of Common Stock equivalents. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
	<us-gaap:EarningsPerShareTextBlock contextRef="FD2017Q3YTD" id="Fact-F3860212C6E0C6BA2BF70825E91CF3BD">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;NET LOSS PER SHARE&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of Common Stock outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional shares of Common Stock that would have been outstanding if the potential shares of Common Stock had been issued and if the additional shares of Common Stock were dilutive. Diluted net loss per share is the same as basic net loss per share of Common Stock, since the effects of potentially dilutive securities are antidilutive.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Potentially dilutive securities include the following:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options to purchase Common Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants to purchase Common Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,067&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants to purchase redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,994&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,365&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
	<us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock contextRef="FD2017Q3YTD" id="Fact-B061C582FDBF4AC9F74A0825E91EA757">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of the beginning and ending balances of the Company&amp;#8217;s liabilities measured at fair value using significant unobservable, or Level 3, inputs are as follows for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance of liability as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Reclassification of preferred stock warrant to common stock warrant&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance of liability as of September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
	<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="FD2017Q3YTD" id="Fact-E1CDA43D7F38CF10427F0825E915B607">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certain of the Company&amp;#8217;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to the short-term nature of their maturities, such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses. The carrying amount of the Company&amp;#8217;s note payable approximates its fair value (a Level 2 fair value measurement), reflecting interest rates currently available to the Company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for its warrants to purchase common and preferred stock pursuant to ASC Topic&amp;#160;480,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Distinguishing Liabilities from Equity&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and classifies warrants for redeemable preferred stock and certain warrants for common stock as liabilities. The warrants are reported at their estimated fair value and any changes in fair value are reflected in interest expense and other related expenses.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following tables present information about the Company&amp;#8217;s financial assets and liabilities that have been measured at fair value and indicate the fair value of the hierarchy of the valuation inputs utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair value determined by Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
	<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-67C0745ADBED3D2D072B0825E91FFD4C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
	<us-gaap:IncomeTaxPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-600FBF3974C21BCC459A0825E91F5099">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for income taxes by using an asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s significant deferred tax assets are for net operating loss carryforwards, tax credits, and capitalized start-up costs. The Company has provided a valuation allowance for its entire net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that its deferred tax assets will not be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has no unrecognized tax benefits. The Company classifies interest and penalties arising from the underpayment of income taxes in the condensed consolidated statements of operations as general and administrative expenses.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
	<us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-D7D8C4C8F926A0170B520825E920D83D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements &amp;#8211; Not Yet Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; (&amp;#8220;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ASU&amp;#8221;) No. 2014-09&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that &amp;#8220;an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&amp;#8221; The standard provides enhancements to the quality and consistency of how revenue is reported by companies, while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or U.S. GAAP.&amp;#160;The new standard also will require enhanced revenue disclosures, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. This accounting standard becomes effective for the Company for reporting periods beginning after December 15, 2018, and interim reporting periods thereafter. Early adoption is permitted for annual reporting periods (including interim periods) beginning after December 15, 2016. This new standard permits the use of either the retrospective or cumulative effect transition method. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-08&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The purpose of this standard is to clarify the implementation of guidance on principal versus agent considerations related to ASU 2014-09. The standard has the same effective date as ASU 2014-09 described above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2016, the FASB issued&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ASU No. 2016-10,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; Revenue from Contracts with Customer, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;which provides clarity related to ASU 2014-09 regarding identifying performance obligations and licensing implementation. The standard has the same effective date as ASU 2014-09 described above. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May&amp;#160;2016, the FASB issued ASU 2016-12:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which provides narrow scope improvements and practical expedients related to ASU 2014-09. The purpose of&amp;#160;this standard&amp;#160;is to clarify certain narrow aspects of ASU 2014-09, such as assessing the collectability criterion, presentation of sales taxes, and other similar taxes collected from customers, noncash consideration, contract modifications at transition, completed contracts at transition, and technical correction. The standard has the same effective date as ASU 2014-09 described above. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December 2016, the FASB issued ASU 2016-20:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The amendments in this standard affect narrow aspects of guidance issued in ASU 2014-09. The standard has the same effective date as ASU 2014-09 described above. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company plans to adopt these new standards in the first quarter of 2019. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there were limited contracts that will be in effect (actively) as of the transition date and, accordingly, the Company has not yet determined the effect of the standard on its condensed consolidated financial statements. The Company&amp;#8217;s selected implementation transition method will be dependent upon contracts that are in place closer to the transition date. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Deferred Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2015, the FASB issued ASU No. 2015-17&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, Balance Sheet Classification of Deferred Taxes&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. ASU No. 2015-17 requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. This standard is effective for the Company for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods thereafter. The Company does not believe the adoption of this standard will have a material impact on its condensed consolidated financial statements due to the full valuation allowance on all net deferred tax assets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, Leases (Topic 842), which supersedes FASB ASC Topic 840, Leases (Topic 840),&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. In September 2017, the FASB issued ASU 2017-13,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842),&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;which provides additional implementation guidance on the previously issued ASU 2016-02&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. ASU 2016-02 requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for the Company for fiscal years beginning after December 15, 2019, and interim periods thereafter, with early adoption permitted. At adoption, this update will be applied using a modified retrospective approach. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Share-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-09&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which is intended to simplify accounting for equity share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This standard is effective for the Company for annual periods beginning after December 15, 2017, and interim periods thereafter. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amendments related to the timing of when excess tax benefits are recognized, minimum statutory withholding requirements, forfeitures, and intrinsic value should be applied using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of the beginning of the period in which the guidance is adopted. Amendments related to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement should be applied retrospectively. Amendments requiring recognition of excess tax benefits and tax deficiencies in the income statement and the practical expedient for estimating the expected term should be applied prospectively. An entity may elect to apply the amendments related to the presentation of excess tax benefits on the statement of cash flows using either a prospective transition method or a retrospective transition method. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other new pronouncements issued but not effective as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are not expected to have a material impact on the Company&amp;#8217;s condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-E50DC5AF12249B100D1F0825E9171E2A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;PROPERTY AND EQUIPMENT&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net, consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lab equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer hardware and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;361&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;281&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;688&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, gross&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,386&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,183&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,776&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,558&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;610&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, depreciation and amortization expense was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; for each period. During the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, depreciation and amortization expense was &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.2 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.3 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, respectively. Depreciation and amortization expense is recorded primarily in research and development expense on the condensed consolidated statements of operations.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
	<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-B6BE6020A68A0B3561E90825E9156D6C">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company carries its property and equipment at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Leasehold improvements are amortized over the shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets. Construction in progress is not depreciated until placed in service. Repairs and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
	<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="FD2017Q3YTD" id="Fact-155A282A204FDB716F3C0825E921CED2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net, consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Lab equipment&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,219&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,163&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Furniture and fixtures&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;77&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Computer hardware and software&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;361&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;281&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Leasehold improvements&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;729&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;688&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, gross&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,386&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,183&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: accumulated depreciation and amortization&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,776&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(2,558&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Property and equipment, net&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;610&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;625&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
	<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="FD2017Q3YTD" id="Fact-B5798F391390F1CDA30A0825E9156E16">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development costs are expensed as incurred in performing research and development activities. The costs include employee-related expense including salaries, benefits, share-based compensation, fees for acquiring and maintaining licenses under third party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&amp;#8217;s behalf, laboratory supplies, depreciation, and facilities and overhead costs. The Company defers and capitalizes non-refundable advance payments for research and development activities until the related goods are received or services performed. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company records upfront and milestone payments to acquire contractual rights to licensed technology as research and development expenses when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. The Company considers future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved by the U.S. Food and Drug Administration or when other significant risk factors are abated.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
	<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-FB4B27B3DCEFE385B1630825E922A2ED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue principally from its strategic alliance and collaboration agreement. Revenue is recognized from upfront payments for licenses and milestone payments that are generated from defined research or development events, as well as from the reimbursement of amounts for research and development services under its strategic alliance and collaboration agreement. The Company recognizes revenue when all four of the following criteria are met: (1)&amp;#160;persuasive evidence of an arrangement exists; (2)&amp;#160;products have been delivered or services rendered; (3)&amp;#160;the selling price is fixed or determinable; and (4)&amp;#160;collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Multiple-element arrangements are examined to determine whether the deliverables can be separated or must be accounted for as a single unit of accounting. The Servier Collaboration Agreement with Servier, for example, includes a combination of upfront license fees, payments for research and development activities, and milestone payments that are evaluated to determine whether each deliverable under the agreement has value to the customer on a stand-alone basis and whether reliable evidence of fair value for the deliverable exists. Deliverables in an arrangement that do not meet this separation criteria are treated as a single unit of accounting, generally applying applicable revenue recognition guidance for the final deliverable to the combined unit of accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue from non-refundable upfront license fees over the term of performance under the Servier Collaboration Agreement. When the performance period is not specified, the Company estimates the performance period based upon provisions contained within the agreement, such as the duration of the research or development term, the existence, or likelihood, of achievement of development commitments, and any other significant commitments. These advance payments are deferred and recorded as deferred revenue upon receipt, pending recognition, and are classified as a short-term or long-term liability in the accompanying condensed consolidated balance sheets. Expected performance periods are reviewed periodically and, if applicable, the amortization period is adjusted, which may accelerate or decelerate revenue recognition. The timing of revenue recognition, specifically as it relates to the amortization of upfront license fees, is significantly influenced by the Company&amp;#8217;s estimates.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
	<us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="FD2017Q3YTD" id="Fact-6CA6C41E08320D6199E00825E91DAC74">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities consisted of the following:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued outsourced clinical and preclinical studies&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,635&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,684&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued employee compensation and related taxes&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,061&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;928&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued legal fees and expenses&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;607&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;759&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued other professional service fees&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;457&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued equipment and lab materials&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;156&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Value of liability-classified stock purchase warrants &lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Deferred and accrued facility lease obligations&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;221&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;74&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;60&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,142&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,909&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
	<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="FD2017Q3YTD" id="Fact-97CE53C417BFE62500080825E91C9C7F">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Potentially dilutive securities include the following:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="6" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Options to purchase Common Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,265&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants to purchase Common Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,067&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants to purchase redeemable convertible preferred stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;26&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,994&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;15,365&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
	<us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock contextRef="FD2017Q3YTD" id="Fact-541A5E7FE99F9DE9CA2F0825E921AA3D">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following table summarizes the net assets acquired based on their estimated fair values as of February 13, 2017, prior to the Merger (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,280&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Prepaid and other assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;248&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accrued liabilities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,324&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Net acquired tangible assets&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;204&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
	<us-gaap:ScheduleOfDebtTableTextBlock contextRef="FD2017Q3YTD" id="Fact-3E7510E1149CE4EB1B110825E91A121A">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amounts outstanding under notes payable are as follows:&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December&amp;#160;31, &lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Principal amount outstanding&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt discount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(6&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Unamortized debt issuance costs&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(14&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(31&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Accreted final payment fee&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;227&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total notes payable&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,374&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4,789&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Less: current maturities&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,983&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Long-term notes payable, net of current portion&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,391&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,820&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtTableTextBlock>
	<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="FD2017Q3YTD" id="Fact-1C5DC8A2CC708A1C0F100825E91E21ED">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Share-based compensation related to all equity awards issued pursuant to the 2008 Plan and 2016 Plan and for estimated shares to be issued under the ESPP for the current purchase period is included in the condensed consolidated statements of operations as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Three Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;263&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;643&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;General and administrative&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;416&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,050&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;107&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total share-based compensation expense&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;679&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;45&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,693&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;129&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:53%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
	<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="FD2017Q3YTD" id="Fact-C4CE97AB135E85435A790825E91DABB2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following tables present information about the Company&amp;#8217;s financial assets and liabilities that have been measured at fair value and indicate the fair value of the hierarchy of the valuation inputs utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair value determined by Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds (included in cash and cash equivalents)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#160;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44,112&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;text-indent:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;text-indent:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,189&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Preferred and common stock warrants (included in accrued and other liabilities)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;______________________&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1)  Amounts presented for each period above differ from cash and cash equivalents reported in the condensed consolidated balance sheets due to outstanding disbursements and deposits.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
	<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="FD2017Q3YTD" id="Fact-889B202F1363501C789E0825E91DE457">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future annual minimum payments under the lease are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017 (remainder of year)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;95&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;391&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;404&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;277&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1,167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
	<us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="FD2017Q3YTD" id="Fact-01665962A1524802BDBC0825E91D9B84">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Future annual minimum principal payments of notes payable are as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September&amp;#160;30, &lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2017 (remainder of year)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;500&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2018&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,000&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;667&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3,167&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
	<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="FD2017Q3YTD" id="Fact-387CE17B9D47A706A4970825E9201FC8">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A summary of Common Stock option activity is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:75%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:10%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of Options &lt;br clear="none"/&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,321&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Granted&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;956&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercised&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(274&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(0.80&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Forfeited&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(34&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(11.40&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2,969&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;4.62&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
	<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="FD2017Q3YTD" id="Fact-DCAA7449306329AFE7740825E91D6F91">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The fair value was determined by the Black-Scholes option pricing model using the following assumptions:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Nine Months Ended&lt;br clear="none"/&gt;September 30,&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected term, in years&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.44&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5.00&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected volatility&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;83.8&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;84.0&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Risk-free interest rate&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Expected dividend yield&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;%&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Weighted average grant date fair value of underlying Common Stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11.48&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1.05&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
	<us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="FD2017Q3YTD" id="Fact-8B3F59AD35DEB661E6D70825E91DC888">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock purchase warrant activity is as follows for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Common Stock Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Preferred Stock Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants acquired in Merger&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,534&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Preferred stock warrants converted into Common Stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(21,092&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;47.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A summary of outstanding Common Stock purchase warrants as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:34%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:30%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of Underlying Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Expiration Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,534&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$80.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019 &amp;amp; 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,718&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
	<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="FD2017Q3YTD" id="Fact-45B9A69A9C767DD439DE0825E92196F5">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company operates in&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;operating segment and, accordingly, no segment disclosures have been presented herein. All equipment, leasehold improvements, and other fixed assets are physically located within the United States and all agreements with the Company&amp;#8217;s partners are denominated in U.S. dollars, except where noted.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
	<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="FD2017Q3YTD" id="Fact-F5BCFE0358DF10EAF32F0825E92270BE">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Share-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for share-based compensation expense related to stock options granted to employees and members of its board of directors under its 2008 Equity Incentive Plan (the &amp;#8220;2008 Plan&amp;#8221;) and under its 2016 Equity Incentive Plan (the &amp;#8220;2016 Plan&amp;#8221;) by estimating the fair value of each stock option or award on the date of grant using the Black-Scholes option pricing model. The Company recognizes share-based compensation expense on a straight-line basis over the vesting term. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for stock options issued to non-employees by valuing the award using an option pricing model and remeasuring such awards to the current fair value until the awards are vested or a performance commitment has otherwise been reached.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
	<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="FD2017Q3YTD" id="Fact-4718B548FD75CFA01FF30825E9220AD1">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Basis of Presentation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Miragen Europe. The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&amp;#8220;U.S. GAAP&amp;#8221;) and follow the requirements of the Securities and Exchange Commission (the &amp;#8220;SEC&amp;#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company&amp;#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&amp;#8217;s financial information. These interim results are not necessarily indicative of the results to be expected for the year ending December 31, 2017, or for any other interim period, or for any other future year. The balance sheet as of December 31, 2016 has been derived from audited consolidated financial statements at that date but does not include all the information required by U.S. GAAP for complete financial statements. All intercompany balances and transactions have been eliminated in consolidation.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements of the Company and the notes thereto contained in the Company&amp;#8217;s Form 8-K/A for the year ended December 31, 2016, filed with the SEC on March 31, 2017. The Company&amp;#8217;s management performed an evaluation of its activities through the date of filing of these financial statements and concluded that there are no subsequent events requiring disclosure, other than as disclosed.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s consolidated financial statements are prepared in accordance with U.S.&amp;#160;GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company&amp;#8217;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue principally from its strategic alliance and collaboration agreement. Revenue is recognized from upfront payments for licenses and milestone payments that are generated from defined research or development events, as well as from the reimbursement of amounts for research and development services under its strategic alliance and collaboration agreement. The Company recognizes revenue when all four of the following criteria are met: (1)&amp;#160;persuasive evidence of an arrangement exists; (2)&amp;#160;products have been delivered or services rendered; (3)&amp;#160;the selling price is fixed or determinable; and (4)&amp;#160;collectability is reasonably assured.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Multiple-element arrangements are examined to determine whether the deliverables can be separated or must be accounted for as a single unit of accounting. The Servier Collaboration Agreement with Servier, for example, includes a combination of upfront license fees, payments for research and development activities, and milestone payments that are evaluated to determine whether each deliverable under the agreement has value to the customer on a stand-alone basis and whether reliable evidence of fair value for the deliverable exists. Deliverables in an arrangement that do not meet this separation criteria are treated as a single unit of accounting, generally applying applicable revenue recognition guidance for the final deliverable to the combined unit of accounting.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company recognizes revenue from non-refundable upfront license fees over the term of performance under the Servier Collaboration Agreement. When the performance period is not specified, the Company estimates the performance period based upon provisions contained within the agreement, such as the duration of the research or development term, the existence, or likelihood, of achievement of development commitments, and any other significant commitments. These advance payments are deferred and recorded as deferred revenue upon receipt, pending recognition, and are classified as a short-term or long-term liability in the accompanying condensed consolidated balance sheets. Expected performance periods are reviewed periodically and, if applicable, the amortization period is adjusted, which may accelerate or decelerate revenue recognition. The timing of revenue recognition, specifically as it relates to the amortization of upfront license fees, is significantly influenced by the Company&amp;#8217;s estimates.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Share-Based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for share-based compensation expense related to stock options granted to employees and members of its board of directors under its 2008 Equity Incentive Plan (the &amp;#8220;2008 Plan&amp;#8221;) and under its 2016 Equity Incentive Plan (the &amp;#8220;2016 Plan&amp;#8221;) by estimating the fair value of each stock option or award on the date of grant using the Black-Scholes option pricing model. The Company recognizes share-based compensation expense on a straight-line basis over the vesting term. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for stock options issued to non-employees by valuing the award using an option pricing model and remeasuring such awards to the current fair value until the awards are vested or a performance commitment has otherwise been reached.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Research and Development&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Research and development costs are expensed as incurred in performing research and development activities. The costs include employee-related expense including salaries, benefits, share-based compensation, fees for acquiring and maintaining licenses under third party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&amp;#8217;s behalf, laboratory supplies, depreciation, and facilities and overhead costs. The Company defers and capitalizes non-refundable advance payments for research and development activities until the related goods are received or services performed. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company records upfront and milestone payments to acquire contractual rights to licensed technology as research and development expenses when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. The Company considers future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved by the U.S. Food and Drug Administration or when other significant risk factors are abated.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Clinical Trial and Preclinical Study Accruals&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company makes estimates of accrued expenses as of each balance sheet date in its condensed consolidated financial statements based on certain facts and circumstances at that time. The Company&amp;#8217;s accrued expenses for clinical trials and preclinical studies are based on estimates of costs incurred for services provided by clinical research organizations, manufacturing organizations, and other providers. Payments under the Company&amp;#8217;s agreements with external service providers depend on a number of factors, such as site initiation, patient screening, enrollment, delivery of reports, and other events. In accruing for these activities, the Company obtains information from various sources and estimates the level of effort or expense allocated to each period. Adjustments to the Company&amp;#8217;s research and development expenses may be necessary in future periods as its estimates change.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Cash and Cash Equivalents&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;All highly-liquid investments that have maturities of 90 days or less at the date of purchase are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value due to the short maturities of these instruments.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Fair Value of Financial Instruments&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The following tables present information about the Company&amp;#8217;s financial assets and liabilities that have been measured at fair value and indicate the fair value of the hierarchy of the valuation inputs utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair value determined by Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.&lt;/font&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="16" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:45%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;September 30,&lt;br clear="none"/&gt;2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;December 31,&lt;br clear="none"/&gt;2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Level 3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;(in thousands)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Assets:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Money market funds (included in cash and cash equivalents)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:7pt"&gt;&amp;#160;(1)&lt;/sup&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;44,112&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;text-indent:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;text-indent:5px;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;22,189&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Liabilities:&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Preferred and common stock warrants (included in accrued and other liabilities)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;______________________&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(1)  Amounts presented for each period above differ from cash and cash equivalents reported in the condensed consolidated balance sheets due to outstanding disbursements and deposits.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A reconciliation of the beginning and ending balances of the Company&amp;#8217;s liabilities measured at fair value using significant unobservable, or Level 3, inputs are as follows for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; (in thousands):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:87%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:11%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance of liability as of December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;133&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Reclassification of preferred stock warrant to common stock warrant&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(51&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Balance of liability as of September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;82&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Certain of the Company&amp;#8217;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to the short-term nature of their maturities, such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses. The carrying amount of the Company&amp;#8217;s note payable approximates its fair value (a Level 2 fair value measurement), reflecting interest rates currently available to the Company. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for its warrants to purchase common and preferred stock pursuant to ASC Topic&amp;#160;480,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Distinguishing Liabilities from Equity&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and classifies warrants for redeemable preferred stock and certain warrants for common stock as liabilities. The warrants are reported at their estimated fair value and any changes in fair value are reflected in interest expense and other related expenses.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Concentrations of Credit Risk&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with two financial institutions.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Property and Equipment&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company carries its property and equipment at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;three&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;five years&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Leasehold improvements are amortized over the shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets. Construction in progress is not depreciated until placed in service. Repairs and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Impairment of Long-Lived Assets&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; impairment charges were recorded during the three and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Net Loss per Share&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of Common Stock outstanding during the period without consideration of Common Stock equivalents. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Comprehensive Loss&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources. If the Company had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&amp;#8217; equity (deficit). There were no elements of comprehensive loss during the three and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Income Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company accounts for income taxes by using an asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s significant deferred tax assets are for net operating loss carryforwards, tax credits, and capitalized start-up costs. The Company has provided a valuation allowance for its entire net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that its deferred tax assets will not be realized.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has no unrecognized tax benefits. The Company classifies interest and penalties arising from the underpayment of income taxes in the condensed consolidated statements of operations as general and administrative expenses. &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;No&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; such expenses have been recognized during the three and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2016&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Segment Information&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company operates in&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;one&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;operating segment and, accordingly, no segment disclosures have been presented herein. All equipment, leasehold improvements, and other fixed assets are physically located within the United States and all agreements with the Company&amp;#8217;s partners are denominated in U.S. dollars, except where noted.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Recent Accounting Pronouncements &amp;#8211; Not Yet Adopted&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May 2014, the Financial Accounting Standards Board (&amp;#8220;FASB&amp;#8221;) issued Accounting Standards Update&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; (&amp;#8220;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ASU&amp;#8221;) No. 2014-09&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, Revenue from Contracts with Customers (Topic 606)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that &amp;#8220;an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&amp;#8221; The standard provides enhancements to the quality and consistency of how revenue is reported by companies, while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or U.S. GAAP.&amp;#160;The new standard also will require enhanced revenue disclosures, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. This accounting standard becomes effective for the Company for reporting periods beginning after December 15, 2018, and interim reporting periods thereafter. Early adoption is permitted for annual reporting periods (including interim periods) beginning after December 15, 2016. This new standard permits the use of either the retrospective or cumulative effect transition method. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-08&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The purpose of this standard is to clarify the implementation of guidance on principal versus agent considerations related to ASU 2014-09. The standard has the same effective date as ASU 2014-09 described above.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In April 2016, the FASB issued&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;ASU No. 2016-10,&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; Revenue from Contracts with Customer, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;which provides clarity related to ASU 2014-09 regarding identifying performance obligations and licensing implementation. The standard has the same effective date as ASU 2014-09 described above. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In May&amp;#160;2016, the FASB issued ASU 2016-12:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which provides narrow scope improvements and practical expedients related to ASU 2014-09. The purpose of&amp;#160;this standard&amp;#160;is to clarify certain narrow aspects of ASU 2014-09, such as assessing the collectability criterion, presentation of sales taxes, and other similar taxes collected from customers, noncash consideration, contract modifications at transition, completed contracts at transition, and technical correction. The standard has the same effective date as ASU 2014-09 described above. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In December 2016, the FASB issued ASU 2016-20:&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt; Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. The amendments in this standard affect narrow aspects of guidance issued in ASU 2014-09. The standard has the same effective date as ASU 2014-09 described above. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company plans to adopt these new standards in the first quarter of 2019. As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, there were limited contracts that will be in effect (actively) as of the transition date and, accordingly, the Company has not yet determined the effect of the standard on its condensed consolidated financial statements. The Company&amp;#8217;s selected implementation transition method will be dependent upon contracts that are in place closer to the transition date. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Deferred Taxes&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In November 2015, the FASB issued ASU No. 2015-17&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, Balance Sheet Classification of Deferred Taxes&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. ASU No. 2015-17 requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. This standard is effective for the Company for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods thereafter. The Company does not believe the adoption of this standard will have a material impact on its condensed consolidated financial statements due to the full valuation allowance on all net deferred tax assets. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February 2016, the FASB issued ASU No. 2016-02&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, Leases (Topic 842), which supersedes FASB ASC Topic 840, Leases (Topic 840),&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. In September 2017, the FASB issued ASU 2017-13,&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842),&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;which provides additional implementation guidance on the previously issued ASU 2016-02&amp;#160;&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Leases (Topic 842)&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. ASU 2016-02 requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for the Company for fiscal years beginning after December 15, 2019, and interim periods thereafter, with early adoption permitted. At adoption, this update will be applied using a modified retrospective approach. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;Share-based Compensation&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In March 2016, the FASB issued ASU No. 2016-09&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;, Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, which is intended to simplify accounting for equity share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This standard is effective for the Company for annual periods beginning after December 15, 2017, and interim periods thereafter. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Amendments related to the timing of when excess tax benefits are recognized, minimum statutory withholding requirements, forfeitures, and intrinsic value should be applied using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of the beginning of the period in which the guidance is adopted. Amendments related to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement should be applied retrospectively. Amendments requiring recognition of excess tax benefits and tax deficiencies in the income statement and the practical expedient for estimating the expected term should be applied prospectively. An entity may elect to apply the amendments related to the presentation of excess tax benefits on the statement of cash flows using either a prospective transition method or a retrospective transition method. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Other new pronouncements issued but not effective as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; are not expected to have a material impact on the Company&amp;#8217;s condensed consolidated financial statements.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
	<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="FD2017Q3YTD" id="Fact-4F46D99067FE289B9B410825E9185CEA">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;CAPITAL STOCK&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is authorized to issue &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;105,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;shares of its stock, of which &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;100,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;shares have been designated as Common Stock and &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;5,000,000&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares have been designated as preferred stock with a par value of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.01&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per&amp;#160;share. The number of authorized shares of Common Stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&amp;#8217;s stock who are entitled to vote. Each share of Common Stock is entitled to one vote. The holders of Common Stock are entitled to receive dividends when and as declared or paid by its board of directors. At the effective date of the Merger, each outstanding share of Private Miragen common stock was converted into the right to receive approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.7031&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of the Company&amp;#8217;s Common Stock. &lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On February 13, 2017, immediately prior to the Merger and in accordance with subscription agreements entered into with certain investors in October 2016, Private Miragen issued and sold an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;9,045,126&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Private Miragen&amp;#8217;s common stock at a price per share of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$4.50&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, or &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6,359,628&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Common Stock at a price per share of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$6.40&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as adjusted for the exchange ratio in the Merger, for aggregate consideration of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$40.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, offset by associated financing fees of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$1.5&amp;#160;million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Series Preferred&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In February&amp;#160;2017, in conjunction with the Merger, all of the outstanding redeemable convertible preferred stock of Private Miragen converted into Private Miragen common stock at a ratio of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;1&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:1 and was immediately exchanged for the Company&amp;#8217;s Common Stock at an exchange ratio of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.7031&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; as a result of the Merger. A summary of the conversion by class of preferred stock is summarized as follows (in thousands, except share data):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Series A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Series B&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Series C&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;7,149,176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;23,124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2,166,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;12,975&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;9,268,563&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;40,877&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;18,584,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;76,976&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Accretion of redeemable convertible preferred stock to redemption value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Conversion of preferred stock to common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(7,149,176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(23,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(2,166,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(12,976&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(9,268,563&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(40,880&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(18,584,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(76,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Balance at February 13, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company had no shares of preferred stock outstanding and had not designated the rights, preferences, or privileges of any class or series of preferred stock. Although the Company&amp;#8217;s board of directors has the authority to issue preferred stock at its discretion in one or more classes or series and to fix the designations, powers, preferences and rights, and the qualifications, limitations, or restrictions thereof, including dividend rights, conversion right, voting rights, terms of redemption, liquidation preferences, and the number of shares constituting any class or series of preferred stock, without further vote or action by the stockholders.&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Common Stock Sales Agreement&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;On March 31,&amp;#160;2017, the Company entered into an ATM Agreement with Cowen, under which the Company may offer and sell, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of up to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$50.0 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through Cowen as its sales agent.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Cowen may sell the Common Stock by any method permitted by law deemed to be an &amp;#8220;at the market offering&amp;#8221; as defined in Rule 415 of the Securities Act of 1933, as amended, including without limitation sales made by means of ordinary brokers&amp;#8217; transactions on The NASDAQ Capital Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise directed by the Company. Cowen will use commercially reasonable efforts to sell the Common Stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay Cowen a commission equal to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of the gross sales proceeds of any Common Stock sold through Cowen under the ATM Agreement, and also has provided Cowen with customary indemnification rights.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company is not obligated to make any sales of Common Stock under the ATM Agreement. The offering of shares of Common Stock pursuant to the ATM Agreement will terminate upon the earlier of: (i) the sale of all Common Stock subject to the ATM Agreement or (ii) termination of the ATM Agreement in accordance with its terms.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;As of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company has sold, pursuant to the terms of the ATM Agreement, &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;297,653&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Common Stock, at a weighted average price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.11&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, for aggregate gross proceeds of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.7 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;. Net proceeds received during the nine months ended &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; were approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$2.5 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, including initial expenses for executing the &amp;#8220;at the market offering&amp;#8221; and commissions to Cowen as sales agent. See Note 13 for a discussion of sales of Common Stock made under the ATM Agreement after &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company has incurred approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.4 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; in offering costs for the ATM Agreement, including costs for the related shelf filing, but excluding the commissions paid to Cowen as sales agent.&amp;#160;The costs incurred are initially included in prepaid expenses and other current assets and are being amortized to a reduction of offering costs as shares are sold under the ATM Agreement.&amp;#160;The costs reflected in the condensed consolidated statement of cash flows include the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.0%&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; commission paid to Cowen on shares sold (&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$0.1 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;) along with &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8 thousand&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; of amortized offering costs.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;WARRANTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Stock purchase warrant activity is as follows for the &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;nine months ended September 30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:37%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:14%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:13%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Common Stock Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Preferred Stock Warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Weighted Average Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;7,031&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;0.57&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Warrants acquired in Merger&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,534&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;80.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Preferred stock warrants converted into Common Stock warrants&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(25,779&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;6.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Exercises&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;(21,092&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;3.04&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Outstanding at September 30, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;47.21&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A summary of outstanding Common Stock purchase warrants as of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; is as follows:&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:34%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:30%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Number of Underlying Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Exercise Price&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Expiration Date&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,534&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$80.70&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2019 &amp;amp; 2020&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;11,718&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$8.53&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;2025&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:center;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;25,252&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;In connection with the Merger, Private Miragen assumed &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;13,534&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; outstanding warrants to purchase shares of the Company&amp;#8217;s Common Stock at a weighted average exercise price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$80.70&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share. The assumed warrants expire on various dates in 2019 and 2020.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
	<us-gaap:SubsequentEventsTextBlock contextRef="FD2017Q3YTD" id="Fact-6C2C60D52AD29A0D4363782A65DD4298">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-weight:bold;"&gt;SUBSEQUENT EVENTS&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;Subsequent to &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;September&amp;#160;30, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, and through &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;November 7, 2017&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, the Company sold, pursuant to the terms of the ATM Agreement, an aggregate of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;403,306&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; shares of Common Stock, at a weighted average price of &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$9.65&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt; per share, for aggregate gross proceeds of approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.9 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;.&amp;#160;Net proceeds were approximately &lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;$3.8 million&lt;/font&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;, including commissions to Cowen, as sales agent.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
	<us-gaap:TemporaryEquityTableTextBlock contextRef="FD2017Q3YTD" id="Fact-A45BA77600884474263D0825E920F1E2">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;A summary of the conversion by class of preferred stock is summarized as follows (in thousands, except share data):&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="28" rowspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:7%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:9%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:8%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;td style="width:1%;" rowspan="1" colspan="1"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Series A&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Series B&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Series C&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Total&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Shares&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;font-weight:bold;"&gt;Amount&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Balance at December 31, 2016&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;7,149,176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;23,124&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;2,166,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;12,975&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;9,268,563&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;40,877&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;18,584,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;76,976&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Accretion of redeemable convertible preferred stock to redemption value&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;1&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;3&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;5&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Conversion of preferred stock to common stock&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(7,149,176&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(23,125&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(2,166,651&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(12,976&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(9,268,563&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(40,880&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(18,584,390&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;(76,981&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;)&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;Balance at February 13, 2017&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;$&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;font style="font-family:inherit;font-size:8pt;"&gt;&amp;#8212;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:TemporaryEquityTableTextBlock>
	<us-gaap:UseOfEstimates contextRef="FD2017Q3YTD" id="Fact-2F7FC9CE4B01713D104A0825E921C901">&lt;div style="font-family:Times New Roman;font-size:10pt;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;"&gt;Use of Estimates&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;&lt;br clear="none"/&gt;&lt;/font&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;font style="font-family:inherit;font-size:10pt;"&gt;The Company&amp;#8217;s consolidated financial statements are prepared in accordance with U.S.&amp;#160;GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company&amp;#8217;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.&lt;/font&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
	<link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
	</link:footnoteLink>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>mgen-20170930.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.miragentherapeutics.com/20170930" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:mgen="http://www.miragentherapeutics.com/20170930" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-roles-2017-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgen-20170930_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgen-20170930_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgen-20170930_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="mgen-20170930_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccruedLiabilities" roleURI="http://www.miragentherapeutics.com/role/AccruedLiabilities">
        <link:definition>2106100 - Disclosure - Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesComponentsOfAccruedLiabilitiesDetails" roleURI="http://www.miragentherapeutics.com/role/AccruedLiabilitiesComponentsOfAccruedLiabilitiesDetails">
        <link:definition>2406402 - Disclosure - Accrued Liabilities - Components of Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccruedLiabilitiesTables" roleURI="http://www.miragentherapeutics.com/role/AccruedLiabilitiesTables">
        <link:definition>2306301 - Disclosure - Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStock" roleURI="http://www.miragentherapeutics.com/role/CapitalStock">
        <link:definition>2109100 - Disclosure - Capital Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockNarrativeDetails" roleURI="http://www.miragentherapeutics.com/role/CapitalStockNarrativeDetails">
        <link:definition>2409402 - Disclosure - Capital Stock - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockSummaryOfSeriesPreferredStockDetails" roleURI="http://www.miragentherapeutics.com/role/CapitalStockSummaryOfSeriesPreferredStockDetails">
        <link:definition>2409403 - Disclosure - Capital Stock - Summary of Series Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CapitalStockTables" roleURI="http://www.miragentherapeutics.com/role/CapitalStockTables">
        <link:definition>2309301 - Disclosure - Capital Stock (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingencies" roleURI="http://www.miragentherapeutics.com/role/CommitmentsAndContingencies">
        <link:definition>2108100 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" roleURI="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails">
        <link:definition>2408403 - Disclosure - Commitments and Contingencies - Future Minimum Rental Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesNarrativeDetails" roleURI="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesNarrativeDetails">
        <link:definition>2408402 - Disclosure - Commitments and Contingencies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsAndContingenciesTables" roleURI="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesTables">
        <link:definition>2308301 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001000 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1001001 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfCashFlows" roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlows">
        <link:definition>1004000 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfOperations" roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfOperations">
        <link:definition>1002000 - Statement - Condensed Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficit" roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficit">
        <link:definition>1003000 - Statement - Condensed Consolidated Statements of Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusiness" roleURI="http://www.miragentherapeutics.com/role/DescriptionOfBusiness">
        <link:definition>2101100 - Disclosure - Description of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DescriptionOfBusinessNarrativeDetails" roleURI="http://www.miragentherapeutics.com/role/DescriptionOfBusinessNarrativeDetails">
        <link:definition>2401401 - Disclosure - Description of Business - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="DocumentAndEntityInformation" roleURI="http://www.miragentherapeutics.com/role/DocumentAndEntityInformation">
        <link:definition>0001000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.miragentherapeutics.com/role/NetLossPerShare">
        <link:definition>2112100 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetails" roleURI="http://www.miragentherapeutics.com/role/NetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetails">
        <link:definition>2412402 - Disclosure - Net Loss Per Share - Summary of Potential Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.miragentherapeutics.com/role/NetLossPerShareTables">
        <link:definition>2312301 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayable" roleURI="http://www.miragentherapeutics.com/role/NotesPayable">
        <link:definition>2107100 - Disclosure - Notes Payable</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableCompositionOfNotesPayableDetails" roleURI="http://www.miragentherapeutics.com/role/NotesPayableCompositionOfNotesPayableDetails">
        <link:definition>2407403 - Disclosure - Notes Payable - Composition of Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableCompositionOfNotesPayableDetailsCalc2" roleURI="http://www.miragentherapeutics.com/role/NotesPayableCompositionOfNotesPayableDetailsCalc2">
        <link:definition>2407403 - Disclosure - Notes Payable - Composition of Notes Payable (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableFutureAnnualMinimumPrincipalPaymentsDetails" roleURI="http://www.miragentherapeutics.com/role/NotesPayableFutureAnnualMinimumPrincipalPaymentsDetails">
        <link:definition>2407404 - Disclosure - Notes Payable - Future Annual Minimum Principal Payments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableNarrativeDetails" roleURI="http://www.miragentherapeutics.com/role/NotesPayableNarrativeDetails">
        <link:definition>2407402 - Disclosure - Notes Payable - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NotesPayableTables" roleURI="http://www.miragentherapeutics.com/role/NotesPayableTables">
        <link:definition>2307301 - Disclosure - Notes Payable (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipment" roleURI="http://www.miragentherapeutics.com/role/PropertyAndEquipment">
        <link:definition>2105100 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" roleURI="http://www.miragentherapeutics.com/role/PropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails">
        <link:definition>2405402 - Disclosure - Property and Equipment - Components of Property and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentNarrativeDetails" roleURI="http://www.miragentherapeutics.com/role/PropertyAndEquipmentNarrativeDetails">
        <link:definition>2405403 - Disclosure - Property and Equipment - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyAndEquipmentTables" roleURI="http://www.miragentherapeutics.com/role/PropertyAndEquipmentTables">
        <link:definition>2305301 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReverseMerger" roleURI="http://www.miragentherapeutics.com/role/ReverseMerger">
        <link:definition>2104100 - Disclosure - Reverse Merger</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReverseMergerNarrativeDetails" roleURI="http://www.miragentherapeutics.com/role/ReverseMergerNarrativeDetails">
        <link:definition>2404402 - Disclosure - Reverse Merger - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReverseMergerSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" roleURI="http://www.miragentherapeutics.com/role/ReverseMergerSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails">
        <link:definition>2404403 - Disclosure - Reverse Merger - Summary of Assets Acquired and Liabilities Assumed (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ReverseMergerTables" roleURI="http://www.miragentherapeutics.com/role/ReverseMergerTables">
        <link:definition>2304301 - Disclosure - Reverse Merger (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensation">
        <link:definition>2111100 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationAllocationOfShareBasedCompensationExpenseOnStatementsOfOperationsDetails" roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationAllocationOfShareBasedCompensationExpenseOnStatementsOfOperationsDetails">
        <link:definition>2411405 - Disclosure - Share-Based Compensation - Allocation of Share-based Compensation Expense on Statements of Operations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationFairValueAssumptionForStockOptionsDetails" roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationFairValueAssumptionForStockOptionsDetails">
        <link:definition>2411404 - Disclosure - Share-Based Compensation - Fair Value Assumption for Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>2411402 - Disclosure - Share-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockOptionActivityDetails" roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails">
        <link:definition>2411403 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationTables">
        <link:definition>2311301 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StrategicAllianceAndCollaborationWithServier" roleURI="http://www.miragentherapeutics.com/role/StrategicAllianceAndCollaborationWithServier">
        <link:definition>2103100 - Disclosure - Strategic Alliance and Collaboration with Servier</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StrategicAllianceAndCollaborationWithServierNarrativeDetails" roleURI="http://www.miragentherapeutics.com/role/StrategicAllianceAndCollaborationWithServierNarrativeDetails">
        <link:definition>2403401 - Disclosure - Strategic Alliance and Collaboration with Servier - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEvents" roleURI="http://www.miragentherapeutics.com/role/SubsequentEvents">
        <link:definition>2135100 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SubsequentEventsNarrativeDetails" roleURI="http://www.miragentherapeutics.com/role/SubsequentEventsNarrativeDetails">
        <link:definition>2435401 - Disclosure - Subsequent Events - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPolicies" roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPolicies">
        <link:definition>2102100 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
        <link:definition>2402403 - Disclosure - Summary of Significant Accounting Policies - Assets and Liabilities Measured on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails" roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails">
        <link:definition>2402404 - Disclosure - Summary of Significant Accounting Policies - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>2402405 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables">
        <link:definition>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Warrants" roleURI="http://www.miragentherapeutics.com/role/Warrants">
        <link:definition>2110100 - Disclosure - Warrants</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsNarrativeDetails" roleURI="http://www.miragentherapeutics.com/role/WarrantsNarrativeDetails">
        <link:definition>2410404 - Disclosure - Warrants - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsStockWarrantActivityDetails" roleURI="http://www.miragentherapeutics.com/role/WarrantsStockWarrantActivityDetails">
        <link:definition>2410402 - Disclosure - Warrants - Stock Warrant Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsStockWarrantsOutstandingDetails" roleURI="http://www.miragentherapeutics.com/role/WarrantsStockWarrantsOutstandingDetails">
        <link:definition>2410403 - Disclosure - Warrants - Stock Warrants Outstanding (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="WarrantsTables" roleURI="http://www.miragentherapeutics.com/role/WarrantsTables">
        <link:definition>2310301 - Disclosure - Warrants (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="mgen_AccretionofOfferingCosts" name="AccretionofOfferingCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mgen_AccruedLegalFeesCurrent" name="AccruedLegalFeesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgen_AccruedLiabilitiesEquipmentandLabMaterials" name="AccruedLiabilitiesEquipmentandLabMaterials" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgen_AccruedLiabilityofWarrantsonTemporaryEquity" name="AccruedLiabilityofWarrantsonTemporaryEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgen_AccruedOutsourcingClinicalandPreclinicalStudies" name="AccruedOutsourcingClinicalandPreclinicalStudies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgen_AccumulatedAmortizationDeferredCosts" name="AccumulatedAmortizationDeferredCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability" name="AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_AtthemarketOfferingMember" name="AtthemarketOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_CapitalStockSharesAuthorized" name="CapitalStockSharesAuthorized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="mgen_ClassofWarrantorRightAcquiredinAcquisition" name="ClassofWarrantorRightAcquiredinAcquisition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice" name="ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_ClassofWarrantorRightActivityRollForward" name="ClassofWarrantorRightActivityRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice" name="ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice" name="ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_ClassofWarrantorRightWarrantsConverted" name="ClassofWarrantorRightWarrantsConverted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_ClassofWarrantorRightWarrantsExercised" name="ClassofWarrantorRightWarrantsExercised" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" name="ClassofWarrantorRightWeightedAverageExercisePriceRollForward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" name="ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_CollaborationArrangementPotentialCashProceedsforServices" name="CollaborationArrangementPotentialCashProceedsforServices" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgen_CollaborationArrangementTermOfAgreement" name="CollaborationArrangementTermOfAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_CollaborationArrangementTermofAgreementTerminationPeriod" name="CollaborationArrangementTermofAgreementTerminationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_CollaborativeArrangementNumberofArrangements" name="CollaborativeArrangementNumberofArrangements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments" name="CollaborativeArrangementPotentialCommercializationMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments" name="CollaborativeArrangementPotentialDevelopmentMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments" name="CollaborativeArrangementPotentialRegulatoryMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mgen_CommitmentsandContingenciesLineItems" name="CommitmentsandContingenciesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_CommitmentsandContingenciesTable" name="CommitmentsandContingenciesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_CommonStockWarrantsExpiring2019and2020Member" name="CommonStockWarrantsExpiring2019and2020Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_CommonStockWarrantsExpiring2025Member" name="CommonStockWarrantsExpiring2025Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_CommonStockWarrantsMember" name="CommonStockWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_ConversionOfStockSharesIssuedConversionRate" name="ConversionOfStockSharesIssuedConversionRate" nillable="true" substitutionGroup="xbrli:item" type="xbrli:pureItemType" xbrli:periodType="instant" />
  <xsd:element id="mgen_ConversionofWarrantstoPermanentEquity" name="ConversionofWarrantstoPermanentEquity" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed" name="DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="mgen_DebtInstrumentNumberOfTranches" name="DebtInstrumentNumberOfTranches" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="mgen_DebtInstrumentTermInterestOnlyPayments" name="DebtInstrumentTermInterestOnlyPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_DescriptionofBusinessLineItems" name="DescriptionofBusinessLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_DescriptionofBusinessTable" name="DescriptionofBusinessTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember" name="DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_EquityPlan2008Member" name="EquityPlan2008Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_EquityPlan2016Member" name="EquityPlan2016Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_EuropeanUnionorJapanMember" name="EuropeanUnionorJapanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_FairValueInputsProbabilityofExercise" name="FairValueInputsProbabilityofExercise" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_LicenseCostAnnualMaintenanceFeePerLicense" name="LicenseCostAnnualMaintenanceFeePerLicense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval" name="LicenseCostPotentialMilestonePaymentRegulatoryApproval" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgen_LicenseCostsOnetimeSalesMilestonePayment" name="LicenseCostsOnetimeSalesMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgen_LicenseCostsPotentialMilestonePayment" name="LicenseCostsPotentialMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials" name="LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct" name="LicenseCostsPotentialMilestonePaymentPerLicensedProduct" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgen_LicenseCostsUpfrontLicensingFeePerLicense" name="LicenseCostsUpfrontLicensingFeePerLicense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee" name="LongTermDebtAccumulatedAccretionOfFinalPaymentFee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="mgen_MarketCapitalization" name="MarketCapitalization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mgen_MiragenShareholdersMember" name="MiragenShareholdersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_NonemployeeStockOptionMember" name="NonemployeeStockOptionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_NonemployeesMember" name="NonemployeesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_OperatingLeasesOperatingExpense" name="OperatingLeasesOperatingExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="mgen_PaymentsForLicensingAgreement" name="PaymentsForLicensingAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgen_PaymentstoAcquireRawMaterials" name="PaymentstoAcquireRawMaterials" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_PostMergerSharesMember" name="PostMergerSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember" name="PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_PreMergerSharesMember" name="PreMergerSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_PreferredStockWarrantsMember" name="PreferredStockWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_PrivateFinancingMember" name="PrivateFinancingMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_RocheInnovationCenterCopenhagenASMember" name="RocheInnovationCenterCopenhagenASMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_SaleofStockAdditionalAuthorizedTransactionAmount" name="SaleofStockAdditionalAuthorizedTransactionAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds" name="SaleofStockCommissionFeePercentageofGrossSaleProceeds" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_SeriesARedeemableConvertiblePreferredStockMember" name="SeriesARedeemableConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_SeriesCRedeemableConvertiblePreferredStockMember" name="SeriesCRedeemableConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition" name="SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions" name="SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="mgen_ShelfRegistrationMember" name="ShelfRegistrationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_SignalMember" name="SignalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_SignalShareholdersMember" name="SignalShareholdersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_SignalSharesIssuedToMiragenCommonShareholdersMember" name="SignalSharesIssuedToMiragenCommonShareholdersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_SiliconValleyBankAgreementMember" name="SiliconValleyBankAgreementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction" name="StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="mgen_StockIssuedDuringPeriodSharesExerciseofWarrants" name="StockIssuedDuringPeriodSharesExerciseofWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_T2cureGmbHMember" name="T2cureGmbHMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_TheBrighamandWomensHospitalMember" name="TheBrighamandWomensHospitalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction" name="TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember" name="TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember" name="TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_UniversityofTexasMember" name="UniversityofTexasMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="mgen_YaleUniversityMember" name="YaleUniversityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>mgen-20170930_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/AccruedLiabilities" xlink:href="mgen-20170930.xsd#AccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/AccruedLiabilitiesComponentsOfAccruedLiabilitiesDetails" xlink:href="mgen-20170930.xsd#AccruedLiabilitiesComponentsOfAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/AccruedLiabilitiesTables" xlink:href="mgen-20170930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CapitalStock" xlink:href="mgen-20170930.xsd#CapitalStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CapitalStockNarrativeDetails" xlink:href="mgen-20170930.xsd#CapitalStockNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CapitalStockSummaryOfSeriesPreferredStockDetails" xlink:href="mgen-20170930.xsd#CapitalStockSummaryOfSeriesPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CapitalStockTables" xlink:href="mgen-20170930.xsd#CapitalStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CommitmentsAndContingencies" xlink:href="mgen-20170930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" xlink:href="mgen-20170930.xsd#CommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="mgen-20170930.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:href="mgen-20170930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:href="mgen-20170930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="mgen-20170930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="mgen-20170930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="mgen-20170930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficit" xlink:href="mgen-20170930.xsd#CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/DescriptionOfBusiness" xlink:href="mgen-20170930.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/DescriptionOfBusinessNarrativeDetails" xlink:href="mgen-20170930.xsd#DescriptionOfBusinessNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/DocumentAndEntityInformation" xlink:href="mgen-20170930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NetLossPerShare" xlink:href="mgen-20170930.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetails" xlink:href="mgen-20170930.xsd#NetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NetLossPerShareTables" xlink:href="mgen-20170930.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NotesPayable" xlink:href="mgen-20170930.xsd#NotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NotesPayableCompositionOfNotesPayableDetails" xlink:href="mgen-20170930.xsd#NotesPayableCompositionOfNotesPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NotesPayableCompositionOfNotesPayableDetailsCalc2" xlink:href="mgen-20170930.xsd#NotesPayableCompositionOfNotesPayableDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NotesPayableFutureAnnualMinimumPrincipalPaymentsDetails" xlink:href="mgen-20170930.xsd#NotesPayableFutureAnnualMinimumPrincipalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NotesPayableNarrativeDetails" xlink:href="mgen-20170930.xsd#NotesPayableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NotesPayableTables" xlink:href="mgen-20170930.xsd#NotesPayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/PropertyAndEquipment" xlink:href="mgen-20170930.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/PropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" xlink:href="mgen-20170930.xsd#PropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="mgen-20170930.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/PropertyAndEquipmentTables" xlink:href="mgen-20170930.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ReverseMerger" xlink:href="mgen-20170930.xsd#ReverseMerger" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ReverseMergerNarrativeDetails" xlink:href="mgen-20170930.xsd#ReverseMergerNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ReverseMergerSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="mgen-20170930.xsd#ReverseMergerSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ReverseMergerTables" xlink:href="mgen-20170930.xsd#ReverseMergerTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensation" xlink:href="mgen-20170930.xsd#ShareBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationAllocationOfShareBasedCompensationExpenseOnStatementsOfOperationsDetails" xlink:href="mgen-20170930.xsd#ShareBasedCompensationAllocationOfShareBasedCompensationExpenseOnStatementsOfOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationFairValueAssumptionForStockOptionsDetails" xlink:href="mgen-20170930.xsd#ShareBasedCompensationFairValueAssumptionForStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:href="mgen-20170930.xsd#ShareBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:href="mgen-20170930.xsd#ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationTables" xlink:href="mgen-20170930.xsd#ShareBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/StrategicAllianceAndCollaborationWithServier" xlink:href="mgen-20170930.xsd#StrategicAllianceAndCollaborationWithServier" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/StrategicAllianceAndCollaborationWithServierNarrativeDetails" xlink:href="mgen-20170930.xsd#StrategicAllianceAndCollaborationWithServierNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SubsequentEvents" xlink:href="mgen-20170930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SubsequentEventsNarrativeDetails" xlink:href="mgen-20170930.xsd#SubsequentEventsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPoliciesFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/Warrants" xlink:href="mgen-20170930.xsd#Warrants" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/WarrantsNarrativeDetails" xlink:href="mgen-20170930.xsd#WarrantsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/WarrantsStockWarrantActivityDetails" xlink:href="mgen-20170930.xsd#WarrantsStockWarrantActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/WarrantsStockWarrantsOutstandingDetails" xlink:href="mgen-20170930.xsd#WarrantsStockWarrantsOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/WarrantsTables" xlink:href="mgen-20170930.xsd#WarrantsTables" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/AccruedLiabilities" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/AccruedLiabilitiesComponentsOfAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccruedOutsourcingClinicalandPreclinicalStudies" xlink:label="loc_mgen_AccruedOutsourcingClinicalandPreclinicalStudies_d6609ced-0c5b-3e07-2528-0825f62c5818" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_mgen_AccruedOutsourcingClinicalandPreclinicalStudies_d6609ced-0c5b-3e07-2528-0825f62c5818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf9ed09f-3dd1-4a4b-d3fc-3b0db18c1b40" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_cf9ed09f-3dd1-4a4b-d3fc-3b0db18c1b40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_98d31a39-575d-6ddd-42a2-18a0e94f1b32" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_98d31a39-575d-6ddd-42a2-18a0e94f1b32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaap_AccruedRentCurrent_446d94f5-0a43-9d72-8e17-d919d50b63ed" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_AccruedRentCurrent_446d94f5-0a43-9d72-8e17-d919d50b63ed" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccruedLiabilityofWarrantsonTemporaryEquity" xlink:label="loc_mgen_AccruedLiabilityofWarrantsonTemporaryEquity_f5c213dd-67fe-f5a8-7e25-0825f6bd5592" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_mgen_AccruedLiabilityofWarrantsonTemporaryEquity_f5c213dd-67fe-f5a8-7e25-0825f6bd5592" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_00b000cf-7f1d-4891-7244-daf9f6335db0" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccruedLiabilitiesEquipmentandLabMaterials" xlink:label="loc_mgen_AccruedLiabilitiesEquipmentandLabMaterials_c2ee389b-fa6c-789e-ee6d-0825f771da5f" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_mgen_AccruedLiabilitiesEquipmentandLabMaterials_c2ee389b-fa6c-789e-ee6d-0825f771da5f" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccruedLegalFeesCurrent" xlink:label="loc_mgen_AccruedLegalFeesCurrent_b8676830-45de-1cc2-cc1f-0825f61ae32f" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:to="loc_mgen_AccruedLegalFeesCurrent_b8676830-45de-1cc2-cc1f-0825f61ae32f" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/AccruedLiabilitiesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/CapitalStock" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/CapitalStockNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/CapitalStockSummaryOfSeriesPreferredStockDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/CapitalStockTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_2a03e078-acdc-ce26-bc2c-c1c04ab9fd4f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_2a03e078-acdc-ce26-bc2c-c1c04ab9fd4f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_483c5d20-89a2-da39-b56f-2ea722d97042" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_b5a3356e-f555-ddd5-297a-b04afe0bfd5c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6818de09-a032-5221-5ee6-896e1c2d0634" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_e7ae0c4b-54d0-1d15-1541-1fb5329d750c" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_6818de09-a032-5221-5ee6-896e1c2d0634" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_CommonStockValue_c3f7606a-e7e9-61d5-b60b-b4b059f68b26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_AdditionalPaidInCapital_2d1b9d27-8b19-82d9-2843-5b3d292b7fbb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b158f76-5f04-5e4d-ead3-d80e1f9943db" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_065cb284-7fca-cc9b-5752-2feaf74d0011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4b3bbfa7-a312-00ec-9070-7ec1d5e4ff40" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_4b3bbfa7-a312-00ec-9070-7ec1d5e4ff40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_CommitmentsAndContingencies_058e01e4-b9a1-623e-29f5-1b5c79bf095a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_159dcb00-b17e-17db-7098-be4159799459" xlink:to="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccountsPayableCurrent_7a72b51a-735c-1ad4-bd3f-d9bcf2d6a26d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_3fe8f96b-142b-97b1-3b39-b8d22cd10e98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_189ed464-8269-5603-b7eb-5de9e1c3102b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_f5e246cf-e80f-d00b-c8ed-4796aa2df4b4" xlink:to="loc_us-gaap_NotesPayableCurrent_189ed464-8269-5603-b7eb-5de9e1c3102b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_cc2cb572-4a61-daed-767d-ea2b10b9fc01" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_LongTermNotesPayable_cc2cb572-4a61-daed-767d-ea2b10b9fc01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_d8bb821f-d155-9d4e-1738-736b4bf4cb19" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f234998c-5e05-09d0-d53e-5c44423c97c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_07da1db4-2708-4446-4250-1fdd5956185e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd7775cd-f4ab-5607-9b31-1ee98f605818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_8a47066b-3628-88d1-49db-ed09aecc7fc7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2294e6a2-7bab-43ed-d02c-bdf73b8fa561" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_c6057b1d-6685-8249-2051-6c57f3a16a9e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_9b27fab9-d497-627b-4cfb-6b585220b978" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_705c41a7-2dd2-c518-462d-7402828faa45" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease_705c41a7-2dd2-c518-462d-7402828faa45" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_1828fb62-411d-fe29-53fa-005da2b99554" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_1828fb62-411d-fe29-53fa-005da2b99554" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_d04df344-47da-0222-79d0-99b7d739fd60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans" xlink:label="loc_us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_1edc4179-1c32-c62a-7332-ea02ea70805b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_1edc4179-1c32-c62a-7332-ea02ea70805b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_ee229799-b721-537b-63bf-a353b2d0682e" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_ee229799-b721-537b-63bf-a353b2d0682e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dbbd5d91-eb58-fa81-2753-d9ddf4ada4c1" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dbbd5d91-eb58-fa81-2753-d9ddf4ada4c1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_07412ee1-a201-44b2-193f-b4912ff57e88" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_deb49b68-c030-7624-a39d-ea301caa5dbf" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_07412ee1-a201-44b2-193f-b4912ff57e88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease_705c41a7-2dd2-c518-462d-7402828faa45" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fee12b15-6b42-6245-2e2f-ff030b98332c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_207a1788-de98-876d-55d2-2ec6bb7931f8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_207a1788-de98-876d-55d2-2ec6bb7931f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5151f7e0-f557-cbe6-275f-5bec3a3b329f" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_70319186-e7bd-7189-88d2-eba26fb93350" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_5151f7e0-f557-cbe6-275f-5bec3a3b329f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease_705c41a7-2dd2-c518-462d-7402828faa45" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_37b0c31d-5d8b-0577-dfd9-aa56a79334e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_ShareBasedCompensation_e3eecf87-b290-4567-8a59-5b0a8e27c85b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_97b15c8a-d8d9-531b-f51b-82fe98727209" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_AccretionExpense_97b15c8a-d8d9-531b-f51b-82fe98727209" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_dd4bfa5e-1979-c817-e8a9-371104c0d4f7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_c998cbd2-a633-c2ec-1932-e3bfedecbc9f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_91397648-589d-3b53-47c8-16b8909c78f4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_a8b6fe35-4809-bddf-7ef6-3144a6c89165" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_74be5b6b-5c06-c74c-89da-2d9660b81d9b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_a03c3c0d-252e-29bc-7cf3-bf2d2a4db702" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_a03c3c0d-252e-29bc-7cf3-bf2d2a4db702" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments_ba1a5d09-7100-688d-b73d-5749ca609a14" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_444b1ac7-f47a-4ce3-0caa-537f7e4ab8c3" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments_ba1a5d09-7100-688d-b73d-5749ca609a14" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3d9b4bd2-957e-ddb5-7841-6a572de70646" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3d9b4bd2-957e-ddb5-7841-6a572de70646" xlink:to="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_25ae5ce2-b413-b975-9a84-c7503d2496cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_23a4428c-a5e3-3b9c-fc88-04ae5be27ab3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_87411e46-c979-a1ff-e8b3-f4f75d86b855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_ff017a48-8743-bfac-8af0-ca31401cb6de" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_9894e895-7695-402a-9f03-08d60b7373b8" xlink:to="loc_us-gaap_SalesRevenueNet_ff017a48-8743-bfac-8af0-ca31401cb6de" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_2c9f311a-e7a2-ea5a-e3c9-f8d74251bac8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueNet_ff017a48-8743-bfac-8af0-ca31401cb6de" xlink:to="loc_us-gaap_LicenseAndServicesRevenue_2c9f311a-e7a2-ea5a-e3c9-f8d74251bac8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_e1b1191c-a943-4c57-06c8-4d3d7fea920e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueNet_ff017a48-8743-bfac-8af0-ca31401cb6de" xlink:to="loc_us-gaap_RevenueFromGrants_e1b1191c-a943-4c57-06c8-4d3d7fea920e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9b894abb-bf85-2810-9d9d-c92a9b0f56f1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_0bc4681c-786a-7862-7fad-f434ce3c21f5" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_641b1cab-a2b3-2e0e-8389-1455ff3f8581" xlink:to="loc_us-gaap_InterestAndDebtExpense_0bc4681c-786a-7862-7fad-f434ce3c21f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_9879acb3-e4c4-43e5-2854-70ab7b492b37" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_3d9b4bd2-957e-ddb5-7841-6a572de70646" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_9879acb3-e4c4-43e5-2854-70ab7b492b37" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficit" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/DescriptionOfBusinessNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/NetLossPerShare" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/NetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/NotesPayable" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/NotesPayableCompositionOfNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_fdfde29b-9f48-5201-ea3a-506064dcffe7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_885301e5-debb-a378-50ee-e1d9b92a7437" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesPayable_fdfde29b-9f48-5201-ea3a-506064dcffe7" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_885301e5-debb-a378-50ee-e1d9b92a7437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_73766903-3249-fcaf-da70-d4416c5998dd" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesPayable_fdfde29b-9f48-5201-ea3a-506064dcffe7" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_73766903-3249-fcaf-da70-d4416c5998dd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_c214629c-0bf1-1803-4b40-d51f88c8f0b8" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesPayable_fdfde29b-9f48-5201-ea3a-506064dcffe7" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_c214629c-0bf1-1803-4b40-d51f88c8f0b8" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee" xlink:label="loc_mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee_445c4f96-6bd9-49b5-f665-0825f6868725" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesPayable_fdfde29b-9f48-5201-ea3a-506064dcffe7" xlink:to="loc_mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee_445c4f96-6bd9-49b5-f665-0825f6868725" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/NotesPayableCompositionOfNotesPayableDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_BCCB3662657674847117782AAB2B6520_fdfde29b-9f48-5201-ea3a-506064dcffe7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_BCCB3662657674847117782AAB2B6520_189ed464-8269-5603-b7eb-5de9e1c3102b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesPayable_BCCB3662657674847117782AAB2B6520_fdfde29b-9f48-5201-ea3a-506064dcffe7" xlink:to="loc_us-gaap_NotesPayableCurrent_BCCB3662657674847117782AAB2B6520_189ed464-8269-5603-b7eb-5de9e1c3102b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_BCCB3662657674847117782AAB2B6520_cc2cb572-4a61-daed-767d-ea2b10b9fc01" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NotesPayable_BCCB3662657674847117782AAB2B6520_fdfde29b-9f48-5201-ea3a-506064dcffe7" xlink:to="loc_us-gaap_LongTermNotesPayable_BCCB3662657674847117782AAB2B6520_cc2cb572-4a61-daed-767d-ea2b10b9fc01" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/NotesPayableFutureAnnualMinimumPrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_34ef8a0b-29ef-b0c9-c6c0-49388912e457" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_34ef8a0b-29ef-b0c9-c6c0-49388912e457" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fd0898b3-8ac6-af74-6eb0-16df5479b1d8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_fd0898b3-8ac6-af74-6eb0-16df5479b1d8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_afae3a47-9c39-3601-518d-0d7ae5a5a6c2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_7e14882f-7ab9-8302-20ff-24c510ab8806" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_afae3a47-9c39-3601-518d-0d7ae5a5a6c2" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/NotesPayableNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/NotesPayableTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/PropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_fe5a8e8b-5934-3dc5-9dae-7d40983185cf" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_1944a381-5c4e-ce3c-9111-13ccd1c639db" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_5551841b-83e0-4644-fca8-d4027d932c0a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/ReverseMerger" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/ReverseMergerNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/ReverseMergerSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e66eb458-8500-fc68-5c5a-c52959376fd5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5a23735a-10c2-64f7-3d5a-453792d1607d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e66eb458-8500-fc68-5c5a-c52959376fd5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_5a23735a-10c2-64f7-3d5a-453792d1607d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_31b59b3c-3561-f961-13ba-e3cc74150736" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e66eb458-8500-fc68-5c5a-c52959376fd5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_31b59b3c-3561-f961-13ba-e3cc74150736" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_e9cfbc01-ec7a-ebc3-f488-1f351e7b5937" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_e66eb458-8500-fc68-5c5a-c52959376fd5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_e9cfbc01-ec7a-ebc3-f488-1f351e7b5937" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/ReverseMergerTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensationAllocationOfShareBasedCompensationExpenseOnStatementsOfOperationsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensationFairValueAssumptionForStockOptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/StrategicAllianceAndCollaborationWithServier" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/StrategicAllianceAndCollaborationWithServierNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/SubsequentEvents" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/Warrants" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/WarrantsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/WarrantsStockWarrantActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/WarrantsStockWarrantsOutstandingDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.miragentherapeutics.com/role/WarrantsTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>mgen-20170930_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/AccruedLiabilities" xlink:href="mgen-20170930.xsd#AccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/AccruedLiabilitiesComponentsOfAccruedLiabilitiesDetails" xlink:href="mgen-20170930.xsd#AccruedLiabilitiesComponentsOfAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/AccruedLiabilitiesTables" xlink:href="mgen-20170930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CapitalStock" xlink:href="mgen-20170930.xsd#CapitalStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CapitalStockNarrativeDetails" xlink:href="mgen-20170930.xsd#CapitalStockNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CapitalStockSummaryOfSeriesPreferredStockDetails" xlink:href="mgen-20170930.xsd#CapitalStockSummaryOfSeriesPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CapitalStockTables" xlink:href="mgen-20170930.xsd#CapitalStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CommitmentsAndContingencies" xlink:href="mgen-20170930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" xlink:href="mgen-20170930.xsd#CommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="mgen-20170930.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:href="mgen-20170930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:href="mgen-20170930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="mgen-20170930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="mgen-20170930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="mgen-20170930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficit" xlink:href="mgen-20170930.xsd#CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/DescriptionOfBusiness" xlink:href="mgen-20170930.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/DescriptionOfBusinessNarrativeDetails" xlink:href="mgen-20170930.xsd#DescriptionOfBusinessNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/DocumentAndEntityInformation" xlink:href="mgen-20170930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NetLossPerShare" xlink:href="mgen-20170930.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetails" xlink:href="mgen-20170930.xsd#NetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NetLossPerShareTables" xlink:href="mgen-20170930.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NotesPayable" xlink:href="mgen-20170930.xsd#NotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NotesPayableCompositionOfNotesPayableDetails" xlink:href="mgen-20170930.xsd#NotesPayableCompositionOfNotesPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NotesPayableFutureAnnualMinimumPrincipalPaymentsDetails" xlink:href="mgen-20170930.xsd#NotesPayableFutureAnnualMinimumPrincipalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NotesPayableNarrativeDetails" xlink:href="mgen-20170930.xsd#NotesPayableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NotesPayableTables" xlink:href="mgen-20170930.xsd#NotesPayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/PropertyAndEquipment" xlink:href="mgen-20170930.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/PropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" xlink:href="mgen-20170930.xsd#PropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="mgen-20170930.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/PropertyAndEquipmentTables" xlink:href="mgen-20170930.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ReverseMerger" xlink:href="mgen-20170930.xsd#ReverseMerger" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ReverseMergerNarrativeDetails" xlink:href="mgen-20170930.xsd#ReverseMergerNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ReverseMergerSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="mgen-20170930.xsd#ReverseMergerSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ReverseMergerTables" xlink:href="mgen-20170930.xsd#ReverseMergerTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensation" xlink:href="mgen-20170930.xsd#ShareBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationAllocationOfShareBasedCompensationExpenseOnStatementsOfOperationsDetails" xlink:href="mgen-20170930.xsd#ShareBasedCompensationAllocationOfShareBasedCompensationExpenseOnStatementsOfOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationFairValueAssumptionForStockOptionsDetails" xlink:href="mgen-20170930.xsd#ShareBasedCompensationFairValueAssumptionForStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:href="mgen-20170930.xsd#ShareBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:href="mgen-20170930.xsd#ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationTables" xlink:href="mgen-20170930.xsd#ShareBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/StrategicAllianceAndCollaborationWithServier" xlink:href="mgen-20170930.xsd#StrategicAllianceAndCollaborationWithServier" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/StrategicAllianceAndCollaborationWithServierNarrativeDetails" xlink:href="mgen-20170930.xsd#StrategicAllianceAndCollaborationWithServierNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SubsequentEvents" xlink:href="mgen-20170930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SubsequentEventsNarrativeDetails" xlink:href="mgen-20170930.xsd#SubsequentEventsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPoliciesFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/Warrants" xlink:href="mgen-20170930.xsd#Warrants" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/WarrantsNarrativeDetails" xlink:href="mgen-20170930.xsd#WarrantsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/WarrantsStockWarrantActivityDetails" xlink:href="mgen-20170930.xsd#WarrantsStockWarrantActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/WarrantsStockWarrantsOutstandingDetails" xlink:href="mgen-20170930.xsd#WarrantsStockWarrantsOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/WarrantsTables" xlink:href="mgen-20170930.xsd#WarrantsTables" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/AccruedLiabilities" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/AccruedLiabilitiesComponentsOfAccruedLiabilitiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/AccruedLiabilitiesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/CapitalStock" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/CapitalStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A7175653CDF2C6B0DBEC782AAB093B72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A7175653CDF2C6B0DBEC782AAB093B72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_B8D2E75697EAD725A9DD782AAB09AEFD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A7175653CDF2C6B0DBEC782AAB093B72" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_B8D2E75697EAD725A9DD782AAB09AEFD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_B8D2E75697EAD725A9DD782AAB09AEFD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A7175653CDF2C6B0DBEC782AAB093B72" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_B8D2E75697EAD725A9DD782AAB09AEFD" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalSharesIssuedToMiragenCommonShareholdersMember" xlink:label="loc_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_986F12A1A3329E068243782AAB09BC54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_B8D2E75697EAD725A9DD782AAB09AEFD" xlink:to="loc_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_986F12A1A3329E068243782AAB09BC54" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PreMergerSharesMember" xlink:label="loc_mgen_PreMergerSharesMember_B9C163BF7DA44099385A782AAB0992EA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_B8D2E75697EAD725A9DD782AAB09AEFD" xlink:to="loc_mgen_PreMergerSharesMember_B9C163BF7DA44099385A782AAB0992EA" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PostMergerSharesMember" xlink:label="loc_mgen_PostMergerSharesMember_5103D6AB6E826368FC94782AAB09B9BF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_B8D2E75697EAD725A9DD782AAB09AEFD" xlink:to="loc_mgen_PostMergerSharesMember_5103D6AB6E826368FC94782AAB09B9BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1799F016A419AA2A44E3782AAB0A83E1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1799F016A419AA2A44E3782AAB0A83E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E62D7ACA5745543C55F782AAB0A1601_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1799F016A419AA2A44E3782AAB0A83E1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E62D7ACA5745543C55F782AAB0A1601_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E62D7ACA5745543C55F782AAB0A1601" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1799F016A419AA2A44E3782AAB0A83E1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E62D7ACA5745543C55F782AAB0A1601" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalMember" xlink:label="loc_mgen_SignalMember_3FB7157AE6C7A89E6772782AAB0A17B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E62D7ACA5745543C55F782AAB0A1601" xlink:to="loc_mgen_SignalMember_3FB7157AE6C7A89E6772782AAB0A17B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_46EEC2FFE3307AE9159E782AAB0AB14C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:to="loc_us-gaap_StatementClassOfStockAxis_46EEC2FFE3307AE9159E782AAB0AB14C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_315E2B35931392780601782AAB0A41E6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_46EEC2FFE3307AE9159E782AAB0AB14C" xlink:to="loc_us-gaap_ClassOfStockDomain_315E2B35931392780601782AAB0A41E6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_315E2B35931392780601782AAB0A41E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_46EEC2FFE3307AE9159E782AAB0AB14C" xlink:to="loc_us-gaap_ClassOfStockDomain_315E2B35931392780601782AAB0A41E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_67AEA918A823C7D50506782AAB0AD634" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_315E2B35931392780601782AAB0A41E6" xlink:to="loc_us-gaap_PreferredStockMember_67AEA918A823C7D50506782AAB0AD634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7EA75E3182AD9064D6DF782AAB0ACAF8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:to="loc_us-gaap_RangeAxis_7EA75E3182AD9064D6DF782AAB0ACAF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9E4398F8C386C063F73B782AAB0A09F9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_7EA75E3182AD9064D6DF782AAB0ACAF8" xlink:to="loc_us-gaap_RangeMember_9E4398F8C386C063F73B782AAB0A09F9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9E4398F8C386C063F73B782AAB0A09F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_7EA75E3182AD9064D6DF782AAB0ACAF8" xlink:to="loc_us-gaap_RangeMember_9E4398F8C386C063F73B782AAB0A09F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_261D33A16D68A87F2AAC782AAB0AAA70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_9E4398F8C386C063F73B782AAB0A09F9" xlink:to="loc_us-gaap_MaximumMember_261D33A16D68A87F2AAC782AAB0AAA70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_DE3798E97702D65C3C0F782AAB0ABFEC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_DE3798E97702D65C3C0F782AAB0ABFEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A43B9A679196D686698F782AAB0B407B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_DE3798E97702D65C3C0F782AAB0ABFEC" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A43B9A679196D686698F782AAB0B407B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A43B9A679196D686698F782AAB0B407B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_DE3798E97702D65C3C0F782AAB0ABFEC" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A43B9A679196D686698F782AAB0B407B" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AtthemarketOfferingMember" xlink:label="loc_mgen_AtthemarketOfferingMember_69D1324D387FA1C9CFA3782AAB0BC528" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A43B9A679196D686698F782AAB0B407B" xlink:to="loc_mgen_AtthemarketOfferingMember_69D1324D387FA1C9CFA3782AAB0BC528" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CapitalStockSharesAuthorized" xlink:label="loc_mgen_CapitalStockSharesAuthorized_6D8CC6ACD5BBC15A069C782AAB0B84C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_mgen_CapitalStockSharesAuthorized_6D8CC6ACD5BBC15A069C782AAB0B84C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_03718E2350F6C4BF6202782AAB0B5955" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_03718E2350F6C4BF6202782AAB0B5955" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_25A8D78CB9A867EE22EE782AAB0B0077" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_25A8D78CB9A867EE22EE782AAB0B0077" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_AE6EDB05A3E895C84798782AAB0B3602" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_AE6EDB05A3E895C84798782AAB0B3602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_C82364B4435659154612782AAB0BAC77" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_C82364B4435659154612782AAB0BAC77" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ConversionOfStockSharesIssuedConversionRate" xlink:label="loc_mgen_ConversionOfStockSharesIssuedConversionRate_0E9D57886BA602F95631782AAB0BA38B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_mgen_ConversionOfStockSharesIssuedConversionRate_0E9D57886BA602F95631782AAB0BA38B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_85E8B55D3AAEA45D168B782AAB0B67F1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_85E8B55D3AAEA45D168B782AAB0B67F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_FCECF4D163A3013CA5DE782AAB0BF097" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_FCECF4D163A3013CA5DE782AAB0BF097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9EB60C2D21901D82311D782AAB0B3174" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9EB60C2D21901D82311D782AAB0B3174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6326F29CD91CC4D88F09782AAB0BC8E9" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6326F29CD91CC4D88F09782AAB0BC8E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F6F632A1850DB6BFC394782AAB0B4BEB" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F6F632A1850DB6BFC394782AAB0B4BEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_DB10D8F965A1A13391907846E2A5629A" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_DB10D8F965A1A13391907846E2A5629A" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds" xlink:label="loc_mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds_E5A2F5AFB35EBE8E069B782AAB0BC589" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds_E5A2F5AFB35EBE8E069B782AAB0BC589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_AE22ED07D6A241BEA21D7844FE78F61C" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_DeferredOfferingCosts_AE22ED07D6A241BEA21D7844FE78F61C" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccumulatedAmortizationDeferredCosts" xlink:label="loc_mgen_AccumulatedAmortizationDeferredCosts_86EEA57CA3B5CB555C6B784AFAE510DE" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_mgen_AccumulatedAmortizationDeferredCosts_86EEA57CA3B5CB555C6B784AFAE510DE" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/CapitalStockSummaryOfSeriesPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_DB6A241DC5636F6C199308261E63F0CD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_27950044CC761635396D08261E62EF08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TemporaryEquityLineItems_DB6A241DC5636F6C199308261E63F0CD" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_27950044CC761635396D08261E62EF08" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9DE3794EF1ECA89D0EAE08261E624D12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_27950044CC761635396D08261E62EF08" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9DE3794EF1ECA89D0EAE08261E624D12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1D3851654A0F4A336C3608261E629D45_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9DE3794EF1ECA89D0EAE08261E624D12" xlink:to="loc_us-gaap_ClassOfStockDomain_1D3851654A0F4A336C3608261E629D45_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1D3851654A0F4A336C3608261E629D45" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9DE3794EF1ECA89D0EAE08261E624D12" xlink:to="loc_us-gaap_ClassOfStockDomain_1D3851654A0F4A336C3608261E629D45" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_AD093B368E1CB1AFAAB108261E63CC02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1D3851654A0F4A336C3608261E629D45" xlink:to="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_AD093B368E1CB1AFAAB108261E63CC02" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesBRedeemableConvertiblePreferredStockMember_3586D5CB416EF5E48D4608261E636E46" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1D3851654A0F4A336C3608261E629D45" xlink:to="loc_mgen_SeriesBRedeemableConvertiblePreferredStockMember_3586D5CB416EF5E48D4608261E636E46" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesCRedeemableConvertiblePreferredStockMember_95EF6F01EBD956963FE708261E637A03" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1D3851654A0F4A336C3608261E629D45" xlink:to="loc_mgen_SeriesCRedeemableConvertiblePreferredStockMember_95EF6F01EBD956963FE708261E637A03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_9150605B1C2930ED40A108261E6311F5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1D3851654A0F4A336C3608261E629D45" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_9150605B1C2930ED40A108261E6311F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TemporaryEquityLineItems_DB6A241DC5636F6C199308261E63F0CD" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_C24A0ADE5493742E0C9C08261E6337F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_C24A0ADE5493742E0C9C08261E6337F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9649107BA563C7D250C608261E63B826" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9649107BA563C7D250C608261E63B826" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_04C5FC82CE3111A1356608261E63119F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_04C5FC82CE3111A1356608261E63119F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7075DFEF2071207138AE08261E63C969" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7075DFEF2071207138AE08261E63C969" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_432C84F2E252BFC4254B08261E633A22" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_432C84F2E252BFC4254B08261E633A22" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/CapitalStockTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/CommitmentsAndContingencies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommitmentsandContingenciesLineItems" xlink:label="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:type="locator" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommitmentsandContingenciesTable" xlink:label="loc_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_4A9CF3C05D85232B746A782AAB1CDABA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:to="loc_us-gaap_CounterpartyNameAxis_4A9CF3C05D85232B746A782AAB1CDABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CounterpartyNameAxis_4A9CF3C05D85232B746A782AAB1CDABA" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CounterpartyNameAxis_4A9CF3C05D85232B746A782AAB1CDABA" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_UniversityofTexasMember" xlink:label="loc_mgen_UniversityofTexasMember_5B31FDF0FDE5C451B9BE782AAB1CB43A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3" xlink:to="loc_mgen_UniversityofTexasMember_5B31FDF0FDE5C451B9BE782AAB1CB43A" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_RocheInnovationCenterCopenhagenASMember" xlink:label="loc_mgen_RocheInnovationCenterCopenhagenASMember_B973187D9F1DE50745D8782AAB1C1EED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3" xlink:to="loc_mgen_RocheInnovationCenterCopenhagenASMember_B973187D9F1DE50745D8782AAB1C1EED" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_T2cureGmbHMember" xlink:label="loc_mgen_T2cureGmbHMember_D215C4E273AC4182CC65782AAB1C31ED" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3" xlink:to="loc_mgen_T2cureGmbHMember_D215C4E273AC4182CC65782AAB1C31ED" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_TheBrighamandWomensHospitalMember" xlink:label="loc_mgen_TheBrighamandWomensHospitalMember_E22A44774039695FB394782AAB1C9220" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3" xlink:to="loc_mgen_TheBrighamandWomensHospitalMember_E22A44774039695FB394782AAB1C9220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_D7779E40A1F6624103C5782AAB1DF009" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:to="loc_us-gaap_StatementGeographicalAxis_D7779E40A1F6624103C5782AAB1DF009" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_D7779E40A1F6624103C5782AAB1DF009" xlink:to="loc_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_D7779E40A1F6624103C5782AAB1DF009" xlink:to="loc_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_78BC908CD47ADCD175B5782AAB1DE6D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD" xlink:to="loc_country_US_78BC908CD47ADCD175B5782AAB1DE6D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_E9A6FCA94382DB2286D7782AAB1D208D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD" xlink:to="loc_us-gaap_NonUsMember_E9A6FCA94382DB2286D7782AAB1D208D" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_EuropeanUnionorJapanMember" xlink:label="loc_mgen_EuropeanUnionorJapanMember_B39E759A19FCE2F02697782AAB1D2A0D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD" xlink:to="loc_mgen_EuropeanUnionorJapanMember_B39E759A19FCE2F02697782AAB1D2A0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_350190A7FD9F4B1AC5F7782AAB1D8529" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_350190A7FD9F4B1AC5F7782AAB1D8529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_51E53DBA5E569FB65703782AAB1DB0E9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_350190A7FD9F4B1AC5F7782AAB1D8529" xlink:to="loc_us-gaap_ClassOfStockDomain_51E53DBA5E569FB65703782AAB1DB0E9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_51E53DBA5E569FB65703782AAB1DB0E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_350190A7FD9F4B1AC5F7782AAB1D8529" xlink:to="loc_us-gaap_ClassOfStockDomain_51E53DBA5E569FB65703782AAB1DB0E9" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_C9D8A8ECB96B8F8DC553782AAB1D58F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_51E53DBA5E569FB65703782AAB1DB0E9" xlink:to="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_C9D8A8ECB96B8F8DC553782AAB1D58F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_471E90F8FB701C4BA77C782AAB1DD187" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:to="loc_us-gaap_MajorCustomersAxis_471E90F8FB701C4BA77C782AAB1DD187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_2BE634C37EFA81D2E194782AAB1DD2EA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_MajorCustomersAxis_471E90F8FB701C4BA77C782AAB1DD187" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_2BE634C37EFA81D2E194782AAB1DD2EA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_2BE634C37EFA81D2E194782AAB1DD2EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_MajorCustomersAxis_471E90F8FB701C4BA77C782AAB1DD187" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_2BE634C37EFA81D2E194782AAB1DD2EA" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_YaleUniversityMember" xlink:label="loc_mgen_YaleUniversityMember_78BE76A8E3CA3C1FA442782AAB1EC380" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_2BE634C37EFA81D2E194782AAB1DD2EA" xlink:to="loc_mgen_YaleUniversityMember_78BE76A8E3CA3C1FA442782AAB1EC380" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborativeArrangementNumberofArrangements" xlink:label="loc_mgen_CollaborativeArrangementNumberofArrangements_9C2DFF2939A98E1D445D782AAB1E5B18" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_CollaborativeArrangementNumberofArrangements_9C2DFF2939A98E1D445D782AAB1E5B18" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostsUpfrontLicensingFeePerLicense" xlink:label="loc_mgen_LicenseCostsUpfrontLicensingFeePerLicense_856378C7C1F8E9D4399E782AAB1E88AF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_LicenseCostsUpfrontLicensingFeePerLicense_856378C7C1F8E9D4399E782AAB1E88AF" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostAnnualMaintenanceFeePerLicense" xlink:label="loc_mgen_LicenseCostAnnualMaintenanceFeePerLicense_5758EC4F68B94C76E744782AAB1E20C9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_LicenseCostAnnualMaintenanceFeePerLicense_5758EC4F68B94C76E744782AAB1E20C9" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials" xlink:label="loc_mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials_5894DD97A3FDC9CEFE76782AAB1E3B2C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials_5894DD97A3FDC9CEFE76782AAB1E3B2C" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval" xlink:label="loc_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval_CBFA3FA31E8E83E4867A782AAB1E443A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval_CBFA3FA31E8E83E4867A782AAB1E443A" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PaymentsForLicensingAgreement" xlink:label="loc_mgen_PaymentsForLicensingAgreement_F4B3B89C1BC6534F1837782AAB1EB250" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_PaymentsForLicensingAgreement_F4B3B89C1BC6534F1837782AAB1EB250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_AA95FCA4F60FC16BA5C4782AAB1EDF92" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_AA95FCA4F60FC16BA5C4782AAB1EDF92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_567BCB458327E7DF1822782AAB1EC46C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_567BCB458327E7DF1822782AAB1EC46C" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct" xlink:label="loc_mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct_158FB5CE023619B8F2A7782AAB1EEF8C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct_158FB5CE023619B8F2A7782AAB1EEF8C" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PaymentstoAcquireRawMaterials" xlink:label="loc_mgen_PaymentstoAcquireRawMaterials_56F099E83A31FB0C4C1F782AAB1E4E74" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_PaymentstoAcquireRawMaterials_56F099E83A31FB0C4C1F782AAB1E4E74" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborationArrangementPotentialCashProceedsforServices" xlink:label="loc_mgen_CollaborationArrangementPotentialCashProceedsforServices_BDA85C37702BAA94116D782AAB1EE819" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_CollaborationArrangementPotentialCashProceedsforServices_BDA85C37702BAA94116D782AAB1EE819" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborationArrangementTermOfAgreement" xlink:label="loc_mgen_CollaborationArrangementTermOfAgreement_E420E1C10D1420AEE733782AAB1E7A59" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_CollaborationArrangementTermOfAgreement_E420E1C10D1420AEE733782AAB1E7A59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators_9C3A9C354205550DC450783792676893" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_us-gaap_ProceedsFromCollaborators_9C3A9C354205550DC450783792676893" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborationArrangementTermofAgreementTerminationPeriod" xlink:label="loc_mgen_CollaborationArrangementTermofAgreementTerminationPeriod_13CA0C044DC2046399D1782AAB1E4FF7" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_CollaborationArrangementTermofAgreementTerminationPeriod_13CA0C044DC2046399D1782AAB1E4FF7" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostsPotentialMilestonePayment" xlink:label="loc_mgen_LicenseCostsPotentialMilestonePayment_2A2238781568D6814FB7782AAB1F76C6" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_LicenseCostsPotentialMilestonePayment_2A2238781568D6814FB7782AAB1F76C6" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostsOnetimeSalesMilestonePayment" xlink:label="loc_mgen_LicenseCostsOnetimeSalesMilestonePayment_0C331E8C69DA9F139882782AAB1F12A6" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_LicenseCostsOnetimeSalesMilestonePayment_0C331E8C69DA9F139882782AAB1F12A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_D739F566548218AC0B13782AAB1FAF89" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_us-gaap_LeaseAndRentalExpense_D739F566548218AC0B13782AAB1FAF89" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_OperatingLeasesOperatingExpense" xlink:label="loc_mgen_OperatingLeasesOperatingExpense_BFD86333EE18F3A3A967782AAB1F4540" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_OperatingLeasesOperatingExpense_BFD86333EE18F3A3A967782AAB1F4540" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_C9335314DA5935321E6931BE40FB8C43" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_F05A18483D6C8B7B6A9F31BE40FB5EA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_C9335314DA5935321E6931BE40FB8C43" xlink:to="loc_us-gaap_StatementTable_F05A18483D6C8B7B6A9F31BE40FB5EA7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5919C87105412417852431BE40FB8D12" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_F05A18483D6C8B7B6A9F31BE40FB5EA7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5919C87105412417852431BE40FB8D12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5656B954B40D833F6D6A31BE40FB1F90_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5919C87105412417852431BE40FB8D12" xlink:to="loc_us-gaap_ClassOfStockDomain_5656B954B40D833F6D6A31BE40FB1F90_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5656B954B40D833F6D6A31BE40FB1F90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5919C87105412417852431BE40FB8D12" xlink:to="loc_us-gaap_ClassOfStockDomain_5656B954B40D833F6D6A31BE40FB1F90" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_748C70EA6B2A82BF638131BE40FB5EB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5656B954B40D833F6D6A31BE40FB1F90" xlink:to="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_748C70EA6B2A82BF638131BE40FB5EB9" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesBRedeemableConvertiblePreferredStockMember_AB47B914A254EA5C382631BE40FB80F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5656B954B40D833F6D6A31BE40FB1F90" xlink:to="loc_mgen_SeriesBRedeemableConvertiblePreferredStockMember_AB47B914A254EA5C382631BE40FB80F5" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesCRedeemableConvertiblePreferredStockMember_FC30F7FE1D4C8878374331BE40FB407B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_5656B954B40D833F6D6A31BE40FB1F90" xlink:to="loc_mgen_SeriesCRedeemableConvertiblePreferredStockMember_FC30F7FE1D4C8878374331BE40FB407B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C9335314DA5935321E6931BE40FB8C43" xlink:to="loc_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660" xlink:to="loc_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AF12147191301768536931BE40FC1116" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AF12147191301768536931BE40FC1116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_645F2DF2BC9D0E7F8C6F31BE41012F73" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_645F2DF2BC9D0E7F8C6F31BE41012F73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9DF97D3E6A6FD1AD262031BE41010438" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9DF97D3E6A6FD1AD262031BE41010438" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_CC693DB9B96101D2877D31BE41015896" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D" xlink:to="loc_us-gaap_AssetsCurrent_CC693DB9B96101D2877D31BE41015896" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3F487162084B1643950031BE4101FC6E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3F487162084B1643950031BE4101FC6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_972C5C6BC525C4F6EFA831BE4101C6F8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_972C5C6BC525C4F6EFA831BE4101C6F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_4DD383360FB2E670909231BE41011DFB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660" xlink:to="loc_us-gaap_Assets_4DD383360FB2E670909231BE41011DFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_C9335314DA5935321E6931BE40FB8C43" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_62FA4087969983C3ACA731BE4102D47A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4" xlink:to="loc_us-gaap_AccountsPayableCurrent_62FA4087969983C3ACA731BE4102D47A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_02E8F999B202466D63A631BE41027FEB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_02E8F999B202466D63A631BE41027FEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_49FCA3F541E2785CB6C931BE410274E2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4" xlink:to="loc_us-gaap_NotesPayableCurrent_49FCA3F541E2785CB6C931BE410274E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_227A98C6DED21D80E5AF31BE4102FC74" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4" xlink:to="loc_us-gaap_LiabilitiesCurrent_227A98C6DED21D80E5AF31BE4102FC74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_08EEA248AD969F5182AE31BE4102F028" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:to="loc_us-gaap_LongTermNotesPayable_08EEA248AD969F5182AE31BE4102F028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_590B79B3D3E1BA2F19EA31BE4102FB54" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_590B79B3D3E1BA2F19EA31BE4102FB54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_E0618BF6C2CA2E4EF9A631BE4102A471" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:to="loc_us-gaap_Liabilities_E0618BF6C2CA2E4EF9A631BE4102A471" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ECF0AA4C34EAEA04EF6B31BE4102E7BD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ECF0AA4C34EAEA04EF6B31BE4102E7BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52B93C674D8D2AF7111931BE4102833C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52B93C674D8D2AF7111931BE4102833C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:to="loc_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_511F98B8333BB4387B1F31BE4103F23C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369" xlink:to="loc_us-gaap_CommonStockValue_511F98B8333BB4387B1F31BE4103F23C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ED1D532D68C0032ABF3B31BE410322B9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ED1D532D68C0032ABF3B31BE410322B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6264B81B646C00084C1D31BE4103C675" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6264B81B646C00084C1D31BE4103C675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_132590E6DD03762F9B0531BE410364E0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369" xlink:to="loc_us-gaap_StockholdersEquity_132590E6DD03762F9B0531BE410364E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_983644BCC6E44F2AF94231BE4103742F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_983644BCC6E44F2AF94231BE4103742F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_71BF768C556BB4CBC93008261E0E1ADE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_StatementTable_71BF768C556BB4CBC93008261E0E1ADE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3EDEF89AE37AA31B9DC408261E0E81D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_71BF768C556BB4CBC93008261E0E1ADE" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3EDEF89AE37AA31B9DC408261E0E81D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3EDEF89AE37AA31B9DC408261E0E81D3" xlink:to="loc_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3EDEF89AE37AA31B9DC408261E0E81D3" xlink:to="loc_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_2F0E553E1E9064C0117208261E0E080D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2" xlink:to="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_2F0E553E1E9064C0117208261E0E080D" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesBRedeemableConvertiblePreferredStockMember_1B6BF9B7471CC6601F5B08261E0EF272" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2" xlink:to="loc_mgen_SeriesBRedeemableConvertiblePreferredStockMember_1B6BF9B7471CC6601F5B08261E0EF272" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesCRedeemableConvertiblePreferredStockMember_8D90393DC6D25912A4C308261E0E0DA9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2" xlink:to="loc_mgen_SeriesCRedeemableConvertiblePreferredStockMember_8D90393DC6D25912A4C308261E0E0DA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_2E6B70F60F4BD477950E08261E0E7E0C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_2E6B70F60F4BD477950E08261E0E7E0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_3B4C12979C08E393F8E208261E0F35FE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_3B4C12979C08E393F8E208261E0F35FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_096EB2DBA0D98528FB4708261E0F8902" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_096EB2DBA0D98528FB4708261E0F8902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_4FD7BF122C4177B6C20F08261E0F12C8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_4FD7BF122C4177B6C20F08261E0F12C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_228CC87D173AD7EC217308261E0FCDEE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_228CC87D173AD7EC217308261E0FCDEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_DDA8FE5F0171E6C9375208261E0F869A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_DDA8FE5F0171E6C9375208261E0F869A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_D641BD2D3A24A738717408261E0FF9DD" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_D641BD2D3A24A738717408261E0FF9DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_EFD2772CB0DF5D412D1308261E0F1B68" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_CommonStockSharesIssued_EFD2772CB0DF5D412D1308261E0F1B68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_B37326A32E9AC612726B08261E0F1BDF" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_B37326A32E9AC612726B08261E0F1BDF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_BF8DB4F3C5B23D9E0FB3929794015B7D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:to="loc_us-gaap_StatementTable_BF8DB4F3C5B23D9E0FB3929794015B7D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_37C41E4083E84F01C8A492979401C4D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_BF8DB4F3C5B23D9E0FB3929794015B7D" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_37C41E4083E84F01C8A492979401C4D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FC20E1660FDD54E57DA92979401DA3D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_37C41E4083E84F01C8A492979401C4D9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FC20E1660FDD54E57DA92979401DA3D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FC20E1660FDD54E57DA92979401DA3D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_37C41E4083E84F01C8A492979401C4D9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FC20E1660FDD54E57DA92979401DA3D" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PrivateFinancingMember" xlink:label="loc_mgen_PrivateFinancingMember_DAEC3AAEECAA01606C1092979401F84D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FC20E1660FDD54E57DA92979401DA3D" xlink:to="loc_mgen_PrivateFinancingMember_DAEC3AAEECAA01606C1092979401F84D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_5307AAFF9A60D5F87A3E92979401B815" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FC20E1660FDD54E57DA92979401DA3D" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_5307AAFF9A60D5F87A3E92979401B815" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AtthemarketOfferingMember" xlink:label="loc_mgen_AtthemarketOfferingMember_E153F1B6F4F79F080031929794018687" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FC20E1660FDD54E57DA92979401DA3D" xlink:to="loc_mgen_AtthemarketOfferingMember_E153F1B6F4F79F080031929794018687" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ShelfRegistrationMember" xlink:label="loc_mgen_ShelfRegistrationMember_F1C72245B4EE1CCDAF0492979401435B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FC20E1660FDD54E57DA92979401DA3D" xlink:to="loc_mgen_ShelfRegistrationMember_F1C72245B4EE1CCDAF0492979401435B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A2CD2DCD79E168E293A992979402691F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A2CD2DCD79E168E293A992979402691F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_796D8997EBE26FFC5CBC929794022686" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A2CD2DCD79E168E293A992979402691F" xlink:to="loc_us-gaap_NetIncomeLoss_796D8997EBE26FFC5CBC929794022686" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A2CD2DCD79E168E293A992979402691F" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_D62DE7260FB24C458754929794024FB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_D62DE7260FB24C458754929794024FB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2C6591BF3837197F207C92979402E59A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:to="loc_us-gaap_ShareBasedCompensation_2C6591BF3837197F207C92979402E59A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_B0FB7C3C88C691FFE70292979402E7FC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:to="loc_us-gaap_AccretionExpense_B0FB7C3C88C691FFE70292979402E7FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_891B3588C28B86FD6300929794026C15" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_891B3588C28B86FD6300929794026C15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments_0FAF373B1A1CED4FB23092979402E034" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments_0FAF373B1A1CED4FB23092979402E034" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_E395D4FCB649CF1C79BE929794039664" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_E395D4FCB649CF1C79BE929794039664" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6113B87C4A63E4D2B36892979403CB5A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6113B87C4A63E4D2B36892979403CB5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_C9FF869EA19CCF87557D92979403B322" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_C9FF869EA19CCF87557D92979403B322" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_DC2EDE7AAA8DFB8E400992979403128C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_DC2EDE7AAA8DFB8E400992979403128C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4BB4D56898339E61BF94929794033DE4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4BB4D56898339E61BF94929794033DE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_B2BB9B3B9FD77ADE4C7192979403749D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A2CD2DCD79E168E293A992979402691F" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_B2BB9B3B9FD77ADE4C7192979403749D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_79099AB2FBB0E0185E0A92979403E473" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_79099AB2FBB0E0185E0A92979403E473" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24470B44DFE2477B040D929794044C54" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24470B44DFE2477B040D929794044C54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_7EA0002901D369C6ED5A929794042F0C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_7EA0002901D369C6ED5A929794042F0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28350EC5224B942152E092979404C0EA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28350EC5224B942152E092979404C0EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A78915B84B5A9AF02C42929794047CB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A78915B84B5A9AF02C42929794047CB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1C948AF34577595F86A992979404E2C6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1C948AF34577595F86A992979404E2C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_E3EDDF2476E6EAAEFEC3929794042B7B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_E3EDDF2476E6EAAEFEC3929794042B7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_0055D4F9F76EF1D4E7259297940471DF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_0055D4F9F76EF1D4E7259297940471DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_03B3C12331448D70CB94929794043821" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_03B3C12331448D70CB94929794043821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans" xlink:label="loc_us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_86566AB3F07DF7150DEB92979405EEEC" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:to="loc_us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_86566AB3F07DF7150DEB92979405EEEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8A96E1EE909C2491E75D929794050CE5" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8A96E1EE909C2491E75D929794050CE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_270E7C6D496625DF3DDB92979405AD1A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_270E7C6D496625DF3DDB92979405AD1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_03E0DE6A045367FD17439297940519E8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_03E0DE6A045367FD17439297940519E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6C22287267E8235EA4A392979405E113" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6C22287267E8235EA4A392979405E113" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_C6AB7E330A4A2E0268E992979405F582" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6C22287267E8235EA4A392979405E113" xlink:to="loc_us-gaap_InterestPaid_C6AB7E330A4A2E0268E992979405F582" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_29A9B09B36412D9BEC23929794065DAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_29A9B09B36412D9BEC23929794065DAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_19320671EF708D54E99892979406F0BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_19320671EF708D54E99892979406F0BC" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction" xlink:label="loc_mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction_DD6107115298674C9C079297940641C8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:to="loc_mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction_DD6107115298674C9C079297940641C8" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ConversionofWarrantstoPermanentEquity" xlink:label="loc_mgen_ConversionofWarrantstoPermanentEquity_0C49844B3774D3D4F08792979406C469" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:to="loc_mgen_ConversionofWarrantstoPermanentEquity_0C49844B3774D3D4F08792979406C469" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccretionofOfferingCosts" xlink:label="loc_mgen_AccretionofOfferingCosts_4F613A32333789038FE5929794069AA8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:to="loc_mgen_AccretionofOfferingCosts_4F613A32333789038FE5929794069AA8" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction" xlink:label="loc_mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_FCADC36226CB651436E292979406B8C5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:to="loc_mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_FCADC36226CB651436E292979406B8C5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6BF9989AADC3E81097955586B8C72105" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_AAA66455F5F2F2096C0A5586B8C65A6B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_6BF9989AADC3E81097955586B8C72105" xlink:to="loc_us-gaap_StatementTable_AAA66455F5F2F2096C0A5586B8C65A6B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6274DF418B107A23271A5586B8C69328" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_AAA66455F5F2F2096C0A5586B8C65A6B" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6274DF418B107A23271A5586B8C69328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_405297F1C46F7B26E0825586B8C60497_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6274DF418B107A23271A5586B8C69328" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_405297F1C46F7B26E0825586B8C60497_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_405297F1C46F7B26E0825586B8C60497" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6274DF418B107A23271A5586B8C69328" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_405297F1C46F7B26E0825586B8C60497" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PrivateFinancingMember" xlink:label="loc_mgen_PrivateFinancingMember_942D12F188C60FD0E3CE5586B8C6DD33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_405297F1C46F7B26E0825586B8C60497" xlink:to="loc_mgen_PrivateFinancingMember_942D12F188C60FD0E3CE5586B8C6DD33" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AtthemarketOfferingMember" xlink:label="loc_mgen_AtthemarketOfferingMember_FD01208CC27671E3063D5586B8C63F87" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_405297F1C46F7B26E0825586B8C60497" xlink:to="loc_mgen_AtthemarketOfferingMember_FD01208CC27671E3063D5586B8C63F87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9A244D1B90571CBC98375586B8C643CB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_AAA66455F5F2F2096C0A5586B8C65A6B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9A244D1B90571CBC98375586B8C643CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_84CFE783D25FAA720B595586B8C6B419_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9A244D1B90571CBC98375586B8C643CB" xlink:to="loc_us-gaap_ClassOfStockDomain_84CFE783D25FAA720B595586B8C6B419_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_84CFE783D25FAA720B595586B8C6B419" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9A244D1B90571CBC98375586B8C643CB" xlink:to="loc_us-gaap_ClassOfStockDomain_84CFE783D25FAA720B595586B8C6B419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_D4E0AF5F93E8E561C3DC5586B8C63286" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_84CFE783D25FAA720B595586B8C6B419" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_D4E0AF5F93E8E561C3DC5586B8C63286" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D66B0A16463480F4707F5586B8C76198" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_AAA66455F5F2F2096C0A5586B8C65A6B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D66B0A16463480F4707F5586B8C76198" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9DE9A9842BAEF7F3D2FD5586B8C702E6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D66B0A16463480F4707F5586B8C76198" xlink:to="loc_us-gaap_EquityComponentDomain_9DE9A9842BAEF7F3D2FD5586B8C702E6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9DE9A9842BAEF7F3D2FD5586B8C702E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D66B0A16463480F4707F5586B8C76198" xlink:to="loc_us-gaap_EquityComponentDomain_9DE9A9842BAEF7F3D2FD5586B8C702E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_5CB2F6E621DF304FE4DC5586B8C7987D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9DE9A9842BAEF7F3D2FD5586B8C702E6" xlink:to="loc_us-gaap_CommonStockMember_5CB2F6E621DF304FE4DC5586B8C7987D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1CBF9B28AFCCB5F2EABE5586B8C7EDE9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9DE9A9842BAEF7F3D2FD5586B8C702E6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1CBF9B28AFCCB5F2EABE5586B8C7EDE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_368810FCFA778D65D0D85586B8C7D5F7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9DE9A9842BAEF7F3D2FD5586B8C702E6" xlink:to="loc_us-gaap_RetainedEarningsMember_368810FCFA778D65D0D85586B8C7D5F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5F39FE72EDAB48EC09305586B8C7FDE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6BF9989AADC3E81097955586B8C72105" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5F39FE72EDAB48EC09305586B8C7FDE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_0BD1BE551CDFC0F551C55586B8C7F379" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5F39FE72EDAB48EC09305586B8C7FDE9" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_0BD1BE551CDFC0F551C55586B8C7F379" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0FDE46F67E4BDA1609FD5586B8C71F64" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5F39FE72EDAB48EC09305586B8C7FDE9" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0FDE46F67E4BDA1609FD5586B8C71F64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_BDD5313194C4836470C15586B8C7DCC5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5F39FE72EDAB48EC09305586B8C7FDE9" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_BDD5313194C4836470C15586B8C7DCC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0A86E42CC3BA84BDC6AD5586B8C801A9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5F39FE72EDAB48EC09305586B8C7FDE9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0A86E42CC3BA84BDC6AD5586B8C801A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_63BF776A03790D07F68A5586B8C8423D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5F39FE72EDAB48EC09305586B8C7FDE9" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_63BF776A03790D07F68A5586B8C8423D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_6BF9989AADC3E81097955586B8C72105" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2322B0368E58779074EA5586B8C88539" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2322B0368E58779074EA5586B8C88539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A1510ECF7456E48DAC165586B8C8FB49" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockholdersEquity_A1510ECF7456E48DAC165586B8C8FB49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CB85ADA01307512F6AA65586B8C80939" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CB85ADA01307512F6AA65586B8C80939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2327EBF5D7C8A5698905586B8C8AE5E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2327EBF5D7C8A5698905586B8C8AE5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount_C7826F98D2EA6C3F31185586B8C818CF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount_C7826F98D2EA6C3F31185586B8C818CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_189A04A0DDB99D2CD6125586B8C8BF38" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_189A04A0DDB99D2CD6125586B8C8BF38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_38C93F57728F570683BA5586B8C83B87" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_38C93F57728F570683BA5586B8C83B87" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability" xlink:label="loc_mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability_0A0E37B574BE9299EDB75586B8C8AF30" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability_0A0E37B574BE9299EDB75586B8C8AF30" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_StockIssuedDuringPeriodSharesExerciseofWarrants" xlink:label="loc_mgen_StockIssuedDuringPeriodSharesExerciseofWarrants_24D1E3F234505A72A0C25586B8C9E6B5" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_mgen_StockIssuedDuringPeriodSharesExerciseofWarrants_24D1E3F234505A72A0C25586B8C9E6B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06C8C891BE888C205B3B5586B8C9A37D" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06C8C891BE888C205B3B5586B8C9A37D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6410155FB9D553CD7E9F5586B8C9BBA7" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6410155FB9D553CD7E9F5586B8C9BBA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_CC623E27026B003264595586B8C93CFD" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_CC623E27026B003264595586B8C93CFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E34B1DD0E55F6783CAB95586B8C91B6E" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E34B1DD0E55F6783CAB95586B8C91B6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_856780A6BAFD9C3693975586B8C96B22" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_856780A6BAFD9C3693975586B8C96B22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CCE67DCC8402D1C40DC35586B8C9007E" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_NetIncomeLoss_CCE67DCC8402D1C40DC35586B8C9007E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/DescriptionOfBusiness" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/DescriptionOfBusinessNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DescriptionofBusinessLineItems" xlink:label="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:type="locator" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DescriptionofBusinessTable" xlink:label="loc_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_F83957A637048BCC2549782AAB84B047" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_F83957A637048BCC2549782AAB84B047" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_F3C1D90DC19BD0D95E5B782AAB84F202_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_F83957A637048BCC2549782AAB84B047" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_F3C1D90DC19BD0D95E5B782AAB84F202_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_F3C1D90DC19BD0D95E5B782AAB84F202" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_F83957A637048BCC2549782AAB84B047" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_F3C1D90DC19BD0D95E5B782AAB84F202" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalSharesIssuedToMiragenCommonShareholdersMember" xlink:label="loc_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_0B7DD6FB9B254427E719782AAB84A129" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_F3C1D90DC19BD0D95E5B782AAB84F202" xlink:to="loc_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_0B7DD6FB9B254427E719782AAB84A129" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B0B8CE21CB15335BEBE0782AAB8428F8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_B0B8CE21CB15335BEBE0782AAB8428F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D88FA808C854B4B23A49782AAB8420D0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B0B8CE21CB15335BEBE0782AAB8428F8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D88FA808C854B4B23A49782AAB8420D0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D88FA808C854B4B23A49782AAB8420D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B0B8CE21CB15335BEBE0782AAB8428F8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D88FA808C854B4B23A49782AAB8420D0" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalMember" xlink:label="loc_mgen_SignalMember_7D32C72F43E12AD4E836782AAB84478B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D88FA808C854B4B23A49782AAB8420D0" xlink:to="loc_mgen_SignalMember_7D32C72F43E12AD4E836782AAB84478B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2C4B205311D42BE3D386782AAB84821F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2C4B205311D42BE3D386782AAB84821F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_C8D551774F168D467CA4782AAB84A302_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2C4B205311D42BE3D386782AAB84821F" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_C8D551774F168D467CA4782AAB84A302_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_C8D551774F168D467CA4782AAB84A302" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2C4B205311D42BE3D386782AAB84821F" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_C8D551774F168D467CA4782AAB84A302" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PrivateFinancingMember" xlink:label="loc_mgen_PrivateFinancingMember_6268243AE7A2EE46175A782AAB8424E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_C8D551774F168D467CA4782AAB84A302" xlink:to="loc_mgen_PrivateFinancingMember_6268243AE7A2EE46175A782AAB8424E7" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AtthemarketOfferingMember" xlink:label="loc_mgen_AtthemarketOfferingMember_E066D63B3D97A8B6A182782AAB8585E6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_C8D551774F168D467CA4782AAB84A302" xlink:to="loc_mgen_AtthemarketOfferingMember_E066D63B3D97A8B6A182782AAB8585E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8114DBA5C36C83FC0AF2782AAB85AD4E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:to="loc_us-gaap_RangeAxis_8114DBA5C36C83FC0AF2782AAB85AD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_156D0202E443AA571A01782AAB8521F0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_8114DBA5C36C83FC0AF2782AAB85AD4E" xlink:to="loc_us-gaap_RangeMember_156D0202E443AA571A01782AAB8521F0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_156D0202E443AA571A01782AAB8521F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_8114DBA5C36C83FC0AF2782AAB85AD4E" xlink:to="loc_us-gaap_RangeMember_156D0202E443AA571A01782AAB8521F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_382533A1D05B8EE5D910782AAB85F647" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_156D0202E443AA571A01782AAB8521F0" xlink:to="loc_us-gaap_MaximumMember_382533A1D05B8EE5D910782AAB85F647" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ConversionOfStockSharesIssuedConversionRate" xlink:label="loc_mgen_ConversionOfStockSharesIssuedConversionRate_49F6C26B5D489239815A782AAB8599BF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_mgen_ConversionOfStockSharesIssuedConversionRate_49F6C26B5D489239815A782AAB8599BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1265E4DC096AEDFEF1D6782AAB8521CE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1265E4DC096AEDFEF1D6782AAB8521CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7CB6ED0B56436347B1B4782AAB854C31" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7CB6ED0B56436347B1B4782AAB854C31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1CC27F582C76E31B324F782AAB8598EF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1CC27F582C76E31B324F782AAB8598EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_B5B8372DA95BD050EFE3782AAB856737" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_NetIncomeLoss_B5B8372DA95BD050EFE3782AAB856737" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_E55310EC4C2100C80B46782AAB85C4A4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_E55310EC4C2100C80B46782AAB85C4A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05A1FC584B25D5821AF7782AAB866F36" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05A1FC584B25D5821AF7782AAB866F36" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SaleofStockAdditionalAuthorizedTransactionAmount" xlink:label="loc_mgen_SaleofStockAdditionalAuthorizedTransactionAmount_E8D8485A6A74D841E633782AAB86FCCC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_mgen_SaleofStockAdditionalAuthorizedTransactionAmount_E8D8485A6A74D841E633782AAB86FCCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91990C58F129F8CA1DA6782E68AB7BE3" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91990C58F129F8CA1DA6782E68AB7BE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_406BB6C19A6F4E24BB9B782DAAECAD1A" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_406BB6C19A6F4E24BB9B782DAAECAD1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_040830D82937311B9F8A782AAB86A456" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_040830D82937311B9F8A782AAB86A456" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/DocumentAndEntityInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/NetLossPerShare" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/NetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_277DD0706ADB589228E208261DA1B572" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8A348C17A70EEC3FBCE08261DA080A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_277DD0706ADB589228E208261DA1B572" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8A348C17A70EEC3FBCE08261DA080A4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_914BD8CB434311F1A5D608261DA0AFC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8A348C17A70EEC3FBCE08261DA080A4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_914BD8CB434311F1A5D608261DA0AFC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_914BD8CB434311F1A5D608261DA0AFC6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_914BD8CB434311F1A5D608261DA0AFC6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_58FAB81B18D43BE0C6B208261DA1F3A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A" xlink:to="loc_us-gaap_EmployeeStockOptionMember_58FAB81B18D43BE0C6B208261DA1F3A5" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommonStockWarrantsMember" xlink:label="loc_mgen_CommonStockWarrantsMember_9BBE774BA6061F846FA308261DA1B983" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A" xlink:to="loc_mgen_CommonStockWarrantsMember_9BBE774BA6061F846FA308261DA1B983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_3008E04756AA7B1AB0E108261DA16359" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_3008E04756AA7B1AB0E108261DA16359" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PreferredStockWarrantsMember" xlink:label="loc_mgen_PreferredStockWarrantsMember_C0B56945AE1107CF7A9208261DA1BB47" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A" xlink:to="loc_mgen_PreferredStockWarrantsMember_C0B56945AE1107CF7A9208261DA1BB47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_092E873706571C3D41B808261DA144C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_277DD0706ADB589228E208261DA1B572" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_092E873706571C3D41B808261DA144C7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/NetLossPerShareTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/NotesPayable" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/NotesPayableCompositionOfNotesPayableDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/NotesPayableFutureAnnualMinimumPrincipalPaymentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/NotesPayableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F2BFFA1DA26E8C38DC2008261D6A9C77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:to="loc_us-gaap_DebtInstrumentAxis_F2BFFA1DA26E8C38DC2008261D6A9C77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_389CC4060760DBAA6F4E08261D6A4F78_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_F2BFFA1DA26E8C38DC2008261D6A9C77" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_389CC4060760DBAA6F4E08261D6A4F78_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_389CC4060760DBAA6F4E08261D6A4F78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_F2BFFA1DA26E8C38DC2008261D6A9C77" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_389CC4060760DBAA6F4E08261D6A4F78" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SiliconValleyBankAgreementMember" xlink:label="loc_mgen_SiliconValleyBankAgreementMember_269746BD2302E0F0A9D608261D6A127D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_389CC4060760DBAA6F4E08261D6A4F78" xlink:to="loc_mgen_SiliconValleyBankAgreementMember_269746BD2302E0F0A9D608261D6A127D" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember" xlink:label="loc_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_6F80161A3203DE37F5C708261D6B2F0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_SiliconValleyBankAgreementMember_269746BD2302E0F0A9D608261D6A127D" xlink:to="loc_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_6F80161A3203DE37F5C708261D6B2F0D" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember" xlink:label="loc_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember_12B2336AC8FC4B41382808261D6B3393" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_SiliconValleyBankAgreementMember_269746BD2302E0F0A9D608261D6A127D" xlink:to="loc_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember_12B2336AC8FC4B41382808261D6B3393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_84A15B08B9F0E46508C608261D6BB31B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_84A15B08B9F0E46508C608261D6BB31B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_D0DF47515071A6BF91B808261D6BEA70_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_84A15B08B9F0E46508C608261D6BB31B" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_D0DF47515071A6BF91B808261D6BEA70_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_D0DF47515071A6BF91B808261D6BEA70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_84A15B08B9F0E46508C608261D6BB31B" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_D0DF47515071A6BF91B808261D6BEA70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="loc_us-gaap_NotesPayableToBanksMember_326C2B784ED0DEC0689408261D6BE628" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D0DF47515071A6BF91B808261D6BEA70" xlink:to="loc_us-gaap_NotesPayableToBanksMember_326C2B784ED0DEC0689408261D6BE628" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_15226D185A28F1B19E0108261D6BD0F5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:to="loc_us-gaap_VariableRateAxis_15226D185A28F1B19E0108261D6BD0F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_3E76A78333721ACDEA7B08261D6B14D4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VariableRateAxis_15226D185A28F1B19E0108261D6BD0F5" xlink:to="loc_us-gaap_VariableRateDomain_3E76A78333721ACDEA7B08261D6B14D4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_3E76A78333721ACDEA7B08261D6B14D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VariableRateAxis_15226D185A28F1B19E0108261D6BD0F5" xlink:to="loc_us-gaap_VariableRateDomain_3E76A78333721ACDEA7B08261D6B14D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_CBC5D906FA6C98B7E49008261D6B7E81" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VariableRateDomain_3E76A78333721ACDEA7B08261D6B14D4" xlink:to="loc_us-gaap_PrimeRateMember_CBC5D906FA6C98B7E49008261D6B7E81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_DD3CCEE246F74E79BF7A08261D6BE2D0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_DD3CCEE246F74E79BF7A08261D6BE2D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7EF2957C33798F3D200808261D6BFDEA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_DD3CCEE246F74E79BF7A08261D6BE2D0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7EF2957C33798F3D200808261D6BFDEA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7EF2957C33798F3D200808261D6BFDEA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_DD3CCEE246F74E79BF7A08261D6BE2D0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7EF2957C33798F3D200808261D6BFDEA" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_A930E7833B34599B654908261D6B116C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7EF2957C33798F3D200808261D6BFDEA" xlink:to="loc_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_A930E7833B34599B654908261D6B116C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_8708E1428542006F7F1908261D6C87B7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:to="loc_us-gaap_ValuationTechniqueAxis_8708E1428542006F7F1908261D6C87B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1BAB5F5DC45E14AB1DCE08261D6CCA03_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationTechniqueAxis_8708E1428542006F7F1908261D6C87B7" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1BAB5F5DC45E14AB1DCE08261D6CCA03_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1BAB5F5DC45E14AB1DCE08261D6CCA03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationTechniqueAxis_8708E1428542006F7F1908261D6C87B7" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1BAB5F5DC45E14AB1DCE08261D6CCA03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember_A55813B573D56C4241C208261D6C3256" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1BAB5F5DC45E14AB1DCE08261D6CCA03" xlink:to="loc_us-gaap_IncomeApproachValuationTechniqueMember_A55813B573D56C4241C208261D6C3256" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareholdersEquityClassAxis" xlink:label="loc_us-gaap_ShareholdersEquityClassAxis_F845EA1776C9ACF591FB08261D6CB84C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:to="loc_us-gaap_ShareholdersEquityClassAxis_F845EA1776C9ACF591FB08261D6CB84C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:label="loc_us-gaap_FairValueByShareholdersEquityClassDomain_53485463EFBE6BB4431F08261D6C5AFC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareholdersEquityClassAxis_F845EA1776C9ACF591FB08261D6CB84C" xlink:to="loc_us-gaap_FairValueByShareholdersEquityClassDomain_53485463EFBE6BB4431F08261D6C5AFC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:label="loc_us-gaap_FairValueByShareholdersEquityClassDomain_53485463EFBE6BB4431F08261D6C5AFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareholdersEquityClassAxis_F845EA1776C9ACF591FB08261D6CB84C" xlink:to="loc_us-gaap_FairValueByShareholdersEquityClassDomain_53485463EFBE6BB4431F08261D6C5AFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashMember" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashMember_5AC07E1CDCA356845A0F08261D6C2D71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueByShareholdersEquityClassDomain_53485463EFBE6BB4431F08261D6C5AFC" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashMember_5AC07E1CDCA356845A0F08261D6C2D71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9A110D1A5625B8600BC808261D6CA063" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9A110D1A5625B8600BC808261D6CA063" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DebtInstrumentNumberOfTranches" xlink:label="loc_mgen_DebtInstrumentNumberOfTranches_BB2BEE068A051AF6DE2E08261D6C75E0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_mgen_DebtInstrumentNumberOfTranches_BB2BEE068A051AF6DE2E08261D6C75E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_3992617184559D9100BF08261D6C19D1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_DebtInstrumentTerm_3992617184559D9100BF08261D6C19D1" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DebtInstrumentTermInterestOnlyPayments" xlink:label="loc_mgen_DebtInstrumentTermInterestOnlyPayments_D0D009AEABAE4E6F457108261D6D611A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_mgen_DebtInstrumentTermInterestOnlyPayments_D0D009AEABAE4E6F457108261D6D611A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9AD282A911D4943726BB08261D6D19BD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9AD282A911D4943726BB08261D6D19BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_698414A7296D49254A9608261D6DA029" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_698414A7296D49254A9608261D6DA029" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed" xlink:label="loc_mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed_5B030FD9FF0BC860A8FC08261D6DFAA5" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed_5B030FD9FF0BC860A8FC08261D6DFAA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7B4E918646E4C05B71B308261D6D440F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7B4E918646E4C05B71B308261D6D440F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DA498C337FC8AF57BF0E08261D6DB1DF" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DA498C337FC8AF57BF0E08261D6DB1DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_F89A798BD3C24BD0B17408261D6DCC38" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_F89A798BD3C24BD0B17408261D6DCC38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_AA59C2E98927FAF5A96B08261D6DADAA" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_AA59C2E98927FAF5A96B08261D6DADAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_0B56B669170EBCD61D4F08261D6D5E51" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_0B56B669170EBCD61D4F08261D6D5E51" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_FairValueInputsProbabilityofExercise" xlink:label="loc_mgen_FairValueInputsProbabilityofExercise_A12D0C6C653A6955ADF308261D6DA25D" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_mgen_FairValueInputsProbabilityofExercise_A12D0C6C653A6955ADF308261D6DA25D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/NotesPayableTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/PropertyAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/PropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CE4A900551BC88A0E07708261DBE44E8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B761E19B7377BC3574A808261DBDD99C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CE4A900551BC88A0E07708261DBE44E8" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B761E19B7377BC3574A808261DBDD99C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00DCD77129909619F33108261DBDDA4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B761E19B7377BC3574A808261DBDD99C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00DCD77129909619F33108261DBDDA4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00DCD77129909619F33108261DBDDA4C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00DCD77129909619F33108261DBDDA4C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_612BE01ADBF8EBAC452E08261DBD2CEC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1" xlink:to="loc_us-gaap_EquipmentMember_612BE01ADBF8EBAC452E08261DBD2CEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_A0DB70408C4FEEDBC53208261DBDB091" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_A0DB70408C4FEEDBC53208261DBDB091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_2FCD15F386F00F45DB9F08261DBD0036" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1" xlink:to="loc_us-gaap_ComputerEquipmentMember_2FCD15F386F00F45DB9F08261DBD0036" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_DD3CFEC2C874EEC8ADE008261DBE1818" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_DD3CFEC2C874EEC8ADE008261DBE1818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2E19ADB0FA7897FF32AF08261DBE7A3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CE4A900551BC88A0E07708261DBE44E8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2E19ADB0FA7897FF32AF08261DBE7A3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1E66EA2DA3A3ABE1917B08261DBEE1AE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CE4A900551BC88A0E07708261DBE44E8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1E66EA2DA3A3ABE1917B08261DBEE1AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_73285EB30F69B7F4B48308261DBE22D3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CE4A900551BC88A0E07708261DBE44E8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_73285EB30F69B7F4B48308261DBE22D3" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/PropertyAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/ReverseMerger" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/ReverseMergerNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DA5626D1F4B80433295D08261DAC2E15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_DA5626D1F4B80433295D08261DAC2E15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8354B2FCE315A604115E08261DACC760_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DA5626D1F4B80433295D08261DAC2E15" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8354B2FCE315A604115E08261DACC760_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8354B2FCE315A604115E08261DACC760" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DA5626D1F4B80433295D08261DAC2E15" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8354B2FCE315A604115E08261DACC760" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalMember" xlink:label="loc_mgen_SignalMember_0FE07AF6639CAC50B73F08261DAC69D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8354B2FCE315A604115E08261DACC760" xlink:to="loc_mgen_SignalMember_0FE07AF6639CAC50B73F08261DAC69D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipAxis" xlink:label="loc_us-gaap_OwnershipAxis_E8C466829EFEDE3924F808261DAD5C69" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:to="loc_us-gaap_OwnershipAxis_E8C466829EFEDE3924F808261DAD5C69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipDomain" xlink:label="loc_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OwnershipAxis_E8C466829EFEDE3924F808261DAD5C69" xlink:to="loc_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipDomain" xlink:label="loc_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OwnershipAxis_E8C466829EFEDE3924F808261DAD5C69" xlink:to="loc_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember" xlink:label="loc_mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember_66260FCBA882090EF4E808261DAD630C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0" xlink:to="loc_mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember_66260FCBA882090EF4E808261DAD630C" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalShareholdersMember" xlink:label="loc_mgen_SignalShareholdersMember_790DF87BD2174A64D1DE08261DADB5DB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0" xlink:to="loc_mgen_SignalShareholdersMember_790DF87BD2174A64D1DE08261DADB5DB" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_MiragenShareholdersMember" xlink:label="loc_mgen_MiragenShareholdersMember_D42ABEA8D8DDF0D13F7B08261DAD2A33" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0" xlink:to="loc_mgen_MiragenShareholdersMember_D42ABEA8D8DDF0D13F7B08261DAD2A33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8F42134D7018466CA7EF08261DADF814" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8F42134D7018466CA7EF08261DADF814" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_258C2A93FAC199CA286408261DADCDC7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8F42134D7018466CA7EF08261DADF814" xlink:to="loc_us-gaap_ClassOfStockDomain_258C2A93FAC199CA286408261DADCDC7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_258C2A93FAC199CA286408261DADCDC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8F42134D7018466CA7EF08261DADF814" xlink:to="loc_us-gaap_ClassOfStockDomain_258C2A93FAC199CA286408261DADCDC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_347CB3838CEC35619E4D08261DAD0BDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_258C2A93FAC199CA286408261DADCDC7" xlink:to="loc_us-gaap_PreferredStockMember_347CB3838CEC35619E4D08261DAD0BDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_FFF212ECE69E3B378F8A08261DAD4060" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_FFF212ECE69E3B378F8A08261DAD4060" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_5AA28C5180CBC95C4FA508261DADA50B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_FFF212ECE69E3B378F8A08261DAD4060" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_5AA28C5180CBC95C4FA508261DADA50B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_5AA28C5180CBC95C4FA508261DADA50B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_FFF212ECE69E3B378F8A08261DAD4060" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_5AA28C5180CBC95C4FA508261DADA50B" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalSharesIssuedToMiragenCommonShareholdersMember" xlink:label="loc_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_CA71B534D9147290C90808261DADA3C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_5AA28C5180CBC95C4FA508261DADA50B" xlink:to="loc_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_CA71B534D9147290C90808261DADA3C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_D9432FF207E234AFBC7808261DAE960E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_D9432FF207E234AFBC7808261DAE960E" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ConversionOfStockSharesIssuedConversionRate" xlink:label="loc_mgen_ConversionOfStockSharesIssuedConversionRate_48EAB800650FE3A8F42908261DAE37D9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:to="loc_mgen_ConversionOfStockSharesIssuedConversionRate_48EAB800650FE3A8F42908261DAE37D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5F338C51B2D3339064D108261DAEB7F8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5F338C51B2D3339064D108261DAEB7F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_9E6DABECEFBF688EC52508261DAE9224" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_9E6DABECEFBF688EC52508261DAE9224" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_MarketCapitalization" xlink:label="loc_mgen_MarketCapitalization_7ADDA673421311D0B1E908261DAEB75A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:to="loc_mgen_MarketCapitalization_7ADDA673421311D0B1E908261DAEB75A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E8CF327FB2CA8C3DA10408261DAED723" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E8CF327FB2CA8C3DA10408261DAED723" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/ReverseMergerSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8A98442E52CFECC04F1708261D716EB6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7A4DD9D8DEE8AB154B7908261D7022F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A98442E52CFECC04F1708261D716EB6" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7A4DD9D8DEE8AB154B7908261D7022F0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_36F20F6F0D9DE6860A7108261D70E3FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7A4DD9D8DEE8AB154B7908261D7022F0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_36F20F6F0D9DE6860A7108261D70E3FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8168E5E258059A3BCE0308261D70D680_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_36F20F6F0D9DE6860A7108261D70E3FF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8168E5E258059A3BCE0308261D70D680_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8168E5E258059A3BCE0308261D70D680" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_36F20F6F0D9DE6860A7108261D70E3FF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8168E5E258059A3BCE0308261D70D680" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalMember" xlink:label="loc_mgen_SignalMember_222B76F92ECF897F01EF08261D717A10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8168E5E258059A3BCE0308261D70D680" xlink:to="loc_mgen_SignalMember_222B76F92ECF897F01EF08261D717A10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_DDBD3501DC35F01D26C008261D716075" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A98442E52CFECC04F1708261D716EB6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_DDBD3501DC35F01D26C008261D716075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_C1C5DDF74DEABBFA330608261D71380B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A98442E52CFECC04F1708261D716EB6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_C1C5DDF74DEABBFA330608261D71380B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_70B934F1B1C8AF00C4A508261D714234" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A98442E52CFECC04F1708261D716EB6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_70B934F1B1C8AF00C4A508261D714234" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_AA23C7AA2494945A8C0808261D715A86" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A98442E52CFECC04F1708261D716EB6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_AA23C7AA2494945A8C0808261D715A86" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/ReverseMergerTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensationAllocationOfShareBasedCompensationExpenseOnStatementsOfOperationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FE5D13FED1485DAFCB4708261D75D573" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_98A9D83505719C8648D908261D74C4C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FE5D13FED1485DAFCB4708261D75D573" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_98A9D83505719C8648D908261D74C4C7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2377250A5EA2F7640C4308261D749DE3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_98A9D83505719C8648D908261D74C4C7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2377250A5EA2F7640C4308261D749DE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_919D1CF804C2BD84F49908261D747D0D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2377250A5EA2F7640C4308261D749DE3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_919D1CF804C2BD84F49908261D747D0D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_919D1CF804C2BD84F49908261D747D0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2377250A5EA2F7640C4308261D749DE3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_919D1CF804C2BD84F49908261D747D0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_583C933FF67D566781FA08261D756CC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_919D1CF804C2BD84F49908261D747D0D" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_583C933FF67D566781FA08261D756CC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1D5D07AC01E101538D0008261D757592" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_919D1CF804C2BD84F49908261D747D0D" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1D5D07AC01E101538D0008261D757592" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_04BB21EF566980B707AC08261D75EA71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FE5D13FED1485DAFCB4708261D75D573" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_04BB21EF566980B707AC08261D75EA71" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensationFairValueAssumptionForStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1BFB2E19F98FF3DC1826782AAAA01F39" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50F7F9F1B8BE3FB0DF43782AAAA0F809" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1BFB2E19F98FF3DC1826782AAAA01F39" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50F7F9F1B8BE3FB0DF43782AAAA0F809" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_799CB745C9A70D603B26782AAAA02D66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50F7F9F1B8BE3FB0DF43782AAAA0F809" xlink:to="loc_us-gaap_AwardTypeAxis_799CB745C9A70D603B26782AAAA02D66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B036D50B12D56D68DB62782AAAA029DF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_799CB745C9A70D603B26782AAAA02D66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B036D50B12D56D68DB62782AAAA029DF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B036D50B12D56D68DB62782AAAA029DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_799CB745C9A70D603B26782AAAA02D66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B036D50B12D56D68DB62782AAAA029DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7F33BEE2222B4C9AE1A0782AAAA0885B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B036D50B12D56D68DB62782AAAA029DF" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7F33BEE2222B4C9AE1A0782AAAA0885B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7302DC74B0AF83D76F32782AAAA0DBC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1BFB2E19F98FF3DC1826782AAAA01F39" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7302DC74B0AF83D76F32782AAAA0DBC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0BB6464D3106B2918315782AAAA0C365" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1BFB2E19F98FF3DC1826782AAAA01F39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0BB6464D3106B2918315782AAAA0C365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D4F7F818A0BDED19FC0E782AAAA07282" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1BFB2E19F98FF3DC1826782AAAA01F39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D4F7F818A0BDED19FC0E782AAAA07282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_32331862B7731AE1E340782AAAA05744" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1BFB2E19F98FF3DC1826782AAAA01F39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_32331862B7731AE1E340782AAAA05744" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7A764C76347AFCA61106782AAAA04154" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1BFB2E19F98FF3DC1826782AAAA01F39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7A764C76347AFCA61106782AAAA04154" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_83435A5DF5F3C229ECF8981617ABC5D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_83435A5DF5F3C229ECF8981617ABC5D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9D97E567AFDA1C3340D2981617ABAAFF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_83435A5DF5F3C229ECF8981617ABC5D4" xlink:to="loc_us-gaap_EquityComponentDomain_9D97E567AFDA1C3340D2981617ABAAFF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9D97E567AFDA1C3340D2981617ABAAFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_83435A5DF5F3C229ECF8981617ABC5D4" xlink:to="loc_us-gaap_EquityComponentDomain_9D97E567AFDA1C3340D2981617ABAAFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_71C3F64CAC6DD9579C7F981617ACF19C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9D97E567AFDA1C3340D2981617ABAAFF" xlink:to="loc_us-gaap_CommonStockMember_71C3F64CAC6DD9579C7F981617ACF19C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_07388D749D7BEA724BD4981617AC5244" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:to="loc_us-gaap_PlanNameAxis_07388D749D7BEA724BD4981617AC5244" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1DB6DB1DFFA6717F06B0981617AC8688_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_07388D749D7BEA724BD4981617AC5244" xlink:to="loc_us-gaap_PlanNameDomain_1DB6DB1DFFA6717F06B0981617AC8688_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1DB6DB1DFFA6717F06B0981617AC8688" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_07388D749D7BEA724BD4981617AC5244" xlink:to="loc_us-gaap_PlanNameDomain_1DB6DB1DFFA6717F06B0981617AC8688" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_EquityPlan2008Member" xlink:label="loc_mgen_EquityPlan2008Member_8B0A349BE9F08002F421981617AC03ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1DB6DB1DFFA6717F06B0981617AC8688" xlink:to="loc_mgen_EquityPlan2008Member_8B0A349BE9F08002F421981617AC03ED" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_EquityPlan2016Member" xlink:label="loc_mgen_EquityPlan2016Member_D5A3BBD020C4C1E9C0BE981617AC4B05" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_1DB6DB1DFFA6717F06B0981617AC8688" xlink:to="loc_mgen_EquityPlan2016Member_D5A3BBD020C4C1E9C0BE981617AC4B05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_14C03EB5BD3D374B5214981617AC0A8C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:to="loc_us-gaap_AwardTypeAxis_14C03EB5BD3D374B5214981617AC0A8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06D5584DC41CB57A4D89981617AC2E9F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_14C03EB5BD3D374B5214981617AC0A8C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06D5584DC41CB57A4D89981617AC2E9F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06D5584DC41CB57A4D89981617AC2E9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_14C03EB5BD3D374B5214981617AC0A8C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06D5584DC41CB57A4D89981617AC2E9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1D3B71B34726D2839411981617AC2C37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06D5584DC41CB57A4D89981617AC2E9F" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1D3B71B34726D2839411981617AC2C37" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_NonemployeeStockOptionMember" xlink:label="loc_mgen_NonemployeeStockOptionMember_21972907E7D226C5972B981617AC8DE2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06D5584DC41CB57A4D89981617AC2E9F" xlink:to="loc_mgen_NonemployeeStockOptionMember_21972907E7D226C5972B981617AC8DE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_339F2E9B83818EB9D93D981617ACC073" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:to="loc_us-gaap_RangeAxis_339F2E9B83818EB9D93D981617ACC073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8F3E04A4E287C3C0C750981617AD4729_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_339F2E9B83818EB9D93D981617ACC073" xlink:to="loc_us-gaap_RangeMember_8F3E04A4E287C3C0C750981617AD4729_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8F3E04A4E287C3C0C750981617AD4729" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_339F2E9B83818EB9D93D981617ACC073" xlink:to="loc_us-gaap_RangeMember_8F3E04A4E287C3C0C750981617AD4729" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_2FA0A5FE7D8EC7680C70981617AD49EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_8F3E04A4E287C3C0C750981617AD4729" xlink:to="loc_us-gaap_MaximumMember_2FA0A5FE7D8EC7680C70981617AD49EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_2ACD8977B424FDAA859B981617AD5C60" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:to="loc_us-gaap_VestingAxis_2ACD8977B424FDAA859B981617AD5C60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_3F9FC30FEC467341E76A981617ADFA47_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_2ACD8977B424FDAA859B981617AD5C60" xlink:to="loc_us-gaap_VestingDomain_3F9FC30FEC467341E76A981617ADFA47_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_3F9FC30FEC467341E76A981617ADFA47" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_2ACD8977B424FDAA859B981617AD5C60" xlink:to="loc_us-gaap_VestingDomain_3F9FC30FEC467341E76A981617ADFA47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5236A173E42626355BBA981617ADD901" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_3F9FC30FEC467341E76A981617ADFA47" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5236A173E42626355BBA981617ADD901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8A9A9BE5B93E363D68DF981617AD0A1D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_3F9FC30FEC467341E76A981617ADFA47" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8A9A9BE5B93E363D68DF981617AD0A1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4338FF2E8A108412F9D0981617AD04F6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4338FF2E8A108412F9D0981617AD04F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_B36EC7EDF231C550D6A8981617AD794D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4338FF2E8A108412F9D0981617AD04F6" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_B36EC7EDF231C550D6A8981617AD794D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_B36EC7EDF231C550D6A8981617AD794D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4338FF2E8A108412F9D0981617AD04F6" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_B36EC7EDF231C550D6A8981617AD794D" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_NonemployeesMember" xlink:label="loc_mgen_NonemployeesMember_EBB1A2D2256EE1C30DCF981617ADFE65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_B36EC7EDF231C550D6A8981617AD794D" xlink:to="loc_mgen_NonemployeesMember_EBB1A2D2256EE1C30DCF981617ADFE65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F501CBB7628DD786308E981617ADD27C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F501CBB7628DD786308E981617ADD27C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_E80DF4FE72535C4F0D37981617AD116D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_E80DF4FE72535C4F0D37981617AD116D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_BC2F954840A92394F6D3981617AD8C10" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_BC2F954840A92394F6D3981617AD8C10" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding" xlink:label="loc_mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding_E157D8CF6E60653036CD981617ADD3A7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding_E157D8CF6E60653036CD981617ADD3A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AEA07E8435651E1DE999981617AEC255" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AEA07E8435651E1DE999981617AEC255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_AB4C69C4E123090F9403981617AEA2E8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_AB4C69C4E123090F9403981617AEA2E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4FA14FC0221C0E1FF2D5981617AE2D04" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4FA14FC0221C0E1FF2D5981617AE2D04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F34CF55AC79FC6B000CF981617AEA0C0" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F34CF55AC79FC6B000CF981617AEA0C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_24D2424B1CACE795FD9A981617AEE9E2" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_24D2424B1CACE795FD9A981617AEE9E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E6F2A81BB7EB5D9794C9981617AF3EA1" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E6F2A81BB7EB5D9794C9981617AF3EA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_D8C35371A88C0ACD9307981617AF4942" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_D8C35371A88C0ACD9307981617AF4942" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0BE477E79DE6B5B5DB7A981617AFF649" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0BE477E79DE6B5B5DB7A981617AFF649" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_B811F6D3E346132E5E2A981617AF824F" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_B811F6D3E346132E5E2A981617AF824F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_928AD385B96CC384EB51981617AF3874" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_928AD385B96CC384EB51981617AF3874" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions" xlink:label="loc_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions_C77F645339728B17CDD0981617AFE92A" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions_C77F645339728B17CDD0981617AFE92A" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition" xlink:label="loc_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition_CC4B9482AF657A116807981617AF1FD8" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition_CC4B9482AF657A116807981617AF1FD8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EE8599F93B9B225927908261D919809" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36275286C510510CEB0908261D911680" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EE8599F93B9B225927908261D919809" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36275286C510510CEB0908261D911680" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_AB11A12E246A565DF36708261D912291" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36275286C510510CEB0908261D911680" xlink:to="loc_us-gaap_AwardTypeAxis_AB11A12E246A565DF36708261D912291" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E6DD5F1248893867614008261D91FE21_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_AB11A12E246A565DF36708261D912291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E6DD5F1248893867614008261D91FE21_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E6DD5F1248893867614008261D91FE21" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_AB11A12E246A565DF36708261D912291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E6DD5F1248893867614008261D91FE21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_47082575FD92BEE08AF708261D915002" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E6DD5F1248893867614008261D91FE21" xlink:to="loc_us-gaap_EmployeeStockOptionMember_47082575FD92BEE08AF708261D915002" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EE8599F93B9B225927908261D919809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CDDA68874F82E439423708261D91D8D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CDDA68874F82E439423708261D91D8D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60717D0CC274D45B104508261D91306C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60717D0CC274D45B104508261D91306C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_DA42C64E8876E06478CD08261D911427" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_DA42C64E8876E06478CD08261D911427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF1661887AA031BC780A08261D92E7F6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF1661887AA031BC780A08261D92E7F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EE8599F93B9B225927908261D919809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_295BAC2694D0BAE817A808261D928EDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_295BAC2694D0BAE817A808261D928EDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BAB0B5B1B3A477CD38CA08261D92AB3F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BAB0B5B1B3A477CD38CA08261D92AB3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_355A1588848B0A390F4F08261D922EF3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_355A1588848B0A390F4F08261D922EF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_EBEFA273657E84A4ED2008261D928B39" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_EBEFA273657E84A4ED2008261D928B39" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/StrategicAllianceAndCollaborationWithServier" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/StrategicAllianceAndCollaborationWithServierNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D9BCE08E049966F3D508782AAB65F5FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D9BCE08E049966F3D508782AAB65F5FB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_59A83E474295EDAE04D7782AAB6529D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D9BCE08E049966F3D508782AAB65F5FB" xlink:to="loc_us-gaap_RangeAxis_59A83E474295EDAE04D7782AAB6529D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_A24F379768FFC75915F9782AAB65FECA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_59A83E474295EDAE04D7782AAB6529D2" xlink:to="loc_us-gaap_RangeMember_A24F379768FFC75915F9782AAB65FECA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_A24F379768FFC75915F9782AAB65FECA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_59A83E474295EDAE04D7782AAB6529D2" xlink:to="loc_us-gaap_RangeMember_A24F379768FFC75915F9782AAB65FECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_60352974B53E12ACAD64782AAB66F43F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_A24F379768FFC75915F9782AAB65FECA" xlink:to="loc_us-gaap_MinimumMember_60352974B53E12ACAD64782AAB66F43F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_EFEBE98BB8E2D5B33974782AAB66B461" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_A24F379768FFC75915F9782AAB65FECA" xlink:to="loc_us-gaap_MaximumMember_EFEBE98BB8E2D5B33974782AAB66B461" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_FDBF78B37552D15F79CA782AAB669155" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D9BCE08E049966F3D508782AAB65F5FB" xlink:to="loc_us-gaap_TypeOfArrangementAxis_FDBF78B37552D15F79CA782AAB669155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2F8217F2847259D6C63B782AAB66FDAF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FDBF78B37552D15F79CA782AAB669155" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2F8217F2847259D6C63B782AAB66FDAF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2F8217F2847259D6C63B782AAB66FDAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FDBF78B37552D15F79CA782AAB669155" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2F8217F2847259D6C63B782AAB66FDAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_2EA89624694A8E12FF2A782AAB662B8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2F8217F2847259D6C63B782AAB66FDAF" xlink:to="loc_us-gaap_CollaborativeArrangementMember_2EA89624694A8E12FF2A782AAB662B8D" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments" xlink:label="loc_mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments_2CF7AFE5C6D8E7FA7398782AAB66F26F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="loc_mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments_2CF7AFE5C6D8E7FA7398782AAB66F26F" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:label="loc_mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments_51868147721B429ADA3E782AAB67B7BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="loc_mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments_51868147721B429ADA3E782AAB67B7BC" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments" xlink:label="loc_mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments_F87080493B6E7CBE6F62782AAB6768E1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="loc_mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments_F87080493B6E7CBE6F62782AAB6768E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReimbursementRevenue" xlink:label="loc_us-gaap_ReimbursementRevenue_3F17566629ABD40B61C1782AAB67F68F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="loc_us-gaap_ReimbursementRevenue_3F17566629ABD40B61C1782AAB67F68F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_88982AF65AFD202D876B782AAB677382" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="loc_us-gaap_LicensesRevenue_88982AF65AFD202D876B782AAB677382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_D29265DE0714252D07EA782AAB67DEBE" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="loc_us-gaap_LicenseAndServicesRevenue_D29265DE0714252D07EA782AAB67DEBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms" xlink:label="loc_us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms_3D407227F65318DCA601782AAB67A8DF" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="loc_us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms_3D407227F65318DCA601782AAB67A8DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_DE936D0212D131B85A847833921EFFC2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="loc_us-gaap_AccountsReceivableNet_DE936D0212D131B85A847833921EFFC2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/SubsequentEvents" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_F653569EAC02CE7758DA9293F1D9C8C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E" xlink:to="loc_us-gaap_SubsequentEventTable_F653569EAC02CE7758DA9293F1D9C8C8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_01C99CA5B8BEC581ED7892961785FC48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_F653569EAC02CE7758DA9293F1D9C8C8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_01C99CA5B8BEC581ED7892961785FC48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7EB4E373806FBF0346679296189C2C43_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_01C99CA5B8BEC581ED7892961785FC48" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7EB4E373806FBF0346679296189C2C43_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7EB4E373806FBF0346679296189C2C43" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_01C99CA5B8BEC581ED7892961785FC48" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7EB4E373806FBF0346679296189C2C43" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AtthemarketOfferingMember" xlink:label="loc_mgen_AtthemarketOfferingMember_062733F4AAF086E863FC92966FDDEC4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7EB4E373806FBF0346679296189C2C43" xlink:to="loc_mgen_AtthemarketOfferingMember_062733F4AAF086E863FC92966FDDEC4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0EFE0A0F426B984562619293F1D92E39" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_F653569EAC02CE7758DA9293F1D9C8C8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0EFE0A0F426B984562619293F1D92E39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5F64FFB8692656770E319293F1DA1ABC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0EFE0A0F426B984562619293F1D92E39" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5F64FFB8692656770E319293F1DA1ABC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5F64FFB8692656770E319293F1DA1ABC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0EFE0A0F426B984562619293F1D92E39" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5F64FFB8692656770E319293F1DA1ABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_CE526D9E1D83989E73EE929638237F24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5F64FFB8692656770E319293F1DA1ABC" xlink:to="loc_us-gaap_SubsequentEventMember_CE526D9E1D83989E73EE929638237F24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E0E5059999671AA03B059294EA2304DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E0E5059999671AA03B059294EA2304DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_DD30059D1260264924DA929424B83E2F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_DD30059D1260264924DA929424B83E2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_D99F2EA8632AB809A1239295C7C0086F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_D99F2EA8632AB809A1239295C7C0086F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635AA76E354C9F1863FE92949EF32D56" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635AA76E354C9F1863FE92949EF32D56" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_80183A80204F098108E708261E38C37A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59CC432CBB4113E53CD808261E371420" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_80183A80204F098108E708261E38C37A" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59CC432CBB4113E53CD808261E371420" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6752E06FED88A33BC14108261E38902E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59CC432CBB4113E53CD808261E371420" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6752E06FED88A33BC14108261E38902E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97C57642A6C7E2B2F2B508261E388166_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6752E06FED88A33BC14108261E38902E" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97C57642A6C7E2B2F2B508261E388166_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97C57642A6C7E2B2F2B508261E388166" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6752E06FED88A33BC14108261E38902E" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97C57642A6C7E2B2F2B508261E388166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5E9023578D90CEE57C5208261E3872BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97C57642A6C7E2B2F2B508261E388166" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5E9023578D90CEE57C5208261E3872BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_54ECA2CD46BE0D8A616108261E38015A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97C57642A6C7E2B2F2B508261E388166" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_54ECA2CD46BE0D8A616108261E38015A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_C3F25F9DA622745C6AE208261E3811C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_80183A80204F098108E708261E38C37A" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_C3F25F9DA622745C6AE208261E3811C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_29A20252C903C43156D108261E383F37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_C3F25F9DA622745C6AE208261E3811C6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_29A20252C903C43156D108261E383F37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_145D1654D361212E3C0E08261E38C817" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_80183A80204F098108E708261E38C37A" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_145D1654D361212E3C0E08261E38C817" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_28DC32A54E6E70CDB2CA08261E3837FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_145D1654D361212E3C0E08261E38C817" xlink:to="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_28DC32A54E6E70CDB2CA08261E3837FC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9DF4C7AD50771EE75C9F08261DB663B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8FBE7868E08E9C02784108261DB6F1E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9DF4C7AD50771EE75C9F08261DB663B7" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8FBE7868E08E9C02784108261DB6F1E4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_21C043CD5F66ED73733108261DB6EB38" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8FBE7868E08E9C02784108261DB6F1E4" xlink:to="loc_us-gaap_RangeAxis_21C043CD5F66ED73733108261DB6EB38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_36122CA02375DBB54E5608261DB6DC74_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_21C043CD5F66ED73733108261DB6EB38" xlink:to="loc_us-gaap_RangeMember_36122CA02375DBB54E5608261DB6DC74_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_36122CA02375DBB54E5608261DB6DC74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_21C043CD5F66ED73733108261DB6EB38" xlink:to="loc_us-gaap_RangeMember_36122CA02375DBB54E5608261DB6DC74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_528F8A854EACE8F5836C08261DB67917" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_36122CA02375DBB54E5608261DB6DC74" xlink:to="loc_us-gaap_MinimumMember_528F8A854EACE8F5836C08261DB67917" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_377DE79F32611A535BA608261DB6F4EB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_36122CA02375DBB54E5608261DB6DC74" xlink:to="loc_us-gaap_MaximumMember_377DE79F32611A535BA608261DB6F4EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_C3581F564FB8B9D6F29608261DB6D3E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9DF4C7AD50771EE75C9F08261DB663B7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_C3581F564FB8B9D6F29608261DB6D3E1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/Warrants" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/WarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_4DBA412D5B4DBF24B0B908261D973CC0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_C8E54C8FA081DFE708E008261D969851" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4DBA412D5B4DBF24B0B908261D973CC0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_C8E54C8FA081DFE708E008261D969851" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_90DB24F113C426D5235908261D96FE11" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_C8E54C8FA081DFE708E008261D969851" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_90DB24F113C426D5235908261D96FE11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_42D2BFD70413AA5BE19B08261D966AE0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_90DB24F113C426D5235908261D96FE11" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_42D2BFD70413AA5BE19B08261D966AE0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_42D2BFD70413AA5BE19B08261D966AE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_90DB24F113C426D5235908261D96FE11" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_42D2BFD70413AA5BE19B08261D966AE0" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommonStockWarrantsMember" xlink:label="loc_mgen_CommonStockWarrantsMember_3A5D28D53D9F1678D0B508261D968EE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_42D2BFD70413AA5BE19B08261D966AE0" xlink:to="loc_mgen_CommonStockWarrantsMember_3A5D28D53D9F1678D0B508261D968EE9" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightAcquiredinAcquisition" xlink:label="loc_mgen_ClassofWarrantorRightAcquiredinAcquisition_813C5AB0E868ED3F968D08261D974C0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4DBA412D5B4DBF24B0B908261D973CC0" xlink:to="loc_mgen_ClassofWarrantorRightAcquiredinAcquisition_813C5AB0E868ED3F968D08261D974C0A" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice" xlink:label="loc_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice_807AC0266B5915D31C0A08261D97210D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4DBA412D5B4DBF24B0B908261D973CC0" xlink:to="loc_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice_807AC0266B5915D31C0A08261D97210D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/WarrantsStockWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_6C90E0F94C478A72AB3608261E2EC395" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_DDD3EE6DFEBB62662ABD08261E2E6069" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6C90E0F94C478A72AB3608261E2EC395" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_DDD3EE6DFEBB62662ABD08261E2E6069" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9E415FBD1BCCE188B5DA08261E2E0B58" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DDD3EE6DFEBB62662ABD08261E2E6069" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9E415FBD1BCCE188B5DA08261E2E0B58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_B363AF9160EC56E5813D08261E2E954B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9E415FBD1BCCE188B5DA08261E2E0B58" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_B363AF9160EC56E5813D08261E2E954B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_B363AF9160EC56E5813D08261E2E954B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9E415FBD1BCCE188B5DA08261E2E0B58" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_B363AF9160EC56E5813D08261E2E954B" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommonStockWarrantsMember" xlink:label="loc_mgen_CommonStockWarrantsMember_1DD90E4B8F380B62AE6908261E2E0815" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_B363AF9160EC56E5813D08261E2E954B" xlink:to="loc_mgen_CommonStockWarrantsMember_1DD90E4B8F380B62AE6908261E2E0815" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PreferredStockWarrantsMember" xlink:label="loc_mgen_PreferredStockWarrantsMember_667CE49873EB24A0F63A08261E2E0842" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_B363AF9160EC56E5813D08261E2E954B" xlink:to="loc_mgen_PreferredStockWarrantsMember_667CE49873EB24A0F63A08261E2E0842" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightActivityRollForward" xlink:label="loc_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6C90E0F94C478A72AB3608261E2EC395" xlink:to="loc_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_BD0A3B88D9C65BCFEC4808261E2E7D7F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_BD0A3B88D9C65BCFEC4808261E2E7D7F" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightAcquiredinAcquisition" xlink:label="loc_mgen_ClassofWarrantorRightAcquiredinAcquisition_A06B182A38A03DCFC7D508261E2EB226" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:to="loc_mgen_ClassofWarrantorRightAcquiredinAcquisition_A06B182A38A03DCFC7D508261E2EB226" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightWarrantsConverted" xlink:label="loc_mgen_ClassofWarrantorRightWarrantsConverted_9C439D819BB1B792255108261E2E02F3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:to="loc_mgen_ClassofWarrantorRightWarrantsConverted_9C439D819BB1B792255108261E2E02F3" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightWarrantsExercised" xlink:label="loc_mgen_ClassofWarrantorRightWarrantsExercised_2E235FE6CAF6CC2CB23F08261E2F1B8D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:to="loc_mgen_ClassofWarrantorRightWarrantsExercised_2E235FE6CAF6CC2CB23F08261E2F1B8D" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" xlink:label="loc_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6C90E0F94C478A72AB3608261E2EC395" xlink:to="loc_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5597E95D13B24419745908261E2F7CE5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5597E95D13B24419745908261E2F7CE5" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice" xlink:label="loc_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice_6B929076F881ACCF7E0D08261E2F8973" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:to="loc_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice_6B929076F881ACCF7E0D08261E2F8973" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice" xlink:label="loc_mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice_1CEB21AEE9287ACCC5D608261E2F3D52" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:to="loc_mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice_1CEB21AEE9287ACCC5D608261E2F3D52" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice" xlink:label="loc_mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice_D11034CA6748FA4F254C08261E2FDF2B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:to="loc_mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice_D11034CA6748FA4F254C08261E2FDF2B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/WarrantsStockWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0635FB0D52AB56BB548E08261E092FF5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_894386F36AB4ED4B606208261E095B9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0635FB0D52AB56BB548E08261E092FF5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_894386F36AB4ED4B606208261E095B9F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_54A5E5DA3C5EC032E7CF08261E09F1E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_894386F36AB4ED4B606208261E095B9F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_54A5E5DA3C5EC032E7CF08261E09F1E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E856D099140FC7D8B69008261E094E77_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_54A5E5DA3C5EC032E7CF08261E09F1E2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_E856D099140FC7D8B69008261E094E77_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E856D099140FC7D8B69008261E094E77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_54A5E5DA3C5EC032E7CF08261E09F1E2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_E856D099140FC7D8B69008261E094E77" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommonStockWarrantsMember" xlink:label="loc_mgen_CommonStockWarrantsMember_D78E0DF4349EE9BE7C4008261E0997E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E856D099140FC7D8B69008261E094E77" xlink:to="loc_mgen_CommonStockWarrantsMember_D78E0DF4349EE9BE7C4008261E0997E4" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommonStockWarrantsExpiring2019and2020Member" xlink:label="loc_mgen_CommonStockWarrantsExpiring2019and2020Member_9AC412EED2118C35BD3208261E090356" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommonStockWarrantsMember_D78E0DF4349EE9BE7C4008261E0997E4" xlink:to="loc_mgen_CommonStockWarrantsExpiring2019and2020Member_9AC412EED2118C35BD3208261E090356" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommonStockWarrantsExpiring2025Member" xlink:label="loc_mgen_CommonStockWarrantsExpiring2025Member_2033EA7D0C76B636DA6908261E09C347" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_mgen_CommonStockWarrantsMember_D78E0DF4349EE9BE7C4008261E0997E4" xlink:to="loc_mgen_CommonStockWarrantsExpiring2025Member_2033EA7D0C76B636DA6908261E09C347" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F414D464303A4FA54CDC08261E098F6C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0635FB0D52AB56BB548E08261E092FF5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F414D464303A4FA54CDC08261E098F6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_F08733DC46125250383E08261E0946D6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0635FB0D52AB56BB548E08261E092FF5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_F08733DC46125250383E08261E0946D6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.miragentherapeutics.com/role/WarrantsTables" xlink:type="extended" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>mgen-20170930_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F0689C5CE25D5A72077908261D87C1BE_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F0689C5CE25D5A72077908261D87C1BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F0689C5CE25D5A72077908261D87C1BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F0689C5CE25D5A72077908261D87C1BE" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F0689C5CE25D5A72077908261D87C1BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_4F17CFAAB7E42ACBD46108261D87E91D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_4F17CFAAB7E42ACBD46108261D87E91D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_4F17CFAAB7E42ACBD46108261D87E91D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_4F17CFAAB7E42ACBD46108261D87E91D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_4F17CFAAB7E42ACBD46108261D87E91D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_4F17CFAAB7E42ACBD46108261D87E91D" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_4F17CFAAB7E42ACBD46108261D87E91D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_B2F8BC8D9A2267C765A908261E4E3B78_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract_B2F8BC8D9A2267C765A908261E4E3B78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_B2F8BC8D9A2267C765A908261E4E3B78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B2F8BC8D9A2267C765A908261E4E3B78" xlink:to="lab_us-gaap_AccountingPoliciesAbstract_B2F8BC8D9A2267C765A908261E4E3B78" xlink:type="arc" />
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8CA0981FAD8BF76C480B08261E4EDE54_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8CA0981FAD8BF76C480B08261E4EDE54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8CA0981FAD8BF76C480B08261E4EDE54_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8CA0981FAD8BF76C480B08261E4EDE54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8CA0981FAD8BF76C480B08261E4EDE54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8CA0981FAD8BF76C480B08261E4EDE54" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock_8CA0981FAD8BF76C480B08261E4EDE54" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_45521FF1E1198583BE3B08261DECE591_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_45521FF1E1198583BE3B08261DECE591" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_45521FF1E1198583BE3B08261DECE591" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_45521FF1E1198583BE3B08261DECE591" xlink:to="lab_us-gaap_EarningsPerShareAbstract_45521FF1E1198583BE3B08261DECE591" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_E88D92405477335AADBE08261DECA462_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_E88D92405477335AADBE08261DECA462" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_E88D92405477335AADBE08261DECA462_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_E88D92405477335AADBE08261DECA462" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_E88D92405477335AADBE08261DECA462" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_E88D92405477335AADBE08261DECA462" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_E88D92405477335AADBE08261DECA462" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8EC540DFC9E6EAC6C76108261E5D6A39_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8EC540DFC9E6EAC6C76108261E5D6A39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8EC540DFC9E6EAC6C76108261E5D6A39_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8EC540DFC9E6EAC6C76108261E5D6A39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8EC540DFC9E6EAC6C76108261E5D6A39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8EC540DFC9E6EAC6C76108261E5D6A39" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8EC540DFC9E6EAC6C76108261E5D6A39" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_191981105306C1EC8F3708261E5DE7AF_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_191981105306C1EC8F3708261E5DE7AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_191981105306C1EC8F3708261E5DE7AF_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_191981105306C1EC8F3708261E5DE7AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_191981105306C1EC8F3708261E5DE7AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_191981105306C1EC8F3708261E5DE7AF" xlink:to="lab_us-gaap_UseOfEstimates_191981105306C1EC8F3708261E5DE7AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_18C2A26B86D90DBCCEB208261E5DD509_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_18C2A26B86D90DBCCEB208261E5DD509" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_18C2A26B86D90DBCCEB208261E5DD509_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock_18C2A26B86D90DBCCEB208261E5DD509" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_18C2A26B86D90DBCCEB208261E5DD509" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock_18C2A26B86D90DBCCEB208261E5DD509" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock_18C2A26B86D90DBCCEB208261E5DD509" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_054791633FBA2F4B998508261E5D9729_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_054791633FBA2F4B998508261E5D9729" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-Based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_054791633FBA2F4B998508261E5D9729_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_054791633FBA2F4B998508261E5D9729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_054791633FBA2F4B998508261E5D9729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_054791633FBA2F4B998508261E5D9729" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_054791633FBA2F4B998508261E5D9729" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_72ED8F6E57DB5779644408261E5DF0DD_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_72ED8F6E57DB5779644408261E5DF0DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_72ED8F6E57DB5779644408261E5DF0DD_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_72ED8F6E57DB5779644408261E5DF0DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_72ED8F6E57DB5779644408261E5DF0DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_72ED8F6E57DB5779644408261E5DF0DD" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_72ED8F6E57DB5779644408261E5DF0DD" xlink:type="arc" />
    <link:label id="lab_mgen_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_853F2246E48B9098B45D08261E5D06DB_terseLabel_en-US" xlink:label="lab_mgen_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_853F2246E48B9098B45D08261E5D06DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Clinical Trials and Preclinical Study Accruals</link:label>
    <link:label id="lab_mgen_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_853F2246E48B9098B45D08261E5D06DB_label_en-US" xlink:label="lab_mgen_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_853F2246E48B9098B45D08261E5D06DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Clinical Trials And Pre-clinical Study Accruals [Policy Text Block]</link:label>
    <link:label id="lab_mgen_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_853F2246E48B9098B45D08261E5D06DB_documentation_en-US" xlink:label="lab_mgen_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_853F2246E48B9098B45D08261E5D06DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Clinical Trials and Pre-clinical Study Accruals [Policy Text Block]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" xlink:label="loc_mgen_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_853F2246E48B9098B45D08261E5D06DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_853F2246E48B9098B45D08261E5D06DB" xlink:to="lab_mgen_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_853F2246E48B9098B45D08261E5D06DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DC4020D20FD4DCBD424708261E5DCA88_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DC4020D20FD4DCBD424708261E5DCA88" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DC4020D20FD4DCBD424708261E5DCA88_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DC4020D20FD4DCBD424708261E5DCA88" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DC4020D20FD4DCBD424708261E5DCA88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DC4020D20FD4DCBD424708261E5DCA88" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DC4020D20FD4DCBD424708261E5DCA88" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_514037D787D155435EBB08261E5DC458_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_514037D787D155435EBB08261E5DC458" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_514037D787D155435EBB08261E5DC458_label_en-US" xlink:label="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_514037D787D155435EBB08261E5DC458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_514037D787D155435EBB08261E5DC458" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_514037D787D155435EBB08261E5DC458" xlink:to="lab_us-gaap_FairValueOfFinancialInstrumentsPolicy_514037D787D155435EBB08261E5DC458" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_7C869550B81976A1F92B08261E5D8596_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_7C869550B81976A1F92B08261E5D8596" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Credit Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_7C869550B81976A1F92B08261E5D8596_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk_7C869550B81976A1F92B08261E5D8596" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_7C869550B81976A1F92B08261E5D8596" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk_7C869550B81976A1F92B08261E5D8596" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk_7C869550B81976A1F92B08261E5D8596" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_92D729EF1BBAC836DC8108261E5D2F10_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_92D729EF1BBAC836DC8108261E5D2F10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_92D729EF1BBAC836DC8108261E5D2F10_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_92D729EF1BBAC836DC8108261E5D2F10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_92D729EF1BBAC836DC8108261E5D2F10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_92D729EF1BBAC836DC8108261E5D2F10" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_92D729EF1BBAC836DC8108261E5D2F10" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_243C5B32B14FB571511408261E5D2469_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_243C5B32B14FB571511408261E5D2469" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_243C5B32B14FB571511408261E5D2469_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_243C5B32B14FB571511408261E5D2469" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_243C5B32B14FB571511408261E5D2469" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_243C5B32B14FB571511408261E5D2469" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_243C5B32B14FB571511408261E5D2469" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_8B46FDC258BB541FA77C08261E5DBB47_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_8B46FDC258BB541FA77C08261E5DBB47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_8B46FDC258BB541FA77C08261E5DBB47_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock_8B46FDC258BB541FA77C08261E5DBB47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_8B46FDC258BB541FA77C08261E5DBB47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock_8B46FDC258BB541FA77C08261E5DBB47" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock_8B46FDC258BB541FA77C08261E5DBB47" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_EE14F607EF495830303508261E5DFC1F_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_EE14F607EF495830303508261E5DFC1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_EE14F607EF495830303508261E5DFC1F_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_EE14F607EF495830303508261E5DFC1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_EE14F607EF495830303508261E5DFC1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_EE14F607EF495830303508261E5DFC1F" xlink:to="lab_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_EE14F607EF495830303508261E5DFC1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_279FD60B97DEFBD8FB0708261E5D61F0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_279FD60B97DEFBD8FB0708261E5D61F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_279FD60B97DEFBD8FB0708261E5D61F0_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_279FD60B97DEFBD8FB0708261E5D61F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_279FD60B97DEFBD8FB0708261E5D61F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_279FD60B97DEFBD8FB0708261E5D61F0" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_279FD60B97DEFBD8FB0708261E5D61F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_6902A8E236C44FC1CBED08261E5E12E9_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_6902A8E236C44FC1CBED08261E5E12E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_6902A8E236C44FC1CBED08261E5E12E9_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_6902A8E236C44FC1CBED08261E5E12E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6902A8E236C44FC1CBED08261E5E12E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6902A8E236C44FC1CBED08261E5E12E9" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_6902A8E236C44FC1CBED08261E5E12E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B039F1B6C520570FA42608261E5E12D3_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B039F1B6C520570FA42608261E5E12D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recent Accounting Pronouncements - Adopted and Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B039F1B6C520570FA42608261E5E12D3_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B039F1B6C520570FA42608261E5E12D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B039F1B6C520570FA42608261E5E12D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B039F1B6C520570FA42608261E5E12D3" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B039F1B6C520570FA42608261E5E12D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_422232A587DB5C26F6B208261DB22009_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_422232A587DB5C26F6B208261DB22009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_422232A587DB5C26F6B208261DB22009" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_422232A587DB5C26F6B208261DB22009" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_422232A587DB5C26F6B208261DB22009" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4107C939D921D0C1035708261DB21A6A_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4107C939D921D0C1035708261DB21A6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4107C939D921D0C1035708261DB21A6A_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4107C939D921D0C1035708261DB21A6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4107C939D921D0C1035708261DB21A6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4107C939D921D0C1035708261DB21A6A" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4107C939D921D0C1035708261DB21A6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_50862EDA481703DEBC9608261E0E3743_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_50862EDA481703DEBC9608261E0E3743" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_50862EDA481703DEBC9608261E0E3743" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_50862EDA481703DEBC9608261E0E3743" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_50862EDA481703DEBC9608261E0E3743" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_71BF768C556BB4CBC93008261E0E1ADE_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_71BF768C556BB4CBC93008261E0E1ADE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_71BF768C556BB4CBC93008261E0E1ADE_label_en-US" xlink:label="lab_us-gaap_StatementTable_71BF768C556BB4CBC93008261E0E1ADE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_71BF768C556BB4CBC93008261E0E1ADE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_71BF768C556BB4CBC93008261E0E1ADE" xlink:to="lab_us-gaap_StatementTable_71BF768C556BB4CBC93008261E0E1ADE" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_3EDEF89AE37AA31B9DC408261E0E81D3_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_3EDEF89AE37AA31B9DC408261E0E81D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_3EDEF89AE37AA31B9DC408261E0E81D3_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_3EDEF89AE37AA31B9DC408261E0E81D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3EDEF89AE37AA31B9DC408261E0E81D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3EDEF89AE37AA31B9DC408261E0E81D3" xlink:to="lab_us-gaap_StatementClassOfStockAxis_3EDEF89AE37AA31B9DC408261E0E81D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2" xlink:to="lab_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2" xlink:type="arc" />
    <link:label id="lab_mgen_SeriesARedeemableConvertiblePreferredStockMember_2F0E553E1E9064C0117208261E0E080D_terseLabel_en-US" xlink:label="lab_mgen_SeriesARedeemableConvertiblePreferredStockMember_2F0E553E1E9064C0117208261E0E080D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A</link:label>
    <link:label id="lab_mgen_SeriesARedeemableConvertiblePreferredStockMember_2F0E553E1E9064C0117208261E0E080D_label_en-US" xlink:label="lab_mgen_SeriesARedeemableConvertiblePreferredStockMember_2F0E553E1E9064C0117208261E0E080D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_mgen_SeriesARedeemableConvertiblePreferredStockMember_2F0E553E1E9064C0117208261E0E080D_documentation_en-US" xlink:label="lab_mgen_SeriesARedeemableConvertiblePreferredStockMember_2F0E553E1E9064C0117208261E0E080D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_2F0E553E1E9064C0117208261E0E080D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_2F0E553E1E9064C0117208261E0E080D" xlink:to="lab_mgen_SeriesARedeemableConvertiblePreferredStockMember_2F0E553E1E9064C0117208261E0E080D" xlink:type="arc" />
    <link:label id="lab_mgen_SeriesBRedeemableConvertiblePreferredStockMember_1B6BF9B7471CC6601F5B08261E0EF272_terseLabel_en-US" xlink:label="lab_mgen_SeriesBRedeemableConvertiblePreferredStockMember_1B6BF9B7471CC6601F5B08261E0EF272" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series B</link:label>
    <link:label id="lab_mgen_SeriesBRedeemableConvertiblePreferredStockMember_1B6BF9B7471CC6601F5B08261E0EF272_label_en-US" xlink:label="lab_mgen_SeriesBRedeemableConvertiblePreferredStockMember_1B6BF9B7471CC6601F5B08261E0EF272" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_mgen_SeriesBRedeemableConvertiblePreferredStockMember_1B6BF9B7471CC6601F5B08261E0EF272_documentation_en-US" xlink:label="lab_mgen_SeriesBRedeemableConvertiblePreferredStockMember_1B6BF9B7471CC6601F5B08261E0EF272" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesBRedeemableConvertiblePreferredStockMember_1B6BF9B7471CC6601F5B08261E0EF272" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_SeriesBRedeemableConvertiblePreferredStockMember_1B6BF9B7471CC6601F5B08261E0EF272" xlink:to="lab_mgen_SeriesBRedeemableConvertiblePreferredStockMember_1B6BF9B7471CC6601F5B08261E0EF272" xlink:type="arc" />
    <link:label id="lab_mgen_SeriesCRedeemableConvertiblePreferredStockMember_8D90393DC6D25912A4C308261E0E0DA9_terseLabel_en-US" xlink:label="lab_mgen_SeriesCRedeemableConvertiblePreferredStockMember_8D90393DC6D25912A4C308261E0E0DA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series C</link:label>
    <link:label id="lab_mgen_SeriesCRedeemableConvertiblePreferredStockMember_8D90393DC6D25912A4C308261E0E0DA9_label_en-US" xlink:label="lab_mgen_SeriesCRedeemableConvertiblePreferredStockMember_8D90393DC6D25912A4C308261E0E0DA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series C Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_mgen_SeriesCRedeemableConvertiblePreferredStockMember_8D90393DC6D25912A4C308261E0E0DA9_documentation_en-US" xlink:label="lab_mgen_SeriesCRedeemableConvertiblePreferredStockMember_8D90393DC6D25912A4C308261E0E0DA9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series C Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesCRedeemableConvertiblePreferredStockMember_8D90393DC6D25912A4C308261E0E0DA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_SeriesCRedeemableConvertiblePreferredStockMember_8D90393DC6D25912A4C308261E0E0DA9" xlink:to="lab_mgen_SeriesCRedeemableConvertiblePreferredStockMember_8D90393DC6D25912A4C308261E0E0DA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="lab_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_2E6B70F60F4BD477950E08261E0E7E0C_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_2E6B70F60F4BD477950E08261E0E7E0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_2E6B70F60F4BD477950E08261E0E7E0C_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_2E6B70F60F4BD477950E08261E0E7E0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_2E6B70F60F4BD477950E08261E0E7E0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_2E6B70F60F4BD477950E08261E0E7E0C" xlink:to="lab_us-gaap_TemporaryEquityParOrStatedValuePerShare_2E6B70F60F4BD477950E08261E0E7E0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_3B4C12979C08E393F8E208261E0F35FE_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_3B4C12979C08E393F8E208261E0F35FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesAuthorized_3B4C12979C08E393F8E208261E0F35FE_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesAuthorized_3B4C12979C08E393F8E208261E0F35FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_3B4C12979C08E393F8E208261E0F35FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesAuthorized_3B4C12979C08E393F8E208261E0F35FE" xlink:to="lab_us-gaap_TemporaryEquitySharesAuthorized_3B4C12979C08E393F8E208261E0F35FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_096EB2DBA0D98528FB4708261E0F8902_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued_096EB2DBA0D98528FB4708261E0F8902" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesIssued_096EB2DBA0D98528FB4708261E0F8902_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesIssued_096EB2DBA0D98528FB4708261E0F8902" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_096EB2DBA0D98528FB4708261E0F8902" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesIssued_096EB2DBA0D98528FB4708261E0F8902" xlink:to="lab_us-gaap_TemporaryEquitySharesIssued_096EB2DBA0D98528FB4708261E0F8902" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_4FD7BF122C4177B6C20F08261E0F12C8_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_4FD7BF122C4177B6C20F08261E0F12C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_4FD7BF122C4177B6C20F08261E0F12C8_label_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_4FD7BF122C4177B6C20F08261E0F12C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_4FD7BF122C4177B6C20F08261E0F12C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_4FD7BF122C4177B6C20F08261E0F12C8" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_4FD7BF122C4177B6C20F08261E0F12C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_228CC87D173AD7EC217308261E0FCDEE_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference_228CC87D173AD7EC217308261E0FCDEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock, liquidation preference</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLiquidationPreference_228CC87D173AD7EC217308261E0FCDEE_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLiquidationPreference_228CC87D173AD7EC217308261E0FCDEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Liquidation Preference</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_228CC87D173AD7EC217308261E0FCDEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLiquidationPreference_228CC87D173AD7EC217308261E0FCDEE" xlink:to="lab_us-gaap_TemporaryEquityLiquidationPreference_228CC87D173AD7EC217308261E0FCDEE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_DDA8FE5F0171E6C9375208261E0F869A_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_DDA8FE5F0171E6C9375208261E0F869A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_DDA8FE5F0171E6C9375208261E0F869A_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_DDA8FE5F0171E6C9375208261E0F869A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_DDA8FE5F0171E6C9375208261E0F869A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_DDA8FE5F0171E6C9375208261E0F869A" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_DDA8FE5F0171E6C9375208261E0F869A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_D641BD2D3A24A738717408261E0FF9DD_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_D641BD2D3A24A738717408261E0FF9DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_D641BD2D3A24A738717408261E0FF9DD_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_D641BD2D3A24A738717408261E0FF9DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_D641BD2D3A24A738717408261E0FF9DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_D641BD2D3A24A738717408261E0FF9DD" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_D641BD2D3A24A738717408261E0FF9DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_EFD2772CB0DF5D412D1308261E0F1B68_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_EFD2772CB0DF5D412D1308261E0F1B68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_EFD2772CB0DF5D412D1308261E0F1B68_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_EFD2772CB0DF5D412D1308261E0F1B68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_EFD2772CB0DF5D412D1308261E0F1B68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_EFD2772CB0DF5D412D1308261E0F1B68" xlink:to="lab_us-gaap_CommonStockSharesIssued_EFD2772CB0DF5D412D1308261E0F1B68" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_B37326A32E9AC612726B08261E0F1BDF_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_B37326A32E9AC612726B08261E0F1BDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_B37326A32E9AC612726B08261E0F1BDF_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_B37326A32E9AC612726B08261E0F1BDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_B37326A32E9AC612726B08261E0F1BDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_B37326A32E9AC612726B08261E0F1BDF" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_B37326A32E9AC612726B08261E0F1BDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_27C4324671998BAC109408261E2717BF_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_27C4324671998BAC109408261E2717BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_27C4324671998BAC109408261E2717BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_27C4324671998BAC109408261E2717BF" xlink:to="lab_us-gaap_EquityAbstract_27C4324671998BAC109408261E2717BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_3EADDD36907209DB4ACE08261E27369A_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock_3EADDD36907209DB4ACE08261E27369A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Series Preferred Stock</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityTableTextBlock_3EADDD36907209DB4ACE08261E27369A_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityTableTextBlock_3EADDD36907209DB4ACE08261E27369A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_3EADDD36907209DB4ACE08261E27369A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityTableTextBlock_3EADDD36907209DB4ACE08261E27369A" xlink:to="lab_us-gaap_TemporaryEquityTableTextBlock_3EADDD36907209DB4ACE08261E27369A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_83435A5DF5F3C229ECF8981617ABC5D4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_83435A5DF5F3C229ECF8981617ABC5D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_83435A5DF5F3C229ECF8981617ABC5D4_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_83435A5DF5F3C229ECF8981617ABC5D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_83435A5DF5F3C229ECF8981617ABC5D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_83435A5DF5F3C229ECF8981617ABC5D4" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_83435A5DF5F3C229ECF8981617ABC5D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_9D97E567AFDA1C3340D2981617ABAAFF_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_9D97E567AFDA1C3340D2981617ABAAFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_9D97E567AFDA1C3340D2981617ABAAFF_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_9D97E567AFDA1C3340D2981617ABAAFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9D97E567AFDA1C3340D2981617ABAAFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_9D97E567AFDA1C3340D2981617ABAAFF" xlink:to="lab_us-gaap_EquityComponentDomain_9D97E567AFDA1C3340D2981617ABAAFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_71C3F64CAC6DD9579C7F981617ACF19C_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_71C3F64CAC6DD9579C7F981617ACF19C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_71C3F64CAC6DD9579C7F981617ACF19C_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_71C3F64CAC6DD9579C7F981617ACF19C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_71C3F64CAC6DD9579C7F981617ACF19C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_71C3F64CAC6DD9579C7F981617ACF19C" xlink:to="lab_us-gaap_CommonStockMember_71C3F64CAC6DD9579C7F981617ACF19C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_07388D749D7BEA724BD4981617AC5244_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_07388D749D7BEA724BD4981617AC5244" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_07388D749D7BEA724BD4981617AC5244_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_07388D749D7BEA724BD4981617AC5244" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_07388D749D7BEA724BD4981617AC5244" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_07388D749D7BEA724BD4981617AC5244" xlink:to="lab_us-gaap_PlanNameAxis_07388D749D7BEA724BD4981617AC5244" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_1DB6DB1DFFA6717F06B0981617AC8688_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_1DB6DB1DFFA6717F06B0981617AC8688" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_1DB6DB1DFFA6717F06B0981617AC8688_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_1DB6DB1DFFA6717F06B0981617AC8688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1DB6DB1DFFA6717F06B0981617AC8688" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_1DB6DB1DFFA6717F06B0981617AC8688" xlink:to="lab_us-gaap_PlanNameDomain_1DB6DB1DFFA6717F06B0981617AC8688" xlink:type="arc" />
    <link:label id="lab_mgen_EquityPlan2008Member_8B0A349BE9F08002F421981617AC03ED_terseLabel_en-US" xlink:label="lab_mgen_EquityPlan2008Member_8B0A349BE9F08002F421981617AC03ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2008 Equity Plan</link:label>
    <link:label id="lab_mgen_EquityPlan2008Member_8B0A349BE9F08002F421981617AC03ED_label_en-US" xlink:label="lab_mgen_EquityPlan2008Member_8B0A349BE9F08002F421981617AC03ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Plan 2008 [Member]</link:label>
    <link:label id="lab_mgen_EquityPlan2008Member_8B0A349BE9F08002F421981617AC03ED_documentation_en-US" xlink:label="lab_mgen_EquityPlan2008Member_8B0A349BE9F08002F421981617AC03ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Plan 2008 [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_EquityPlan2008Member" xlink:label="loc_mgen_EquityPlan2008Member_8B0A349BE9F08002F421981617AC03ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_EquityPlan2008Member_8B0A349BE9F08002F421981617AC03ED" xlink:to="lab_mgen_EquityPlan2008Member_8B0A349BE9F08002F421981617AC03ED" xlink:type="arc" />
    <link:label id="lab_mgen_EquityPlan2016Member_D5A3BBD020C4C1E9C0BE981617AC4B05_terseLabel_en-US" xlink:label="lab_mgen_EquityPlan2016Member_D5A3BBD020C4C1E9C0BE981617AC4B05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2016 Equity Plan</link:label>
    <link:label id="lab_mgen_EquityPlan2016Member_D5A3BBD020C4C1E9C0BE981617AC4B05_label_en-US" xlink:label="lab_mgen_EquityPlan2016Member_D5A3BBD020C4C1E9C0BE981617AC4B05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Plan 2016 [Member]</link:label>
    <link:label id="lab_mgen_EquityPlan2016Member_D5A3BBD020C4C1E9C0BE981617AC4B05_documentation_en-US" xlink:label="lab_mgen_EquityPlan2016Member_D5A3BBD020C4C1E9C0BE981617AC4B05" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Plan 2016 [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_EquityPlan2016Member" xlink:label="loc_mgen_EquityPlan2016Member_D5A3BBD020C4C1E9C0BE981617AC4B05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_EquityPlan2016Member_D5A3BBD020C4C1E9C0BE981617AC4B05" xlink:to="lab_mgen_EquityPlan2016Member_D5A3BBD020C4C1E9C0BE981617AC4B05" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_14C03EB5BD3D374B5214981617AC0A8C_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_14C03EB5BD3D374B5214981617AC0A8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_14C03EB5BD3D374B5214981617AC0A8C_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_14C03EB5BD3D374B5214981617AC0A8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_14C03EB5BD3D374B5214981617AC0A8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_14C03EB5BD3D374B5214981617AC0A8C" xlink:to="lab_us-gaap_AwardTypeAxis_14C03EB5BD3D374B5214981617AC0A8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06D5584DC41CB57A4D89981617AC2E9F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06D5584DC41CB57A4D89981617AC2E9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06D5584DC41CB57A4D89981617AC2E9F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06D5584DC41CB57A4D89981617AC2E9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06D5584DC41CB57A4D89981617AC2E9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06D5584DC41CB57A4D89981617AC2E9F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06D5584DC41CB57A4D89981617AC2E9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1D3B71B34726D2839411981617AC2C37_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_1D3B71B34726D2839411981617AC2C37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options to purchase Common Stock</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_1D3B71B34726D2839411981617AC2C37_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_1D3B71B34726D2839411981617AC2C37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1D3B71B34726D2839411981617AC2C37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_1D3B71B34726D2839411981617AC2C37" xlink:to="lab_us-gaap_EmployeeStockOptionMember_1D3B71B34726D2839411981617AC2C37" xlink:type="arc" />
    <link:label id="lab_mgen_NonemployeeStockOptionMember_21972907E7D226C5972B981617AC8DE2_terseLabel_en-US" xlink:label="lab_mgen_NonemployeeStockOptionMember_21972907E7D226C5972B981617AC8DE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-employee Stock Option</link:label>
    <link:label id="lab_mgen_NonemployeeStockOptionMember_21972907E7D226C5972B981617AC8DE2_label_en-US" xlink:label="lab_mgen_NonemployeeStockOptionMember_21972907E7D226C5972B981617AC8DE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-employee Stock Option [Member]</link:label>
    <link:label id="lab_mgen_NonemployeeStockOptionMember_21972907E7D226C5972B981617AC8DE2_documentation_en-US" xlink:label="lab_mgen_NonemployeeStockOptionMember_21972907E7D226C5972B981617AC8DE2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-employee Stock Option [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_NonemployeeStockOptionMember" xlink:label="loc_mgen_NonemployeeStockOptionMember_21972907E7D226C5972B981617AC8DE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_NonemployeeStockOptionMember_21972907E7D226C5972B981617AC8DE2" xlink:to="lab_mgen_NonemployeeStockOptionMember_21972907E7D226C5972B981617AC8DE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeAxis_339F2E9B83818EB9D93D981617ACC073_terseLabel_en-US" xlink:label="lab_us-gaap_RangeAxis_339F2E9B83818EB9D93D981617ACC073" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_us-gaap_RangeAxis_339F2E9B83818EB9D93D981617ACC073_label_en-US" xlink:label="lab_us-gaap_RangeAxis_339F2E9B83818EB9D93D981617ACC073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_339F2E9B83818EB9D93D981617ACC073" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeAxis_339F2E9B83818EB9D93D981617ACC073" xlink:to="lab_us-gaap_RangeAxis_339F2E9B83818EB9D93D981617ACC073" xlink:type="arc" />
    <link:label id="lab_us-gaap_RangeMember_8F3E04A4E287C3C0C750981617AD4729_terseLabel_en-US" xlink:label="lab_us-gaap_RangeMember_8F3E04A4E287C3C0C750981617AD4729" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_us-gaap_RangeMember_8F3E04A4E287C3C0C750981617AD4729_label_en-US" xlink:label="lab_us-gaap_RangeMember_8F3E04A4E287C3C0C750981617AD4729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8F3E04A4E287C3C0C750981617AD4729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RangeMember_8F3E04A4E287C3C0C750981617AD4729" xlink:to="lab_us-gaap_RangeMember_8F3E04A4E287C3C0C750981617AD4729" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaximumMember_2FA0A5FE7D8EC7680C70981617AD49EC_terseLabel_en-US" xlink:label="lab_us-gaap_MaximumMember_2FA0A5FE7D8EC7680C70981617AD49EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_us-gaap_MaximumMember_2FA0A5FE7D8EC7680C70981617AD49EC_label_en-US" xlink:label="lab_us-gaap_MaximumMember_2FA0A5FE7D8EC7680C70981617AD49EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_2FA0A5FE7D8EC7680C70981617AD49EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaximumMember_2FA0A5FE7D8EC7680C70981617AD49EC" xlink:to="lab_us-gaap_MaximumMember_2FA0A5FE7D8EC7680C70981617AD49EC" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingAxis_2ACD8977B424FDAA859B981617AD5C60_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis_2ACD8977B424FDAA859B981617AD5C60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_2ACD8977B424FDAA859B981617AD5C60_label_en-US" xlink:label="lab_us-gaap_VestingAxis_2ACD8977B424FDAA859B981617AD5C60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_2ACD8977B424FDAA859B981617AD5C60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis_2ACD8977B424FDAA859B981617AD5C60" xlink:to="lab_us-gaap_VestingAxis_2ACD8977B424FDAA859B981617AD5C60" xlink:type="arc" />
    <link:label id="lab_us-gaap_VestingDomain_3F9FC30FEC467341E76A981617ADFA47_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain_3F9FC30FEC467341E76A981617ADFA47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_3F9FC30FEC467341E76A981617ADFA47_label_en-US" xlink:label="lab_us-gaap_VestingDomain_3F9FC30FEC467341E76A981617ADFA47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_3F9FC30FEC467341E76A981617ADFA47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain_3F9FC30FEC467341E76A981617ADFA47" xlink:to="lab_us-gaap_VestingDomain_3F9FC30FEC467341E76A981617ADFA47" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5236A173E42626355BBA981617ADD901_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5236A173E42626355BBA981617ADD901" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5236A173E42626355BBA981617ADD901_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5236A173E42626355BBA981617ADD901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche One [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5236A173E42626355BBA981617ADD901" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5236A173E42626355BBA981617ADD901" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5236A173E42626355BBA981617ADD901" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8A9A9BE5B93E363D68DF981617AD0A1D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8A9A9BE5B93E363D68DF981617AD0A1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8A9A9BE5B93E363D68DF981617AD0A1D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8A9A9BE5B93E363D68DF981617AD0A1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Award, Tranche Two [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8A9A9BE5B93E363D68DF981617AD0A1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8A9A9BE5B93E363D68DF981617AD0A1D" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8A9A9BE5B93E363D68DF981617AD0A1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4338FF2E8A108412F9D0981617AD04F6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4338FF2E8A108412F9D0981617AD04F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4338FF2E8A108412F9D0981617AD04F6_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4338FF2E8A108412F9D0981617AD04F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplier [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4338FF2E8A108412F9D0981617AD04F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4338FF2E8A108412F9D0981617AD04F6" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4338FF2E8A108412F9D0981617AD04F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_B36EC7EDF231C550D6A8981617AD794D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_B36EC7EDF231C550D6A8981617AD794D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Supplier [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_B36EC7EDF231C550D6A8981617AD794D_label_en-US" xlink:label="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_B36EC7EDF231C550D6A8981617AD794D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Supplier [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_B36EC7EDF231C550D6A8981617AD794D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_B36EC7EDF231C550D6A8981617AD794D" xlink:to="lab_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_B36EC7EDF231C550D6A8981617AD794D" xlink:type="arc" />
    <link:label id="lab_mgen_NonemployeesMember_EBB1A2D2256EE1C30DCF981617ADFE65_terseLabel_en-US" xlink:label="lab_mgen_NonemployeesMember_EBB1A2D2256EE1C30DCF981617ADFE65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-employees</link:label>
    <link:label id="lab_mgen_NonemployeesMember_EBB1A2D2256EE1C30DCF981617ADFE65_label_en-US" xlink:label="lab_mgen_NonemployeesMember_EBB1A2D2256EE1C30DCF981617ADFE65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-employees [Member]</link:label>
    <link:label id="lab_mgen_NonemployeesMember_EBB1A2D2256EE1C30DCF981617ADFE65_documentation_en-US" xlink:label="lab_mgen_NonemployeesMember_EBB1A2D2256EE1C30DCF981617ADFE65" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-employees [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_NonemployeesMember" xlink:label="loc_mgen_NonemployeesMember_EBB1A2D2256EE1C30DCF981617ADFE65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_NonemployeesMember_EBB1A2D2256EE1C30DCF981617ADFE65" xlink:to="lab_mgen_NonemployeesMember_EBB1A2D2256EE1C30DCF981617ADFE65" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F501CBB7628DD786308E981617ADD27C_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F501CBB7628DD786308E981617ADD27C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F501CBB7628DD786308E981617ADD27C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F501CBB7628DD786308E981617ADD27C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F501CBB7628DD786308E981617ADD27C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F501CBB7628DD786308E981617ADD27C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F501CBB7628DD786308E981617ADD27C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_E80DF4FE72535C4F0D37981617AD116D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_E80DF4FE72535C4F0D37981617AD116D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_E80DF4FE72535C4F0D37981617AD116D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_E80DF4FE72535C4F0D37981617AD116D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_E80DF4FE72535C4F0D37981617AD116D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_E80DF4FE72535C4F0D37981617AD116D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_E80DF4FE72535C4F0D37981617AD116D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_BC2F954840A92394F6D3981617AD8C10_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_BC2F954840A92394F6D3981617AD8C10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis for equity incentive plan (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_BC2F954840A92394F6D3981617AD8C10_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_BC2F954840A92394F6D3981617AD8C10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_BC2F954840A92394F6D3981617AD8C10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_BC2F954840A92394F6D3981617AD8C10" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_BC2F954840A92394F6D3981617AD8C10" xlink:type="arc" />
    <link:label id="lab_mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding_E157D8CF6E60653036CD981617ADD3A7_terseLabel_en-US" xlink:label="lab_mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding_E157D8CF6E60653036CD981617ADD3A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity awards outstanding</link:label>
    <link:label id="lab_mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding_E157D8CF6E60653036CD981617ADD3A7_label_en-US" xlink:label="lab_mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding_E157D8CF6E60653036CD981617ADD3A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Awards Outstanding</link:label>
    <link:label id="lab_mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding_E157D8CF6E60653036CD981617ADD3A7_documentation_en-US" xlink:label="lab_mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding_E157D8CF6E60653036CD981617ADD3A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Awards Outstanding</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding" xlink:label="loc_mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding_E157D8CF6E60653036CD981617ADD3A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding_E157D8CF6E60653036CD981617ADD3A7" xlink:to="lab_mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding_E157D8CF6E60653036CD981617ADD3A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AEA07E8435651E1DE999981617AEC255_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AEA07E8435651E1DE999981617AEC255" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining equity awards available for future issuances</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AEA07E8435651E1DE999981617AEC255_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AEA07E8435651E1DE999981617AEC255" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AEA07E8435651E1DE999981617AEC255" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AEA07E8435651E1DE999981617AEC255" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AEA07E8435651E1DE999981617AEC255" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_AB4C69C4E123090F9403981617AEA2E8_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_AB4C69C4E123090F9403981617AEA2E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_AB4C69C4E123090F9403981617AEA2E8_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_AB4C69C4E123090F9403981617AEA2E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_AB4C69C4E123090F9403981617AEA2E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_AB4C69C4E123090F9403981617AEA2E8" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_AB4C69C4E123090F9403981617AEA2E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4FA14FC0221C0E1FF2D5981617AE2D04_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4FA14FC0221C0E1FF2D5981617AE2D04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percent</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4FA14FC0221C0E1FF2D5981617AE2D04_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4FA14FC0221C0E1FF2D5981617AE2D04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4FA14FC0221C0E1FF2D5981617AE2D04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4FA14FC0221C0E1FF2D5981617AE2D04" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4FA14FC0221C0E1FF2D5981617AE2D04" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F34CF55AC79FC6B000CF981617AEA0C0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F34CF55AC79FC6B000CF981617AEA0C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F34CF55AC79FC6B000CF981617AEA0C0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F34CF55AC79FC6B000CF981617AEA0C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F34CF55AC79FC6B000CF981617AEA0C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F34CF55AC79FC6B000CF981617AEA0C0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F34CF55AC79FC6B000CF981617AEA0C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_24D2424B1CACE795FD9A981617AEE9E2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_24D2424B1CACE795FD9A981617AEE9E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average fair value per option (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_24D2424B1CACE795FD9A981617AEE9E2_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_24D2424B1CACE795FD9A981617AEE9E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_24D2424B1CACE795FD9A981617AEE9E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_24D2424B1CACE795FD9A981617AEE9E2" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_24D2424B1CACE795FD9A981617AEE9E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E6F2A81BB7EB5D9794C9981617AF3EA1_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E6F2A81BB7EB5D9794C9981617AF3EA1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E6F2A81BB7EB5D9794C9981617AF3EA1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E6F2A81BB7EB5D9794C9981617AF3EA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E6F2A81BB7EB5D9794C9981617AF3EA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E6F2A81BB7EB5D9794C9981617AF3EA1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E6F2A81BB7EB5D9794C9981617AF3EA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_D8C35371A88C0ACD9307981617AF4942_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_D8C35371A88C0ACD9307981617AF4942" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares available for issuance under ESPP (in shares)</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_D8C35371A88C0ACD9307981617AF4942_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_D8C35371A88C0ACD9307981617AF4942" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Number of Allocated Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_D8C35371A88C0ACD9307981617AF4942" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_D8C35371A88C0ACD9307981617AF4942" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_D8C35371A88C0ACD9307981617AF4942" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0BE477E79DE6B5B5DB7A981617AFF649_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0BE477E79DE6B5B5DB7A981617AFF649" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee share purchases (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0BE477E79DE6B5B5DB7A981617AFF649_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0BE477E79DE6B5B5DB7A981617AFF649" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0BE477E79DE6B5B5DB7A981617AFF649" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0BE477E79DE6B5B5DB7A981617AFF649" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0BE477E79DE6B5B5DB7A981617AFF649" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_B811F6D3E346132E5E2A981617AF824F_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_B811F6D3E346132E5E2A981617AF824F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized employee stock-based compensation costs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_B811F6D3E346132E5E2A981617AF824F_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_B811F6D3E346132E5E2A981617AF824F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_B811F6D3E346132E5E2A981617AF824F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_B811F6D3E346132E5E2A981617AF824F" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_B811F6D3E346132E5E2A981617AF824F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_928AD385B96CC384EB51981617AF3874_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_928AD385B96CC384EB51981617AF3874" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Remaining weighted-average period for RSUs</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_928AD385B96CC384EB51981617AF3874_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_928AD385B96CC384EB51981617AF3874" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_928AD385B96CC384EB51981617AF3874" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_928AD385B96CC384EB51981617AF3874" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_928AD385B96CC384EB51981617AF3874" xlink:type="arc" />
    <link:label id="lab_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions_C77F645339728B17CDD0981617AFE92A_terseLabel_en-US" xlink:label="lab_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions_C77F645339728B17CDD0981617AFE92A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized stock-based compensation expense for non-employees</link:label>
    <link:label id="lab_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions_C77F645339728B17CDD0981617AFE92A_label_en-US" xlink:label="lab_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions_C77F645339728B17CDD0981617AFE92A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Compensation Not yet Recognized, Stock Options</link:label>
    <link:label id="lab_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions_C77F645339728B17CDD0981617AFE92A_documentation_en-US" xlink:label="lab_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions_C77F645339728B17CDD0981617AFE92A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Compensation Not yet Recognized, Stock Options</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions" xlink:label="loc_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions_C77F645339728B17CDD0981617AFE92A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions_C77F645339728B17CDD0981617AFE92A" xlink:to="lab_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions_C77F645339728B17CDD0981617AFE92A" xlink:type="arc" />
    <link:label id="lab_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition_CC4B9482AF657A116807981617AF1FD8_terseLabel_en-US" xlink:label="lab_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition_CC4B9482AF657A116807981617AF1FD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average remaining period for recognition of non-employee stock-based compensation expense</link:label>
    <link:label id="lab_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition_CC4B9482AF657A116807981617AF1FD8_label_en-US" xlink:label="lab_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition_CC4B9482AF657A116807981617AF1FD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Compensation Not yet Recognized, Period for Recognition</link:label>
    <link:label id="lab_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition_CC4B9482AF657A116807981617AF1FD8_documentation_en-US" xlink:label="lab_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition_CC4B9482AF657A116807981617AF1FD8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Goods and Nonemployee Services Transaction, Compensation Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition" xlink:label="loc_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition_CC4B9482AF657A116807981617AF1FD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition_CC4B9482AF657A116807981617AF1FD8" xlink:to="lab_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition_CC4B9482AF657A116807981617AF1FD8" xlink:type="arc" />
    <link:label id="lab_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6_label_en-US" xlink:label="lab_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:label id="lab_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6_documentation_en-US" xlink:label="lab_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Document And Entity Information [Abstract]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DocumentAndEntityInformationAbstract" xlink:label="loc_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6" xlink:to="lab_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_BD10A4F1B89D84C47DD208261E248B8E_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_BD10A4F1B89D84C47DD208261E248B8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_BD10A4F1B89D84C47DD208261E248B8E_label_en-US" xlink:label="lab_dei_EntityRegistrantName_BD10A4F1B89D84C47DD208261E248B8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_BD10A4F1B89D84C47DD208261E248B8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_BD10A4F1B89D84C47DD208261E248B8E" xlink:to="lab_dei_EntityRegistrantName_BD10A4F1B89D84C47DD208261E248B8E" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_1302D906431B0E7F562708261E2483E6_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_1302D906431B0E7F562708261E2483E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_1302D906431B0E7F562708261E2483E6_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_1302D906431B0E7F562708261E2483E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1302D906431B0E7F562708261E2483E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_1302D906431B0E7F562708261E2483E6" xlink:to="lab_dei_EntityCentralIndexKey_1302D906431B0E7F562708261E2483E6" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_170E460AE734BD71AC6A08261E24AC48_terseLabel_en-US" xlink:label="lab_dei_DocumentType_170E460AE734BD71AC6A08261E24AC48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_170E460AE734BD71AC6A08261E24AC48_label_en-US" xlink:label="lab_dei_DocumentType_170E460AE734BD71AC6A08261E24AC48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_170E460AE734BD71AC6A08261E24AC48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_170E460AE734BD71AC6A08261E24AC48" xlink:to="lab_dei_DocumentType_170E460AE734BD71AC6A08261E24AC48" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_21037306BB37B7C643B108261E245838_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_21037306BB37B7C643B108261E245838" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_21037306BB37B7C643B108261E245838_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_21037306BB37B7C643B108261E245838" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_21037306BB37B7C643B108261E245838" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_21037306BB37B7C643B108261E245838" xlink:to="lab_dei_DocumentPeriodEndDate_21037306BB37B7C643B108261E245838" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_BF9730B0428BA0E3528008261E24002E_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_BF9730B0428BA0E3528008261E24002E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_BF9730B0428BA0E3528008261E24002E_label_en-US" xlink:label="lab_dei_AmendmentFlag_BF9730B0428BA0E3528008261E24002E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_BF9730B0428BA0E3528008261E24002E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_BF9730B0428BA0E3528008261E24002E" xlink:to="lab_dei_AmendmentFlag_BF9730B0428BA0E3528008261E24002E" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_6947DEB8A99E1D8755F908261E24822C_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_6947DEB8A99E1D8755F908261E24822C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_6947DEB8A99E1D8755F908261E24822C_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_6947DEB8A99E1D8755F908261E24822C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_6947DEB8A99E1D8755F908261E24822C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_6947DEB8A99E1D8755F908261E24822C" xlink:to="lab_dei_DocumentFiscalYearFocus_6947DEB8A99E1D8755F908261E24822C" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_D56056E937268EFF21C308261E24B754_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_D56056E937268EFF21C308261E24B754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_D56056E937268EFF21C308261E24B754_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_D56056E937268EFF21C308261E24B754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_D56056E937268EFF21C308261E24B754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_D56056E937268EFF21C308261E24B754" xlink:to="lab_dei_DocumentFiscalPeriodFocus_D56056E937268EFF21C308261E24B754" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6B114936F462CF971C8C08261E25B59E_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_6B114936F462CF971C8C08261E25B59E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_6B114936F462CF971C8C08261E25B59E_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_6B114936F462CF971C8C08261E25B59E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_6B114936F462CF971C8C08261E25B59E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_6B114936F462CF971C8C08261E25B59E" xlink:to="lab_dei_CurrentFiscalYearEndDate_6B114936F462CF971C8C08261E25B59E" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_5CE54A4D7AC8715EE3DE08261E25D148_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_5CE54A4D7AC8715EE3DE08261E25D148" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_5CE54A4D7AC8715EE3DE08261E25D148_label_en-US" xlink:label="lab_dei_EntityFilerCategory_5CE54A4D7AC8715EE3DE08261E25D148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5CE54A4D7AC8715EE3DE08261E25D148" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_5CE54A4D7AC8715EE3DE08261E25D148" xlink:to="lab_dei_EntityFilerCategory_5CE54A4D7AC8715EE3DE08261E25D148" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_DF26F15840DDDBFABD7F08261E254074_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_DF26F15840DDDBFABD7F08261E254074" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_DF26F15840DDDBFABD7F08261E254074_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_DF26F15840DDDBFABD7F08261E254074" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_DF26F15840DDDBFABD7F08261E254074" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_DF26F15840DDDBFABD7F08261E254074" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_DF26F15840DDDBFABD7F08261E254074" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_E2B0DB539461AD2E0EE908261E08A2DB_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_E2B0DB539461AD2E0EE908261E08A2DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_E2B0DB539461AD2E0EE908261E08A2DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_E2B0DB539461AD2E0EE908261E08A2DB" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_E2B0DB539461AD2E0EE908261E08A2DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_894386F36AB4ED4B606208261E095B9F_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_894386F36AB4ED4B606208261E095B9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightTable_894386F36AB4ED4B606208261E095B9F_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightTable_894386F36AB4ED4B606208261E095B9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_894386F36AB4ED4B606208261E095B9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_894386F36AB4ED4B606208261E095B9F" xlink:to="lab_us-gaap_ClassOfWarrantOrRightTable_894386F36AB4ED4B606208261E095B9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_54A5E5DA3C5EC032E7CF08261E09F1E2_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_54A5E5DA3C5EC032E7CF08261E09F1E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_54A5E5DA3C5EC032E7CF08261E09F1E2_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis_54A5E5DA3C5EC032E7CF08261E09F1E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_54A5E5DA3C5EC032E7CF08261E09F1E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_54A5E5DA3C5EC032E7CF08261E09F1E2" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis_54A5E5DA3C5EC032E7CF08261E09F1E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_E856D099140FC7D8B69008261E094E77_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_E856D099140FC7D8B69008261E094E77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_E856D099140FC7D8B69008261E094E77_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain_E856D099140FC7D8B69008261E094E77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E856D099140FC7D8B69008261E094E77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E856D099140FC7D8B69008261E094E77" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain_E856D099140FC7D8B69008261E094E77" xlink:type="arc" />
    <link:label id="lab_mgen_CommonStockWarrantsMember_D78E0DF4349EE9BE7C4008261E0997E4_verboseLabel_en-US" xlink:label="lab_mgen_CommonStockWarrantsMember_D78E0DF4349EE9BE7C4008261E0997E4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock Warrants</link:label>
    <link:label id="lab_mgen_CommonStockWarrantsMember_D78E0DF4349EE9BE7C4008261E0997E4_label_en-US" xlink:label="lab_mgen_CommonStockWarrantsMember_D78E0DF4349EE9BE7C4008261E0997E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
    <link:label id="lab_mgen_CommonStockWarrantsMember_D78E0DF4349EE9BE7C4008261E0997E4_documentation_en-US" xlink:label="lab_mgen_CommonStockWarrantsMember_D78E0DF4349EE9BE7C4008261E0997E4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Warrants [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommonStockWarrantsMember" xlink:label="loc_mgen_CommonStockWarrantsMember_D78E0DF4349EE9BE7C4008261E0997E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_CommonStockWarrantsMember_D78E0DF4349EE9BE7C4008261E0997E4" xlink:to="lab_mgen_CommonStockWarrantsMember_D78E0DF4349EE9BE7C4008261E0997E4" xlink:type="arc" />
    <link:label id="lab_mgen_CommonStockWarrantsExpiring2019and2020Member_9AC412EED2118C35BD3208261E090356_terseLabel_en-US" xlink:label="lab_mgen_CommonStockWarrantsExpiring2019and2020Member_9AC412EED2118C35BD3208261E090356" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date 2019 and 2020</link:label>
    <link:label id="lab_mgen_CommonStockWarrantsExpiring2019and2020Member_9AC412EED2118C35BD3208261E090356_label_en-US" xlink:label="lab_mgen_CommonStockWarrantsExpiring2019and2020Member_9AC412EED2118C35BD3208261E090356" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrants Expiring 2019 and 2020 [Member]</link:label>
    <link:label id="lab_mgen_CommonStockWarrantsExpiring2019and2020Member_9AC412EED2118C35BD3208261E090356_documentation_en-US" xlink:label="lab_mgen_CommonStockWarrantsExpiring2019and2020Member_9AC412EED2118C35BD3208261E090356" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Warrants Expiring 2019 and 2020 [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommonStockWarrantsExpiring2019and2020Member" xlink:label="loc_mgen_CommonStockWarrantsExpiring2019and2020Member_9AC412EED2118C35BD3208261E090356" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_CommonStockWarrantsExpiring2019and2020Member_9AC412EED2118C35BD3208261E090356" xlink:to="lab_mgen_CommonStockWarrantsExpiring2019and2020Member_9AC412EED2118C35BD3208261E090356" xlink:type="arc" />
    <link:label id="lab_mgen_CommonStockWarrantsExpiring2025Member_2033EA7D0C76B636DA6908261E09C347_terseLabel_en-US" xlink:label="lab_mgen_CommonStockWarrantsExpiring2025Member_2033EA7D0C76B636DA6908261E09C347" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date 2025</link:label>
    <link:label id="lab_mgen_CommonStockWarrantsExpiring2025Member_2033EA7D0C76B636DA6908261E09C347_label_en-US" xlink:label="lab_mgen_CommonStockWarrantsExpiring2025Member_2033EA7D0C76B636DA6908261E09C347" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock Warrants Expiring 2025 [Member]</link:label>
    <link:label id="lab_mgen_CommonStockWarrantsExpiring2025Member_2033EA7D0C76B636DA6908261E09C347_documentation_en-US" xlink:label="lab_mgen_CommonStockWarrantsExpiring2025Member_2033EA7D0C76B636DA6908261E09C347" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common Stock Warrants Expiring 2025 [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommonStockWarrantsExpiring2025Member" xlink:label="loc_mgen_CommonStockWarrantsExpiring2025Member_2033EA7D0C76B636DA6908261E09C347" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_CommonStockWarrantsExpiring2025Member_2033EA7D0C76B636DA6908261E09C347" xlink:to="lab_mgen_CommonStockWarrantsExpiring2025Member_2033EA7D0C76B636DA6908261E09C347" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_0635FB0D52AB56BB548E08261E092FF5_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_0635FB0D52AB56BB548E08261E092FF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightLineItems_0635FB0D52AB56BB548E08261E092FF5_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightLineItems_0635FB0D52AB56BB548E08261E092FF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0635FB0D52AB56BB548E08261E092FF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0635FB0D52AB56BB548E08261E092FF5" xlink:to="lab_us-gaap_ClassOfWarrantOrRightLineItems_0635FB0D52AB56BB548E08261E092FF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F414D464303A4FA54CDC08261E098F6C_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F414D464303A4FA54CDC08261E098F6C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of Underlying Shares (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F414D464303A4FA54CDC08261E098F6C_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F414D464303A4FA54CDC08261E098F6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F414D464303A4FA54CDC08261E098F6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F414D464303A4FA54CDC08261E098F6C" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F414D464303A4FA54CDC08261E098F6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_F08733DC46125250383E08261E0946D6_verboseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_F08733DC46125250383E08261E0946D6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_F08733DC46125250383E08261E0946D6_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_F08733DC46125250383E08261E0946D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_F08733DC46125250383E08261E0946D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_F08733DC46125250383E08261E0946D6" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_F08733DC46125250383E08261E0946D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_391462BF2E966EA94F43782AAB84A7A1_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_391462BF2E966EA94F43782AAB84A7A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_391462BF2E966EA94F43782AAB84A7A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_391462BF2E966EA94F43782AAB84A7A1" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_391462BF2E966EA94F43782AAB84A7A1" xlink:type="arc" />
    <link:label id="lab_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868_terseLabel_en-US" xlink:label="lab_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business [Table]</link:label>
    <link:label id="lab_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868_label_en-US" xlink:label="lab_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of Business [Table]</link:label>
    <link:label id="lab_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868_documentation_en-US" xlink:label="lab_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Description of Business [Table]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DescriptionofBusinessTable" xlink:label="loc_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:to="lab_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_F83957A637048BCC2549782AAB84B047_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_F83957A637048BCC2549782AAB84B047" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_F83957A637048BCC2549782AAB84B047_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_F83957A637048BCC2549782AAB84B047" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Conversion Description [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_F83957A637048BCC2549782AAB84B047" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_F83957A637048BCC2549782AAB84B047" xlink:to="lab_us-gaap_ConversionOfStockByUniqueDescriptionAxis_F83957A637048BCC2549782AAB84B047" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_F3C1D90DC19BD0D95E5B782AAB84F202_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain_F3C1D90DC19BD0D95E5B782AAB84F202" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockNameDomain_F3C1D90DC19BD0D95E5B782AAB84F202_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockNameDomain_F3C1D90DC19BD0D95E5B782AAB84F202" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_F3C1D90DC19BD0D95E5B782AAB84F202" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_F3C1D90DC19BD0D95E5B782AAB84F202" xlink:to="lab_us-gaap_ConversionOfStockNameDomain_F3C1D90DC19BD0D95E5B782AAB84F202" xlink:type="arc" />
    <link:label id="lab_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_0B7DD6FB9B254427E719782AAB84A129_terseLabel_en-US" xlink:label="lab_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_0B7DD6FB9B254427E719782AAB84A129" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Signal Shares issued to Miragen Common Shareholders</link:label>
    <link:label id="lab_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_0B7DD6FB9B254427E719782AAB84A129_label_en-US" xlink:label="lab_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_0B7DD6FB9B254427E719782AAB84A129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Signal Shares Issued To Miragen Common Shareholders [Member]</link:label>
    <link:label id="lab_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_0B7DD6FB9B254427E719782AAB84A129_documentation_en-US" xlink:label="lab_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_0B7DD6FB9B254427E719782AAB84A129" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Signal Shares issued to Miragen Common Shareholders [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalSharesIssuedToMiragenCommonShareholdersMember" xlink:label="loc_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_0B7DD6FB9B254427E719782AAB84A129" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_0B7DD6FB9B254427E719782AAB84A129" xlink:to="lab_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_0B7DD6FB9B254427E719782AAB84A129" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_B0B8CE21CB15335BEBE0782AAB8428F8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_B0B8CE21CB15335BEBE0782AAB8428F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_B0B8CE21CB15335BEBE0782AAB8428F8_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_B0B8CE21CB15335BEBE0782AAB8428F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B0B8CE21CB15335BEBE0782AAB8428F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B0B8CE21CB15335BEBE0782AAB8428F8" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_B0B8CE21CB15335BEBE0782AAB8428F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_D88FA808C854B4B23A49782AAB8420D0_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_D88FA808C854B4B23A49782AAB8420D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_D88FA808C854B4B23A49782AAB8420D0_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_D88FA808C854B4B23A49782AAB8420D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D88FA808C854B4B23A49782AAB8420D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D88FA808C854B4B23A49782AAB8420D0" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_D88FA808C854B4B23A49782AAB8420D0" xlink:type="arc" />
    <link:label id="lab_mgen_SignalMember_7D32C72F43E12AD4E836782AAB84478B_terseLabel_en-US" xlink:label="lab_mgen_SignalMember_7D32C72F43E12AD4E836782AAB84478B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Signal</link:label>
    <link:label id="lab_mgen_SignalMember_7D32C72F43E12AD4E836782AAB84478B_label_en-US" xlink:label="lab_mgen_SignalMember_7D32C72F43E12AD4E836782AAB84478B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Signal [Member]</link:label>
    <link:label id="lab_mgen_SignalMember_7D32C72F43E12AD4E836782AAB84478B_documentation_en-US" xlink:label="lab_mgen_SignalMember_7D32C72F43E12AD4E836782AAB84478B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Signal [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalMember" xlink:label="loc_mgen_SignalMember_7D32C72F43E12AD4E836782AAB84478B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_SignalMember_7D32C72F43E12AD4E836782AAB84478B" xlink:to="lab_mgen_SignalMember_7D32C72F43E12AD4E836782AAB84478B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_2C4B205311D42BE3D386782AAB84821F_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_2C4B205311D42BE3D386782AAB84821F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_2C4B205311D42BE3D386782AAB84821F_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis_2C4B205311D42BE3D386782AAB84821F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2C4B205311D42BE3D386782AAB84821F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2C4B205311D42BE3D386782AAB84821F" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis_2C4B205311D42BE3D386782AAB84821F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_C8D551774F168D467CA4782AAB84A302_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_C8D551774F168D467CA4782AAB84A302" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_C8D551774F168D467CA4782AAB84A302_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain_C8D551774F168D467CA4782AAB84A302" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_C8D551774F168D467CA4782AAB84A302" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_C8D551774F168D467CA4782AAB84A302" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain_C8D551774F168D467CA4782AAB84A302" xlink:type="arc" />
    <link:label id="lab_mgen_PrivateFinancingMember_6268243AE7A2EE46175A782AAB8424E7_terseLabel_en-US" xlink:label="lab_mgen_PrivateFinancingMember_6268243AE7A2EE46175A782AAB8424E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Financing</link:label>
    <link:label id="lab_mgen_PrivateFinancingMember_6268243AE7A2EE46175A782AAB8424E7_label_en-US" xlink:label="lab_mgen_PrivateFinancingMember_6268243AE7A2EE46175A782AAB8424E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Financing [Member]</link:label>
    <link:label id="lab_mgen_PrivateFinancingMember_6268243AE7A2EE46175A782AAB8424E7_documentation_en-US" xlink:label="lab_mgen_PrivateFinancingMember_6268243AE7A2EE46175A782AAB8424E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Financing [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PrivateFinancingMember" xlink:label="loc_mgen_PrivateFinancingMember_6268243AE7A2EE46175A782AAB8424E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_PrivateFinancingMember_6268243AE7A2EE46175A782AAB8424E7" xlink:to="lab_mgen_PrivateFinancingMember_6268243AE7A2EE46175A782AAB8424E7" xlink:type="arc" />
    <link:label id="lab_mgen_AtthemarketOfferingMember_E066D63B3D97A8B6A182782AAB8585E6_terseLabel_en-US" xlink:label="lab_mgen_AtthemarketOfferingMember_E066D63B3D97A8B6A182782AAB8585E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ATM Agreement</link:label>
    <link:label id="lab_mgen_AtthemarketOfferingMember_E066D63B3D97A8B6A182782AAB8585E6_label_en-US" xlink:label="lab_mgen_AtthemarketOfferingMember_E066D63B3D97A8B6A182782AAB8585E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-the-market Offering [Member]</link:label>
    <link:label id="lab_mgen_AtthemarketOfferingMember_E066D63B3D97A8B6A182782AAB8585E6_documentation_en-US" xlink:label="lab_mgen_AtthemarketOfferingMember_E066D63B3D97A8B6A182782AAB8585E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-the-market Offering [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AtthemarketOfferingMember" xlink:label="loc_mgen_AtthemarketOfferingMember_E066D63B3D97A8B6A182782AAB8585E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_AtthemarketOfferingMember_E066D63B3D97A8B6A182782AAB8585E6" xlink:to="lab_mgen_AtthemarketOfferingMember_E066D63B3D97A8B6A182782AAB8585E6" xlink:type="arc" />
    <link:label id="lab_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9_terseLabel_en-US" xlink:label="lab_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business [Line Items]</link:label>
    <link:label id="lab_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9_label_en-US" xlink:label="lab_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Description of Business [Line Items]</link:label>
    <link:label id="lab_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9_documentation_en-US" xlink:label="lab_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Description of Business [Table]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DescriptionofBusinessLineItems" xlink:label="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="lab_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:type="arc" />
    <link:label id="lab_mgen_ConversionOfStockSharesIssuedConversionRate_49F6C26B5D489239815A782AAB8599BF_terseLabel_en-US" xlink:label="lab_mgen_ConversionOfStockSharesIssuedConversionRate_49F6C26B5D489239815A782AAB8599BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange rate of common stock</link:label>
    <link:label id="lab_mgen_ConversionOfStockSharesIssuedConversionRate_49F6C26B5D489239815A782AAB8599BF_label_en-US" xlink:label="lab_mgen_ConversionOfStockSharesIssuedConversionRate_49F6C26B5D489239815A782AAB8599BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion Of Stock, Shares Issued, Conversion Rate</link:label>
    <link:label id="lab_mgen_ConversionOfStockSharesIssuedConversionRate_49F6C26B5D489239815A782AAB8599BF_documentation_en-US" xlink:label="lab_mgen_ConversionOfStockSharesIssuedConversionRate_49F6C26B5D489239815A782AAB8599BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued, Conversion Rate</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ConversionOfStockSharesIssuedConversionRate" xlink:label="loc_mgen_ConversionOfStockSharesIssuedConversionRate_49F6C26B5D489239815A782AAB8599BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_ConversionOfStockSharesIssuedConversionRate_49F6C26B5D489239815A782AAB8599BF" xlink:to="lab_mgen_ConversionOfStockSharesIssuedConversionRate_49F6C26B5D489239815A782AAB8599BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1CC27F582C76E31B324F782AAB8598EF_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1CC27F582C76E31B324F782AAB8598EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1CC27F582C76E31B324F782AAB8598EF_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1CC27F582C76E31B324F782AAB8598EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1CC27F582C76E31B324F782AAB8598EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1CC27F582C76E31B324F782AAB8598EF" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_1CC27F582C76E31B324F782AAB8598EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_B5B8372DA95BD050EFE3782AAB856737_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_B5B8372DA95BD050EFE3782AAB856737" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_B5B8372DA95BD050EFE3782AAB856737_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_B5B8372DA95BD050EFE3782AAB856737" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_B5B8372DA95BD050EFE3782AAB856737" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_B5B8372DA95BD050EFE3782AAB856737" xlink:to="lab_us-gaap_NetIncomeLoss_B5B8372DA95BD050EFE3782AAB856737" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_E55310EC4C2100C80B46782AAB85C4A4_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_E55310EC4C2100C80B46782AAB85C4A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of common stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_E55310EC4C2100C80B46782AAB85C4A4_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_E55310EC4C2100C80B46782AAB85C4A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_E55310EC4C2100C80B46782AAB85C4A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_E55310EC4C2100C80B46782AAB85C4A4" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_E55310EC4C2100C80B46782AAB85C4A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05A1FC584B25D5821AF7782AAB866F36_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05A1FC584B25D5821AF7782AAB866F36" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate offering</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05A1FC584B25D5821AF7782AAB866F36_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05A1FC584B25D5821AF7782AAB866F36" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05A1FC584B25D5821AF7782AAB866F36" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05A1FC584B25D5821AF7782AAB866F36" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05A1FC584B25D5821AF7782AAB866F36" xlink:type="arc" />
    <link:label id="lab_mgen_SaleofStockAdditionalAuthorizedTransactionAmount_E8D8485A6A74D841E633782AAB86FCCC_terseLabel_en-US" xlink:label="lab_mgen_SaleofStockAdditionalAuthorizedTransactionAmount_E8D8485A6A74D841E633782AAB86FCCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Authorized transaction amount</link:label>
    <link:label id="lab_mgen_SaleofStockAdditionalAuthorizedTransactionAmount_E8D8485A6A74D841E633782AAB86FCCC_label_en-US" xlink:label="lab_mgen_SaleofStockAdditionalAuthorizedTransactionAmount_E8D8485A6A74D841E633782AAB86FCCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Additional Authorized Transaction, Amount</link:label>
    <link:label id="lab_mgen_SaleofStockAdditionalAuthorizedTransactionAmount_E8D8485A6A74D841E633782AAB86FCCC_documentation_en-US" xlink:label="lab_mgen_SaleofStockAdditionalAuthorizedTransactionAmount_E8D8485A6A74D841E633782AAB86FCCC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Additional Authorized Transaction, Amount</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SaleofStockAdditionalAuthorizedTransactionAmount" xlink:label="loc_mgen_SaleofStockAdditionalAuthorizedTransactionAmount_E8D8485A6A74D841E633782AAB86FCCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_SaleofStockAdditionalAuthorizedTransactionAmount_E8D8485A6A74D841E633782AAB86FCCC" xlink:to="lab_mgen_SaleofStockAdditionalAuthorizedTransactionAmount_E8D8485A6A74D841E633782AAB86FCCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91990C58F129F8CA1DA6782E68AB7BE3_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91990C58F129F8CA1DA6782E68AB7BE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares sold (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91990C58F129F8CA1DA6782E68AB7BE3_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91990C58F129F8CA1DA6782E68AB7BE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91990C58F129F8CA1DA6782E68AB7BE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91990C58F129F8CA1DA6782E68AB7BE3" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91990C58F129F8CA1DA6782E68AB7BE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_406BB6C19A6F4E24BB9B782DAAECAD1A_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_406BB6C19A6F4E24BB9B782DAAECAD1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_406BB6C19A6F4E24BB9B782DAAECAD1A_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare_406BB6C19A6F4E24BB9B782DAAECAD1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_406BB6C19A6F4E24BB9B782DAAECAD1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare_406BB6C19A6F4E24BB9B782DAAECAD1A" xlink:to="lab_us-gaap_SaleOfStockPricePerShare_406BB6C19A6F4E24BB9B782DAAECAD1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_040830D82937311B9F8A782AAB86A456_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_040830D82937311B9F8A782AAB86A456" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_040830D82937311B9F8A782AAB86A456_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_040830D82937311B9F8A782AAB86A456" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_040830D82937311B9F8A782AAB86A456" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_040830D82937311B9F8A782AAB86A456" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_040830D82937311B9F8A782AAB86A456" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_3C5B03983EFA8003DF1808261DB860F4_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_3C5B03983EFA8003DF1808261DB860F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 (remainder of year)</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_3C5B03983EFA8003DF1808261DB860F4_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_3C5B03983EFA8003DF1808261DB860F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_3C5B03983EFA8003DF1808261DB860F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_3C5B03983EFA8003DF1808261DB860F4" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_3C5B03983EFA8003DF1808261DB860F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C4A43CC63EAA378034B508261DB926E3_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C4A43CC63EAA378034B508261DB926E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C4A43CC63EAA378034B508261DB926E3_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C4A43CC63EAA378034B508261DB926E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C4A43CC63EAA378034B508261DB926E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C4A43CC63EAA378034B508261DB926E3" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C4A43CC63EAA378034B508261DB926E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B95FB7622AC1FF57A6E08261DB92F4A_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B95FB7622AC1FF57A6E08261DB92F4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B95FB7622AC1FF57A6E08261DB92F4A_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B95FB7622AC1FF57A6E08261DB92F4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B95FB7622AC1FF57A6E08261DB92F4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B95FB7622AC1FF57A6E08261DB92F4A" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B95FB7622AC1FF57A6E08261DB92F4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_703663AEAAB687F8283408261DB97B75_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_703663AEAAB687F8283408261DB97B75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_703663AEAAB687F8283408261DB97B75_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_703663AEAAB687F8283408261DB97B75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_703663AEAAB687F8283408261DB97B75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_703663AEAAB687F8283408261DB97B75" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_703663AEAAB687F8283408261DB97B75" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6DE1A86D6805978727DE08261DB9DDFE_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6DE1A86D6805978727DE08261DB9DDFE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6DE1A86D6805978727DE08261DB9DDFE_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6DE1A86D6805978727DE08261DB9DDFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6DE1A86D6805978727DE08261DB9DDFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6DE1A86D6805978727DE08261DB9DDFE" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6DE1A86D6805978727DE08261DB9DDFE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D2834D0947D948BF272782AAAB8A98E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D2834D0947D948BF272782AAAB8A98E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D2834D0947D948BF272782AAAB8A98E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D2834D0947D948BF272782AAAB8A98E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D2834D0947D948BF272782AAAB8A98E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D2834D0947D948BF272782AAAB8A98E" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D2834D0947D948BF272782AAAB8A98E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F03F5DFC05643BCB9968782AAAB849C2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F03F5DFC05643BCB9968782AAAB849C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions for Stock Options</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F03F5DFC05643BCB9968782AAAB849C2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F03F5DFC05643BCB9968782AAAB849C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F03F5DFC05643BCB9968782AAAB849C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F03F5DFC05643BCB9968782AAAB849C2" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F03F5DFC05643BCB9968782AAAB849C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EBCB33C0CAFF109709A2782AAAB8F7BE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EBCB33C0CAFF109709A2782AAAB8F7BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allocation of Share-based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EBCB33C0CAFF109709A2782AAAB8F7BE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EBCB33C0CAFF109709A2782AAAB8F7BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EBCB33C0CAFF109709A2782AAAB8F7BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EBCB33C0CAFF109709A2782AAAB8F7BE" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EBCB33C0CAFF109709A2782AAAB8F7BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_D69F9EE7EAB66B8764B708261D6AB782_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_D69F9EE7EAB66B8764B708261D6AB782" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_D69F9EE7EAB66B8764B708261D6AB782" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_D69F9EE7EAB66B8764B708261D6AB782" xlink:to="lab_us-gaap_DebtDisclosureAbstract_D69F9EE7EAB66B8764B708261D6AB782" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:to="lab_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_F2BFFA1DA26E8C38DC2008261D6A9C77_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_F2BFFA1DA26E8C38DC2008261D6A9C77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_F2BFFA1DA26E8C38DC2008261D6A9C77_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_F2BFFA1DA26E8C38DC2008261D6A9C77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F2BFFA1DA26E8C38DC2008261D6A9C77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_F2BFFA1DA26E8C38DC2008261D6A9C77" xlink:to="lab_us-gaap_DebtInstrumentAxis_F2BFFA1DA26E8C38DC2008261D6A9C77" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_389CC4060760DBAA6F4E08261D6A4F78_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_389CC4060760DBAA6F4E08261D6A4F78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_389CC4060760DBAA6F4E08261D6A4F78_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_389CC4060760DBAA6F4E08261D6A4F78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_389CC4060760DBAA6F4E08261D6A4F78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_389CC4060760DBAA6F4E08261D6A4F78" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_389CC4060760DBAA6F4E08261D6A4F78" xlink:type="arc" />
    <link:label id="lab_mgen_SiliconValleyBankAgreementMember_269746BD2302E0F0A9D608261D6A127D_terseLabel_en-US" xlink:label="lab_mgen_SiliconValleyBankAgreementMember_269746BD2302E0F0A9D608261D6A127D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Silicon Valley Bank Agreement</link:label>
    <link:label id="lab_mgen_SiliconValleyBankAgreementMember_269746BD2302E0F0A9D608261D6A127D_label_en-US" xlink:label="lab_mgen_SiliconValleyBankAgreementMember_269746BD2302E0F0A9D608261D6A127D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Silicon Valley Bank Agreement [Member]</link:label>
    <link:label id="lab_mgen_SiliconValleyBankAgreementMember_269746BD2302E0F0A9D608261D6A127D_documentation_en-US" xlink:label="lab_mgen_SiliconValleyBankAgreementMember_269746BD2302E0F0A9D608261D6A127D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Silicon Valley Bank Agreement [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SiliconValleyBankAgreementMember" xlink:label="loc_mgen_SiliconValleyBankAgreementMember_269746BD2302E0F0A9D608261D6A127D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_SiliconValleyBankAgreementMember_269746BD2302E0F0A9D608261D6A127D" xlink:to="lab_mgen_SiliconValleyBankAgreementMember_269746BD2302E0F0A9D608261D6A127D" xlink:type="arc" />
    <link:label id="lab_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_6F80161A3203DE37F5C708261D6B2F0D_terseLabel_en-US" xlink:label="lab_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_6F80161A3203DE37F5C708261D6B2F0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Notes Payable to Silicon Valley Bank - Tranche One</link:label>
    <link:label id="lab_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_6F80161A3203DE37F5C708261D6B2F0D_label_en-US" xlink:label="lab_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_6F80161A3203DE37F5C708261D6B2F0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Fifteen Notes Payable to Silicon Valley Bank - Tranche One [Member]</link:label>
    <link:label id="lab_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_6F80161A3203DE37F5C708261D6B2F0D_documentation_en-US" xlink:label="lab_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_6F80161A3203DE37F5C708261D6B2F0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Fifteen Notes Payable to Silicon Valley Bank - Tranche One [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember" xlink:label="loc_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_6F80161A3203DE37F5C708261D6B2F0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_6F80161A3203DE37F5C708261D6B2F0D" xlink:to="lab_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_6F80161A3203DE37F5C708261D6B2F0D" xlink:type="arc" />
    <link:label id="lab_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember_12B2336AC8FC4B41382808261D6B3393_terseLabel_en-US" xlink:label="lab_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember_12B2336AC8FC4B41382808261D6B3393" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2015 Notes Payable to Silicon Valley Bank - Tranche Two</link:label>
    <link:label id="lab_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember_12B2336AC8FC4B41382808261D6B3393_label_en-US" xlink:label="lab_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember_12B2336AC8FC4B41382808261D6B3393" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Fifteen Notes Payable to Silicon Valley Bank - Tranche Two [Member]</link:label>
    <link:label id="lab_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember_12B2336AC8FC4B41382808261D6B3393_documentation_en-US" xlink:label="lab_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember_12B2336AC8FC4B41382808261D6B3393" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two Thousand Fifteen Notes Payable to Silicon Valley Bank - Tranche Two [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember" xlink:label="loc_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember_12B2336AC8FC4B41382808261D6B3393" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember_12B2336AC8FC4B41382808261D6B3393" xlink:to="lab_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember_12B2336AC8FC4B41382808261D6B3393" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_84A15B08B9F0E46508C608261D6BB31B_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_84A15B08B9F0E46508C608261D6BB31B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_84A15B08B9F0E46508C608261D6BB31B_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_84A15B08B9F0E46508C608261D6BB31B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_84A15B08B9F0E46508C608261D6BB31B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_84A15B08B9F0E46508C608261D6BB31B" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_84A15B08B9F0E46508C608261D6BB31B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_D0DF47515071A6BF91B808261D6BEA70_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_D0DF47515071A6BF91B808261D6BEA70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_D0DF47515071A6BF91B808261D6BEA70_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_D0DF47515071A6BF91B808261D6BEA70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_D0DF47515071A6BF91B808261D6BEA70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D0DF47515071A6BF91B808261D6BEA70" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_D0DF47515071A6BF91B808261D6BEA70" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_326C2B784ED0DEC0689408261D6BE628_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember_326C2B784ED0DEC0689408261D6BE628" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable to Banks</link:label>
    <link:label id="lab_us-gaap_NotesPayableToBanksMember_326C2B784ED0DEC0689408261D6BE628_label_en-US" xlink:label="lab_us-gaap_NotesPayableToBanksMember_326C2B784ED0DEC0689408261D6BE628" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable to Banks [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="loc_us-gaap_NotesPayableToBanksMember_326C2B784ED0DEC0689408261D6BE628" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableToBanksMember_326C2B784ED0DEC0689408261D6BE628" xlink:to="lab_us-gaap_NotesPayableToBanksMember_326C2B784ED0DEC0689408261D6BE628" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateAxis_15226D185A28F1B19E0108261D6BD0F5_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateAxis_15226D185A28F1B19E0108261D6BD0F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:label id="lab_us-gaap_VariableRateAxis_15226D185A28F1B19E0108261D6BD0F5_label_en-US" xlink:label="lab_us-gaap_VariableRateAxis_15226D185A28F1B19E0108261D6BD0F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_15226D185A28F1B19E0108261D6BD0F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateAxis_15226D185A28F1B19E0108261D6BD0F5" xlink:to="lab_us-gaap_VariableRateAxis_15226D185A28F1B19E0108261D6BD0F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableRateDomain_3E76A78333721ACDEA7B08261D6B14D4_terseLabel_en-US" xlink:label="lab_us-gaap_VariableRateDomain_3E76A78333721ACDEA7B08261D6B14D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:label id="lab_us-gaap_VariableRateDomain_3E76A78333721ACDEA7B08261D6B14D4_label_en-US" xlink:label="lab_us-gaap_VariableRateDomain_3E76A78333721ACDEA7B08261D6B14D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Rate [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_3E76A78333721ACDEA7B08261D6B14D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableRateDomain_3E76A78333721ACDEA7B08261D6B14D4" xlink:to="lab_us-gaap_VariableRateDomain_3E76A78333721ACDEA7B08261D6B14D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrimeRateMember_CBC5D906FA6C98B7E49008261D6B7E81_terseLabel_en-US" xlink:label="lab_us-gaap_PrimeRateMember_CBC5D906FA6C98B7E49008261D6B7E81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prime Rate</link:label>
    <link:label id="lab_us-gaap_PrimeRateMember_CBC5D906FA6C98B7E49008261D6B7E81_label_en-US" xlink:label="lab_us-gaap_PrimeRateMember_CBC5D906FA6C98B7E49008261D6B7E81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prime Rate [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_CBC5D906FA6C98B7E49008261D6B7E81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrimeRateMember_CBC5D906FA6C98B7E49008261D6B7E81" xlink:to="lab_us-gaap_PrimeRateMember_CBC5D906FA6C98B7E49008261D6B7E81" xlink:type="arc" />
    <link:label id="lab_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_A930E7833B34599B654908261D6B116C_terseLabel_en-US" xlink:label="lab_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_A930E7833B34599B654908261D6B116C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Detachable Warrants - Series B Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_A930E7833B34599B654908261D6B116C_label_en-US" xlink:label="lab_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_A930E7833B34599B654908261D6B116C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Detachable Warrants - Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_A930E7833B34599B654908261D6B116C_documentation_en-US" xlink:label="lab_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_A930E7833B34599B654908261D6B116C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Detachable Warrants - Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_A930E7833B34599B654908261D6B116C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_A930E7833B34599B654908261D6B116C" xlink:to="lab_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_A930E7833B34599B654908261D6B116C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_8708E1428542006F7F1908261D6C87B7_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis_8708E1428542006F7F1908261D6C87B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Technique [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueAxis_8708E1428542006F7F1908261D6C87B7_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueAxis_8708E1428542006F7F1908261D6C87B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Technique [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_8708E1428542006F7F1908261D6C87B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueAxis_8708E1428542006F7F1908261D6C87B7" xlink:to="lab_us-gaap_ValuationTechniqueAxis_8708E1428542006F7F1908261D6C87B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_1BAB5F5DC45E14AB1DCE08261D6CCA03_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain_1BAB5F5DC45E14AB1DCE08261D6CCA03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Technique [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationTechniqueDomain_1BAB5F5DC45E14AB1DCE08261D6CCA03_label_en-US" xlink:label="lab_us-gaap_ValuationTechniqueDomain_1BAB5F5DC45E14AB1DCE08261D6CCA03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Technique [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1BAB5F5DC45E14AB1DCE08261D6CCA03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1BAB5F5DC45E14AB1DCE08261D6CCA03" xlink:to="lab_us-gaap_ValuationTechniqueDomain_1BAB5F5DC45E14AB1DCE08261D6CCA03" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeApproachValuationTechniqueMember_A55813B573D56C4241C208261D6C3256_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeApproachValuationTechniqueMember_A55813B573D56C4241C208261D6C3256" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Approach Valuation Technique</link:label>
    <link:label id="lab_us-gaap_IncomeApproachValuationTechniqueMember_A55813B573D56C4241C208261D6C3256_label_en-US" xlink:label="lab_us-gaap_IncomeApproachValuationTechniqueMember_A55813B573D56C4241C208261D6C3256" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Approach Valuation Technique [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember_A55813B573D56C4241C208261D6C3256" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeApproachValuationTechniqueMember_A55813B573D56C4241C208261D6C3256" xlink:to="lab_us-gaap_IncomeApproachValuationTechniqueMember_A55813B573D56C4241C208261D6C3256" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareholdersEquityClassAxis_F845EA1776C9ACF591FB08261D6CB84C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareholdersEquityClassAxis_F845EA1776C9ACF591FB08261D6CB84C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders' Equity Class [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareholdersEquityClassAxis_F845EA1776C9ACF591FB08261D6CB84C_label_en-US" xlink:label="lab_us-gaap_ShareholdersEquityClassAxis_F845EA1776C9ACF591FB08261D6CB84C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shareholders' Equity Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareholdersEquityClassAxis" xlink:label="loc_us-gaap_ShareholdersEquityClassAxis_F845EA1776C9ACF591FB08261D6CB84C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareholdersEquityClassAxis_F845EA1776C9ACF591FB08261D6CB84C" xlink:to="lab_us-gaap_ShareholdersEquityClassAxis_F845EA1776C9ACF591FB08261D6CB84C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByShareholdersEquityClassDomain_53485463EFBE6BB4431F08261D6C5AFC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByShareholdersEquityClassDomain_53485463EFBE6BB4431F08261D6C5AFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value by Shareholders' Equity Class [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueByShareholdersEquityClassDomain_53485463EFBE6BB4431F08261D6C5AFC_label_en-US" xlink:label="lab_us-gaap_FairValueByShareholdersEquityClassDomain_53485463EFBE6BB4431F08261D6C5AFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value by Shareholders' Equity Class [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:label="loc_us-gaap_FairValueByShareholdersEquityClassDomain_53485463EFBE6BB4431F08261D6C5AFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByShareholdersEquityClassDomain_53485463EFBE6BB4431F08261D6C5AFC" xlink:to="lab_us-gaap_FairValueByShareholdersEquityClassDomain_53485463EFBE6BB4431F08261D6C5AFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashMember_5AC07E1CDCA356845A0F08261D6C2D71_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashMember_5AC07E1CDCA356845A0F08261D6C2D71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants Not Settleable in Cash</link:label>
    <link:label id="lab_us-gaap_WarrantsNotSettleableInCashMember_5AC07E1CDCA356845A0F08261D6C2D71_label_en-US" xlink:label="lab_us-gaap_WarrantsNotSettleableInCashMember_5AC07E1CDCA356845A0F08261D6C2D71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Not Settleable in Cash [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashMember" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashMember_5AC07E1CDCA356845A0F08261D6C2D71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsNotSettleableInCashMember_5AC07E1CDCA356845A0F08261D6C2D71" xlink:to="lab_us-gaap_WarrantsNotSettleableInCashMember_5AC07E1CDCA356845A0F08261D6C2D71" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="lab_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_9A110D1A5625B8600BC808261D6CA063_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_9A110D1A5625B8600BC808261D6CA063" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_9A110D1A5625B8600BC808261D6CA063_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_9A110D1A5625B8600BC808261D6CA063" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9A110D1A5625B8600BC808261D6CA063" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_9A110D1A5625B8600BC808261D6CA063" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_9A110D1A5625B8600BC808261D6CA063" xlink:type="arc" />
    <link:label id="lab_mgen_DebtInstrumentNumberOfTranches_BB2BEE068A051AF6DE2E08261D6C75E0_terseLabel_en-US" xlink:label="lab_mgen_DebtInstrumentNumberOfTranches_BB2BEE068A051AF6DE2E08261D6C75E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_mgen_DebtInstrumentNumberOfTranches_BB2BEE068A051AF6DE2E08261D6C75E0_label_en-US" xlink:label="lab_mgen_DebtInstrumentNumberOfTranches_BB2BEE068A051AF6DE2E08261D6C75E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Tranches</link:label>
    <link:label id="lab_mgen_DebtInstrumentNumberOfTranches_BB2BEE068A051AF6DE2E08261D6C75E0_documentation_en-US" xlink:label="lab_mgen_DebtInstrumentNumberOfTranches_BB2BEE068A051AF6DE2E08261D6C75E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number of Tranches</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DebtInstrumentNumberOfTranches" xlink:label="loc_mgen_DebtInstrumentNumberOfTranches_BB2BEE068A051AF6DE2E08261D6C75E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_DebtInstrumentNumberOfTranches_BB2BEE068A051AF6DE2E08261D6C75E0" xlink:to="lab_mgen_DebtInstrumentNumberOfTranches_BB2BEE068A051AF6DE2E08261D6C75E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTerm_3992617184559D9100BF08261D6C19D1_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_3992617184559D9100BF08261D6C19D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repayment period</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTerm_3992617184559D9100BF08261D6C19D1_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTerm_3992617184559D9100BF08261D6C19D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_3992617184559D9100BF08261D6C19D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTerm_3992617184559D9100BF08261D6C19D1" xlink:to="lab_us-gaap_DebtInstrumentTerm_3992617184559D9100BF08261D6C19D1" xlink:type="arc" />
    <link:label id="lab_mgen_DebtInstrumentTermInterestOnlyPayments_D0D009AEABAE4E6F457108261D6D611A_terseLabel_en-US" xlink:label="lab_mgen_DebtInstrumentTermInterestOnlyPayments_D0D009AEABAE4E6F457108261D6D611A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest-only period</link:label>
    <link:label id="lab_mgen_DebtInstrumentTermInterestOnlyPayments_D0D009AEABAE4E6F457108261D6D611A_label_en-US" xlink:label="lab_mgen_DebtInstrumentTermInterestOnlyPayments_D0D009AEABAE4E6F457108261D6D611A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term, Interest Only Payments</link:label>
    <link:label id="lab_mgen_DebtInstrumentTermInterestOnlyPayments_D0D009AEABAE4E6F457108261D6D611A_documentation_en-US" xlink:label="lab_mgen_DebtInstrumentTermInterestOnlyPayments_D0D009AEABAE4E6F457108261D6D611A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Term, Interest Only Payments</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DebtInstrumentTermInterestOnlyPayments" xlink:label="loc_mgen_DebtInstrumentTermInterestOnlyPayments_D0D009AEABAE4E6F457108261D6D611A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_DebtInstrumentTermInterestOnlyPayments_D0D009AEABAE4E6F457108261D6D611A" xlink:to="lab_mgen_DebtInstrumentTermInterestOnlyPayments_D0D009AEABAE4E6F457108261D6D611A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9AD282A911D4943726BB08261D6D19BD_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9AD282A911D4943726BB08261D6D19BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9AD282A911D4943726BB08261D6D19BD_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9AD282A911D4943726BB08261D6D19BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Basis Spread on Variable Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9AD282A911D4943726BB08261D6D19BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9AD282A911D4943726BB08261D6D19BD" xlink:to="lab_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9AD282A911D4943726BB08261D6D19BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_698414A7296D49254A9608261D6DA029_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_698414A7296D49254A9608261D6DA029" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate at period end</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_698414A7296D49254A9608261D6DA029_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_698414A7296D49254A9608261D6DA029" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Interest Rate at Period End</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_698414A7296D49254A9608261D6DA029" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_698414A7296D49254A9608261D6DA029" xlink:to="lab_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_698414A7296D49254A9608261D6DA029" xlink:type="arc" />
    <link:label id="lab_mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed_5B030FD9FF0BC860A8FC08261D6DFAA5_terseLabel_en-US" xlink:label="lab_mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed_5B030FD9FF0BC860A8FC08261D6DFAA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Final payment fee percent</link:label>
    <link:label id="lab_mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed_5B030FD9FF0BC860A8FC08261D6DFAA5_label_en-US" xlink:label="lab_mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed_5B030FD9FF0BC860A8FC08261D6DFAA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Final Payment Fee, Percentage Of Amount Borrowed</link:label>
    <link:label id="lab_mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed_5B030FD9FF0BC860A8FC08261D6DFAA5_documentation_en-US" xlink:label="lab_mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed_5B030FD9FF0BC860A8FC08261D6DFAA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Final Payment Fee, Percentage of Amount Borrowed</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed" xlink:label="loc_mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed_5B030FD9FF0BC860A8FC08261D6DFAA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed_5B030FD9FF0BC860A8FC08261D6DFAA5" xlink:to="lab_mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed_5B030FD9FF0BC860A8FC08261D6DFAA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7B4E918646E4C05B71B308261D6D440F_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7B4E918646E4C05B71B308261D6D440F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares eligible for purchase under warrants (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7B4E918646E4C05B71B308261D6D440F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7B4E918646E4C05B71B308261D6D440F" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7B4E918646E4C05B71B308261D6D440F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DA498C337FC8AF57BF0E08261D6DB1DF_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DA498C337FC8AF57BF0E08261D6DB1DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise price (in usd per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DA498C337FC8AF57BF0E08261D6DB1DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DA498C337FC8AF57BF0E08261D6DB1DF" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DA498C337FC8AF57BF0E08261D6DB1DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_F89A798BD3C24BD0B17408261D6DCC38_terseLabel_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_F89A798BD3C24BD0B17408261D6DCC38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of warrants</link:label>
    <link:label id="lab_us-gaap_WarrantsAndRightsOutstanding_F89A798BD3C24BD0B17408261D6DCC38_label_en-US" xlink:label="lab_us-gaap_WarrantsAndRightsOutstanding_F89A798BD3C24BD0B17408261D6DCC38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_F89A798BD3C24BD0B17408261D6DCC38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WarrantsAndRightsOutstanding_F89A798BD3C24BD0B17408261D6DCC38" xlink:to="lab_us-gaap_WarrantsAndRightsOutstanding_F89A798BD3C24BD0B17408261D6DCC38" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_AA59C2E98927FAF5A96B08261D6DADAA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_AA59C2E98927FAF5A96B08261D6DADAA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term</link:label>
    <link:label id="lab_us-gaap_FairValueAssumptionsExpectedTerm_AA59C2E98927FAF5A96B08261D6DADAA_label_en-US" xlink:label="lab_us-gaap_FairValueAssumptionsExpectedTerm_AA59C2E98927FAF5A96B08261D6DADAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_AA59C2E98927FAF5A96B08261D6DADAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssumptionsExpectedTerm_AA59C2E98927FAF5A96B08261D6DADAA" xlink:to="lab_us-gaap_FairValueAssumptionsExpectedTerm_AA59C2E98927FAF5A96B08261D6DADAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_0B56B669170EBCD61D4F08261D6D5E51_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_0B56B669170EBCD61D4F08261D6D5E51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discount rate</link:label>
    <link:label id="lab_us-gaap_FairValueInputsDiscountRate_0B56B669170EBCD61D4F08261D6D5E51_label_en-US" xlink:label="lab_us-gaap_FairValueInputsDiscountRate_0B56B669170EBCD61D4F08261D6D5E51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Discount Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_0B56B669170EBCD61D4F08261D6D5E51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsDiscountRate_0B56B669170EBCD61D4F08261D6D5E51" xlink:to="lab_us-gaap_FairValueInputsDiscountRate_0B56B669170EBCD61D4F08261D6D5E51" xlink:type="arc" />
    <link:label id="lab_mgen_FairValueInputsProbabilityofExercise_A12D0C6C653A6955ADF308261D6DA25D_terseLabel_en-US" xlink:label="lab_mgen_FairValueInputsProbabilityofExercise_A12D0C6C653A6955ADF308261D6DA25D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Probability of exercise</link:label>
    <link:label id="lab_mgen_FairValueInputsProbabilityofExercise_A12D0C6C653A6955ADF308261D6DA25D_label_en-US" xlink:label="lab_mgen_FairValueInputsProbabilityofExercise_A12D0C6C653A6955ADF308261D6DA25D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Probability of Exercise</link:label>
    <link:label id="lab_mgen_FairValueInputsProbabilityofExercise_A12D0C6C653A6955ADF308261D6DA25D_documentation_en-US" xlink:label="lab_mgen_FairValueInputsProbabilityofExercise_A12D0C6C653A6955ADF308261D6DA25D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fair Value Inputs, Probability of Exercise</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_FairValueInputsProbabilityofExercise" xlink:label="loc_mgen_FairValueInputsProbabilityofExercise_A12D0C6C653A6955ADF308261D6DA25D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_FairValueInputsProbabilityofExercise_A12D0C6C653A6955ADF308261D6DA25D" xlink:to="lab_mgen_FairValueInputsProbabilityofExercise_A12D0C6C653A6955ADF308261D6DA25D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_A71FF8ED5E39E7890B9608261E19BBD2_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract_A71FF8ED5E39E7890B9608261E19BBD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_A71FF8ED5E39E7890B9608261E19BBD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_A71FF8ED5E39E7890B9608261E19BBD2" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract_A71FF8ED5E39E7890B9608261E19BBD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0AD4CC5E833CFC1BF0D708261E1AA5F9_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0AD4CC5E833CFC1BF0D708261E1AA5F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0AD4CC5E833CFC1BF0D708261E1AA5F9_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0AD4CC5E833CFC1BF0D708261E1AA5F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0AD4CC5E833CFC1BF0D708261E1AA5F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0AD4CC5E833CFC1BF0D708261E1AA5F9" xlink:to="lab_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0AD4CC5E833CFC1BF0D708261E1AA5F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_606CD80969991BB82CBF08261D61483B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_606CD80969991BB82CBF08261D61483B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_606CD80969991BB82CBF08261D61483B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_606CD80969991BB82CBF08261D61483B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_606CD80969991BB82CBF08261D61483B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_DF3EC8149CB752DD8A6A08261D61B312_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_DF3EC8149CB752DD8A6A08261D61B312" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_DF3EC8149CB752DD8A6A08261D61B312_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_DF3EC8149CB752DD8A6A08261D61B312" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_DF3EC8149CB752DD8A6A08261D61B312" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_DF3EC8149CB752DD8A6A08261D61B312" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_DF3EC8149CB752DD8A6A08261D61B312" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B761E19B7377BC3574A808261DBDD99C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B761E19B7377BC3574A808261DBDD99C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B761E19B7377BC3574A808261DBDD99C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B761E19B7377BC3574A808261DBDD99C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B761E19B7377BC3574A808261DBDD99C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B761E19B7377BC3574A808261DBDD99C" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B761E19B7377BC3574A808261DBDD99C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00DCD77129909619F33108261DBDDA4C_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00DCD77129909619F33108261DBDDA4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00DCD77129909619F33108261DBDDA4C_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00DCD77129909619F33108261DBDDA4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00DCD77129909619F33108261DBDDA4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00DCD77129909619F33108261DBDDA4C" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00DCD77129909619F33108261DBDDA4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquipmentMember_612BE01ADBF8EBAC452E08261DBD2CEC_terseLabel_en-US" xlink:label="lab_us-gaap_EquipmentMember_612BE01ADBF8EBAC452E08261DBD2CEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lab equipment</link:label>
    <link:label id="lab_us-gaap_EquipmentMember_612BE01ADBF8EBAC452E08261DBD2CEC_label_en-US" xlink:label="lab_us-gaap_EquipmentMember_612BE01ADBF8EBAC452E08261DBD2CEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_612BE01ADBF8EBAC452E08261DBD2CEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquipmentMember_612BE01ADBF8EBAC452E08261DBD2CEC" xlink:to="lab_us-gaap_EquipmentMember_612BE01ADBF8EBAC452E08261DBD2CEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_A0DB70408C4FEEDBC53208261DBDB091_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_A0DB70408C4FEEDBC53208261DBDB091" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture and fixtures</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_A0DB70408C4FEEDBC53208261DBDB091_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_A0DB70408C4FEEDBC53208261DBDB091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_A0DB70408C4FEEDBC53208261DBDB091" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_A0DB70408C4FEEDBC53208261DBDB091" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_A0DB70408C4FEEDBC53208261DBDB091" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComputerEquipmentMember_2FCD15F386F00F45DB9F08261DBD0036_terseLabel_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_2FCD15F386F00F45DB9F08261DBD0036" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Computer hardware and software</link:label>
    <link:label id="lab_us-gaap_ComputerEquipmentMember_2FCD15F386F00F45DB9F08261DBD0036_label_en-US" xlink:label="lab_us-gaap_ComputerEquipmentMember_2FCD15F386F00F45DB9F08261DBD0036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Computer Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_2FCD15F386F00F45DB9F08261DBD0036" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComputerEquipmentMember_2FCD15F386F00F45DB9F08261DBD0036" xlink:to="lab_us-gaap_ComputerEquipmentMember_2FCD15F386F00F45DB9F08261DBD0036" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_DD3CFEC2C874EEC8ADE008261DBE1818_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_DD3CFEC2C874EEC8ADE008261DBE1818" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_DD3CFEC2C874EEC8ADE008261DBE1818_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember_DD3CFEC2C874EEC8ADE008261DBE1818" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_DD3CFEC2C874EEC8ADE008261DBE1818" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember_DD3CFEC2C874EEC8ADE008261DBE1818" xlink:to="lab_us-gaap_LeaseholdImprovementsMember_DD3CFEC2C874EEC8ADE008261DBE1818" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_CE4A900551BC88A0E07708261DBE44E8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_CE4A900551BC88A0E07708261DBE44E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_CE4A900551BC88A0E07708261DBE44E8_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_CE4A900551BC88A0E07708261DBE44E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CE4A900551BC88A0E07708261DBE44E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CE4A900551BC88A0E07708261DBE44E8" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_CE4A900551BC88A0E07708261DBE44E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_2E19ADB0FA7897FF32AF08261DBE7A3A_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_2E19ADB0FA7897FF32AF08261DBE7A3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_2E19ADB0FA7897FF32AF08261DBE7A3A_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_2E19ADB0FA7897FF32AF08261DBE7A3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2E19ADB0FA7897FF32AF08261DBE7A3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_2E19ADB0FA7897FF32AF08261DBE7A3A" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_2E19ADB0FA7897FF32AF08261DBE7A3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1E66EA2DA3A3ABE1917B08261DBEE1AE_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1E66EA2DA3A3ABE1917B08261DBEE1AE" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1E66EA2DA3A3ABE1917B08261DBEE1AE_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1E66EA2DA3A3ABE1917B08261DBEE1AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1E66EA2DA3A3ABE1917B08261DBEE1AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1E66EA2DA3A3ABE1917B08261DBEE1AE" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1E66EA2DA3A3ABE1917B08261DBEE1AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_73285EB30F69B7F4B48308261DBE22D3_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_73285EB30F69B7F4B48308261DBE22D3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_73285EB30F69B7F4B48308261DBE22D3_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_73285EB30F69B7F4B48308261DBE22D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_73285EB30F69B7F4B48308261DBE22D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_73285EB30F69B7F4B48308261DBE22D3" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_73285EB30F69B7F4B48308261DBE22D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E9251B75A35D50919C4808261DAF465C_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E9251B75A35D50919C4808261DAF465C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Warrants</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E9251B75A35D50919C4808261DAF465C_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E9251B75A35D50919C4808261DAF465C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E9251B75A35D50919C4808261DAF465C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E9251B75A35D50919C4808261DAF465C" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E9251B75A35D50919C4808261DAF465C" xlink:type="arc" />
    <link:label id="lab_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B_terseLabel_en-US" xlink:label="lab_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B_label_en-US" xlink:label="lab_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:label id="lab_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B_documentation_en-US" xlink:label="lab_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Table]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommitmentsandContingenciesTable" xlink:label="loc_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:to="lab_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CounterpartyNameAxis_4A9CF3C05D85232B746A782AAB1CDABA_terseLabel_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_4A9CF3C05D85232B746A782AAB1CDABA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_us-gaap_CounterpartyNameAxis_4A9CF3C05D85232B746A782AAB1CDABA_label_en-US" xlink:label="lab_us-gaap_CounterpartyNameAxis_4A9CF3C05D85232B746A782AAB1CDABA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_4A9CF3C05D85232B746A782AAB1CDABA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CounterpartyNameAxis_4A9CF3C05D85232B746A782AAB1CDABA" xlink:to="lab_us-gaap_CounterpartyNameAxis_4A9CF3C05D85232B746A782AAB1CDABA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3_terseLabel_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3_label_en-US" xlink:label="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3" xlink:to="lab_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3" xlink:type="arc" />
    <link:label id="lab_mgen_UniversityofTexasMember_5B31FDF0FDE5C451B9BE782AAB1CB43A_terseLabel_en-US" xlink:label="lab_mgen_UniversityofTexasMember_5B31FDF0FDE5C451B9BE782AAB1CB43A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">University of Texas</link:label>
    <link:label id="lab_mgen_UniversityofTexasMember_5B31FDF0FDE5C451B9BE782AAB1CB43A_label_en-US" xlink:label="lab_mgen_UniversityofTexasMember_5B31FDF0FDE5C451B9BE782AAB1CB43A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">University of Texas [Member]</link:label>
    <link:label id="lab_mgen_UniversityofTexasMember_5B31FDF0FDE5C451B9BE782AAB1CB43A_documentation_en-US" xlink:label="lab_mgen_UniversityofTexasMember_5B31FDF0FDE5C451B9BE782AAB1CB43A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">University of Texas [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_UniversityofTexasMember" xlink:label="loc_mgen_UniversityofTexasMember_5B31FDF0FDE5C451B9BE782AAB1CB43A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_UniversityofTexasMember_5B31FDF0FDE5C451B9BE782AAB1CB43A" xlink:to="lab_mgen_UniversityofTexasMember_5B31FDF0FDE5C451B9BE782AAB1CB43A" xlink:type="arc" />
    <link:label id="lab_mgen_RocheInnovationCenterCopenhagenASMember_B973187D9F1DE50745D8782AAB1C1EED_terseLabel_en-US" xlink:label="lab_mgen_RocheInnovationCenterCopenhagenASMember_B973187D9F1DE50745D8782AAB1C1EED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RICC</link:label>
    <link:label id="lab_mgen_RocheInnovationCenterCopenhagenASMember_B973187D9F1DE50745D8782AAB1C1EED_label_en-US" xlink:label="lab_mgen_RocheInnovationCenterCopenhagenASMember_B973187D9F1DE50745D8782AAB1C1EED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Roche Innovation Center Copenhagen A/S [Member]</link:label>
    <link:label id="lab_mgen_RocheInnovationCenterCopenhagenASMember_B973187D9F1DE50745D8782AAB1C1EED_documentation_en-US" xlink:label="lab_mgen_RocheInnovationCenterCopenhagenASMember_B973187D9F1DE50745D8782AAB1C1EED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Roche Innovation Center Copenhagen A/S [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_RocheInnovationCenterCopenhagenASMember" xlink:label="loc_mgen_RocheInnovationCenterCopenhagenASMember_B973187D9F1DE50745D8782AAB1C1EED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_RocheInnovationCenterCopenhagenASMember_B973187D9F1DE50745D8782AAB1C1EED" xlink:to="lab_mgen_RocheInnovationCenterCopenhagenASMember_B973187D9F1DE50745D8782AAB1C1EED" xlink:type="arc" />
    <link:label id="lab_mgen_T2cureGmbHMember_D215C4E273AC4182CC65782AAB1C31ED_terseLabel_en-US" xlink:label="lab_mgen_T2cureGmbHMember_D215C4E273AC4182CC65782AAB1C31ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">t2cure</link:label>
    <link:label id="lab_mgen_T2cureGmbHMember_D215C4E273AC4182CC65782AAB1C31ED_label_en-US" xlink:label="lab_mgen_T2cureGmbHMember_D215C4E273AC4182CC65782AAB1C31ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">t2cure GmbH [Member]</link:label>
    <link:label id="lab_mgen_T2cureGmbHMember_D215C4E273AC4182CC65782AAB1C31ED_documentation_en-US" xlink:label="lab_mgen_T2cureGmbHMember_D215C4E273AC4182CC65782AAB1C31ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">t2cure GmbH [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_T2cureGmbHMember" xlink:label="loc_mgen_T2cureGmbHMember_D215C4E273AC4182CC65782AAB1C31ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_T2cureGmbHMember_D215C4E273AC4182CC65782AAB1C31ED" xlink:to="lab_mgen_T2cureGmbHMember_D215C4E273AC4182CC65782AAB1C31ED" xlink:type="arc" />
    <link:label id="lab_mgen_TheBrighamandWomensHospitalMember_E22A44774039695FB394782AAB1C9220_terseLabel_en-US" xlink:label="lab_mgen_TheBrighamandWomensHospitalMember_E22A44774039695FB394782AAB1C9220" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BWH</link:label>
    <link:label id="lab_mgen_TheBrighamandWomensHospitalMember_E22A44774039695FB394782AAB1C9220_label_en-US" xlink:label="lab_mgen_TheBrighamandWomensHospitalMember_E22A44774039695FB394782AAB1C9220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The Brigham and Womens Hospital [Member]</link:label>
    <link:label id="lab_mgen_TheBrighamandWomensHospitalMember_E22A44774039695FB394782AAB1C9220_documentation_en-US" xlink:label="lab_mgen_TheBrighamandWomensHospitalMember_E22A44774039695FB394782AAB1C9220" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The Brigham and Womens Hospital [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_TheBrighamandWomensHospitalMember" xlink:label="loc_mgen_TheBrighamandWomensHospitalMember_E22A44774039695FB394782AAB1C9220" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_TheBrighamandWomensHospitalMember_E22A44774039695FB394782AAB1C9220" xlink:to="lab_mgen_TheBrighamandWomensHospitalMember_E22A44774039695FB394782AAB1C9220" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementGeographicalAxis_D7779E40A1F6624103C5782AAB1DF009_terseLabel_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_D7779E40A1F6624103C5782AAB1DF009" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementGeographicalAxis_D7779E40A1F6624103C5782AAB1DF009_label_en-US" xlink:label="lab_us-gaap_StatementGeographicalAxis_D7779E40A1F6624103C5782AAB1DF009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_D7779E40A1F6624103C5782AAB1DF009" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementGeographicalAxis_D7779E40A1F6624103C5782AAB1DF009" xlink:to="lab_us-gaap_StatementGeographicalAxis_D7779E40A1F6624103C5782AAB1DF009" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD_label_en-US" xlink:label="lab_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD" xlink:to="lab_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD" xlink:type="arc" />
    <link:label id="lab_country_US_78BC908CD47ADCD175B5782AAB1DE6D7_terseLabel_en-US" xlink:label="lab_country_US_78BC908CD47ADCD175B5782AAB1DE6D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_country_US_78BC908CD47ADCD175B5782AAB1DE6D7_label_en-US" xlink:label="lab_country_US_78BC908CD47ADCD175B5782AAB1DE6D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_78BC908CD47ADCD175B5782AAB1DE6D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_78BC908CD47ADCD175B5782AAB1DE6D7" xlink:to="lab_country_US_78BC908CD47ADCD175B5782AAB1DE6D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonUsMember_E9A6FCA94382DB2286D7782AAB1D208D_terseLabel_en-US" xlink:label="lab_us-gaap_NonUsMember_E9A6FCA94382DB2286D7782AAB1D208D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Regions</link:label>
    <link:label id="lab_us-gaap_NonUsMember_E9A6FCA94382DB2286D7782AAB1D208D_label_en-US" xlink:label="lab_us-gaap_NonUsMember_E9A6FCA94382DB2286D7782AAB1D208D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_E9A6FCA94382DB2286D7782AAB1D208D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonUsMember_E9A6FCA94382DB2286D7782AAB1D208D" xlink:to="lab_us-gaap_NonUsMember_E9A6FCA94382DB2286D7782AAB1D208D" xlink:type="arc" />
    <link:label id="lab_mgen_EuropeanUnionorJapanMember_B39E759A19FCE2F02697782AAB1D2A0D_terseLabel_en-US" xlink:label="lab_mgen_EuropeanUnionorJapanMember_B39E759A19FCE2F02697782AAB1D2A0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">European Union or Japan</link:label>
    <link:label id="lab_mgen_EuropeanUnionorJapanMember_B39E759A19FCE2F02697782AAB1D2A0D_label_en-US" xlink:label="lab_mgen_EuropeanUnionorJapanMember_B39E759A19FCE2F02697782AAB1D2A0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">European Union or Japan [Member]</link:label>
    <link:label id="lab_mgen_EuropeanUnionorJapanMember_B39E759A19FCE2F02697782AAB1D2A0D_documentation_en-US" xlink:label="lab_mgen_EuropeanUnionorJapanMember_B39E759A19FCE2F02697782AAB1D2A0D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">European Union or Japan [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_EuropeanUnionorJapanMember" xlink:label="loc_mgen_EuropeanUnionorJapanMember_B39E759A19FCE2F02697782AAB1D2A0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_EuropeanUnionorJapanMember_B39E759A19FCE2F02697782AAB1D2A0D" xlink:to="lab_mgen_EuropeanUnionorJapanMember_B39E759A19FCE2F02697782AAB1D2A0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MajorCustomersAxis_471E90F8FB701C4BA77C782AAB1DD187_terseLabel_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_471E90F8FB701C4BA77C782AAB1DD187" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_us-gaap_MajorCustomersAxis_471E90F8FB701C4BA77C782AAB1DD187_label_en-US" xlink:label="lab_us-gaap_MajorCustomersAxis_471E90F8FB701C4BA77C782AAB1DD187" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_471E90F8FB701C4BA77C782AAB1DD187" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MajorCustomersAxis_471E90F8FB701C4BA77C782AAB1DD187" xlink:to="lab_us-gaap_MajorCustomersAxis_471E90F8FB701C4BA77C782AAB1DD187" xlink:type="arc" />
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_2BE634C37EFA81D2E194782AAB1DD2EA_terseLabel_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_2BE634C37EFA81D2E194782AAB1DD2EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_us-gaap_NameOfMajorCustomerDomain_2BE634C37EFA81D2E194782AAB1DD2EA_label_en-US" xlink:label="lab_us-gaap_NameOfMajorCustomerDomain_2BE634C37EFA81D2E194782AAB1DD2EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_2BE634C37EFA81D2E194782AAB1DD2EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_2BE634C37EFA81D2E194782AAB1DD2EA" xlink:to="lab_us-gaap_NameOfMajorCustomerDomain_2BE634C37EFA81D2E194782AAB1DD2EA" xlink:type="arc" />
    <link:label id="lab_mgen_YaleUniversityMember_78BE76A8E3CA3C1FA442782AAB1EC380_terseLabel_en-US" xlink:label="lab_mgen_YaleUniversityMember_78BE76A8E3CA3C1FA442782AAB1EC380" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Yale University</link:label>
    <link:label id="lab_mgen_YaleUniversityMember_78BE76A8E3CA3C1FA442782AAB1EC380_label_en-US" xlink:label="lab_mgen_YaleUniversityMember_78BE76A8E3CA3C1FA442782AAB1EC380" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Yale University [Member]</link:label>
    <link:label id="lab_mgen_YaleUniversityMember_78BE76A8E3CA3C1FA442782AAB1EC380_documentation_en-US" xlink:label="lab_mgen_YaleUniversityMember_78BE76A8E3CA3C1FA442782AAB1EC380" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Yale University [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_YaleUniversityMember" xlink:label="loc_mgen_YaleUniversityMember_78BE76A8E3CA3C1FA442782AAB1EC380" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_YaleUniversityMember_78BE76A8E3CA3C1FA442782AAB1EC380" xlink:to="lab_mgen_YaleUniversityMember_78BE76A8E3CA3C1FA442782AAB1EC380" xlink:type="arc" />
    <link:label id="lab_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434_terseLabel_en-US" xlink:label="lab_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434_label_en-US" xlink:label="lab_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies [Line Items]</link:label>
    <link:label id="lab_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434_documentation_en-US" xlink:label="lab_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Commitments and Contingencies [Table]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommitmentsandContingenciesLineItems" xlink:label="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="lab_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:type="arc" />
    <link:label id="lab_mgen_CollaborativeArrangementNumberofArrangements_9C2DFF2939A98E1D445D782AAB1E5B18_terseLabel_en-US" xlink:label="lab_mgen_CollaborativeArrangementNumberofArrangements_9C2DFF2939A98E1D445D782AAB1E5B18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of arrangements</link:label>
    <link:label id="lab_mgen_CollaborativeArrangementNumberofArrangements_9C2DFF2939A98E1D445D782AAB1E5B18_label_en-US" xlink:label="lab_mgen_CollaborativeArrangementNumberofArrangements_9C2DFF2939A98E1D445D782AAB1E5B18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Number of Arrangements</link:label>
    <link:label id="lab_mgen_CollaborativeArrangementNumberofArrangements_9C2DFF2939A98E1D445D782AAB1E5B18_documentation_en-US" xlink:label="lab_mgen_CollaborativeArrangementNumberofArrangements_9C2DFF2939A98E1D445D782AAB1E5B18" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Number of Arrangements</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborativeArrangementNumberofArrangements" xlink:label="loc_mgen_CollaborativeArrangementNumberofArrangements_9C2DFF2939A98E1D445D782AAB1E5B18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_CollaborativeArrangementNumberofArrangements_9C2DFF2939A98E1D445D782AAB1E5B18" xlink:to="lab_mgen_CollaborativeArrangementNumberofArrangements_9C2DFF2939A98E1D445D782AAB1E5B18" xlink:type="arc" />
    <link:label id="lab_mgen_LicenseCostsUpfrontLicensingFeePerLicense_856378C7C1F8E9D4399E782AAB1E88AF_terseLabel_en-US" xlink:label="lab_mgen_LicenseCostsUpfrontLicensingFeePerLicense_856378C7C1F8E9D4399E782AAB1E88AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonrefundable upfront license documentation fee</link:label>
    <link:label id="lab_mgen_LicenseCostsUpfrontLicensingFeePerLicense_856378C7C1F8E9D4399E782AAB1E88AF_label_en-US" xlink:label="lab_mgen_LicenseCostsUpfrontLicensingFeePerLicense_856378C7C1F8E9D4399E782AAB1E88AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Costs, Upfront Licensing Fee Per License</link:label>
    <link:label id="lab_mgen_LicenseCostsUpfrontLicensingFeePerLicense_856378C7C1F8E9D4399E782AAB1E88AF_documentation_en-US" xlink:label="lab_mgen_LicenseCostsUpfrontLicensingFeePerLicense_856378C7C1F8E9D4399E782AAB1E88AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Costs, Upfront Licensing Fee per License</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostsUpfrontLicensingFeePerLicense" xlink:label="loc_mgen_LicenseCostsUpfrontLicensingFeePerLicense_856378C7C1F8E9D4399E782AAB1E88AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_LicenseCostsUpfrontLicensingFeePerLicense_856378C7C1F8E9D4399E782AAB1E88AF" xlink:to="lab_mgen_LicenseCostsUpfrontLicensingFeePerLicense_856378C7C1F8E9D4399E782AAB1E88AF" xlink:type="arc" />
    <link:label id="lab_mgen_LicenseCostAnnualMaintenanceFeePerLicense_5758EC4F68B94C76E744782AAB1E20C9_terseLabel_en-US" xlink:label="lab_mgen_LicenseCostAnnualMaintenanceFeePerLicense_5758EC4F68B94C76E744782AAB1E20C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual license maintenance fee</link:label>
    <link:label id="lab_mgen_LicenseCostAnnualMaintenanceFeePerLicense_5758EC4F68B94C76E744782AAB1E20C9_label_en-US" xlink:label="lab_mgen_LicenseCostAnnualMaintenanceFeePerLicense_5758EC4F68B94C76E744782AAB1E20C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Cost, Annual Maintenance Fee Per License</link:label>
    <link:label id="lab_mgen_LicenseCostAnnualMaintenanceFeePerLicense_5758EC4F68B94C76E744782AAB1E20C9_documentation_en-US" xlink:label="lab_mgen_LicenseCostAnnualMaintenanceFeePerLicense_5758EC4F68B94C76E744782AAB1E20C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Cost, Annual Maintenance Fee per License</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostAnnualMaintenanceFeePerLicense" xlink:label="loc_mgen_LicenseCostAnnualMaintenanceFeePerLicense_5758EC4F68B94C76E744782AAB1E20C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_LicenseCostAnnualMaintenanceFeePerLicense_5758EC4F68B94C76E744782AAB1E20C9" xlink:to="lab_mgen_LicenseCostAnnualMaintenanceFeePerLicense_5758EC4F68B94C76E744782AAB1E20C9" xlink:type="arc" />
    <link:label id="lab_mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials_5894DD97A3FDC9CEFE76782AAB1E3B2C_terseLabel_en-US" xlink:label="lab_mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials_5894DD97A3FDC9CEFE76782AAB1E3B2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payment for initiation of defined clinical trials</link:label>
    <link:label id="lab_mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials_5894DD97A3FDC9CEFE76782AAB1E3B2C_label_en-US" xlink:label="lab_mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials_5894DD97A3FDC9CEFE76782AAB1E3B2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Costs, Potential Milestone Payment, Initiation Of Defined Clinical Trials</link:label>
    <link:label id="lab_mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials_5894DD97A3FDC9CEFE76782AAB1E3B2C_documentation_en-US" xlink:label="lab_mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials_5894DD97A3FDC9CEFE76782AAB1E3B2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Costs, Potential Milestone Payment, Initiation of Defined Clinical Trials</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials" xlink:label="loc_mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials_5894DD97A3FDC9CEFE76782AAB1E3B2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials_5894DD97A3FDC9CEFE76782AAB1E3B2C" xlink:to="lab_mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials_5894DD97A3FDC9CEFE76782AAB1E3B2C" xlink:type="arc" />
    <link:label id="lab_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval_CBFA3FA31E8E83E4867A782AAB1E443A_terseLabel_en-US" xlink:label="lab_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval_CBFA3FA31E8E83E4867A782AAB1E443A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payment for regulatory approval</link:label>
    <link:label id="lab_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval_CBFA3FA31E8E83E4867A782AAB1E443A_label_en-US" xlink:label="lab_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval_CBFA3FA31E8E83E4867A782AAB1E443A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Cost, Potential Milestone Payment, Regulatory Approval</link:label>
    <link:label id="lab_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval_CBFA3FA31E8E83E4867A782AAB1E443A_documentation_en-US" xlink:label="lab_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval_CBFA3FA31E8E83E4867A782AAB1E443A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Cost, Potential Milestone Payment, Regulatory Approval</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval" xlink:label="loc_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval_CBFA3FA31E8E83E4867A782AAB1E443A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval_CBFA3FA31E8E83E4867A782AAB1E443A" xlink:to="lab_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval_CBFA3FA31E8E83E4867A782AAB1E443A" xlink:type="arc" />
    <link:label id="lab_mgen_PaymentsForLicensingAgreement_F4B3B89C1BC6534F1837782AAB1EB250_terseLabel_en-US" xlink:label="lab_mgen_PaymentsForLicensingAgreement_F4B3B89C1BC6534F1837782AAB1EB250" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for the grant of license and option</link:label>
    <link:label id="lab_mgen_PaymentsForLicensingAgreement_F4B3B89C1BC6534F1837782AAB1EB250_label_en-US" xlink:label="lab_mgen_PaymentsForLicensingAgreement_F4B3B89C1BC6534F1837782AAB1EB250" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Licensing Agreement</link:label>
    <link:label id="lab_mgen_PaymentsForLicensingAgreement_F4B3B89C1BC6534F1837782AAB1EB250_documentation_en-US" xlink:label="lab_mgen_PaymentsForLicensingAgreement_F4B3B89C1BC6534F1837782AAB1EB250" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for Licensing Agreement</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PaymentsForLicensingAgreement" xlink:label="loc_mgen_PaymentsForLicensingAgreement_F4B3B89C1BC6534F1837782AAB1EB250" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_PaymentsForLicensingAgreement_F4B3B89C1BC6534F1837782AAB1EB250" xlink:to="lab_mgen_PaymentsForLicensingAgreement_F4B3B89C1BC6534F1837782AAB1EB250" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_AA95FCA4F60FC16BA5C4782AAB1EDF92_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_AA95FCA4F60FC16BA5C4782AAB1EDF92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in agreement (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_AA95FCA4F60FC16BA5C4782AAB1EDF92_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_AA95FCA4F60FC16BA5C4782AAB1EDF92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_AA95FCA4F60FC16BA5C4782AAB1EDF92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_AA95FCA4F60FC16BA5C4782AAB1EDF92" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_AA95FCA4F60FC16BA5C4782AAB1EDF92" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_567BCB458327E7DF1822782AAB1EC46C_terseLabel_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_567BCB458327E7DF1822782AAB1EC46C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued in conversion (in shares)</link:label>
    <link:label id="lab_us-gaap_ConversionOfStockSharesIssued1_567BCB458327E7DF1822782AAB1EC46C_label_en-US" xlink:label="lab_us-gaap_ConversionOfStockSharesIssued1_567BCB458327E7DF1822782AAB1EC46C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_567BCB458327E7DF1822782AAB1EC46C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConversionOfStockSharesIssued1_567BCB458327E7DF1822782AAB1EC46C" xlink:to="lab_us-gaap_ConversionOfStockSharesIssued1_567BCB458327E7DF1822782AAB1EC46C" xlink:type="arc" />
    <link:label id="lab_mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct_158FB5CE023619B8F2A7782AAB1EEF8C_terseLabel_en-US" xlink:label="lab_mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct_158FB5CE023619B8F2A7782AAB1EEF8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential future milestone payments per licensed product</link:label>
    <link:label id="lab_mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct_158FB5CE023619B8F2A7782AAB1EEF8C_label_en-US" xlink:label="lab_mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct_158FB5CE023619B8F2A7782AAB1EEF8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Costs, Potential Milestone Payment Per Licensed Product</link:label>
    <link:label id="lab_mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct_158FB5CE023619B8F2A7782AAB1EEF8C_documentation_en-US" xlink:label="lab_mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct_158FB5CE023619B8F2A7782AAB1EEF8C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Costs, Potential Milestone Payment per Licensed Product</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct" xlink:label="loc_mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct_158FB5CE023619B8F2A7782AAB1EEF8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct_158FB5CE023619B8F2A7782AAB1EEF8C" xlink:to="lab_mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct_158FB5CE023619B8F2A7782AAB1EEF8C" xlink:type="arc" />
    <link:label id="lab_mgen_PaymentstoAcquireRawMaterials_56F099E83A31FB0C4C1F782AAB1E4E74_terseLabel_en-US" xlink:label="lab_mgen_PaymentstoAcquireRawMaterials_56F099E83A31FB0C4C1F782AAB1E4E74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for raw materials</link:label>
    <link:label id="lab_mgen_PaymentstoAcquireRawMaterials_56F099E83A31FB0C4C1F782AAB1E4E74_label_en-US" xlink:label="lab_mgen_PaymentstoAcquireRawMaterials_56F099E83A31FB0C4C1F782AAB1E4E74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Raw Materials</link:label>
    <link:label id="lab_mgen_PaymentstoAcquireRawMaterials_56F099E83A31FB0C4C1F782AAB1E4E74_documentation_en-US" xlink:label="lab_mgen_PaymentstoAcquireRawMaterials_56F099E83A31FB0C4C1F782AAB1E4E74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments to Acquire Raw Materials</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PaymentstoAcquireRawMaterials" xlink:label="loc_mgen_PaymentstoAcquireRawMaterials_56F099E83A31FB0C4C1F782AAB1E4E74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_PaymentstoAcquireRawMaterials_56F099E83A31FB0C4C1F782AAB1E4E74" xlink:to="lab_mgen_PaymentstoAcquireRawMaterials_56F099E83A31FB0C4C1F782AAB1E4E74" xlink:type="arc" />
    <link:label id="lab_mgen_CollaborationArrangementPotentialCashProceedsforServices_BDA85C37702BAA94116D782AAB1EE819_terseLabel_en-US" xlink:label="lab_mgen_CollaborationArrangementPotentialCashProceedsforServices_BDA85C37702BAA94116D782AAB1EE819" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential cash proceeds from agreement</link:label>
    <link:label id="lab_mgen_CollaborationArrangementPotentialCashProceedsforServices_BDA85C37702BAA94116D782AAB1EE819_label_en-US" xlink:label="lab_mgen_CollaborationArrangementPotentialCashProceedsforServices_BDA85C37702BAA94116D782AAB1EE819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Potential Cash Proceeds for Services</link:label>
    <link:label id="lab_mgen_CollaborationArrangementPotentialCashProceedsforServices_BDA85C37702BAA94116D782AAB1EE819_documentation_en-US" xlink:label="lab_mgen_CollaborationArrangementPotentialCashProceedsforServices_BDA85C37702BAA94116D782AAB1EE819" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Potential Cash Proceeds for Services</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborationArrangementPotentialCashProceedsforServices" xlink:label="loc_mgen_CollaborationArrangementPotentialCashProceedsforServices_BDA85C37702BAA94116D782AAB1EE819" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_CollaborationArrangementPotentialCashProceedsforServices_BDA85C37702BAA94116D782AAB1EE819" xlink:to="lab_mgen_CollaborationArrangementPotentialCashProceedsforServices_BDA85C37702BAA94116D782AAB1EE819" xlink:type="arc" />
    <link:label id="lab_mgen_CollaborationArrangementTermOfAgreement_E420E1C10D1420AEE733782AAB1E7A59_terseLabel_en-US" xlink:label="lab_mgen_CollaborationArrangementTermOfAgreement_E420E1C10D1420AEE733782AAB1E7A59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Term of agreement</link:label>
    <link:label id="lab_mgen_CollaborationArrangementTermOfAgreement_E420E1C10D1420AEE733782AAB1E7A59_label_en-US" xlink:label="lab_mgen_CollaborationArrangementTermOfAgreement_E420E1C10D1420AEE733782AAB1E7A59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Term Of Agreement</link:label>
    <link:label id="lab_mgen_CollaborationArrangementTermOfAgreement_E420E1C10D1420AEE733782AAB1E7A59_documentation_en-US" xlink:label="lab_mgen_CollaborationArrangementTermOfAgreement_E420E1C10D1420AEE733782AAB1E7A59" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Term of Agreement</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborationArrangementTermOfAgreement" xlink:label="loc_mgen_CollaborationArrangementTermOfAgreement_E420E1C10D1420AEE733782AAB1E7A59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_CollaborationArrangementTermOfAgreement_E420E1C10D1420AEE733782AAB1E7A59" xlink:to="lab_mgen_CollaborationArrangementTermOfAgreement_E420E1C10D1420AEE733782AAB1E7A59" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_9C3A9C354205550DC450783792676893_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators_9C3A9C354205550DC450783792676893" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from collaboration</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_9C3A9C354205550DC450783792676893_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators_9C3A9C354205550DC450783792676893" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators_9C3A9C354205550DC450783792676893" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators_9C3A9C354205550DC450783792676893" xlink:to="lab_us-gaap_ProceedsFromCollaborators_9C3A9C354205550DC450783792676893" xlink:type="arc" />
    <link:label id="lab_mgen_CollaborationArrangementTermofAgreementTerminationPeriod_13CA0C044DC2046399D1782AAB1E4FF7_terseLabel_en-US" xlink:label="lab_mgen_CollaborationArrangementTermofAgreementTerminationPeriod_13CA0C044DC2046399D1782AAB1E4FF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Period to terminate agreement</link:label>
    <link:label id="lab_mgen_CollaborationArrangementTermofAgreementTerminationPeriod_13CA0C044DC2046399D1782AAB1E4FF7_label_en-US" xlink:label="lab_mgen_CollaborationArrangementTermofAgreementTerminationPeriod_13CA0C044DC2046399D1782AAB1E4FF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Term of Agreement, Termination Period</link:label>
    <link:label id="lab_mgen_CollaborationArrangementTermofAgreementTerminationPeriod_13CA0C044DC2046399D1782AAB1E4FF7_documentation_en-US" xlink:label="lab_mgen_CollaborationArrangementTermofAgreementTerminationPeriod_13CA0C044DC2046399D1782AAB1E4FF7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Arrangement, Term of Agreement, Termination Period</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborationArrangementTermofAgreementTerminationPeriod" xlink:label="loc_mgen_CollaborationArrangementTermofAgreementTerminationPeriod_13CA0C044DC2046399D1782AAB1E4FF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_CollaborationArrangementTermofAgreementTerminationPeriod_13CA0C044DC2046399D1782AAB1E4FF7" xlink:to="lab_mgen_CollaborationArrangementTermofAgreementTerminationPeriod_13CA0C044DC2046399D1782AAB1E4FF7" xlink:type="arc" />
    <link:label id="lab_mgen_LicenseCostsPotentialMilestonePayment_2A2238781568D6814FB7782AAB1F76C6_terseLabel_en-US" xlink:label="lab_mgen_LicenseCostsPotentialMilestonePayment_2A2238781568D6814FB7782AAB1F76C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_mgen_LicenseCostsPotentialMilestonePayment_2A2238781568D6814FB7782AAB1F76C6_label_en-US" xlink:label="lab_mgen_LicenseCostsPotentialMilestonePayment_2A2238781568D6814FB7782AAB1F76C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Costs, Potential Milestone Payment</link:label>
    <link:label id="lab_mgen_LicenseCostsPotentialMilestonePayment_2A2238781568D6814FB7782AAB1F76C6_documentation_en-US" xlink:label="lab_mgen_LicenseCostsPotentialMilestonePayment_2A2238781568D6814FB7782AAB1F76C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Costs, Potential Milestone Payment</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostsPotentialMilestonePayment" xlink:label="loc_mgen_LicenseCostsPotentialMilestonePayment_2A2238781568D6814FB7782AAB1F76C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_LicenseCostsPotentialMilestonePayment_2A2238781568D6814FB7782AAB1F76C6" xlink:to="lab_mgen_LicenseCostsPotentialMilestonePayment_2A2238781568D6814FB7782AAB1F76C6" xlink:type="arc" />
    <link:label id="lab_mgen_LicenseCostsOnetimeSalesMilestonePayment_0C331E8C69DA9F139882782AAB1F12A6_terseLabel_en-US" xlink:label="lab_mgen_LicenseCostsOnetimeSalesMilestonePayment_0C331E8C69DA9F139882782AAB1F12A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One-time sales milestone payment</link:label>
    <link:label id="lab_mgen_LicenseCostsOnetimeSalesMilestonePayment_0C331E8C69DA9F139882782AAB1F12A6_label_en-US" xlink:label="lab_mgen_LicenseCostsOnetimeSalesMilestonePayment_0C331E8C69DA9F139882782AAB1F12A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License Costs, One-time Sales Milestone Payment</link:label>
    <link:label id="lab_mgen_LicenseCostsOnetimeSalesMilestonePayment_0C331E8C69DA9F139882782AAB1F12A6_documentation_en-US" xlink:label="lab_mgen_LicenseCostsOnetimeSalesMilestonePayment_0C331E8C69DA9F139882782AAB1F12A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License Costs, One-time Sales Milestone Payment</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostsOnetimeSalesMilestonePayment" xlink:label="loc_mgen_LicenseCostsOnetimeSalesMilestonePayment_0C331E8C69DA9F139882782AAB1F12A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_LicenseCostsOnetimeSalesMilestonePayment_0C331E8C69DA9F139882782AAB1F12A6" xlink:to="lab_mgen_LicenseCostsOnetimeSalesMilestonePayment_0C331E8C69DA9F139882782AAB1F12A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_D739F566548218AC0B13782AAB1FAF89_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_D739F566548218AC0B13782AAB1FAF89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rent expense</link:label>
    <link:label id="lab_us-gaap_LeaseAndRentalExpense_D739F566548218AC0B13782AAB1FAF89_label_en-US" xlink:label="lab_us-gaap_LeaseAndRentalExpense_D739F566548218AC0B13782AAB1FAF89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_D739F566548218AC0B13782AAB1FAF89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseAndRentalExpense_D739F566548218AC0B13782AAB1FAF89" xlink:to="lab_us-gaap_LeaseAndRentalExpense_D739F566548218AC0B13782AAB1FAF89" xlink:type="arc" />
    <link:label id="lab_mgen_OperatingLeasesOperatingExpense_BFD86333EE18F3A3A967782AAB1F4540_terseLabel_en-US" xlink:label="lab_mgen_OperatingLeasesOperatingExpense_BFD86333EE18F3A3A967782AAB1F4540" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses of leases</link:label>
    <link:label id="lab_mgen_OperatingLeasesOperatingExpense_BFD86333EE18F3A3A967782AAB1F4540_label_en-US" xlink:label="lab_mgen_OperatingLeasesOperatingExpense_BFD86333EE18F3A3A967782AAB1F4540" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Operating Expense</link:label>
    <link:label id="lab_mgen_OperatingLeasesOperatingExpense_BFD86333EE18F3A3A967782AAB1F4540_documentation_en-US" xlink:label="lab_mgen_OperatingLeasesOperatingExpense_BFD86333EE18F3A3A967782AAB1F4540" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Leases, Operating Expense</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_OperatingLeasesOperatingExpense" xlink:label="loc_mgen_OperatingLeasesOperatingExpense_BFD86333EE18F3A3A967782AAB1F4540" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_OperatingLeasesOperatingExpense_BFD86333EE18F3A3A967782AAB1F4540" xlink:to="lab_mgen_OperatingLeasesOperatingExpense_BFD86333EE18F3A3A967782AAB1F4540" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of Options (in thousands)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CDDA68874F82E439423708261D91D8D9_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CDDA68874F82E439423708261D91D8D9" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CDDA68874F82E439423708261D91D8D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CDDA68874F82E439423708261D91D8D9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CDDA68874F82E439423708261D91D8D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60717D0CC274D45B104508261D91306C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60717D0CC274D45B104508261D91306C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60717D0CC274D45B104508261D91306C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60717D0CC274D45B104508261D91306C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60717D0CC274D45B104508261D91306C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_DA42C64E8876E06478CD08261D911427_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_DA42C64E8876E06478CD08261D911427" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_DA42C64E8876E06478CD08261D911427_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_DA42C64E8876E06478CD08261D911427" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_DA42C64E8876E06478CD08261D911427" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_DA42C64E8876E06478CD08261D911427" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_DA42C64E8876E06478CD08261D911427" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF1661887AA031BC780A08261D92E7F6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF1661887AA031BC780A08261D92E7F6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF1661887AA031BC780A08261D92E7F6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF1661887AA031BC780A08261D92E7F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF1661887AA031BC780A08261D92E7F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF1661887AA031BC780A08261D92E7F6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF1661887AA031BC780A08261D92E7F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0952AACBF61288DAB71108261D92DACD_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0952AACBF61288DAB71108261D92DACD" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0952AACBF61288DAB71108261D92DACD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0952AACBF61288DAB71108261D92DACD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0952AACBF61288DAB71108261D92DACD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_295BAC2694D0BAE817A808261D928EDB_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_295BAC2694D0BAE817A808261D928EDB" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_295BAC2694D0BAE817A808261D928EDB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_295BAC2694D0BAE817A808261D928EDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_295BAC2694D0BAE817A808261D928EDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_295BAC2694D0BAE817A808261D928EDB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_295BAC2694D0BAE817A808261D928EDB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BAB0B5B1B3A477CD38CA08261D92AB3F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BAB0B5B1B3A477CD38CA08261D92AB3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BAB0B5B1B3A477CD38CA08261D92AB3F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BAB0B5B1B3A477CD38CA08261D92AB3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BAB0B5B1B3A477CD38CA08261D92AB3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BAB0B5B1B3A477CD38CA08261D92AB3F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BAB0B5B1B3A477CD38CA08261D92AB3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_355A1588848B0A390F4F08261D922EF3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_355A1588848B0A390F4F08261D922EF3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_355A1588848B0A390F4F08261D922EF3_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_355A1588848B0A390F4F08261D922EF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_355A1588848B0A390F4F08261D922EF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_355A1588848B0A390F4F08261D922EF3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_355A1588848B0A390F4F08261D922EF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_EBEFA273657E84A4ED2008261D928B39_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_EBEFA273657E84A4ED2008261D928B39" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_EBEFA273657E84A4ED2008261D928B39_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_EBEFA273657E84A4ED2008261D928B39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_EBEFA273657E84A4ED2008261D928B39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_EBEFA273657E84A4ED2008261D928B39" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_EBEFA273657E84A4ED2008261D928B39" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7836D110F2F5857C462508261D9273B0_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7836D110F2F5857C462508261D9273B0" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in usd per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7836D110F2F5857C462508261D9273B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7836D110F2F5857C462508261D9273B0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7836D110F2F5857C462508261D9273B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsAbstract_C3DDADB62F9FFF9718D208261DACC983_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsAbstract_C3DDADB62F9FFF9718D208261DACC983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_C3DDADB62F9FFF9718D208261DACC983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_C3DDADB62F9FFF9718D208261DACC983" xlink:to="lab_us-gaap_BusinessCombinationsAbstract_C3DDADB62F9FFF9718D208261DACC983" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:type="arc" />
    <link:label id="lab_us-gaap_OwnershipAxis_E8C466829EFEDE3924F808261DAD5C69_terseLabel_en-US" xlink:label="lab_us-gaap_OwnershipAxis_E8C466829EFEDE3924F808261DAD5C69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_us-gaap_OwnershipAxis_E8C466829EFEDE3924F808261DAD5C69_label_en-US" xlink:label="lab_us-gaap_OwnershipAxis_E8C466829EFEDE3924F808261DAD5C69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipAxis" xlink:label="loc_us-gaap_OwnershipAxis_E8C466829EFEDE3924F808261DAD5C69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OwnershipAxis_E8C466829EFEDE3924F808261DAD5C69" xlink:to="lab_us-gaap_OwnershipAxis_E8C466829EFEDE3924F808261DAD5C69" xlink:type="arc" />
    <link:label id="lab_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0_terseLabel_en-US" xlink:label="lab_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0_label_en-US" xlink:label="lab_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipDomain" xlink:label="loc_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0" xlink:to="lab_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0" xlink:type="arc" />
    <link:label id="lab_mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember_66260FCBA882090EF4E808261DAD630C_terseLabel_en-US" xlink:label="lab_mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember_66260FCBA882090EF4E808261DAD630C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Merger MIragen Stockholders, Warrantholders, and Optionholders</link:label>
    <link:label id="lab_mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember_66260FCBA882090EF4E808261DAD630C_label_en-US" xlink:label="lab_mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember_66260FCBA882090EF4E808261DAD630C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Merger MIragen Stockholders, Warrantholders, and Optionholders [Member]</link:label>
    <link:label id="lab_mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember_66260FCBA882090EF4E808261DAD630C_documentation_en-US" xlink:label="lab_mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember_66260FCBA882090EF4E808261DAD630C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Merger MIragen Stockholders, Warrantholders, and Optionholders [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember" xlink:label="loc_mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember_66260FCBA882090EF4E808261DAD630C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember_66260FCBA882090EF4E808261DAD630C" xlink:to="lab_mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember_66260FCBA882090EF4E808261DAD630C" xlink:type="arc" />
    <link:label id="lab_mgen_SignalShareholdersMember_790DF87BD2174A64D1DE08261DADB5DB_terseLabel_en-US" xlink:label="lab_mgen_SignalShareholdersMember_790DF87BD2174A64D1DE08261DADB5DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Signal Shareholders</link:label>
    <link:label id="lab_mgen_SignalShareholdersMember_790DF87BD2174A64D1DE08261DADB5DB_label_en-US" xlink:label="lab_mgen_SignalShareholdersMember_790DF87BD2174A64D1DE08261DADB5DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Signal Shareholders [Member]</link:label>
    <link:label id="lab_mgen_SignalShareholdersMember_790DF87BD2174A64D1DE08261DADB5DB_documentation_en-US" xlink:label="lab_mgen_SignalShareholdersMember_790DF87BD2174A64D1DE08261DADB5DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Signal Shareholders [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalShareholdersMember" xlink:label="loc_mgen_SignalShareholdersMember_790DF87BD2174A64D1DE08261DADB5DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_SignalShareholdersMember_790DF87BD2174A64D1DE08261DADB5DB" xlink:to="lab_mgen_SignalShareholdersMember_790DF87BD2174A64D1DE08261DADB5DB" xlink:type="arc" />
    <link:label id="lab_mgen_MiragenShareholdersMember_D42ABEA8D8DDF0D13F7B08261DAD2A33_terseLabel_en-US" xlink:label="lab_mgen_MiragenShareholdersMember_D42ABEA8D8DDF0D13F7B08261DAD2A33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Miragen Shareholders</link:label>
    <link:label id="lab_mgen_MiragenShareholdersMember_D42ABEA8D8DDF0D13F7B08261DAD2A33_label_en-US" xlink:label="lab_mgen_MiragenShareholdersMember_D42ABEA8D8DDF0D13F7B08261DAD2A33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Miragen Shareholders [Member]</link:label>
    <link:label id="lab_mgen_MiragenShareholdersMember_D42ABEA8D8DDF0D13F7B08261DAD2A33_documentation_en-US" xlink:label="lab_mgen_MiragenShareholdersMember_D42ABEA8D8DDF0D13F7B08261DAD2A33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Miragen Shareholders [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_MiragenShareholdersMember" xlink:label="loc_mgen_MiragenShareholdersMember_D42ABEA8D8DDF0D13F7B08261DAD2A33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_MiragenShareholdersMember_D42ABEA8D8DDF0D13F7B08261DAD2A33" xlink:to="lab_mgen_MiragenShareholdersMember_D42ABEA8D8DDF0D13F7B08261DAD2A33" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_347CB3838CEC35619E4D08261DAD0BDE_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_347CB3838CEC35619E4D08261DAD0BDE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_347CB3838CEC35619E4D08261DAD0BDE_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_347CB3838CEC35619E4D08261DAD0BDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_347CB3838CEC35619E4D08261DAD0BDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_347CB3838CEC35619E4D08261DAD0BDE" xlink:to="lab_us-gaap_PreferredStockMember_347CB3838CEC35619E4D08261DAD0BDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_D9432FF207E234AFBC7808261DAE960E_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_D9432FF207E234AFBC7808261DAE960E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_D9432FF207E234AFBC7808261DAE960E_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_D9432FF207E234AFBC7808261DAE960E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Percentage of Voting Interests Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_D9432FF207E234AFBC7808261DAE960E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_D9432FF207E234AFBC7808261DAE960E" xlink:to="lab_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_D9432FF207E234AFBC7808261DAE960E" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_9E6DABECEFBF688EC52508261DAE9224_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_9E6DABECEFBF688EC52508261DAE9224" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership interest prior to merger</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_9E6DABECEFBF688EC52508261DAE9224_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_9E6DABECEFBF688EC52508261DAE9224" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_9E6DABECEFBF688EC52508261DAE9224" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_9E6DABECEFBF688EC52508261DAE9224" xlink:to="lab_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_9E6DABECEFBF688EC52508261DAE9224" xlink:type="arc" />
    <link:label id="lab_mgen_MarketCapitalization_7ADDA673421311D0B1E908261DAEB75A_terseLabel_en-US" xlink:label="lab_mgen_MarketCapitalization_7ADDA673421311D0B1E908261DAEB75A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Market capitalization</link:label>
    <link:label id="lab_mgen_MarketCapitalization_7ADDA673421311D0B1E908261DAEB75A_label_en-US" xlink:label="lab_mgen_MarketCapitalization_7ADDA673421311D0B1E908261DAEB75A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Market Capitalization</link:label>
    <link:label id="lab_mgen_MarketCapitalization_7ADDA673421311D0B1E908261DAEB75A_documentation_en-US" xlink:label="lab_mgen_MarketCapitalization_7ADDA673421311D0B1E908261DAEB75A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Market Capitalization</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_MarketCapitalization" xlink:label="loc_mgen_MarketCapitalization_7ADDA673421311D0B1E908261DAEB75A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_MarketCapitalization_7ADDA673421311D0B1E908261DAEB75A" xlink:to="lab_mgen_MarketCapitalization_7ADDA673421311D0B1E908261DAEB75A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E8CF327FB2CA8C3DA10408261DAED723_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E8CF327FB2CA8C3DA10408261DAED723" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net acquired tangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E8CF327FB2CA8C3DA10408261DAED723_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E8CF327FB2CA8C3DA10408261DAED723" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E8CF327FB2CA8C3DA10408261DAED723" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E8CF327FB2CA8C3DA10408261DAED723" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E8CF327FB2CA8C3DA10408261DAED723" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_AF96BCB43D994623EA5F782AAB2DCB68_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_AF96BCB43D994623EA5F782AAB2DCB68" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount outstanding</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_AF96BCB43D994623EA5F782AAB2DCB68_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_AF96BCB43D994623EA5F782AAB2DCB68" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_AF96BCB43D994623EA5F782AAB2DCB68" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_AF96BCB43D994623EA5F782AAB2DCB68" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_AF96BCB43D994623EA5F782AAB2DCB68" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_07059EFFFB7E0A5DE8BD782AAB2D0415_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_07059EFFFB7E0A5DE8BD782AAB2D0415" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt discount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscount_07059EFFFB7E0A5DE8BD782AAB2D0415_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscount_07059EFFFB7E0A5DE8BD782AAB2D0415" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_07059EFFFB7E0A5DE8BD782AAB2D0415" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscount_07059EFFFB7E0A5DE8BD782AAB2D0415" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscount_07059EFFFB7E0A5DE8BD782AAB2D0415" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_5619EA902476CD385358782AAB2D844B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_5619EA902476CD385358782AAB2D844B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unamortized debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DeferredFinanceCostsNet_5619EA902476CD385358782AAB2D844B_label_en-US" xlink:label="lab_us-gaap_DeferredFinanceCostsNet_5619EA902476CD385358782AAB2D844B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_5619EA902476CD385358782AAB2D844B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFinanceCostsNet_5619EA902476CD385358782AAB2D844B" xlink:to="lab_us-gaap_DeferredFinanceCostsNet_5619EA902476CD385358782AAB2D844B" xlink:type="arc" />
    <link:label id="lab_mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee_CE22F2E1D46F4545EB98782AAB2DB8E9_terseLabel_en-US" xlink:label="lab_mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee_CE22F2E1D46F4545EB98782AAB2DB8E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accreted final payment fee</link:label>
    <link:label id="lab_mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee_CE22F2E1D46F4545EB98782AAB2DB8E9_label_en-US" xlink:label="lab_mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee_CE22F2E1D46F4545EB98782AAB2DB8E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Accumulated Accretion Of Final Payment Fee</link:label>
    <link:label id="lab_mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee_CE22F2E1D46F4545EB98782AAB2DB8E9_documentation_en-US" xlink:label="lab_mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee_CE22F2E1D46F4545EB98782AAB2DB8E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt, Accumulated Accretion of Final Payment Fee</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee" xlink:label="loc_mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee_CE22F2E1D46F4545EB98782AAB2DB8E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee_CE22F2E1D46F4545EB98782AAB2DB8E9" xlink:to="lab_mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee_CE22F2E1D46F4545EB98782AAB2DB8E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayable_474F4B0E179CF0DE6A21782AAB2D8E06_totalLabel_en-US" xlink:label="lab_us-gaap_NotesPayable_474F4B0E179CF0DE6A21782AAB2D8E06" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total notes payable</link:label>
    <link:label id="lab_us-gaap_NotesPayable_474F4B0E179CF0DE6A21782AAB2D8E06_label_en-US" xlink:label="lab_us-gaap_NotesPayable_474F4B0E179CF0DE6A21782AAB2D8E06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_474F4B0E179CF0DE6A21782AAB2D8E06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayable_474F4B0E179CF0DE6A21782AAB2D8E06" xlink:to="lab_us-gaap_NotesPayable_474F4B0E179CF0DE6A21782AAB2D8E06" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableCurrent_AA9E992FBC7032F1669D782AAB2D08EA_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_AA9E992FBC7032F1669D782AAB2D08EA" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: current maturities</link:label>
    <link:label id="lab_us-gaap_NotesPayableCurrent_AA9E992FBC7032F1669D782AAB2D08EA_label_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_AA9E992FBC7032F1669D782AAB2D08EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_AA9E992FBC7032F1669D782AAB2D08EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent_AA9E992FBC7032F1669D782AAB2D08EA" xlink:to="lab_us-gaap_NotesPayableCurrent_AA9E992FBC7032F1669D782AAB2D08EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_A3353DF909211600BEAB782AAB2D03F7_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_A3353DF909211600BEAB782AAB2D03F7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term notes payable, net of current portion</link:label>
    <link:label id="lab_us-gaap_LongTermNotesPayable_A3353DF909211600BEAB782AAB2D03F7_label_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_A3353DF909211600BEAB782AAB2D03F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Payable, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_A3353DF909211600BEAB782AAB2D03F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_A3353DF909211600BEAB782AAB2D03F7" xlink:to="lab_us-gaap_LongTermNotesPayable_A3353DF909211600BEAB782AAB2D03F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_439C1180D657B317CC3E08261DE8D6BF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_439C1180D657B317CC3E08261DE8D6BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Components of Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_439C1180D657B317CC3E08261DE8D6BF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_439C1180D657B317CC3E08261DE8D6BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_439C1180D657B317CC3E08261DE8D6BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_439C1180D657B317CC3E08261DE8D6BF" xlink:to="lab_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_439C1180D657B317CC3E08261DE8D6BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6A615B36F75A5510075308261E6779BD_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6A615B36F75A5510075308261E6779BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 (remainder of year)</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6A615B36F75A5510075308261E6779BD_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6A615B36F75A5510075308261E6779BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal, Remainder of Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6A615B36F75A5510075308261E6779BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6A615B36F75A5510075308261E6779BD" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6A615B36F75A5510075308261E6779BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_E0DF8D449704BDF6D3AD08261E67E28E_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_E0DF8D449704BDF6D3AD08261E67E28E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_E0DF8D449704BDF6D3AD08261E67E28E_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_E0DF8D449704BDF6D3AD08261E67E28E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_E0DF8D449704BDF6D3AD08261E67E28E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_E0DF8D449704BDF6D3AD08261E67E28E" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_E0DF8D449704BDF6D3AD08261E67E28E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_F6597E44BFF2C3D6775E08261E67FB2C_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_F6597E44BFF2C3D6775E08261E67FB2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_F6597E44BFF2C3D6775E08261E67FB2C_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_F6597E44BFF2C3D6775E08261E67FB2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Maturities, Repayments of Principal in Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_F6597E44BFF2C3D6775E08261E67FB2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_F6597E44BFF2C3D6775E08261E67FB2C" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_F6597E44BFF2C3D6775E08261E67FB2C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_E0DABC8B8423275F35FC08261E675AB8_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_E0DABC8B8423275F35FC08261E675AB8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_E0DABC8B8423275F35FC08261E675AB8_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_E0DABC8B8423275F35FC08261E675AB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_E0DABC8B8423275F35FC08261E675AB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_E0DABC8B8423275F35FC08261E675AB8" xlink:to="lab_us-gaap_LongTermDebt_E0DABC8B8423275F35FC08261E675AB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_2460C7E1750CB48C518908261E1574AC_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_2460C7E1750CB48C518908261E1574AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_2460C7E1750CB48C518908261E1574AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_2460C7E1750CB48C518908261E1574AC" xlink:to="lab_us-gaap_IncomeStatementAbstract_2460C7E1750CB48C518908261E1574AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesAbstract_75C806AD643338D0919408261E154142_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_75C806AD643338D0919408261E154142" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_75C806AD643338D0919408261E154142_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract_75C806AD643338D0919408261E154142" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_75C806AD643338D0919408261E154142" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract_75C806AD643338D0919408261E154142" xlink:to="lab_us-gaap_RevenuesAbstract_75C806AD643338D0919408261E154142" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicenseAndServicesRevenue_05FB8959CE04A321D25008261E16D0E0_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseAndServicesRevenue_05FB8959CE04A321D25008261E16D0E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration revenue</link:label>
    <link:label id="lab_us-gaap_LicenseAndServicesRevenue_05FB8959CE04A321D25008261E16D0E0_label_en-US" xlink:label="lab_us-gaap_LicenseAndServicesRevenue_05FB8959CE04A321D25008261E16D0E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License and Services Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_05FB8959CE04A321D25008261E16D0E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseAndServicesRevenue_05FB8959CE04A321D25008261E16D0E0" xlink:to="lab_us-gaap_LicenseAndServicesRevenue_05FB8959CE04A321D25008261E16D0E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromGrants_C849E4E552F03C08F11308261E16BE18_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromGrants_C849E4E552F03C08F11308261E16BE18" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromGrants_C849E4E552F03C08F11308261E16BE18_label_en-US" xlink:label="lab_us-gaap_RevenueFromGrants_C849E4E552F03C08F11308261E16BE18" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Grants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_C849E4E552F03C08F11308261E16BE18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromGrants_C849E4E552F03C08F11308261E16BE18" xlink:to="lab_us-gaap_RevenueFromGrants_C849E4E552F03C08F11308261E16BE18" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueNet_DA89BE5ABC1D1A3CEB2708261E16F334_totalLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_DA89BE5ABC1D1A3CEB2708261E16F334" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNet_DA89BE5ABC1D1A3CEB2708261E16F334_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNet_DA89BE5ABC1D1A3CEB2708261E16F334" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_DA89BE5ABC1D1A3CEB2708261E16F334" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNet_DA89BE5ABC1D1A3CEB2708261E16F334" xlink:to="lab_us-gaap_SalesRevenueNet_DA89BE5ABC1D1A3CEB2708261E16F334" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_9B9C0EAC3C282CF1E90A08261E16109F_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_9B9C0EAC3C282CF1E90A08261E16109F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_9B9C0EAC3C282CF1E90A08261E16109F_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract_9B9C0EAC3C282CF1E90A08261E16109F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_9B9C0EAC3C282CF1E90A08261E16109F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9B9C0EAC3C282CF1E90A08261E16109F" xlink:to="lab_us-gaap_OperatingExpensesAbstract_9B9C0EAC3C282CF1E90A08261E16109F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_96F09E7D9EA9F968A13D08261E166AF3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_96F09E7D9EA9F968A13D08261E166AF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_96F09E7D9EA9F968A13D08261E166AF3_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense_96F09E7D9EA9F968A13D08261E166AF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_96F09E7D9EA9F968A13D08261E166AF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_96F09E7D9EA9F968A13D08261E166AF3" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense_96F09E7D9EA9F968A13D08261E166AF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_4F3B944500059462087308261E1687E0_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_4F3B944500059462087308261E1687E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_4F3B944500059462087308261E1687E0_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense_4F3B944500059462087308261E1687E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4F3B944500059462087308261E1687E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense_4F3B944500059462087308261E1687E0" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense_4F3B944500059462087308261E1687E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingExpenses_047B00501438805AAA4C08261E17987C_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses_047B00501438805AAA4C08261E17987C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_047B00501438805AAA4C08261E17987C_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses_047B00501438805AAA4C08261E17987C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_047B00501438805AAA4C08261E17987C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses_047B00501438805AAA4C08261E17987C" xlink:to="lab_us-gaap_OperatingExpenses_047B00501438805AAA4C08261E17987C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4F84C01047FFE62D44BF08261E17C072_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_4F84C01047FFE62D44BF08261E17C072" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_4F84C01047FFE62D44BF08261E17C072_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss_4F84C01047FFE62D44BF08261E17C072" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_4F84C01047FFE62D44BF08261E17C072" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss_4F84C01047FFE62D44BF08261E17C072" xlink:to="lab_us-gaap_OperatingIncomeLoss_4F84C01047FFE62D44BF08261E17C072" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_B6FD71ED1148993CE1A708261E17CD33_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_B6FD71ED1148993CE1A708261E17CD33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense):</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpenseAbstract_B6FD71ED1148993CE1A708261E17CD33_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpenseAbstract_B6FD71ED1148993CE1A708261E17CD33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_B6FD71ED1148993CE1A708261E17CD33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_B6FD71ED1148993CE1A708261E17CD33" xlink:to="lab_us-gaap_NonoperatingIncomeExpenseAbstract_B6FD71ED1148993CE1A708261E17CD33" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_0C518CDA396FCE75AB5908261E17733C_terseLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_0C518CDA396FCE75AB5908261E17733C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest and other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_0C518CDA396FCE75AB5908261E17733C_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense_0C518CDA396FCE75AB5908261E17733C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0C518CDA396FCE75AB5908261E17733C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_0C518CDA396FCE75AB5908261E17733C" xlink:to="lab_us-gaap_NonoperatingIncomeExpense_0C518CDA396FCE75AB5908261E17733C" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestAndDebtExpense_DA2FDAD2B06051F3DB6D08261E17C76B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense_DA2FDAD2B06051F3DB6D08261E17C76B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest and other related expense</link:label>
    <link:label id="lab_us-gaap_InterestAndDebtExpense_DA2FDAD2B06051F3DB6D08261E17C76B_label_en-US" xlink:label="lab_us-gaap_InterestAndDebtExpense_DA2FDAD2B06051F3DB6D08261E17C76B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest and Debt Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_DA2FDAD2B06051F3DB6D08261E17C76B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestAndDebtExpense_DA2FDAD2B06051F3DB6D08261E17C76B" xlink:to="lab_us-gaap_InterestAndDebtExpense_DA2FDAD2B06051F3DB6D08261E17C76B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_33980A4D5B23E27AE09E08261E175048_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_33980A4D5B23E27AE09E08261E175048" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_33980A4D5B23E27AE09E08261E175048" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_33980A4D5B23E27AE09E08261E175048" xlink:to="lab_us-gaap_NetIncomeLoss_33980A4D5B23E27AE09E08261E175048" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_C3550841BE7D09998C5408261E1772C2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_C3550841BE7D09998C5408261E1772C2" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accretion of redeemable convertible preferred stock to redemption value</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_C3550841BE7D09998C5408261E1772C2_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_C3550841BE7D09998C5408261E1772C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value, Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_C3550841BE7D09998C5408261E1772C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_C3550841BE7D09998C5408261E1772C2" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_C3550841BE7D09998C5408261E1772C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_197D981280265D78138C08261E178A76_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_197D981280265D78138C08261E178A76" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss available to common stockholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_197D981280265D78138C08261E178A76_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_197D981280265D78138C08261E178A76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_197D981280265D78138C08261E178A76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_197D981280265D78138C08261E178A76" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_197D981280265D78138C08261E178A76" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_CFEC468B2B26D73CC70508261E17F82E_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_CFEC468B2B26D73CC70508261E17F82E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share, basic and diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAndDiluted_CFEC468B2B26D73CC70508261E17F82E_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAndDiluted_CFEC468B2B26D73CC70508261E17F82E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_CFEC468B2B26D73CC70508261E17F82E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDiluted_CFEC468B2B26D73CC70508261E17F82E" xlink:to="lab_us-gaap_EarningsPerShareBasicAndDiluted_CFEC468B2B26D73CC70508261E17F82E" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1E29C4F4EB88E0448F0408261E17B0A6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1E29C4F4EB88E0448F0408261E17B0A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares used to compute basic and diluted net loss per share (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1E29C4F4EB88E0448F0408261E17B0A6_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1E29C4F4EB88E0448F0408261E17B0A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1E29C4F4EB88E0448F0408261E17B0A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1E29C4F4EB88E0448F0408261E17B0A6" xlink:to="lab_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1E29C4F4EB88E0448F0408261E17B0A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7302DC74B0AF83D76F32782AAAA0DBC1_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7302DC74B0AF83D76F32782AAAA0DBC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term, in years</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7302DC74B0AF83D76F32782AAAA0DBC1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7302DC74B0AF83D76F32782AAAA0DBC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7302DC74B0AF83D76F32782AAAA0DBC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7302DC74B0AF83D76F32782AAAA0DBC1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7302DC74B0AF83D76F32782AAAA0DBC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0BB6464D3106B2918315782AAAA0C365_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0BB6464D3106B2918315782AAAA0C365" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0BB6464D3106B2918315782AAAA0C365_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0BB6464D3106B2918315782AAAA0C365" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0BB6464D3106B2918315782AAAA0C365" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0BB6464D3106B2918315782AAAA0C365" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0BB6464D3106B2918315782AAAA0C365" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D4F7F818A0BDED19FC0E782AAAA07282_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D4F7F818A0BDED19FC0E782AAAA07282" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D4F7F818A0BDED19FC0E782AAAA07282_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D4F7F818A0BDED19FC0E782AAAA07282" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D4F7F818A0BDED19FC0E782AAAA07282" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D4F7F818A0BDED19FC0E782AAAA07282" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D4F7F818A0BDED19FC0E782AAAA07282" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_32331862B7731AE1E340782AAAA05744_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_32331862B7731AE1E340782AAAA05744" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_32331862B7731AE1E340782AAAA05744_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_32331862B7731AE1E340782AAAA05744" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_32331862B7731AE1E340782AAAA05744" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_32331862B7731AE1E340782AAAA05744" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_32331862B7731AE1E340782AAAA05744" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7A764C76347AFCA61106782AAAA04154_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7A764C76347AFCA61106782AAAA04154" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value of underlying common stock (in usd per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7A764C76347AFCA61106782AAAA04154" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7A764C76347AFCA61106782AAAA04154" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7A764C76347AFCA61106782AAAA04154" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_401F7F8DBAB6DAA78D1C08261D7E8AA7_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_401F7F8DBAB6DAA78D1C08261D7E8AA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Strategic Alliance and Collaboration with Servier</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_401F7F8DBAB6DAA78D1C08261D7E8AA7_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_401F7F8DBAB6DAA78D1C08261D7E8AA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_401F7F8DBAB6DAA78D1C08261D7E8AA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_401F7F8DBAB6DAA78D1C08261D7E8AA7" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_401F7F8DBAB6DAA78D1C08261D7E8AA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_B6067BE9A81058A82AC908261E3A1B47_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_B6067BE9A81058A82AC908261E3A1B47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reverse Merger</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationDisclosureTextBlock_B6067BE9A81058A82AC908261E3A1B47_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationDisclosureTextBlock_B6067BE9A81058A82AC908261E3A1B47" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_B6067BE9A81058A82AC908261E3A1B47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationDisclosureTextBlock_B6067BE9A81058A82AC908261E3A1B47" xlink:to="lab_us-gaap_BusinessCombinationDisclosureTextBlock_B6067BE9A81058A82AC908261E3A1B47" xlink:type="arc" />
    <link:label id="lab_mgen_PreferredStockWarrantsMember_667CE49873EB24A0F63A08261E2E0842_verboseLabel_en-US" xlink:label="lab_mgen_PreferredStockWarrantsMember_667CE49873EB24A0F63A08261E2E0842" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock Warrants</link:label>
    <link:label id="lab_mgen_PreferredStockWarrantsMember_667CE49873EB24A0F63A08261E2E0842_label_en-US" xlink:label="lab_mgen_PreferredStockWarrantsMember_667CE49873EB24A0F63A08261E2E0842" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Warrants [Member]</link:label>
    <link:label id="lab_mgen_PreferredStockWarrantsMember_667CE49873EB24A0F63A08261E2E0842_documentation_en-US" xlink:label="lab_mgen_PreferredStockWarrantsMember_667CE49873EB24A0F63A08261E2E0842" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock Warrants [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PreferredStockWarrantsMember" xlink:label="loc_mgen_PreferredStockWarrantsMember_667CE49873EB24A0F63A08261E2E0842" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_PreferredStockWarrantsMember_667CE49873EB24A0F63A08261E2E0842" xlink:to="lab_mgen_PreferredStockWarrantsMember_667CE49873EB24A0F63A08261E2E0842" xlink:type="arc" />
    <link:label id="lab_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C_terseLabel_en-US" xlink:label="lab_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number</link:label>
    <link:label id="lab_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C_label_en-US" xlink:label="lab_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Activity [Roll Forward]</link:label>
    <link:label id="lab_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C_documentation_en-US" xlink:label="lab_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Activity[Roll Forward]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightActivityRollForward" xlink:label="loc_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:to="lab_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_BD0A3B88D9C65BCFEC4808261E2E7D7F_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_BD0A3B88D9C65BCFEC4808261E2E7D7F" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_BD0A3B88D9C65BCFEC4808261E2E7D7F_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_BD0A3B88D9C65BCFEC4808261E2E7D7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_BD0A3B88D9C65BCFEC4808261E2E7D7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_BD0A3B88D9C65BCFEC4808261E2E7D7F" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_BD0A3B88D9C65BCFEC4808261E2E7D7F" xlink:type="arc" />
    <link:label id="lab_mgen_ClassofWarrantorRightAcquiredinAcquisition_A06B182A38A03DCFC7D508261E2EB226_terseLabel_en-US" xlink:label="lab_mgen_ClassofWarrantorRightAcquiredinAcquisition_A06B182A38A03DCFC7D508261E2EB226" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants acquired in Merger (in shares)</link:label>
    <link:label id="lab_mgen_ClassofWarrantorRightAcquiredinAcquisition_A06B182A38A03DCFC7D508261E2EB226_label_en-US" xlink:label="lab_mgen_ClassofWarrantorRightAcquiredinAcquisition_A06B182A38A03DCFC7D508261E2EB226" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Acquired in Acquisition</link:label>
    <link:label id="lab_mgen_ClassofWarrantorRightAcquiredinAcquisition_A06B182A38A03DCFC7D508261E2EB226_documentation_en-US" xlink:label="lab_mgen_ClassofWarrantorRightAcquiredinAcquisition_A06B182A38A03DCFC7D508261E2EB226" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Acquired in Acquisition</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightAcquiredinAcquisition" xlink:label="loc_mgen_ClassofWarrantorRightAcquiredinAcquisition_A06B182A38A03DCFC7D508261E2EB226" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_ClassofWarrantorRightAcquiredinAcquisition_A06B182A38A03DCFC7D508261E2EB226" xlink:to="lab_mgen_ClassofWarrantorRightAcquiredinAcquisition_A06B182A38A03DCFC7D508261E2EB226" xlink:type="arc" />
    <link:label id="lab_mgen_ClassofWarrantorRightWarrantsConverted_9C439D819BB1B792255108261E2E02F3_terseLabel_en-US" xlink:label="lab_mgen_ClassofWarrantorRightWarrantsConverted_9C439D819BB1B792255108261E2E02F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock warrants converted into common stock warrants (in shares)</link:label>
    <link:label id="lab_mgen_ClassofWarrantorRightWarrantsConverted_9C439D819BB1B792255108261E2E02F3_label_en-US" xlink:label="lab_mgen_ClassofWarrantorRightWarrantsConverted_9C439D819BB1B792255108261E2E02F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Warrants Converted</link:label>
    <link:label id="lab_mgen_ClassofWarrantorRightWarrantsConverted_9C439D819BB1B792255108261E2E02F3_documentation_en-US" xlink:label="lab_mgen_ClassofWarrantorRightWarrantsConverted_9C439D819BB1B792255108261E2E02F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Warrants Converted</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightWarrantsConverted" xlink:label="loc_mgen_ClassofWarrantorRightWarrantsConverted_9C439D819BB1B792255108261E2E02F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_ClassofWarrantorRightWarrantsConverted_9C439D819BB1B792255108261E2E02F3" xlink:to="lab_mgen_ClassofWarrantorRightWarrantsConverted_9C439D819BB1B792255108261E2E02F3" xlink:type="arc" />
    <link:label id="lab_mgen_ClassofWarrantorRightWarrantsExercised_2E235FE6CAF6CC2CB23F08261E2F1B8D_negatedTerseLabel_en-US" xlink:label="lab_mgen_ClassofWarrantorRightWarrantsExercised_2E235FE6CAF6CC2CB23F08261E2F1B8D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cashless exercise (in shares)</link:label>
    <link:label id="lab_mgen_ClassofWarrantorRightWarrantsExercised_2E235FE6CAF6CC2CB23F08261E2F1B8D_label_en-US" xlink:label="lab_mgen_ClassofWarrantorRightWarrantsExercised_2E235FE6CAF6CC2CB23F08261E2F1B8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Warrants Exercised</link:label>
    <link:label id="lab_mgen_ClassofWarrantorRightWarrantsExercised_2E235FE6CAF6CC2CB23F08261E2F1B8D_documentation_en-US" xlink:label="lab_mgen_ClassofWarrantorRightWarrantsExercised_2E235FE6CAF6CC2CB23F08261E2F1B8D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Warrants Exercised</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightWarrantsExercised" xlink:label="loc_mgen_ClassofWarrantorRightWarrantsExercised_2E235FE6CAF6CC2CB23F08261E2F1B8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_ClassofWarrantorRightWarrantsExercised_2E235FE6CAF6CC2CB23F08261E2F1B8D" xlink:to="lab_mgen_ClassofWarrantorRightWarrantsExercised_2E235FE6CAF6CC2CB23F08261E2F1B8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightOutstanding_3D0DF8C25B28A697DF8C08261E2F69B4_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightOutstanding_3D0DF8C25B28A697DF8C08261E2F69B4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3D0DF8C25B28A697DF8C08261E2F69B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3D0DF8C25B28A697DF8C08261E2F69B4" xlink:to="lab_us-gaap_ClassOfWarrantOrRightOutstanding_3D0DF8C25B28A697DF8C08261E2F69B4" xlink:type="arc" />
    <link:label id="lab_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6_terseLabel_en-US" xlink:label="lab_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average Exercise Price</link:label>
    <link:label id="lab_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6_label_en-US" xlink:label="lab_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6_documentation_en-US" xlink:label="lab_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" xlink:label="loc_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:to="lab_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5597E95D13B24419745908261E2F7CE5_periodStartLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5597E95D13B24419745908261E2F7CE5" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in usd per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5597E95D13B24419745908261E2F7CE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5597E95D13B24419745908261E2F7CE5" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5597E95D13B24419745908261E2F7CE5" xlink:type="arc" />
    <link:label id="lab_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice_6B929076F881ACCF7E0D08261E2F8973_terseLabel_en-US" xlink:label="lab_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice_6B929076F881ACCF7E0D08261E2F8973" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants acquired in Merger (in usd per share)</link:label>
    <link:label id="lab_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice_6B929076F881ACCF7E0D08261E2F8973_label_en-US" xlink:label="lab_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice_6B929076F881ACCF7E0D08261E2F8973" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Acquired in Acquisition, Weighted Average Exercise Price</link:label>
    <link:label id="lab_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice_6B929076F881ACCF7E0D08261E2F8973_documentation_en-US" xlink:label="lab_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice_6B929076F881ACCF7E0D08261E2F8973" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Acquired in Acquisition, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice" xlink:label="loc_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice_6B929076F881ACCF7E0D08261E2F8973" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice_6B929076F881ACCF7E0D08261E2F8973" xlink:to="lab_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice_6B929076F881ACCF7E0D08261E2F8973" xlink:type="arc" />
    <link:label id="lab_mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice_1CEB21AEE9287ACCC5D608261E2F3D52_terseLabel_en-US" xlink:label="lab_mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice_1CEB21AEE9287ACCC5D608261E2F3D52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock warrants converted into common stock warrants (in usd per share)</link:label>
    <link:label id="lab_mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice_1CEB21AEE9287ACCC5D608261E2F3D52_label_en-US" xlink:label="lab_mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice_1CEB21AEE9287ACCC5D608261E2F3D52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Converted in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice_1CEB21AEE9287ACCC5D608261E2F3D52_documentation_en-US" xlink:label="lab_mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice_1CEB21AEE9287ACCC5D608261E2F3D52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Converted in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice" xlink:label="loc_mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice_1CEB21AEE9287ACCC5D608261E2F3D52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice_1CEB21AEE9287ACCC5D608261E2F3D52" xlink:to="lab_mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice_1CEB21AEE9287ACCC5D608261E2F3D52" xlink:type="arc" />
    <link:label id="lab_mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice_D11034CA6748FA4F254C08261E2FDF2B_terseLabel_en-US" xlink:label="lab_mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice_D11034CA6748FA4F254C08261E2FDF2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cashless exercise (in usd per share)</link:label>
    <link:label id="lab_mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice_D11034CA6748FA4F254C08261E2FDF2B_label_en-US" xlink:label="lab_mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice_D11034CA6748FA4F254C08261E2FDF2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label id="lab_mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice_D11034CA6748FA4F254C08261E2FDF2B_documentation_en-US" xlink:label="lab_mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice_D11034CA6748FA4F254C08261E2FDF2B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice" xlink:label="loc_mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice_D11034CA6748FA4F254C08261E2FDF2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice_D11034CA6748FA4F254C08261E2FDF2B" xlink:to="lab_mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice_D11034CA6748FA4F254C08261E2FDF2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0F075B6E5CA3D8393C5F08261E2F67C8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0F075B6E5CA3D8393C5F08261E2F67C8" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in usd per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0F075B6E5CA3D8393C5F08261E2F67C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0F075B6E5CA3D8393C5F08261E2F67C8" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0F075B6E5CA3D8393C5F08261E2F67C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_D37BCAA6F9ECF277E44708261D86C2A3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_D37BCAA6F9ECF277E44708261D86C2A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Payable</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_D37BCAA6F9ECF277E44708261D86C2A3_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock_D37BCAA6F9ECF277E44708261D86C2A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_D37BCAA6F9ECF277E44708261D86C2A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock_D37BCAA6F9ECF277E44708261D86C2A3" xlink:to="lab_us-gaap_DebtDisclosureTextBlock_D37BCAA6F9ECF277E44708261D86C2A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1477609AC214566C7FEC08261D788E7C_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1477609AC214566C7FEC08261D788E7C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1477609AC214566C7FEC08261D788E7C_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1477609AC214566C7FEC08261D788E7C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1477609AC214566C7FEC08261D788E7C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1477609AC214566C7FEC08261D788E7C" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1477609AC214566C7FEC08261D788E7C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_B0BDC018CDD387C850A208261D798493_periodStartLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_B0BDC018CDD387C850A208261D798493" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_B0BDC018CDD387C850A208261D798493_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_B0BDC018CDD387C850A208261D798493" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliations, Recurring Basis, Liability Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_B0BDC018CDD387C850A208261D798493" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_B0BDC018CDD387C850A208261D798493" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_B0BDC018CDD387C850A208261D798493" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_EF29B892FE9909FC21EF08261D79A026_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_EF29B892FE9909FC21EF08261D79A026" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of preferred stock warrant to common stock warrant</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_EF29B892FE9909FC21EF08261D79A026_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_EF29B892FE9909FC21EF08261D79A026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Transfers, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_EF29B892FE9909FC21EF08261D79A026" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_EF29B892FE9909FC21EF08261D79A026" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_EF29B892FE9909FC21EF08261D79A026" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_F1C50FBBAE6E03EE9C0208261D7975D8_periodEndLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_F1C50FBBAE6E03EE9C0208261D7975D8" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_F1C50FBBAE6E03EE9C0208261D7975D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_F1C50FBBAE6E03EE9C0208261D7975D8" xlink:to="lab_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_F1C50FBBAE6E03EE9C0208261D7975D8" xlink:type="arc" />
    <link:label id="lab_mgen_AccruedOutsourcingClinicalandPreclinicalStudies_F5DE2FD8DE545BC3425B782AAB409649_terseLabel_en-US" xlink:label="lab_mgen_AccruedOutsourcingClinicalandPreclinicalStudies_F5DE2FD8DE545BC3425B782AAB409649" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued outsourced clinical and preclinical studies</link:label>
    <link:label id="lab_mgen_AccruedOutsourcingClinicalandPreclinicalStudies_F5DE2FD8DE545BC3425B782AAB409649_label_en-US" xlink:label="lab_mgen_AccruedOutsourcingClinicalandPreclinicalStudies_F5DE2FD8DE545BC3425B782AAB409649" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Outsourcing Clinical and Pre-clinical Studies</link:label>
    <link:label id="lab_mgen_AccruedOutsourcingClinicalandPreclinicalStudies_F5DE2FD8DE545BC3425B782AAB409649_documentation_en-US" xlink:label="lab_mgen_AccruedOutsourcingClinicalandPreclinicalStudies_F5DE2FD8DE545BC3425B782AAB409649" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Outsourcing Clinical and Pre-clinical Studies</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccruedOutsourcingClinicalandPreclinicalStudies" xlink:label="loc_mgen_AccruedOutsourcingClinicalandPreclinicalStudies_F5DE2FD8DE545BC3425B782AAB409649" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_AccruedOutsourcingClinicalandPreclinicalStudies_F5DE2FD8DE545BC3425B782AAB409649" xlink:to="lab_mgen_AccruedOutsourcingClinicalandPreclinicalStudies_F5DE2FD8DE545BC3425B782AAB409649" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_B339298E8AE827DAE518782AAB404FCD_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_B339298E8AE827DAE518782AAB404FCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued employee compensation and related taxes</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_B339298E8AE827DAE518782AAB404FCD_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_B339298E8AE827DAE518782AAB404FCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_B339298E8AE827DAE518782AAB404FCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_B339298E8AE827DAE518782AAB404FCD" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_B339298E8AE827DAE518782AAB404FCD" xlink:type="arc" />
    <link:label id="lab_mgen_AccruedLegalFeesCurrent_7405CD3BE5873CF2F69B782AAB418647_terseLabel_en-US" xlink:label="lab_mgen_AccruedLegalFeesCurrent_7405CD3BE5873CF2F69B782AAB418647" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued legal fees and expenses</link:label>
    <link:label id="lab_mgen_AccruedLegalFeesCurrent_7405CD3BE5873CF2F69B782AAB418647_label_en-US" xlink:label="lab_mgen_AccruedLegalFeesCurrent_7405CD3BE5873CF2F69B782AAB418647" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Legal Fees, Current</link:label>
    <link:label id="lab_mgen_AccruedLegalFeesCurrent_7405CD3BE5873CF2F69B782AAB418647_documentation_en-US" xlink:label="lab_mgen_AccruedLegalFeesCurrent_7405CD3BE5873CF2F69B782AAB418647" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Legal Fees, Current</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccruedLegalFeesCurrent" xlink:label="loc_mgen_AccruedLegalFeesCurrent_7405CD3BE5873CF2F69B782AAB418647" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_AccruedLegalFeesCurrent_7405CD3BE5873CF2F69B782AAB418647" xlink:to="lab_mgen_AccruedLegalFeesCurrent_7405CD3BE5873CF2F69B782AAB418647" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_8E4BB816205AF0D02419782AAB41BD2C_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_8E4BB816205AF0D02419782AAB41BD2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued other professional service fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_8E4BB816205AF0D02419782AAB41BD2C_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent_8E4BB816205AF0D02419782AAB41BD2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_8E4BB816205AF0D02419782AAB41BD2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent_8E4BB816205AF0D02419782AAB41BD2C" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent_8E4BB816205AF0D02419782AAB41BD2C" xlink:type="arc" />
    <link:label id="lab_mgen_AccruedLiabilitiesEquipmentandLabMaterials_3F300DD22EE0484A85C2782AAB418641_terseLabel_en-US" xlink:label="lab_mgen_AccruedLiabilitiesEquipmentandLabMaterials_3F300DD22EE0484A85C2782AAB418641" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued equipment and lab materials</link:label>
    <link:label id="lab_mgen_AccruedLiabilitiesEquipmentandLabMaterials_3F300DD22EE0484A85C2782AAB418641_label_en-US" xlink:label="lab_mgen_AccruedLiabilitiesEquipmentandLabMaterials_3F300DD22EE0484A85C2782AAB418641" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Equipment and Lab Materials</link:label>
    <link:label id="lab_mgen_AccruedLiabilitiesEquipmentandLabMaterials_3F300DD22EE0484A85C2782AAB418641_documentation_en-US" xlink:label="lab_mgen_AccruedLiabilitiesEquipmentandLabMaterials_3F300DD22EE0484A85C2782AAB418641" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Equipment and Lab Materials</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccruedLiabilitiesEquipmentandLabMaterials" xlink:label="loc_mgen_AccruedLiabilitiesEquipmentandLabMaterials_3F300DD22EE0484A85C2782AAB418641" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_AccruedLiabilitiesEquipmentandLabMaterials_3F300DD22EE0484A85C2782AAB418641" xlink:to="lab_mgen_AccruedLiabilitiesEquipmentandLabMaterials_3F300DD22EE0484A85C2782AAB418641" xlink:type="arc" />
    <link:label id="lab_mgen_AccruedLiabilityofWarrantsonTemporaryEquity_44885FC316AF73F9329B782AAB41EA98_verboseLabel_en-US" xlink:label="lab_mgen_AccruedLiabilityofWarrantsonTemporaryEquity_44885FC316AF73F9329B782AAB41EA98" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Value of liability-classified stock purchase warrants</link:label>
    <link:label id="lab_mgen_AccruedLiabilityofWarrantsonTemporaryEquity_44885FC316AF73F9329B782AAB41EA98_label_en-US" xlink:label="lab_mgen_AccruedLiabilityofWarrantsonTemporaryEquity_44885FC316AF73F9329B782AAB41EA98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liability of Warrants on Temporary Equity</link:label>
    <link:label id="lab_mgen_AccruedLiabilityofWarrantsonTemporaryEquity_44885FC316AF73F9329B782AAB41EA98_documentation_en-US" xlink:label="lab_mgen_AccruedLiabilityofWarrantsonTemporaryEquity_44885FC316AF73F9329B782AAB41EA98" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Liability of Warrants on Temporary Equity</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccruedLiabilityofWarrantsonTemporaryEquity" xlink:label="loc_mgen_AccruedLiabilityofWarrantsonTemporaryEquity_44885FC316AF73F9329B782AAB41EA98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_AccruedLiabilityofWarrantsonTemporaryEquity_44885FC316AF73F9329B782AAB41EA98" xlink:to="lab_mgen_AccruedLiabilityofWarrantsonTemporaryEquity_44885FC316AF73F9329B782AAB41EA98" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedRentCurrent_A92DF04FA8F3E8F82407782AAB41F9E2_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedRentCurrent_A92DF04FA8F3E8F82407782AAB41F9E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred and accrued facility lease obligations</link:label>
    <link:label id="lab_us-gaap_AccruedRentCurrent_A92DF04FA8F3E8F82407782AAB41F9E2_label_en-US" xlink:label="lab_us-gaap_AccruedRentCurrent_A92DF04FA8F3E8F82407782AAB41F9E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Rent, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaap_AccruedRentCurrent_A92DF04FA8F3E8F82407782AAB41F9E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedRentCurrent_A92DF04FA8F3E8F82407782AAB41F9E2" xlink:to="lab_us-gaap_AccruedRentCurrent_A92DF04FA8F3E8F82407782AAB41F9E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1AF4029743A51347F356782AAB417A44_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1AF4029743A51347F356782AAB417A44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1AF4029743A51347F356782AAB417A44_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1AF4029743A51347F356782AAB417A44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1AF4029743A51347F356782AAB417A44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1AF4029743A51347F356782AAB417A44" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent_1AF4029743A51347F356782AAB417A44" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_490F70D656CC11DBF588782AAB41591A_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_490F70D656CC11DBF588782AAB41591A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_490F70D656CC11DBF588782AAB41591A_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_490F70D656CC11DBF588782AAB41591A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_490F70D656CC11DBF588782AAB41591A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_490F70D656CC11DBF588782AAB41591A" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_490F70D656CC11DBF588782AAB41591A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_98A9D83505719C8648D908261D74C4C7_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_98A9D83505719C8648D908261D74C4C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_98A9D83505719C8648D908261D74C4C7_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_98A9D83505719C8648D908261D74C4C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_98A9D83505719C8648D908261D74C4C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_98A9D83505719C8648D908261D74C4C7" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_98A9D83505719C8648D908261D74C4C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2377250A5EA2F7640C4308261D749DE3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_2377250A5EA2F7640C4308261D749DE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_2377250A5EA2F7640C4308261D749DE3_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_2377250A5EA2F7640C4308261D749DE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2377250A5EA2F7640C4308261D749DE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2377250A5EA2F7640C4308261D749DE3" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_2377250A5EA2F7640C4308261D749DE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_919D1CF804C2BD84F49908261D747D0D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_919D1CF804C2BD84F49908261D747D0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_919D1CF804C2BD84F49908261D747D0D_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_919D1CF804C2BD84F49908261D747D0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_919D1CF804C2BD84F49908261D747D0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_919D1CF804C2BD84F49908261D747D0D" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_919D1CF804C2BD84F49908261D747D0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_583C933FF67D566781FA08261D756CC3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_583C933FF67D566781FA08261D756CC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_583C933FF67D566781FA08261D756CC3_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_583C933FF67D566781FA08261D756CC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_583C933FF67D566781FA08261D756CC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_583C933FF67D566781FA08261D756CC3" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_583C933FF67D566781FA08261D756CC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1D5D07AC01E101538D0008261D757592_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1D5D07AC01E101538D0008261D757592" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1D5D07AC01E101538D0008261D757592_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1D5D07AC01E101538D0008261D757592" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1D5D07AC01E101538D0008261D757592" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1D5D07AC01E101538D0008261D757592" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember_1D5D07AC01E101538D0008261D757592" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FE5D13FED1485DAFCB4708261D75D573_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FE5D13FED1485DAFCB4708261D75D573" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FE5D13FED1485DAFCB4708261D75D573_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FE5D13FED1485DAFCB4708261D75D573" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FE5D13FED1485DAFCB4708261D75D573" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FE5D13FED1485DAFCB4708261D75D573" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FE5D13FED1485DAFCB4708261D75D573" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_04BB21EF566980B707AC08261D75EA71_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_04BB21EF566980B707AC08261D75EA71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_04BB21EF566980B707AC08261D75EA71_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_04BB21EF566980B707AC08261D75EA71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_04BB21EF566980B707AC08261D75EA71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_04BB21EF566980B707AC08261D75EA71" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_04BB21EF566980B707AC08261D75EA71" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3199A4DC4D605AB44CB808261E65D3FD_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3199A4DC4D605AB44CB808261E65D3FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capital Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3199A4DC4D605AB44CB808261E65D3FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3199A4DC4D605AB44CB808261E65D3FD" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3199A4DC4D605AB44CB808261E65D3FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8A348C17A70EEC3FBCE08261DA080A4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8A348C17A70EEC3FBCE08261DA080A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8A348C17A70EEC3FBCE08261DA080A4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8A348C17A70EEC3FBCE08261DA080A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8A348C17A70EEC3FBCE08261DA080A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8A348C17A70EEC3FBCE08261DA080A4" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8A348C17A70EEC3FBCE08261DA080A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_914BD8CB434311F1A5D608261DA0AFC6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_914BD8CB434311F1A5D608261DA0AFC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_914BD8CB434311F1A5D608261DA0AFC6_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_914BD8CB434311F1A5D608261DA0AFC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_914BD8CB434311F1A5D608261DA0AFC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_914BD8CB434311F1A5D608261DA0AFC6" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_914BD8CB434311F1A5D608261DA0AFC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A" xlink:type="arc" />
    <link:label id="lab_mgen_CommonStockWarrantsMember_9BBE774BA6061F846FA308261DA1B983_terseLabel_en-US" xlink:label="lab_mgen_CommonStockWarrantsMember_9BBE774BA6061F846FA308261DA1B983" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase Common Stock</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommonStockWarrantsMember" xlink:label="loc_mgen_CommonStockWarrantsMember_9BBE774BA6061F846FA308261DA1B983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_CommonStockWarrantsMember_9BBE774BA6061F846FA308261DA1B983" xlink:to="lab_mgen_CommonStockWarrantsMember_9BBE774BA6061F846FA308261DA1B983" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_3008E04756AA7B1AB0E108261DA16359_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_3008E04756AA7B1AB0E108261DA16359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ConvertibleDebtSecuritiesMember_3008E04756AA7B1AB0E108261DA16359_label_en-US" xlink:label="lab_us-gaap_ConvertibleDebtSecuritiesMember_3008E04756AA7B1AB0E108261DA16359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_3008E04756AA7B1AB0E108261DA16359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertibleDebtSecuritiesMember_3008E04756AA7B1AB0E108261DA16359" xlink:to="lab_us-gaap_ConvertibleDebtSecuritiesMember_3008E04756AA7B1AB0E108261DA16359" xlink:type="arc" />
    <link:label id="lab_mgen_PreferredStockWarrantsMember_C0B56945AE1107CF7A9208261DA1BB47_terseLabel_en-US" xlink:label="lab_mgen_PreferredStockWarrantsMember_C0B56945AE1107CF7A9208261DA1BB47" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to purchase redeemable convertible preferred stock</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PreferredStockWarrantsMember" xlink:label="loc_mgen_PreferredStockWarrantsMember_C0B56945AE1107CF7A9208261DA1BB47" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_PreferredStockWarrantsMember_C0B56945AE1107CF7A9208261DA1BB47" xlink:to="lab_mgen_PreferredStockWarrantsMember_C0B56945AE1107CF7A9208261DA1BB47" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_277DD0706ADB589228E208261DA1B572_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_277DD0706ADB589228E208261DA1B572" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_277DD0706ADB589228E208261DA1B572_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_277DD0706ADB589228E208261DA1B572" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_277DD0706ADB589228E208261DA1B572" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_277DD0706ADB589228E208261DA1B572" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_277DD0706ADB589228E208261DA1B572" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_092E873706571C3D41B808261DA144C7_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_092E873706571C3D41B808261DA144C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_092E873706571C3D41B808261DA144C7_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_092E873706571C3D41B808261DA144C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_092E873706571C3D41B808261DA144C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_092E873706571C3D41B808261DA144C7" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_092E873706571C3D41B808261DA144C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_27950044CC761635396D08261E62EF08_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable_27950044CC761635396D08261E62EF08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityByClassOfStockTable_27950044CC761635396D08261E62EF08_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityByClassOfStockTable_27950044CC761635396D08261E62EF08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, by Class of Stock [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_27950044CC761635396D08261E62EF08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_27950044CC761635396D08261E62EF08" xlink:to="lab_us-gaap_TemporaryEquityByClassOfStockTable_27950044CC761635396D08261E62EF08" xlink:type="arc" />
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_9150605B1C2930ED40A108261E6311F5_verboseLabel_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember_9150605B1C2930ED40A108261E6311F5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_9150605B1C2930ED40A108261E6311F5_label_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember_9150605B1C2930ED40A108261E6311F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_9150605B1C2930ED40A108261E6311F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember_9150605B1C2930ED40A108261E6311F5" xlink:to="lab_us-gaap_RedeemableConvertiblePreferredStockMember_9150605B1C2930ED40A108261E6311F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_DB6A241DC5636F6C199308261E63F0CD_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems_DB6A241DC5636F6C199308261E63F0CD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityLineItems_DB6A241DC5636F6C199308261E63F0CD_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityLineItems_DB6A241DC5636F6C199308261E63F0CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_DB6A241DC5636F6C199308261E63F0CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityLineItems_DB6A241DC5636F6C199308261E63F0CD" xlink:to="lab_us-gaap_TemporaryEquityLineItems_DB6A241DC5636F6C199308261E63F0CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Temporary Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:to="lab_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_C24A0ADE5493742E0C9C08261E6337F9_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_C24A0ADE5493742E0C9C08261E6337F9" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_C24A0ADE5493742E0C9C08261E6337F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_C24A0ADE5493742E0C9C08261E6337F9" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_C24A0ADE5493742E0C9C08261E6337F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9649107BA563C7D250C608261E63B826_periodStartLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9649107BA563C7D250C608261E63B826" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9649107BA563C7D250C608261E63B826_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9649107BA563C7D250C608261E63B826" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9649107BA563C7D250C608261E63B826" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9649107BA563C7D250C608261E63B826" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9649107BA563C7D250C608261E63B826" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_04C5FC82CE3111A1356608261E63119F_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_04C5FC82CE3111A1356608261E63119F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of redeemable convertible preferred stock to redemption value</link:label>
    <link:label id="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_04C5FC82CE3111A1356608261E63119F_label_en-US" xlink:label="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_04C5FC82CE3111A1356608261E63119F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Temporary Equity, Accretion to Redemption Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_04C5FC82CE3111A1356608261E63119F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_04C5FC82CE3111A1356608261E63119F" xlink:to="lab_us-gaap_TemporaryEquityAccretionToRedemptionValue_04C5FC82CE3111A1356608261E63119F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7075DFEF2071207138AE08261E63C969_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7075DFEF2071207138AE08261E63C969" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7075DFEF2071207138AE08261E63C969_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7075DFEF2071207138AE08261E63C969" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7075DFEF2071207138AE08261E63C969" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7075DFEF2071207138AE08261E63C969" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7075DFEF2071207138AE08261E63C969" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_432C84F2E252BFC4254B08261E633A22_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_432C84F2E252BFC4254B08261E633A22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_432C84F2E252BFC4254B08261E633A22_label_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_432C84F2E252BFC4254B08261E633A22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassifications of Temporary to Permanent Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_432C84F2E252BFC4254B08261E633A22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_432C84F2E252BFC4254B08261E633A22" xlink:to="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_432C84F2E252BFC4254B08261E633A22" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquitySharesOutstanding_3ED224E34E177344EEF708261E633959_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquitySharesOutstanding_3ED224E34E177344EEF708261E633959" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_3ED224E34E177344EEF708261E633959" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquitySharesOutstanding_3ED224E34E177344EEF708261E633959" xlink:to="lab_us-gaap_TemporaryEquitySharesOutstanding_3ED224E34E177344EEF708261E633959" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_C9E05C5E0D9BD116814E08261E635E85_periodEndLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_C9E05C5E0D9BD116814E08261E635E85" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_C9E05C5E0D9BD116814E08261E635E85" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_C9E05C5E0D9BD116814E08261E635E85" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_C9E05C5E0D9BD116814E08261E635E85" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsAbstract_B74588908EBA39E97A7A9293F1991565_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsAbstract_B74588908EBA39E97A7A9293F1991565" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_B74588908EBA39E97A7A9293F1991565" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsAbstract_B74588908EBA39E97A7A9293F1991565" xlink:to="lab_us-gaap_SubsequentEventsAbstract_B74588908EBA39E97A7A9293F1991565" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTable_F653569EAC02CE7758DA9293F1D9C8C8_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_F653569EAC02CE7758DA9293F1D9C8C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTable_F653569EAC02CE7758DA9293F1D9C8C8_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTable_F653569EAC02CE7758DA9293F1D9C8C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_F653569EAC02CE7758DA9293F1D9C8C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTable_F653569EAC02CE7758DA9293F1D9C8C8" xlink:to="lab_us-gaap_SubsequentEventTable_F653569EAC02CE7758DA9293F1D9C8C8" xlink:type="arc" />
    <link:label id="lab_mgen_AtthemarketOfferingMember_062733F4AAF086E863FC92966FDDEC4E_verboseLabel_en-US" xlink:label="lab_mgen_AtthemarketOfferingMember_062733F4AAF086E863FC92966FDDEC4E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">At-the-Market Offering</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AtthemarketOfferingMember" xlink:label="loc_mgen_AtthemarketOfferingMember_062733F4AAF086E863FC92966FDDEC4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_AtthemarketOfferingMember_062733F4AAF086E863FC92966FDDEC4E" xlink:to="lab_mgen_AtthemarketOfferingMember_062733F4AAF086E863FC92966FDDEC4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0EFE0A0F426B984562619293F1D92E39_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0EFE0A0F426B984562619293F1D92E39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_0EFE0A0F426B984562619293F1D92E39_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_0EFE0A0F426B984562619293F1D92E39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0EFE0A0F426B984562619293F1D92E39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0EFE0A0F426B984562619293F1D92E39" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_0EFE0A0F426B984562619293F1D92E39" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_5F64FFB8692656770E319293F1DA1ABC_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_5F64FFB8692656770E319293F1DA1ABC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_5F64FFB8692656770E319293F1DA1ABC_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_5F64FFB8692656770E319293F1DA1ABC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5F64FFB8692656770E319293F1DA1ABC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5F64FFB8692656770E319293F1DA1ABC" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_5F64FFB8692656770E319293F1DA1ABC" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_CE526D9E1D83989E73EE929638237F24_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_CE526D9E1D83989E73EE929638237F24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_CE526D9E1D83989E73EE929638237F24_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_CE526D9E1D83989E73EE929638237F24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_CE526D9E1D83989E73EE929638237F24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_CE526D9E1D83989E73EE929638237F24" xlink:to="lab_us-gaap_SubsequentEventMember_CE526D9E1D83989E73EE929638237F24" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E_label_en-US" xlink:label="lab_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E" xlink:to="lab_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635AA76E354C9F1863FE92949EF32D56_verboseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635AA76E354C9F1863FE92949EF32D56" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from offering</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635AA76E354C9F1863FE92949EF32D56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635AA76E354C9F1863FE92949EF32D56" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635AA76E354C9F1863FE92949EF32D56" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_2F87DDF3CA8B31360D2C782A65CC23E9_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_2F87DDF3CA8B31360D2C782A65CC23E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Events</link:label>
    <link:label id="lab_us-gaap_SubsequentEventsTextBlock_2F87DDF3CA8B31360D2C782A65CC23E9_label_en-US" xlink:label="lab_us-gaap_SubsequentEventsTextBlock_2F87DDF3CA8B31360D2C782A65CC23E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Events [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_2F87DDF3CA8B31360D2C782A65CC23E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventsTextBlock_2F87DDF3CA8B31360D2C782A65CC23E9" xlink:to="lab_us-gaap_SubsequentEventsTextBlock_2F87DDF3CA8B31360D2C782A65CC23E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_E85D0F8BAB1BD8621751929794010DAA_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_E85D0F8BAB1BD8621751929794010DAA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_E85D0F8BAB1BD8621751929794010DAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E85D0F8BAB1BD8621751929794010DAA" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_E85D0F8BAB1BD8621751929794010DAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_5307AAFF9A60D5F87A3E92979401B815_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_5307AAFF9A60D5F87A3E92979401B815" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockMember_5307AAFF9A60D5F87A3E92979401B815_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockMember_5307AAFF9A60D5F87A3E92979401B815" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_5307AAFF9A60D5F87A3E92979401B815" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockMember_5307AAFF9A60D5F87A3E92979401B815" xlink:to="lab_us-gaap_ConvertiblePreferredStockMember_5307AAFF9A60D5F87A3E92979401B815" xlink:type="arc" />
    <link:label id="lab_mgen_ShelfRegistrationMember_F1C72245B4EE1CCDAF0492979401435B_terseLabel_en-US" xlink:label="lab_mgen_ShelfRegistrationMember_F1C72245B4EE1CCDAF0492979401435B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shelf Registration</link:label>
    <link:label id="lab_mgen_ShelfRegistrationMember_F1C72245B4EE1CCDAF0492979401435B_label_en-US" xlink:label="lab_mgen_ShelfRegistrationMember_F1C72245B4EE1CCDAF0492979401435B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shelf Registration [Member]</link:label>
    <link:label id="lab_mgen_ShelfRegistrationMember_F1C72245B4EE1CCDAF0492979401435B_documentation_en-US" xlink:label="lab_mgen_ShelfRegistrationMember_F1C72245B4EE1CCDAF0492979401435B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shelf Registration [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ShelfRegistrationMember" xlink:label="loc_mgen_ShelfRegistrationMember_F1C72245B4EE1CCDAF0492979401435B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_ShelfRegistrationMember_F1C72245B4EE1CCDAF0492979401435B" xlink:to="lab_mgen_ShelfRegistrationMember_F1C72245B4EE1CCDAF0492979401435B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A2CD2DCD79E168E293A992979402691F_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A2CD2DCD79E168E293A992979402691F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A2CD2DCD79E168E293A992979402691F_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A2CD2DCD79E168E293A992979402691F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A2CD2DCD79E168E293A992979402691F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A2CD2DCD79E168E293A992979402691F" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A2CD2DCD79E168E293A992979402691F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_D62DE7260FB24C458754929794024FB3_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_D62DE7260FB24C458754929794024FB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_D62DE7260FB24C458754929794024FB3_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_D62DE7260FB24C458754929794024FB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_D62DE7260FB24C458754929794024FB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_D62DE7260FB24C458754929794024FB3" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_D62DE7260FB24C458754929794024FB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_2C6591BF3837197F207C92979402E59A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_2C6591BF3837197F207C92979402E59A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_2C6591BF3837197F207C92979402E59A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_2C6591BF3837197F207C92979402E59A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2C6591BF3837197F207C92979402E59A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_2C6591BF3837197F207C92979402E59A" xlink:to="lab_us-gaap_ShareBasedCompensation_2C6591BF3837197F207C92979402E59A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccretionExpense_B0FB7C3C88C691FFE70292979402E7FC_terseLabel_en-US" xlink:label="lab_us-gaap_AccretionExpense_B0FB7C3C88C691FFE70292979402E7FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-cash interest expense</link:label>
    <link:label id="lab_us-gaap_AccretionExpense_B0FB7C3C88C691FFE70292979402E7FC_label_en-US" xlink:label="lab_us-gaap_AccretionExpense_B0FB7C3C88C691FFE70292979402E7FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_B0FB7C3C88C691FFE70292979402E7FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionExpense_B0FB7C3C88C691FFE70292979402E7FC" xlink:to="lab_us-gaap_AccretionExpense_B0FB7C3C88C691FFE70292979402E7FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_891B3588C28B86FD6300929794026C15_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_891B3588C28B86FD6300929794026C15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of preferred stock warrants</link:label>
    <link:label id="lab_us-gaap_FairValueAdjustmentOfWarrants_891B3588C28B86FD6300929794026C15_label_en-US" xlink:label="lab_us-gaap_FairValueAdjustmentOfWarrants_891B3588C28B86FD6300929794026C15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Adjustment of Warrants</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_891B3588C28B86FD6300929794026C15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAdjustmentOfWarrants_891B3588C28B86FD6300929794026C15" xlink:to="lab_us-gaap_FairValueAdjustmentOfWarrants_891B3588C28B86FD6300929794026C15" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments_0FAF373B1A1CED4FB23092979402E034_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments_0FAF373B1A1CED4FB23092979402E034" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on short term investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments_0FAF373B1A1CED4FB23092979402E034_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments_0FAF373B1A1CED4FB23092979402E034" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Unrealized Gain (Loss), Excluding Other than Temporary Impairments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments_0FAF373B1A1CED4FB23092979402E034" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments_0FAF373B1A1CED4FB23092979402E034" xlink:to="lab_us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments_0FAF373B1A1CED4FB23092979402E034" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_E395D4FCB649CF1C79BE929794039664_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_E395D4FCB649CF1C79BE929794039664" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_E395D4FCB649CF1C79BE929794039664_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_E395D4FCB649CF1C79BE929794039664" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_E395D4FCB649CF1C79BE929794039664" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_E395D4FCB649CF1C79BE929794039664" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_E395D4FCB649CF1C79BE929794039664" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6113B87C4A63E4D2B36892979403CB5A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6113B87C4A63E4D2B36892979403CB5A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6113B87C4A63E4D2B36892979403CB5A_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6113B87C4A63E4D2B36892979403CB5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6113B87C4A63E4D2B36892979403CB5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6113B87C4A63E4D2B36892979403CB5A" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6113B87C4A63E4D2B36892979403CB5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_C9FF869EA19CCF87557D92979403B322_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_C9FF869EA19CCF87557D92979403B322" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_C9FF869EA19CCF87557D92979403B322_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_C9FF869EA19CCF87557D92979403B322" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_C9FF869EA19CCF87557D92979403B322" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_C9FF869EA19CCF87557D92979403B322" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredRevenue_C9FF869EA19CCF87557D92979403B322" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_DC2EDE7AAA8DFB8E400992979403128C_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_DC2EDE7AAA8DFB8E400992979403128C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_DC2EDE7AAA8DFB8E400992979403128C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable_DC2EDE7AAA8DFB8E400992979403128C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_DC2EDE7AAA8DFB8E400992979403128C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable_DC2EDE7AAA8DFB8E400992979403128C" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable_DC2EDE7AAA8DFB8E400992979403128C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4BB4D56898339E61BF94929794033DE4_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4BB4D56898339E61BF94929794033DE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4BB4D56898339E61BF94929794033DE4_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4BB4D56898339E61BF94929794033DE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4BB4D56898339E61BF94929794033DE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4BB4D56898339E61BF94929794033DE4" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_4BB4D56898339E61BF94929794033DE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_B2BB9B3B9FD77ADE4C7192979403749D_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_B2BB9B3B9FD77ADE4C7192979403749D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_B2BB9B3B9FD77ADE4C7192979403749D_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_B2BB9B3B9FD77ADE4C7192979403749D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_B2BB9B3B9FD77ADE4C7192979403749D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_B2BB9B3B9FD77ADE4C7192979403749D" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_B2BB9B3B9FD77ADE4C7192979403749D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_79099AB2FBB0E0185E0A92979403E473_terseLabel_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition_79099AB2FBB0E0185E0A92979403E473" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash acquired in reverse merger</link:label>
    <link:label id="lab_us-gaap_CashAcquiredFromAcquisition_79099AB2FBB0E0185E0A92979403E473_label_en-US" xlink:label="lab_us-gaap_CashAcquiredFromAcquisition_79099AB2FBB0E0185E0A92979403E473" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Acquired from Acquisition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_79099AB2FBB0E0185E0A92979403E473" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAcquiredFromAcquisition_79099AB2FBB0E0185E0A92979403E473" xlink:to="lab_us-gaap_CashAcquiredFromAcquisition_79099AB2FBB0E0185E0A92979403E473" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24470B44DFE2477B040D929794044C54_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24470B44DFE2477B040D929794044C54" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24470B44DFE2477B040D929794044C54_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24470B44DFE2477B040D929794044C54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24470B44DFE2477B040D929794044C54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24470B44DFE2477B040D929794044C54" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24470B44DFE2477B040D929794044C54" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_7EA0002901D369C6ED5A929794042F0C_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_7EA0002901D369C6ED5A929794042F0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_7EA0002901D369C6ED5A929794042F0C_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_7EA0002901D369C6ED5A929794042F0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_7EA0002901D369C6ED5A929794042F0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_7EA0002901D369C6ED5A929794042F0C" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_7EA0002901D369C6ED5A929794042F0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_28350EC5224B942152E092979404C0EA_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_28350EC5224B942152E092979404C0EA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_28350EC5224B942152E092979404C0EA_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_28350EC5224B942152E092979404C0EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28350EC5224B942152E092979404C0EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28350EC5224B942152E092979404C0EA" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_28350EC5224B942152E092979404C0EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_1C948AF34577595F86A992979404E2C6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1C948AF34577595F86A992979404E2C6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payment of issuance costs associated with the sale of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_1C948AF34577595F86A992979404E2C6_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_1C948AF34577595F86A992979404E2C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1C948AF34577595F86A992979404E2C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_1C948AF34577595F86A992979404E2C6" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_1C948AF34577595F86A992979404E2C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_E3EDDF2476E6EAAEFEC3929794042B7B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_E3EDDF2476E6EAAEFEC3929794042B7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of redeemable convertible preferred stock</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_E3EDDF2476E6EAAEFEC3929794042B7B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_E3EDDF2476E6EAAEFEC3929794042B7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_E3EDDF2476E6EAAEFEC3929794042B7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_E3EDDF2476E6EAAEFEC3929794042B7B" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_E3EDDF2476E6EAAEFEC3929794042B7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_0055D4F9F76EF1D4E7259297940471DF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable_0055D4F9F76EF1D4E7259297940471DF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments of principal on notes payable</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfNotesPayable_0055D4F9F76EF1D4E7259297940471DF_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfNotesPayable_0055D4F9F76EF1D4E7259297940471DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Notes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_0055D4F9F76EF1D4E7259297940471DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfNotesPayable_0055D4F9F76EF1D4E7259297940471DF" xlink:to="lab_us-gaap_RepaymentsOfNotesPayable_0055D4F9F76EF1D4E7259297940471DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_03B3C12331448D70CB94929794043821_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_03B3C12331448D70CB94929794043821" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from the exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_03B3C12331448D70CB94929794043821_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_03B3C12331448D70CB94929794043821" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_03B3C12331448D70CB94929794043821" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_03B3C12331448D70CB94929794043821" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_03B3C12331448D70CB94929794043821" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_86566AB3F07DF7150DEB92979405EEEC_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_86566AB3F07DF7150DEB92979405EEEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from employee stock purchases</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_86566AB3F07DF7150DEB92979405EEEC_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_86566AB3F07DF7150DEB92979405EEEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Repayment of Loans by Employee Stock Ownership Plans</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans" xlink:label="loc_us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_86566AB3F07DF7150DEB92979405EEEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_86566AB3F07DF7150DEB92979405EEEC" xlink:to="lab_us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_86566AB3F07DF7150DEB92979405EEEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8A96E1EE909C2491E75D929794050CE5_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8A96E1EE909C2491E75D929794050CE5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8A96E1EE909C2491E75D929794050CE5_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8A96E1EE909C2491E75D929794050CE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8A96E1EE909C2491E75D929794050CE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8A96E1EE909C2491E75D929794050CE5" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_8A96E1EE909C2491E75D929794050CE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashPeriodIncreaseDecrease_270E7C6D496625DF3DDB92979405AD1A_totalLabel_en-US" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease_270E7C6D496625DF3DDB92979405AD1A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashPeriodIncreaseDecrease_270E7C6D496625DF3DDB92979405AD1A_label_en-US" xlink:label="lab_us-gaap_CashPeriodIncreaseDecrease_270E7C6D496625DF3DDB92979405AD1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Period Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_270E7C6D496625DF3DDB92979405AD1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashPeriodIncreaseDecrease_270E7C6D496625DF3DDB92979405AD1A" xlink:to="lab_us-gaap_CashPeriodIncreaseDecrease_270E7C6D496625DF3DDB92979405AD1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_03E0DE6A045367FD17439297940519E8_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_03E0DE6A045367FD17439297940519E8" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_03E0DE6A045367FD17439297940519E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_03E0DE6A045367FD17439297940519E8" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_03E0DE6A045367FD17439297940519E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4B749FDAE617D7B5170E929794054811_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4B749FDAE617D7B5170E929794054811" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4B749FDAE617D7B5170E929794054811" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4B749FDAE617D7B5170E929794054811" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_4B749FDAE617D7B5170E929794054811" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6C22287267E8235EA4A392979405E113_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_6C22287267E8235EA4A392979405E113" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_6C22287267E8235EA4A392979405E113_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_6C22287267E8235EA4A392979405E113" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6C22287267E8235EA4A392979405E113" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6C22287267E8235EA4A392979405E113" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_6C22287267E8235EA4A392979405E113" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaid_C6AB7E330A4A2E0268E992979405F582_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaid_C6AB7E330A4A2E0268E992979405F582" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaid_C6AB7E330A4A2E0268E992979405F582_label_en-US" xlink:label="lab_us-gaap_InterestPaid_C6AB7E330A4A2E0268E992979405F582" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_C6AB7E330A4A2E0268E992979405F582" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaid_C6AB7E330A4A2E0268E992979405F582" xlink:to="lab_us-gaap_InterestPaid_C6AB7E330A4A2E0268E992979405F582" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities</link:label>
    <link:label id="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2_label_en-US" xlink:label="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:to="lab_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_19320671EF708D54E99892979406F0BC_terseLabel_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_19320671EF708D54E99892979406F0BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities assumed, net of non-cash assets received in reverse merger</link:label>
    <link:label id="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_19320671EF708D54E99892979406F0BC_label_en-US" xlink:label="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_19320671EF708D54E99892979406F0BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Acquisition, Value of Liabilities Assumed</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_19320671EF708D54E99892979406F0BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_19320671EF708D54E99892979406F0BC" xlink:to="lab_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_19320671EF708D54E99892979406F0BC" xlink:type="arc" />
    <link:label id="lab_mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction_DD6107115298674C9C079297940641C8_terseLabel_en-US" xlink:label="lab_mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction_DD6107115298674C9C079297940641C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer of common stock issuance costs from prepaid expenses and other current assets to equity (private financing and at the market sales)</link:label>
    <link:label id="lab_mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction_DD6107115298674C9C079297940641C8_label_en-US" xlink:label="lab_mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction_DD6107115298674C9C079297940641C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Transfer of Stock Issuance Costs, Noncash or Partial Noncash Transaction</link:label>
    <link:label id="lab_mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction_DD6107115298674C9C079297940641C8_documentation_en-US" xlink:label="lab_mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction_DD6107115298674C9C079297940641C8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Transfer of Stock Issuance Costs, Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction" xlink:label="loc_mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction_DD6107115298674C9C079297940641C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction_DD6107115298674C9C079297940641C8" xlink:to="lab_mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction_DD6107115298674C9C079297940641C8" xlink:type="arc" />
    <link:label id="lab_mgen_ConversionofWarrantstoPermanentEquity_0C49844B3774D3D4F08792979406C469_terseLabel_en-US" xlink:label="lab_mgen_ConversionofWarrantstoPermanentEquity_0C49844B3774D3D4F08792979406C469" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of preferred stock warrant (accrued liability) to common stock warrant (equity)</link:label>
    <link:label id="lab_mgen_ConversionofWarrantstoPermanentEquity_0C49844B3774D3D4F08792979406C469_label_en-US" xlink:label="lab_mgen_ConversionofWarrantstoPermanentEquity_0C49844B3774D3D4F08792979406C469" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Conversion of Warrants to Permanent Equity</link:label>
    <link:label id="lab_mgen_ConversionofWarrantstoPermanentEquity_0C49844B3774D3D4F08792979406C469_documentation_en-US" xlink:label="lab_mgen_ConversionofWarrantstoPermanentEquity_0C49844B3774D3D4F08792979406C469" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Conversion of Warrants to Permanent Equity</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ConversionofWarrantstoPermanentEquity" xlink:label="loc_mgen_ConversionofWarrantstoPermanentEquity_0C49844B3774D3D4F08792979406C469" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_ConversionofWarrantstoPermanentEquity_0C49844B3774D3D4F08792979406C469" xlink:to="lab_mgen_ConversionofWarrantstoPermanentEquity_0C49844B3774D3D4F08792979406C469" xlink:type="arc" />
    <link:label id="lab_mgen_AccretionofOfferingCosts_4F613A32333789038FE5929794069AA8_terseLabel_en-US" xlink:label="lab_mgen_AccretionofOfferingCosts_4F613A32333789038FE5929794069AA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of redeemable convertible preferred stock to redemption value</link:label>
    <link:label id="lab_mgen_AccretionofOfferingCosts_4F613A32333789038FE5929794069AA8_label_en-US" xlink:label="lab_mgen_AccretionofOfferingCosts_4F613A32333789038FE5929794069AA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion of Offering Costs</link:label>
    <link:label id="lab_mgen_AccretionofOfferingCosts_4F613A32333789038FE5929794069AA8_documentation_en-US" xlink:label="lab_mgen_AccretionofOfferingCosts_4F613A32333789038FE5929794069AA8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accretion of Offering Costs</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccretionofOfferingCosts" xlink:label="loc_mgen_AccretionofOfferingCosts_4F613A32333789038FE5929794069AA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_AccretionofOfferingCosts_4F613A32333789038FE5929794069AA8" xlink:to="lab_mgen_AccretionofOfferingCosts_4F613A32333789038FE5929794069AA8" xlink:type="arc" />
    <link:label id="lab_mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_FCADC36226CB651436E292979406B8C5_terseLabel_en-US" xlink:label="lab_mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_FCADC36226CB651436E292979406B8C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unpaid common stock issuance costs included in prepaid expenses and other assets, accounts payable, and accrued liabilities</link:label>
    <link:label id="lab_mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_FCADC36226CB651436E292979406B8C5_label_en-US" xlink:label="lab_mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_FCADC36226CB651436E292979406B8C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:label id="lab_mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_FCADC36226CB651436E292979406B8C5_documentation_en-US" xlink:label="lab_mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_FCADC36226CB651436E292979406B8C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issuance Costs Incurred During Noncash or Partial Noncash Transaction</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction" xlink:label="loc_mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_FCADC36226CB651436E292979406B8C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_FCADC36226CB651436E292979406B8C5" xlink:to="lab_mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_FCADC36226CB651436E292979406B8C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_DDBD3501DC35F01D26C008261D716075_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_DDBD3501DC35F01D26C008261D716075" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_DDBD3501DC35F01D26C008261D716075_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_DDBD3501DC35F01D26C008261D716075" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_DDBD3501DC35F01D26C008261D716075" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_DDBD3501DC35F01D26C008261D716075" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_DDBD3501DC35F01D26C008261D716075" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_C1C5DDF74DEABBFA330608261D71380B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_C1C5DDF74DEABBFA330608261D71380B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_C1C5DDF74DEABBFA330608261D71380B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_C1C5DDF74DEABBFA330608261D71380B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_C1C5DDF74DEABBFA330608261D71380B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_C1C5DDF74DEABBFA330608261D71380B" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_C1C5DDF74DEABBFA330608261D71380B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_70B934F1B1C8AF00C4A508261D714234_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_70B934F1B1C8AF00C4A508261D714234" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_70B934F1B1C8AF00C4A508261D714234_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_70B934F1B1C8AF00C4A508261D714234" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_70B934F1B1C8AF00C4A508261D714234" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_70B934F1B1C8AF00C4A508261D714234" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_70B934F1B1C8AF00C4A508261D714234" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_AA23C7AA2494945A8C0808261D715A86_totalLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_AA23C7AA2494945A8C0808261D715A86" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net acquired tangible assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_AA23C7AA2494945A8C0808261D715A86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_AA23C7AA2494945A8C0808261D715A86" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_AA23C7AA2494945A8C0808261D715A86" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D9BCE08E049966F3D508782AAB65F5FB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D9BCE08E049966F3D508782AAB65F5FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D9BCE08E049966F3D508782AAB65F5FB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D9BCE08E049966F3D508782AAB65F5FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D9BCE08E049966F3D508782AAB65F5FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D9BCE08E049966F3D508782AAB65F5FB" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D9BCE08E049966F3D508782AAB65F5FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinimumMember_60352974B53E12ACAD64782AAB66F43F_terseLabel_en-US" xlink:label="lab_us-gaap_MinimumMember_60352974B53E12ACAD64782AAB66F43F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_us-gaap_MinimumMember_60352974B53E12ACAD64782AAB66F43F_label_en-US" xlink:label="lab_us-gaap_MinimumMember_60352974B53E12ACAD64782AAB66F43F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_60352974B53E12ACAD64782AAB66F43F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinimumMember_60352974B53E12ACAD64782AAB66F43F" xlink:to="lab_us-gaap_MinimumMember_60352974B53E12ACAD64782AAB66F43F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_FDBF78B37552D15F79CA782AAB669155_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_FDBF78B37552D15F79CA782AAB669155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_FDBF78B37552D15F79CA782AAB669155_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_FDBF78B37552D15F79CA782AAB669155" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_FDBF78B37552D15F79CA782AAB669155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FDBF78B37552D15F79CA782AAB669155" xlink:to="lab_us-gaap_TypeOfArrangementAxis_FDBF78B37552D15F79CA782AAB669155" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2F8217F2847259D6C63B782AAB66FDAF_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2F8217F2847259D6C63B782AAB66FDAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2F8217F2847259D6C63B782AAB66FDAF_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2F8217F2847259D6C63B782AAB66FDAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2F8217F2847259D6C63B782AAB66FDAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2F8217F2847259D6C63B782AAB66FDAF" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2F8217F2847259D6C63B782AAB66FDAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_2EA89624694A8E12FF2A782AAB662B8D_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_2EA89624694A8E12FF2A782AAB662B8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Servier Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_2EA89624694A8E12FF2A782AAB662B8D_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_2EA89624694A8E12FF2A782AAB662B8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_2EA89624694A8E12FF2A782AAB662B8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_2EA89624694A8E12FF2A782AAB662B8D" xlink:to="lab_us-gaap_CollaborativeArrangementMember_2EA89624694A8E12FF2A782AAB662B8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:type="arc" />
    <link:label id="lab_mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments_2CF7AFE5C6D8E7FA7398782AAB66F26F_terseLabel_en-US" xlink:label="lab_mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments_2CF7AFE5C6D8E7FA7398782AAB66F26F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential development milestone payments</link:label>
    <link:label id="lab_mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments_2CF7AFE5C6D8E7FA7398782AAB66F26F_label_en-US" xlink:label="lab_mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments_2CF7AFE5C6D8E7FA7398782AAB66F26F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Potential Development Milestone Payments</link:label>
    <link:label id="lab_mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments_2CF7AFE5C6D8E7FA7398782AAB66F26F_documentation_en-US" xlink:label="lab_mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments_2CF7AFE5C6D8E7FA7398782AAB66F26F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Potential Development Milestone Payments</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments" xlink:label="loc_mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments_2CF7AFE5C6D8E7FA7398782AAB66F26F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments_2CF7AFE5C6D8E7FA7398782AAB66F26F" xlink:to="lab_mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments_2CF7AFE5C6D8E7FA7398782AAB66F26F" xlink:type="arc" />
    <link:label id="lab_mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments_51868147721B429ADA3E782AAB67B7BC_terseLabel_en-US" xlink:label="lab_mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments_51868147721B429ADA3E782AAB67B7BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential regulatory milestone payments</link:label>
    <link:label id="lab_mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments_51868147721B429ADA3E782AAB67B7BC_label_en-US" xlink:label="lab_mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments_51868147721B429ADA3E782AAB67B7BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Potential Regulatory Milestone Payments</link:label>
    <link:label id="lab_mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments_51868147721B429ADA3E782AAB67B7BC_documentation_en-US" xlink:label="lab_mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments_51868147721B429ADA3E782AAB67B7BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Potential Regulatory Milestone Payments</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:label="loc_mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments_51868147721B429ADA3E782AAB67B7BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments_51868147721B429ADA3E782AAB67B7BC" xlink:to="lab_mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments_51868147721B429ADA3E782AAB67B7BC" xlink:type="arc" />
    <link:label id="lab_mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments_F87080493B6E7CBE6F62782AAB6768E1_terseLabel_en-US" xlink:label="lab_mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments_F87080493B6E7CBE6F62782AAB6768E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential commercialization milestone payments</link:label>
    <link:label id="lab_mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments_F87080493B6E7CBE6F62782AAB6768E1_label_en-US" xlink:label="lab_mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments_F87080493B6E7CBE6F62782AAB6768E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Potential Commercialization Milestone Payments</link:label>
    <link:label id="lab_mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments_F87080493B6E7CBE6F62782AAB6768E1_documentation_en-US" xlink:label="lab_mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments_F87080493B6E7CBE6F62782AAB6768E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Potential Commercialization Milestone Payments</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments" xlink:label="loc_mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments_F87080493B6E7CBE6F62782AAB6768E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments_F87080493B6E7CBE6F62782AAB6768E1" xlink:to="lab_mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments_F87080493B6E7CBE6F62782AAB6768E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReimbursementRevenue_3F17566629ABD40B61C1782AAB67F68F_terseLabel_en-US" xlink:label="lab_us-gaap_ReimbursementRevenue_3F17566629ABD40B61C1782AAB67F68F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from research and development activities</link:label>
    <link:label id="lab_us-gaap_ReimbursementRevenue_3F17566629ABD40B61C1782AAB67F68F_label_en-US" xlink:label="lab_us-gaap_ReimbursementRevenue_3F17566629ABD40B61C1782AAB67F68F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reimbursement Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReimbursementRevenue" xlink:label="loc_us-gaap_ReimbursementRevenue_3F17566629ABD40B61C1782AAB67F68F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReimbursementRevenue_3F17566629ABD40B61C1782AAB67F68F" xlink:to="lab_us-gaap_ReimbursementRevenue_3F17566629ABD40B61C1782AAB67F68F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensesRevenue_88982AF65AFD202D876B782AAB677382_terseLabel_en-US" xlink:label="lab_us-gaap_LicensesRevenue_88982AF65AFD202D876B782AAB677382" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licenses revenue</link:label>
    <link:label id="lab_us-gaap_LicensesRevenue_88982AF65AFD202D876B782AAB677382_label_en-US" xlink:label="lab_us-gaap_LicensesRevenue_88982AF65AFD202D876B782AAB677382" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licenses Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_88982AF65AFD202D876B782AAB677382" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensesRevenue_88982AF65AFD202D876B782AAB677382" xlink:to="lab_us-gaap_LicensesRevenue_88982AF65AFD202D876B782AAB677382" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms_3D407227F65318DCA601782AAB67A8DF_terseLabel_en-US" xlink:label="lab_us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms_3D407227F65318DCA601782AAB67A8DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amounts incurred but not yet billed</link:label>
    <link:label id="lab_us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms_3D407227F65318DCA601782AAB67A8DF_label_en-US" xlink:label="lab_us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms_3D407227F65318DCA601782AAB67A8DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs in Excess of Billings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms" xlink:label="loc_us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms_3D407227F65318DCA601782AAB67A8DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms_3D407227F65318DCA601782AAB67A8DF" xlink:to="lab_us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms_3D407227F65318DCA601782AAB67A8DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNet_DE936D0212D131B85A847833921EFFC2_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet_DE936D0212D131B85A847833921EFFC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNet_DE936D0212D131B85A847833921EFFC2_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNet_DE936D0212D131B85A847833921EFFC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_DE936D0212D131B85A847833921EFFC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNet_DE936D0212D131B85A847833921EFFC2" xlink:to="lab_us-gaap_AccountsReceivableNet_DE936D0212D131B85A847833921EFFC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stock by Class [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:type="arc" />
    <link:label id="lab_mgen_PreMergerSharesMember_B9C163BF7DA44099385A782AAB0992EA_terseLabel_en-US" xlink:label="lab_mgen_PreMergerSharesMember_B9C163BF7DA44099385A782AAB0992EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Merger</link:label>
    <link:label id="lab_mgen_PreMergerSharesMember_B9C163BF7DA44099385A782AAB0992EA_label_en-US" xlink:label="lab_mgen_PreMergerSharesMember_B9C163BF7DA44099385A782AAB0992EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Merger Shares [Member]</link:label>
    <link:label id="lab_mgen_PreMergerSharesMember_B9C163BF7DA44099385A782AAB0992EA_documentation_en-US" xlink:label="lab_mgen_PreMergerSharesMember_B9C163BF7DA44099385A782AAB0992EA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Merger Shares [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PreMergerSharesMember" xlink:label="loc_mgen_PreMergerSharesMember_B9C163BF7DA44099385A782AAB0992EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_PreMergerSharesMember_B9C163BF7DA44099385A782AAB0992EA" xlink:to="lab_mgen_PreMergerSharesMember_B9C163BF7DA44099385A782AAB0992EA" xlink:type="arc" />
    <link:label id="lab_mgen_PostMergerSharesMember_5103D6AB6E826368FC94782AAB09B9BF_terseLabel_en-US" xlink:label="lab_mgen_PostMergerSharesMember_5103D6AB6E826368FC94782AAB09B9BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post-Merger</link:label>
    <link:label id="lab_mgen_PostMergerSharesMember_5103D6AB6E826368FC94782AAB09B9BF_label_en-US" xlink:label="lab_mgen_PostMergerSharesMember_5103D6AB6E826368FC94782AAB09B9BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Post-Merger Shares [Member]</link:label>
    <link:label id="lab_mgen_PostMergerSharesMember_5103D6AB6E826368FC94782AAB09B9BF_documentation_en-US" xlink:label="lab_mgen_PostMergerSharesMember_5103D6AB6E826368FC94782AAB09B9BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Post-Merger Shares [Member]</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PostMergerSharesMember" xlink:label="loc_mgen_PostMergerSharesMember_5103D6AB6E826368FC94782AAB09B9BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_PostMergerSharesMember_5103D6AB6E826368FC94782AAB09B9BF" xlink:to="lab_mgen_PostMergerSharesMember_5103D6AB6E826368FC94782AAB09B9BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="lab_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:type="arc" />
    <link:label id="lab_mgen_CapitalStockSharesAuthorized_6D8CC6ACD5BBC15A069C782AAB0B84C1_terseLabel_en-US" xlink:label="lab_mgen_CapitalStockSharesAuthorized_6D8CC6ACD5BBC15A069C782AAB0B84C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_mgen_CapitalStockSharesAuthorized_6D8CC6ACD5BBC15A069C782AAB0B84C1_label_en-US" xlink:label="lab_mgen_CapitalStockSharesAuthorized_6D8CC6ACD5BBC15A069C782AAB0B84C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Stock, Shares Authorized</link:label>
    <link:label id="lab_mgen_CapitalStockSharesAuthorized_6D8CC6ACD5BBC15A069C782AAB0B84C1_documentation_en-US" xlink:label="lab_mgen_CapitalStockSharesAuthorized_6D8CC6ACD5BBC15A069C782AAB0B84C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capital Stock, Shares Authorized</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CapitalStockSharesAuthorized" xlink:label="loc_mgen_CapitalStockSharesAuthorized_6D8CC6ACD5BBC15A069C782AAB0B84C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_CapitalStockSharesAuthorized_6D8CC6ACD5BBC15A069C782AAB0B84C1" xlink:to="lab_mgen_CapitalStockSharesAuthorized_6D8CC6ACD5BBC15A069C782AAB0B84C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_25A8D78CB9A867EE22EE782AAB0B0077_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_25A8D78CB9A867EE22EE782AAB0B0077" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_25A8D78CB9A867EE22EE782AAB0B0077_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_25A8D78CB9A867EE22EE782AAB0B0077" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_25A8D78CB9A867EE22EE782AAB0B0077" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_25A8D78CB9A867EE22EE782AAB0B0077" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_25A8D78CB9A867EE22EE782AAB0B0077" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_C82364B4435659154612782AAB0BAC77_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_C82364B4435659154612782AAB0BAC77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, par value (in usd per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_C82364B4435659154612782AAB0BAC77_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_C82364B4435659154612782AAB0BAC77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_C82364B4435659154612782AAB0BAC77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_C82364B4435659154612782AAB0BAC77" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_C82364B4435659154612782AAB0BAC77" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_85E8B55D3AAEA45D168B782AAB0B67F1_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_85E8B55D3AAEA45D168B782AAB0B67F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock to investors, net of issuance cost (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_85E8B55D3AAEA45D168B782AAB0B67F1_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_85E8B55D3AAEA45D168B782AAB0B67F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_85E8B55D3AAEA45D168B782AAB0B67F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_85E8B55D3AAEA45D168B782AAB0B67F1" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_85E8B55D3AAEA45D168B782AAB0B67F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_6326F29CD91CC4D88F09782AAB0BC8E9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts_6326F29CD91CC4D88F09782AAB0BC8E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of stock issuance costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6326F29CD91CC4D88F09782AAB0BC8E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts_6326F29CD91CC4D88F09782AAB0BC8E9" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts_6326F29CD91CC4D88F09782AAB0BC8E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_DB10D8F965A1A13391907846E2A5629A_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_DB10D8F965A1A13391907846E2A5629A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering costs incurred</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_DB10D8F965A1A13391907846E2A5629A_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_DB10D8F965A1A13391907846E2A5629A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_DB10D8F965A1A13391907846E2A5629A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_DB10D8F965A1A13391907846E2A5629A" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_DB10D8F965A1A13391907846E2A5629A" xlink:type="arc" />
    <link:label id="lab_mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds_E5A2F5AFB35EBE8E069B782AAB0BC589_terseLabel_en-US" xlink:label="lab_mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds_E5A2F5AFB35EBE8E069B782AAB0BC589" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commission fee percent</link:label>
    <link:label id="lab_mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds_E5A2F5AFB35EBE8E069B782AAB0BC589_label_en-US" xlink:label="lab_mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds_E5A2F5AFB35EBE8E069B782AAB0BC589" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Commission Fee, Percentage of Gross Sale Proceeds</link:label>
    <link:label id="lab_mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds_E5A2F5AFB35EBE8E069B782AAB0BC589_documentation_en-US" xlink:label="lab_mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds_E5A2F5AFB35EBE8E069B782AAB0BC589" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of Stock, Commission Fee, Percentage of Gross Sale Proceeds</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds" xlink:label="loc_mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds_E5A2F5AFB35EBE8E069B782AAB0BC589" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds_E5A2F5AFB35EBE8E069B782AAB0BC589" xlink:to="lab_mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds_E5A2F5AFB35EBE8E069B782AAB0BC589" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredOfferingCosts_AE22ED07D6A241BEA21D7844FE78F61C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts_AE22ED07D6A241BEA21D7844FE78F61C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Offering costs</link:label>
    <link:label id="lab_us-gaap_DeferredOfferingCosts_AE22ED07D6A241BEA21D7844FE78F61C_label_en-US" xlink:label="lab_us-gaap_DeferredOfferingCosts_AE22ED07D6A241BEA21D7844FE78F61C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Offering Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_AE22ED07D6A241BEA21D7844FE78F61C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredOfferingCosts_AE22ED07D6A241BEA21D7844FE78F61C" xlink:to="lab_us-gaap_DeferredOfferingCosts_AE22ED07D6A241BEA21D7844FE78F61C" xlink:type="arc" />
    <link:label id="lab_mgen_AccumulatedAmortizationDeferredCosts_86EEA57CA3B5CB555C6B784AFAE510DE_terseLabel_en-US" xlink:label="lab_mgen_AccumulatedAmortizationDeferredCosts_86EEA57CA3B5CB555C6B784AFAE510DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated amortization, offering costs</link:label>
    <link:label id="lab_mgen_AccumulatedAmortizationDeferredCosts_86EEA57CA3B5CB555C6B784AFAE510DE_label_en-US" xlink:label="lab_mgen_AccumulatedAmortizationDeferredCosts_86EEA57CA3B5CB555C6B784AFAE510DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Amortization, Deferred Costs</link:label>
    <link:label id="lab_mgen_AccumulatedAmortizationDeferredCosts_86EEA57CA3B5CB555C6B784AFAE510DE_documentation_en-US" xlink:label="lab_mgen_AccumulatedAmortizationDeferredCosts_86EEA57CA3B5CB555C6B784AFAE510DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accumulated Amortization, Deferred Costs</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccumulatedAmortizationDeferredCosts" xlink:label="loc_mgen_AccumulatedAmortizationDeferredCosts_86EEA57CA3B5CB555C6B784AFAE510DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_AccumulatedAmortizationDeferredCosts_86EEA57CA3B5CB555C6B784AFAE510DE" xlink:to="lab_mgen_AccumulatedAmortizationDeferredCosts_86EEA57CA3B5CB555C6B784AFAE510DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_DE6CAD43747353049AFD08261D763EC9_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_DE6CAD43747353049AFD08261D763EC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_DE6CAD43747353049AFD08261D763EC9_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_DE6CAD43747353049AFD08261D763EC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_DE6CAD43747353049AFD08261D763EC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_DE6CAD43747353049AFD08261D763EC9" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_DE6CAD43747353049AFD08261D763EC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_259D622B776E5F8BCD8108261DB53B93_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_259D622B776E5F8BCD8108261DB53B93" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment charges</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_259D622B776E5F8BCD8108261DB53B93_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_259D622B776E5F8BCD8108261DB53B93" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets Held-for-use</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_259D622B776E5F8BCD8108261DB53B93" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_259D622B776E5F8BCD8108261DB53B93" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_259D622B776E5F8BCD8108261DB53B93" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_559B4AA0DDBC07C5790D08261DB6C0F2_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_559B4AA0DDBC07C5790D08261DB6C0F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax penalties and interest expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_559B4AA0DDBC07C5790D08261DB6C0F2_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_559B4AA0DDBC07C5790D08261DB6C0F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination, Penalties and Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_559B4AA0DDBC07C5790D08261DB6C0F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_559B4AA0DDBC07C5790D08261DB6C0F2" xlink:to="lab_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_559B4AA0DDBC07C5790D08261DB6C0F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_9A58D44FC784F432502908261DB689A8_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_9A58D44FC784F432502908261DB689A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_9A58D44FC784F432502908261DB689A8_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_9A58D44FC784F432502908261DB689A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_9A58D44FC784F432502908261DB689A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_9A58D44FC784F432502908261DB689A8" xlink:to="lab_us-gaap_NumberOfOperatingSegments_9A58D44FC784F432502908261DB689A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_C3581F564FB8B9D6F29608261DB6D3E1_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_C3581F564FB8B9D6F29608261DB6D3E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated useful lives</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_C3581F564FB8B9D6F29608261DB6D3E1_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_C3581F564FB8B9D6F29608261DB6D3E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_C3581F564FB8B9D6F29608261DB6D3E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_C3581F564FB8B9D6F29608261DB6D3E1" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_C3581F564FB8B9D6F29608261DB6D3E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_EAEF0AE4FC57EBDE8C9108261E51041C_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_EAEF0AE4FC57EBDE8C9108261E51041C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_EAEF0AE4FC57EBDE8C9108261E51041C_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_EAEF0AE4FC57EBDE8C9108261E51041C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_EAEF0AE4FC57EBDE8C9108261E51041C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_EAEF0AE4FC57EBDE8C9108261E51041C" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_EAEF0AE4FC57EBDE8C9108261E51041C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_AD5A8B069B09412BCF845586B8C6425F_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_AD5A8B069B09412BCF845586B8C6425F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_AD5A8B069B09412BCF845586B8C6425F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_AD5A8B069B09412BCF845586B8C6425F" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_AD5A8B069B09412BCF845586B8C6425F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RedeemableConvertiblePreferredStockMember_D4E0AF5F93E8E561C3DC5586B8C63286_terseLabel_en-US" xlink:label="lab_us-gaap_RedeemableConvertiblePreferredStockMember_D4E0AF5F93E8E561C3DC5586B8C63286" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable Convertible Preferred Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_D4E0AF5F93E8E561C3DC5586B8C63286" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RedeemableConvertiblePreferredStockMember_D4E0AF5F93E8E561C3DC5586B8C63286" xlink:to="lab_us-gaap_RedeemableConvertiblePreferredStockMember_D4E0AF5F93E8E561C3DC5586B8C63286" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1CBF9B28AFCCB5F2EABE5586B8C7EDE9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1CBF9B28AFCCB5F2EABE5586B8C7EDE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_1CBF9B28AFCCB5F2EABE5586B8C7EDE9_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_1CBF9B28AFCCB5F2EABE5586B8C7EDE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1CBF9B28AFCCB5F2EABE5586B8C7EDE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_1CBF9B28AFCCB5F2EABE5586B8C7EDE9" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_1CBF9B28AFCCB5F2EABE5586B8C7EDE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_368810FCFA778D65D0D85586B8C7D5F7_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_368810FCFA778D65D0D85586B8C7D5F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_368810FCFA778D65D0D85586B8C7D5F7_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_368810FCFA778D65D0D85586B8C7D5F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_368810FCFA778D65D0D85586B8C7D5F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_368810FCFA778D65D0D85586B8C7D5F7" xlink:to="lab_us-gaap_RetainedEarningsMember_368810FCFA778D65D0D85586B8C7D5F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0A86E42CC3BA84BDC6AD5586B8C801A9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0A86E42CC3BA84BDC6AD5586B8C801A9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock to common stock (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0A86E42CC3BA84BDC6AD5586B8C801A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0A86E42CC3BA84BDC6AD5586B8C801A9" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0A86E42CC3BA84BDC6AD5586B8C801A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_63BF776A03790D07F68A5586B8C8423D_netLabel_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_63BF776A03790D07F68A5586B8C8423D" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_63BF776A03790D07F68A5586B8C8423D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_63BF776A03790D07F68A5586B8C8423D" xlink:to="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_63BF776A03790D07F68A5586B8C8423D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; deficit</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_2322B0368E58779074EA5586B8C88539_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_2322B0368E58779074EA5586B8C88539" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2322B0368E58779074EA5586B8C88539" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_2322B0368E58779074EA5586B8C88539" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_2322B0368E58779074EA5586B8C88539" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_A1510ECF7456E48DAC165586B8C8FB49_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_A1510ECF7456E48DAC165586B8C8FB49" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_A1510ECF7456E48DAC165586B8C8FB49_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_A1510ECF7456E48DAC165586B8C8FB49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A1510ECF7456E48DAC165586B8C8FB49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_A1510ECF7456E48DAC165586B8C8FB49" xlink:to="lab_us-gaap_StockholdersEquity_A1510ECF7456E48DAC165586B8C8FB49" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2327EBF5D7C8A5698905586B8C8AE5E_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2327EBF5D7C8A5698905586B8C8AE5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock to investors, net of issuance cost</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2327EBF5D7C8A5698905586B8C8AE5E_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2327EBF5D7C8A5698905586B8C8AE5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2327EBF5D7C8A5698905586B8C8AE5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2327EBF5D7C8A5698905586B8C8AE5E" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2327EBF5D7C8A5698905586B8C8AE5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockAccretionOfRedemptionDiscount_C7826F98D2EA6C3F31185586B8C818CF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockAccretionOfRedemptionDiscount_C7826F98D2EA6C3F31185586B8C818CF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accretion of preferred stock to current redemption value</link:label>
    <link:label id="lab_us-gaap_PreferredStockAccretionOfRedemptionDiscount_C7826F98D2EA6C3F31185586B8C818CF_label_en-US" xlink:label="lab_us-gaap_PreferredStockAccretionOfRedemptionDiscount_C7826F98D2EA6C3F31185586B8C818CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Accretion of Redemption Discount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount_C7826F98D2EA6C3F31185586B8C818CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount_C7826F98D2EA6C3F31185586B8C818CF" xlink:to="lab_us-gaap_PreferredStockAccretionOfRedemptionDiscount_C7826F98D2EA6C3F31185586B8C818CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_0E6CFBDA53B14925BF4B5586B8C829B0_verboseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_0E6CFBDA53B14925BF4B5586B8C829B0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Conversion of preferred stock to common stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_0E6CFBDA53B14925BF4B5586B8C829B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_0E6CFBDA53B14925BF4B5586B8C829B0" xlink:to="lab_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_0E6CFBDA53B14925BF4B5586B8C829B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_189A04A0DDB99D2CD6125586B8C8BF38_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_189A04A0DDB99D2CD6125586B8C8BF38" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon reverse merger (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_189A04A0DDB99D2CD6125586B8C8BF38_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_189A04A0DDB99D2CD6125586B8C8BF38" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_189A04A0DDB99D2CD6125586B8C8BF38" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_189A04A0DDB99D2CD6125586B8C8BF38" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_189A04A0DDB99D2CD6125586B8C8BF38" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_38C93F57728F570683BA5586B8C83B87_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_38C93F57728F570683BA5586B8C83B87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon reverse merger</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_38C93F57728F570683BA5586B8C83B87_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_38C93F57728F570683BA5586B8C83B87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Acquisitions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_38C93F57728F570683BA5586B8C83B87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_38C93F57728F570683BA5586B8C83B87" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueAcquisitions_38C93F57728F570683BA5586B8C83B87" xlink:type="arc" />
    <link:label id="lab_mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability_0A0E37B574BE9299EDB75586B8C8AF30_terseLabel_en-US" xlink:label="lab_mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability_0A0E37B574BE9299EDB75586B8C8AF30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of preferred stock warrant to common stock warrant</link:label>
    <link:label id="lab_mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability_0A0E37B574BE9299EDB75586B8C8AF30_label_en-US" xlink:label="lab_mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability_0A0E37B574BE9299EDB75586B8C8AF30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Reclassification of Warrant Liability</link:label>
    <link:label id="lab_mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability_0A0E37B574BE9299EDB75586B8C8AF30_documentation_en-US" xlink:label="lab_mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability_0A0E37B574BE9299EDB75586B8C8AF30" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Reclassification of Warrant Liability</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability" xlink:label="loc_mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability_0A0E37B574BE9299EDB75586B8C8AF30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability_0A0E37B574BE9299EDB75586B8C8AF30" xlink:to="lab_mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability_0A0E37B574BE9299EDB75586B8C8AF30" xlink:type="arc" />
    <link:label id="lab_mgen_StockIssuedDuringPeriodSharesExerciseofWarrants_24D1E3F234505A72A0C25586B8C9E6B5_terseLabel_en-US" xlink:label="lab_mgen_StockIssuedDuringPeriodSharesExerciseofWarrants_24D1E3F234505A72A0C25586B8C9E6B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of warrant (in shares)</link:label>
    <link:label id="lab_mgen_StockIssuedDuringPeriodSharesExerciseofWarrants_24D1E3F234505A72A0C25586B8C9E6B5_label_en-US" xlink:label="lab_mgen_StockIssuedDuringPeriodSharesExerciseofWarrants_24D1E3F234505A72A0C25586B8C9E6B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exercise of Warrants</link:label>
    <link:label id="lab_mgen_StockIssuedDuringPeriodSharesExerciseofWarrants_24D1E3F234505A72A0C25586B8C9E6B5_documentation_en-US" xlink:label="lab_mgen_StockIssuedDuringPeriodSharesExerciseofWarrants_24D1E3F234505A72A0C25586B8C9E6B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exercise of Warrants</link:label>
    <link:loc xlink:href="mgen-20170930.xsd#mgen_StockIssuedDuringPeriodSharesExerciseofWarrants" xlink:label="loc_mgen_StockIssuedDuringPeriodSharesExerciseofWarrants_24D1E3F234505A72A0C25586B8C9E6B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_mgen_StockIssuedDuringPeriodSharesExerciseofWarrants_24D1E3F234505A72A0C25586B8C9E6B5" xlink:to="lab_mgen_StockIssuedDuringPeriodSharesExerciseofWarrants_24D1E3F234505A72A0C25586B8C9E6B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06C8C891BE888C205B3B5586B8C9A37D_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06C8C891BE888C205B3B5586B8C9A37D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercises of stock options and issuance of restricted stock awards (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06C8C891BE888C205B3B5586B8C9A37D_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06C8C891BE888C205B3B5586B8C9A37D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06C8C891BE888C205B3B5586B8C9A37D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06C8C891BE888C205B3B5586B8C9A37D" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06C8C891BE888C205B3B5586B8C9A37D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6410155FB9D553CD7E9F5586B8C9BBA7_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6410155FB9D553CD7E9F5586B8C9BBA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercises of stock options and issuance of restricted stock awards</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6410155FB9D553CD7E9F5586B8C9BBA7_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6410155FB9D553CD7E9F5586B8C9BBA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Share-based Compensation, Net of Forfeitures</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6410155FB9D553CD7E9F5586B8C9BBA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6410155FB9D553CD7E9F5586B8C9BBA7" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6410155FB9D553CD7E9F5586B8C9BBA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E34B1DD0E55F6783CAB95586B8C91B6E_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E34B1DD0E55F6783CAB95586B8C91B6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued for cash under employee share purchase plan</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E34B1DD0E55F6783CAB95586B8C91B6E_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E34B1DD0E55F6783CAB95586B8C91B6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E34B1DD0E55F6783CAB95586B8C91B6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E34B1DD0E55F6783CAB95586B8C91B6E" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E34B1DD0E55F6783CAB95586B8C91B6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_856780A6BAFD9C3693975586B8C96B22_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_856780A6BAFD9C3693975586B8C96B22" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_856780A6BAFD9C3693975586B8C96B22_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_856780A6BAFD9C3693975586B8C96B22" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_856780A6BAFD9C3693975586B8C96B22" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_856780A6BAFD9C3693975586B8C96B22" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_856780A6BAFD9C3693975586B8C96B22" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6480BDF1AA3439BDF7005586B8C96057_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding_6480BDF1AA3439BDF7005586B8C96057" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6480BDF1AA3439BDF7005586B8C96057" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding_6480BDF1AA3439BDF7005586B8C96057" xlink:to="lab_us-gaap_CommonStockSharesOutstanding_6480BDF1AA3439BDF7005586B8C96057" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_8D25D1324DAB01FD99AB5586B8C9D541_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_8D25D1324DAB01FD99AB5586B8C9D541" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8D25D1324DAB01FD99AB5586B8C9D541" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_8D25D1324DAB01FD99AB5586B8C9D541" xlink:to="lab_us-gaap_StockholdersEquity_8D25D1324DAB01FD99AB5586B8C9D541" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_B03601A6F826ED2746A808261DA70F6C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_B03601A6F826ED2746A808261DA70F6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_B03601A6F826ED2746A808261DA70F6C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_B03601A6F826ED2746A808261DA70F6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_B03601A6F826ED2746A808261DA70F6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_B03601A6F826ED2746A808261DA70F6C" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_B03601A6F826ED2746A808261DA70F6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B81239C3E258C87FC6C308261E0529DC_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B81239C3E258C87FC6C308261E0529DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B81239C3E258C87FC6C308261E0529DC_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B81239C3E258C87FC6C308261E0529DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B81239C3E258C87FC6C308261E0529DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B81239C3E258C87FC6C308261E0529DC" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B81239C3E258C87FC6C308261E0529DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59CC432CBB4113E53CD808261E371420_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59CC432CBB4113E53CD808261E371420" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59CC432CBB4113E53CD808261E371420_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59CC432CBB4113E53CD808261E371420" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59CC432CBB4113E53CD808261E371420" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59CC432CBB4113E53CD808261E371420" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59CC432CBB4113E53CD808261E371420" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6752E06FED88A33BC14108261E38902E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6752E06FED88A33BC14108261E38902E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6752E06FED88A33BC14108261E38902E_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6752E06FED88A33BC14108261E38902E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Hierarchy [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6752E06FED88A33BC14108261E38902E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6752E06FED88A33BC14108261E38902E" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_6752E06FED88A33BC14108261E38902E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97C57642A6C7E2B2F2B508261E388166_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97C57642A6C7E2B2F2B508261E388166" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97C57642A6C7E2B2F2B508261E388166_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97C57642A6C7E2B2F2B508261E388166" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97C57642A6C7E2B2F2B508261E388166" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97C57642A6C7E2B2F2B508261E388166" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97C57642A6C7E2B2F2B508261E388166" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5E9023578D90CEE57C5208261E3872BC_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_5E9023578D90CEE57C5208261E3872BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_5E9023578D90CEE57C5208261E3872BC_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_5E9023578D90CEE57C5208261E3872BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5E9023578D90CEE57C5208261E3872BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_5E9023578D90CEE57C5208261E3872BC" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_5E9023578D90CEE57C5208261E3872BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_54ECA2CD46BE0D8A616108261E38015A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_54ECA2CD46BE0D8A616108261E38015A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_54ECA2CD46BE0D8A616108261E38015A_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_54ECA2CD46BE0D8A616108261E38015A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_54ECA2CD46BE0D8A616108261E38015A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_54ECA2CD46BE0D8A616108261E38015A" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_54ECA2CD46BE0D8A616108261E38015A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_80183A80204F098108E708261E38C37A_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_80183A80204F098108E708261E38C37A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_80183A80204F098108E708261E38C37A_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_80183A80204F098108E708261E38C37A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_80183A80204F098108E708261E38C37A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_80183A80204F098108E708261E38C37A" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_80183A80204F098108E708261E38C37A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_C3F25F9DA622745C6AE208261E3811C6_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_C3F25F9DA622745C6AE208261E3811C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets:</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosureAbstract_C3F25F9DA622745C6AE208261E3811C6_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosureAbstract_C3F25F9DA622745C6AE208261E3811C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_C3F25F9DA622745C6AE208261E3811C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_C3F25F9DA622745C6AE208261E3811C6" xlink:to="lab_us-gaap_AssetsFairValueDisclosureAbstract_C3F25F9DA622745C6AE208261E3811C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_29A20252C903C43156D108261E383F37_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_29A20252C903C43156D108261E383F37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_29A20252C903C43156D108261E383F37_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_29A20252C903C43156D108261E383F37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_29A20252C903C43156D108261E383F37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_29A20252C903C43156D108261E383F37" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_29A20252C903C43156D108261E383F37" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_145D1654D361212E3C0E08261E38C817_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_145D1654D361212E3C0E08261E38C817" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_145D1654D361212E3C0E08261E38C817_label_en-US" xlink:label="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_145D1654D361212E3C0E08261E38C817" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Fair Value Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_145D1654D361212E3C0E08261E38C817" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_145D1654D361212E3C0E08261E38C817" xlink:to="lab_us-gaap_LiabilitiesFairValueDisclosureAbstract_145D1654D361212E3C0E08261E38C817" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesFairValueDisclosure_28DC32A54E6E70CDB2CA08261E3837FC_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesFairValueDisclosure_28DC32A54E6E70CDB2CA08261E3837FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, fair value disclosure</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesFairValueDisclosure_28DC32A54E6E70CDB2CA08261E3837FC_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesFairValueDisclosure_28DC32A54E6E70CDB2CA08261E3837FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_28DC32A54E6E70CDB2CA08261E3837FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_28DC32A54E6E70CDB2CA08261E3837FC" xlink:to="lab_us-gaap_AccruedLiabilitiesFairValueDisclosure_28DC32A54E6E70CDB2CA08261E3837FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_C3356DAB37A593BC4A9F08261E104D1A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_C3356DAB37A593BC4A9F08261E104D1A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Composition of Notes Payable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtTableTextBlock_C3356DAB37A593BC4A9F08261E104D1A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtTableTextBlock_C3356DAB37A593BC4A9F08261E104D1A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_C3356DAB37A593BC4A9F08261E104D1A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtTableTextBlock_C3356DAB37A593BC4A9F08261E104D1A" xlink:to="lab_us-gaap_ScheduleOfDebtTableTextBlock_C3356DAB37A593BC4A9F08261E104D1A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_54221E9A484F7796886F08261E1058B8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_54221E9A484F7796886F08261E1058B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future Annual Minimum Principal Payments of Notes Payable</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_54221E9A484F7796886F08261E1058B8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_54221E9A484F7796886F08261E1058B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_54221E9A484F7796886F08261E1058B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_54221E9A484F7796886F08261E1058B8" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_54221E9A484F7796886F08261E1058B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A8F0FCF987BA03BCCAED08261E50C038_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A8F0FCF987BA03BCCAED08261E50C038" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A8F0FCF987BA03BCCAED08261E50C038_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A8F0FCF987BA03BCCAED08261E50C038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A8F0FCF987BA03BCCAED08261E50C038" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A8F0FCF987BA03BCCAED08261E50C038" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A8F0FCF987BA03BCCAED08261E50C038" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8851E64E8A1E9E7A72C908261E50E729_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8851E64E8A1E9E7A72C908261E50E729" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</link:label>
    <link:label id="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8851E64E8A1E9E7A72C908261E50E729_label_en-US" xlink:label="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8851E64E8A1E9E7A72C908261E50E729" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8851E64E8A1E9E7A72C908261E50E729" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8851E64E8A1E9E7A72C908261E50E729" xlink:to="lab_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8851E64E8A1E9E7A72C908261E50E729" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_C3FFDD7A5885B50688F008261E266F3D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_C3FFDD7A5885B50688F008261E266F3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Warrants</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_C3FFDD7A5885B50688F008261E266F3D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_C3FFDD7A5885B50688F008261E266F3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_C3FFDD7A5885B50688F008261E266F3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_C3FFDD7A5885B50688F008261E266F3D" xlink:to="lab_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_C3FFDD7A5885B50688F008261E266F3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EF9402BED4B8AA571FEE08261E53A37A_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EF9402BED4B8AA571FEE08261E53A37A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Description of Business</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EF9402BED4B8AA571FEE08261E53A37A_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EF9402BED4B8AA571FEE08261E53A37A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EF9402BED4B8AA571FEE08261E53A37A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EF9402BED4B8AA571FEE08261E53A37A" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EF9402BED4B8AA571FEE08261E53A37A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660" xlink:to="lab_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D" xlink:to="lab_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_645F2DF2BC9D0E7F8C6F31BE41012F73_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_645F2DF2BC9D0E7F8C6F31BE41012F73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_645F2DF2BC9D0E7F8C6F31BE41012F73_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_645F2DF2BC9D0E7F8C6F31BE41012F73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Net, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_645F2DF2BC9D0E7F8C6F31BE41012F73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_645F2DF2BC9D0E7F8C6F31BE41012F73" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_645F2DF2BC9D0E7F8C6F31BE41012F73" xlink:type="arc" />
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9DF97D3E6A6FD1AD262031BE41010438_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9DF97D3E6A6FD1AD262031BE41010438" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9DF97D3E6A6FD1AD262031BE41010438_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9DF97D3E6A6FD1AD262031BE41010438" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9DF97D3E6A6FD1AD262031BE41010438" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9DF97D3E6A6FD1AD262031BE41010438" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9DF97D3E6A6FD1AD262031BE41010438" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_CC693DB9B96101D2877D31BE41015896_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_CC693DB9B96101D2877D31BE41015896" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_CC693DB9B96101D2877D31BE41015896_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_CC693DB9B96101D2877D31BE41015896" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_CC693DB9B96101D2877D31BE41015896" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_CC693DB9B96101D2877D31BE41015896" xlink:to="lab_us-gaap_AssetsCurrent_CC693DB9B96101D2877D31BE41015896" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_3F487162084B1643950031BE4101FC6E_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_3F487162084B1643950031BE4101FC6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3F487162084B1643950031BE4101FC6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_3F487162084B1643950031BE4101FC6E" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_3F487162084B1643950031BE4101FC6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_972C5C6BC525C4F6EFA831BE4101C6F8_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_972C5C6BC525C4F6EFA831BE4101C6F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_972C5C6BC525C4F6EFA831BE4101C6F8_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_972C5C6BC525C4F6EFA831BE4101C6F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_972C5C6BC525C4F6EFA831BE4101C6F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_972C5C6BC525C4F6EFA831BE4101C6F8" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_972C5C6BC525C4F6EFA831BE4101C6F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_4DD383360FB2E670909231BE41011DFB_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_4DD383360FB2E670909231BE41011DFB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_4DD383360FB2E670909231BE41011DFB_label_en-US" xlink:label="lab_us-gaap_Assets_4DD383360FB2E670909231BE41011DFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_4DD383360FB2E670909231BE41011DFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_4DD383360FB2E670909231BE41011DFB" xlink:to="lab_us-gaap_Assets_4DD383360FB2E670909231BE41011DFB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities, Preferred Stock, and Stockholders&#8217; Equity (Deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_62FA4087969983C3ACA731BE4102D47A_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_62FA4087969983C3ACA731BE4102D47A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_62FA4087969983C3ACA731BE4102D47A_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_62FA4087969983C3ACA731BE4102D47A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_62FA4087969983C3ACA731BE4102D47A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_62FA4087969983C3ACA731BE4102D47A" xlink:to="lab_us-gaap_AccountsPayableCurrent_62FA4087969983C3ACA731BE4102D47A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_02E8F999B202466D63A631BE41027FEB_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent_02E8F999B202466D63A631BE41027FEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_02E8F999B202466D63A631BE41027FEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_02E8F999B202466D63A631BE41027FEB" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent_02E8F999B202466D63A631BE41027FEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_NotesPayableCurrent_49FCA3F541E2785CB6C931BE410274E2_terseLabel_en-US" xlink:label="lab_us-gaap_NotesPayableCurrent_49FCA3F541E2785CB6C931BE410274E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of notes payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_49FCA3F541E2785CB6C931BE410274E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NotesPayableCurrent_49FCA3F541E2785CB6C931BE410274E2" xlink:to="lab_us-gaap_NotesPayableCurrent_49FCA3F541E2785CB6C931BE410274E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_227A98C6DED21D80E5AF31BE4102FC74_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_227A98C6DED21D80E5AF31BE4102FC74" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_227A98C6DED21D80E5AF31BE4102FC74_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_227A98C6DED21D80E5AF31BE4102FC74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_227A98C6DED21D80E5AF31BE4102FC74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_227A98C6DED21D80E5AF31BE4102FC74" xlink:to="lab_us-gaap_LiabilitiesCurrent_227A98C6DED21D80E5AF31BE4102FC74" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermNotesPayable_08EEA248AD969F5182AE31BE4102F028_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermNotesPayable_08EEA248AD969F5182AE31BE4102F028" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes payable, less current portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_08EEA248AD969F5182AE31BE4102F028" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermNotesPayable_08EEA248AD969F5182AE31BE4102F028" xlink:to="lab_us-gaap_LongTermNotesPayable_08EEA248AD969F5182AE31BE4102F028" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_590B79B3D3E1BA2F19EA31BE4102FB54_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_590B79B3D3E1BA2F19EA31BE4102FB54" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_590B79B3D3E1BA2F19EA31BE4102FB54_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_590B79B3D3E1BA2F19EA31BE4102FB54" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_590B79B3D3E1BA2F19EA31BE4102FB54" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_590B79B3D3E1BA2F19EA31BE4102FB54" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_590B79B3D3E1BA2F19EA31BE4102FB54" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_E0618BF6C2CA2E4EF9A631BE4102A471_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_E0618BF6C2CA2E4EF9A631BE4102A471" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_E0618BF6C2CA2E4EF9A631BE4102A471_label_en-US" xlink:label="lab_us-gaap_Liabilities_E0618BF6C2CA2E4EF9A631BE4102A471" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_E0618BF6C2CA2E4EF9A631BE4102A471" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_E0618BF6C2CA2E4EF9A631BE4102A471" xlink:to="lab_us-gaap_Liabilities_E0618BF6C2CA2E4EF9A631BE4102A471" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ECF0AA4C34EAEA04EF6B31BE4102E7BD_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_ECF0AA4C34EAEA04EF6B31BE4102E7BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_ECF0AA4C34EAEA04EF6B31BE4102E7BD_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_ECF0AA4C34EAEA04EF6B31BE4102E7BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ECF0AA4C34EAEA04EF6B31BE4102E7BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_ECF0AA4C34EAEA04EF6B31BE4102E7BD" xlink:to="lab_us-gaap_CommitmentsAndContingencies_ECF0AA4C34EAEA04EF6B31BE4102E7BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52B93C674D8D2AF7111931BE4102833C_terseLabel_en-US" xlink:label="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52B93C674D8D2AF7111931BE4102833C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redeemable convertible preferred stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52B93C674D8D2AF7111931BE4102833C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52B93C674D8D2AF7111931BE4102833C" xlink:to="lab_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52B93C674D8D2AF7111931BE4102833C" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; equity (deficit):</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369" xlink:to="lab_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_511F98B8333BB4387B1F31BE4103F23C_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_511F98B8333BB4387B1F31BE4103F23C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.01 par value; 100,000,000 shares authorized; 21,886,568 and 833,744 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_511F98B8333BB4387B1F31BE4103F23C_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_511F98B8333BB4387B1F31BE4103F23C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_511F98B8333BB4387B1F31BE4103F23C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_511F98B8333BB4387B1F31BE4103F23C" xlink:to="lab_us-gaap_CommonStockValue_511F98B8333BB4387B1F31BE4103F23C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_ED1D532D68C0032ABF3B31BE410322B9_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_ED1D532D68C0032ABF3B31BE410322B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_ED1D532D68C0032ABF3B31BE410322B9_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_ED1D532D68C0032ABF3B31BE410322B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ED1D532D68C0032ABF3B31BE410322B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_ED1D532D68C0032ABF3B31BE410322B9" xlink:to="lab_us-gaap_AdditionalPaidInCapital_ED1D532D68C0032ABF3B31BE410322B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_132590E6DD03762F9B0531BE410364E0_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_132590E6DD03762F9B0531BE410364E0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#8217; equity (deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_132590E6DD03762F9B0531BE410364E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_132590E6DD03762F9B0531BE410364E0" xlink:to="lab_us-gaap_StockholdersEquity_132590E6DD03762F9B0531BE410364E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_983644BCC6E44F2AF94231BE4103742F_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_983644BCC6E44F2AF94231BE4103742F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities, preferred stock, and stockholders&#8217; equity (deficit)</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_983644BCC6E44F2AF94231BE4103742F_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_983644BCC6E44F2AF94231BE4103742F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_983644BCC6E44F2AF94231BE4103742F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_983644BCC6E44F2AF94231BE4103742F" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_983644BCC6E44F2AF94231BE4103742F" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>mgen-20170930_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/AccruedLiabilities" xlink:href="mgen-20170930.xsd#AccruedLiabilities" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/AccruedLiabilitiesComponentsOfAccruedLiabilitiesDetails" xlink:href="mgen-20170930.xsd#AccruedLiabilitiesComponentsOfAccruedLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/AccruedLiabilitiesTables" xlink:href="mgen-20170930.xsd#AccruedLiabilitiesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CapitalStock" xlink:href="mgen-20170930.xsd#CapitalStock" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CapitalStockNarrativeDetails" xlink:href="mgen-20170930.xsd#CapitalStockNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CapitalStockSummaryOfSeriesPreferredStockDetails" xlink:href="mgen-20170930.xsd#CapitalStockSummaryOfSeriesPreferredStockDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CapitalStockTables" xlink:href="mgen-20170930.xsd#CapitalStockTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CommitmentsAndContingencies" xlink:href="mgen-20170930.xsd#CommitmentsAndContingencies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" xlink:href="mgen-20170930.xsd#CommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:href="mgen-20170930.xsd#CommitmentsAndContingenciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:href="mgen-20170930.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:href="mgen-20170930.xsd#CondensedConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:href="mgen-20170930.xsd#CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:href="mgen-20170930.xsd#CondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfOperations" xlink:href="mgen-20170930.xsd#CondensedConsolidatedStatementsOfOperations" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficit" xlink:href="mgen-20170930.xsd#CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficit" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/DescriptionOfBusiness" xlink:href="mgen-20170930.xsd#DescriptionOfBusiness" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/DescriptionOfBusinessNarrativeDetails" xlink:href="mgen-20170930.xsd#DescriptionOfBusinessNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/DocumentAndEntityInformation" xlink:href="mgen-20170930.xsd#DocumentAndEntityInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NetLossPerShare" xlink:href="mgen-20170930.xsd#NetLossPerShare" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetails" xlink:href="mgen-20170930.xsd#NetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NetLossPerShareTables" xlink:href="mgen-20170930.xsd#NetLossPerShareTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NotesPayable" xlink:href="mgen-20170930.xsd#NotesPayable" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NotesPayableCompositionOfNotesPayableDetails" xlink:href="mgen-20170930.xsd#NotesPayableCompositionOfNotesPayableDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NotesPayableFutureAnnualMinimumPrincipalPaymentsDetails" xlink:href="mgen-20170930.xsd#NotesPayableFutureAnnualMinimumPrincipalPaymentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NotesPayableNarrativeDetails" xlink:href="mgen-20170930.xsd#NotesPayableNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/NotesPayableTables" xlink:href="mgen-20170930.xsd#NotesPayableTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/PropertyAndEquipment" xlink:href="mgen-20170930.xsd#PropertyAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/PropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" xlink:href="mgen-20170930.xsd#PropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/PropertyAndEquipmentNarrativeDetails" xlink:href="mgen-20170930.xsd#PropertyAndEquipmentNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/PropertyAndEquipmentTables" xlink:href="mgen-20170930.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ReverseMerger" xlink:href="mgen-20170930.xsd#ReverseMerger" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ReverseMergerNarrativeDetails" xlink:href="mgen-20170930.xsd#ReverseMergerNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ReverseMergerSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:href="mgen-20170930.xsd#ReverseMergerSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ReverseMergerTables" xlink:href="mgen-20170930.xsd#ReverseMergerTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensation" xlink:href="mgen-20170930.xsd#ShareBasedCompensation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationAllocationOfShareBasedCompensationExpenseOnStatementsOfOperationsDetails" xlink:href="mgen-20170930.xsd#ShareBasedCompensationAllocationOfShareBasedCompensationExpenseOnStatementsOfOperationsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationFairValueAssumptionForStockOptionsDetails" xlink:href="mgen-20170930.xsd#ShareBasedCompensationFairValueAssumptionForStockOptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:href="mgen-20170930.xsd#ShareBasedCompensationNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:href="mgen-20170930.xsd#ShareBasedCompensationStockOptionActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/ShareBasedCompensationTables" xlink:href="mgen-20170930.xsd#ShareBasedCompensationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/StrategicAllianceAndCollaborationWithServier" xlink:href="mgen-20170930.xsd#StrategicAllianceAndCollaborationWithServier" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/StrategicAllianceAndCollaborationWithServierNarrativeDetails" xlink:href="mgen-20170930.xsd#StrategicAllianceAndCollaborationWithServierNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SubsequentEvents" xlink:href="mgen-20170930.xsd#SubsequentEvents" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SubsequentEventsNarrativeDetails" xlink:href="mgen-20170930.xsd#SubsequentEventsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPoliciesFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:href="mgen-20170930.xsd#SummaryOfSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/Warrants" xlink:href="mgen-20170930.xsd#Warrants" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/WarrantsNarrativeDetails" xlink:href="mgen-20170930.xsd#WarrantsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/WarrantsStockWarrantActivityDetails" xlink:href="mgen-20170930.xsd#WarrantsStockWarrantActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/WarrantsStockWarrantsOutstandingDetails" xlink:href="mgen-20170930.xsd#WarrantsStockWarrantsOutstandingDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.miragentherapeutics.com/role/WarrantsTables" xlink:href="mgen-20170930.xsd#WarrantsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/AccruedLiabilities" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_A71FF8ED5E39E7890B9608261E19BBD2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0AD4CC5E833CFC1BF0D708261E1AA5F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_A71FF8ED5E39E7890B9608261E19BBD2" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_0AD4CC5E833CFC1BF0D708261E1AA5F9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/AccruedLiabilitiesComponentsOfAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_13132D6AE8EF0BD887EF782AAB408663" xlink:type="locator" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccruedOutsourcingClinicalandPreclinicalStudies" xlink:label="loc_mgen_AccruedOutsourcingClinicalandPreclinicalStudies_F5DE2FD8DE545BC3425B782AAB409649" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13132D6AE8EF0BD887EF782AAB408663" xlink:to="loc_mgen_AccruedOutsourcingClinicalandPreclinicalStudies_F5DE2FD8DE545BC3425B782AAB409649" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_B339298E8AE827DAE518782AAB404FCD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13132D6AE8EF0BD887EF782AAB408663" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_B339298E8AE827DAE518782AAB404FCD" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccruedLegalFeesCurrent" xlink:label="loc_mgen_AccruedLegalFeesCurrent_7405CD3BE5873CF2F69B782AAB418647" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13132D6AE8EF0BD887EF782AAB408663" xlink:to="loc_mgen_AccruedLegalFeesCurrent_7405CD3BE5873CF2F69B782AAB418647" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_8E4BB816205AF0D02419782AAB41BD2C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13132D6AE8EF0BD887EF782AAB408663" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_8E4BB816205AF0D02419782AAB41BD2C" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccruedLiabilitiesEquipmentandLabMaterials" xlink:label="loc_mgen_AccruedLiabilitiesEquipmentandLabMaterials_3F300DD22EE0484A85C2782AAB418641" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13132D6AE8EF0BD887EF782AAB408663" xlink:to="loc_mgen_AccruedLiabilitiesEquipmentandLabMaterials_3F300DD22EE0484A85C2782AAB418641" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccruedLiabilityofWarrantsonTemporaryEquity" xlink:label="loc_mgen_AccruedLiabilityofWarrantsonTemporaryEquity_44885FC316AF73F9329B782AAB41EA98" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13132D6AE8EF0BD887EF782AAB408663" xlink:to="loc_mgen_AccruedLiabilityofWarrantsonTemporaryEquity_44885FC316AF73F9329B782AAB41EA98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedRentCurrent" xlink:label="loc_us-gaap_AccruedRentCurrent_A92DF04FA8F3E8F82407782AAB41F9E2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13132D6AE8EF0BD887EF782AAB408663" xlink:to="loc_us-gaap_AccruedRentCurrent_A92DF04FA8F3E8F82407782AAB41F9E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1AF4029743A51347F356782AAB417A44" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13132D6AE8EF0BD887EF782AAB408663" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_1AF4029743A51347F356782AAB417A44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_490F70D656CC11DBF588782AAB41591A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_13132D6AE8EF0BD887EF782AAB408663" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_490F70D656CC11DBF588782AAB41591A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/AccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_CECE75A2DC79D81EFF8D08261DE8654A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_439C1180D657B317CC3E08261DE8D6BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_CECE75A2DC79D81EFF8D08261DE8654A" xlink:to="loc_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_439C1180D657B317CC3E08261DE8D6BF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/CapitalStock" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_44AD47B8C03A1B6B979A08261E659D74" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3199A4DC4D605AB44CB808261E65D3FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_44AD47B8C03A1B6B979A08261E659D74" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_3199A4DC4D605AB44CB808261E65D3FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/CapitalStockNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_B798A61998E4226E0D4A782AAB093313" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_B798A61998E4226E0D4A782AAB093313" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A7175653CDF2C6B0DBEC782AAB093B72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A7175653CDF2C6B0DBEC782AAB093B72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_B8D2E75697EAD725A9DD782AAB09AEFD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_A7175653CDF2C6B0DBEC782AAB093B72" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_B8D2E75697EAD725A9DD782AAB09AEFD" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalSharesIssuedToMiragenCommonShareholdersMember" xlink:label="loc_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_986F12A1A3329E068243782AAB09BC54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_B8D2E75697EAD725A9DD782AAB09AEFD" xlink:to="loc_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_986F12A1A3329E068243782AAB09BC54" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PreMergerSharesMember" xlink:label="loc_mgen_PreMergerSharesMember_B9C163BF7DA44099385A782AAB0992EA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_B8D2E75697EAD725A9DD782AAB09AEFD" xlink:to="loc_mgen_PreMergerSharesMember_B9C163BF7DA44099385A782AAB0992EA" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PostMergerSharesMember" xlink:label="loc_mgen_PostMergerSharesMember_5103D6AB6E826368FC94782AAB09B9BF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_B8D2E75697EAD725A9DD782AAB09AEFD" xlink:to="loc_mgen_PostMergerSharesMember_5103D6AB6E826368FC94782AAB09B9BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1799F016A419AA2A44E3782AAB0A83E1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1799F016A419AA2A44E3782AAB0A83E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E62D7ACA5745543C55F782AAB0A1601" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1799F016A419AA2A44E3782AAB0A83E1" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E62D7ACA5745543C55F782AAB0A1601" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalMember" xlink:label="loc_mgen_SignalMember_3FB7157AE6C7A89E6772782AAB0A17B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1E62D7ACA5745543C55F782AAB0A1601" xlink:to="loc_mgen_SignalMember_3FB7157AE6C7A89E6772782AAB0A17B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_46EEC2FFE3307AE9159E782AAB0AB14C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:to="loc_us-gaap_StatementClassOfStockAxis_46EEC2FFE3307AE9159E782AAB0AB14C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_315E2B35931392780601782AAB0A41E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_46EEC2FFE3307AE9159E782AAB0AB14C" xlink:to="loc_us-gaap_ClassOfStockDomain_315E2B35931392780601782AAB0A41E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_67AEA918A823C7D50506782AAB0AD634" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_315E2B35931392780601782AAB0A41E6" xlink:to="loc_us-gaap_PreferredStockMember_67AEA918A823C7D50506782AAB0AD634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7EA75E3182AD9064D6DF782AAB0ACAF8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:to="loc_us-gaap_RangeAxis_7EA75E3182AD9064D6DF782AAB0ACAF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_9E4398F8C386C063F73B782AAB0A09F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_7EA75E3182AD9064D6DF782AAB0ACAF8" xlink:to="loc_us-gaap_RangeMember_9E4398F8C386C063F73B782AAB0A09F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_261D33A16D68A87F2AAC782AAB0AAA70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_9E4398F8C386C063F73B782AAB0A09F9" xlink:to="loc_us-gaap_MaximumMember_261D33A16D68A87F2AAC782AAB0AAA70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_DE3798E97702D65C3C0F782AAB0ABFEC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_DE3798E97702D65C3C0F782AAB0ABFEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A43B9A679196D686698F782AAB0B407B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_DE3798E97702D65C3C0F782AAB0ABFEC" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A43B9A679196D686698F782AAB0B407B" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AtthemarketOfferingMember" xlink:label="loc_mgen_AtthemarketOfferingMember_69D1324D387FA1C9CFA3782AAB0BC528" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_A43B9A679196D686698F782AAB0B407B" xlink:to="loc_mgen_AtthemarketOfferingMember_69D1324D387FA1C9CFA3782AAB0BC528" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_CBF82DD24EA79A7F4ACA782AAB0927DB" xlink:to="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CapitalStockSharesAuthorized" xlink:label="loc_mgen_CapitalStockSharesAuthorized_6D8CC6ACD5BBC15A069C782AAB0B84C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_mgen_CapitalStockSharesAuthorized_6D8CC6ACD5BBC15A069C782AAB0B84C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_03718E2350F6C4BF6202782AAB0B5955" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_03718E2350F6C4BF6202782AAB0B5955" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_25A8D78CB9A867EE22EE782AAB0B0077" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_25A8D78CB9A867EE22EE782AAB0B0077" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_AE6EDB05A3E895C84798782AAB0B3602" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_AE6EDB05A3E895C84798782AAB0B3602" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_C82364B4435659154612782AAB0BAC77" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_C82364B4435659154612782AAB0BAC77" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ConversionOfStockSharesIssuedConversionRate" xlink:label="loc_mgen_ConversionOfStockSharesIssuedConversionRate_0E9D57886BA602F95631782AAB0BA38B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_mgen_ConversionOfStockSharesIssuedConversionRate_0E9D57886BA602F95631782AAB0BA38B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_85E8B55D3AAEA45D168B782AAB0B67F1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_85E8B55D3AAEA45D168B782AAB0B67F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_FCECF4D163A3013CA5DE782AAB0BF097" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_FCECF4D163A3013CA5DE782AAB0BF097" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9EB60C2D21901D82311D782AAB0B3174" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_9EB60C2D21901D82311D782AAB0B3174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_6326F29CD91CC4D88F09782AAB0BC8E9" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_6326F29CD91CC4D88F09782AAB0BC8E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F6F632A1850DB6BFC394782AAB0B4BEB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_F6F632A1850DB6BFC394782AAB0B4BEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_DB10D8F965A1A13391907846E2A5629A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_DB10D8F965A1A13391907846E2A5629A" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds" xlink:label="loc_mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds_E5A2F5AFB35EBE8E069B782AAB0BC589" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds_E5A2F5AFB35EBE8E069B782AAB0BC589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredOfferingCosts" xlink:label="loc_us-gaap_DeferredOfferingCosts_AE22ED07D6A241BEA21D7844FE78F61C" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_us-gaap_DeferredOfferingCosts_AE22ED07D6A241BEA21D7844FE78F61C" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccumulatedAmortizationDeferredCosts" xlink:label="loc_mgen_AccumulatedAmortizationDeferredCosts_86EEA57CA3B5CB555C6B784AFAE510DE" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_0E5954354C375B354F61782AAB0B8E1D" xlink:to="loc_mgen_AccumulatedAmortizationDeferredCosts_86EEA57CA3B5CB555C6B784AFAE510DE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/CapitalStockSummaryOfSeriesPreferredStockDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_4284E7418F62F5D54E1808261E62F017" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityByClassOfStockTable" xlink:label="loc_us-gaap_TemporaryEquityByClassOfStockTable_27950044CC761635396D08261E62EF08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_4284E7418F62F5D54E1808261E62F017" xlink:to="loc_us-gaap_TemporaryEquityByClassOfStockTable_27950044CC761635396D08261E62EF08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9DE3794EF1ECA89D0EAE08261E624D12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_27950044CC761635396D08261E62EF08" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9DE3794EF1ECA89D0EAE08261E624D12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1D3851654A0F4A336C3608261E629D45" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9DE3794EF1ECA89D0EAE08261E624D12" xlink:to="loc_us-gaap_ClassOfStockDomain_1D3851654A0F4A336C3608261E629D45" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_AD093B368E1CB1AFAAB108261E63CC02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1D3851654A0F4A336C3608261E629D45" xlink:to="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_AD093B368E1CB1AFAAB108261E63CC02" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesBRedeemableConvertiblePreferredStockMember_3586D5CB416EF5E48D4608261E636E46" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1D3851654A0F4A336C3608261E629D45" xlink:to="loc_mgen_SeriesBRedeemableConvertiblePreferredStockMember_3586D5CB416EF5E48D4608261E636E46" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesCRedeemableConvertiblePreferredStockMember_95EF6F01EBD956963FE708261E637A03" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1D3851654A0F4A336C3608261E629D45" xlink:to="loc_mgen_SeriesCRedeemableConvertiblePreferredStockMember_95EF6F01EBD956963FE708261E637A03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_9150605B1C2930ED40A108261E6311F5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1D3851654A0F4A336C3608261E629D45" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_9150605B1C2930ED40A108261E6311F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityLineItems" xlink:label="loc_us-gaap_TemporaryEquityLineItems_DB6A241DC5636F6C199308261E63F0CD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityByClassOfStockTable_27950044CC761635396D08261E62EF08" xlink:to="loc_us-gaap_TemporaryEquityLineItems_DB6A241DC5636F6C199308261E63F0CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TemporaryEquityLineItems_DB6A241DC5636F6C199308261E63F0CD" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_C24A0ADE5493742E0C9C08261E6337F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_C24A0ADE5493742E0C9C08261E6337F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9649107BA563C7D250C608261E63B826" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_9649107BA563C7D250C608261E63B826" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_04C5FC82CE3111A1356608261E63119F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_04C5FC82CE3111A1356608261E63119F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7075DFEF2071207138AE08261E63C969" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_7075DFEF2071207138AE08261E63C969" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_432C84F2E252BFC4254B08261E633A22" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_432C84F2E252BFC4254B08261E633A22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_3ED224E34E177344EEF708261E633959" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_3ED224E34E177344EEF708261E633959" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_C9E05C5E0D9BD116814E08261E635E85" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_52FDEC0D6827897991D208261E63D6E0" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_C9E05C5E0D9BD116814E08261E635E85" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/CapitalStockTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_27C4324671998BAC109408261E2717BF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityTableTextBlock" xlink:label="loc_us-gaap_TemporaryEquityTableTextBlock_3EADDD36907209DB4ACE08261E27369A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_27C4324671998BAC109408261E2717BF" xlink:to="loc_us-gaap_TemporaryEquityTableTextBlock_3EADDD36907209DB4ACE08261E27369A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/CommitmentsAndContingencies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CF0B941445A7B5A7B69108261E51D2F4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_EAEF0AE4FC57EBDE8C9108261E51041C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_CF0B941445A7B5A7B69108261E51D2F4" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_EAEF0AE4FC57EBDE8C9108261E51041C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1E49E58646C17ABD246708261DB8516B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_3C5B03983EFA8003DF1808261DB860F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1E49E58646C17ABD246708261DB8516B" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear_3C5B03983EFA8003DF1808261DB860F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C4A43CC63EAA378034B508261DB926E3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1E49E58646C17ABD246708261DB8516B" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_C4A43CC63EAA378034B508261DB926E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B95FB7622AC1FF57A6E08261DB92F4A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1E49E58646C17ABD246708261DB8516B" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_1B95FB7622AC1FF57A6E08261DB92F4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_703663AEAAB687F8283408261DB97B75" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1E49E58646C17ABD246708261DB8516B" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_703663AEAAB687F8283408261DB97B75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6DE1A86D6805978727DE08261DB9DDFE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1E49E58646C17ABD246708261DB8516B" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_6DE1A86D6805978727DE08261DB9DDFE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4B8DB26C6B2B9ABF8857782AAB1C77B9" xlink:type="locator" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommitmentsandContingenciesTable" xlink:label="loc_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_4B8DB26C6B2B9ABF8857782AAB1C77B9" xlink:to="loc_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:label="loc_us-gaap_CounterpartyNameAxis_4A9CF3C05D85232B746A782AAB1CDABA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:to="loc_us-gaap_CounterpartyNameAxis_4A9CF3C05D85232B746A782AAB1CDABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CounterpartyNameAxis_4A9CF3C05D85232B746A782AAB1CDABA" xlink:to="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_UniversityofTexasMember" xlink:label="loc_mgen_UniversityofTexasMember_5B31FDF0FDE5C451B9BE782AAB1CB43A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3" xlink:to="loc_mgen_UniversityofTexasMember_5B31FDF0FDE5C451B9BE782AAB1CB43A" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_RocheInnovationCenterCopenhagenASMember" xlink:label="loc_mgen_RocheInnovationCenterCopenhagenASMember_B973187D9F1DE50745D8782AAB1C1EED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3" xlink:to="loc_mgen_RocheInnovationCenterCopenhagenASMember_B973187D9F1DE50745D8782AAB1C1EED" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_T2cureGmbHMember" xlink:label="loc_mgen_T2cureGmbHMember_D215C4E273AC4182CC65782AAB1C31ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3" xlink:to="loc_mgen_T2cureGmbHMember_D215C4E273AC4182CC65782AAB1C31ED" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_TheBrighamandWomensHospitalMember" xlink:label="loc_mgen_TheBrighamandWomensHospitalMember_E22A44774039695FB394782AAB1C9220" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RepurchaseAgreementCounterpartyNameDomain_1C8BB6DAE31C998888AE782AAB1C25E3" xlink:to="loc_mgen_TheBrighamandWomensHospitalMember_E22A44774039695FB394782AAB1C9220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_D7779E40A1F6624103C5782AAB1DF009" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:to="loc_us-gaap_StatementGeographicalAxis_D7779E40A1F6624103C5782AAB1DF009" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_D7779E40A1F6624103C5782AAB1DF009" xlink:to="loc_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_78BC908CD47ADCD175B5782AAB1DE6D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD" xlink:to="loc_country_US_78BC908CD47ADCD175B5782AAB1DE6D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonUsMember" xlink:label="loc_us-gaap_NonUsMember_E9A6FCA94382DB2286D7782AAB1D208D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD" xlink:to="loc_us-gaap_NonUsMember_E9A6FCA94382DB2286D7782AAB1D208D" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_EuropeanUnionorJapanMember" xlink:label="loc_mgen_EuropeanUnionorJapanMember_B39E759A19FCE2F02697782AAB1D2A0D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_F79D6127CBCA12652092782AAB1D05AD" xlink:to="loc_mgen_EuropeanUnionorJapanMember_B39E759A19FCE2F02697782AAB1D2A0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_350190A7FD9F4B1AC5F7782AAB1D8529" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_350190A7FD9F4B1AC5F7782AAB1D8529" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_51E53DBA5E569FB65703782AAB1DB0E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_350190A7FD9F4B1AC5F7782AAB1D8529" xlink:to="loc_us-gaap_ClassOfStockDomain_51E53DBA5E569FB65703782AAB1DB0E9" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_C9D8A8ECB96B8F8DC553782AAB1D58F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_51E53DBA5E569FB65703782AAB1DB0E9" xlink:to="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_C9D8A8ECB96B8F8DC553782AAB1D58F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorCustomersAxis" xlink:label="loc_us-gaap_MajorCustomersAxis_471E90F8FB701C4BA77C782AAB1DD187" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:to="loc_us-gaap_MajorCustomersAxis_471E90F8FB701C4BA77C782AAB1DD187" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NameOfMajorCustomerDomain" xlink:label="loc_us-gaap_NameOfMajorCustomerDomain_2BE634C37EFA81D2E194782AAB1DD2EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MajorCustomersAxis_471E90F8FB701C4BA77C782AAB1DD187" xlink:to="loc_us-gaap_NameOfMajorCustomerDomain_2BE634C37EFA81D2E194782AAB1DD2EA" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_YaleUniversityMember" xlink:label="loc_mgen_YaleUniversityMember_78BE76A8E3CA3C1FA442782AAB1EC380" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NameOfMajorCustomerDomain_2BE634C37EFA81D2E194782AAB1DD2EA" xlink:to="loc_mgen_YaleUniversityMember_78BE76A8E3CA3C1FA442782AAB1EC380" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommitmentsandContingenciesLineItems" xlink:label="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesTable_1B885D9BE6B7FD831A6A782AAB1CC17B" xlink:to="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborativeArrangementNumberofArrangements" xlink:label="loc_mgen_CollaborativeArrangementNumberofArrangements_9C2DFF2939A98E1D445D782AAB1E5B18" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_CollaborativeArrangementNumberofArrangements_9C2DFF2939A98E1D445D782AAB1E5B18" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostsUpfrontLicensingFeePerLicense" xlink:label="loc_mgen_LicenseCostsUpfrontLicensingFeePerLicense_856378C7C1F8E9D4399E782AAB1E88AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_LicenseCostsUpfrontLicensingFeePerLicense_856378C7C1F8E9D4399E782AAB1E88AF" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostAnnualMaintenanceFeePerLicense" xlink:label="loc_mgen_LicenseCostAnnualMaintenanceFeePerLicense_5758EC4F68B94C76E744782AAB1E20C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_LicenseCostAnnualMaintenanceFeePerLicense_5758EC4F68B94C76E744782AAB1E20C9" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials" xlink:label="loc_mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials_5894DD97A3FDC9CEFE76782AAB1E3B2C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials_5894DD97A3FDC9CEFE76782AAB1E3B2C" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval" xlink:label="loc_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval_CBFA3FA31E8E83E4867A782AAB1E443A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval_CBFA3FA31E8E83E4867A782AAB1E443A" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PaymentsForLicensingAgreement" xlink:label="loc_mgen_PaymentsForLicensingAgreement_F4B3B89C1BC6534F1837782AAB1EB250" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_PaymentsForLicensingAgreement_F4B3B89C1BC6534F1837782AAB1EB250" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_AA95FCA4F60FC16BA5C4782AAB1EDF92" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_AA95FCA4F60FC16BA5C4782AAB1EDF92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesIssued1" xlink:label="loc_us-gaap_ConversionOfStockSharesIssued1_567BCB458327E7DF1822782AAB1EC46C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_us-gaap_ConversionOfStockSharesIssued1_567BCB458327E7DF1822782AAB1EC46C" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct" xlink:label="loc_mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct_158FB5CE023619B8F2A7782AAB1EEF8C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct_158FB5CE023619B8F2A7782AAB1EEF8C" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PaymentstoAcquireRawMaterials" xlink:label="loc_mgen_PaymentstoAcquireRawMaterials_56F099E83A31FB0C4C1F782AAB1E4E74" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_PaymentstoAcquireRawMaterials_56F099E83A31FB0C4C1F782AAB1E4E74" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborationArrangementPotentialCashProceedsforServices" xlink:label="loc_mgen_CollaborationArrangementPotentialCashProceedsforServices_BDA85C37702BAA94116D782AAB1EE819" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_CollaborationArrangementPotentialCashProceedsforServices_BDA85C37702BAA94116D782AAB1EE819" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborationArrangementTermOfAgreement" xlink:label="loc_mgen_CollaborationArrangementTermOfAgreement_E420E1C10D1420AEE733782AAB1E7A59" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_CollaborationArrangementTermOfAgreement_E420E1C10D1420AEE733782AAB1E7A59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators_9C3A9C354205550DC450783792676893" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_us-gaap_ProceedsFromCollaborators_9C3A9C354205550DC450783792676893" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborationArrangementTermofAgreementTerminationPeriod" xlink:label="loc_mgen_CollaborationArrangementTermofAgreementTerminationPeriod_13CA0C044DC2046399D1782AAB1E4FF7" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_CollaborationArrangementTermofAgreementTerminationPeriod_13CA0C044DC2046399D1782AAB1E4FF7" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostsPotentialMilestonePayment" xlink:label="loc_mgen_LicenseCostsPotentialMilestonePayment_2A2238781568D6814FB7782AAB1F76C6" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_LicenseCostsPotentialMilestonePayment_2A2238781568D6814FB7782AAB1F76C6" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LicenseCostsOnetimeSalesMilestonePayment" xlink:label="loc_mgen_LicenseCostsOnetimeSalesMilestonePayment_0C331E8C69DA9F139882782AAB1F12A6" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_LicenseCostsOnetimeSalesMilestonePayment_0C331E8C69DA9F139882782AAB1F12A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaap_LeaseAndRentalExpense_D739F566548218AC0B13782AAB1FAF89" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_us-gaap_LeaseAndRentalExpense_D739F566548218AC0B13782AAB1FAF89" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_OperatingLeasesOperatingExpense" xlink:label="loc_mgen_OperatingLeasesOperatingExpense_BFD86333EE18F3A3A967782AAB1F4540" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommitmentsandContingenciesLineItems_F802D740BE9A95876607782AAB1E1434" xlink:to="loc_mgen_OperatingLeasesOperatingExpense_BFD86333EE18F3A3A967782AAB1F4540" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F0689C5CE25D5A72077908261D87C1BE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_4F17CFAAB7E42ACBD46108261D87E91D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_F0689C5CE25D5A72077908261D87C1BE" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_4F17CFAAB7E42ACBD46108261D87E91D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_69C122D6E58A380B526531BE40FB9D31" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_F05A18483D6C8B7B6A9F31BE40FB5EA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_69C122D6E58A380B526531BE40FB9D31" xlink:to="loc_us-gaap_StatementTable_F05A18483D6C8B7B6A9F31BE40FB5EA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_5919C87105412417852431BE40FB8D12" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_F05A18483D6C8B7B6A9F31BE40FB5EA7" xlink:to="loc_us-gaap_StatementClassOfStockAxis_5919C87105412417852431BE40FB8D12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_5656B954B40D833F6D6A31BE40FB1F90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_5919C87105412417852431BE40FB8D12" xlink:to="loc_us-gaap_ClassOfStockDomain_5656B954B40D833F6D6A31BE40FB1F90" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_748C70EA6B2A82BF638131BE40FB5EB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5656B954B40D833F6D6A31BE40FB1F90" xlink:to="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_748C70EA6B2A82BF638131BE40FB5EB9" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesBRedeemableConvertiblePreferredStockMember_AB47B914A254EA5C382631BE40FB80F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5656B954B40D833F6D6A31BE40FB1F90" xlink:to="loc_mgen_SeriesBRedeemableConvertiblePreferredStockMember_AB47B914A254EA5C382631BE40FB80F5" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesCRedeemableConvertiblePreferredStockMember_FC30F7FE1D4C8878374331BE40FB407B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_5656B954B40D833F6D6A31BE40FB1F90" xlink:to="loc_mgen_SeriesCRedeemableConvertiblePreferredStockMember_FC30F7FE1D4C8878374331BE40FB407B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_C9335314DA5935321E6931BE40FB8C43" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_F05A18483D6C8B7B6A9F31BE40FB5EA7" xlink:to="loc_us-gaap_StatementLineItems_C9335314DA5935321E6931BE40FB8C43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C9335314DA5935321E6931BE40FB8C43" xlink:to="loc_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660" xlink:to="loc_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AF12147191301768536931BE40FC1116" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_AF12147191301768536931BE40FC1116" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_645F2DF2BC9D0E7F8C6F31BE41012F73" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_645F2DF2BC9D0E7F8C6F31BE41012F73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9DF97D3E6A6FD1AD262031BE41010438" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9DF97D3E6A6FD1AD262031BE41010438" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_CC693DB9B96101D2877D31BE41015896" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_C11A71BA99407408CBFD31BE40FCDC3D" xlink:to="loc_us-gaap_AssetsCurrent_CC693DB9B96101D2877D31BE41015896" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_3F487162084B1643950031BE4101FC6E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_3F487162084B1643950031BE4101FC6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_972C5C6BC525C4F6EFA831BE4101C6F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_972C5C6BC525C4F6EFA831BE4101C6F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_4DD383360FB2E670909231BE41011DFB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_86BB11DF6ED5941DC6A931BE40FBF660" xlink:to="loc_us-gaap_Assets_4DD383360FB2E670909231BE41011DFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_C9335314DA5935321E6931BE40FB8C43" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_62FA4087969983C3ACA731BE4102D47A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4" xlink:to="loc_us-gaap_AccountsPayableCurrent_62FA4087969983C3ACA731BE4102D47A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_02E8F999B202466D63A631BE41027FEB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_02E8F999B202466D63A631BE41027FEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_49FCA3F541E2785CB6C931BE410274E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4" xlink:to="loc_us-gaap_NotesPayableCurrent_49FCA3F541E2785CB6C931BE410274E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_227A98C6DED21D80E5AF31BE4102FC74" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_87245DA2BDA9F65C3E8A31BE410256A4" xlink:to="loc_us-gaap_LiabilitiesCurrent_227A98C6DED21D80E5AF31BE4102FC74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_08EEA248AD969F5182AE31BE4102F028" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:to="loc_us-gaap_LongTermNotesPayable_08EEA248AD969F5182AE31BE4102F028" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_590B79B3D3E1BA2F19EA31BE4102FB54" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_590B79B3D3E1BA2F19EA31BE4102FB54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_E0618BF6C2CA2E4EF9A631BE4102A471" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:to="loc_us-gaap_Liabilities_E0618BF6C2CA2E4EF9A631BE4102A471" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_ECF0AA4C34EAEA04EF6B31BE4102E7BD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:to="loc_us-gaap_CommitmentsAndContingencies_ECF0AA4C34EAEA04EF6B31BE4102E7BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52B93C674D8D2AF7111931BE4102833C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_52B93C674D8D2AF7111931BE4102833C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:to="loc_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_511F98B8333BB4387B1F31BE4103F23C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369" xlink:to="loc_us-gaap_CommonStockValue_511F98B8333BB4387B1F31BE4103F23C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_ED1D532D68C0032ABF3B31BE410322B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369" xlink:to="loc_us-gaap_AdditionalPaidInCapital_ED1D532D68C0032ABF3B31BE410322B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6264B81B646C00084C1D31BE4103C675" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_6264B81B646C00084C1D31BE4103C675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_132590E6DD03762F9B0531BE410364E0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_11896F3FC50E5A3DB89E31BE4103B369" xlink:to="loc_us-gaap_StockholdersEquity_132590E6DD03762F9B0531BE410364E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_983644BCC6E44F2AF94231BE4103742F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_02D36205003B8B91C04D31BE4102021C" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_983644BCC6E44F2AF94231BE4103742F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_50862EDA481703DEBC9608261E0E3743" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_71BF768C556BB4CBC93008261E0E1ADE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_50862EDA481703DEBC9608261E0E3743" xlink:to="loc_us-gaap_StatementTable_71BF768C556BB4CBC93008261E0E1ADE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_3EDEF89AE37AA31B9DC408261E0E81D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_71BF768C556BB4CBC93008261E0E1ADE" xlink:to="loc_us-gaap_StatementClassOfStockAxis_3EDEF89AE37AA31B9DC408261E0E81D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_3EDEF89AE37AA31B9DC408261E0E81D3" xlink:to="loc_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesARedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_2F0E553E1E9064C0117208261E0E080D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2" xlink:to="loc_mgen_SeriesARedeemableConvertiblePreferredStockMember_2F0E553E1E9064C0117208261E0E080D" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesBRedeemableConvertiblePreferredStockMember_1B6BF9B7471CC6601F5B08261E0EF272" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2" xlink:to="loc_mgen_SeriesBRedeemableConvertiblePreferredStockMember_1B6BF9B7471CC6601F5B08261E0EF272" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SeriesCRedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_SeriesCRedeemableConvertiblePreferredStockMember_8D90393DC6D25912A4C308261E0E0DA9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_B946B0E3947818230C5A08261E0EA4C2" xlink:to="loc_mgen_SeriesCRedeemableConvertiblePreferredStockMember_8D90393DC6D25912A4C308261E0E0DA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_71BF768C556BB4CBC93008261E0E1ADE" xlink:to="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityParOrStatedValuePerShare" xlink:label="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_2E6B70F60F4BD477950E08261E0E7E0C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_TemporaryEquityParOrStatedValuePerShare_2E6B70F60F4BD477950E08261E0E7E0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesAuthorized" xlink:label="loc_us-gaap_TemporaryEquitySharesAuthorized_3B4C12979C08E393F8E208261E0F35FE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_TemporaryEquitySharesAuthorized_3B4C12979C08E393F8E208261E0F35FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesIssued" xlink:label="loc_us-gaap_TemporaryEquitySharesIssued_096EB2DBA0D98528FB4708261E0F8902" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_TemporaryEquitySharesIssued_096EB2DBA0D98528FB4708261E0F8902" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_4FD7BF122C4177B6C20F08261E0F12C8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_4FD7BF122C4177B6C20F08261E0F12C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityLiquidationPreference" xlink:label="loc_us-gaap_TemporaryEquityLiquidationPreference_228CC87D173AD7EC217308261E0FCDEE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_TemporaryEquityLiquidationPreference_228CC87D173AD7EC217308261E0FCDEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_DDA8FE5F0171E6C9375208261E0F869A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_DDA8FE5F0171E6C9375208261E0F869A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_D641BD2D3A24A738717408261E0FF9DD" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_D641BD2D3A24A738717408261E0FF9DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_EFD2772CB0DF5D412D1308261E0F1B68" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_CommonStockSharesIssued_EFD2772CB0DF5D412D1308261E0F1B68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_B37326A32E9AC612726B08261E0F1BDF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_27FA6927E121E567D20A08261E0EA23D" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_B37326A32E9AC612726B08261E0F1BDF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_E85D0F8BAB1BD8621751929794010DAA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_BF8DB4F3C5B23D9E0FB3929794015B7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_E85D0F8BAB1BD8621751929794010DAA" xlink:to="loc_us-gaap_StatementTable_BF8DB4F3C5B23D9E0FB3929794015B7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_37C41E4083E84F01C8A492979401C4D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_BF8DB4F3C5B23D9E0FB3929794015B7D" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_37C41E4083E84F01C8A492979401C4D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FC20E1660FDD54E57DA92979401DA3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_37C41E4083E84F01C8A492979401C4D9" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FC20E1660FDD54E57DA92979401DA3D" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PrivateFinancingMember" xlink:label="loc_mgen_PrivateFinancingMember_DAEC3AAEECAA01606C1092979401F84D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FC20E1660FDD54E57DA92979401DA3D" xlink:to="loc_mgen_PrivateFinancingMember_DAEC3AAEECAA01606C1092979401F84D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_5307AAFF9A60D5F87A3E92979401B815" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FC20E1660FDD54E57DA92979401DA3D" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_5307AAFF9A60D5F87A3E92979401B815" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AtthemarketOfferingMember" xlink:label="loc_mgen_AtthemarketOfferingMember_E153F1B6F4F79F080031929794018687" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FC20E1660FDD54E57DA92979401DA3D" xlink:to="loc_mgen_AtthemarketOfferingMember_E153F1B6F4F79F080031929794018687" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ShelfRegistrationMember" xlink:label="loc_mgen_ShelfRegistrationMember_F1C72245B4EE1CCDAF0492979401435B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1FC20E1660FDD54E57DA92979401DA3D" xlink:to="loc_mgen_ShelfRegistrationMember_F1C72245B4EE1CCDAF0492979401435B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_BF8DB4F3C5B23D9E0FB3929794015B7D" xlink:to="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A2CD2DCD79E168E293A992979402691F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A2CD2DCD79E168E293A992979402691F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_796D8997EBE26FFC5CBC929794022686" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A2CD2DCD79E168E293A992979402691F" xlink:to="loc_us-gaap_NetIncomeLoss_796D8997EBE26FFC5CBC929794022686" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A2CD2DCD79E168E293A992979402691F" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_D62DE7260FB24C458754929794024FB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_D62DE7260FB24C458754929794024FB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_2C6591BF3837197F207C92979402E59A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:to="loc_us-gaap_ShareBasedCompensation_2C6591BF3837197F207C92979402E59A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionExpense" xlink:label="loc_us-gaap_AccretionExpense_B0FB7C3C88C691FFE70292979402E7FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:to="loc_us-gaap_AccretionExpense_B0FB7C3C88C691FFE70292979402E7FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaap_FairValueAdjustmentOfWarrants_891B3588C28B86FD6300929794026C15" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:to="loc_us-gaap_FairValueAdjustmentOfWarrants_891B3588C28B86FD6300929794026C15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments" xlink:label="loc_us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments_0FAF373B1A1CED4FB23092979402E034" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:to="loc_us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments_0FAF373B1A1CED4FB23092979402E034" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_372D1042E468C53B9F3192979402DE97" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_E395D4FCB649CF1C79BE929794039664" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_E395D4FCB649CF1C79BE929794039664" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6113B87C4A63E4D2B36892979403CB5A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_6113B87C4A63E4D2B36892979403CB5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_C9FF869EA19CCF87557D92979403B322" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredRevenue_C9FF869EA19CCF87557D92979403B322" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_DC2EDE7AAA8DFB8E400992979403128C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_DC2EDE7AAA8DFB8E400992979403128C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4BB4D56898339E61BF94929794033DE4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_03986241F67D46A3799A9297940340AE" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_4BB4D56898339E61BF94929794033DE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_B2BB9B3B9FD77ADE4C7192979403749D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A2CD2DCD79E168E293A992979402691F" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_B2BB9B3B9FD77ADE4C7192979403749D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="loc_us-gaap_CashAcquiredFromAcquisition_79099AB2FBB0E0185E0A92979403E473" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C" xlink:to="loc_us-gaap_CashAcquiredFromAcquisition_79099AB2FBB0E0185E0A92979403E473" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24470B44DFE2477B040D929794044C54" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24470B44DFE2477B040D929794044C54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_7EA0002901D369C6ED5A929794042F0C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_7EA0002901D369C6ED5A929794042F0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28350EC5224B942152E092979404C0EA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_F75062BD466DE8E3E5C792979403B86C" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_28350EC5224B942152E092979404C0EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A78915B84B5A9AF02C42929794047CB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_A78915B84B5A9AF02C42929794047CB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1C948AF34577595F86A992979404E2C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1C948AF34577595F86A992979404E2C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_E3EDDF2476E6EAAEFEC3929794042B7B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock_E3EDDF2476E6EAAEFEC3929794042B7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaap_RepaymentsOfNotesPayable_0055D4F9F76EF1D4E7259297940471DF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:to="loc_us-gaap_RepaymentsOfNotesPayable_0055D4F9F76EF1D4E7259297940471DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_03B3C12331448D70CB94929794043821" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_03B3C12331448D70CB94929794043821" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans" xlink:label="loc_us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_86566AB3F07DF7150DEB92979405EEEC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:to="loc_us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans_86566AB3F07DF7150DEB92979405EEEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8A96E1EE909C2491E75D929794050CE5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_20BB02355949E6A6509492979404F9AB" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8A96E1EE909C2491E75D929794050CE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashPeriodIncreaseDecrease_270E7C6D496625DF3DDB92979405AD1A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:to="loc_us-gaap_CashPeriodIncreaseDecrease_270E7C6D496625DF3DDB92979405AD1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_03E0DE6A045367FD17439297940519E8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_03E0DE6A045367FD17439297940519E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4B749FDAE617D7B5170E929794054811" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_4B749FDAE617D7B5170E929794054811" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_6C22287267E8235EA4A392979405E113" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_6C22287267E8235EA4A392979405E113" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestPaid" xlink:label="loc_us-gaap_InterestPaid_C6AB7E330A4A2E0268E992979405F582" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_6C22287267E8235EA4A392979405E113" xlink:to="loc_us-gaap_InterestPaid_C6AB7E330A4A2E0268E992979405F582" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_D862D00F218CFF6EE32492979402BE56" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_29A9B09B36412D9BEC23929794065DAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_29A9B09B36412D9BEC23929794065DAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1" xlink:label="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_19320671EF708D54E99892979406F0BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:to="loc_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1_19320671EF708D54E99892979406F0BC" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction" xlink:label="loc_mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction_DD6107115298674C9C079297940641C8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:to="loc_mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction_DD6107115298674C9C079297940641C8" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ConversionofWarrantstoPermanentEquity" xlink:label="loc_mgen_ConversionofWarrantstoPermanentEquity_0C49844B3774D3D4F08792979406C469" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:to="loc_mgen_ConversionofWarrantstoPermanentEquity_0C49844B3774D3D4F08792979406C469" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AccretionofOfferingCosts" xlink:label="loc_mgen_AccretionofOfferingCosts_4F613A32333789038FE5929794069AA8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:to="loc_mgen_AccretionofOfferingCosts_4F613A32333789038FE5929794069AA8" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction" xlink:label="loc_mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_FCADC36226CB651436E292979406B8C5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_C8A0DDA468631BB22E389297940599C2" xlink:to="loc_mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction_FCADC36226CB651436E292979406B8C5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfOperations" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_2460C7E1750CB48C518908261E1574AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="loc_us-gaap_RevenuesAbstract_75C806AD643338D0919408261E154142" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2460C7E1750CB48C518908261E1574AC" xlink:to="loc_us-gaap_RevenuesAbstract_75C806AD643338D0919408261E154142" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_05FB8959CE04A321D25008261E16D0E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_75C806AD643338D0919408261E154142" xlink:to="loc_us-gaap_LicenseAndServicesRevenue_05FB8959CE04A321D25008261E16D0E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_C849E4E552F03C08F11308261E16BE18" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_75C806AD643338D0919408261E154142" xlink:to="loc_us-gaap_RevenueFromGrants_C849E4E552F03C08F11308261E16BE18" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_DA89BE5ABC1D1A3CEB2708261E16F334" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_75C806AD643338D0919408261E154142" xlink:to="loc_us-gaap_SalesRevenueNet_DA89BE5ABC1D1A3CEB2708261E16F334" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_9B9C0EAC3C282CF1E90A08261E16109F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2460C7E1750CB48C518908261E1574AC" xlink:to="loc_us-gaap_OperatingExpensesAbstract_9B9C0EAC3C282CF1E90A08261E16109F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_96F09E7D9EA9F968A13D08261E166AF3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9B9C0EAC3C282CF1E90A08261E16109F" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_96F09E7D9EA9F968A13D08261E166AF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4F3B944500059462087308261E1687E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9B9C0EAC3C282CF1E90A08261E16109F" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4F3B944500059462087308261E1687E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaap_OperatingExpenses_047B00501438805AAA4C08261E17987C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_9B9C0EAC3C282CF1E90A08261E16109F" xlink:to="loc_us-gaap_OperatingExpenses_047B00501438805AAA4C08261E17987C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_4F84C01047FFE62D44BF08261E17C072" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2460C7E1750CB48C518908261E1574AC" xlink:to="loc_us-gaap_OperatingIncomeLoss_4F84C01047FFE62D44BF08261E17C072" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_B6FD71ED1148993CE1A708261E17CD33" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2460C7E1750CB48C518908261E1574AC" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_B6FD71ED1148993CE1A708261E17CD33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_0C518CDA396FCE75AB5908261E17733C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_B6FD71ED1148993CE1A708261E17CD33" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_0C518CDA396FCE75AB5908261E17733C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestAndDebtExpense" xlink:label="loc_us-gaap_InterestAndDebtExpense_DA2FDAD2B06051F3DB6D08261E17C76B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_B6FD71ED1148993CE1A708261E17CD33" xlink:to="loc_us-gaap_InterestAndDebtExpense_DA2FDAD2B06051F3DB6D08261E17C76B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_33980A4D5B23E27AE09E08261E175048" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2460C7E1750CB48C518908261E1574AC" xlink:to="loc_us-gaap_NetIncomeLoss_33980A4D5B23E27AE09E08261E175048" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_C3550841BE7D09998C5408261E1772C2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2460C7E1750CB48C518908261E1574AC" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment_C3550841BE7D09998C5408261E1772C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_197D981280265D78138C08261E178A76" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2460C7E1750CB48C518908261E1574AC" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_197D981280265D78138C08261E178A76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_CFEC468B2B26D73CC70508261E17F82E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2460C7E1750CB48C518908261E1574AC" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_CFEC468B2B26D73CC70508261E17F82E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1E29C4F4EB88E0448F0408261E17B0A6" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_2460C7E1750CB48C518908261E1574AC" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1E29C4F4EB88E0448F0408261E17B0A6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficit" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_AD5A8B069B09412BCF845586B8C6425F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_AAA66455F5F2F2096C0A5586B8C65A6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_AD5A8B069B09412BCF845586B8C6425F" xlink:to="loc_us-gaap_StatementTable_AAA66455F5F2F2096C0A5586B8C65A6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_6274DF418B107A23271A5586B8C69328" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_AAA66455F5F2F2096C0A5586B8C65A6B" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_6274DF418B107A23271A5586B8C69328" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_405297F1C46F7B26E0825586B8C60497" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_6274DF418B107A23271A5586B8C69328" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_405297F1C46F7B26E0825586B8C60497" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PrivateFinancingMember" xlink:label="loc_mgen_PrivateFinancingMember_942D12F188C60FD0E3CE5586B8C6DD33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_405297F1C46F7B26E0825586B8C60497" xlink:to="loc_mgen_PrivateFinancingMember_942D12F188C60FD0E3CE5586B8C6DD33" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AtthemarketOfferingMember" xlink:label="loc_mgen_AtthemarketOfferingMember_FD01208CC27671E3063D5586B8C63F87" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_405297F1C46F7B26E0825586B8C60497" xlink:to="loc_mgen_AtthemarketOfferingMember_FD01208CC27671E3063D5586B8C63F87" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_9A244D1B90571CBC98375586B8C643CB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_AAA66455F5F2F2096C0A5586B8C65A6B" xlink:to="loc_us-gaap_StatementClassOfStockAxis_9A244D1B90571CBC98375586B8C643CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_84CFE783D25FAA720B595586B8C6B419" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_9A244D1B90571CBC98375586B8C643CB" xlink:to="loc_us-gaap_ClassOfStockDomain_84CFE783D25FAA720B595586B8C6B419" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="loc_us-gaap_RedeemableConvertiblePreferredStockMember_D4E0AF5F93E8E561C3DC5586B8C63286" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_84CFE783D25FAA720B595586B8C6B419" xlink:to="loc_us-gaap_RedeemableConvertiblePreferredStockMember_D4E0AF5F93E8E561C3DC5586B8C63286" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D66B0A16463480F4707F5586B8C76198" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_AAA66455F5F2F2096C0A5586B8C65A6B" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D66B0A16463480F4707F5586B8C76198" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9DE9A9842BAEF7F3D2FD5586B8C702E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D66B0A16463480F4707F5586B8C76198" xlink:to="loc_us-gaap_EquityComponentDomain_9DE9A9842BAEF7F3D2FD5586B8C702E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_5CB2F6E621DF304FE4DC5586B8C7987D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9DE9A9842BAEF7F3D2FD5586B8C702E6" xlink:to="loc_us-gaap_CommonStockMember_5CB2F6E621DF304FE4DC5586B8C7987D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_1CBF9B28AFCCB5F2EABE5586B8C7EDE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9DE9A9842BAEF7F3D2FD5586B8C702E6" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_1CBF9B28AFCCB5F2EABE5586B8C7EDE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_368810FCFA778D65D0D85586B8C7D5F7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9DE9A9842BAEF7F3D2FD5586B8C702E6" xlink:to="loc_us-gaap_RetainedEarningsMember_368810FCFA778D65D0D85586B8C7D5F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6BF9989AADC3E81097955586B8C72105" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_AAA66455F5F2F2096C0A5586B8C65A6B" xlink:to="loc_us-gaap_StatementLineItems_6BF9989AADC3E81097955586B8C72105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInTemporaryEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5F39FE72EDAB48EC09305586B8C7FDE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6BF9989AADC3E81097955586B8C72105" xlink:to="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5F39FE72EDAB48EC09305586B8C7FDE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_0BD1BE551CDFC0F551C55586B8C7F379" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5F39FE72EDAB48EC09305586B8C7FDE9" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_0BD1BE551CDFC0F551C55586B8C7F379" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0FDE46F67E4BDA1609FD5586B8C71F64" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5F39FE72EDAB48EC09305586B8C7FDE9" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_0FDE46F67E4BDA1609FD5586B8C71F64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityAccretionToRedemptionValue" xlink:label="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_BDD5313194C4836470C15586B8C7DCC5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5F39FE72EDAB48EC09305586B8C7FDE9" xlink:to="loc_us-gaap_TemporaryEquityAccretionToRedemptionValue_BDD5313194C4836470C15586B8C7DCC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0A86E42CC3BA84BDC6AD5586B8C801A9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5F39FE72EDAB48EC09305586B8C7FDE9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_0A86E42CC3BA84BDC6AD5586B8C801A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_63BF776A03790D07F68A5586B8C8423D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5F39FE72EDAB48EC09305586B8C7FDE9" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_63BF776A03790D07F68A5586B8C8423D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="loc_us-gaap_TemporaryEquitySharesOutstanding_5993F0A1113463E0F3CD5586B8C81B64" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5F39FE72EDAB48EC09305586B8C7FDE9" xlink:to="loc_us-gaap_TemporaryEquitySharesOutstanding_5993F0A1113463E0F3CD5586B8C81B64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_16EAE429B07BA131DAB55586B8C872D3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward_5F39FE72EDAB48EC09305586B8C7FDE9" xlink:to="loc_us-gaap_TemporaryEquityCarryingAmountAttributableToParent_16EAE429B07BA131DAB55586B8C872D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6BF9989AADC3E81097955586B8C72105" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_2322B0368E58779074EA5586B8C88539" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_2322B0368E58779074EA5586B8C88539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_A1510ECF7456E48DAC165586B8C8FB49" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockholdersEquity_A1510ECF7456E48DAC165586B8C8FB49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CB85ADA01307512F6AA65586B8C80939" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_CB85ADA01307512F6AA65586B8C80939" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2327EBF5D7C8A5698905586B8C8AE5E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_B2327EBF5D7C8A5698905586B8C8AE5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockAccretionOfRedemptionDiscount" xlink:label="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount_C7826F98D2EA6C3F31185586B8C818CF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_PreferredStockAccretionOfRedemptionDiscount_C7826F98D2EA6C3F31185586B8C818CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_397413EF9E7358C8F5255586B8C8FC04" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_397413EF9E7358C8F5255586B8C8FC04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReclassificationsOfTemporaryToPermanentEquity" xlink:label="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_0E6CFBDA53B14925BF4B5586B8C829B0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_ReclassificationsOfTemporaryToPermanentEquity_0E6CFBDA53B14925BF4B5586B8C829B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_189A04A0DDB99D2CD6125586B8C8BF38" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesAcquisitions_189A04A0DDB99D2CD6125586B8C8BF38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueAcquisitions" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_38C93F57728F570683BA5586B8C83B87" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueAcquisitions_38C93F57728F570683BA5586B8C83B87" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability" xlink:label="loc_mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability_0A0E37B574BE9299EDB75586B8C8AF30" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability_0A0E37B574BE9299EDB75586B8C8AF30" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_StockIssuedDuringPeriodSharesExerciseofWarrants" xlink:label="loc_mgen_StockIssuedDuringPeriodSharesExerciseofWarrants_24D1E3F234505A72A0C25586B8C9E6B5" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_mgen_StockIssuedDuringPeriodSharesExerciseofWarrants_24D1E3F234505A72A0C25586B8C9E6B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06C8C891BE888C205B3B5586B8C9A37D" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_06C8C891BE888C205B3B5586B8C9A37D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6410155FB9D553CD7E9F5586B8C9BBA7" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_6410155FB9D553CD7E9F5586B8C9BBA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_CC623E27026B003264595586B8C93CFD" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_CC623E27026B003264595586B8C93CFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E34B1DD0E55F6783CAB95586B8C91B6E" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_E34B1DD0E55F6783CAB95586B8C91B6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_856780A6BAFD9C3693975586B8C96B22" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_856780A6BAFD9C3693975586B8C96B22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_CCE67DCC8402D1C40DC35586B8C9007E" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_NetIncomeLoss_CCE67DCC8402D1C40DC35586B8C9007E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_6480BDF1AA3439BDF7005586B8C96057" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_6480BDF1AA3439BDF7005586B8C96057" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_8D25D1324DAB01FD99AB5586B8C9D541" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_CDB8774DE8D422CBF6335586B8C85674" xlink:to="loc_us-gaap_StockholdersEquity_8D25D1324DAB01FD99AB5586B8C9D541" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/DescriptionOfBusiness" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FDA0E694370BB9BE13B408261E539929" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EF9402BED4B8AA571FEE08261E53A37A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_FDA0E694370BB9BE13B408261E539929" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_EF9402BED4B8AA571FEE08261E53A37A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/DescriptionOfBusinessNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_391462BF2E966EA94F43782AAB84A7A1" xlink:type="locator" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DescriptionofBusinessTable" xlink:label="loc_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_391462BF2E966EA94F43782AAB84A7A1" xlink:to="loc_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_F83957A637048BCC2549782AAB84B047" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_F83957A637048BCC2549782AAB84B047" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_F3C1D90DC19BD0D95E5B782AAB84F202" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_F83957A637048BCC2549782AAB84B047" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_F3C1D90DC19BD0D95E5B782AAB84F202" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalSharesIssuedToMiragenCommonShareholdersMember" xlink:label="loc_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_0B7DD6FB9B254427E719782AAB84A129" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_F3C1D90DC19BD0D95E5B782AAB84F202" xlink:to="loc_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_0B7DD6FB9B254427E719782AAB84A129" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_B0B8CE21CB15335BEBE0782AAB8428F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_B0B8CE21CB15335BEBE0782AAB8428F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D88FA808C854B4B23A49782AAB8420D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_B0B8CE21CB15335BEBE0782AAB8428F8" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D88FA808C854B4B23A49782AAB8420D0" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalMember" xlink:label="loc_mgen_SignalMember_7D32C72F43E12AD4E836782AAB84478B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_D88FA808C854B4B23A49782AAB8420D0" xlink:to="loc_mgen_SignalMember_7D32C72F43E12AD4E836782AAB84478B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_2C4B205311D42BE3D386782AAB84821F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_2C4B205311D42BE3D386782AAB84821F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_C8D551774F168D467CA4782AAB84A302" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_2C4B205311D42BE3D386782AAB84821F" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_C8D551774F168D467CA4782AAB84A302" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PrivateFinancingMember" xlink:label="loc_mgen_PrivateFinancingMember_6268243AE7A2EE46175A782AAB8424E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_C8D551774F168D467CA4782AAB84A302" xlink:to="loc_mgen_PrivateFinancingMember_6268243AE7A2EE46175A782AAB8424E7" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AtthemarketOfferingMember" xlink:label="loc_mgen_AtthemarketOfferingMember_E066D63B3D97A8B6A182782AAB8585E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_C8D551774F168D467CA4782AAB84A302" xlink:to="loc_mgen_AtthemarketOfferingMember_E066D63B3D97A8B6A182782AAB8585E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_8114DBA5C36C83FC0AF2782AAB85AD4E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:to="loc_us-gaap_RangeAxis_8114DBA5C36C83FC0AF2782AAB85AD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_156D0202E443AA571A01782AAB8521F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_8114DBA5C36C83FC0AF2782AAB85AD4E" xlink:to="loc_us-gaap_RangeMember_156D0202E443AA571A01782AAB8521F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_382533A1D05B8EE5D910782AAB85F647" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_156D0202E443AA571A01782AAB8521F0" xlink:to="loc_us-gaap_MaximumMember_382533A1D05B8EE5D910782AAB85F647" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DescriptionofBusinessLineItems" xlink:label="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DescriptionofBusinessTable_CF330758D4459C9E20DF782AAB84A868" xlink:to="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ConversionOfStockSharesIssuedConversionRate" xlink:label="loc_mgen_ConversionOfStockSharesIssuedConversionRate_49F6C26B5D489239815A782AAB8599BF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_mgen_ConversionOfStockSharesIssuedConversionRate_49F6C26B5D489239815A782AAB8599BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_1265E4DC096AEDFEF1D6782AAB8521CE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_1265E4DC096AEDFEF1D6782AAB8521CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7CB6ED0B56436347B1B4782AAB854C31" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7CB6ED0B56436347B1B4782AAB854C31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1CC27F582C76E31B324F782AAB8598EF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_1CC27F582C76E31B324F782AAB8598EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_B5B8372DA95BD050EFE3782AAB856737" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_NetIncomeLoss_B5B8372DA95BD050EFE3782AAB856737" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_E55310EC4C2100C80B46782AAB85C4A4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_E55310EC4C2100C80B46782AAB85C4A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05A1FC584B25D5821AF7782AAB866F36" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_05A1FC584B25D5821AF7782AAB866F36" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SaleofStockAdditionalAuthorizedTransactionAmount" xlink:label="loc_mgen_SaleofStockAdditionalAuthorizedTransactionAmount_E8D8485A6A74D841E633782AAB86FCCC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_mgen_SaleofStockAdditionalAuthorizedTransactionAmount_E8D8485A6A74D841E633782AAB86FCCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91990C58F129F8CA1DA6782E68AB7BE3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_91990C58F129F8CA1DA6782E68AB7BE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_406BB6C19A6F4E24BB9B782DAAECAD1A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_406BB6C19A6F4E24BB9B782DAAECAD1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_040830D82937311B9F8A782AAB86A456" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DescriptionofBusinessLineItems_790BAC81DF807DDED776782AAB8518A9" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_040830D82937311B9F8A782AAB86A456" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/DocumentAndEntityInformation" xlink:type="extended">
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DocumentAndEntityInformationAbstract" xlink:label="loc_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_BD10A4F1B89D84C47DD208261E248B8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6" xlink:to="loc_dei_EntityRegistrantName_BD10A4F1B89D84C47DD208261E248B8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_1302D906431B0E7F562708261E2483E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6" xlink:to="loc_dei_EntityCentralIndexKey_1302D906431B0E7F562708261E2483E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_170E460AE734BD71AC6A08261E24AC48" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6" xlink:to="loc_dei_DocumentType_170E460AE734BD71AC6A08261E24AC48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_21037306BB37B7C643B108261E245838" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6" xlink:to="loc_dei_DocumentPeriodEndDate_21037306BB37B7C643B108261E245838" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_BF9730B0428BA0E3528008261E24002E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6" xlink:to="loc_dei_AmendmentFlag_BF9730B0428BA0E3528008261E24002E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_6947DEB8A99E1D8755F908261E24822C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6" xlink:to="loc_dei_DocumentFiscalYearFocus_6947DEB8A99E1D8755F908261E24822C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_D56056E937268EFF21C308261E24B754" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_D56056E937268EFF21C308261E24B754" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_6B114936F462CF971C8C08261E25B59E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6" xlink:to="loc_dei_CurrentFiscalYearEndDate_6B114936F462CF971C8C08261E25B59E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_5CE54A4D7AC8715EE3DE08261E25D148" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6" xlink:to="loc_dei_EntityFilerCategory_5CE54A4D7AC8715EE3DE08261E25D148" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_DF26F15840DDDBFABD7F08261E254074" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_DocumentAndEntityInformationAbstract_6B35E9755F7AA09E354608261E2457D6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_DF26F15840DDDBFABD7F08261E254074" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_24E7C39BC611C6981F7408261D765ABF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_DE6CAD43747353049AFD08261D763EC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_24E7C39BC611C6981F7408261D765ABF" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_DE6CAD43747353049AFD08261D763EC9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/NetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_877D7F7AA59C9261C4EF08261DA0DE61" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8A348C17A70EEC3FBCE08261DA080A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_877D7F7AA59C9261C4EF08261DA0DE61" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8A348C17A70EEC3FBCE08261DA080A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_914BD8CB434311F1A5D608261DA0AFC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8A348C17A70EEC3FBCE08261DA080A4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_914BD8CB434311F1A5D608261DA0AFC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_914BD8CB434311F1A5D608261DA0AFC6" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_58FAB81B18D43BE0C6B208261DA1F3A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A" xlink:to="loc_us-gaap_EmployeeStockOptionMember_58FAB81B18D43BE0C6B208261DA1F3A5" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommonStockWarrantsMember" xlink:label="loc_mgen_CommonStockWarrantsMember_9BBE774BA6061F846FA308261DA1B983" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A" xlink:to="loc_mgen_CommonStockWarrantsMember_9BBE774BA6061F846FA308261DA1B983" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="loc_us-gaap_ConvertibleDebtSecuritiesMember_3008E04756AA7B1AB0E108261DA16359" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A" xlink:to="loc_us-gaap_ConvertibleDebtSecuritiesMember_3008E04756AA7B1AB0E108261DA16359" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PreferredStockWarrantsMember" xlink:label="loc_mgen_PreferredStockWarrantsMember_C0B56945AE1107CF7A9208261DA1BB47" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_6B37ACCE58522107EC2008261DA03C2A" xlink:to="loc_mgen_PreferredStockWarrantsMember_C0B56945AE1107CF7A9208261DA1BB47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_277DD0706ADB589228E208261DA1B572" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_F8A348C17A70EEC3FBCE08261DA080A4" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_277DD0706ADB589228E208261DA1B572" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_092E873706571C3D41B808261DA144C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_277DD0706ADB589228E208261DA1B572" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_092E873706571C3D41B808261DA144C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_45521FF1E1198583BE3B08261DECE591" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_E88D92405477335AADBE08261DECA462" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_45521FF1E1198583BE3B08261DECE591" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_E88D92405477335AADBE08261DECA462" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/NotesPayable" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_F922E5517F44DB09491608261D865A20" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_D37BCAA6F9ECF277E44708261D86C2A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_F922E5517F44DB09491608261D865A20" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_D37BCAA6F9ECF277E44708261D86C2A3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/NotesPayableCompositionOfNotesPayableDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_4533B16C2A006F3FC3FF782AAB2D1E6D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_AF96BCB43D994623EA5F782AAB2DCB68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4533B16C2A006F3FC3FF782AAB2D1E6D" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_AF96BCB43D994623EA5F782AAB2DCB68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscount_07059EFFFB7E0A5DE8BD782AAB2D0415" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4533B16C2A006F3FC3FF782AAB2D1E6D" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscount_07059EFFFB7E0A5DE8BD782AAB2D0415" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFinanceCostsNet" xlink:label="loc_us-gaap_DeferredFinanceCostsNet_5619EA902476CD385358782AAB2D844B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4533B16C2A006F3FC3FF782AAB2D1E6D" xlink:to="loc_us-gaap_DeferredFinanceCostsNet_5619EA902476CD385358782AAB2D844B" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee" xlink:label="loc_mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee_CE22F2E1D46F4545EB98782AAB2DB8E9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4533B16C2A006F3FC3FF782AAB2D1E6D" xlink:to="loc_mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee_CE22F2E1D46F4545EB98782AAB2DB8E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayable" xlink:label="loc_us-gaap_NotesPayable_474F4B0E179CF0DE6A21782AAB2D8E06" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4533B16C2A006F3FC3FF782AAB2D1E6D" xlink:to="loc_us-gaap_NotesPayable_474F4B0E179CF0DE6A21782AAB2D8E06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaap_NotesPayableCurrent_AA9E992FBC7032F1669D782AAB2D08EA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4533B16C2A006F3FC3FF782AAB2D1E6D" xlink:to="loc_us-gaap_NotesPayableCurrent_AA9E992FBC7032F1669D782AAB2D08EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermNotesPayable" xlink:label="loc_us-gaap_LongTermNotesPayable_A3353DF909211600BEAB782AAB2D03F7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_4533B16C2A006F3FC3FF782AAB2D1E6D" xlink:to="loc_us-gaap_LongTermNotesPayable_A3353DF909211600BEAB782AAB2D03F7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/NotesPayableFutureAnnualMinimumPrincipalPaymentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_ADBFF70FA3FBBDF6426F08261E67B94A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6A615B36F75A5510075308261E6779BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ADBFF70FA3FBBDF6426F08261E67B94A" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear_6A615B36F75A5510075308261E6779BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_E0DF8D449704BDF6D3AD08261E67E28E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ADBFF70FA3FBBDF6426F08261E67B94A" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_E0DF8D449704BDF6D3AD08261E67E28E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_F6597E44BFF2C3D6775E08261E67FB2C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ADBFF70FA3FBBDF6426F08261E67B94A" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_F6597E44BFF2C3D6775E08261E67FB2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_E0DABC8B8423275F35FC08261E675AB8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_ADBFF70FA3FBBDF6426F08261E67B94A" xlink:to="loc_us-gaap_LongTermDebt_E0DABC8B8423275F35FC08261E675AB8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/NotesPayableNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_D69F9EE7EAB66B8764B708261D6AB782" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_D69F9EE7EAB66B8764B708261D6AB782" xlink:to="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_F2BFFA1DA26E8C38DC2008261D6A9C77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:to="loc_us-gaap_DebtInstrumentAxis_F2BFFA1DA26E8C38DC2008261D6A9C77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_389CC4060760DBAA6F4E08261D6A4F78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_F2BFFA1DA26E8C38DC2008261D6A9C77" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_389CC4060760DBAA6F4E08261D6A4F78" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SiliconValleyBankAgreementMember" xlink:label="loc_mgen_SiliconValleyBankAgreementMember_269746BD2302E0F0A9D608261D6A127D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_389CC4060760DBAA6F4E08261D6A4F78" xlink:to="loc_mgen_SiliconValleyBankAgreementMember_269746BD2302E0F0A9D608261D6A127D" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember" xlink:label="loc_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_6F80161A3203DE37F5C708261D6B2F0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_SiliconValleyBankAgreementMember_269746BD2302E0F0A9D608261D6A127D" xlink:to="loc_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember_6F80161A3203DE37F5C708261D6B2F0D" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember" xlink:label="loc_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember_12B2336AC8FC4B41382808261D6B3393" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_SiliconValleyBankAgreementMember_269746BD2302E0F0A9D608261D6A127D" xlink:to="loc_mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember_12B2336AC8FC4B41382808261D6B3393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_84A15B08B9F0E46508C608261D6BB31B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_84A15B08B9F0E46508C608261D6BB31B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_D0DF47515071A6BF91B808261D6BEA70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_84A15B08B9F0E46508C608261D6BB31B" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_D0DF47515071A6BF91B808261D6BEA70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NotesPayableToBanksMember" xlink:label="loc_us-gaap_NotesPayableToBanksMember_326C2B784ED0DEC0689408261D6BE628" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D0DF47515071A6BF91B808261D6BEA70" xlink:to="loc_us-gaap_NotesPayableToBanksMember_326C2B784ED0DEC0689408261D6BE628" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="loc_us-gaap_VariableRateAxis_15226D185A28F1B19E0108261D6BD0F5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:to="loc_us-gaap_VariableRateAxis_15226D185A28F1B19E0108261D6BD0F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="loc_us-gaap_VariableRateDomain_3E76A78333721ACDEA7B08261D6B14D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateAxis_15226D185A28F1B19E0108261D6BD0F5" xlink:to="loc_us-gaap_VariableRateDomain_3E76A78333721ACDEA7B08261D6B14D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="loc_us-gaap_PrimeRateMember_CBC5D906FA6C98B7E49008261D6B7E81" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VariableRateDomain_3E76A78333721ACDEA7B08261D6B14D4" xlink:to="loc_us-gaap_PrimeRateMember_CBC5D906FA6C98B7E49008261D6B7E81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_DD3CCEE246F74E79BF7A08261D6BE2D0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_DD3CCEE246F74E79BF7A08261D6BE2D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_7EF2957C33798F3D200808261D6BFDEA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_DD3CCEE246F74E79BF7A08261D6BE2D0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_7EF2957C33798F3D200808261D6BFDEA" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember" xlink:label="loc_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_A930E7833B34599B654908261D6B116C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_7EF2957C33798F3D200808261D6BFDEA" xlink:to="loc_mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember_A930E7833B34599B654908261D6B116C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationTechniqueAxis" xlink:label="loc_us-gaap_ValuationTechniqueAxis_8708E1428542006F7F1908261D6C87B7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:to="loc_us-gaap_ValuationTechniqueAxis_8708E1428542006F7F1908261D6C87B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationTechniqueDomain" xlink:label="loc_us-gaap_ValuationTechniqueDomain_1BAB5F5DC45E14AB1DCE08261D6CCA03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueAxis_8708E1428542006F7F1908261D6C87B7" xlink:to="loc_us-gaap_ValuationTechniqueDomain_1BAB5F5DC45E14AB1DCE08261D6CCA03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeApproachValuationTechniqueMember" xlink:label="loc_us-gaap_IncomeApproachValuationTechniqueMember_A55813B573D56C4241C208261D6C3256" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationTechniqueDomain_1BAB5F5DC45E14AB1DCE08261D6CCA03" xlink:to="loc_us-gaap_IncomeApproachValuationTechniqueMember_A55813B573D56C4241C208261D6C3256" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareholdersEquityClassAxis" xlink:label="loc_us-gaap_ShareholdersEquityClassAxis_F845EA1776C9ACF591FB08261D6CB84C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:to="loc_us-gaap_ShareholdersEquityClassAxis_F845EA1776C9ACF591FB08261D6CB84C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByShareholdersEquityClassDomain" xlink:label="loc_us-gaap_FairValueByShareholdersEquityClassDomain_53485463EFBE6BB4431F08261D6C5AFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareholdersEquityClassAxis_F845EA1776C9ACF591FB08261D6CB84C" xlink:to="loc_us-gaap_FairValueByShareholdersEquityClassDomain_53485463EFBE6BB4431F08261D6C5AFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsNotSettleableInCashMember" xlink:label="loc_us-gaap_WarrantsNotSettleableInCashMember_5AC07E1CDCA356845A0F08261D6C2D71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByShareholdersEquityClassDomain_53485463EFBE6BB4431F08261D6C5AFC" xlink:to="loc_us-gaap_WarrantsNotSettleableInCashMember_5AC07E1CDCA356845A0F08261D6C2D71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_10E061FFB140359154B308261D6A9918" xlink:to="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_9A110D1A5625B8600BC808261D6CA063" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_9A110D1A5625B8600BC808261D6CA063" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DebtInstrumentNumberOfTranches" xlink:label="loc_mgen_DebtInstrumentNumberOfTranches_BB2BEE068A051AF6DE2E08261D6C75E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_mgen_DebtInstrumentNumberOfTranches_BB2BEE068A051AF6DE2E08261D6C75E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_3992617184559D9100BF08261D6C19D1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_DebtInstrumentTerm_3992617184559D9100BF08261D6C19D1" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DebtInstrumentTermInterestOnlyPayments" xlink:label="loc_mgen_DebtInstrumentTermInterestOnlyPayments_D0D009AEABAE4E6F457108261D6D611A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_mgen_DebtInstrumentTermInterestOnlyPayments_D0D009AEABAE4E6F457108261D6D611A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentBasisSpreadOnVariableRate1" xlink:label="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9AD282A911D4943726BB08261D6D19BD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1_9AD282A911D4943726BB08261D6D19BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd" xlink:label="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_698414A7296D49254A9608261D6DA029" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd_698414A7296D49254A9608261D6DA029" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed" xlink:label="loc_mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed_5B030FD9FF0BC860A8FC08261D6DFAA5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed_5B030FD9FF0BC860A8FC08261D6DFAA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7B4E918646E4C05B71B308261D6D440F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_7B4E918646E4C05B71B308261D6D440F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DA498C337FC8AF57BF0E08261D6DB1DF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_DA498C337FC8AF57BF0E08261D6DB1DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_F89A798BD3C24BD0B17408261D6DCC38" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_F89A798BD3C24BD0B17408261D6DCC38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssumptionsExpectedTerm" xlink:label="loc_us-gaap_FairValueAssumptionsExpectedTerm_AA59C2E98927FAF5A96B08261D6DADAA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_FairValueAssumptionsExpectedTerm_AA59C2E98927FAF5A96B08261D6DADAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsDiscountRate" xlink:label="loc_us-gaap_FairValueInputsDiscountRate_0B56B669170EBCD61D4F08261D6D5E51" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_us-gaap_FairValueInputsDiscountRate_0B56B669170EBCD61D4F08261D6D5E51" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_FairValueInputsProbabilityofExercise" xlink:label="loc_mgen_FairValueInputsProbabilityofExercise_A12D0C6C653A6955ADF308261D6DA25D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_64199E9EA43D9A51204A08261D6CA1D9" xlink:to="loc_mgen_FairValueInputsProbabilityofExercise_A12D0C6C653A6955ADF308261D6DA25D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/NotesPayableTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_7765AC0176D948C433A708261E101513" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtTableTextBlock_C3356DAB37A593BC4A9F08261E104D1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7765AC0176D948C433A708261E101513" xlink:to="loc_us-gaap_ScheduleOfDebtTableTextBlock_C3356DAB37A593BC4A9F08261E104D1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_54221E9A484F7796886F08261E1058B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_7765AC0176D948C433A708261E101513" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_54221E9A484F7796886F08261E1058B8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/PropertyAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_33F582DA750FDA9E73F608261E05EFBF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B81239C3E258C87FC6C308261E0529DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_33F582DA750FDA9E73F608261E05EFBF" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_B81239C3E258C87FC6C308261E0529DC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/PropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_E170E9756063EDF1438B08261DBD25F0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B761E19B7377BC3574A808261DBDD99C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_E170E9756063EDF1438B08261DBD25F0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B761E19B7377BC3574A808261DBDD99C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00DCD77129909619F33108261DBDDA4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B761E19B7377BC3574A808261DBDD99C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00DCD77129909619F33108261DBDDA4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_00DCD77129909619F33108261DBDDA4C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_612BE01ADBF8EBAC452E08261DBD2CEC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1" xlink:to="loc_us-gaap_EquipmentMember_612BE01ADBF8EBAC452E08261DBD2CEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_A0DB70408C4FEEDBC53208261DBDB091" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_A0DB70408C4FEEDBC53208261DBDB091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="loc_us-gaap_ComputerEquipmentMember_2FCD15F386F00F45DB9F08261DBD0036" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1" xlink:to="loc_us-gaap_ComputerEquipmentMember_2FCD15F386F00F45DB9F08261DBD0036" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_DD3CFEC2C874EEC8ADE008261DBE1818" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_46F78A4D5A04108EB60508261DBD41A1" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_DD3CFEC2C874EEC8ADE008261DBE1818" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CE4A900551BC88A0E07708261DBE44E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_B761E19B7377BC3574A808261DBDD99C" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CE4A900551BC88A0E07708261DBE44E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_2E19ADB0FA7897FF32AF08261DBE7A3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CE4A900551BC88A0E07708261DBE44E8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_2E19ADB0FA7897FF32AF08261DBE7A3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1E66EA2DA3A3ABE1917B08261DBEE1AE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CE4A900551BC88A0E07708261DBE44E8" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_1E66EA2DA3A3ABE1917B08261DBEE1AE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_73285EB30F69B7F4B48308261DBE22D3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_CE4A900551BC88A0E07708261DBE44E8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_73285EB30F69B7F4B48308261DBE22D3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/PropertyAndEquipmentNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_EFD5539C4ABEC007F2B09D2B4D2CF377" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1BC74B088698B4D2026C9D2B4D2CB612" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_EFD5539C4ABEC007F2B09D2B4D2CF377" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1BC74B088698B4D2026C9D2B4D2CB612" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/PropertyAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_606CD80969991BB82CBF08261D61483B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_DF3EC8149CB752DD8A6A08261D61B312" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_606CD80969991BB82CBF08261D61483B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_DF3EC8149CB752DD8A6A08261D61B312" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/ReverseMerger" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_173DC7B566D72A6E5D4708261E3A0E7B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="loc_us-gaap_BusinessCombinationDisclosureTextBlock_B6067BE9A81058A82AC908261E3A1B47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_173DC7B566D72A6E5D4708261E3A0E7B" xlink:to="loc_us-gaap_BusinessCombinationDisclosureTextBlock_B6067BE9A81058A82AC908261E3A1B47" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/ReverseMergerNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_C3DDADB62F9FFF9718D208261DACC983" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_C3DDADB62F9FFF9718D208261DACC983" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_DA5626D1F4B80433295D08261DAC2E15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_DA5626D1F4B80433295D08261DAC2E15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8354B2FCE315A604115E08261DACC760" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_DA5626D1F4B80433295D08261DAC2E15" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8354B2FCE315A604115E08261DACC760" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalMember" xlink:label="loc_mgen_SignalMember_0FE07AF6639CAC50B73F08261DAC69D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8354B2FCE315A604115E08261DACC760" xlink:to="loc_mgen_SignalMember_0FE07AF6639CAC50B73F08261DAC69D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipAxis" xlink:label="loc_us-gaap_OwnershipAxis_E8C466829EFEDE3924F808261DAD5C69" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:to="loc_us-gaap_OwnershipAxis_E8C466829EFEDE3924F808261DAD5C69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OwnershipDomain" xlink:label="loc_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OwnershipAxis_E8C466829EFEDE3924F808261DAD5C69" xlink:to="loc_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember" xlink:label="loc_mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember_66260FCBA882090EF4E808261DAD630C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0" xlink:to="loc_mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember_66260FCBA882090EF4E808261DAD630C" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalShareholdersMember" xlink:label="loc_mgen_SignalShareholdersMember_790DF87BD2174A64D1DE08261DADB5DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0" xlink:to="loc_mgen_SignalShareholdersMember_790DF87BD2174A64D1DE08261DADB5DB" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_MiragenShareholdersMember" xlink:label="loc_mgen_MiragenShareholdersMember_D42ABEA8D8DDF0D13F7B08261DAD2A33" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OwnershipDomain_91E02252D58C806B974608261DAD33C0" xlink:to="loc_mgen_MiragenShareholdersMember_D42ABEA8D8DDF0D13F7B08261DAD2A33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_8F42134D7018466CA7EF08261DADF814" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:to="loc_us-gaap_StatementClassOfStockAxis_8F42134D7018466CA7EF08261DADF814" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_258C2A93FAC199CA286408261DADCDC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_8F42134D7018466CA7EF08261DADF814" xlink:to="loc_us-gaap_ClassOfStockDomain_258C2A93FAC199CA286408261DADCDC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_347CB3838CEC35619E4D08261DAD0BDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_258C2A93FAC199CA286408261DADCDC7" xlink:to="loc_us-gaap_PreferredStockMember_347CB3838CEC35619E4D08261DAD0BDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockByUniqueDescriptionAxis" xlink:label="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_FFF212ECE69E3B378F8A08261DAD4060" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:to="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_FFF212ECE69E3B378F8A08261DAD4060" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockNameDomain" xlink:label="loc_us-gaap_ConversionOfStockNameDomain_5AA28C5180CBC95C4FA508261DADA50B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockByUniqueDescriptionAxis_FFF212ECE69E3B378F8A08261DAD4060" xlink:to="loc_us-gaap_ConversionOfStockNameDomain_5AA28C5180CBC95C4FA508261DADA50B" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalSharesIssuedToMiragenCommonShareholdersMember" xlink:label="loc_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_CA71B534D9147290C90808261DADA3C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConversionOfStockNameDomain_5AA28C5180CBC95C4FA508261DADA50B" xlink:to="loc_mgen_SignalSharesIssuedToMiragenCommonShareholdersMember_CA71B534D9147290C90808261DADA3C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_412B0299F73DCF381AEC08261DAC0050" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired" xlink:label="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_D9432FF207E234AFBC7808261DAE960E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:to="loc_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired_D9432FF207E234AFBC7808261DAE960E" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ConversionOfStockSharesIssuedConversionRate" xlink:label="loc_mgen_ConversionOfStockSharesIssuedConversionRate_48EAB800650FE3A8F42908261DAE37D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:to="loc_mgen_ConversionOfStockSharesIssuedConversionRate_48EAB800650FE3A8F42908261DAE37D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5F338C51B2D3339064D108261DAEB7F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5F338C51B2D3339064D108261DAEB7F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_9E6DABECEFBF688EC52508261DAE9224" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:to="loc_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_9E6DABECEFBF688EC52508261DAE9224" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_MarketCapitalization" xlink:label="loc_mgen_MarketCapitalization_7ADDA673421311D0B1E908261DAEB75A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:to="loc_mgen_MarketCapitalization_7ADDA673421311D0B1E908261DAEB75A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E8CF327FB2CA8C3DA10408261DAED723" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_C74AD0882821E35B12AB08261DAD4B93" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_E8CF327FB2CA8C3DA10408261DAED723" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/ReverseMergerSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_00A2CCA8ED7BE02EFD4B08261D708974" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7A4DD9D8DEE8AB154B7908261D7022F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_00A2CCA8ED7BE02EFD4B08261D708974" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7A4DD9D8DEE8AB154B7908261D7022F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_36F20F6F0D9DE6860A7108261D70E3FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7A4DD9D8DEE8AB154B7908261D7022F0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_36F20F6F0D9DE6860A7108261D70E3FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8168E5E258059A3BCE0308261D70D680" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_36F20F6F0D9DE6860A7108261D70E3FF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8168E5E258059A3BCE0308261D70D680" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SignalMember" xlink:label="loc_mgen_SignalMember_222B76F92ECF897F01EF08261D717A10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_8168E5E258059A3BCE0308261D70D680" xlink:to="loc_mgen_SignalMember_222B76F92ECF897F01EF08261D717A10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8A98442E52CFECC04F1708261D716EB6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_7A4DD9D8DEE8AB154B7908261D7022F0" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8A98442E52CFECC04F1708261D716EB6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_DDBD3501DC35F01D26C008261D716075" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A98442E52CFECC04F1708261D716EB6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_DDBD3501DC35F01D26C008261D716075" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_C1C5DDF74DEABBFA330608261D71380B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A98442E52CFECC04F1708261D716EB6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_C1C5DDF74DEABBFA330608261D71380B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_70B934F1B1C8AF00C4A508261D714234" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A98442E52CFECC04F1708261D716EB6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities_70B934F1B1C8AF00C4A508261D714234" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_AA23C7AA2494945A8C0808261D715A86" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A98442E52CFECC04F1708261D716EB6" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet_AA23C7AA2494945A8C0808261D715A86" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/ReverseMergerTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="loc_us-gaap_BusinessCombinationsAbstract_0DDAB83E69515B578EF508261DA7E6EC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_B03601A6F826ED2746A808261DA70F6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessCombinationsAbstract_0DDAB83E69515B578EF508261DA7E6EC" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_B03601A6F826ED2746A808261DA70F6C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_422232A587DB5C26F6B208261DB22009" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4107C939D921D0C1035708261DB21A6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_422232A587DB5C26F6B208261DB22009" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_4107C939D921D0C1035708261DB21A6A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensationAllocationOfShareBasedCompensationExpenseOnStatementsOfOperationsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_44324C4AA0D5B546704708261D74F7D1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_98A9D83505719C8648D908261D74C4C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_44324C4AA0D5B546704708261D74F7D1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_98A9D83505719C8648D908261D74C4C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2377250A5EA2F7640C4308261D749DE3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_98A9D83505719C8648D908261D74C4C7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2377250A5EA2F7640C4308261D749DE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_919D1CF804C2BD84F49908261D747D0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2377250A5EA2F7640C4308261D749DE3" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_919D1CF804C2BD84F49908261D747D0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_583C933FF67D566781FA08261D756CC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_919D1CF804C2BD84F49908261D747D0D" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_583C933FF67D566781FA08261D756CC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1D5D07AC01E101538D0008261D757592" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_919D1CF804C2BD84F49908261D747D0D" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_1D5D07AC01E101538D0008261D757592" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FE5D13FED1485DAFCB4708261D75D573" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_98A9D83505719C8648D908261D74C4C7" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FE5D13FED1485DAFCB4708261D75D573" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_04BB21EF566980B707AC08261D75EA71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_FE5D13FED1485DAFCB4708261D75D573" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_04BB21EF566980B707AC08261D75EA71" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensationFairValueAssumptionForStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4FA1BAF317AC1F747AA9782AAA9F70B1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50F7F9F1B8BE3FB0DF43782AAAA0F809" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4FA1BAF317AC1F747AA9782AAA9F70B1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50F7F9F1B8BE3FB0DF43782AAAA0F809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_799CB745C9A70D603B26782AAAA02D66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50F7F9F1B8BE3FB0DF43782AAAA0F809" xlink:to="loc_us-gaap_AwardTypeAxis_799CB745C9A70D603B26782AAAA02D66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B036D50B12D56D68DB62782AAAA029DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_799CB745C9A70D603B26782AAAA02D66" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B036D50B12D56D68DB62782AAAA029DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7F33BEE2222B4C9AE1A0782AAAA0885B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B036D50B12D56D68DB62782AAAA029DF" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7F33BEE2222B4C9AE1A0782AAAA0885B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1BFB2E19F98FF3DC1826782AAAA01F39" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_50F7F9F1B8BE3FB0DF43782AAAA0F809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1BFB2E19F98FF3DC1826782AAAA01F39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7302DC74B0AF83D76F32782AAAA0DBC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1BFB2E19F98FF3DC1826782AAAA01F39" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7302DC74B0AF83D76F32782AAAA0DBC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0BB6464D3106B2918315782AAAA0C365" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1BFB2E19F98FF3DC1826782AAAA01F39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_0BB6464D3106B2918315782AAAA0C365" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D4F7F818A0BDED19FC0E782AAAA07282" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1BFB2E19F98FF3DC1826782AAAA01F39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_D4F7F818A0BDED19FC0E782AAAA07282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_32331862B7731AE1E340782AAAA05744" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1BFB2E19F98FF3DC1826782AAAA01F39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_32331862B7731AE1E340782AAAA05744" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7A764C76347AFCA61106782AAAA04154" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1BFB2E19F98FF3DC1826782AAAA01F39" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_7A764C76347AFCA61106782AAAA04154" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4DC2ABEA7A98A2FD6F4A981617AB1B57" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4DC2ABEA7A98A2FD6F4A981617AB1B57" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_83435A5DF5F3C229ECF8981617ABC5D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_83435A5DF5F3C229ECF8981617ABC5D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_9D97E567AFDA1C3340D2981617ABAAFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_83435A5DF5F3C229ECF8981617ABC5D4" xlink:to="loc_us-gaap_EquityComponentDomain_9D97E567AFDA1C3340D2981617ABAAFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_71C3F64CAC6DD9579C7F981617ACF19C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9D97E567AFDA1C3340D2981617ABAAFF" xlink:to="loc_us-gaap_CommonStockMember_71C3F64CAC6DD9579C7F981617ACF19C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_07388D749D7BEA724BD4981617AC5244" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:to="loc_us-gaap_PlanNameAxis_07388D749D7BEA724BD4981617AC5244" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_1DB6DB1DFFA6717F06B0981617AC8688" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_07388D749D7BEA724BD4981617AC5244" xlink:to="loc_us-gaap_PlanNameDomain_1DB6DB1DFFA6717F06B0981617AC8688" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_EquityPlan2008Member" xlink:label="loc_mgen_EquityPlan2008Member_8B0A349BE9F08002F421981617AC03ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1DB6DB1DFFA6717F06B0981617AC8688" xlink:to="loc_mgen_EquityPlan2008Member_8B0A349BE9F08002F421981617AC03ED" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_EquityPlan2016Member" xlink:label="loc_mgen_EquityPlan2016Member_D5A3BBD020C4C1E9C0BE981617AC4B05" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_1DB6DB1DFFA6717F06B0981617AC8688" xlink:to="loc_mgen_EquityPlan2016Member_D5A3BBD020C4C1E9C0BE981617AC4B05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_14C03EB5BD3D374B5214981617AC0A8C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:to="loc_us-gaap_AwardTypeAxis_14C03EB5BD3D374B5214981617AC0A8C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06D5584DC41CB57A4D89981617AC2E9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_14C03EB5BD3D374B5214981617AC0A8C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06D5584DC41CB57A4D89981617AC2E9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_1D3B71B34726D2839411981617AC2C37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06D5584DC41CB57A4D89981617AC2E9F" xlink:to="loc_us-gaap_EmployeeStockOptionMember_1D3B71B34726D2839411981617AC2C37" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_NonemployeeStockOptionMember" xlink:label="loc_mgen_NonemployeeStockOptionMember_21972907E7D226C5972B981617AC8DE2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_06D5584DC41CB57A4D89981617AC2E9F" xlink:to="loc_mgen_NonemployeeStockOptionMember_21972907E7D226C5972B981617AC8DE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_339F2E9B83818EB9D93D981617ACC073" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:to="loc_us-gaap_RangeAxis_339F2E9B83818EB9D93D981617ACC073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8F3E04A4E287C3C0C750981617AD4729" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_339F2E9B83818EB9D93D981617ACC073" xlink:to="loc_us-gaap_RangeMember_8F3E04A4E287C3C0C750981617AD4729" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_2FA0A5FE7D8EC7680C70981617AD49EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_8F3E04A4E287C3C0C750981617AD4729" xlink:to="loc_us-gaap_MaximumMember_2FA0A5FE7D8EC7680C70981617AD49EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:label="loc_us-gaap_VestingAxis_2ACD8977B424FDAA859B981617AD5C60" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:to="loc_us-gaap_VestingAxis_2ACD8977B424FDAA859B981617AD5C60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:label="loc_us-gaap_VestingDomain_3F9FC30FEC467341E76A981617ADFA47" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_2ACD8977B424FDAA859B981617AD5C60" xlink:to="loc_us-gaap_VestingDomain_3F9FC30FEC467341E76A981617ADFA47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5236A173E42626355BBA981617ADD901" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_3F9FC30FEC467341E76A981617ADFA47" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_5236A173E42626355BBA981617ADD901" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8A9A9BE5B93E363D68DF981617AD0A1D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_3F9FC30FEC467341E76A981617ADFA47" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8A9A9BE5B93E363D68DF981617AD0A1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4338FF2E8A108412F9D0981617AD04F6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4338FF2E8A108412F9D0981617AD04F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain" xlink:label="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_B36EC7EDF231C550D6A8981617AD794D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis_4338FF2E8A108412F9D0981617AD04F6" xlink:to="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_B36EC7EDF231C550D6A8981617AD794D" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_NonemployeesMember" xlink:label="loc_mgen_NonemployeesMember_EBB1A2D2256EE1C30DCF981617ADFE65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionSupplierDomain_B36EC7EDF231C550D6A8981617AD794D" xlink:to="loc_mgen_NonemployeesMember_EBB1A2D2256EE1C30DCF981617ADFE65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_DEFD39D46E93254920BE981617AB2164" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F501CBB7628DD786308E981617ADD27C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_F501CBB7628DD786308E981617ADD27C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_E80DF4FE72535C4F0D37981617AD116D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_E80DF4FE72535C4F0D37981617AD116D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_BC2F954840A92394F6D3981617AD8C10" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_BC2F954840A92394F6D3981617AD8C10" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding" xlink:label="loc_mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding_E157D8CF6E60653036CD981617ADD3A7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding_E157D8CF6E60653036CD981617ADD3A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AEA07E8435651E1DE999981617AEC255" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_AEA07E8435651E1DE999981617AEC255" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_AB4C69C4E123090F9403981617AEA2E8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_AB4C69C4E123090F9403981617AEA2E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4FA14FC0221C0E1FF2D5981617AE2D04" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_4FA14FC0221C0E1FF2D5981617AE2D04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F34CF55AC79FC6B000CF981617AEA0C0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_F34CF55AC79FC6B000CF981617AEA0C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_24D2424B1CACE795FD9A981617AEE9E2" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_24D2424B1CACE795FD9A981617AEE9E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E6F2A81BB7EB5D9794C9981617AF3EA1" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_E6F2A81BB7EB5D9794C9981617AF3EA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_D8C35371A88C0ACD9307981617AF4942" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares_D8C35371A88C0ACD9307981617AF4942" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0BE477E79DE6B5B5DB7A981617AFF649" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_0BE477E79DE6B5B5DB7A981617AFF649" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_B811F6D3E346132E5E2A981617AF824F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_B811F6D3E346132E5E2A981617AF824F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_928AD385B96CC384EB51981617AF3874" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_928AD385B96CC384EB51981617AF3874" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions" xlink:label="loc_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions_C77F645339728B17CDD0981617AFE92A" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions_C77F645339728B17CDD0981617AFE92A" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition" xlink:label="loc_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition_CC4B9482AF657A116807981617AF1FD8" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5CF792A3BED611FEE6C5981617AD8AC5" xlink:to="loc_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition_CC4B9482AF657A116807981617AF1FD8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2AB9F12BD00DB987AD4208261D91FFD6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36275286C510510CEB0908261D911680" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_2AB9F12BD00DB987AD4208261D91FFD6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36275286C510510CEB0908261D911680" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_AB11A12E246A565DF36708261D912291" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36275286C510510CEB0908261D911680" xlink:to="loc_us-gaap_AwardTypeAxis_AB11A12E246A565DF36708261D912291" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E6DD5F1248893867614008261D91FE21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_AB11A12E246A565DF36708261D912291" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E6DD5F1248893867614008261D91FE21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_47082575FD92BEE08AF708261D915002" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E6DD5F1248893867614008261D91FE21" xlink:to="loc_us-gaap_EmployeeStockOptionMember_47082575FD92BEE08AF708261D915002" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EE8599F93B9B225927908261D919809" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_36275286C510510CEB0908261D911680" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EE8599F93B9B225927908261D919809" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EE8599F93B9B225927908261D919809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CDDA68874F82E439423708261D91D8D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_CDDA68874F82E439423708261D91D8D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60717D0CC274D45B104508261D91306C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_60717D0CC274D45B104508261D91306C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_DA42C64E8876E06478CD08261D911427" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_DA42C64E8876E06478CD08261D911427" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF1661887AA031BC780A08261D92E7F6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_AF1661887AA031BC780A08261D92E7F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0952AACBF61288DAB71108261D92DACD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_8368719DE9EE9478B90A08261D913B00" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0952AACBF61288DAB71108261D92DACD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0EE8599F93B9B225927908261D919809" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_295BAC2694D0BAE817A808261D928EDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_295BAC2694D0BAE817A808261D928EDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BAB0B5B1B3A477CD38CA08261D92AB3F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_BAB0B5B1B3A477CD38CA08261D92AB3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_355A1588848B0A390F4F08261D922EF3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_355A1588848B0A390F4F08261D922EF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_EBEFA273657E84A4ED2008261D928B39" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_EBEFA273657E84A4ED2008261D928B39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7836D110F2F5857C462508261D9273B0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_53F80416E8EC4686B2AD08261D925F2E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7836D110F2F5857C462508261D9273B0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6B3BFB74A37CBA45810D782AAAB8E170" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D2834D0947D948BF272782AAAB8A98E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6B3BFB74A37CBA45810D782AAAB8E170" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_3D2834D0947D948BF272782AAAB8A98E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F03F5DFC05643BCB9968782AAAB849C2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6B3BFB74A37CBA45810D782AAAB8E170" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_F03F5DFC05643BCB9968782AAAB849C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EBCB33C0CAFF109709A2782AAAB8F7BE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6B3BFB74A37CBA45810D782AAAB8E170" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_EBCB33C0CAFF109709A2782AAAB8F7BE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/StrategicAllianceAndCollaborationWithServier" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DA68569BA92420D5DD7008261D7E07C6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_401F7F8DBAB6DAA78D1C08261D7E8AA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_DA68569BA92420D5DD7008261D7E07C6" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_401F7F8DBAB6DAA78D1C08261D7E8AA7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/StrategicAllianceAndCollaborationWithServierNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9F321CA916633F0E97A3782AAB65896D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D9BCE08E049966F3D508782AAB65F5FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9F321CA916633F0E97A3782AAB65896D" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D9BCE08E049966F3D508782AAB65F5FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_59A83E474295EDAE04D7782AAB6529D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D9BCE08E049966F3D508782AAB65F5FB" xlink:to="loc_us-gaap_RangeAxis_59A83E474295EDAE04D7782AAB6529D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_A24F379768FFC75915F9782AAB65FECA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_59A83E474295EDAE04D7782AAB6529D2" xlink:to="loc_us-gaap_RangeMember_A24F379768FFC75915F9782AAB65FECA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_60352974B53E12ACAD64782AAB66F43F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_A24F379768FFC75915F9782AAB65FECA" xlink:to="loc_us-gaap_MinimumMember_60352974B53E12ACAD64782AAB66F43F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_EFEBE98BB8E2D5B33974782AAB66B461" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_A24F379768FFC75915F9782AAB65FECA" xlink:to="loc_us-gaap_MaximumMember_EFEBE98BB8E2D5B33974782AAB66B461" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_FDBF78B37552D15F79CA782AAB669155" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D9BCE08E049966F3D508782AAB65F5FB" xlink:to="loc_us-gaap_TypeOfArrangementAxis_FDBF78B37552D15F79CA782AAB669155" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2F8217F2847259D6C63B782AAB66FDAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_FDBF78B37552D15F79CA782AAB669155" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2F8217F2847259D6C63B782AAB66FDAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_2EA89624694A8E12FF2A782AAB662B8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_2F8217F2847259D6C63B782AAB66FDAF" xlink:to="loc_us-gaap_CollaborativeArrangementMember_2EA89624694A8E12FF2A782AAB662B8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_D9BCE08E049966F3D508782AAB65F5FB" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments" xlink:label="loc_mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments_2CF7AFE5C6D8E7FA7398782AAB66F26F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="loc_mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments_2CF7AFE5C6D8E7FA7398782AAB66F26F" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments" xlink:label="loc_mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments_51868147721B429ADA3E782AAB67B7BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="loc_mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments_51868147721B429ADA3E782AAB67B7BC" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments" xlink:label="loc_mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments_F87080493B6E7CBE6F62782AAB6768E1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="loc_mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments_F87080493B6E7CBE6F62782AAB6768E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ReimbursementRevenue" xlink:label="loc_us-gaap_ReimbursementRevenue_3F17566629ABD40B61C1782AAB67F68F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="loc_us-gaap_ReimbursementRevenue_3F17566629ABD40B61C1782AAB67F68F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:label="loc_us-gaap_LicensesRevenue_88982AF65AFD202D876B782AAB677382" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="loc_us-gaap_LicensesRevenue_88982AF65AFD202D876B782AAB677382" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:label="loc_us-gaap_LicenseAndServicesRevenue_D29265DE0714252D07EA782AAB67DEBE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="loc_us-gaap_LicenseAndServicesRevenue_D29265DE0714252D07EA782AAB67DEBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms" xlink:label="loc_us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms_3D407227F65318DCA601782AAB67A8DF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="loc_us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms_3D407227F65318DCA601782AAB67A8DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNet" xlink:label="loc_us-gaap_AccountsReceivableNet_DE936D0212D131B85A847833921EFFC2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_EC9F2E4110184577F5CE782AAB66C627" xlink:to="loc_us-gaap_AccountsReceivableNet_DE936D0212D131B85A847833921EFFC2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/SubsequentEvents" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_A0AD2BB21142C5A1353D782A437A0F2C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_2F87DDF3CA8B31360D2C782A65CC23E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_A0AD2BB21142C5A1353D782A437A0F2C" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_2F87DDF3CA8B31360D2C782A65CC23E9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/SubsequentEventsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_B74588908EBA39E97A7A9293F1991565" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_F653569EAC02CE7758DA9293F1D9C8C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_B74588908EBA39E97A7A9293F1991565" xlink:to="loc_us-gaap_SubsequentEventTable_F653569EAC02CE7758DA9293F1D9C8C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_01C99CA5B8BEC581ED7892961785FC48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_F653569EAC02CE7758DA9293F1D9C8C8" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_01C99CA5B8BEC581ED7892961785FC48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7EB4E373806FBF0346679296189C2C43" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_01C99CA5B8BEC581ED7892961785FC48" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7EB4E373806FBF0346679296189C2C43" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_AtthemarketOfferingMember" xlink:label="loc_mgen_AtthemarketOfferingMember_062733F4AAF086E863FC92966FDDEC4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_7EB4E373806FBF0346679296189C2C43" xlink:to="loc_mgen_AtthemarketOfferingMember_062733F4AAF086E863FC92966FDDEC4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_0EFE0A0F426B984562619293F1D92E39" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_F653569EAC02CE7758DA9293F1D9C8C8" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_0EFE0A0F426B984562619293F1D92E39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_5F64FFB8692656770E319293F1DA1ABC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_0EFE0A0F426B984562619293F1D92E39" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_5F64FFB8692656770E319293F1DA1ABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_CE526D9E1D83989E73EE929638237F24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_5F64FFB8692656770E319293F1DA1ABC" xlink:to="loc_us-gaap_SubsequentEventMember_CE526D9E1D83989E73EE929638237F24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_F653569EAC02CE7758DA9293F1D9C8C8" xlink:to="loc_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E0E5059999671AA03B059294EA2304DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_E0E5059999671AA03B059294EA2304DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_DD30059D1260264924DA929424B83E2F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_DD30059D1260264924DA929424B83E2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_D99F2EA8632AB809A1239295C7C0086F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_D99F2EA8632AB809A1239295C7C0086F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635AA76E354C9F1863FE92949EF32D56" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_F1EBA56D052A732DED7B9293F1DBBC3E" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_635AA76E354C9F1863FE92949EF32D56" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_B2F8BC8D9A2267C765A908261E4E3B78" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8CA0981FAD8BF76C480B08261E4EDE54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_B2F8BC8D9A2267C765A908261E4E3B78" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8CA0981FAD8BF76C480B08261E4EDE54" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_FC60A11E752FAC4C56DC08261E37EB6B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59CC432CBB4113E53CD808261E371420" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_FC60A11E752FAC4C56DC08261E37EB6B" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59CC432CBB4113E53CD808261E371420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6752E06FED88A33BC14108261E38902E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59CC432CBB4113E53CD808261E371420" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6752E06FED88A33BC14108261E38902E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97C57642A6C7E2B2F2B508261E388166" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_6752E06FED88A33BC14108261E38902E" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97C57642A6C7E2B2F2B508261E388166" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_5E9023578D90CEE57C5208261E3872BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97C57642A6C7E2B2F2B508261E388166" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_5E9023578D90CEE57C5208261E3872BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_54ECA2CD46BE0D8A616108261E38015A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_97C57642A6C7E2B2F2B508261E388166" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_54ECA2CD46BE0D8A616108261E38015A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_80183A80204F098108E708261E38C37A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_59CC432CBB4113E53CD808261E371420" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_80183A80204F098108E708261E38C37A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_C3F25F9DA622745C6AE208261E3811C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_80183A80204F098108E708261E38C37A" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_C3F25F9DA622745C6AE208261E3811C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_29A20252C903C43156D108261E383F37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_C3F25F9DA622745C6AE208261E3811C6" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_29A20252C903C43156D108261E383F37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosureAbstract" xlink:label="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_145D1654D361212E3C0E08261E38C817" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_80183A80204F098108E708261E38C37A" xlink:to="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_145D1654D361212E3C0E08261E38C817" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesFairValueDisclosure" xlink:label="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_28DC32A54E6E70CDB2CA08261E3837FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesFairValueDisclosureAbstract_145D1654D361212E3C0E08261E38C817" xlink:to="loc_us-gaap_AccruedLiabilitiesFairValueDisclosure_28DC32A54E6E70CDB2CA08261E3837FC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_D229B518343528605C2F08261D783375" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1477609AC214566C7FEC08261D788E7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_D229B518343528605C2F08261D783375" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1477609AC214566C7FEC08261D788E7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_B0BDC018CDD387C850A208261D798493" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1477609AC214566C7FEC08261D788E7C" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_B0BDC018CDD387C850A208261D798493" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_EF29B892FE9909FC21EF08261D79A026" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1477609AC214566C7FEC08261D788E7C" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet_EF29B892FE9909FC21EF08261D79A026" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_F1C50FBBAE6E03EE9C0208261D7975D8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward_1477609AC214566C7FEC08261D788E7C" xlink:to="loc_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_F1C50FBBAE6E03EE9C0208261D7975D8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_DC3A5C5CAF02EE7C2B5208261DB52901" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_259D622B776E5F8BCD8108261DB53B93" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DC3A5C5CAF02EE7C2B5208261DB52901" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_259D622B776E5F8BCD8108261DB53B93" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense" xlink:label="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_559B4AA0DDBC07C5790D08261DB6C0F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DC3A5C5CAF02EE7C2B5208261DB52901" xlink:to="loc_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense_559B4AA0DDBC07C5790D08261DB6C0F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_9A58D44FC784F432502908261DB689A8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DC3A5C5CAF02EE7C2B5208261DB52901" xlink:to="loc_us-gaap_NumberOfOperatingSegments_9A58D44FC784F432502908261DB689A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8FBE7868E08E9C02784108261DB6F1E4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_DC3A5C5CAF02EE7C2B5208261DB52901" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8FBE7868E08E9C02784108261DB6F1E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_21C043CD5F66ED73733108261DB6EB38" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8FBE7868E08E9C02784108261DB6F1E4" xlink:to="loc_us-gaap_RangeAxis_21C043CD5F66ED73733108261DB6EB38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_36122CA02375DBB54E5608261DB6DC74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_21C043CD5F66ED73733108261DB6EB38" xlink:to="loc_us-gaap_RangeMember_36122CA02375DBB54E5608261DB6DC74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_528F8A854EACE8F5836C08261DB67917" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_36122CA02375DBB54E5608261DB6DC74" xlink:to="loc_us-gaap_MinimumMember_528F8A854EACE8F5836C08261DB67917" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_377DE79F32611A535BA608261DB6F4EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_36122CA02375DBB54E5608261DB6DC74" xlink:to="loc_us-gaap_MaximumMember_377DE79F32611A535BA608261DB6F4EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9DF4C7AD50771EE75C9F08261DB663B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_8FBE7868E08E9C02784108261DB6F1E4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9DF4C7AD50771EE75C9F08261DB663B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_C3581F564FB8B9D6F29608261DB6D3E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_9DF4C7AD50771EE75C9F08261DB663B7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_C3581F564FB8B9D6F29608261DB6D3E1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_01D6E05FC09E89B7372E08261E5D925B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8EC540DFC9E6EAC6C76108261E5D6A39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01D6E05FC09E89B7372E08261E5D925B" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8EC540DFC9E6EAC6C76108261E5D6A39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_191981105306C1EC8F3708261E5DE7AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01D6E05FC09E89B7372E08261E5D925B" xlink:to="loc_us-gaap_UseOfEstimates_191981105306C1EC8F3708261E5DE7AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_18C2A26B86D90DBCCEB208261E5DD509" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01D6E05FC09E89B7372E08261E5D925B" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_18C2A26B86D90DBCCEB208261E5DD509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_054791633FBA2F4B998508261E5D9729" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01D6E05FC09E89B7372E08261E5D925B" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_054791633FBA2F4B998508261E5D9729" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_72ED8F6E57DB5779644408261E5DF0DD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01D6E05FC09E89B7372E08261E5D925B" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_72ED8F6E57DB5779644408261E5DF0DD" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock" xlink:label="loc_mgen_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_853F2246E48B9098B45D08261E5D06DB" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01D6E05FC09E89B7372E08261E5D925B" xlink:to="loc_mgen_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock_853F2246E48B9098B45D08261E5D06DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DC4020D20FD4DCBD424708261E5DCA88" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01D6E05FC09E89B7372E08261E5D925B" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_DC4020D20FD4DCBD424708261E5DCA88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_514037D787D155435EBB08261E5DC458" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01D6E05FC09E89B7372E08261E5D925B" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_514037D787D155435EBB08261E5DC458" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_7C869550B81976A1F92B08261E5D8596" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01D6E05FC09E89B7372E08261E5D925B" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_7C869550B81976A1F92B08261E5D8596" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_92D729EF1BBAC836DC8108261E5D2F10" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01D6E05FC09E89B7372E08261E5D925B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_92D729EF1BBAC836DC8108261E5D2F10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_243C5B32B14FB571511408261E5D2469" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01D6E05FC09E89B7372E08261E5D925B" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_243C5B32B14FB571511408261E5D2469" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_8B46FDC258BB541FA77C08261E5DBB47" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01D6E05FC09E89B7372E08261E5D925B" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_8B46FDC258BB541FA77C08261E5DBB47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_EE14F607EF495830303508261E5DFC1F" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01D6E05FC09E89B7372E08261E5D925B" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_EE14F607EF495830303508261E5DFC1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_279FD60B97DEFBD8FB0708261E5D61F0" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01D6E05FC09E89B7372E08261E5D925B" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_279FD60B97DEFBD8FB0708261E5D61F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6902A8E236C44FC1CBED08261E5E12E9" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01D6E05FC09E89B7372E08261E5D925B" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_6902A8E236C44FC1CBED08261E5E12E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B039F1B6C520570FA42608261E5E12D3" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_01D6E05FC09E89B7372E08261E5D925B" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_B039F1B6C520570FA42608261E5E12D3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_AC397813976F633784FA08261E50662B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A8F0FCF987BA03BCCAED08261E50C038" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AC397813976F633784FA08261E50662B" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_A8F0FCF987BA03BCCAED08261E50C038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8851E64E8A1E9E7A72C908261E50E729" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_AC397813976F633784FA08261E50662B" xlink:to="loc_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_8851E64E8A1E9E7A72C908261E50E729" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/Warrants" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_CEA6106B5D350FAED82508261DAF3615" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E9251B75A35D50919C4808261DAF465C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_CEA6106B5D350FAED82508261DAF3615" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_E9251B75A35D50919C4808261DAF465C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/WarrantsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_53A05DC269A86614BB5E08261D96FDDF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_C8E54C8FA081DFE708E008261D969851" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_53A05DC269A86614BB5E08261D96FDDF" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_C8E54C8FA081DFE708E008261D969851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_90DB24F113C426D5235908261D96FE11" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_C8E54C8FA081DFE708E008261D969851" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_90DB24F113C426D5235908261D96FE11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_42D2BFD70413AA5BE19B08261D966AE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_90DB24F113C426D5235908261D96FE11" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_42D2BFD70413AA5BE19B08261D966AE0" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommonStockWarrantsMember" xlink:label="loc_mgen_CommonStockWarrantsMember_3A5D28D53D9F1678D0B508261D968EE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_42D2BFD70413AA5BE19B08261D966AE0" xlink:to="loc_mgen_CommonStockWarrantsMember_3A5D28D53D9F1678D0B508261D968EE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_4DBA412D5B4DBF24B0B908261D973CC0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_C8E54C8FA081DFE708E008261D969851" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_4DBA412D5B4DBF24B0B908261D973CC0" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightAcquiredinAcquisition" xlink:label="loc_mgen_ClassofWarrantorRightAcquiredinAcquisition_813C5AB0E868ED3F968D08261D974C0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4DBA412D5B4DBF24B0B908261D973CC0" xlink:to="loc_mgen_ClassofWarrantorRightAcquiredinAcquisition_813C5AB0E868ED3F968D08261D974C0A" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice" xlink:label="loc_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice_807AC0266B5915D31C0A08261D97210D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_4DBA412D5B4DBF24B0B908261D973CC0" xlink:to="loc_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice_807AC0266B5915D31C0A08261D97210D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/WarrantsStockWarrantActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_4D104D72752A2FF790C208261E2E89ED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_DDD3EE6DFEBB62662ABD08261E2E6069" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_4D104D72752A2FF790C208261E2E89ED" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_DDD3EE6DFEBB62662ABD08261E2E6069" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_9E415FBD1BCCE188B5DA08261E2E0B58" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DDD3EE6DFEBB62662ABD08261E2E6069" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_9E415FBD1BCCE188B5DA08261E2E0B58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_B363AF9160EC56E5813D08261E2E954B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_9E415FBD1BCCE188B5DA08261E2E0B58" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_B363AF9160EC56E5813D08261E2E954B" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommonStockWarrantsMember" xlink:label="loc_mgen_CommonStockWarrantsMember_1DD90E4B8F380B62AE6908261E2E0815" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_B363AF9160EC56E5813D08261E2E954B" xlink:to="loc_mgen_CommonStockWarrantsMember_1DD90E4B8F380B62AE6908261E2E0815" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_PreferredStockWarrantsMember" xlink:label="loc_mgen_PreferredStockWarrantsMember_667CE49873EB24A0F63A08261E2E0842" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_B363AF9160EC56E5813D08261E2E954B" xlink:to="loc_mgen_PreferredStockWarrantsMember_667CE49873EB24A0F63A08261E2E0842" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_6C90E0F94C478A72AB3608261E2EC395" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_DDD3EE6DFEBB62662ABD08261E2E6069" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_6C90E0F94C478A72AB3608261E2EC395" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightActivityRollForward" xlink:label="loc_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6C90E0F94C478A72AB3608261E2EC395" xlink:to="loc_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_BD0A3B88D9C65BCFEC4808261E2E7D7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_BD0A3B88D9C65BCFEC4808261E2E7D7F" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightAcquiredinAcquisition" xlink:label="loc_mgen_ClassofWarrantorRightAcquiredinAcquisition_A06B182A38A03DCFC7D508261E2EB226" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:to="loc_mgen_ClassofWarrantorRightAcquiredinAcquisition_A06B182A38A03DCFC7D508261E2EB226" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightWarrantsConverted" xlink:label="loc_mgen_ClassofWarrantorRightWarrantsConverted_9C439D819BB1B792255108261E2E02F3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:to="loc_mgen_ClassofWarrantorRightWarrantsConverted_9C439D819BB1B792255108261E2E02F3" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightWarrantsExercised" xlink:label="loc_mgen_ClassofWarrantorRightWarrantsExercised_2E235FE6CAF6CC2CB23F08261E2F1B8D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:to="loc_mgen_ClassofWarrantorRightWarrantsExercised_2E235FE6CAF6CC2CB23F08261E2F1B8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3D0DF8C25B28A697DF8C08261E2F69B4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_ClassofWarrantorRightActivityRollForward_B8B2A5178F09CFB1274B08261E2EBA1C" xlink:to="loc_us-gaap_ClassOfWarrantOrRightOutstanding_3D0DF8C25B28A697DF8C08261E2F69B4" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward" xlink:label="loc_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_6C90E0F94C478A72AB3608261E2EC395" xlink:to="loc_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5597E95D13B24419745908261E2F7CE5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_5597E95D13B24419745908261E2F7CE5" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice" xlink:label="loc_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice_6B929076F881ACCF7E0D08261E2F8973" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:to="loc_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice_6B929076F881ACCF7E0D08261E2F8973" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice" xlink:label="loc_mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice_1CEB21AEE9287ACCC5D608261E2F3D52" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:to="loc_mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice_1CEB21AEE9287ACCC5D608261E2F3D52" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice" xlink:label="loc_mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice_D11034CA6748FA4F254C08261E2FDF2B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:to="loc_mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice_D11034CA6748FA4F254C08261E2FDF2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0F075B6E5CA3D8393C5F08261E2F67C8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward_97FCF6EBED137E2F8D0308261E2FFEE6" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_0F075B6E5CA3D8393C5F08261E2F67C8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/WarrantsStockWarrantsOutstandingDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_E2B0DB539461AD2E0EE908261E08A2DB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaap_ClassOfWarrantOrRightTable_894386F36AB4ED4B606208261E095B9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_E2B0DB539461AD2E0EE908261E08A2DB" xlink:to="loc_us-gaap_ClassOfWarrantOrRightTable_894386F36AB4ED4B606208261E095B9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_54A5E5DA3C5EC032E7CF08261E09F1E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_894386F36AB4ED4B606208261E095B9F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_54A5E5DA3C5EC032E7CF08261E09F1E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_E856D099140FC7D8B69008261E094E77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_54A5E5DA3C5EC032E7CF08261E09F1E2" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_E856D099140FC7D8B69008261E094E77" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommonStockWarrantsMember" xlink:label="loc_mgen_CommonStockWarrantsMember_D78E0DF4349EE9BE7C4008261E0997E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_E856D099140FC7D8B69008261E094E77" xlink:to="loc_mgen_CommonStockWarrantsMember_D78E0DF4349EE9BE7C4008261E0997E4" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommonStockWarrantsExpiring2019and2020Member" xlink:label="loc_mgen_CommonStockWarrantsExpiring2019and2020Member_9AC412EED2118C35BD3208261E090356" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommonStockWarrantsMember_D78E0DF4349EE9BE7C4008261E0997E4" xlink:to="loc_mgen_CommonStockWarrantsExpiring2019and2020Member_9AC412EED2118C35BD3208261E090356" xlink:type="arc" />
    <link:loc xlink:href="mgen-20170930.xsd#mgen_CommonStockWarrantsExpiring2025Member" xlink:label="loc_mgen_CommonStockWarrantsExpiring2025Member_2033EA7D0C76B636DA6908261E09C347" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_mgen_CommonStockWarrantsMember_D78E0DF4349EE9BE7C4008261E0997E4" xlink:to="loc_mgen_CommonStockWarrantsExpiring2025Member_2033EA7D0C76B636DA6908261E09C347" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaap_ClassOfWarrantOrRightLineItems_0635FB0D52AB56BB548E08261E092FF5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightTable_894386F36AB4ED4B606208261E095B9F" xlink:to="loc_us-gaap_ClassOfWarrantOrRightLineItems_0635FB0D52AB56BB548E08261E092FF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F414D464303A4FA54CDC08261E098F6C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0635FB0D52AB56BB548E08261E092FF5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_F414D464303A4FA54CDC08261E098F6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_F08733DC46125250383E08261E0946D6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightLineItems_0635FB0D52AB56BB548E08261E092FF5" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_F08733DC46125250383E08261E0946D6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.miragentherapeutics.com/role/WarrantsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_13E803BC61353968B3F808261E26FF2F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_C3FFDD7A5885B50688F008261E266F3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_13E803BC61353968B3F808261E26FF2F" xlink:to="loc_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_C3FFDD7A5885B50688F008261E266F3D" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>a102yaletouploadctr001.jpg
<TEXT>
begin 644 a102yaletouploadctr001.jpg
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MIP'H(=2F#I43+P@,4=059Y"X%2QHW4ZO9./4;;CA*KL 9F,94#AE$,"J"8%
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M9=0"G ! Q1$#%ZC4EB^$-Y&-].I).ZXU*\[,>G72F&EN)MD'Z1V78U <-R+
M)U3);1YHJ=#%Z% ODU9G#WHZ7071FV]/TI8TTE"(';D?G;@B94#*'/D2 8V,
M;\>?XJI>RN$MMH);<%(*"_U+1LN!DHF+@6;-)!=V1^Z!9V8^]7:<VT1(4N2A
MM ?A&$*M_AMTA2T0T?A+23<.G0M04'F/5.8L4ACCRDC#YON27*2#'3"85 6'
M!TS1OY6;>W&H\BCWZ?4/N>5H":@2 -S((I\W>/W(@&W"&W)C!YP#I61%<*C^
M#T63L!C?!VP]\Y[A6?DC"B#E,[TSI1H=,5/@&$PD$Q3@(E /B$0&/V'P3N],
M4]/%K<OXS:1M-&5C3K.8<BJ,A'/G1G)T#I<T (<AQ 2J ./)#)!#I6>TX,^Y
M6M,OJ5&WBJSF)6<7?/$2LC"DXCEVR2"T>H7G !@$44U"J@ &*<N<"'2M9#<#
M*<1HHKIZ%V-3]E<L#Q<T2WT4G9$&;P'2"+LQ5 %S@0V9 4PQU N1$1V=T\+U
MS15WWQ?UAWH%LWQ/,1:E681:8(N5.TIJ)JNT5%!14.F0AT05*0I]BAA'>8 S
M8W$'HJ?7W2M2SG,R$,99XR>*/$VO.ZMUTU]H$WEP!C)@&<] 'XZUNE7#PEIE
MJM>=[HRX&5N<H"\CF#86K5=?G'4[4JGO,47&PQ4Q.0" 8"B8P"8PC6DU3X5A
MU,N34V5&Y^YQ;VM%*TS(A'\P6A"'4-SP-S0WB/..&W!0^#UZ#F%7%P'%G+AF
M[@3O4K>;=2-O2S$ZD.59NV<130[4H*I"M]V36344W$R40$0P/3KVZH<"25_,
MKD91UVM[:8W-!QL/+-6D&GRMS%WVE%5L0JI"H (B8@DP8," YW (CZ%U'T_8
MZH:;W#9TP('8S<:M'.%"DZE!1,2[RAGS@(@8.OG *IZ)X,(&WX34!I&S3M)W
M>%I-K7=.UT^;L,FV.W4>B7<&]94HIB<1'J*0=1R-:8G!"#>U;K@F]YG(A<=A
M1UD.E%(P#"3L:1T4W1,*A@1(<V4QSY6!W8Z58VBV@0Z1WA?=P'G>ZZMU#&F4
M1!IR ;BT9E:A@=YMVX" ;XL"..M0S47@[+?<=J_')W:>/8ZAR49*K$-' J=D
MLT%OD"FYA=Y3@V)T$ $N3=3=*T\AP.%7G5)]O=C89H+TD[M2+(PA7;(2/VZ;
M=RS5;F6#F%$B91*?< @/7 U?\U:+U2Q6\# RQ;>=-2-B-GJ+-,Q$RHG(.SDA
MM)L,4@D$@;0 IA ,8"J!G>!:+D9!]/1,M'VU<B]RL;E238PQ31!%6R"B!B&9
M"J&\%B+*\PP'*81$HAC:.Z:VAPUK:?ZMK7A;MR-XV-E(Q@PFH$D.F"#@[,#
M@JVVG*5K@IS%$H$.&!Z"!O*JN[#X" L5<Y4KZ.Z9)6S.6LS0/$@4Z+>1>*.N
M8<X+>6=,ZHAT H&  Z%'K5@MN&+LMK:%PI+C#EZ7+MEB*]@ZR((M#M0 0YGW
M(1*<3"(;NOQ8JOV7  Q"T-.+7D+R</86S(V?ATR)QY4EG;630.B8#'!00*=,
MIQ$#  @80^" =*S)3@=3N+1R,L>8N")<NV(I[)]C;A&+PJB*()-79%$E@.5T
MD 9Y@G$I_@B0"U=FK6FTCJ-IX:VHVYG-ON#+-5#2/9RN3J$15(H9,Y1$N04
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M!0WF%%,YL 8-E;+7?662=<&%UZE6A*)Q4BG"J2<;(1;E-VF E/Y!RG$NTY3
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MBL<YQRF7:0! IMPDZ;M@SXRD#ZN!9SRTUVD>-UN[2[L@_*<.T(L@>%/R=@&
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MM'Y["KRDS@03) 82E$0^".!R%2"!T1M6U[9DX*(;O8YC(RRDZN*$@N"O;3K
ML=4J@GW%RH4#"4!VCU#;M$0&&3G!=I#<4,QBGEKG*P:1"T&"+61<MP59*N"N
M3I*"FH43@*Y05Z^8W4*W!>%W3DE](WB6'=!<2,F28(["4=8!V5L#4%>7S-F1
M1 "F#;@V SFM;%<'&DT,P!DVME3L80CZW>0K).E"]@>+&7<HX,H/PU3F/N^$
M41\D0  "II<6C=J7;I6MIU,L%9*TU6:;%1JX=K&4,D3:),K;^9N 2%$#;LY
M.M:M3AVL-:\FUSJPPK2R#EJ_WK.53D5=MD3(-W2A!,(*+$3.8H*&R;S".1*4
M0VMRZ.VK=VH%O7K*,%7-PP""[:.<=J5*1%-<-JQ12 VPX'*  .XH] ^*H43@
MYTH0MV'@F]NKM(F'=O7D>V;RCI,&@O$C).DDC IN(BH0YP%(! GE#@ K[6X/
MM*',0I%N+:,ZCU+;1M$4'#]PH4(M%7FHH!E3H)%/+*H'E@/7=4W\%<&?3MY9
M2YY1U#/&QVCE1Q*N3O%TSAM/N="ISA$2^3NWYQT# 5H+%X:].].;3EK;A8$X
M1$H<3NTG[]P^.<11!'HHNH<Y !,-H 40 .N,9K4N.$/2MPRCV?>V9-HR@4K7
M(BF^< 52*35YH-%/+^Z$%3!C;LF-CRA$,@,^O_3>!U,LM_:<\V65@7R947#9
MHZ5:"=,! 0)O1,4X%Z  @ AD.@].E:FT-"[)L?3Z3LB,AA/;,IVCMS*0=KO1
M=<\NU;F*+G.<^XO3J;S= J/#PI:;*6\]AE85PLV>O&#YRJ>0<=H749%(5F!U
M@/O$J)4R 4F=ODY$!$1$9I?NF-NZF(PB=P,CNQA91&9CU4G"B"C=VEN BA3)
MF*/F.<!#.! P@(5#(_A1TQC;@:S25O&4?MG\I)D,N^75)VB1(";XQDS'$I@5
M*  )1 2A\0!4ETWT:MC2FTS6U;R#U*%Y8H)MGLBX=\E' @5%,5CF$B90,(%(
M40 ,UJ X;;"5BR1CZ)6F8U&'6M]LUE7JSLK5@L4A544A4,)B@8$TP$V=V"%
M!   *PW/"W8#R%M:/7:RZJEL.1=1,D:=>]T&IA3!(Q2NN;S=@I@!!()MHE
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M@)0, E$.H>8PA7BW6O3>Z)=#5BQ+=MG52!=74^>"C;\,1!>V))POT+(&D#)
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MLB(QY.2FHJV("ADR[<%,.S&2]>IOE&O.)(&X8CA_X0+NE'AX2QX(9E*1E7T
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MG(?GKC!0$1QU'X\5SD/STR'YZX$I3" B&1#J'2N<A^>@X'Y:X+@H  !@ ^(
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MSY-F+8@K'02$@*J 0.HE**A $<><P!\=:VU+'T.O=.,-"P-N/3R48G,M4 :
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MT;F:-P8,DT 10$^\4B;"AM()_*$H=,]<9KI-IS:APAP-;$,8(90ZT8 QZ7^
MJ' 0.='R?N9C 8V1+C.1SYZU\[IC$K1S52 C(2"N&)8JLX"7-#HKC$ <FS[B
M3R1 F, *93% P=,A75H[I>VTCLA&#3>J2KY5RXD9*462*DH^>N%3+.%S$+T+
MN.<<%#H4H%+D<5UN-)V"NI4I=)3IF:SD,$/.1"[<JJ$@5,QA04-GIN(55=,0
M$! Y5  <; J;-FR+-NDW;I$002*!$TDR@4I"@&   #H   8Q6.:$CCS!)8S!
ML:530,U(^%$O/*B8P&,F!\;@*)BE$2YP(@ _%46N#1'3J[)9>5F["MB8DUQ
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MH3U]#T[R7OY%T)Z^AZR]"TC0G%6C&K:/--)%G%E/%P09O6CDKPI'[4-QA;]
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M 3!MQ%^$.0/%/4&]RL&[F:342F#KQR[L# 9Z#LID#+.3*%4R E,<YS[AVGP
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M_F\E?[285>]*4I2E*4I2E*4I6!/?P)(?R=3^@->8-+W["-_Z/_2]>1@)6ZD
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M,T.)Q 7&4T14* F* F2$2@<V:VVCVMURG-:EOR\NWD&18)M=3NY5DPV'AP8
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MU/Z U17#--2%N\#^F\G%1H2\BULYBJ@R,N"!53 W+@#*" [2_&(X$< . $<
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M9IG[NGBJ:*^B&Q/9MG[NGBJ:*^B&Q/9MG[NGBJZ*Y_S0V)[-,_=T\5714?\
MLAL3V:9^[IXJFBOHAL3V;9^[IXJFBOHAL3V;9^[IXJFBOHAL3V;9^[IXJFBO
MHAL3V;9^[IXJFBOHAL3V;9^[IXJFBOHAL3V;9^[H/"KHJ'_9#8GLTS]W7'BJ
MZ*A_V0V)[-,_=T#A5T5'_LAL3V:9^[KGQ5-%?1#8GLVS]W3Q5-%?1#8GLVS]
MW3Q5-%?1#8GLVS]W3Q5-%?1#8GLVS]W3Q5-%?1#8GLVS]W3Q5-%?1#8GLVS]
MW3Q5-%?1#8GLVS]W3Q5-%?1#8GLVS]W3Q5-%?1#8GLVS]W3Q5-%?1#8GLVS]
MW3Q5-%?1#8GLVS]W3Q5-%?1#8GLVS]W3Q5-%?1#8GLVS]W3Q5-%?1#8GLVS]
MW3Q5-%?1#8GLVS]W3Q5-%?1#8GLVS]W3Q5-%?1#8GLVS]W5;V[IK:.FO&O!M
M;1M:%M9LZT_DU'",+'I-"+&+),0*8X)E #" "( (^;->FZ4I2E*4I2E*4I2N
MIS_DZG^J/_"O*D)=L_:O"-H(E;LL:$>3*UM0RKY-NDL=-!P)"*["JE,3=M\P
MB4<5DZP7?K=8-D:IW*^F(N(C(ERU=6XK'LTE5%T.<1)1)<J@G H&+Y0X\K*@
M"!R  IAZESDH_P"VO)ED<3UT-9;7!C<1DGZ\3*O"V>FFW*07"9'8L"-1V@&X
MQ70MP$1R(@Y+D?-6ITBO[5?6*7MR!<:C*V\]2LLDJ^>1T.Q5!V^[I.FISB55
M(0*3:@7!2;:OWA]U"EM0++D N#LREP0,U(6_(.F20I(.E6BYDN>F01$2 H4"
MF$N1VB)@R(!FK.I2E*4I2E*4I2E*4I2E*4I2E>;.*JVU[NU+T9BT("#N<59"
M4,,9<AC Q4VQR@[CX24ZE\Y?('K\8>>HS:EJ7OI=/L;%[XFD5#C$3UV.H6):
M%<,DR]J0*C'(&<$$Q&Y2K'SM HB)AV@0, &@L'5V_P L! RC6:3;1,:^LR'3
MMMM&-TVRZ,@R8]H 3;-Y! SD13V&*!-N! Q1P&5":Q2=U0=E.9&]F-TSLE+P
M#B6M<\*D(6ZX4DTTU$@4*7*)D]QDP(N)E1,D*A3 !3!6AMKBDN@VG<;.GU#2
MN%Q)VZJ[EP91;,>]QYVYLW;A@13(F"@+*D'M)Q* I"M_BRF(,DT7U*G-1]5+
M4&8E1F>X\_/1C=YS6ZIE$.YC)<O,5;$(BH8#+G+O3*!1 H!U$!$=K*S%R-N(
MF[(> FUH#N_>,1&NWR+9-=4C8+=<N# D"I3$*<3MR8,)3 'Q@/FK'B-;M2S,
MK0B5WY'DI>>Z%C)-*.('9WK*362?.3D -H;F)1< 4WD[T#@7 &P$.;\3>I3T
M)Y8]P0\'("WEC.XN47;'""Y#HJ2(\I% ZR&"B!#J.]Z8BH50  A1*.DO/6"<
MN:$M^5>7*]<%8L;SCSH2)&"K65<)QJ:J"!CM\MW@8%0 .D!-VQ0HD*8I\SQU
MK]<L+=T0BI>*,6X"ZFL+WE$C4%#J1/8><#PA0+SA%02B8#E-R\?<B@!PS4%;
MZ_W)?<6JV?ZB+MH8A+6GU9@5(PJC0%)M%%P!NSE,D@CRS%.**IU3DVAO.)3&
M 9==O$A>\-#S\I'W6U<W.7OG3=V6+%$PV^BQ0=':.C8+S?A(-MPJF$BH.R[
M+Y.?75D1LI$VLP;34VM<4F!!.M(KMTD#*B81-C8D4I2@7.T,!G !D1'(CO#>
M;_:%>%HEH\D^"712.9)).E'US1C4[5RX400<$-(*@9-4Z8"8""'GP _HK;6/
M><QHA.3;9^JPM%(MY1+&7M\7*SF-BXQ9NL4C]%RN8,$=*%( FVD*0Z8D$N\#
M&-E'XJKC6G[;>C., @'C]=)-M'M45';I()MRS(<4%CIG62%!-( ,U,90AA,<
MZ9BB4H]D7K1>NGD!(?\ PV6\7$A=%QVNU2<(E,LRF3/S=RTE=HY*B9,#"("
M8**6,%$*RM:KXD]*.)F*O-W(/'<';MG-R33-ON!-TDY>K("J"09#>5<K80QD
M0*)@\U132^^[NL%.0MR?O=O:O="[IU>5NN73*Y2;.B-F2Y628JF!,A3'<+[0
M_ ;&*7 CN"7VKKQJ1="K*<=.F,2S:J6B1W!A&#]V&5.DFYRH<V]/;S0.0/.4
M0P?<'0(.SU[O.R]-7J;G4)FR<1,?<LD66F&B;@TC(M9!<B<9@3!@Q$P(<4RC
MS1*J3;@I! ;*C-?+J=ZCL&AYF/%PM<B4$>R@:D[7W/,S!8TF!]V_'45=V.5R
MPV?#\JHDVUPU896LRN)Y<T8X)WKP-VK,RPI4RF,]="@JTW;Q$$@(43 ;_&;Q
MSNV^11YQ2:@HKZ@.4U8I)U&,+F7+!.#-SK1W8 5!HH*29Q6'<)$Q4YP%*<%B
MBF(!@#64IJ#J':&HUN:>2,DWGI.Y 9OF$T$:#<A6J)CFE2F*41*!B$!N4F1S
MET7X6T:Q^*QV[U"L33=2Q9T#.G]U(.(V0C764EED6CQ=$HG*.#)F51(4P#T$
M!'->>-4]2WVI"FH=_-I&096]/:=JFCF9USH@V;-Y)LD=00 0VG,H=UDW0=@%
MZXKT1HR>UVFN[YCI;)ED[%&WCJS!8Z0.]C4)'M) :\LXG.0BID>T[RD$,E*D
M)@^"(^D*4I2E*4I2E*4I2J(E/OXK9_F\E?[285>]*4I2E*4I2E*4I74Y_P G
M4_U1_P"%>6("R[@O+A%T(/;+!&4D84]MS9F:[D&X+)-A(H<H'$! #"'FS5H\
M45EW%J3HI-6M;,>B]E)8R#<>T.@0(@GS2'.J)A =VT"?! ,CFIU:D1+Q3B?-
M*RQY-)Y)*.6*9RA_@C84TRE1 0*7( 8JANN1\O&1QFJ[#A8M US0LXHYE57<
M5<DA<Z28KE!-1P[.54Z2@ 0-R154T52E\X'13$1''76L.$]C;C^/>VQ?EUVL
MZ:Q PIE6'853+MQ=JN@W<]JI@P*+GP8NWI@!S5H:<:>P^EMHM+>A"KBT0,HL
MHN[5%9PY754,HLNLH/4ZBBAS',8?.)AP !@*DV?T_LIG]/[*9_3^RF?T_LIG
M]/[*9_3^RF?T_LIG]/[*9_3^RF?T_LIG]/[*9_3^RF?T_LIG]/[*9_3^RF?T
M_LIG]/[*9_3^RF?T_LIG]/[*9_3^RF?T_LIG]/[*9_3^RF?T_LIG]/[*9_3^
MRF?T_LK@0 1 1#(AYAQYJ"!1'(AUQC.*X!,@!@"!CI_%^3S5UIM$$CJ'(B0A
ME# <YBD !,8/,(_*/0.M:6S;$A+"M1C;D.R!")9MRM4T5!%013 , !C&R)NG
M3KFMXD@D@0A$TRIE(  4I2X   ,  ?[*^MI=V=H9SG.* 4H8P7&.H=/-765H
MW*LJJ") 56  4.! W' /, C\>/SUPFQ;)()(D;ID12_Q:94P I/T!C ><?-4
M(4T3MM>^D[I6&4<.4GG=))@M)+G8)O.5RNT%;B;84^P1 ,!@!$3  &$35-4X
M]HDB=$C9(B1]PF(5, *.1R.0Q\8^?Y:^P:H%646!$@*J% IS@0-Q@#. $?C
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M'+6&AVZZD<Q(  HHMN,3(@?>F!";CF,0^"B!1$.TEP<.2ERI1(:=Q0)*.$F
MR Q[,$2O%&P."-A)S>;O$ABAO!,4@.8""?=TKIB;BT"E8I)X.CIV:CUE'OXA
MDY@6Y5Y=)ZIRFPMP!00 1/T$JHIB4/*-@GE5MG :#Q3&05F=)DX%ZRBU)0\;
M(P"1'"H$="U,DD &$JJG.Y10$IA(8%T1*80-D+)@] =+)I-V<^E<3&BW=*M@
M*^BD2"J!#8YI-HCE,WG*(X$0^(*V7BT:4^CVW/5R?U4\6C2GT>VYZN3^JGBT
M:4^CVW/5R?U4\6C2GT>VYZN3^JGBT:4^CVW/5R?U4\6C2GT>VYZN3^JGBT:4
M^CVW/5R?U4\6C2GT>VYZN3^JGBT:4^CVW/5R?U4\6C2GT>VYZN3^JGBT:4^C
MVW/5R?U4\6C2GT>VYZN3^JGBT:4^CVW/5R?U4\6C2GT>VYZN3^JGBT:4^CVW
M/5R?U5$K:T[MC3WB>8)6S 1\$FYLYV*Y8]N5$%!*^;;1-M#KC</G^6KYI2E*
M4I2E*4I2E*ZG1@*V5$1   @B(C^BO'W#LTTD>678-U7+=-H/G_>)#0G<R5<,
MSF:&;BLJ)P%0PB4PBOM$N QRP_V6W<MR:;7'J59-WCJ7;;=2V4GZ9&A91J)5
M^TIID')N;Y.WEY\PYS\50.T&4%8MQR+F*ULT_-$/KA>3IVKQBU5=%[2Y,NHD
M#GM@8QO,4I]G0,=!QBII)2FEDOJ\TOIYJ%:KD6\$M"!'+2#0Y!!1RDOS=PJ=
M!#E;<8^/.:KZ[=.=);IU3D;J-J+8HLI9\RD)!J^!DZ=<QLFFF!&[@RV$DSE0
M2 P"F<Q1*(D,01R&AD=(;#N"&9PLUKG;#^&AH$(&#; +(IFZ:;QHZ04<&%P(
M.#%%DBF8 *F4Y0'H4PB(R:P+,TTLJ>:31=4[,:/DNZ0G3MX64<@ ND6J)13+
MSCF 4RM"B!E#*&$3CU H%*$:M#1W3FWIEE*/-9;2=O6[:/;*N&ZC=-9\+62;
MO@7<JJ.E#JKJ&;[#G$=OEY*4N,#8]^0VBVJ>H!;BO"^+8G63:*[F,(E690(D
MUWJB=RKN*L F,J (D$!P %2#S[AJN'&B6ESJ*CFBFM\2*D9;BL"P<=T&>]!0
MBQS1KS_&^4LT24,D41^& Y$2^:ONZ]']-[@4CFZ&LMK)1+!C%-&J#Y=LZ69&
M9*%4WM3"Y*FESQ('-'EF.(YP</BF/<RR89"VG5M:RVM%W!!+RXI/G:[5RBHW
MD7 KKIF1!P3RBG!(2' _G2\HI@,):R6$7IJRTLTVLPVK%O+%LQY%O"OAD&@&
M>&9F P 8@*X)O'SX$<?%FHP33/2^#NV=N*V=7[>AWCB98SL2T7?-7#.+703=
M$52!/G%$R"O;G(BF!B"0R@B4P= "P=+I^S-.16YFKMKRH2#A[)2V7;5(73]P
ML0_-((+CRDR$**94O*R E$3B("(V)X;]._GY;'KEM^_3PWZ=_/RV/7+;]^GA
MOT[^?EL>N6W[]/#?IW\_+8]<MOWZ>&_3OY^6QZY;?OT\-^G?S\MCURV_?IX;
M]._GY;'KEM^_3PWZ=_/RV/7+;]^GAOT[^?EL>N6W[]/#?IW\_+8]<MOWZ>&_
M3OY^6QZY;?OT\-^G?S\MCURV_?IX;]._GY;'KEM^_3PWZ=_/RV/7+;]^GAOT
M[^?EL>N6W[] UNT[$<!?ELB/_KEM^_0=;M.\X[_+9 <X_AEM^_6!H&_;2NGJ
MCUDX2=LW$W,JHN$% .FH09-T(&*8!$! 0^,*L6E5_KQ9$UJ9I=,VE!O4HQ6<
M!./>/%%#$,BQ44*5V*>"CE04!5*3S!N, B( %4'J/P:2C-C<[:T+G6<0UQVY
MW(ED[NE55^6=LX259*$,)#8(1,729BCC *%$,X&NR]HRV;@N#4*19ZBV*GWP
MW):\PVYLXB4P)1JS4ZQ5,9\H00.! #(=0R)>N*\@]-(F+?=RE-0;.>1,:XFW
MK"5>7^NH!SO4GI$=L=N!%!0HO1!0^XY1*4PE)D_D;NY+#A)2,LU-EJ9I\DXM
MVRHR&(FO-I"@N_92#%X0I@#_ /%S]C,038W !P$"#C%9\2T:3^J:=\7%>FF\
M296\V%QGC6-S)NA2;MX1RPVBH8A .MS%B&S@ VAY\@&=?+:;6S.VE 6^IJA8
MT>B@M>(/'+>:1,8B<N#LJ!TRY#<<@.2"8!$O4HX$?/6A9Z<1TQ&..ZM[V*QD
M$&L/'('<W^XF 63;2C5XX$O/$I4$A(UPFD!#&W&ZG*7SSZ^6,'(7^_NF'O\
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M0!J6+</<8WCH@L/.RT)+Q,Q(3+.8;\A19-1ZJJHY2$BB9DS)FYQ@ !+D-I!
M<ER.JM+A0M6SW=O.6TG-.EH4[!1$[M=,YE3-$WI$Q4$$PW"8)!83"&,B!,8P
M.:\UAX6[BDDYR&L9=5E'73&NX^5D1ER(&-VAZY<F!PB+8_,23[6MR^2=-0=P
MD.82B!BWI=VC-LW_ '/!R]R,4YQ*&:.&S2+D$4EV93K"GN7%,Q!RJ!4@(4<X
M ISX#RLU16I_"I,QC23C],C*QK2:CY6-4.G*HLBL$WJO-% $Q:*@+0BAU5"@
MF)%B&4.4AMI\%G4/PF0,1/)R2<U()IG$CATR0;M2$7= U*V,KS12%<I# 0IQ
M2!38)P <8$0'9/\ AAMUU'6^@WEI=B\M^(CHJ,?HJ)"JW[$J"K=?!DQ*93("
M!@, D,4Q@$O6M/.</SZ;OO3CMSMW.1EMOG4X_GY22R[>N%!W$9]G(F"94 6*
MW6 "[2$[*F4"B/E5=4+%+Q1'95Y-W*"NZ5<$,[Y>42G-D$2;"%\@GF+NR;'G
M,(]:V-*4I2E*4I2E*55#S[Z2'_4U[_7VM6O2E*4I2E*4I2E*5@3W\"2'\G4_
MH#7D+06S-';3X3M&YNY]-X.9DIF&CVR?9;43DGKUR=L*IAVD2,<X[4U#F,/F
M HB(U;$!8&A-Q/)!FAIA;#9]'QC67=M'MI(-UD$''.Y6\AT0$#_X.KD@^47'
M4 R%8]GVCP^WTDHI#Z=VBX(G"L;@,)[6;DPS>$5.W/U2\YBHJ9+YPQU#J%:1
M@;AMDWEO(M].[941G$&"S=Z%FI]F3%Z4#,TU5>1M345 0VD,(#DQ0' F+G=I
M6EP^K6NRN$NG=HC%O)H+?15&UFX"+P7PL0)MY60#G@)=WFQUSCK6SM33#0B\
M[0+<\=IY97<0>?ETYMUHB4@(J'35$V],-H%,F?J/3 9\U1=)OPX2%IQ-PQ.G
MEK3[&8>.6$8G$6@BZ6>JH&4*L*294=QB%Y*@[^A1  $!'<7/63Q:UW$&5"P+
M6<M)9)FLG()6<F+5N#I04FH+J\C:B910HD I\"!@P8"Y#/8"'#869F8]Q8-I
MLRQ:3Y95\ZM%)-HJ5D.'O*6%#:H* ]#@41$! V,[1QT-PX=7,2JZ)I=" _(]
M2C@A3V.0LD==1$5TRE;"AO$#(E,INQM I#B(AM, 2QMIOH(XL ;U-I]9;:VR
M,C2"CMU;+=$4D2E$QQ.0R('*)=H@)1#< @(8STK21<+P[/[3N.X7.GEJ0K*W
M""I+)3%IH,W#,G*!4ICI*(@;!B& Q1 !W9P'E (!+[9T0T8NZVXJ=C-,[.5C
MI-HD];*'MMJ0QDE" <@B44L@(E,'0>H5LO%OTE]%]F>SS3W=/%OTE]%]F>SS
M3W=/%OTE]%]F>SS3W=/%OTE]%]F>SS3W=/%OTE]%]F>SS3W=/%OTE]%]F>SS
M3W=/%OTE]%]F>SS3W=/%OTE]%]F>SS3W=/%OTE]%]F>SS3W=/%OTE]%]F>SS
M3W=/%OTE]%]F>SS3W=/%OTE]%]F>SS3W=/%OTE]%]F>SS3W=/%OTE]%]F>SS
M3W=/%OTE]%]F>SS3W=/%OTE]%]F>SS3W=/%OTE]%]F>SS3W=0[6;A[TMCM(;
MW=-=-;0;.4(-^HDLC M"G3.#=00,403R @( ("%-&>'O2V0TBL=VZTUM!RZ6
M@V"JJRL"T,=0XMTQ$QA%/(B(B(B(U,.'^+90>G QT<T081[6:F46[5JD5))%
M,LFZ I"$*  4H!T  # 58]*5$-81$-)KT$.@A"/OZNI5(:0Z4Z-6[PL6)=MU
M6)9J31M9\?(2,D]@FIS8!FF=10YA3$3&$<C\8B(_&(U8ULZ(:,7=;<5.QFF=
MG*QTFT2>ME#VVU(8R2A .01**60$2F#H/4*V7BWZ2^B^S/9YI[NGBWZ2^B^S
M/9YI[NGBWZ2^B^S/9YI[NGBWZ2^B^S/9YI[NGBWZ2^B^S/9YI[NGBWZ2^B^S
M/9YI[NJ[L:Q[<L+C&N%C;-OQ=NLE;#CUE&\2R2:IG4[HO WF*F4 $<  9'X@
M"O15*^3>;_:'_&J\X>?\R]I_R(/Z1JK:_M>[BTZXG^Y$AR%-+TH*+[I+;"E5
MC';UX[10=F/\: F0(DID<$YA#]  XUI6?%O)6;I6SGKBB F72C^?YSU:0913
M<B#*2<H)HD,L<H*+BFF7:F4/*VB)C%SD>$>*68N&^9)%%HXC+0,[L\8F0;IH
MG<+DE52Y(LFH([2F ^TPAY1 (;;D1 :D#OC'81MN&NI]9\NTLY\RD7<#,F60
M$)06C=9P).4!MR/-2;JG2$_P@+UV"( .Q:\4#@D?<0RM@S$3*QL:PF&T>L]9
MB#ID[5.DFL9;F D@!#)G%7>;!"AN 3>:M1:'$\MJ?<=AI0J24<@M=S^VYM!)
MTW?HJBC$+/""@Y2$2F((B@;<7 Y Q1 ,#6^U.US=::Z\6U!.FTO(V](6U(OE
M&<'"+23CM*3IH1-02H$.<I (JJ C\')@SUQ596IQL=@CIL\VB+R3?WE,Q<$R
MEE$($$&#,J CV@[K9RS%YQ"[3 *AC*%Z8 1+);JXYK>@K$AKR9P+AY;KV+/*
MK.G4JQ9&*5-51)9N@517_"G!#)*9(EDHAMP<=Y0'HUEXK+H@(+4!6S+&</26
MK),(M2<?.D"-55W!V1MA$A."@CRG@>4( !38SG A7IMLH=5NF=1/DJ&* F3W
M ;8/QAD//CS9JI-+=59&0TMO2Z)\W;SP<Y<2!2()E3$6S)ZY32(&,!D$TBER
M/G'J-:2[N+F&M&W8N64MZ4>ED+89W.FW;&2%44W#MLV(B&3  J;G1!\X%\D>
MM<EXHG(/'=N*V)(IZ@IS*<,C;?=!L8%1.S,]!?M(&V%2! AC&$0W 8-H%,(E
M$;"T@U/)JQ:[F6[C/8!=K)O8IQ'R!DS+)+-ES(J9$@B40W$$0$!'(8'XZB'$
M!Q(M]!2$6=P"D@S(Q5D5W:\HT8)<M/X22(KJ%%=P( )@2*'FQDP;B@.G7XLT
M!N)ZDRLR8>VU&R$1'R$^5= A$#2238[8P(B;F' !>) I@/) <ANZ@&!XQD_=
MFJ&FS2!M]XPL6<N.2BAGG!VZB<B1JS>[@!,!%1$!7;;B&$ $Y4S9VY !<3NJ
M%PV;J/IU 15P3\!&S+*7<O%;9ML)MX=1OV3E!R>0L)2!SE-Q@* ?!R(9"H39
M7%A-Q<9:LO=DEV^)2BKJ7DR-XTK=\[.P?LF[(%&X]6[HY7  9 1* '5+D"AC
M%F/.*)6"=K6_.V-*1M^JJLDXVVR/&RXR .A6!(Y%RGY92D%LOS=WP.6(AO Q
M-W8CQ.J/G;.WF-E2CG4 TFXC7=M"Z;D%KV=%%=98S@3<L4A2<MS$,'4PK$+@
MH@;;L-"M2YV_>'-I>$N8Q)M9&15,"B)$S)"DX<$3(8A<EW%*F4HXR B4>HYS
M5<6[QC2$9IK#R<I:4G<BT794'==T2[)5LW201>(',HH1,QBB<X"BJ;EE  VA
MT$!P S&3XIB&U*N:RH:VSR,I# LB)5)1HBX%4K3M!%1:'."W93Y*0'  (;A'
MIM 354<QQ<7S'Z2Q-R)1P'NQW9L#.*0QRM^P@+V3!L9<BF=X&,00$$Q':0#%
MSD0-F]#<1[ &+58(1X*[B\U;**CS2='1.9]T$?P!%,0^7J XJF[.X]3--,;/
MD+M@FW?5)0JEP/VB<LS8IILP<*I$,CSU"\U4_*4VHE$1^YCN,7)<^L[8N-A>
M%MQ4]%K=HC)1HD^:K"42[TE" <AL#U#)3 .*V=*JAY]])#_J:]_K[6K7I2E*
M4I2E*4I2E*P)[^!)#^3J?T!KREI58"U]<'_#\<MG0]\MXV$9KK14L\.U-@[$
MR0*(G#)!,&_ E4*("4QA 0, 9W=L:3:HZ4-RJ1K**O9_+VHR@'ZKV94;BS<M
ME'9DS\PZ1S+H@1X"8F'"@\@!VB)QV]EL<("39ZNG/KJOVS.R(.V8]Q'2[Q@9
M19FDZ(L=0B*A $IN:D)=PF_C!T^/J0T4U!-:NDMINHV',2T$()1M<#:56)V!
M5J1$KTJC42['0G*F<B1A   %1$=AB 8W6QX15&=MPSDH&+=36_2W(L;NX\,S
M[($X9Y@J GY6_LX@&.6'E_'GRJFW#W:]\V%;B-D7+:\5W";J2!^Z[>7YXKE6
M=JK$*+842X 2JX')QQCX\UJI^Q-4+;TT-;MGI,2NI*Y)9[(/49,&KEO'N'KA
MP0K90R)RD6,55,HG$H\L-XER8"B&NNC22\YZ"LBVXVTX6W8F%4C'D8NVG%CC
M!+MU@,L"J8EVO@%,@<L3 &3G,)]H@"@QIUPR7R[N"ZE6(1T3)OV]Q)*W(M('
M<I219 3"W3!D8@D:[/N/,.0,CR?_ "N\PA@MN%F=*JVEN]-H2%82Z3TEBN+D
M6="Z)W-49+F.].41-G+<2I'$2;4!SM%02A8I^'R\9K0H]IRE\O.Z*MON(T8P
MYDG,>"QS*&1$ZZB(N5 2 R:>_>&XJ0&$N1$!U4UH'>NJ+^Y;EEGS6RI21<-5
M$85MRY-NH#5JLFB+@YB% P@LN=0N \GEI&')@P6X]$;0E=/]'K*MF<>)/Y:(
MAVK%RNB4"D$Z:12"!?E ,8 ?CQD>HU-J4I2E*4I2E*4I2H/KE_F6O[]7Y#^K
M*4T._P RU@_^H(_^K)UU:)_]2G?_ *_F_P"U'53VE*A^L7^:6]?_ %(^_JZE
M4U:^E<GJKPHZ--(VX30IF-LQKL&YV:;A!VKW.(5(%2G^(AS H7'F.4IL")0Q
M;^B-H2NG^CUE6S./$G\M$0[5BY71*!2"=-(I! OR@&, /QXR/4:FU*4I2J09
M??JSG\WT?_:3RKOI7R;S?[0_XU7G#S_F7M/^1!_2-6?(Z16_,W?<D_))*2 W
M!!H6^_CW.TS51JDHX. ;<9R;M2@&R., 7 !U$:GBN!^UK<BH./AKGN./2C8I
M]"'7.=JY<.&;IRJY4)S54#"F<#K'#FI[3B7&X3" "&\8<)%M1KR-.A.396C)
M"WT^QB= 4U58=4IVBQAY6X#"!=AP*(%, C@"C@:PW'!S;;Z&4M]Y<EPNK3;,
MY%G#01E4 0AP>HJH*G1,"7,4,1-=4B7.,<$RG$  >F-]J)PRV]J(!U7$E),G
MA646S062!%0J0L')W+=04E$S$4'>H8#%.!BB&/) 0 :^K.X:X6TIQI,FG)F6
MDT;@5N4RSPR!04=J1O<\X"5-(A2I\H $"% -I@#'3I4V<Z>QSK4J/O8ZSD)5
ME$.89-(#%Y(HKK(+',(8SN S<@ .<8$W0>F*W?\ "A ]O<RT1/3$+<"DY(SB
M<FF5LX%,SXJ0.4.4LB=,R)N0D( 8HF Q"B!OEU5P<&-O3J*Z 77<K9-_;H6U
M*K<ULNZ?M@%<P&%=5 YTCB+E7=RA(4P"4-H 4,2Z=X<X&=L:]K:/)RB"5U/T
M)1P\2.ESF[E%)JFD=+*8EZ"R1/M,4P".[/0<!-+.A)F%&:"7FE)DKF0,NR%4
MI ,W0Y2102\DA0'RR*'\W3F8R( %0& X="VZ\ED6]]7*K;$K(2$@\ME8C$6:
MHO5%%'">\&P+@03+&$,*@8.G6HVWX,H%:.39R]WW/.%;Q+2!9F=*-2"V8MGB
M#I!,H)H% 3 =N0IE# )C%$<CD $.S6/0EZ,^XO:T$)%[=+J;:2BIVDF@S<L^
M2R49[FAED5$3"9,^TZ2X"0Q3&$!*8I:R] M';QT\A+=[JW"JF(OIN4F8TRQ7
M0N57SGG(E46Y9=YT@$V3E A1,8V"B AMVNJW#7$ZJW8ZGEY^6A7#^"/;D@6/
M(V,*[(PJ&VD.LBH= V5E,G2$HF 0SG:40[6'#3;<?;\]$DD)4R,R[B'KA45$
M]Y5(Y)HFALP3  8&*0F# Y$Q\;<AC'@.&:+MZ\8.6;W-/##P$J\F8FVS'0!B
MT<.B+D7QA(%3D_PE42E,<=@F$"].@;_4K1P-0+IMNXVEU3=IS4$W>-6[J'*U
M/O2<\GFE.5P@J4>J">!  $.O7K4-'@YLES&JM9%]-RRSIM+(OWSIT3M#Y:04
M:J+.3F(F4"JE,R;\OE@0I (  7H%9"_"RPE5'4K,WE<<S>0K,5F5TKBU3=1_
M9#*B@5%,B)4=N5U]X&3-S.:?=TV@7M0X86#$6LJRNR?:WNE)N996[ %LH[<J
MN$4T5R'2.B*'*%)% @)@F $Y*8AU 1&9:=Z2Q>FVE[6Q6#V0>QK=%='M;]4J
MCI3G**'.8YP* ";<J;KMJ&MN%"TVUCW%:Q9"7&/G+2CK.<*"LGS2,V:*R21R
M#R\ J)5SB81 0$0#!0ZYR9[AKB[GU#8W++7'-R+)A(]UV<*Y,@HBU=<H4ON2
MPI=H32P(FY!503W"/3:(EJ/CP:6TK9P0#BY+A<BE;K2V6S\YVP+H-FCP730P
M "($,HF;87)BB!BIAN 1$PCLTN%>+)=K:7/=EPJ1[>XRW:G";VP->ZFP2*K"
M((\P2J;C&%/?M*8QA* = #3L>#2'@HI@S@[SN2'4:,%8;MB(,U%CQIESK)-L
MJ-S 443*J\M8H J',-DQNF+[B8Q&%BF<>W%06[1$B"8K*&4/M*4"AN.81$PX
M#J(B(CYQK+I54//OI(?]37O]?:U:]*4I2E*4I2E*4I6',)&7B7J9<;CHG*&?
ME$HUY:X:)[66U>'K3:)8Z96W*,FEO,4D'JMY&0,NF")=IQ3[";8(A@=NX<>;
M(U9??]K?Z([8]NC_ -WT[_M;_1';'MT?^[Z=_P!K?Z([8]NC_P!WT[_M;_1'
M;'MT?^[Z=_VM_HCMCVZ/_=]._P"UO]$=L>W1_P"[Z=_VM_HCMCVZ/_=]1J?U
M^U:MN[[6MIYI';_=*Y#NDV/+O8QDP%NB*RF\W8/)\D.F '(_)YZDG?\ :W^B
M.V/;H_\ =] O_6\?^R.V/;H_]WT[_M;P_P"R.V/;H_\ =].__6[&?!):^/UZ
M/_=]<]_VM_HCMCVZ/_=]._[6_P!$=L>W1_[OIW_:W^B.V/;H_P#=]._[6_T1
MVQ[='_N^G?\ :W^B.V/;H_\ =]._[6_T1VQ[='_N^G?]K?Z([8]NC_W?3O\
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MUWXP42TBQ=A>QTP6Y")$M^WL [=VS.,CC/G&I-W_ &M_HCMCVZ/_ '?7'?\
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MF9(,' 2I4SI-5>T3RL89("&-O Q"I&$!\QCE/T H!F>L.)ZTY:3=LF+68>F
MCTT<HW9;RS!FAMCDC, -N4,00'H(%W@ F)N* B&JU@'_ .<AH)_*IS^S35 '
M^NUSZ>Z_ZOI2C]23M@4TF-NQBA0VHRJ4>S7*W3$ R(N>V".!SU1'%132WB O
MJU;%C$Y=9>]KR1;*L5%G[X&S1TY/=1XHIS%(D(EV@8H[@SY! +MSY57I=VIC
M>8M::A)"ZW-A34&BW<7#+MHET5JBF!B"NFS=.$BIG$^>64Y-YPW9 HFQBJB2
M^I 1EJIS<C?K*TW[V87:FC6B:EQ%;@"'<PKT@)B<A1W.3&$2>3EL5<2^7F<P
M>N]VN-!]')Y*(8R-VWLHQ8*%>K&;-T556JRIUS<LIL@')$=I>@[L (!@:A<Q
MQ2W<OIZ_DIFWF<2W>P$V[9J0<NH+I-S%N4V[@!.=#:4J@G$R9@ PE H 8!$>
MDF/Q#:A2U[IPD+:=O@TD;AEK9C73^47*8%F1%%1<K%*B/W,Q45"["CNW;1S@
M1QKXGB@E9PT,\C83$U=,/;H,(]])#W/:NGRDGO$P@EN I"LCB)@R*F$B@4@Y
M&MX;7#4YY<[FVHVS+<>S,3 K2\D"<VHHFJJ5PZ;I-VXE1$=R@MR&PIM%/>)3
M (@ C*].N(!IJ5%7/<,:T12M6(CVK@DDY=%3*JX.U[4ND<1\E,$2*(%,81Z&
M,H @&P<UE!\6UUR;.Y&Y;-1D9AM%1\S'DC49#EJ-W3H6YQV+-DU7 )  J 9N
M0W.#H0 -4^8\0"RV@CZ^5$X0THT<'8&;=L<HM^T@X! I#E4;@X34$3%'LXHB
MKN$" !A$!'6VQKG<=XZ-ZIRG<Y")NFTA>LTCF0<H(JJD8)NDE11<I$63#"Q0
M$ARCU+D!$#!5=6-K]J1'/WTK*HQ\Y"MVUH%D2*NCI*)*R*2:2IFI"I;1^Z+$
M5'>( /4H 'GJ1P'%Y,3<B_>DLQP:V%"3'870-WJ9DA8%7$#+K*(%;F*MV<X
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M;"E*5;:81/G.,!YZKDG%Y<\78K6ZIJTHI-G,V[)3T0W8R:BJA>Q&3 Z3@12
M WD5 P&+G:("00$1 U2F^M9Y8^LL1:+ !CFT==L8P=+I*;A>(.8MZX,F<HE\
MD ,DGYAZX#S5!6_%UJ&>T>^%6R;>3:C9R=^\D)A<QPCPZ*-Q'D8%<0\HIO@!
MYA\V1L W$1.$NM-P: 8=Y*MVFLI-P#TXR/; ,9/M I;-G*YI1)MW;MOW3/\
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MI0#X@  K<3G#3PWVU+P<7*:=V,PD9MP=K&MEXQ$IW2I2"H8A QU$"E$?_P
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M1/NJK[1?2/5EY;D\HQUYDXY,ES3:9TRVO%J<Q0L@N4ZN3)Y 3F 3X#H&[ 8
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M]3D5(U,_$XY(>2ZLBFMJ& 773=]R#9Y?00'R<]!KL;:8ZJO))W'H<2[U9^T
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MK;<,GVGM\E7/*R3L )""8.6N^763Z@?S[%"Y#XAZ57=E:R*V#KGK%-R^G.I
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M@';7H_571ZXKDN]:X[4FHR-?2,"M;3\DPR.Y3*V.H*A5D@(<OW0@F/DIO).
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MD%FB0=Q0*<@" ER(F&8Z;\-S*P)J/EPD6P/FYI$YD8>(;QC0.U$:DPFDD'D
M0K0F!,8YA$QA$V, $(MK@?C8.7C)%>YCNG3 C=+M"46BBX>@C(M7Q57:P")W
M#@QVA2F5,( (',($*.<W;(:<-9#56'O=1TH#J-AWL.1IL**9R.%FRICB/GR
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M!4 >AA-D,8#%JPS!6*AV+)=\XDUFR!$3OG>SG.#%* "H?84I=QL9':4 R(X
M Z5FTI2E*4I2E50\#_YTD./_ -ASW^O-:M>E*4I2E*4I2E*4K GOX$D/Y.I_
M0&J$X/-.+4D^%?29T[MF'=.5K88'466CT3G.842B(F,)<B(_*-6##06FT[<4
M]"-;8A.WPCE)H[(I$H%#F*-R."@41)Y7W,Y1Z>;K\E?*,/IHYO4+62MF$4E1
MCNZ@ 2*0%,4.=R<[P+C._IBL&V%=([SO>YK4A(:WI*7MLJ RA4(M$R;<ZIE0
M*F)]FT3@*)]Q0$1*. ' ]*[-0&FG&G:$;VVRF,B_DW M6,;%0*3ETY4 AE#;
M2%)T I"&,)C"!0 //D0 84_U6T-9Q<9(DMMH\8NF0R;E9K;('[F-"JF1.N\#
MEY0*54BA# 8-P"DH.,$,(2Y9UI"GJ4SL$D/;KFZG+%61[ WC$%#)()\O)E!
MF";N:7: ]3!D0# "-:FS;DTNO2]AM-'3Y:+FP9&D>3,6B+,O(*<$]^XZ0 &3
M#@,_"P;&=HXU&HMHP=M<2FA!XF&CXLZCF<*<S)JFB)@[FFZ")0#->B:4I2E*
M4I7!O-_M"JJX81SHZP_]8RO]I.JM:E*4I2E*4I2E:JY[JA[*@W4S/RC2&B6I
M=R[U\L5)),,X#)C" =1$  /C$0 *PS:AVL2WXZ=/<D22$D3IILY$[Y(K=R8_
MP"IJ";:838'  (B.*R6=XP,A)MXUK-QSF1<M>W(M$G:9EE6^<<XI '(DSTW
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M$ &I[H'Q$WKJ9>$.6:A&S*!N%D_>M"<M)!5EV=8B8$ W:E#N?A"50W)2Y:@
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M33N#7>-^YS45&2R9$Q!PLY RQ#<S:8RB3<@J;0*<"CFK$MW52Y[OT$U+<N9
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M'3J/FZ5\,M*K+C863AVEI0;6)E#;GS!&-1(@Z' !E4@%VGZ 'P@'S!6P969
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MQC9$V   G2-@VRVNE>YDK>BDKC73Y2LN1DF#M0F #:97;O$,  8$?, ?)6-
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M XA/$3Q@DLNS[T"S(R8>2$"^;Q*MQ]R^=$-WQG")3MCJ;@$3@502B8"B0IS
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M>OGKS9:'!1*VE,,((MLV?)P+.X!E"77(R+U9Z=EVLSD$!C\ CV@IAV MS-@
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MBEVB B7)<#O+AX:+FEM'K^M1)]%ED9^_PNILJ=50$B->ZK=YL.($R"G+1,&
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M-@, (_%50ZD<6UE:?N;V8)KEFI>UK6+=:S-FZ1_PAL;F"4B8[A$3[4P./DX
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MP%)M =P@;'FK6:V:VO\ 2V:LN#A;1=7E/74[<M63%L^09@ H-S+G,9180+\
MAOC^*NK3+7TUV7-<-K79:SW3ZZ81@C+KL9)XW<HJL53*%*X371.)!*!DCE,!
MMHE$/C#K4ZB-1[3N""5FXNYX:2ADE014D6<@BJW(H(@ $%0IA*!LF*&!'.3!
M\M:F"U7BKEN9ZTC'$=(0#>,)(!/LY=JLB8W.5243Y9#B<H$Y0B*@@!,B)0'<
M4P!N[;ORVKRC%Y* N&*G(] PD5=QKU)PDF8 R(&.0P@ @'7 C4(A^(ZT+AU)
M<VO%RC"28-K>4N!>?9R"*K)),CCDG3,<IA HE^$(B. #SU(]4M2V6F.E-RWV
MHB:5CX6*6E12:*%RX333$^"&'IU .@^;K59O^+!O;M^6!9D]:,M'W%=C85R-
MD/\ "B(".-A2JD+L4Z9$XY+L H_"J;:*ZMKZL,[I![ *VW)VY.+03UFJZ(Y#
MFIHHJ[BG(  )1*N7XL]!JQZ4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4J
MB)3[^*V?YO)7^TF%7O2E*4I2E*4I2E*5@3W\"2'\G4_H#53<%X9X3-(?U6CO
M^06L3A\X7&?#W=^I5PM[MG+C/><F$DJA**;BM<"<V"X^&;[H("<<")2D#'3(
M^>GO#MJ]K-8=_7\VN5"T9BZYCOFC;:E+:,,DU/'G (E,7)ER&1$2-DA$.6.W
MGJ9 =PUL96]IQ8VKDO)V%=R,EJ?8,8:&CFD Z6-VXK)VBX9+&!/:W4345+GG
M"0!+U 1Z9B^H.G4PRM2[F)++EUIJ=T(CHIBLTA5E3*/FY'/:&QCD(.Q;8= -
MAQ QL%*&1  J>ZV:"2Y9=\PTSM<L$[D=(IB&!:,:@T14<@Y8&0;'4* %*H8G
M:2DW" AN./0,C44U8MYOJ9&.5M)].9VV&T1II<D5,('MI>*.H9=B!&444ADR
MBY5(N3> )@<I-O0WW0,VG):?L-*+VTP?Q-BN5+9@[#N 9-E!P_,,LL*<9M1,
MF0N#KJ@B<I2FZG$HA\0XI16V'FJ.EVI;N-LVX(/62[(-9JR8)VB]C&,/'%.5
M0\6@Z4032,JJF!P44,8.<H;: @0I #O-IE<&H43?YK$+<@RRNGCV%2,M99+4
M: =0Z1DXXP&*0RJY2D5*4Q0%-(#F#>&_K:6F;:W[BXJ[)GK*TZF;4A(ZQY"+
M?O'ELKQ*22W/9"BS,*B9-QTRE5\V2]1VF-@<;W4319;4WC'3>R!KIBH!"PB(
M%E;?DW<60[GND8W(.NW,3>.P=W+$1^(V/,-=^H<:71#5K1R=,RNF>M&'B)R&
M=R22+R=>(+.3,U4!7$H*KG XMU" <0$ ': B 8JK=,=+96YY/1=2Y+&D4X]"
M][SF';&9C1$&95S/#M3KE$!*7(J$VB.0$V,"(XK"MRQ%=.=44;AN>QI1?3F)
MO2[2(M&L&L\38'=]C,S>D:)D,8R(E3=I@HF00**P^8#B-=VC.GLPROC2AXQL
M>8MN ;:@7G($9.HP[?N>R<,W(-A4+C"13[RE*'FR(%#S5WZ=:'OK5TFX5E(B
MT3VY=+([CNO(EC13<L#K0KX#J.S;=Q2\\R6[?TW 4//@*T-B(PT0^X3[9-IU
M*6W><!,]CEIAY#"@BJL$4\[1RGF-KL%U0Y^](QP$ W&$HB #Z3UBL<UQ<0VA
M4MW!&29QCN6,\>]CYI&I18'Y0J'P($#FXVY$/*QCK7G>W;+>)Z=VKIX:QY@F
MM;"^T)9]<IH%4$B@66[0XE#20D!)1-1IN)@%!.;>">SH(!?_  8Z8M+$T=;.
MG-L$@KE?R$JL^5<,00>*E/).3I@H(E XEV"02@/3;MQTJ@+PLFV!UJUS-?-M
M:O+]V)=$\<:R6TT#1ZV[EMDC"'9<-SFWE4)E3/FP/DU)-+E[RT=N;22Y-2+9
MF3F/I\O;BPP$*=Z9L[*^15;-UDFA# D<S<I0S@$P.4P9 *A^AEHN--PL&:U.
MT]FW\"M9CN&;,3V^M)J1T@:7=++HJMR$.*0N$5$"@H)0(8$A 3 &,_&@UH.]
M-6&D<G?>GDY+V\WLV1B$(4D(I).H5XI***#S68%,<@+-]B7.V[0Y>TQ@ ^1B
MFG-HRG@[T3NA!E(V_8T:>[6H)MK9"X30CI695,@*C4H'$ Y)%$06(4VP0$N0
M*IFK(TNTX6LB]-"9QW;-QK0HS%RD25?VZ"2D;VTR1FF6R!3=B;F4*L<A3[>4
M!QW;*N+B<TUE]2=7M#&\>ZN&&9-9654>SMNCRUX\HQBH$$51(<J8'-A/R@Z[
ML!U&H;K_ ,*ZT'HS=+BV7ER7M<\F^B59MY-+!+2+^+:NRJJ-$DC 1,Q (*A^
MSE I51R4=PF"JHN?2Y_?5E:L/89I<UR-)>/@HMP!K-[@-I$4Y-(Y@(TV$654
M21%0IU1(!0(.T!'9TFG$/HM)&U'OEO:EC+K6L%HVWS8V'CP2;R""$^NY?LD@
M*!2'4.WR(I .3@< 'X?74ZK6-(ZPR>H\SI99DM'6LM9S.+D&BD0M"FGG"4FD
MX.V206(D90Q69'*&\2@ ]H!,##UQ-+2&UYSB NF\(;3*:;6-X-U6$B1:TEVA
M910CK<+,K11(@K*%2RGLV^7G:&X"]+/XL#ME.#'4\S-F:/:&LUZ*+0Z'(,B3
MLH[2"GTV"4,!M^+&/BJTXF C'T7%O7$<U7>)M6^QPJ@4RA=A=Q,&$,AM$QA#
MY!,./.-55PO?]9->?YQG?]GL*O>E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4
MI2E*HB4^_BMG^;R5_M)A5[TI2E*4I2E*4I2E8$]_ DA_)U/Z U4W!?\ >F:0
M_JM'_P#(+5T4KC 4KFN,8KFN,4Q3&*YKBE,4Q7"B952&(<H'(8,"4P9 0^2J
MOL;AGT^TYN%C,PD2Z2<1I%4XM!U*.G36*(J&%2LVZJIDVP&#(#RREZ")0P4<
M5:5<8"N:XI@*8J!:C:'VGJC)1\E,MW[>68)*-D).&E74:[!!02BHB*S90AS)
MF$I1$AA$,@ X >M2:T+/AK"MF-MZWHY")A8U$K=HS;%P1(@>8 ^,?C$1'(B(
MB(B(C6WQ7-*XQ3%,4Q6GO&T8F_K5EK;GF82$++-5&3QJ8YB JB<HE.7<40,&
M0$>H" U]6M:L?9MN,8*,!R$<S2Y*)7;M5TJ!>O0553&.;S^<QA'S!\5:C3?2
MJVM)HV18VRR7:(R+X\D\.Z?+O%5W)RD(90ZJYSG$1*F0//\ Q0J74I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I5$2GW\5L_S>2O\ :3"KWI2E*4I2E*4I
M2E*P)[^!)#^3J?T!JIN"_P"],TA_5:/_ .06KHI2E*4I2E*4I2E*4I2E*4I2
ME*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I2E*4I5$2GW\5L_P WDK_:
M3"KWI2E*4I2E*4I2E*P)[^!)#^3J?T!JIN"_[TS2']5H_P#Y!:NBJ^U,U]L#
M1YVS:7;<K:+?O""J@Q*11PY43 <"H"*13GV /03[=H?+4IM.[X2^[<83]O2K
M2:A7Z?-;/V2P*I*ER(9*8.G00$!#S@(" ]0K;Y#Y:9#Y0I3(9QFF:9#.,TR&
M?/6FB[RA9JX9N"8R*+F7A10"1:$$=[85B<Q+=T_C%ZA6Y <TR'RTR'RUA1\W
M'RSE^W9/F[M>/7[,[305*<S=784_+. #Y)MAR&P/7!@'XPK-R'RTS6$SG(Z1
M?2#)J^;N7D>H5)X@DJ4QVYS$ Y2J  Y*(D,4P /Q& ?,-9N0^6FX/E"@B ><
M:CUSZB6U9K:67FIQE'DB6'=1\558-[9KDP L<H9,!!$AP V,")3 'F&I 4Y3
M  @(" AD*Y$<4R'RA3(?+6HC[NAY2Y): :2"*\Q%)(+O69!^Z($7W\DQ@^0W
M+/C_ %1K;Y#Y: (#YAIN#Y0K"FYIC;<,_EI-R1G',&ZCIRX4'R4DB%$QSC^8
M"@(_[*YAIAE<$2QDXYR1VP>H)N6ZZ8^2JF<H&(8/S" @/^VLS(#\= $!\PYH
M(@'QUP8X% 1$<  9K4VC=\-?EM1UP0$@C*0TBB"[1X@(B19,?,8N<=.E;?(?
M+01Q3(?*%,A\M,A\M-P?*%,T$P!YQ *U4!=<1=*DJ2*?HOCQ;T\<]!(1'D."
M%*8R9O\ ZP <H_[0K;4I2E*4I2E*4I2E*4I2E*4I2E*4I2J(E/OXK9_F\E?[
M285>]*4I2E*4I2E*4I6!/?P)(?R=3^@-5-P7_>F:0X^:T=_R"UB</+/79M>.
MI1M6WT(ZM]23 ;6)%E(!DVV3Y =H .W;RL ID^X#Y'&*T>C3V-B>*'7MK.K(
MM[K=NXQVQ%TH!%%H8&*94A1R("*1%RN@-MZ <1SU$!&O;LOZUKF?0MO:0A<P
MH2]P3KUS&6>[1B$IQ=N*(.W82*BA=K<JJW7D9%4^>FTAA&#:<7K?>K<?IC9S
MZ_KBB&KR\;K@WLC$3!%7RS%F@J=!/MI285,4Q2 "X% 3  B&!'-3EE:VH5ZP
MNNL] ZB7::Y;6GGT9;,2$A_@0@U1:+D353VY5,J<#D$QAZ%5,  &1JT.'#51
MYQ W;=FH4?(.2V&1HQAX9AS!!([@$0<OES%^,Y5'!&^?B%L</CJH;^O.Y)"T
MN(/49QJ)-VQ<FGLR\:04&U?%2CTTVR*1VA%V@AA<7AC]14R(@H4$]NT*V%P:
MEWVVO>2T?-*2D?<MZ3L9,0ST5Q[3&PKA/GR9$SXZ=F.T=)%^,O:D0^2H'-:G
MZK3+V_KV:RSV&>V_>;B':&?76V9PK)%%V"*+-S'B014%=(0'>.5#&6(9,0#:
M%>@>'UA-W=JIJI<\Q>5PO4(6[9""CH$7F(U!L"+4_5+;Y9P,<X@81\D!P !U
MS6NK%^WN[U"ULMZ'O,(D&LY:K.,8.Y48[M!%VHJ+LFKK8?LRS@2B *;1\KID
M!'(6UPHW6\DHZ]+=EE;H1G;?EBHNXFZWJ$BO&\UNFL1%-ZB8P.4A V\ICCS"
M[Q*8 P%4=/35Y-+3U"U,)J)<Z<E;NIXPT=% ] (PC 9=LU.@HWVX5 2+*=3"
M(E\G:)=O5>=^W,CIGJ?JVGJ%-M;TM>\'L5'6LD] L:!6[_L[:.49@&%3.41*
M83C]T$5BF(8   JV^%>VD(75+B'63F)-ZL>]A(+5X^,L1,HQ[-4# 0?,.51)
MN_ 3(7S$"J#XA]7KPBB:BWW:D[=RK>VKG3B4)5>;;QT0U61<(I*L$XT#'.\Z
MG.!CJE*)Q,(E$"E 1L#5?6:<MK1WBM=!=;B.F+=N K6'4,YV*LB*L(\R)$L]
M0 ZAU1* ><3&Q43NA[)Z:WQQ O(6ZYB*4F-0;;A9"55? H$0Q>MF'.=IE4 2
M)G*"IDB*& 0(4"!_$"LK6R\+OT?=:HV/:-^S[]BV@(*60E9)]V][!OG,N1J9
M,%SY,)540Y@)J";&TV/)/BLR^K3NFWIW72'9ZL7\6-LNT&MU18*3 &7"052?
M"(J*[-QT<LB#R!'EY.?R?, :+6'56[+KB;NEX><NY9[:]H1[]\O%SC>WXJ$=
MK,>U@H?RA4>G4R4VP4Q3*&"!U$V-1=]R3K=QJ7J:A<TNSN]QH3#39>SO3)))
MN5>U@<Z:(="@4Q .4 Z%,J<0ZGJV;@F7EVW3K?.W%JS-Z;$T^DFK6-(R<@#1
MDT!FW<$=N&H!AWVA154NU3.2EV$P8,U:'%+>"\#IY M&,K/,)*XIMG$,T;:*
MBB^?J* =3LR:RYBD:[RIFRL([B%*(%R80KRFVU,U$1<7597?5<%O=EU%M.(2
M%2>3EY".0?\ 1TW%V)1 _P NPV_8(XR;%2FZ+WN_3BZ[_P!-&E\W"-M)W;:D
M6-Q2C[M,C$,I)(XNA(Z4 1+DZ9"$.?.P5A$.N,6?PV02-K\4&O40A<4A<B3-
MA;9 6E7G:W+813>FY!UA\HXEW9 3B)\' !$0 *@NKMVWS;C_ (E[_B+NGSN+
M!40;P5OIN [FH M$M#K+K(B4>;L%<RP 8=I13$<=39CTIJ)JEHS#7D]C9-^X
M*%@R$V@RN.[&UP.U%T3(@E)MB$( E2 JB@G)_BAP3:4,#G?7X_F-++O7BK6U
M5N6Z&S[2JX;@*C(2O;5 =I$; V?)GQD /N.)2E'8 E-L*&1K+U7UKG$(+34\
M'=JX+O\ 2JXIYUV1T F663CFAVSDV/C!051*8?CW8^.M19MVWS/]_%X&N^Y)
M!U9&G\%/QENMW8@TD9!:(<*J"Y( ;E@.<A!V ( )LCY\8UFF]]:D0O>;-.+T
M5C6=SVU(OGDI=-U-I9N[,1@=P1^T9ID#DE15VB<B>" D(E$!, #4^X6;KN2$
MU)B;=O.0N@\E/6VI(M#NKB0N"'F01.COD&RP 59J)N<&$A3(F)3ACJ2M[J&5
MQ>W%?/6C):DSUGV^QL-G,HQ\-+ P$RXO'B:KL3^?"1")[@^ .2[P$  *@&AU
MV7QK]>^GBEQWI<$.U2T]9W&X:0K@&:<JZ+)+I)N%0 H_<U44RF,F7 &!0 'H
M4 K7Z"WC<^NR&E-M79J!<,.R<:<IW(9S%20L7DN^.[415,=P7RS%03*F;840
M#*P"?(  5FZ67)>&O%RZ70LEJ-<32+&&N1TM)0#HC0\X2/F6[5DY.8I1  42
M,!C"3 'R;^*;%7%Q3W-((S%@6E#/+G5EYUR\73A+6>(QR\BDV1 RG,?*G(+=
M),3D,()Y.<1 H!@#5YYTYU'O"]XNR;6FK_FH)FIJG,VLL_:S1'#M5FC'JK),
MS/@*'-,*N$P5  /YMH[@ :D$I>5QEE&UA%U+G6MM,]7$K50N<'Q>VN6:D,JZ
M58'<B&3G(Y'D H.3@.WKO* U\3D]>+F\S:71.H-R$MYMJ<S@$[B2D 4D>R+P
M3EX[8"Y$HB<R2I  #FR<F\H".X@"&5<<A.A:NO<\\U3N>W9;2HQF$"U-*E*F
M"3>.07;N7J1BX=G=JG,!A5 0,'DDVB&:[I?5?4$LT\TQ6D9*)NO4=Q"2]OK
MJ8SB)8ND@-,)I&$/)!H+5P)0'J7M20=:AG$-JY>$2CJ+?-J3MW*M[:N=.)0E
M7$XWCXAJLBNBDJP3C0,<[WJ<X&.J4HG$PB40*4!'T=PS2C2.E-90>.T6PN=2
MY!N@"RA2<Q06S00(7(]3" #@ Z]!KT!2E*4I2E*4I2E*4I2E*4I2E*4I2E*H
MB4^_BMG^;R5_M)A5[TI2E*4I2E*4I2E8$]_ DA_)U/Z U4W!?]Z9I#^JT?\
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MA@I@5$N[<4.@#G(!T 0"MJPL:W8JZ92Y64''M+@E$TT7THBV(1RZ(GT(510
MW' H= R(XJ.RV@6FL]<4A/25@VU(3,@3ENWSJ*046<!@ \LQBB)AP !D>N
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M[NGWKY1!RE+.FPPB2;M5%!NS*DH4$!2*D7)@#<8^X3".<54;:Z-4[ZG]'9.
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MY*4% )M!/F%$#'P.9'H#Q47+JAJ4WMR?+:\.]71<G>6FJ+MC.PQR"(D*8C@
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M\D<CDHEKZF.,!"W5(Z!@(4ES23&WF$Q*'FKC:1BA"N$MZ*)#*@ .')RD.80
MI"!Y.3EW %=[CC&>7%VA?3[3UY><<WM=A=RSQ2408%*R=%7,5/!P,//#LYP
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MQR?H6MY9O%7W=F8&)F[0=6X^=W,]L^2$[Y-=!A)HM0=(I@H4 YI%TA'8?!1
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M@Y,(&(&X!* B(#5?J\35Z::WAKM)/[4?W=8MI7&EVJ1))HHFBV0L&9SD00,
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M2\I98F2'.0#)GP8-X=!J<WMQ/PUE3=P1Z=M7+<J%KMDG-R2<(T24;Q!5$P5
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ME/OXK9_F\E?[285>]*4I2E*4I2E*4I6!/?P)(?R=3^@-5-P7_>F:0_JM'_\
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M_#R[MZH99&#.DH4B+5NKV90RQ2 4_-%9,1V )0-M')R"-:V.UKU,FE;-Y/\
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M$!K0<3]]R=BZ.3)K=(=>[ID4X. ;I'*5160=&Y2.P3"!<DW&4$3"  "8B(@
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MXDW!_@Y\B(#D8=9&@-YL+CGCS4=.J7<DWN(591G$L$F<OVLC@$06?@KSW!#
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MV4I2"HY,!W&XH8 P*F ICE-DIA* B B 5MFFE5GL$$46]M1B*2*[1TF0C8H
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M*."C@*I727B4DG=HOAU+BDH.Z8Z7CH]ZTBTCF202DN49@J;>81 OW<J*ALB
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M0'FD*7<8=M8Y>+RS7EOQ<O&1MQ3*#N)-/N$6,;N6CXXJITA<N"&,42@)DE0
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M4I2E*4I2E*51$I]_%;/\WDK_ &DPJ]Z4I2E*4I2E*4I2NEV43M52E#(B0P
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MMYK2_34'\ZI:=JW=9+"=M]>%D6$38#\B2RW-*JT>@ )% %FZF\2B(#D#X'&
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M>I# 4M>A=-+DMW3.2N=PTB+[=(S+AFL5$]DOT^SE;L&[,I0V(  Y*V W0I0
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MYAR%2BTM:- +$2C20%F7#%=SEUG34[?3R9 Z:RJ8)JJ[NR;A.<@%()A$1$H
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M!2D8B.1;  -.B0CUV>:M<?5SAY4N2#N ;&G>[,(@DUCG@:<S ';))!A$I?\
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+*4I2E*4I2E*5_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772738800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Nov. 02, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MIRAGEN THERAPEUTICS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001590750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 30,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,309,419<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document And Entity Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773377776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 42,805<span></span>
</td>
<td class="nump">$ 22,104<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">635<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,981<span></span>
</td>
<td class="nump">1,753<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">46,421<span></span>
</td>
<td class="nump">23,877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">610<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">47,081<span></span>
</td>
<td class="nump">24,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued liabilities</a></td>
<td class="nump">4,142<span></span>
</td>
<td class="nump">3,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Current portion of notes payable</a></td>
<td class="nump">1,983<span></span>
</td>
<td class="nump">1,969<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">6,534<span></span>
</td>
<td class="nump">6,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Notes payable, less current portion</a></td>
<td class="nump">1,391<span></span>
</td>
<td class="nump">2,820<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">171<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">8,096<span></span>
</td>
<td class="nump">9,705<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 100,000,000 shares authorized; 21,886,568 and 833,744 shares issued and outstanding at September 30, 2017 and December 31, 2016, respectively</a></td>
<td class="nump">219<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">125,973<span></span>
</td>
<td class="nump">5,147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(87,207)<span></span>
</td>
<td class="num">(67,076)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity (deficit)</a></td>
<td class="nump">38,985<span></span>
</td>
<td class="num">(61,921)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, preferred stock, and stockholders&#8217; equity (deficit)</a></td>
<td class="nump">47,081<span></span>
</td>
<td class="nump">24,760<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">23,124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12,975<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Redeemable convertible preferred stock</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 40,877<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgen_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgen_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgen_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773360832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">21,886,568<span></span>
</td>
<td class="nump">833,744<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">21,886,568<span></span>
</td>
<td class="nump">833,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,169,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,149,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,149,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Redeemable convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21,448<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,183,318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,166,651<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,166,651<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Redeemable convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityParOrStatedValuePerShare', window );">Redeemable convertible preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesAuthorized', window );">Redeemable convertible preferred stock, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,303,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesIssued', window );">Redeemable convertible preferred stock, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,268,563<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Redeemable convertible preferred stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,268,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityLiquidationPreference', window );">Redeemable convertible preferred stock, liquidation preference</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 41,060<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate liquidation preference (or restrictions) of stock classified as temporary equity that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.28(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of par value or stated value of stock classified as temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of securities classified as temporary equity that are permitted to be issued by an entity's charter and bylaws. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been sold (or granted) to the entity's shareholders. Securities issued include securities outstanding and securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgen_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgen_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgen_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773361776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenue:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Collaboration revenue</a></td>
<td class="nump">$ 1,493<span></span>
</td>
<td class="nump">$ 715<span></span>
</td>
<td class="nump">$ 1,991<span></span>
</td>
<td class="nump">$ 2,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant revenue</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">820<span></span>
</td>
<td class="nump">489<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenue</a></td>
<td class="nump">1,631<span></span>
</td>
<td class="nump">936<span></span>
</td>
<td class="nump">2,811<span></span>
</td>
<td class="nump">2,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">5,018<span></span>
</td>
<td class="nump">2,965<span></span>
</td>
<td class="nump">14,625<span></span>
</td>
<td class="nump">9,786<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">2,502<span></span>
</td>
<td class="nump">2,053<span></span>
</td>
<td class="nump">8,364<span></span>
</td>
<td class="nump">4,255<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">7,520<span></span>
</td>
<td class="nump">5,018<span></span>
</td>
<td class="nump">22,989<span></span>
</td>
<td class="nump">14,041<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(5,889)<span></span>
</td>
<td class="num">(4,082)<span></span>
</td>
<td class="num">(20,178)<span></span>
</td>
<td class="num">(11,073)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest and other income</a></td>
<td class="nump">113<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">245<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndDebtExpense', window );">Interest and other related expense</a></td>
<td class="num">(58)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="num">(193)<span></span>
</td>
<td class="num">(250)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(5,834)<span></span>
</td>
<td class="num">(4,153)<span></span>
</td>
<td class="num">(20,126)<span></span>
</td>
<td class="num">(11,300)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment', window );">Accretion of redeemable convertible preferred stock to redemption value</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss available to common stockholders</a></td>
<td class="num">$ (5,834)<span></span>
</td>
<td class="num">$ (4,166)<span></span>
</td>
<td class="num">$ (20,131)<span></span>
</td>
<td class="num">$ (11,337)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (6.92)<span></span>
</td>
<td class="num">$ (1.11)<span></span>
</td>
<td class="num">$ (18.84)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used to compute basic and diluted net loss per share (in shares)</a></td>
<td class="nump">21,572,498<span></span>
</td>
<td class="nump">601,667<span></span>
</td>
<td class="nump">18,215,857<span></span>
</td>
<td class="nump">601,667<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndDebtExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest and debt related expenses associated with nonoperating financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndDebtExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to net income for accretion of temporary equity to its redemption value to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValueAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775655280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common stock</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Private Financing</div></th>
<th class="th">
<div>Private Financing </div>
<div>Common stock</div>
</th>
<th class="th">
<div>Private Financing </div>
<div>Additional paid-in capital</div>
</th>
<th class="th"><div>At-the-Market Offering</div></th>
<th class="th">
<div>At-the-Market Offering </div>
<div>Common stock</div>
</th>
<th class="th">
<div>At-the-Market Offering </div>
<div>Additional paid-in capital</div>
</th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,584,390.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,584,390.00)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (76,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Feb. 13, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Feb. 13, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2016</a></td>
<td class="nump">833,744<span></span>
</td>
<td class="nump">833,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2016</a></td>
<td class="num">$ (61,921)<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 5,147<span></span>
</td>
<td class="num">$ (67,076)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,584,390.00)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (76,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,584,390.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock to redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,066,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,584,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">$ 76,981<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">76,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (76,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Sep. 30, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2016</a></td>
<td class="nump">833,744<span></span>
</td>
<td class="nump">833,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2016</a></td>
<td class="num">$ (61,921)<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">5,147<span></span>
</td>
<td class="num">(67,076)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Stockholders&#8217; deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock to investors, net of issuance cost (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,359,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock to investors, net of issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39,156<span></span>
</td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 39,092<span></span>
</td>
<td class="nump">$ 2,622<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 2,619<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount', window );">Accretion of preferred stock to current redemption value</a></td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,066,666<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(18,584,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">76,981<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
<td class="nump">76,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (76,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions', window );">Issuance of common stock upon reverse merger (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,024,960<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions', window );">Issuance of common stock upon reverse merger</a></td>
<td class="nump">204<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability', window );">Reclassification of preferred stock warrant to common stock warrant</a></td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_StockIssuedDuringPeriodSharesExerciseofWarrants', window );">Issuance of common stock upon exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Exercises of stock options and issuance of restricted stock awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">274,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Exercises of stock options and issuance of restricted stock awards</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee share purchases (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Shares issued for cash under employee share purchase plan</a></td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">1,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,126)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Sep. 30, 2017</a></td>
<td class="nump">21,886,568<span></span>
</td>
<td class="nump">21,886,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Sep. 30, 2017</a></td>
<td class="nump">$ 38,985<span></span>
</td>
<td class="nump">$ 219<span></span>
</td>
<td class="nump">$ 125,973<span></span>
</td>
<td class="num">$ (87,207)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares) at Feb. 13, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance at Feb. 13, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Reclassification of Warrant Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_AdjustmentstoAdditionalPaidinCapitalReclassificationofWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_StockIssuedDuringPeriodSharesExerciseofWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exercise of Warrants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_StockIssuedDuringPeriodSharesExerciseofWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAccretionOfRedemptionDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of accretion of the preferred stock redemption discount during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAccretionOfRedemptionDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90193-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued during the period pursuant to acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueAcquisitions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued pursuant to acquisitions during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueAcquisitions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_PrivateFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgen_PrivateFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_AtthemarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgen_AtthemarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774090880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (20,126)<span></span>
</td>
<td class="num">$ (11,300)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">1,693<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionExpense', window );">Non-cash interest expense</a></td>
<td class="nump">85<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of preferred stock warrants</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments', window );">Unrealized gain on short term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(615)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(719)<span></span>
</td>
<td class="num">(545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(439)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(598)<span></span>
</td>
<td class="num">(586)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(871)<span></span>
</td>
<td class="nump">893<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(20,924)<span></span>
</td>
<td class="num">(11,468)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash acquired in reverse merger</a></td>
<td class="nump">1,280<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(212)<span></span>
</td>
<td class="num">(240)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,010<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">1,068<span></span>
</td>
<td class="num">(1,250)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock', window );">Proceeds from issuance of redeemable convertible preferred stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,091<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Payments of principal on notes payable</a></td>
<td class="num">(1,500)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from the exercise of stock options</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans', window );">Proceeds from employee stock purchases</a></td>
<td class="nump">110<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">40,557<span></span>
</td>
<td class="nump">16,081<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashPeriodIncreaseDecrease', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">20,701<span></span>
</td>
<td class="nump">3,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">22,104<span></span>
</td>
<td class="nump">21,235<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">42,805<span></span>
</td>
<td class="nump">24,598<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaid', window );">Interest paid</a></td>
<td class="nump">112<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of preferred stock to common stock</a></td>
<td class="nump">76,981<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1', window );">Liabilities assumed, net of non-cash assets received in reverse merger</a></td>
<td class="nump">1,076<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction', window );">Transfer of common stock issuance costs from prepaid expenses and other current assets to equity (private financing and at the market sales)</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ConversionofWarrantstoPermanentEquity', window );">Reclassification of preferred stock warrant (accrued liability) to common stock warrant (equity)</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_AccretionofOfferingCosts', window );">Accretion of redeemable convertible preferred stock to redemption value</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction', window );">Unpaid common stock issuance costs included in prepaid expenses and other assets, accounts payable, and accrued liabilities</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_PrivateFinancingMember', window );">Private Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock</a></td>
<td class="nump">40,703<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs associated with the sale of common stock</a></td>
<td class="num">(1,216)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs associated with the sale of common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_AtthemarketOfferingMember', window );">At-the-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock</a></td>
<td class="nump">2,711<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs associated with the sale of common stock</a></td>
<td class="num">(172)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_ShelfRegistrationMember', window );">Shelf Registration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of issuance costs associated with the sale of common stock</a></td>
<td class="num">$ (299)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_AccretionofOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accretion of Offering Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_AccretionofOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_ConversionofWarrantstoPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Warrants to Permanent Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_ConversionofWarrantstoPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issuance Costs Incurred During Noncash or Partial Noncash Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_StockIssuanceCostsIncurredDuringNoncashorPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transfer of Stock Issuance Costs, Noncash or Partial Noncash Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_TransferofStockIssuanceCostsNoncashorPartialNoncashTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 410<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6392676&amp;loc=d3e7480-110848<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6394232&amp;loc=d3e17558-110866<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash. Cash is the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=6939902&amp;loc=d3e20148-110875<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest. Includes, but is not limited to, payment to settle zero-coupon bond attributable to accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the total unrealized gain (loss) included in earnings for the period as a result of holding marketable securities categorized as trading, including the unrealized holding gain (loss) of held-to-maturity securities transferred to the trading security category and the cumulative unrealized gain (loss) which was included in other comprehensive income (a separate component of shareholders' equity) for available-for-sale securities transferred to trading securities during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27405-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesUnrealizedGainLossExcludingOtherThanTemporaryImpairments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of [all] liabilities that an Entity assumes in acquiring a business or in consideration for an asset received in a noncash (or part noncash) acquisition. Noncash is defined as transactions during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashOrPartNoncashAcquisitionValueOfLiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuance of callable preferred stock which is identified as being convertible to another type of financial security at the option of the issuer or the holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfRedeemableConvertiblePreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the financed defined contribution plan to acquire shares of the entity. The plan initially holds the shares in a suspense account, which is collateral for the loan. As the plan makes payment on the debt, the shares are released from the suspense account and become available to be allocated to participant accounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentOfLoansByEmployeeStockOwnershipPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90193-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_PrivateFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgen_PrivateFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_AtthemarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgen_AtthemarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_ShelfRegistrationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgen_ShelfRegistrationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763847936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Description of Business</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">DESCRIPTION OF BUSINESS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Miragen Therapeutics, Inc., a Delaware corporation (the &#8220;Company&#8221; or &#8220;Miragen&#8221;), is a clinical-stage biopharmaceutical company discovering and developing proprietary RNA-targeted therapeutics with a specific focus on microRNAs and their roles in diseases where there is a high unmet medical need. microRNAs are short RNA molecules, or oligonucleotides, that regulate gene expression or activity and play vital roles in influencing the pathways responsible for many disease processes. The Company&#8217;s two lead product candidates, MRG-106 and MRG-201, are currently in clinical development. MRG-106 is an inhibitor of microRNA-155, which is found at abnormally high levels in malignant cells of several blood cancers. MRG-201 is a replacement for microRNA-29 (&#8220;miR-29&#8221;), which is found at abnormally low levels in a number of pathological fibrotic conditions, including cutaneous, cardiac, renal, hepatic, pulmonary, and ocular fibrosis, as well as in systemic sclerosis. Miragen is also developing MRG-110, an inhibitor of microRNA-92, under a License and Collaboration Agreement (the &#8220;Servier Collaboration Agreement&#8221;) with Les Laboratoires Servier and Institut de Recherches Servier (collectively, &#8220;Servier&#8221;). MRG-110 is being developed for the treatment of heart failure and other ischemic disease. In addition to these programs, the Company continues to develop a pipeline of wholly-owned preclinical product candidates. The goal of the Company&#8217;s translational medicine strategy is to progress rapidly to first-in-human trials once it has adequately established the pharmacokinetics (the movement of drug into, through, and out of the body), pharmacodynamics (the effect and mechanism of action of a drug), safety, and manufacturability of the product candidate in preclinical studies.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Miragen Therapeutics Europe Limited (&#8220;Miragen Europe&#8221;), the Company&#8217;s wholly-owned subsidiary, was formed in January 2011 for the sole purpose of submitting regulatory filings in Europe. Miragen Europe has no employees or operations. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 13, 2017, the Company, then known as Signal Genetics, Inc. (&#8220;Signal&#8221;), completed its merger with Miragen Therapeutics, Inc., a then privately-held Delaware corporation (&#8220;Private Miragen&#8221;). Pursuant to the Agreement and Plan of Merger and Reorganization (the &#8220;Merger Agreement&#8221;) by and among the Company, Private Miragen, and Signal Merger Sub, Inc., a wholly-owned subsidiary of the Company (&#8220;Merger Sub&#8221;), Merger Sub merged with and into Private Miragen, with Private Miragen surviving as a wholly-owned subsidiary of the Company (the &#8220;Merger&#8221;). Immediately, following the Merger, Private Miragen merged with and into the Company, with the Company as the surviving corporation (the &#8220;Short-Form Merger&#8221; and, together with the Merger, the &#8220;Mergers&#8221;). In connection with the Short-Form Merger, the Company changed its corporate name to &#8220;Miragen Therapeutics, Inc.&#8221; </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The holders of shares of Private Miragen common stock outstanding immediately prior to the Merger received approximately </font><font style="font-family:inherit;font-size:10pt;">0.7031</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s common stock in exchange for each share of Private Miragen common stock in the Merger. Following the Merger on February 13, 2017, the combined company had </font><font style="font-family:inherit;font-size:10pt;">21,309,440</font><font style="font-family:inherit;font-size:10pt;"> shares of common stock outstanding at a par value of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per share (the &#8220;Common Stock&#8221;) as compared to the par value of Private Miragen&#8217;s common stock of </font><font style="font-family:inherit;font-size:10pt;">$0.001</font><font style="font-family:inherit;font-size:10pt;"> per share. The accompanying unaudited condensed consolidated financial statements and notes to the unaudited condensed consolidated financial statements give retroactive effect to the exchange ratio and change in par value for all periods presented.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Liquidity</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has incurred annual net operating losses since its inception. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;">$87.2</font><font style="font-family:inherit;font-size:10pt;"> million and net losses of </font><font style="font-family:inherit;font-size:10pt;">$5.8 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$20.1 million</font><font style="font-family:inherit;font-size:10pt;"> for the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, respectively. On February 13, 2017, the date of the Merger, Private Miragen received </font><font style="font-family:inherit;font-size:10pt;">$40.7 million</font><font style="font-family:inherit;font-size:10pt;"> in cash, before offering expenses, from the issuance of common stock to investors. Additionally, on March 31, 2017, the Company entered into an at the market issuance Common Stock Sales Agreement (the &#8220;ATM Agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;) under which the Company may offer and sell, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$50,000,000</font><font style="font-family:inherit;font-size:10pt;"> through Cowen, as its sales agent. As of September 30, 2017, the Company has sold, pursuant to the terms of such ATM Agreement, an aggregate of </font><font style="font-family:inherit;font-size:10pt;">297,653</font><font style="font-family:inherit;font-size:10pt;"> shares of its Common Stock, at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$9.11</font><font style="font-family:inherit;font-size:10pt;"> per share, for aggregate gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">. Net proceeds received during the nine months ended September 30, 2017 were approximately </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, including initial expenses for executing the &#8220;at the market offering&#8221; and commissions to Cowen as sales agent. The Company&#8217;s management believes that the </font><font style="font-family:inherit;font-size:10pt;">$42.8 million</font><font style="font-family:inherit;font-size:10pt;"> of cash and cash equivalents on hand at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> will be sufficient to fund its operations in the normal course of business and allow the Company to meet its liquidity needs through the end of 2018.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759283744">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Miragen Europe. The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and follow the requirements of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#8217;s financial information. These interim results are not necessarily indicative of the results to be expected for the year ending December 31, 2017, or for any other interim period, or for any other future year. The balance sheet as of December 31, 2016 has been derived from audited consolidated financial statements at that date but does not include all the information required by U.S. GAAP for complete financial statements. All intercompany balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements of the Company and the notes thereto contained in the Company&#8217;s Form 8-K/A for the year ended December 31, 2016, filed with the SEC on March 31, 2017. The Company&#8217;s management performed an evaluation of its activities through the date of filing of these financial statements and concluded that there are no subsequent events requiring disclosure, other than as disclosed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s consolidated financial statements are prepared in accordance with U.S.&#160;GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue principally from its strategic alliance and collaboration agreement. Revenue is recognized from upfront payments for licenses and milestone payments that are generated from defined research or development events, as well as from the reimbursement of amounts for research and development services under its strategic alliance and collaboration agreement. The Company recognizes revenue when all four of the following criteria are met: (1)&#160;persuasive evidence of an arrangement exists; (2)&#160;products have been delivered or services rendered; (3)&#160;the selling price is fixed or determinable; and (4)&#160;collectability is reasonably assured.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple-element arrangements are examined to determine whether the deliverables can be separated or must be accounted for as a single unit of accounting. The Servier Collaboration Agreement with Servier, for example, includes a combination of upfront license fees, payments for research and development activities, and milestone payments that are evaluated to determine whether each deliverable under the agreement has value to the customer on a stand-alone basis and whether reliable evidence of fair value for the deliverable exists. Deliverables in an arrangement that do not meet this separation criteria are treated as a single unit of accounting, generally applying applicable revenue recognition guidance for the final deliverable to the combined unit of accounting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue from non-refundable upfront license fees over the term of performance under the Servier Collaboration Agreement. When the performance period is not specified, the Company estimates the performance period based upon provisions contained within the agreement, such as the duration of the research or development term, the existence, or likelihood, of achievement of development commitments, and any other significant commitments. These advance payments are deferred and recorded as deferred revenue upon receipt, pending recognition, and are classified as a short-term or long-term liability in the accompanying condensed consolidated balance sheets. Expected performance periods are reviewed periodically and, if applicable, the amortization period is adjusted, which may accelerate or decelerate revenue recognition. The timing of revenue recognition, specifically as it relates to the amortization of upfront license fees, is significantly influenced by the Company&#8217;s estimates.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for share-based compensation expense related to stock options granted to employees and members of its board of directors under its 2008 Equity Incentive Plan (the &#8220;2008 Plan&#8221;) and under its 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;) by estimating the fair value of each stock option or award on the date of grant using the Black-Scholes option pricing model. The Company recognizes share-based compensation expense on a straight-line basis over the vesting term. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for stock options issued to non-employees by valuing the award using an option pricing model and remeasuring such awards to the current fair value until the awards are vested or a performance commitment has otherwise been reached.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred in performing research and development activities. The costs include employee-related expense including salaries, benefits, share-based compensation, fees for acquiring and maintaining licenses under third party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#8217;s behalf, laboratory supplies, depreciation, and facilities and overhead costs. The Company defers and capitalizes non-refundable advance payments for research and development activities until the related goods are received or services performed. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records upfront and milestone payments to acquire contractual rights to licensed technology as research and development expenses when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. The Company considers future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved by the U.S. Food and Drug Administration or when other significant risk factors are abated.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Trial and Preclinical Study Accruals</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company makes estimates of accrued expenses as of each balance sheet date in its condensed consolidated financial statements based on certain facts and circumstances at that time. The Company&#8217;s accrued expenses for clinical trials and preclinical studies are based on estimates of costs incurred for services provided by clinical research organizations, manufacturing organizations, and other providers. Payments under the Company&#8217;s agreements with external service providers depend on a number of factors, such as site initiation, patient screening, enrollment, delivery of reports, and other events. In accruing for these activities, the Company obtains information from various sources and estimates the level of effort or expense allocated to each period. Adjustments to the Company&#8217;s research and development expenses may be necessary in future periods as its estimates change.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All highly-liquid investments that have maturities of 90 days or less at the date of purchase are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value due to the short maturities of these instruments.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present information about the Company&#8217;s financial assets and liabilities that have been measured at fair value and indicate the fair value of the hierarchy of the valuation inputs utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair value determined by Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,<br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,<br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds (included in cash and cash equivalents)</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,112</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;text-indent:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred and common stock warrants (included in accrued and other liabilities)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">______________________</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)  Amounts presented for each period above differ from cash and cash equivalents reported in the condensed consolidated balance sheets due to outstanding disbursements and deposits.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balances of the Company&#8217;s liabilities measured at fair value using significant unobservable, or Level 3, inputs are as follows for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance of liability as of December 31, 2016</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassification of preferred stock warrant to common stock warrant</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance of liability as of September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to the short-term nature of their maturities, such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses. The carrying amount of the Company&#8217;s note payable approximates its fair value (a Level 2 fair value measurement), reflecting interest rates currently available to the Company. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for its warrants to purchase common and preferred stock pursuant to ASC Topic&#160;480,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Distinguishing Liabilities from Equity</font><font style="font-family:inherit;font-size:10pt;">, and classifies warrants for redeemable preferred stock and certain warrants for common stock as liabilities. The warrants are reported at their estimated fair value and any changes in fair value are reflected in interest expense and other related expenses.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with two financial institutions.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company carries its property and equipment at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">. Leasehold improvements are amortized over the shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets. Construction in progress is not depreciated until placed in service. Repairs and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> impairment charges were recorded during the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Share</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of Common Stock outstanding during the period without consideration of Common Stock equivalents. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Loss</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources. If the Company had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity (deficit). There were no elements of comprehensive loss during the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes by using an asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s significant deferred tax assets are for net operating loss carryforwards, tax credits, and capitalized start-up costs. The Company has provided a valuation allowance for its entire net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that its deferred tax assets will not be realized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has no unrecognized tax benefits. The Company classifies interest and penalties arising from the underpayment of income taxes in the condensed consolidated statements of operations as general and administrative expenses. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> such expenses have been recognized during the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in&#160;</font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#160;operating segment and, accordingly, no segment disclosures have been presented herein. All equipment, leasehold improvements, and other fixed assets are physically located within the United States and all agreements with the Company&#8217;s partners are denominated in U.S. dollars, except where noted.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements &#8211; Not Yet Adopted</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> (&#8220;</font><font style="font-family:inherit;font-size:10pt;">ASU&#8221;) No. 2014-09</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that &#8220;an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&#8221; The standard provides enhancements to the quality and consistency of how revenue is reported by companies, while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or U.S. GAAP.&#160;The new standard also will require enhanced revenue disclosures, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. This accounting standard becomes effective for the Company for reporting periods beginning after December 15, 2018, and interim reporting periods thereafter. Early adoption is permitted for annual reporting periods (including interim periods) beginning after December 15, 2016. This new standard permits the use of either the retrospective or cumulative effect transition method. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-08</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations</font><font style="font-family:inherit;font-size:10pt;">. The purpose of this standard is to clarify the implementation of guidance on principal versus agent considerations related to ASU 2014-09. The standard has the same effective date as ASU 2014-09 described above.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2016, the FASB issued</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">ASU No. 2016-10,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Revenue from Contracts with Customer, </font><font style="font-family:inherit;font-size:10pt;">which provides clarity related to ASU 2014-09 regarding identifying performance obligations and licensing implementation. The standard has the same effective date as ASU 2014-09 described above. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May&#160;2016, the FASB issued ASU 2016-12:</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:inherit;font-size:10pt;">, which provides narrow scope improvements and practical expedients related to ASU 2014-09. The purpose of&#160;this standard&#160;is to clarify certain narrow aspects of ASU 2014-09, such as assessing the collectability criterion, presentation of sales taxes, and other similar taxes collected from customers, noncash consideration, contract modifications at transition, completed contracts at transition, and technical correction. The standard has the same effective date as ASU 2014-09 described above. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2016, the FASB issued ASU 2016-20:</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">. The amendments in this standard affect narrow aspects of guidance issued in ASU 2014-09. The standard has the same effective date as ASU 2014-09 described above. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company plans to adopt these new standards in the first quarter of 2019. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were limited contracts that will be in effect (actively) as of the transition date and, accordingly, the Company has not yet determined the effect of the standard on its condensed consolidated financial statements. The Company&#8217;s selected implementation transition method will be dependent upon contracts that are in place closer to the transition date. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred Taxes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Balance Sheet Classification of Deferred Taxes</font><font style="font-family:inherit;font-size:10pt;">. ASU No. 2015-17 requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. This standard is effective for the Company for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods thereafter. The Company does not believe the adoption of this standard will have a material impact on its condensed consolidated financial statements due to the full valuation allowance on all net deferred tax assets. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Leases (Topic 842), which supersedes FASB ASC Topic 840, Leases (Topic 840),</font><font style="font-family:inherit;font-size:10pt;"> and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. In September 2017, the FASB issued ASU 2017-13,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842),&#160;</font><font style="font-family:inherit;font-size:10pt;">which provides additional implementation guidance on the previously issued ASU 2016-02&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">. ASU 2016-02 requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for the Company for fiscal years beginning after December 15, 2019, and interim periods thereafter, with early adoption permitted. At adoption, this update will be applied using a modified retrospective approach. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share-based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, which is intended to simplify accounting for equity share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This standard is effective for the Company for annual periods beginning after December 15, 2017, and interim periods thereafter. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendments related to the timing of when excess tax benefits are recognized, minimum statutory withholding requirements, forfeitures, and intrinsic value should be applied using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of the beginning of the period in which the guidance is adopted. Amendments related to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement should be applied retrospectively. Amendments requiring recognition of excess tax benefits and tax deficiencies in the income statement and the practical expedient for estimating the expected term should be applied prospectively. An entity may elect to apply the amendments related to the presentation of excess tax benefits on the statement of cash flows using either a prospective transition method or a retrospective transition method. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other new pronouncements issued but not effective as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> are not expected to have a material impact on the Company&#8217;s condensed consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763877200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic Alliance and Collaboration with Servier<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Strategic Alliance and Collaboration with Servier</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">STRATEGIC ALLIANCE AND COLLABORATION WITH SERVIER</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2011, the Company entered into the Servier Collaboration Agreement with Servier for the research, development, and commercialization of RNA-targeting therapeutics in cardiovascular disease, which was subsequently amended. Under the Servier Collaboration Agreement, the Company granted Servier an exclusive license to research, develop, and commercialize RNA-targeting therapeutics for three targets in the cardiovascular field. In 2017, the Company and Servier agreed to amend the Servier Collaboration Agreement to remove three existing targets, add one named target, and provide Servier with the right to add one additional target through September 2019. Under the terms of the amended agreement, the term of the Research Collaboration has been extended through September 2019. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Servier&#8217;s rights to each named target is limited to therapeutics in the cardiovascular field in their territory, which is worldwide except for the United States and Japan. The Company retains all rights in the United States and Japan.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is eligible to receive development milestone payments of </font><font style="font-family:inherit;font-size:10pt;">&#8364;5.8 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">&#8364;13.8 million</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">$6.9 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$16.3 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">) and regulatory milestone payments of </font><font style="font-family:inherit;font-size:10pt;">&#8364;10.0 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">&#8364;40.0 million</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">$11.8 million</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">$47.3 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">) for each target. Additionally, the Company may receive up to </font><font style="font-family:inherit;font-size:10pt;">&#8364;175 million</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">$206.7 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">) in commercialization milestones, as well as quarterly royalty payments expressed in percentages ranging from the low-double digits to the mid-teens (subject to reductions for patent expiration, generic competition, third-party royalty, and costs of goods) on the net sales of any licensed product commercialized by Servier. Servier is obligated to make royalty payments for a period specified under the Servier Collaboration Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As part of the Servier Collaboration Agreement, the Company established a multiple-year research collaboration, under which it jointly performs agreed upon research activities directed to the identification and characterization of named targets and oligonucleotides in the cardiovascular field, which is referred to as the Research Collaboration. The current term of the Research Collaboration extends through September 2019. Servier is responsible for funding the costs of the Research Collaboration, as defined under the Servier Collaboration Agreement. During the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized as revenue amounts reimbursable under the Servier Collaboration Agreement of </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized as revenue amounts reimbursable under the Servier Collaboration Agreement of </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The development of each product candidate (commencing with registration enabling toxicology studies) under the Servier Collaboration Agreement is performed pursuant to a mutually agreed upon development plan to be conducted by the parties as necessary to generate data useful for both parties to obtain regulatory approval of such product candidates. Servier is responsible for a specified percentage of the cost of research and development activities under the development plan through the completion of one or more Phase 2 clinical trials and will reimburse the Company for a specified portion of such costs it incurs. The costs of Phase 3 clinical trials for each product candidate will be allocated between the parties at a specified percentage of costs. The applicable percentage for each product candidate will be based upon whether certain events under the Servier Collaboration Agreement occur, including if the Company enters into a third-party agreement for the development and/or commercialization of a product in the United States at least 180 days before the initiation of the first Phase 3 clinical trial, or&#160;if the Company subsequently enters into a U.S. partner agreement, or if it does not enter into a U.S. partner agreement but files for approval in the United States using data from the Phase 3 clinical trial.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the Servier Collaboration Agreement, the Company also granted Servier a royalty-free, non-exclusive license to develop a companion diagnostic in its territory for any therapeutic product that may be developed by Servier under the Servier Collaboration Agreement. The Company also granted Servier an exclusive, royalty-free license to commercialize such a companion diagnostic in its territory for use in connection with the development and commercialization of such therapeutic product in its territory.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Servier Collaboration Agreement will expire as to each underlying product candidate when Servier&#8217;s royalty obligations as to such product candidate have expired. Servier may also terminate the Servier Collaboration Agreement for (i) convenience upon a specified number of days&#8217; prior notice to the Company or (ii) upon determination of a safety issue relating to development under the agreement upon a specified number of days&#8217; prior notice to the Company. Either party may terminate the Servier Collaboration Agreement upon a material breach by the other party which is not cured within a specified number of days. The Company may also terminate the agreement if Servier challenges any of the patents licensed by the Company to Servier.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determined that the elements within the Servier Collaboration Agreement should be treated as a single unit of accounting because the delivered elements, the licenses, did not have stand-alone value to Servier at the time the license was granted. As such, the Company recognized license fees earned under the Servier Collaboration Agreement as revenue on a proportional performance basis over the estimated period to complete the activities under the Research Collaboration. The total period of performance is equal to the estimated term of the Research Collaboration. The Company measures its progress under the proportional performance method based on actual and estimated full-time equivalents. The Company received a total of </font><font style="font-family:inherit;font-size:10pt;">$12.4 million</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">&#8364;9.0 million</font><font style="font-family:inherit;font-size:10pt;">) in non-refundable license fees under the Servier Collaboration Agreement. Based on earlier estimates of the term of the Research Collaboration, these license fees had been fully recognized as revenue during the period from October 2011 through December 2016. Accordingly, </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> amounts were recognized as revenue during the three and </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">. During the three months and </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized license revenue of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In total, for the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, as revenue under the Servier Collaboration Agreement. For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, the Company recognized </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, as revenue under the Servier Collaboration Agreement. Amounts incurred but not billed to Servier for research and related intellectual property activities totaled </font><font style="font-family:inherit;font-size:10pt;">$1.4 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, respectively. These amounts are included in prepaid expenses and other current assets in the Company&#8217;s condensed consolidated balance sheets. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, accounts receivable for Servier research and related intellectual property activities totaled </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;">. At </font><font style="font-family:inherit;font-size:10pt;">December&#160;31, 2016</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">no</font><font style="font-family:inherit;font-size:10pt;"> amounts billed to Servier included in accounts receivable.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759352480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Merger<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Reverse Merger</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;"> REVERSE MERGER</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 13, 2017, Private Miragen completed the Merger as discussed in Note 1.&#160;For accounting purposes, Private Miragen is considered to be acquiring Signal in the Merger. Private Miragen was determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i) the Private Miragen security holders own approximately </font><font style="font-family:inherit;font-size:10pt;">95.2%</font><font style="font-family:inherit;font-size:10pt;"> of the combined company&#8217;s outstanding common stock immediately following the closing of the Merger; (ii) former Private Miragen directors hold all of the board seats in the combined company; and (iii) Private Miragen management holds key management positions of the combined company. The Merger has been accounted for as an asset acquisition rather than business combination because the assets acquired and liabilities assumed by Private Miragen do not meet the definition of a business as defined by U.S. GAAP. The net assets acquired in connection with this transaction were recorded at their estimated acquisition date fair values as of February 13, 2017, the date the Mergers were completed.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Immediately prior to the effective date of the Merger, all shares of preferred stock of Private Miragen converted into shares of common stock of Private Miragen on a </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">-for-one basis. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">At the effective date of the Merger, the Company issued shares of its Common Stock to Private Miragen stockholders, at an exchange rate of approximately </font><font style="font-family:inherit;font-size:10pt;">0.7031</font><font style="font-family:inherit;font-size:10pt;"> shares of Signal Common Stock in exchange for each share of Private Miragen common stock outstanding immediately prior to the Merger. The exchange rate was calculated by a formula that was determined through arms-length negotiations between the Company and Private Miragen. The combined company assumed all of the outstanding options, whether or not vested, under the 2008 Plan with such options representing the right to purchase a number of shares of Common Stock equal to approximately </font><font style="font-family:inherit;font-size:10pt;">0.7031</font><font style="font-family:inherit;font-size:10pt;"> multiplied by the number of shares of Private Miragen common stock previously represented by such options.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Immediately after the Merger on February 13, 2017, there were </font><font style="font-family:inherit;font-size:10pt;">21,309,440</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock outstanding. In addition, immediately after the Merger, Private Miragen stockholders, warrant holders, and option holders owned approximately </font><font style="font-family:inherit;font-size:10pt;">95.9%</font><font style="font-family:inherit;font-size:10pt;"> of the aggregate number of shares of Common Stock, and the stockholders of the Company immediately prior to the Merger owned approximately </font><font style="font-family:inherit;font-size:10pt;">4.1%</font><font style="font-family:inherit;font-size:10pt;"> of the aggregate number of shares of Common Stock (each on a fully diluted basis).</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 13, 2017, prior to the effectiveness of the Merger, Signal had </font><font style="font-family:inherit;font-size:10pt;">1,024,960</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock outstanding and a market capitalization of </font><font style="font-family:inherit;font-size:10pt;">$12.6 million</font><font style="font-family:inherit;font-size:10pt;">. The estimated fair value of the net assets of Signal on February 13, 2017, prior to the Merger, was </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">. The fair value of Common Stock on the Merger closing date, prior to the Merger, was above the fair value of the Company&#8217;s net assets. As the Company&#8217;s net assets were predominantly comprised of cash offset by current liabilities, the fair value of the Company&#8217;s net assets as of February 13, 2017, prior to the Merger, is considered to be the best indicator of the fair value and, therefore, the estimated preliminary purchase consideration.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the net assets acquired based on their estimated fair values as of February 13, 2017, prior to the Merger (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">248</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net acquired tangible assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763851824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">PROPERTY AND EQUIPMENT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net, consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">729</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">688</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,183</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,776</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,558</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">610</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, depreciation and amortization expense was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for each period. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, depreciation and amortization expense was </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. Depreciation and amortization expense is recorded primarily in research and development expense on the condensed consolidated statements of operations.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763852624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">ACCRUED LIABILITIES</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued outsourced clinical and preclinical studies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued employee compensation and related taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,061</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">928</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued legal fees and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">607</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued other professional service fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">457</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued equipment and lab materials</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Value of liability-classified stock purchase warrants </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred and accrued facility lease obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accrued liabilities</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,909</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759351520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NOTES PAYABLE</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">2015 Silicon Valley Bank Loan Agreement</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2015, Private Miragen entered into a loan and security agreement with Silicon Valley Bank (the &#8220;2015 SVB Loan Agreement&#8221;) to borrow up to </font><font style="font-family:inherit;font-size:10pt;">$10.0 million</font><font style="font-family:inherit;font-size:10pt;"> in </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> separate tranches. The first tranche of </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> was funded in May 2015 and had a </font><font style="font-family:inherit;font-size:10pt;">30</font><font style="font-family:inherit;font-size:10pt;">-month payment period following an </font><font style="font-family:inherit;font-size:10pt;">18</font><font style="font-family:inherit;font-size:10pt;">-month interest-only payment period that ended in November 2016.&#160;Amounts outstanding bear interest at the prime rate minus </font><font style="font-family:inherit;font-size:10pt;">0.25%</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">4.00%</font><font style="font-family:inherit;font-size:10pt;"> at </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">), with a final payment fee equal to </font><font style="font-family:inherit;font-size:10pt;">5.50%</font><font style="font-family:inherit;font-size:10pt;"> of amounts borrowed. Borrowings are secured by a priority security interest, right, and title in all business assets, excluding the Company&#8217;s intellectual property, which is subject to a negative pledge.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the first tranche, in April 2015, Private Miragen issued detachable warrants to purchase up to </font><font style="font-family:inherit;font-size:10pt;">11,718</font><font style="font-family:inherit;font-size:10pt;"> shares of Private Miragen preferred stock at an adjusted exercise price of </font><font style="font-family:inherit;font-size:10pt;">$8.53</font><font style="font-family:inherit;font-size:10pt;"> per share. At issuance, the warrants were classified as a liability subject to remeasurement at each balance sheet date. Immediately prior to the Merger, these warrants became exercisable for Private Miragen common stock, which was immediately exchanged for the right to purchase the Company&#8217;s Common Stock. The Company determined that although the warrants were no longer exercisable for redeemable preferred stock, the warrants continued to be classified as a liability after the Merger due to the right of the holder to require the Company to repurchase the warrants for </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> under certain circumstances. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company estimated the fair value of the warrants to be </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> using a probability adjusted present value method with the following assumptions: term of </font><font style="font-family:inherit;font-size:10pt;">two</font><font style="font-family:inherit;font-size:10pt;"> years, discount rate of </font><font style="font-family:inherit;font-size:10pt;">6.8%</font><font style="font-family:inherit;font-size:10pt;">, and probability of </font><font style="font-family:inherit;font-size:10pt;">90.0%</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2016, the 2015 SVB Loan Agreement was amended to extend the end of the draw period from December 31, 2016 to July 31, 2017. The Company chose not to draw the second </font><font style="font-family:inherit;font-size:10pt;">$5.0 million</font><font style="font-family:inherit;font-size:10pt;"> tranche prior to the expiration of the draw period in July 2017.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts outstanding under notes payable are as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount outstanding</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt discount</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accreted final payment fee</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total notes payable</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,374</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: current maturities</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,983</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,969</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term notes payable, net of current portion</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,391</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,820</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future annual minimum principal payments of notes payable are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017 (remainder of year)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,167</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759286864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">COMMITMENTS AND CONTINGENCIES</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Indemnification Agreements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has entered into indemnification agreements with each of its directors and officers whereby it has agreed to indemnify such persons for certain events or occurrences while the individual is, or was, serving as a director, officer, employee, or other agent of the Company. The maximum potential amount of future payments the Company could be required to make under these indemnification agreements is unlimited. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employment Agreements</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has entered into agreements with its executives that provide for base salary, severance, eligibility for bonuses, and other generally available benefits. The agreements provide that the Company may terminate the employment of its executives at any time, with or without cause. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an executive is terminated without cause, as defined in the employment agreements, or an executive resigns for good reason, as defined in the employment agreements, then the executive is entitled to receive, upon the execution of a release agreement, a severance package consisting of: (i)&#160;the equivalent of 12 months of the executive&#8217;s base salary in effect immediately prior to date of termination, (ii)&#160;acceleration of vesting of the equivalent of 12 months of vesting of the executive&#8217;s outstanding unvested stock options or other equity awards that were outstanding as of the effective date of the executive&#8217;s employment agreement, and (iii)&#160;12 months of continued health coverage. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If an executive is terminated without cause or resigns for good reason within one month prior to or 12 months following a change of control, as defined in the employment agreements, the executive is entitled to receive, upon the execution of a release agreement, a severance package consisting of: (i)&#160;the equivalent of 12 months of the executive&#8217;s base salary in effect immediately prior to date of termination, (ii)&#160;the vesting in full of the executive&#8217;s then-outstanding stock options or other equity awards subject to time-based vesting, and (iii)&#160;12 months of continued health coverage. Solely in the case of the Company&#8217;s Chief Executive Officer, if such termination occurs one month before or 12 months following a change of control, then, upon the execution of a release agreement, the executive is entitled to: (i)&#160;the equivalent of 24 months of the executive&#8217;s base salary in effect immediately prior to the date of termination, (ii)&#160;the vesting in full of the executive&#8217;s outstanding stock options or other equity awards subject to time-based vesting, and (iii)&#160;12 months of continued health coverage.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreements with the University of Texas</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">five</font><font style="font-family:inherit;font-size:10pt;"> exclusive patent license agreements (the &#8220;UT License Agreements&#8221;) with the Board of Regents of The University of Texas System (the &#8220;University of Texas&#8221;). Under each of the UT License Agreements, the University of Texas granted the Company exclusive and nonexclusive licenses to certain patent and technology rights. The University of Texas is a minority stockholder of the Company.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In consideration of rights granted by the University of Texas, the Company is required to: (i) pay a nonrefundable upfront license documentation fee in the amount of </font><font style="font-family:inherit;font-size:10pt;">$10 thousand</font><font style="font-family:inherit;font-size:10pt;"> per license; (ii) pay an annual license maintenance fee in the amount of </font><font style="font-family:inherit;font-size:10pt;">$10 thousand</font><font style="font-family:inherit;font-size:10pt;"> per license starting one year from the date of each agreement; (iii) reimburse the University of Texas for actual costs incurred in conjunction with the filing, prosecution, enforcement, and maintenance of patent rights prior to the effective date; and (iv) bear all future costs of and manage the filing, prosecution, enforcement, and maintenance of patent rights. During the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016, the Company incurred immaterial upfront and maintenance fees, which were recorded as research and development expense. All costs related to the filing, prosecution, and maintenance of patent and technology rights are recorded as general and administrative expense when incurred.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the UT License Agreements, the Company may be obligated to make the following future milestone payments for each licensed product candidate: (i) up to approximately </font><font style="font-family:inherit;font-size:10pt;">$0.6 million</font><font style="font-family:inherit;font-size:10pt;"> upon the initiation of defined clinical trials; (ii) </font><font style="font-family:inherit;font-size:10pt;">$2.0 million</font><font style="font-family:inherit;font-size:10pt;"> upon regulatory approval in the United States; and (iii) </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> per region upon regulatory approval in other specified regions. Additionally, if the Company or its sublicensees successfully commercializes any product candidate subject to the UT License Agreements, it is responsible for royalty payments in the low-single digits based upon net sales of such licensed products and payments at a percentage in the mid-teens of any sublicense income, subject to specified exceptions. The University of Texas&#8217;s right to these royalty payments will expire as to each license agreement upon the expiration of the last patent claim subject to the applicable UT License Agreement.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The license term extends on a product by product and country by country basis until the expiration of the last to expire of the licensed patents that covers such product in such country. Upon expiration of the royalty payment obligation, the Company will have a fully paid license in such country. The Company may also terminate each UT License Agreement for convenience upon a specified number of days&#8217; prior notice to the University of Texas. The University of Texas also has the right to earlier terminate the UT License Agreements after a defined date under specified circumstances where the Company has effectively abandoned its research and development efforts or has no sales. The UT License Agreements will terminate under customary termination provisions including automatic termination upon the Company&#8217;s bankruptcy or insolvency, upon notice of an uncured material breach, and upon mutual written consent. All charges incurred under the UT License Agreements have been expensed to date due to the uncertainty as to future economic benefit from the acquired rights.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreement with Roche Innovation Center Copenhagen A/S (formerly Santaris Pharma A/S)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In June 2010, Private Miragen entered into a license agreement with the Santaris Pharma A/S, which was acquired by F. Hoffmann-La Roche Ltd (&#8220;Roche&#8221;) in 2014 and subsequently changed its name to Roche Innovation Center Copenhagen A/S (&#8220;RICC&#8221;). The agreement was amended in October 2011 and amended and restated in December 2012 (the &#8220;RICC License Agreement&#8221;).&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the RICC License Agreement, the Company has received exclusive and nonexclusive licenses from RICC to use specified technology of RICC (the &#8220;RICC Technology&#8221;) for specified uses including research, development, and commercialization of pharmaceutical products using this technology worldwide. Under the RICC License Agreement, the Company has the right to develop and commercialize the RICC Technology directed to four specified targets and the option to obtain exclusive product licenses for up to six additional targets. The acquisition of Santaris Pharma A/S by Roche was considered a change-of-control under the RICC License Agreement, and as such, certain terms and conditions of the RICC License Agreement changed, as contemplated and in accordance with the RICC License Agreement. These changes primarily relate to milestone payments reflected in the disclosures below. As consideration for the grant of the license and option, Private Miragen previously paid RICC </font><font style="font-family:inherit;font-size:10pt;">$2.3 million</font><font style="font-family:inherit;font-size:10pt;"> and issued RICC </font><font style="font-family:inherit;font-size:10pt;">856,806</font><font style="font-family:inherit;font-size:10pt;"> shares of Private Miragen&#8217;s Series A convertible preferred stock, which subsequently converted to </font><font style="font-family:inherit;font-size:10pt;">602,420</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock. If the Company exercises its option to obtain additional product licenses or to replace the target families, it will be required to make additional payments to RICC.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the RICC License Agreement, milestone payments were previously decreased by a specified percentage as a result of the change of control by RICC referenced above. The Company is obligated to make future milestone payments for each licensed product for up to </font><font style="font-family:inherit;font-size:10pt;">$5.2 million</font><font style="font-family:inherit;font-size:10pt;">, which is inclusive of a potential product license option fee. Certain of these milestones will be increased by a specified percentage if the Company undergoes a change in control during the term of the RICC License Agreement. If the Company grants a third party a sublicense to the RICC Technology, it is required to remit to Roche up to a specified percentage of the upfront and milestone and other specified payments it receives under its sublicense, and if such sublicense covers use of the RICC Technology in the United States or the entire European Union, the Company will not have any further obligation to pay the fixed milestone payments noted above.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">If the Company or its sublicensee successfully commercializes any product candidate subject to the RICC License Agreements, then RICC is entitled to royalty payments in the mid-single digits on the net sales of such product, provided that if such net sales are made by a sublicensee under the RICC License Agreement, RICC is entitled to royalty payments equal to the lesser of a percentage in the mid-single digits on the net sales of such product or a specified percentage of the royalties paid to the Company by such sublicensee, subject to specified restrictions. The Company is obligated to make any such royalty payments until the later of: (i) a specified anniversary of the first commercial sale of the applicable product or (ii) the expiration of the last valid patent claim licensed by RICC under the RICC License Agreement underlying such product. Upon the occurrence of specified events, the royalty owed to RICC will be decreased by a specified percentage.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The RICC License Agreement will terminate upon the latest of the expiration of all of RICC&#8217;s royalty rights, the termination of the last Miragen target, or the expiration of its right to obtain a product license for a new target under the RICC License Agreement. The Company may also terminate the RICC License Agreement for convenience upon a specified number of days&#8217; prior notice to RICC, subject to specified terms and conditions. Either party may terminate the RICC License Agreement upon an uncured material breach by the other party and RICC may terminate the RICC License Agreement upon the occurrence of other specified events immediately or after such event is not cured within a specified number of days, as applicable.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All charges incurred under the RICC License Agreement have been expensed to date due to the uncertainty as to future economic benefit from the acquired rights. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">For the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and 2016, the Company paid </font><font style="font-family:inherit;font-size:10pt;">$0.5 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;">, respectively, to Roche for raw materials to be used in its drug manufacturing process. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Subcontract Agreement with Yale University</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2014, Private Miragen and Yale University (&#8220;Yale&#8221;) entered into a subcontract agreement and into a subaward agreement in March 2015 (the &#8220;Yale Agreements&#8221;), which was subsequently amended. Under the Yale Agreements, the Company is providing specified services regarding the development of a proprietary compound that targets miR-29 in the indication of idiopathic pulmonary fibrosis. Yale entered into the Yale Agreements in connection with a grant that Yale received from the National Institutes of Health (&#8220;NIH&#8221;) for the development of a miR-29 mimic as a potential therapy for pulmonary fibrosis.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In consideration of the Company&#8217;s services under the Yale Agreements, Yale has agreed to pay the Company up to </font><font style="font-family:inherit;font-size:10pt;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;"> over </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">, subject to the availably of funds under the grant and continued eligibility. Under the terms of the Yale Agreements, the Company retains all rights to any and all intellectual property developed solely by the Company in connection with the Yale Agreements. Yale has also agreed to provide the Company with an exclusive option to negotiate in good faith for an exclusive, royalty-bearing license from Yale for any intellectual property developed by Yale or jointly by the parties under the Yale Agreements. Yale is responsible for filing, prosecuting, and maintaining foreign and domestic patent applications and patents on all inventions jointly developed by the parties under the Yale Agreements. Through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has received </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> under the Yale Agreements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Yale Agreements terminate automatically on the date that Yale delivers its final research report to the NIH under the terms of the grant underlying the Yale Agreements. Each party may also terminate the Yale Agreements upon a specified number of days&#8217; notice in the event that the NIH&#8217;s grant funding is reduced or terminated or upon material breach by the other party.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreements with the t2cure GmbH</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In October 2010, Private Miragen entered into a license and collaboration agreement (the &#8220;t2cure Agreement&#8221;) with t2cure GmbH (&#8220;t2cure&#8221;), which was subsequently amended. Under the t2cure Agreement, the Company has received a worldwide, royalty-bearing, and exclusive license to specified patent and technology rights relating to miR-92.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In consideration of rights granted by t2cure, Private Miragen paid an upfront fee of </font><font style="font-family:inherit;font-size:10pt;">$46 thousand</font><font style="font-family:inherit;font-size:10pt;"> and agreed to: (i) pay an annual license maintenance fee in the amount of </font><font style="font-family:inherit;font-size:10pt;">&#8364;3 thousand</font><font style="font-family:inherit;font-size:10pt;"> (</font><font style="font-family:inherit;font-size:10pt;">$3 thousand</font><font style="font-family:inherit;font-size:10pt;"> as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">); and (ii) reimburse t2cure for costs incurred in conjunction with the filing, prosecution, enforcement, and maintenance of patent rights. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Under the terms of the t2cure Agreement, the Company is obligated to make the following future milestone payments for each licensed product: (i) up to approximately </font><font style="font-family:inherit;font-size:10pt;">$0.7 million</font><font style="font-family:inherit;font-size:10pt;"> upon the initiation of certain defined clinical trials; (ii) </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;"> upon regulatory approval in the United States; and (iii) up to </font><font style="font-family:inherit;font-size:10pt;">$1.5 million</font><font style="font-family:inherit;font-size:10pt;"> per region upon regulatory approval in the European Union or Japan. Additionally, if the Company or its sublicensees successfully commercialize any product candidate subject to the t2cure Agreement, it is responsible for royalty payments equal to percentages in the low-single digits upon net sales of licensed products and sublicense fees equal to a percentage in the low-twenties of sublicense income received by it. The Company is obligated to make any such royalty payment until the later of (i) the tenth anniversary of the first commercial sale of the applicable product or (ii) the expiration of the last valid claim to a patent licensed by t2cure under the t2cure Agreement covering such product. If such patent claims expire prior to the end of the </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;">-year term, then the royalty owed to t2cure will be decreased by a specified percentage. The Company also has the right to decrease its royalty payments by a specified percentage for royalties paid to third parties for licenses to certain third-party intellectual property.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The license term extends on a country by country basis until the later of: (i) the tenth anniversary of the first commercial sale of a licensed product in a country and (ii) the expiration of the last to expire valid claim that claims such licensed product in such country. Upon expiration of the royalty payment obligation, the Company will have a fully paid license in such country. The Company has the right to terminate the t2cure Agreement at will, on a country-by-country basis, after </font><font style="font-family:inherit;font-size:10pt;">60</font><font style="font-family:inherit;font-size:10pt;"> days&#8217; written notice. The t2cure Agreement will also automatically terminate upon the Company&#8217;s bankruptcy or insolvency or upon notice of an uncured material breach.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has expensed all charges incurred under the t2cure Agreement to date, due to the uncertainty as to future economic benefit from the acquired rights.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">License Agreement with The Brigham and Women&#8217;s Hospital</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2016, Private Miragen and The Brigham and Women&#8217;s Hospital (&#8220;BWH&#8221;) entered into an exclusive patent license agreement (the &#8220;BWH License Agreement&#8221;). Under the BWH License Agreement, the Company has an exclusive, worldwide license, including a right to sublicense, to specified patent rights and a nonexclusive, worldwide license, including a right to sublicense, to specified technology rights of BWH, each related to certain microRNAs believed to be involved in various neurodegenerative disorders. As consideration for these rights, the Company is obligated to pay a specified annual license fee. BWH is also entitled to milestone payments of up to approximately </font><font style="font-family:inherit;font-size:10pt;">$2.6 million</font><font style="font-family:inherit;font-size:10pt;"> for each of the Company&#8217;s product candidates developed based on the patent rights subject to the BWH License Agreement plus a one-time sales milestone payment of </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;"> for all product candidates developed based on the patent rights subject to the BWH License Agreement. If the Company were to successfully commercialize any product candidate subject to the BWH License Agreement, then BWH is entitled to royalty payments in the low-single digits on the net sales of such product. BWH&#8217;s right to these royalty payments will expire on a product by product and country by country basis upon the expiration of the last patent claim in such country that is subject to the BWH License Agreement and covers the product, and the Company&#8217;s license to such product in such country will become fully paid at such time. BWH is also entitled to a percentage in the low-double digits of any sublicense income from such product, subject to specified exceptions. The Company is also responsible for all costs associated with the preparation, filing, prosecution, and maintenance of the patent rights subject to the BWH License Agreement. Additionally, the Company is obligated to use commercially reasonable efforts to develop a product under the BWH License Agreement and to meet specified diligence milestones thereunder. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The BWH License Agreement will terminate upon the expiration of all issued patents and patent applications subject to the patent rights under the agreement. The Company may also terminate the BWH License Agreement for convenience upon a specified number of days&#8217; prior notice to BWH. BWH may terminate the BWH License Agreement upon a breach by the Company of its payment obligations and upon the occurrence of other specified events that are not cured within a specified number of days, provided that such termination is automatic upon the Company&#8217;s bankruptcy or insolvency.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company paid the first annual license fee, which was immaterial. To date, the Company has not met any milestones that have required milestone payments.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Facility Lease</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2010, Private Miragen entered into a multi-year lease agreement for its current office and lab space. The agreement was subsequently amended to extend the term through August 2020. This lease is noncancelable. Minimum base lease payments, including the impact of tenant improvement allowances, under the operating lease are recognized on a straight-line basis over the full term of the lease. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">During the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, rent expense was </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for each period. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, rent expense was </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.3 million</font><font style="font-family:inherit;font-size:10pt;">, respectively. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is also required to pay for operating expenses. During the </font><font style="font-family:inherit;font-size:10pt;">three months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, operating expenses were </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> for each period. During the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">, operating expenses related to the leased space were </font><font style="font-family:inherit;font-size:10pt;">$0.2 million</font><font style="font-family:inherit;font-size:10pt;"> for each period.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future annual minimum payments under the lease are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,<br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017 (remainder of year)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,167</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759316864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Capital Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CAPITAL STOCK</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is authorized to issue </font><font style="font-family:inherit;font-size:10pt;">105,000,000</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of its stock, of which </font><font style="font-family:inherit;font-size:10pt;">100,000,000</font><font style="font-family:inherit;font-size:10pt;">&#160;shares have been designated as Common Stock and </font><font style="font-family:inherit;font-size:10pt;">5,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares have been designated as preferred stock with a par value of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per&#160;share. The number of authorized shares of Common Stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#8217;s stock who are entitled to vote. Each share of Common Stock is entitled to one vote. The holders of Common Stock are entitled to receive dividends when and as declared or paid by its board of directors. At the effective date of the Merger, each outstanding share of Private Miragen common stock was converted into the right to receive approximately </font><font style="font-family:inherit;font-size:10pt;">0.7031</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s Common Stock. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 13, 2017, immediately prior to the Merger and in accordance with subscription agreements entered into with certain investors in October 2016, Private Miragen issued and sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;">9,045,126</font><font style="font-family:inherit;font-size:10pt;"> shares of Private Miragen&#8217;s common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$4.50</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">6,359,628</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$6.40</font><font style="font-family:inherit;font-size:10pt;"> as adjusted for the exchange ratio in the Merger, for aggregate consideration of </font><font style="font-family:inherit;font-size:10pt;">$40.7 million</font><font style="font-family:inherit;font-size:10pt;">, offset by associated financing fees of </font><font style="font-family:inherit;font-size:10pt;">$1.5&#160;million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Series Preferred</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February&#160;2017, in conjunction with the Merger, all of the outstanding redeemable convertible preferred stock of Private Miragen converted into Private Miragen common stock at a ratio of </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;">:1 and was immediately exchanged for the Company&#8217;s Common Stock at an exchange ratio of </font><font style="font-family:inherit;font-size:10pt;">0.7031</font><font style="font-family:inherit;font-size:10pt;"> as a result of the Merger. A summary of the conversion by class of preferred stock is summarized as follows (in thousands, except share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Series A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Series B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Series C</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,149,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,166,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,268,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">40,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18,584,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">76,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accretion of redeemable convertible preferred stock to redemption value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Conversion of preferred stock to common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(7,149,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(23,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,166,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(12,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(9,268,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(40,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(18,584,390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(76,981</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at February 13, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had no shares of preferred stock outstanding and had not designated the rights, preferences, or privileges of any class or series of preferred stock. Although the Company&#8217;s board of directors has the authority to issue preferred stock at its discretion in one or more classes or series and to fix the designations, powers, preferences and rights, and the qualifications, limitations, or restrictions thereof, including dividend rights, conversion right, voting rights, terms of redemption, liquidation preferences, and the number of shares constituting any class or series of preferred stock, without further vote or action by the stockholders.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Sales Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 31,&#160;2017, the Company entered into an ATM Agreement with Cowen, under which the Company may offer and sell, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> through Cowen as its sales agent.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cowen may sell the Common Stock by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 of the Securities Act of 1933, as amended, including without limitation sales made by means of ordinary brokers&#8217; transactions on The NASDAQ Capital Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise directed by the Company. Cowen will use commercially reasonable efforts to sell the Common Stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay Cowen a commission equal to </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> of the gross sales proceeds of any Common Stock sold through Cowen under the ATM Agreement, and also has provided Cowen with customary indemnification rights.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is not obligated to make any sales of Common Stock under the ATM Agreement. The offering of shares of Common Stock pursuant to the ATM Agreement will terminate upon the earlier of: (i) the sale of all Common Stock subject to the ATM Agreement or (ii) termination of the ATM Agreement in accordance with its terms.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has sold, pursuant to the terms of the ATM Agreement, </font><font style="font-family:inherit;font-size:10pt;">297,653</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock, at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$9.11</font><font style="font-family:inherit;font-size:10pt;"> per share, for aggregate gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">. Net proceeds received during the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> were approximately </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, including initial expenses for executing the &#8220;at the market offering&#8221; and commissions to Cowen as sales agent. See Note 13 for a discussion of sales of Common Stock made under the ATM Agreement after </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has incurred approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> in offering costs for the ATM Agreement, including costs for the related shelf filing, but excluding the commissions paid to Cowen as sales agent.&#160;The costs incurred are initially included in prepaid expenses and other current assets and are being amortized to a reduction of offering costs as shares are sold under the ATM Agreement.&#160;The costs reflected in the condensed consolidated statement of cash flows include the </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> commission paid to Cowen on shares sold (</font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">) along with </font><font style="font-family:inherit;font-size:10pt;">$8 thousand</font><font style="font-family:inherit;font-size:10pt;"> of amortized offering costs.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WARRANTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock purchase warrant activity is as follows for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred Stock Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants acquired in Merger</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,534</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock warrants converted into Common Stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercises</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,092</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.04</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of outstanding Common Stock purchase warrants as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:30%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Underlying Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration Date</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$80.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 &amp; 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,718</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.53</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2025</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, Private Miragen assumed </font><font style="font-family:inherit;font-size:10pt;">13,534</font><font style="font-family:inherit;font-size:10pt;"> outstanding warrants to purchase shares of the Company&#8217;s Common Stock at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$80.70</font><font style="font-family:inherit;font-size:10pt;"> per share. The assumed warrants expire on various dates in 2019 and 2020.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763849136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">CAPITAL STOCK</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is authorized to issue </font><font style="font-family:inherit;font-size:10pt;">105,000,000</font><font style="font-family:inherit;font-size:10pt;">&#160;shares of its stock, of which </font><font style="font-family:inherit;font-size:10pt;">100,000,000</font><font style="font-family:inherit;font-size:10pt;">&#160;shares have been designated as Common Stock and </font><font style="font-family:inherit;font-size:10pt;">5,000,000</font><font style="font-family:inherit;font-size:10pt;"> shares have been designated as preferred stock with a par value of </font><font style="font-family:inherit;font-size:10pt;">$0.01</font><font style="font-family:inherit;font-size:10pt;"> per&#160;share. The number of authorized shares of Common Stock may be increased or decreased by the affirmative vote of the holders of a majority of the Company&#8217;s stock who are entitled to vote. Each share of Common Stock is entitled to one vote. The holders of Common Stock are entitled to receive dividends when and as declared or paid by its board of directors. At the effective date of the Merger, each outstanding share of Private Miragen common stock was converted into the right to receive approximately </font><font style="font-family:inherit;font-size:10pt;">0.7031</font><font style="font-family:inherit;font-size:10pt;"> shares of the Company&#8217;s Common Stock. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On February 13, 2017, immediately prior to the Merger and in accordance with subscription agreements entered into with certain investors in October 2016, Private Miragen issued and sold an aggregate of </font><font style="font-family:inherit;font-size:10pt;">9,045,126</font><font style="font-family:inherit;font-size:10pt;"> shares of Private Miragen&#8217;s common stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$4.50</font><font style="font-family:inherit;font-size:10pt;">, or </font><font style="font-family:inherit;font-size:10pt;">6,359,628</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock at a price per share of </font><font style="font-family:inherit;font-size:10pt;">$6.40</font><font style="font-family:inherit;font-size:10pt;"> as adjusted for the exchange ratio in the Merger, for aggregate consideration of </font><font style="font-family:inherit;font-size:10pt;">$40.7 million</font><font style="font-family:inherit;font-size:10pt;">, offset by associated financing fees of </font><font style="font-family:inherit;font-size:10pt;">$1.5&#160;million</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Series Preferred</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February&#160;2017, in conjunction with the Merger, all of the outstanding redeemable convertible preferred stock of Private Miragen converted into Private Miragen common stock at a ratio of </font><font style="font-family:inherit;font-size:10pt;">1</font><font style="font-family:inherit;font-size:10pt;">:1 and was immediately exchanged for the Company&#8217;s Common Stock at an exchange ratio of </font><font style="font-family:inherit;font-size:10pt;">0.7031</font><font style="font-family:inherit;font-size:10pt;"> as a result of the Merger. A summary of the conversion by class of preferred stock is summarized as follows (in thousands, except share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Series A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Series B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Series C</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,149,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,166,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,268,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">40,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18,584,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">76,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accretion of redeemable convertible preferred stock to redemption value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Conversion of preferred stock to common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(7,149,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(23,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,166,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(12,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(9,268,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(40,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(18,584,390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(76,981</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at February 13, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had no shares of preferred stock outstanding and had not designated the rights, preferences, or privileges of any class or series of preferred stock. Although the Company&#8217;s board of directors has the authority to issue preferred stock at its discretion in one or more classes or series and to fix the designations, powers, preferences and rights, and the qualifications, limitations, or restrictions thereof, including dividend rights, conversion right, voting rights, terms of redemption, liquidation preferences, and the number of shares constituting any class or series of preferred stock, without further vote or action by the stockholders.&#160;</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Common Stock Sales Agreement</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">On March 31,&#160;2017, the Company entered into an ATM Agreement with Cowen, under which the Company may offer and sell, from time to time at its sole discretion, shares of its Common Stock having an aggregate offering price of up to </font><font style="font-family:inherit;font-size:10pt;">$50.0 million</font><font style="font-family:inherit;font-size:10pt;"> through Cowen as its sales agent.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cowen may sell the Common Stock by any method permitted by law deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 of the Securities Act of 1933, as amended, including without limitation sales made by means of ordinary brokers&#8217; transactions on The NASDAQ Capital Market or otherwise at market prices prevailing at the time of sale, in block transactions, or as otherwise directed by the Company. Cowen will use commercially reasonable efforts to sell the Common Stock from time to time, based upon instructions from the Company (including any price, time or size limits or other customary parameters or conditions the Company may impose). The Company will pay Cowen a commission equal to </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> of the gross sales proceeds of any Common Stock sold through Cowen under the ATM Agreement, and also has provided Cowen with customary indemnification rights.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company is not obligated to make any sales of Common Stock under the ATM Agreement. The offering of shares of Common Stock pursuant to the ATM Agreement will terminate upon the earlier of: (i) the sale of all Common Stock subject to the ATM Agreement or (ii) termination of the ATM Agreement in accordance with its terms.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company has sold, pursuant to the terms of the ATM Agreement, </font><font style="font-family:inherit;font-size:10pt;">297,653</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock, at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$9.11</font><font style="font-family:inherit;font-size:10pt;"> per share, for aggregate gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$2.7 million</font><font style="font-family:inherit;font-size:10pt;">. Net proceeds received during the nine months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> were approximately </font><font style="font-family:inherit;font-size:10pt;">$2.5 million</font><font style="font-family:inherit;font-size:10pt;">, including initial expenses for executing the &#8220;at the market offering&#8221; and commissions to Cowen as sales agent. See Note 13 for a discussion of sales of Common Stock made under the ATM Agreement after </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has incurred approximately </font><font style="font-family:inherit;font-size:10pt;">$0.4 million</font><font style="font-family:inherit;font-size:10pt;"> in offering costs for the ATM Agreement, including costs for the related shelf filing, but excluding the commissions paid to Cowen as sales agent.&#160;The costs incurred are initially included in prepaid expenses and other current assets and are being amortized to a reduction of offering costs as shares are sold under the ATM Agreement.&#160;The costs reflected in the condensed consolidated statement of cash flows include the </font><font style="font-family:inherit;font-size:10pt;">3.0%</font><font style="font-family:inherit;font-size:10pt;"> commission paid to Cowen on shares sold (</font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> through </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">) along with </font><font style="font-family:inherit;font-size:10pt;">$8 thousand</font><font style="font-family:inherit;font-size:10pt;"> of amortized offering costs.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">WARRANTS</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock purchase warrant activity is as follows for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred Stock Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants acquired in Merger</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,534</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock warrants converted into Common Stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercises</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,092</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.04</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of outstanding Common Stock purchase warrants as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:30%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Underlying Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration Date</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$80.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 &amp; 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,718</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.53</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2025</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In connection with the Merger, Private Miragen assumed </font><font style="font-family:inherit;font-size:10pt;">13,534</font><font style="font-family:inherit;font-size:10pt;"> outstanding warrants to purchase shares of the Company&#8217;s Common Stock at a weighted average exercise price of </font><font style="font-family:inherit;font-size:10pt;">$80.70</font><font style="font-family:inherit;font-size:10pt;"> per share. The assumed warrants expire on various dates in 2019 and 2020.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759156064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SHARE-BASED COMPENSATION</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Equity Incentive Plans</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2017, the Company&#8217;s 2014 Stock Incentive Plan (the &#8220;2014 Plan&#8221;) was terminated as a result of the Merger. There are no awards outstanding under the 2014 Plan and no future awards will be issued under the 2014 Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">2,060,993</font><font style="font-family:inherit;font-size:10pt;"> options outstanding and no remaining equity awards available for future issuances under the 2008 Plan. All awards granted under the 2008 Plan that, after February 13, 2017, expire or terminate for any reason prior to exercise or settlement, are forfeited, or are reacquired, withheld, or not issued to satisfy a tax withholding obligation or to satisfy the exercise price of a stock award, will become available for grant under the 2016 Plan in accordance with its terms. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Plan provides for the grant of incentive stock options, nonstatutory stock options, stock appreciation rights, restricted stock awards, restricted stock unit awards, other stock awards, and performance awards that may be settled in cash, stock, or other property. All employees and non-employee directors are eligible to participate in the 2016 Plan and may receive all types of awards other than incentive stock options. Incentive stock options may be granted under the 2016 Plan only to employees (including officers) and employees of the Company&#8217;s affiliates. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The aggregate number of shares of Common Stock that may be issued under the 2016 Plan will not exceed </font><font style="font-family:inherit;font-size:10pt;">4,182,404</font><font style="font-family:inherit;font-size:10pt;"> shares, which number is the sum of: (i) </font><font style="font-family:inherit;font-size:10pt;">1,681,294</font><font style="font-family:inherit;font-size:10pt;"> shares, plus (ii) the number of shares subject to outstanding stock awards that were granted under the 2008 Plan, that, from and after the closing date of the Merger, expire or terminate for any reason prior to exercise or settlement, are forfeited because of the failure to meet a contingency or condition required to vest such shares, or are reacquired, withheld, or not issued to satisfy a tax withholding obligation in connection with an award or to satisfy the purchase price or exercise price of a stock award, if any, as such shares become available from time to time. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were </font><font style="font-family:inherit;font-size:10pt;">908,227</font><font style="font-family:inherit;font-size:10pt;"> equity awards outstanding and </font><font style="font-family:inherit;font-size:10pt;">773,067</font><font style="font-family:inherit;font-size:10pt;"> remaining equity awards available for future issuances under the 2016 Plan.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options granted under the 2008 Plan and 2016 Plan have an exercise price equal to the market value of the Common Stock at the date of grant and expire </font><font style="font-family:inherit;font-size:10pt;">ten</font><font style="font-family:inherit;font-size:10pt;"> years from the date of grant. Generally, options vest </font><font style="font-family:inherit;font-size:10pt;">25%</font><font style="font-family:inherit;font-size:10pt;"> on the first anniversary of the vesting commencement date and </font><font style="font-family:inherit;font-size:10pt;">75%</font><font style="font-family:inherit;font-size:10pt;"> ratably in equal monthly installments over the remaining </font><font style="font-family:inherit;font-size:10pt;">36 months</font><font style="font-family:inherit;font-size:10pt;">. The Company has also granted options that vest in equal monthly or quarterly amounts over periods up to </font><font style="font-family:inherit;font-size:10pt;">48 months</font><font style="font-family:inherit;font-size:10pt;">.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of Common Stock option activity is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Options <br clear="none"/>(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">956</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11.40</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,969</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value Assumptions</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company uses the Black-Scholes option pricing model to estimate the fair value of stock options granted. The Black-Scholes model requires inputs for risk-free interest rate, dividend yield, volatility, and expected lives of the options. Because the Company has a limited history of stock purchase and sale activity, expected volatility is based on historical data from public companies similar to the Company in size and nature of operations. The Company will continue to use similar entity volatility information until its historical volatility is relevant to measure expected volatility for option grants. The Company has not applied a forfeiture rate to its assumptions as the impact would not be material to the consolidated financial statements. The risk-free rate for periods within the contractual life of each option is based on the U.S.&#160;Treasury yield curve in effect at the time of the grant for a period commensurate with the expected term of the grant. The expected term (without regard to forfeitures) for options granted represents the period of time that options granted are expected to be outstanding and is derived from the contractual terms of the options granted and expected option exercise behaviors. Prior to the Merger, Private Miragen estimated the fair value of underlying shares of common stock using a third-party valuation report that derived the fair value using the probability-weighted expected return method. After the Merger, the fair value of the underlying Common Stock is based on the closing price of the Common Stock on the NASDAQ Capital Market at the date of grant. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options Granted to Employees</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The weighted-average fair value of options granted during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;"> was </font><font style="font-family:inherit;font-size:10pt;">$8.32</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">$0.70</font><font style="font-family:inherit;font-size:10pt;">, respectively. The fair value was determined by the Black-Scholes option pricing model using the following assumptions:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term, in years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average grant date fair value of underlying Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Stock Options Granted to Non-Employees</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company determines the value of Common Stock options issued to non-employees using the Black-Scholes option pricing model and adjusting the value of such awards to current fair value each reporting period until the awards are vested or a performance commitment has otherwise been reached. </font><font style="font-family:inherit;font-size:10pt;">No</font><font style="font-family:inherit;font-size:10pt;"> Common Stock options were issued to non-employees during the </font><font style="font-family:inherit;font-size:10pt;">nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2016</font><font style="font-family:inherit;font-size:10pt;">. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Employee Stock Purchase Plan</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The 2016 Employee Stock Purchase Plan (&#8220;ESPP&#8221;) allows qualified employees to purchase shares of the Company's Common Stock at a price equal to&#160;85%&#160;of the lower of: (i) the closing price at the beginning of the offering period or (ii) the closing price at the end of the offering period. The Company expects that a new 6-month offering period will begin each August&#160;22 and February&#160;22. As of&#160;</font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had&#160;</font><font style="font-family:inherit;font-size:10pt;">0.2 million</font><font style="font-family:inherit;font-size:10pt;">&#160;shares available for issuance and </font><font style="font-family:inherit;font-size:10pt;">13 thousand</font><font style="font-family:inherit;font-size:10pt;"> shares had been issued under the ESPP.</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation Expense</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation related to all equity awards issued pursuant to the 2008 Plan and 2016 Plan and for estimated shares to be issued under the ESPP for the current purchase period is included in the condensed consolidated statements of operations as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">416</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,050</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share-based compensation expense</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,693</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company had </font><font style="font-family:inherit;font-size:10pt;">$7.4 million</font><font style="font-family:inherit;font-size:10pt;"> of total unrecognized employee share-based compensation costs, which the Company expects to recognize over a weighted-average remaining period of </font><font style="font-family:inherit;font-size:10pt;">3.2</font><font style="font-family:inherit;font-size:10pt;">&#160;years. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, based on the current estimate of fair value, the Company estimates that the remaining unrecognized share-based compensation expense related to non-employees of </font><font style="font-family:inherit;font-size:10pt;">$0.1 million</font><font style="font-family:inherit;font-size:10pt;"> will be recorded to expense over a weighted-average remaining period of </font><font style="font-family:inherit;font-size:10pt;">0.9</font><font style="font-family:inherit;font-size:10pt;">&#160;years.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759303088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">NET LOSS PER SHARE</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is computed by dividing the net loss available to common stockholders by the weighted-average number of Common Stock outstanding. Diluted net loss per share is computed similarly to basic net loss per share except that the denominator is increased to include the number of additional shares of Common Stock that would have been outstanding if the potential shares of Common Stock had been issued and if the additional shares of Common Stock were dilutive. Diluted net loss per share is the same as basic net loss per share of Common Stock, since the effects of potentially dilutive securities are antidilutive.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Potentially dilutive securities include the following:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options to purchase Common Stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,067</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,994</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,365</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6650516528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SUBSEQUENT EVENTS</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Subsequent to </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, and through </font><font style="font-family:inherit;font-size:10pt;">November 7, 2017</font><font style="font-family:inherit;font-size:10pt;">, the Company sold, pursuant to the terms of the ATM Agreement, an aggregate of </font><font style="font-family:inherit;font-size:10pt;">403,306</font><font style="font-family:inherit;font-size:10pt;"> shares of Common Stock, at a weighted average price of </font><font style="font-family:inherit;font-size:10pt;">$9.65</font><font style="font-family:inherit;font-size:10pt;"> per share, for aggregate gross proceeds of approximately </font><font style="font-family:inherit;font-size:10pt;">$3.9 million</font><font style="font-family:inherit;font-size:10pt;">.&#160;Net proceeds were approximately </font><font style="font-family:inherit;font-size:10pt;">$3.8 million</font><font style="font-family:inherit;font-size:10pt;">, including commissions to Cowen, as sales agent.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774930160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, Miragen Europe. The financial statements have been prepared in accordance with U.S. generally accepted accounting principles (&#8220;U.S. GAAP&#8221;) and follow the requirements of the Securities and Exchange Commission (the &#8220;SEC&#8221;) for interim reporting. As permitted under those rules, certain footnotes or other financial information that are normally required by U.S. GAAP can be condensed or omitted. These financial statements have been prepared on the same basis as the Company&#8217;s annual financial statements and, in the opinion of management, reflect all adjustments, consisting only of normal recurring adjustments, which are necessary for a fair statement of the Company&#8217;s financial information. These interim results are not necessarily indicative of the results to be expected for the year ending December 31, 2017, or for any other interim period, or for any other future year. The balance sheet as of December 31, 2016 has been derived from audited consolidated financial statements at that date but does not include all the information required by U.S. GAAP for complete financial statements. All intercompany balances and transactions have been eliminated in consolidation.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The accompanying unaudited condensed consolidated financial statements and related financial information should be read in conjunction with the audited consolidated financial statements of the Company and the notes thereto contained in the Company&#8217;s Form 8-K/A for the year ended December 31, 2016, filed with the SEC on March 31, 2017. The Company&#8217;s management performed an evaluation of its activities through the date of filing of these financial statements and concluded that there are no subsequent events requiring disclosure, other than as disclosed.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Use of Estimates</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s consolidated financial statements are prepared in accordance with U.S.&#160;GAAP, which requires it to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and contingent liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Although these estimates are based on the Company&#8217;s knowledge of current events and actions it may take in the future, actual results may ultimately differ from these estimates and assumptions.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Revenue Recognition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue principally from its strategic alliance and collaboration agreement. Revenue is recognized from upfront payments for licenses and milestone payments that are generated from defined research or development events, as well as from the reimbursement of amounts for research and development services under its strategic alliance and collaboration agreement. The Company recognizes revenue when all four of the following criteria are met: (1)&#160;persuasive evidence of an arrangement exists; (2)&#160;products have been delivered or services rendered; (3)&#160;the selling price is fixed or determinable; and (4)&#160;collectability is reasonably assured.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Multiple-element arrangements are examined to determine whether the deliverables can be separated or must be accounted for as a single unit of accounting. The Servier Collaboration Agreement with Servier, for example, includes a combination of upfront license fees, payments for research and development activities, and milestone payments that are evaluated to determine whether each deliverable under the agreement has value to the customer on a stand-alone basis and whether reliable evidence of fair value for the deliverable exists. Deliverables in an arrangement that do not meet this separation criteria are treated as a single unit of accounting, generally applying applicable revenue recognition guidance for the final deliverable to the combined unit of accounting.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company recognizes revenue from non-refundable upfront license fees over the term of performance under the Servier Collaboration Agreement. When the performance period is not specified, the Company estimates the performance period based upon provisions contained within the agreement, such as the duration of the research or development term, the existence, or likelihood, of achievement of development commitments, and any other significant commitments. These advance payments are deferred and recorded as deferred revenue upon receipt, pending recognition, and are classified as a short-term or long-term liability in the accompanying condensed consolidated balance sheets. Expected performance periods are reviewed periodically and, if applicable, the amortization period is adjusted, which may accelerate or decelerate revenue recognition. The timing of revenue recognition, specifically as it relates to the amortization of upfront license fees, is significantly influenced by the Company&#8217;s estimates.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Share-Based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for share-based compensation expense related to stock options granted to employees and members of its board of directors under its 2008 Equity Incentive Plan (the &#8220;2008 Plan&#8221;) and under its 2016 Equity Incentive Plan (the &#8220;2016 Plan&#8221;) by estimating the fair value of each stock option or award on the date of grant using the Black-Scholes option pricing model. The Company recognizes share-based compensation expense on a straight-line basis over the vesting term. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for stock options issued to non-employees by valuing the award using an option pricing model and remeasuring such awards to the current fair value until the awards are vested or a performance commitment has otherwise been reached.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Research and Development</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development costs are expensed as incurred in performing research and development activities. The costs include employee-related expense including salaries, benefits, share-based compensation, fees for acquiring and maintaining licenses under third party license agreements, consulting fees, costs of research and development activities conducted by third parties on the Company&#8217;s behalf, laboratory supplies, depreciation, and facilities and overhead costs. The Company defers and capitalizes non-refundable advance payments for research and development activities until the related goods are received or services performed. In circumstances where amounts have been paid in excess of costs incurred, the Company records a prepaid expense. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company records upfront and milestone payments to acquire contractual rights to licensed technology as research and development expenses when incurred if there is uncertainty in the Company receiving future economic benefit from the acquired contractual rights. The Company considers future economic benefits from acquired contractual rights to licensed technology to be uncertain until such a drug candidate is approved by the U.S. Food and Drug Administration or when other significant risk factors are abated.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock', window );">Clinical Trials and Preclinical Study Accruals</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Clinical Trial and Preclinical Study Accruals</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company makes estimates of accrued expenses as of each balance sheet date in its condensed consolidated financial statements based on certain facts and circumstances at that time. The Company&#8217;s accrued expenses for clinical trials and preclinical studies are based on estimates of costs incurred for services provided by clinical research organizations, manufacturing organizations, and other providers. Payments under the Company&#8217;s agreements with external service providers depend on a number of factors, such as site initiation, patient screening, enrollment, delivery of reports, and other events. In accruing for these activities, the Company obtains information from various sources and estimates the level of effort or expense allocated to each period. Adjustments to the Company&#8217;s research and development expenses may be necessary in future periods as its estimates change.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">All highly-liquid investments that have maturities of 90 days or less at the date of purchase are classified as cash equivalents. Cash equivalents are reported at cost, which approximates fair value due to the short maturities of these instruments.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Certain of the Company&#8217;s financial instruments are not measured at fair value on a recurring basis but are recorded at amounts that approximate their fair value due to the short-term nature of their maturities, such as cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses. The carrying amount of the Company&#8217;s note payable approximates its fair value (a Level 2 fair value measurement), reflecting interest rates currently available to the Company. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for its warrants to purchase common and preferred stock pursuant to ASC Topic&#160;480,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Distinguishing Liabilities from Equity</font><font style="font-family:inherit;font-size:10pt;">, and classifies warrants for redeemable preferred stock and certain warrants for common stock as liabilities. The warrants are reported at their estimated fair value and any changes in fair value are reflected in interest expense and other related expenses.</font></div></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present information about the Company&#8217;s financial assets and liabilities that have been measured at fair value and indicate the fair value of the hierarchy of the valuation inputs utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair value determined by Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Concentrations of Credit Risk</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, which include short-term investments that have maturities of less than three months. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts. The Company invests its excess cash primarily in deposits and money market funds held with two financial institutions.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Property and Equipment</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company carries its property and equipment at cost, less accumulated depreciation and amortization. Depreciation is computed using the straight-line method over the estimated useful lives of the assets, generally </font><font style="font-family:inherit;font-size:10pt;">three</font><font style="font-family:inherit;font-size:10pt;"> to </font><font style="font-family:inherit;font-size:10pt;">five years</font><font style="font-family:inherit;font-size:10pt;">. Leasehold improvements are amortized over the shorter of the life of the lease (including any renewal periods that are deemed to be reasonably assured) or the estimated useful life of the assets. Construction in progress is not depreciated until placed in service. Repairs and maintenance costs are expensed as incurred and expenditures for major improvements are capitalized.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Impairment of Long-Lived Assets</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company assesses the carrying amount of its property and equipment whenever events or changes in circumstances indicate the carrying amount of such assets may not be recoverable.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Net Loss per Share</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Basic net loss per share is calculated by dividing the net loss applicable to common stockholders by the weighted average number of shares of Common Stock outstanding during the period without consideration of Common Stock equivalents. Since the Company was in a loss position for all periods presented, diluted net loss per share is the same as basic net loss per share for all periods, as the inclusion of all potential common shares outstanding is anti-dilutive.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Comprehensive Loss</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Comprehensive loss is defined as the change in equity during a period from transactions and other events and/or circumstances from non-owner sources. If the Company had comprehensive gains (losses), they would be reflected in the statement of operations and comprehensive loss and as a separate component in the statement of stockholders&#8217; equity (deficit).</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Income Taxes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company accounts for income taxes by using an asset and liability method of accounting for deferred income taxes. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is recorded to the extent it is more likely than not that a deferred tax asset will not be realized. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period that includes the enactment date.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company&#8217;s significant deferred tax assets are for net operating loss carryforwards, tax credits, and capitalized start-up costs. The Company has provided a valuation allowance for its entire net deferred tax assets since inception as, due to its history of operating losses, the Company has concluded that it is more likely than not that its deferred tax assets will not be realized.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company has no unrecognized tax benefits. The Company classifies interest and penalties arising from the underpayment of income taxes in the condensed consolidated statements of operations as general and administrative expenses.</font></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Segment Information</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company operates in&#160;</font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;">&#160;operating segment and, accordingly, no segment disclosures have been presented herein. All equipment, leasehold improvements, and other fixed assets are physically located within the United States and all agreements with the Company&#8217;s partners are denominated in U.S. dollars, except where noted.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements - Adopted and Not Yet Adopted</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;font-weight:bold;">Recent Accounting Pronouncements &#8211; Not Yet Adopted</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May 2014, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> (&#8220;</font><font style="font-family:inherit;font-size:10pt;">ASU&#8221;) No. 2014-09</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Revenue from Contracts with Customers (Topic 606)</font><font style="font-family:inherit;font-size:10pt;">, which outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The core principle of the revenue model is that &#8220;an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.&#8221; The standard provides enhancements to the quality and consistency of how revenue is reported by companies, while also improving comparability in the financial statements of companies reporting using International Financial Reporting Standards or U.S. GAAP.&#160;The new standard also will require enhanced revenue disclosures, provide guidance for transactions that were not previously addressed comprehensively and improve guidance for multiple-element arrangements. This accounting standard becomes effective for the Company for reporting periods beginning after December 15, 2018, and interim reporting periods thereafter. Early adoption is permitted for annual reporting periods (including interim periods) beginning after December 15, 2016. This new standard permits the use of either the retrospective or cumulative effect transition method. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-08</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Revenue from Contracts with Customers (Topic 606): Principal versus Agent Considerations</font><font style="font-family:inherit;font-size:10pt;">. The purpose of this standard is to clarify the implementation of guidance on principal versus agent considerations related to ASU 2014-09. The standard has the same effective date as ASU 2014-09 described above.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In April 2016, the FASB issued</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> </font><font style="font-family:inherit;font-size:10pt;">ASU No. 2016-10,</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Revenue from Contracts with Customer, </font><font style="font-family:inherit;font-size:10pt;">which provides clarity related to ASU 2014-09 regarding identifying performance obligations and licensing implementation. The standard has the same effective date as ASU 2014-09 described above. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In May&#160;2016, the FASB issued ASU 2016-12:</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Revenue from Contracts with Customers (Topic 606): Narrow-Scope Improvements and Practical Expedients</font><font style="font-family:inherit;font-size:10pt;">, which provides narrow scope improvements and practical expedients related to ASU 2014-09. The purpose of&#160;this standard&#160;is to clarify certain narrow aspects of ASU 2014-09, such as assessing the collectability criterion, presentation of sales taxes, and other similar taxes collected from customers, noncash consideration, contract modifications at transition, completed contracts at transition, and technical correction. The standard has the same effective date as ASU 2014-09 described above. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In December 2016, the FASB issued ASU 2016-20:</font><font style="font-family:inherit;font-size:10pt;font-style:italic;"> Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers</font><font style="font-family:inherit;font-size:10pt;">. The amendments in this standard affect narrow aspects of guidance issued in ASU 2014-09. The standard has the same effective date as ASU 2014-09 described above. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The Company plans to adopt these new standards in the first quarter of 2019. As of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;">, there were limited contracts that will be in effect (actively) as of the transition date and, accordingly, the Company has not yet determined the effect of the standard on its condensed consolidated financial statements. The Company&#8217;s selected implementation transition method will be dependent upon contracts that are in place closer to the transition date. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Deferred Taxes</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In November 2015, the FASB issued ASU No. 2015-17</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Balance Sheet Classification of Deferred Taxes</font><font style="font-family:inherit;font-size:10pt;">. ASU No. 2015-17 requires that deferred tax liabilities and assets be classified as noncurrent in a classified statement of financial position. This standard is effective for the Company for financial statements issued for fiscal years beginning after December 15, 2017, and interim periods thereafter. The Company does not believe the adoption of this standard will have a material impact on its condensed consolidated financial statements due to the full valuation allowance on all net deferred tax assets. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In February 2016, the FASB issued ASU No. 2016-02</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Leases (Topic 842), which supersedes FASB ASC Topic 840, Leases (Topic 840),</font><font style="font-family:inherit;font-size:10pt;"> and provides principles for the recognition, measurement, presentation and disclosure of leases for both lessees and lessors. In September 2017, the FASB issued ASU 2017-13,&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Revenue Recognition (Topic 605), Revenue from Contracts with Customers (Topic 606), Leases (Topic 840), and Leases (Topic 842),&#160;</font><font style="font-family:inherit;font-size:10pt;">which provides additional implementation guidance on the previously issued ASU 2016-02&#160;</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">Leases (Topic 842)</font><font style="font-family:inherit;font-size:10pt;">. ASU 2016-02 requires lessees to apply a dual approach, classifying leases as either finance or operating leases based on the principle of whether or not the lease is effectively a financed purchase by the lessee. This classification will determine whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease, respectively. A lessee is also required to record a right-of-use asset and a lease liability for all leases with a term of greater than twelve months regardless of classification. Leases with a term of twelve months or less will be accounted for similar to existing guidance for operating leases. The standard is effective for the Company for fiscal years beginning after December 15, 2019, and interim periods thereafter, with early adoption permitted. At adoption, this update will be applied using a modified retrospective approach. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Share-based Compensation</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">In March 2016, the FASB issued ASU No. 2016-09</font><font style="font-family:inherit;font-size:10pt;font-style:italic;">, Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting</font><font style="font-family:inherit;font-size:10pt;">, which is intended to simplify accounting for equity share-based payment transactions, including the income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. This standard is effective for the Company for annual periods beginning after December 15, 2017, and interim periods thereafter. </font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amendments related to the timing of when excess tax benefits are recognized, minimum statutory withholding requirements, forfeitures, and intrinsic value should be applied using a modified retrospective transition method by means of a cumulative-effect adjustment to equity as of the beginning of the period in which the guidance is adopted. Amendments related to the presentation of employee taxes paid on the statement of cash flows when an employer withholds shares to meet the minimum statutory withholding requirement should be applied retrospectively. Amendments requiring recognition of excess tax benefits and tax deficiencies in the income statement and the practical expedient for estimating the expected term should be applied prospectively. An entity may elect to apply the amendments related to the presentation of excess tax benefits on the statement of cash flows using either a prospective transition method or a retrospective transition method. The Company is currently evaluating the impact of this standard on its condensed consolidated financial statements.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other new pronouncements issued but not effective as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> are not expected to have a material impact on the Company&#8217;s condensed consolidated financial statements.</font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Clinical Trials and Pre-clinical Study Accruals [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_ClinicalTrialsAndPreclinicalStudyAccrualsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 55<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027168&amp;loc=d3e14489-108613<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61082-112788<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75027451&amp;loc=SL29635902-196195<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=75032840&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6706510784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following tables present information about the Company&#8217;s financial assets and liabilities that have been measured at fair value and indicate the fair value of the hierarchy of the valuation inputs utilized to determine such fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair value determined by Level 2 inputs utilize observable inputs other than Level 1 prices, such as quoted prices, for similar assets or liabilities, quoted market prices in markets that are not active or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and include situations where there is little, if any, market activity for the asset or liability.</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:45%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,<br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December 31,<br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 1</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Level 3</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Assets:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Money market funds (included in cash and cash equivalents)</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">&#160;(1)</sup></font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">44,112</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;text-indent:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;text-indent:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22,189</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Liabilities:</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred and common stock warrants (included in accrued and other liabilities)</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">______________________</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1)  Amounts presented for each period above differ from cash and cash equivalents reported in the condensed consolidated balance sheets due to outstanding disbursements and deposits.</font></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A reconciliation of the beginning and ending balances of the Company&#8217;s liabilities measured at fair value using significant unobservable, or Level 3, inputs are as follows for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;"> (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance of liability as of December 31, 2016</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Reclassification of preferred stock warrant to common stock warrant</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(51</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Balance of liability as of September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759264016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Reverse Merger (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Business Acquisitions, by Acquisition</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table summarizes the net assets acquired based on their estimated fair values as of February 13, 2017, prior to the Merger (in thousands):</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cash and cash equivalents</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,280</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Prepaid and other assets</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">248</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,324</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Net acquired tangible assets</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">204</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763909120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Components of Property and Equipment</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net, consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Lab equipment</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,219</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,163</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Furniture and fixtures</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">77</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">51</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Computer hardware and software</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">361</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">281</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Leasehold improvements</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">729</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">688</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, gross</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,386</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,183</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: accumulated depreciation and amortization</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,776</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(2,558</font></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Property and equipment, net</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">610</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">625</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773397536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Components of Accrued Liabilities</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued liabilities consisted of the following:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued outsourced clinical and preclinical studies</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,635</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,684</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued employee compensation and related taxes</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,061</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">928</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued legal fees and expenses</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">607</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">759</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued other professional service fees</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">457</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">124</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accrued equipment and lab materials</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">156</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Value of liability-classified stock purchase warrants </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">82</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">133</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Deferred and accrued facility lease obligations</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">221</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Other accrued liabilities</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">74</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">60</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total accrued liabilities</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,142</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,909</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763907776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtTableTextBlock', window );">Composition of Notes Payable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Amounts outstanding under notes payable are as follows:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">December&#160;31, <br clear="none"/>2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Principal amount outstanding</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,167</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt discount</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(6</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Unamortized debt issuance costs</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(14</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(31</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Accreted final payment fee</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">227</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">167</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total notes payable</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,374</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4,789</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Less: current maturities</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,983</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(1,969</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Long-term notes payable, net of current portion</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,391</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,820</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Future Annual Minimum Principal Payments of Notes Payable</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future annual minimum principal payments of notes payable are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, <br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017 (remainder of year)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">500</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,000</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">667</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,167</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to short-term and long-debt instruments or arrangements, including but not limited to identification of terms, features, collateral requirements and other information necessary to a fair presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the combined aggregate amount of maturities and sinking fund requirements for all long-term borrowings for each of the five years following the date of the latest balance sheet date presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759251520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Future annual minimum payments under the lease are as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4" rowspan="1"></td></tr><tr><td style="width:87%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September 30,<br clear="none"/>2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2017 (remainder of year)</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">95</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2018</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">391</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019</font></div></td><td colspan="2" style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">404</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2020</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">277</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,167</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6650746752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityTableTextBlock', window );">Summary of Series Preferred Stock</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of the conversion by class of preferred stock is summarized as follows (in thousands, except share data):</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="28" rowspan="1"></td></tr><tr><td style="width:19%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:7%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:8%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Series A</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Series B</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Series C</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Total</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Amount</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">7,149,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">23,124</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">2,166,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">12,975</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">9,268,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">40,877</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">18,584,390</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">76,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Accretion of redeemable convertible preferred stock to redemption value</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">1</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">3</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">5</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Conversion of preferred stock to common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(7,149,176</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(23,125</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(2,166,651</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(12,976</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(9,268,563</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(40,880</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(18,584,390</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">(76,981</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">Balance at February 13, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">$</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of temporary equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=d3e177068-122764<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (27)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759251520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Summary of Warrants</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Stock purchase warrant activity is as follows for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended September 30, 2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="14" rowspan="1"></td></tr><tr><td style="width:37%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:14%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:13%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Common Stock Warrants</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Preferred Stock Warrants</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7,031</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">0.57</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants acquired in Merger</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,534</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">80.70</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Preferred stock warrants converted into Common Stock warrants</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(25,779</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercises</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(21,092</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3.04</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,252</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">47.21</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of outstanding Common Stock purchase warrants as of </font><font style="font-family:inherit;font-size:10pt;">September&#160;30, 2017</font><font style="font-family:inherit;font-size:10pt;"> is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5" rowspan="1"></td></tr><tr><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:34%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:30%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Underlying Shares</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Exercise Price</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Expiration Date</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,534</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$80.70</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2019 &amp; 2020</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11,718</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$8.53</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2025</font></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25,252</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68057994&amp;loc=d3e25284-112666<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6650684016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Stock Option Activity</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">A summary of Common Stock option activity is as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7" rowspan="1"></td></tr><tr><td style="width:75%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Number of Options <br clear="none"/>(in thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Weighted Average Exercise Price</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at December 31, 2016</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,321</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Granted</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">956</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.48</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Exercised</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(274</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(0.80</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Forfeited</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(34</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(11.40</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">)</font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Outstanding at September 30, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,969</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">4.62</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Fair Value Assumptions for Stock Options</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The fair value was determined by the Black-Scholes option pricing model using the following assumptions:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:73%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected term, in years</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">6.44</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5.00</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected volatility</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">83.8</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">84.0</font></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Risk-free interest rate</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.1</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Expected dividend yield</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">%</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">&#8212;</font></div></td><td style="vertical-align:middle;padding-right:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;">%</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Weighted average grant date fair value of underlying Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">11.48</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1.05</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Allocation of Share-based Compensation Expense</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Share-based compensation related to all equity awards issued pursuant to the 2008 Plan and 2016 Plan and for estimated shares to be issued under the ESPP for the current purchase period is included in the condensed consolidated statements of operations as follows:</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="16" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:9%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Three Months Ended<br clear="none"/>September 30,</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended<br clear="none"/>September 30,</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Research and development</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">263</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">5</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">643</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">22</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">General and administrative</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">416</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">40</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,050</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">107</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total share-based compensation expense</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">679</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">45</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,693</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">129</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="8" rowspan="1"></td></tr><tr><td style="width:53%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:11%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759348176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th"><div>Sep. 30, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share</a></td>
<td class="text"><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Potentially dilutive securities include the following:</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="6" rowspan="1"></td></tr><tr><td style="width:77%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td><td style="width:10%;" rowspan="1" colspan="1"></td><td style="width:1%;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2017</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">September&#160;30, 2016</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(in thousands)</font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Options to purchase Common Stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,969</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,265</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase Common Stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">25</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">7</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">13,067</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants to purchase redeemable convertible preferred stock</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#8212;</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">26</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:middle;background-color:#cceeff;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Total</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2,994</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">15,365</font></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;border-top:1px solid #000000;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774205424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Description of Business - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 13, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Feb. 12, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_DescriptionofBusinessLineItems', window );"><strong>Description of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,886,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,886,568<span></span>
</td>
<td class="nump">21,886,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,744<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (87,207,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (87,207,000)<span></span>
</td>
<td class="num">$ (87,207,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (67,076,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,834,000)<span></span>
</td>
<td class="num">$ (4,153,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,126,000)<span></span>
</td>
<td class="num">$ (11,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock</a></td>
<td class="nump">$ 40,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 42,805,000<span></span>
</td>
<td class="nump">$ 24,598,000<span></span>
</td>
<td class="nump">42,805,000<span></span>
</td>
<td class="nump">42,805,000<span></span>
</td>
<td class="nump">24,598,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,104,000<span></span>
</td>
<td class="nump">$ 21,235,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_PrivateFinancingMember', window );">Private Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_DescriptionofBusinessLineItems', window );"><strong>Description of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,703,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_AtthemarketOfferingMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_DescriptionofBusinessLineItems', window );"><strong>Description of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,711,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.11<span></span>
</td>
<td class="nump">$ 9.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_AtthemarketOfferingMember', window );">ATM Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_DescriptionofBusinessLineItems', window );"><strong>Description of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_SaleofStockAdditionalAuthorizedTransactionAmount', window );">Authorized transaction amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mgen_SignalMember', window );">Signal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_DescriptionofBusinessLineItems', window );"><strong>Description of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares) | shares</a></td>
<td class="nump">21,309,440.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,024,960.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=mgen_SignalSharesIssuedToMiragenCommonShareholdersMember', window );">Signal Shares issued to Miragen Common Shareholders | Signal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_DescriptionofBusinessLineItems', window );"><strong>Description of Business [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ConversionOfStockSharesIssuedConversionRate', window );">Exchange rate of common stock</a></td>
<td class="nump">0.7031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_ConversionOfStockSharesIssuedConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Shares Issued, Conversion Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_ConversionOfStockSharesIssuedConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_DescriptionofBusinessLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Description of Business [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_DescriptionofBusinessLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_SaleofStockAdditionalAuthorizedTransactionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Additional Authorized Transaction, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_SaleofStockAdditionalAuthorizedTransactionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_PrivateFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgen_PrivateFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_AtthemarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgen_AtthemarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mgen_SignalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mgen_SignalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=mgen_SignalSharesIssuedToMiragenCommonShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=mgen_SignalSharesIssuedToMiragenCommonShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773439312">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Assets and Liabilities Measured on a Recurring Basis (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">$ 44,112<span></span>
</td>
<td class="nump">$ 22,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesFairValueDisclosure', window );">Liabilities, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Assets, fair value disclosure</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosureAbstract', window );"><strong>Liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesFairValueDisclosure', window );">Liabilities, fair value disclosure</a></td>
<td class="nump">$ 82<span></span>
</td>
<td class="nump">$ 133<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6650679584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward', window );"><strong>Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Beginning balance</a></td>
<td class="nump">$ 133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet', window );">Reclassification of preferred stock warrant to common stock warrant</a></td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Ending balance</a></td>
<td class="nump">$ 82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as a liability into (out of) level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774939104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Impairment charges</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense', window );">Income tax penalties and interest expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 225<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84241808&amp;loc=d3e92212-112881<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68055307&amp;loc=d3e2420-110228<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84176398&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773757696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Strategic Alliance and Collaboration with Servier - Narrative (Details)<br> &#8364; in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="2">63 Months Ended</th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Collaboration revenue</a></td>
<td class="nump">$ 1,493,000<span></span>
</td>
<td class="nump">$ 715,000<span></span>
</td>
<td class="nump">$ 1,991,000<span></span>
</td>
<td class="nump">$ 2,479,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Servier Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments', window );">Potential commercialization milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 175.0<span></span>
</td>
<td class="nump">$ 206,700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReimbursementRevenue', window );">Revenue from research and development activities</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Licenses revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">&#8364; 9.0<span></span>
</td>
<td class="nump">$ 12,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Collaboration revenue</a></td>
<td class="nump">$ 1,500,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="nump">$ 2,000,000<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms', window );">Amounts incurred but not yet billed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,439,871.000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNet', window );">Accounts receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum | Servier Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments', window );">Potential development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.8<span></span>
</td>
<td class="nump">6,900,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments', window );">Potential regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.0<span></span>
</td>
<td class="nump">11,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | Servier Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments', window );">Potential development milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
<td class="nump">16,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments', window );">Potential regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 40.0<span></span>
</td>
<td class="nump">$ 47,300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Commercialization Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_CollaborativeArrangementPotentialCommercializationMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_CollaborativeArrangementPotentialDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Potential Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_CollaborativeArrangementPotentialRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivable reflecting the cost incurred on uncompleted contracts in excess of related billings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=68054760&amp;loc=d3e55302-109406<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(c)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(c)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 35<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=68068069&amp;loc=d3e57795-111642<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3)(c)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 35<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68068069&amp;loc=d3e57807-111642<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsInExcessOfBillingsOnUncompletedContractsOrPrograms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReimbursementRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Repayment received or receivable for expenses incurred on behalf of a client or customer, other than those reimbursements received by landlords from tenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 45<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=68075638&amp;loc=d3e60722-111653<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReimbursementRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773219792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reverse Merger - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>shares</div>
</th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th">
<div>Feb. 13, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 12, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares) | shares</a></td>
<td class="nump">21,886,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">833,744<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ConversionOfStockSharesIssuedConversionRate', window );">Exchange rate of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mgen_SignalMember', window );">Signal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,309,440.00<span></span>
</td>
<td class="nump">1,024,960.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_MarketCapitalization', window );">Market capitalization | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net acquired tangible assets | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mgen_SignalMember', window );">Signal | Signal Shares issued to Miragen Common Shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ConversionOfStockSharesIssuedConversionRate', window );">Exchange rate of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mgen_SignalMember', window );">Signal | Pre-Merger MIragen Stockholders, Warrantholders, and Optionholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mgen_SignalMember', window );">Signal | Signal Shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Ownership interest prior to merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">95.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mgen_SignalMember', window );">Signal | Miragen Shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Ownership interest prior to merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.10%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_ConversionOfStockSharesIssuedConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Shares Issued, Conversion Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_ConversionOfStockSharesIssuedConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_MarketCapitalization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Market Capitalization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_MarketCapitalization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of voting equity interests acquired at the acquisition date in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionPercentageOfVotingInterestsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=84160947&amp;loc=d3e2207-128464<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mgen_SignalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mgen_SignalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=mgen_SignalSharesIssuedToMiragenCommonShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=mgen_SignalSharesIssuedToMiragenCommonShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OwnershipAxis=mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OwnershipAxis=mgen_PreMergerMIragenStockholdersWarrantholdersandOptionholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OwnershipAxis=mgen_SignalShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OwnershipAxis=mgen_SignalShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OwnershipAxis=mgen_MiragenShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OwnershipAxis=mgen_MiragenShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6649643760">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Reverse Merger - Summary of Assets Acquired and Liabilities Assumed (Details) - Signal<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Feb. 13, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid and other assets</a></td>
<td class="nump">248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities', window );">Accrued liabilities</a></td>
<td class="num">(1,324)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet', window );">Net acquired tangible assets</a></td>
<td class="nump">$ 204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized as of the acquisition date for the identifiable assets acquired in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=84160947&amp;loc=d3e2207-128464<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84161108&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mgen_SignalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mgen_SignalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773802912">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Components of Property and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 3,386<span></span>
</td>
<td class="nump">$ 3,183<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(2,776)<span></span>
</td>
<td class="num">(2,558)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">610<span></span>
</td>
<td class="nump">625<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Lab equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">2,219<span></span>
</td>
<td class="nump">2,163<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">77<span></span>
</td>
<td class="nump">51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer hardware and software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">361<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment</a></td>
<td class="nump">$ 729<span></span>
</td>
<td class="nump">$ 688<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759216592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 227<span></span>
</td>
<td class="nump">$ 253<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762117488">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities - Components of Accrued Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_AccruedOutsourcingClinicalandPreclinicalStudies', window );">Accrued outsourced clinical and preclinical studies</a></td>
<td class="nump">$ 1,635<span></span>
</td>
<td class="nump">$ 1,684<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued employee compensation and related taxes</a></td>
<td class="nump">1,061<span></span>
</td>
<td class="nump">928<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_AccruedLegalFeesCurrent', window );">Accrued legal fees and expenses</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued other professional service fees</a></td>
<td class="nump">457<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_AccruedLiabilitiesEquipmentandLabMaterials', window );">Accrued equipment and lab materials</a></td>
<td class="nump">156<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_AccruedLiabilityofWarrantsonTemporaryEquity', window );">Value of liability-classified stock purchase warrants</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedRentCurrent', window );">Deferred and accrued facility lease obligations</a></td>
<td class="nump">70<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued liabilities</a></td>
<td class="nump">74<span></span>
</td>
<td class="nump">60<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total accrued liabilities</a></td>
<td class="nump">$ 4,142<span></span>
</td>
<td class="nump">$ 3,909<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_AccruedLegalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Legal Fees, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_AccruedLegalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_AccruedLiabilitiesEquipmentandLabMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liabilities, Equipment and Lab Materials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_AccruedLiabilitiesEquipmentandLabMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_AccruedLiabilityofWarrantsonTemporaryEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Liability of Warrants on Temporary Equity</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_AccruedLiabilityofWarrantsonTemporaryEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_AccruedOutsourcingClinicalandPreclinicalStudies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Outsourcing Clinical and Pre-clinical Studies</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_AccruedOutsourcingClinicalandPreclinicalStudies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedRentCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for contractual rent under lease arrangements. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedRentCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773540816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable - Narrative (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 30, 2015 </div>
<div>USD ($) </div>
<div>tranche </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember', window );">Detachable Warrants - Series B Redeemable Convertible Preferred Stock | Income Approach Valuation Technique | Warrants Not Settleable in Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssumptionsExpectedTerm', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueInputsDiscountRate', window );">Discount rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_FairValueInputsProbabilityofExercise', window );">Probability of exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mgen_SiliconValleyBankAgreementMember', window );">Silicon Valley Bank Agreement | Notes Payable to Banks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_DebtInstrumentNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember', window );">2015 Notes Payable to Silicon Valley Bank - Tranche One | Detachable Warrants - Series B Redeemable Convertible Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Shares eligible for purchase under warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Fair value of warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember', window );">2015 Notes Payable to Silicon Valley Bank - Tranche One | Notes Payable to Banks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Repayment period</a></td>
<td class="text">30 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_DebtInstrumentTermInterestOnlyPayments', window );">Interest-only period</a></td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember', window );">2015 Notes Payable to Silicon Valley Bank - Tranche One | Notes Payable to Banks | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1', window );">Variable rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd', window );">Interest rate at period end</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed', window );">Final payment fee percent</a></td>
<td class="nump">5.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember', window );">2015 Notes Payable to Silicon Valley Bank - Tranche Two | Notes Payable to Banks</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Final Payment Fee, Percentage of Amount Borrowed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_DebtInstrumentFinalPaymentFeePercentageOfAmountBorrowed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number of Tranches</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_DebtInstrumentTermInterestOnlyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Term, Interest Only Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_DebtInstrumentTermInterestOnlyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_FairValueInputsProbabilityofExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair Value Inputs, Probability of Exercise</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_FairValueInputsProbabilityofExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentBasisSpreadOnVariableRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage points added to the reference rate to compute the variable rate on the debt instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentBasisSpreadOnVariableRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28551-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssumptionsExpectedTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the instrument, asset or liability is expected to be outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssumptionsExpectedTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueInputsDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest rate used to find the present value of an amount to be paid or received in the future as an input to measure fair value.  For example, but not limited to, weighted average cost of capital (WACC), cost of capital, cost of equity and cost of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueInputsDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effective interest rate at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityInterestRateAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mgen_DetachableWarrantsSeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationTechniqueAxis=us-gaap_IncomeApproachValuationTechniqueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareholdersEquityClassAxis=us-gaap_WarrantsNotSettleableInCashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareholdersEquityClassAxis=us-gaap_WarrantsNotSettleableInCashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mgen_SiliconValleyBankAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mgen_SiliconValleyBankAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_NotesPayableToBanksMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=mgen_TwoThousandFifteenNotesPayabletoSiliconValleyBankTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762150320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable - Composition of Notes Payable (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Principal amount outstanding</a></td>
<td class="nump">$ 3,167<span></span>
</td>
<td class="nump">$ 4,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Unamortized debt discount</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsNet', window );">Unamortized debt issuance costs</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee', window );">Accreted final payment fee</a></td>
<td class="nump">227<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayable', window );">Total notes payable</a></td>
<td class="nump">3,374<span></span>
</td>
<td class="nump">4,789<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Less: current maturities</a></td>
<td class="num">(1,983)<span></span>
</td>
<td class="num">(1,969)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermNotesPayable', window );">Long-term notes payable, net of current portion</a></td>
<td class="nump">$ 1,391<span></span>
</td>
<td class="nump">$ 2,820<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Accumulated Accretion of Final Payment Fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_LongTermDebtAccumulatedAccretionOfFinalPaymentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28541-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=64930739&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64930785&amp;loc=d3e28555-108399<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of notes payable (with maturities initially due after one year or beyond the operating cycle if longer), excluding current portion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying amount of all types of notes payable, as of the balance sheet date, with initial maturities beyond one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759321280">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Notes Payable - Future Annual Minimum Principal Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear', window );">2017 (remainder of year)</a></td>
<td class="nump">$ 500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2018</a></td>
<td class="nump">2,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2019</a></td>
<td class="nump">667<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 3,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6802200&amp;loc=d3e1835-112601<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirements, and other securities issued that are redeemable by holder at fixed or determinable prices and dates maturing in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04.(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774520624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Narrative (Details)<br> &#8364; in Thousands</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1">36 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2010 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Oct. 31, 2010 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>arrangement</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>arrangement </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>arrangement</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CommitmentsandContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_OperatingLeasesOperatingExpense', window );">Operating expenses of leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorCustomersAxis=mgen_YaleUniversityMember', window );">Yale University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CommitmentsandContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CollaborationArrangementPotentialCashProceedsforServices', window );">Potential cash proceeds from agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CollaborationArrangementTermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds from collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgen_UniversityofTexasMember', window );">University of Texas</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CommitmentsandContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CollaborativeArrangementNumberofArrangements', window );">Number of arrangements | arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_LicenseCostsUpfrontLicensingFeePerLicense', window );">Nonrefundable upfront license documentation fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_LicenseCostAnnualMaintenanceFeePerLicense', window );">Annual license maintenance fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials', window );">Potential milestone payment for initiation of defined clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgen_UniversityofTexasMember', window );">University of Texas | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CommitmentsandContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval', window );">Potential milestone payment for regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgen_UniversityofTexasMember', window );">University of Texas | Other Regions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CommitmentsandContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval', window );">Potential milestone payment for regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgen_RocheInnovationCenterCopenhagenASMember', window );">RICC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CommitmentsandContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_PaymentsForLicensingAgreement', window );">Payments for the grant of license and option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct', window );">Potential future milestone payments per licensed product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,200,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_PaymentstoAcquireRawMaterials', window );">Payments for raw materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgen_RocheInnovationCenterCopenhagenASMember', window );">RICC | Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CommitmentsandContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Shares issued in agreement (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">856,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesIssued1', window );">Shares issued in conversion (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">602,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgen_T2cureGmbHMember', window );">t2cure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CommitmentsandContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_LicenseCostsUpfrontLicensingFeePerLicense', window );">Nonrefundable upfront license documentation fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_LicenseCostAnnualMaintenanceFeePerLicense', window );">Annual license maintenance fee</a></td>
<td class="nump">&#8364; 3<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials', window );">Potential milestone payment for initiation of defined clinical trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CollaborationArrangementTermOfAgreement', window );">Term of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CollaborationArrangementTermofAgreementTerminationPeriod', window );">Period to terminate agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgen_T2cureGmbHMember', window );">t2cure | United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CommitmentsandContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval', window );">Potential milestone payment for regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgen_T2cureGmbHMember', window );">t2cure | European Union or Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CommitmentsandContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval', window );">Potential milestone payment for regulatory approval</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=mgen_TheBrighamandWomensHospitalMember', window );">BWH</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CommitmentsandContingenciesLineItems', window );"><strong>Commitments and Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_LicenseCostsPotentialMilestonePayment', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_LicenseCostsOnetimeSalesMilestonePayment', window );">One-time sales milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_CollaborationArrangementPotentialCashProceedsforServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Potential Cash Proceeds for Services</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_CollaborationArrangementPotentialCashProceedsforServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_CollaborationArrangementTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Term of Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_CollaborationArrangementTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_CollaborationArrangementTermofAgreementTerminationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Arrangement, Term of Agreement, Termination Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_CollaborationArrangementTermofAgreementTerminationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_CollaborativeArrangementNumberofArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Number of Arrangements</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_CollaborativeArrangementNumberofArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_CommitmentsandContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Commitments and Contingencies [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_CommitmentsandContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_LicenseCostAnnualMaintenanceFeePerLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Cost, Annual Maintenance Fee per License</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_LicenseCostAnnualMaintenanceFeePerLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Cost, Potential Milestone Payment, Regulatory Approval</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_LicenseCostPotentialMilestonePaymentRegulatoryApproval</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_LicenseCostsOnetimeSalesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Costs, One-time Sales Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_LicenseCostsOnetimeSalesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_LicenseCostsPotentialMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Costs, Potential Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_LicenseCostsPotentialMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Costs, Potential Milestone Payment, Initiation of Defined Clinical Trials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_LicenseCostsPotentialMilestonePaymentInitiationOfDefinedClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Costs, Potential Milestone Payment per Licensed Product</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_LicenseCostsPotentialMilestonePaymentPerLicensedProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_LicenseCostsUpfrontLicensingFeePerLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Costs, Upfront Licensing Fee per License</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_LicenseCostsUpfrontLicensingFeePerLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_OperatingLeasesOperatingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases, Operating Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_OperatingLeasesOperatingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_PaymentsForLicensingAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Licensing Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_PaymentsForLicensingAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_PaymentstoAcquireRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments to Acquire Raw Materials</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_PaymentstoAcquireRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorCustomersAxis=mgen_YaleUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorCustomersAxis=mgen_YaleUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgen_UniversityofTexasMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgen_UniversityofTexasMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=us-gaap_NonUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=us-gaap_NonUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgen_RocheInnovationCenterCopenhagenASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgen_RocheInnovationCenterCopenhagenASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgen_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgen_T2cureGmbHMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgen_T2cureGmbHMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=mgen_EuropeanUnionorJapanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=mgen_EuropeanUnionorJapanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=mgen_TheBrighamandWomensHospitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=mgen_TheBrighamandWomensHospitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774011152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Future Minimum Rental Payments (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear', window );">2017 (remainder of year)</a></td>
<td class="nump">$ 95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2018</a></td>
<td class="nump">391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2019</a></td>
<td class="nump">404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2020</a></td>
<td class="nump">277<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 1,167<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the remainder of the fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6775062528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - Narrative (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th">
<div>Feb. 13, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th">
<div>Feb. 12, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_CapitalStockSharesAuthorized', window );">Shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105,000,000<span></span>
</td>
<td class="nump">105,000,000<span></span>
</td>
<td class="nump">105,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Offering costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredOfferingCosts', window );">Offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_AccumulatedAmortizationDeferredCosts', window );">Accumulated amortization, offering costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_AtthemarketOfferingMember', window );">ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock to investors, net of issuance cost (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.11<span></span>
</td>
<td class="nump">$ 9.11<span></span>
</td>
<td class="nump">$ 9.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,711<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of stock issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds', window );">Commission fee percent</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum | ATM Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Aggregate offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember', window );">Preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ConversionOfStockSharesIssuedConversionRate', window );">Exchange rate of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=mgen_SignalMember', window );">Signal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=mgen_SignalSharesIssuedToMiragenCommonShareholdersMember', window );">Signal Shares issued to Miragen Common Shareholders | Signal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ConversionOfStockSharesIssuedConversionRate', window );">Exchange rate of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7031<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=mgen_PreMergerSharesMember', window );">Pre-Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock to investors, net of issuance cost (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,045,126<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=mgen_PostMergerSharesMember', window );">Post-Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock to investors, net of issuance cost (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,359,628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_AccumulatedAmortizationDeferredCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated Amortization, Deferred Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_AccumulatedAmortizationDeferredCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_CapitalStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital Stock, Shares Authorized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_CapitalStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_ConversionOfStockSharesIssuedConversionRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of Stock, Shares Issued, Conversion Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_ConversionOfStockSharesIssuedConversionRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of Stock, Commission Fee, Percentage of Gross Sale Proceeds</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_SaleofStockCommissionFeePercentageofGrossSaleProceeds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredOfferingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specific incremental costs directly attributable to a proposed or actual offering of securities which are deferred at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.A)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011391&amp;loc=d3e105025-122735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredOfferingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_AtthemarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgen_AtthemarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=mgen_SignalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=mgen_SignalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=mgen_SignalSharesIssuedToMiragenCommonShareholdersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=mgen_SignalSharesIssuedToMiragenCommonShareholdersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=mgen_PreMergerSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=mgen_PreMergerSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockByUniqueDescriptionAxis=mgen_PostMergerSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockByUniqueDescriptionAxis=mgen_PostMergerSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761558096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Capital Stock - Summary of Series Preferred Stock (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of preferred stock to common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 76,981<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesARedeemableConvertiblePreferredStockMember', window );">Series A</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="nump">7,149,176<span></span>
</td>
<td class="nump">7,149,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">$ 23,124<span></span>
</td>
<td class="nump">$ 23,124<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock to redemption value</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="num">(7,149,176)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of preferred stock to common stock</a></td>
<td class="num">$ (23,125)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesBRedeemableConvertiblePreferredStockMember', window );">Series B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,166,651<span></span>
</td>
<td class="nump">2,166,651<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">$ 12,975<span></span>
</td>
<td class="nump">$ 12,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock to redemption value</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="num">(2,166,651)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of preferred stock to common stock</a></td>
<td class="num">$ (12,976)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesCRedeemableConvertiblePreferredStockMember', window );">Series C</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="nump">9,268,563<span></span>
</td>
<td class="nump">9,268,563<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">$ 40,877<span></span>
</td>
<td class="nump">$ 40,877<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock to redemption value</a></td>
<td class="nump">$ 3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="num">(9,268,563)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of preferred stock to common stock</a></td>
<td class="num">$ (40,880)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward', window );"><strong>Redeemable Convertible Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Beginning balance (in shares)</a></td>
<td class="nump">18,584,390.00<span></span>
</td>
<td class="nump">18,584,390.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Beginning balance</a></td>
<td class="nump">$ 76,976<span></span>
</td>
<td class="nump">$ 76,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityAccretionToRedemptionValue', window );">Accretion of redeemable convertible preferred stock to redemption value</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Conversion of preferred stock to common stock (in shares)</a></td>
<td class="num">(18,584,390.00)<span></span>
</td>
<td class="num">(18,584,390)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity', window );">Conversion of preferred stock to common stock</a></td>
<td class="num">$ (76,981)<span></span>
</td>
<td class="num">$ (76,981)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Ending balance (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInTemporaryEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInTemporaryEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReclassificationsOfTemporaryToPermanentEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the carrying amount of a financial instrument subject to a registration payment arrangement recorded as temporary equity prior to adoption of FSP EITF 00-19-2 and the carrying amount reclassified to permanent equity upon the adoption of FSP EITF 00-19-2. Recorded as a cumulative effect adjustment to the beginning balance of retained earnings. Does not apply to registration payment arrangements that are no longer outstanding upon adoption of FSP EITF 00-19-2.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=65877616&amp;loc=SL6540498-122764<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6445032&amp;loc=d3e90193-114008<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReclassificationsOfTemporaryToPermanentEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityAccretionToRedemptionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of accretion of temporary equity to its redemption value during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityAccretionToRedemptionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesARedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgen_SeriesARedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesBRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgen_SeriesBRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=mgen_SeriesCRedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=mgen_SeriesCRedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_RedeemableConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6776369248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Stock Warrant Activity (Details)<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mgen_CommonStockWarrantsMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightActivityRollForward', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">7,031<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightAcquiredinAcquisition', window );">Warrants acquired in Merger (in shares) | shares</a></td>
<td class="nump">13,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightWarrantsConverted', window );">Preferred stock warrants converted into common stock warrants (in shares) | shares</a></td>
<td class="nump">25,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightWarrantsExercised', window );">Cashless exercise (in shares) | shares</a></td>
<td class="num">(21,092.000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">25,252<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice', window );">Warrants acquired in Merger (in usd per share) | $ / shares</a></td>
<td class="nump">80.70<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice', window );">Preferred stock warrants converted into common stock warrants (in usd per share) | $ / shares</a></td>
<td class="nump">6.21<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice', window );">Cashless exercise (in usd per share) | $ / shares</a></td>
<td class="nump">3.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 47.21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mgen_PreferredStockWarrantsMember', window );">Preferred Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightActivityRollForward', window );"><strong>Number</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Beginning balance (in shares) | shares</a></td>
<td class="nump">25,779<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightAcquiredinAcquisition', window );">Warrants acquired in Merger (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightWarrantsConverted', window );">Preferred stock warrants converted into common stock warrants (in shares) | shares</a></td>
<td class="num">(25,779.000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightWarrantsExercised', window );">Cashless exercise (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Ending balance (in shares) | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Beginning balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 6.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice', window );">Warrants acquired in Merger (in usd per share) | $ / shares</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice', window );">Preferred stock warrants converted into common stock warrants (in usd per share) | $ / shares</a></td>
<td class="nump">6.21<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice', window );">Cashless exercise (in usd per share) | $ / shares</a></td>
<td class="nump">0.00<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Ending balance (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.00<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_ClassofWarrantorRightAcquiredinAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Acquired in Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_ClassofWarrantorRightAcquiredinAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Acquired in Acquisition, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_ClassofWarrantorRightActivityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Activity[Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_ClassofWarrantorRightActivityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Converted in Period, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_ClassofWarrantorRightConvertedinPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Exercises in Period, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_ClassofWarrantorRightExercisesinPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_ClassofWarrantorRightWarrantsConverted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Warrants Converted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_ClassofWarrantorRightWarrantsConverted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_ClassofWarrantorRightWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Warrants Exercised</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_ClassofWarrantorRightWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right Weighted Average Exercise Price [Roll Forward]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_ClassofWarrantorRightWeightedAverageExercisePriceRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mgen_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mgen_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mgen_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mgen_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762723120">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Warrants - Stock Warrants Outstanding (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mgen_CommonStockWarrantsMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Underlying Shares (in shares)</a></td>
<td class="nump">25,252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 47.21<span></span>
</td>
<td class="nump">$ 0.57<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mgen_CommonStockWarrantsExpiring2019and2020Member', window );">Expiration Date 2019 and 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Underlying Shares (in shares)</a></td>
<td class="nump">13,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 80.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=mgen_CommonStockWarrantsExpiring2025Member', window );">Expiration Date 2025</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Number of Underlying Shares (in shares)</a></td>
<td class="nump">11,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Exercise price (in usd per share)</a></td>
<td class="nump">$ 8.53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mgen_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mgen_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mgen_CommonStockWarrantsExpiring2019and2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mgen_CommonStockWarrantsExpiring2019and2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mgen_CommonStockWarrantsExpiring2025Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mgen_CommonStockWarrantsExpiring2025Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763916880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Narrative (Details) - Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">9 Months Ended</th>
</tr>
<tr><th class="th">
<div>Sep. 30, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightAcquiredinAcquisition', window );">Warrants acquired in Merger (in shares) | shares</a></td>
<td class="nump">13,534<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice', window );">Warrants acquired in Merger (in usd per share) | $ / shares</a></td>
<td class="nump">$ 80.70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_ClassofWarrantorRightAcquiredinAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Acquired in Acquisition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_ClassofWarrantorRightAcquiredinAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class of Warrant or Right, Acquired in Acquisition, Weighted Average Exercise Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_ClassofWarrantorRightAcquiredinAcquisitionWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=mgen_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=mgen_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6762781712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding', window );">Equity awards outstanding</a></td>
<td class="nump">908,227<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Remaining equity awards available for future issuances</a></td>
<td class="nump">773,067<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized employee stock-based compensation costs</a></td>
<td class="nump">$ 7.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Remaining weighted-average period for RSUs</a></td>
<td class="text">3 years 2 months 11 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding (in shares)</a></td>
<td class="nump">2,969,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,321,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average fair value per option (in usd per share)</a></td>
<td class="nump">$ 8.32<span></span>
</td>
<td class="nump">$ 0.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares issued in period (in shares)</a></td>
<td class="nump">956,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock | Initial vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percent</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock | Subsequent vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percent</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">36 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">48 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mgen_NonemployeeStockOptionMember', window );">Non-employee Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions', window );">Unrecognized stock-based compensation expense for non-employees</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition', window );">Weighted-average remaining period for recognition of non-employee stock-based compensation expense</a></td>
<td class="text">11 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=mgen_NonemployeeStockOptionMember', window );">Non-employee Stock Option | Non-employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares issued in period (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgen_EquityPlan2008Member', window );">2008 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares outstanding (in shares)</a></td>
<td class="nump">2,060,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=mgen_EquityPlan2016Member', window );">2016 Equity Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Shares authorized for issuance (in shares)</a></td>
<td class="nump">4,182,404<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Basis for equity incentive plan (in shares)</a></td>
<td class="nump">1,681,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares', window );">Number of shares available for issuance under ESPP (in shares)</a></td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Employee share purchases (in shares)</a></td>
<td class="nump">13,193<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Awards Outstanding</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityAwardsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Goods and Nonemployee Services Transaction, Compensation Not yet Recognized, Period for Recognition</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedPeriodforRecognition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Goods and Nonemployee Services Transaction, Compensation Not yet Recognized, Stock Options</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">mgen_SharebasedGoodsandNonemployeeServicesTransactionCompensationNotyetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>mgen_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The shares or units in an ESOP trust that have been assigned to individual participant accounts based on a known formula. IRS rules require allocations to be nondiscriminatory generally based on compensation, length of service, or a combination of both. For any particular participant such shares or units may be vested, unvested, or partially vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=65895303&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPNumberOfAllocatedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=mgen_NonemployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=mgen_NonemployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=mgen_NonemployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedGoodsAndNonemployeeServicesTransactionBySupplierAxis=mgen_NonemployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgen_EquityPlan2008Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgen_EquityPlan2008Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=mgen_EquityPlan2016Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=mgen_EquityPlan2016Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759291232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Option Activity (Details) - Options to purchase Common Stock - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options (in thousands)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,321<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">956<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="num">(274)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">2,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in usd per share)</a></td>
<td class="nump">$ 1.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in usd per share)</a></td>
<td class="nump">11.48<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in usd per share)</a></td>
<td class="num">(0.80)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in usd per share)</a></td>
<td class="num">(11.40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in usd per share)</a></td>
<td class="nump">$ 4.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759225424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Fair Value Assumption for Stock Options (Details) - Options to purchase Common Stock - $ / shares<br></strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term, in years</a></td>
<td class="text">6 years 5 months 9 days<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">83.80%<span></span>
</td>
<td class="nump">84.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.10%<span></span>
</td>
<td class="nump">1.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average grant date fair value of underlying common stock (in usd per share)</a></td>
<td class="nump">$ 11.48<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6759204768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Allocation of Share-based Compensation Expense on Statements of Operations (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 679<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 1,693<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">263<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="nump">643<span></span>
</td>
<td class="nump">22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total share-based compensation expense</a></td>
<td class="nump">$ 416<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="nump">$ 1,050<span></span>
</td>
<td class="nump">$ 107<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763077968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Summary of Potential Dilutive Securities (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities (in shares)</a></td>
<td class="nump">2,994<span></span>
</td>
<td class="nump">15,365<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities (in shares)</a></td>
<td class="nump">2,969<span></span>
</td>
<td class="nump">2,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgen_CommonStockWarrantsMember', window );">Warrants to purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities (in shares)</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,067<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgen_PreferredStockWarrantsMember', window );">Warrants to purchase redeemable convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Dilutive securities (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgen_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgen_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgen_PreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=mgen_PreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6761373120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">8 Months Ended</th>
<th class="th" colspan="2">9 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 13, 2017</div></th>
<th class="th"><div>Nov. 07, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock</a></td>
<td class="nump">$ 40,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_AtthemarketOfferingMember', window );">At-the-Market Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">297,653<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.11<span></span>
</td>
<td class="nump">$ 9.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,711<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,700<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_AtthemarketOfferingMember', window );">At-the-Market Offering | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares sold (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">403,306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.65<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=mgen_AtthemarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=mgen_AtthemarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>70
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M/_QNPBX8N[?_V/@JV#;PZR[:+U!+ P04    "  HD&A+F5R<(Q &  "<)P
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MHS[ZHN@Q3B<0X)L7!A:B5GM@7?FX<[\R,!4JA6O .$,W,:PC2(0B":*@J"B
M3SJ;GD%O MR,O9AN+H)TJ '2H09+!X.\(AU:D X]0#HT1_=4.O00Z6!]4>E@
M?/5)AQ:D0U/I !^775/MJ&?))*%42D%!-*<@I);TUEG1C*C,@(\+R=R#)P+S
M:^G^FXH1^"'.F*I,0':U%]/-15 A354(_ @7AJH"A/KB64LWE" *FAZCP8]Q
M*'J.5I&IY56():B'YM0CP25F1$'Y."%ZUM9X&Q@_("4L*(MFE 4WW]R!NDP%
MB2!B6N!GS? S *X-Y5Z2S^(*J)N-P-":,C0 /IIIAJ)#?%I:7$-U'UH)S&PH
M,T=H'F:&H4GE@T(S_-E0UD6X;DH"G9KK)_&9H6RJ(([#(,03-@3934L@7C/@
MZ#XSE%-UG."'O7,&I@"M<<& 0 5)I''9*>XFCI0OC*01:-HP]PSX1& H PO]
M;Z2GI,QM 'Z89NCQ'D?Q+MX4-&_>?D^+U\VN'#WE595OVS<#+WE>V=J=_ZE.
M=VW3U>DBLR]5\S6JOQ?'-U['BRK?N[=YWNF5XO0_4$L#!!0    ( "B0:$L(
M3I3L,04  ,L;   8    >&PO=V]R:W-H965T<R]S:&5E=#8N>&ULE9E;;^,V
M$(7_BN%WKT0.J4O@&(A5%"W0 HLMMGU6;"8V5K)<28FW_[Z4K'B=F4/O[DLL
M*8?DX>V;D;@\->V7;N=</_M:5X?N?K[K^^-=%'6;G:O+[D-S= ?_GZ>FK<O>
MW[;/47=L7;D="]55I.,XB>IR?YBOEN.SC^UJV;STU?[@/K:S[J6NR_:_M:N:
MT_U<S=\>?-H_[_KA0;1:'LMG]Y?K/Q\_MOXNNM2RW=?NT.V;PZQU3_?S!W57
M6#,4&!5_[]VIN[J>#5UY;)HOP\WOV_MY/#ARE=OT0Q6E_WEUA:NJH2;OX]^I
MTOFES:'@]?5;[;^.G?>=>2P[5S35/_MMO[N?9_/9UCV5+U7_J3G]YJ8.V?EL
MZOT?[M557CXX\6ULFJH;_\XV+UW?U%,MWDI=?CW_[@_C[VFJ_ZT8+J"G OI2
MP+=]JP!-!>A;@7$TH[.SL:N_E'VY6K;-:=:>9^M8#HM"W9$?S,WP<!R[\7^^
MMYU_^KI2BI;1ZU#1I%F?-?I:<U%$OO9+$QHUL=:BN'[?0"$5B<$M$.P$C>7I
M72<"%1A8@1DK,%<5I"D;A+,D'26'4;+0L=()ZPJ0^0&-8^S&0C<6=,?B"A)8
M02*ZHQ0SNCYK[)51K5F?"Z"QA(VDT$@*C+#)7Z>B$97D; D60*1S["2#3C+@
MA$]Q)AK)+/,A)4H'IB:'/G+@(V,^<M%(S&Q(A<8F5(QW?0QLY'S;Q]_U 22!
M65$!_"BYUG5@LRB(EP>E15_XKEQ/FFN?BT3QR46J4'<PB!3)<=6*FR'93,I'
MOT J:P)K36&L*<DUI?G^FT0WIUE*%H9"0X.AIJSP0B+06-#G/.-ND"I+ FXP
M(95$)!GN1N)OD:6*NY&J+ ] 4F%**H!)+<9&(M 'H%P;[@?H?#1,LH EC$N5
M@7T9"*D*DTX!U&G+>R5)IG0FUM\M(K[/0##O-."=@(26,%MH'JX*J#(A.YAZ
M6@$[/!I-HEO[$DA4K$)>,#ZUQ*>? >Y%DE'%"=^80+7P4Q[R@Q&J03(7"O4:
M8T\#[%',N_1][ &)2N(\E/QB[FG)/44\)&B -&5C84C*0H.+L:=!9D@\(&B4
M&@HK4A2R@J&G ?1$0- @[U/"BA2%K&#8:9 <BFB@9>IG8FMYR@QD?LUDH36#
MT:D!.HFC4X,D,$YC'I^ C"@)!"C"^"2 3^+X) E&K57,XQ.2^6@72&P( Y0
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M_F5C_VM$!U[*YLJ/4.L_V&Q(J%TXWOBS&<=L-!QVTP]B\S<N_@!02P,$%
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M_0>;# 6E"\>]/YMAS ;#83O^(#9]X^PO4$L#!!0    ( "B0:$O3< 8!M0$
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M_=G,8S8;#H?T@]CRC<M?4$L#!!0    ( "B0:$N0/T;@M $  -(#   9
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MSR=<<J.4!6<EN7->.C?%:R"@L7[[T>WU_);GP*IA&5.R_E>4?P!02P,$%
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M.#Y@<S:53;JC<-],\\ID+R7>1SFZ6*(9<_08O,+$"P(9]D4";TD<\5TYWG]
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M)RCR/:?^JSB)W,!M)2;'1N:J^?<V1Z5EX5A,*05_:Z]9V5S/[9.8N3 X@+@
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MZ$[O;J!XV]],O.%ZE/T#4$L#!!0    ( "B0:$M"_9Q<" (  (P%   9
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MQV6SNV].I#BT;RY.]_HT_P]02P,$%     @ *)!H2^!Z$ITR @  #P<  !D
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M,'<"2"(N",6,(87)/$: !7.;,Q\CAP0,J3L&O*H(A,T84G?LAKIC2-TQZ,W
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MCK-@J!BLJV>#^B3$ZSE:S[MZ/JA/0V<0/23N(%4'B:,T<13?0]02YQ&B/$+
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M(4ZJO8WU?=T?I?4/2E[-,6'P.*O<_ ]02P,$%     @ *)!H2]0,"O<* P
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M)-XTB2=-,DO38[))FCA=1&1F^2TJ7"2I7\O2JV7IT;+T$Z1>@O1QTS,O0?:
MZ=F-Z80F-/:G67G3K!XP?75C9Q8N[MA)0G\KA9X\]RCN="-YW%+B;R7BZ:4;
M4P?0E:LD)7=:COA[CM '?!U 5\8NDF@U_<RRXLG992^3'TR>JD8%.Z'-,>@.
MJZ,0&@R]>>514)K[:YQP.&H[3,U8]H=X/]&B'2XH/-Z2Q3]02P,$%     @
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M<^D?M%]H,<R]BI<?1OD'4$L#!!0    ( "B0:$L@X?N&K@,  (,1   9
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MTX+!29GI6L_%T!V'A>+=V/C)]/?)_P)02P,$%     @ *)!H2P42&/1J @
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M$"5(2:JJE5HINJK7WP[9!'0&4]L)U[>O;0B7@&FY/\$VN[,S$Y9EU5#VRG,
M8;V5I.)K.Q>B7CH.SW(H,7^B-53RSHFR$@NY96>'UPSP42>5Q/%<-W)*7%1V
MNM)G>Y:NZ$60HH(]L_BE+#'[LP5"F[6-[-O!<W'.A3IPTE6-S_ #Q,]ZS^3.
MZ5&.10D5+VAE,3BM[0U:[E"D$G3$2P$-OUM;2LJ!TE>U^7I<VZYB! 0RH2"P
MO%QA!X0H),GC=P=J]S55XOWZAOY9BY=B#IC#CI)?Q5'D:WMA6T<XX0L1S[3Y
M IV@T+8Z]=_@"D2&*R:R1D8)U[]6=N&"EAV*I%+BM_9:5/K:=/BW-'."UR5X
M?8*L_:\$OTOPWQ,"+;YEIJ5^P@*G*T8;B[7_5HW50X&6OC0S4X?:.WU/JN7R
M])J&?KARK@JHB]FV,=Y=#.HC'(G>E_!,);;>*-U[++ ;1T2!N8)O%.'K?/]!
M1&0&"(P @08('@#B@0MM3*ACJE9&D@0#)>,@)*F$9BZAD4LXXA(L)L1$1H!H
MOANQ$2">X49L<"-*!FX8@KPI,Q9&*@L#E849(#$")//-0*ZY0]P9=G1!#U('
M;;0SQ,033"9Z%8T?C60"P=B*&^1]P YSKR%_CAW^2*H[=&,<@GPWFG+$W+?(
MU+A3EIC;#84?L,3<<"B:8TGT?TO&(=Z0B7/W8B^!G?4,Y%9&+Y50K]"[TW[.
M;CPU& ;G6S5_]<!XAVF']W?,SD7%K0,5<NSHX7"B5("DZ#Y)<KG\7N@W!$Y"
M+6.Y9NW0;#>"UMT'@=-_E:1_ 5!+ P04    "  HD&A+R)PA-I,"  !Y"0
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MN0FA)80= :)_$B)+B.XE($M ]Q*P)>![";$EQ"-"T&Z6V?TUD62UX.SB\;:
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M5-7%O^?S'Y/I)+VX.$M/SRYH$Q?'Q^GYR8D^630-GBFAL[_42=8F0$K;?/4
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M6W*!%D_$:E.CD?.7=/-<B'.&\<0+MO44*ZVOKD89AW0<RQU.2J5:0AK5V,P
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M#U/AW\+F3?DS/?$@*=:$(45LM%O29<F3X3@/P% I\D S2O$S5>>$[7O2YZM
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ME_-G!*C$C>AEZH:J_',&AQ_73N$$%-3-9.6#D2X]KZ/@MRP>"PF>E#HQ0<F
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MO;Z> J,)DFUK/YCZ&177JTC)(T:U7M7>>S:Z^(?$)?*YB2MLPSH"$CA45FV
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MW-)E10>ELA.FD(1,XBM*55S4R0-"*G2F=G,>NEPMC0$\P/?"FFX"FZ:GW--
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ML?JO22N(."R+ ,6>:,3+(#,5G;6&(F@L8HS3UI*P)0- A4F2]8U4 "OC[&!
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MMXUC9* TFWSN.$@ $-(*PIOB+1L!&9!2$!HAY.S!>C2HH+CMQN7/;1E+8TE
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M'9^-YW;5:0RUY\B>:.P9CTWJFH30(0JM.$2M6O0P319A'  ],]Y'Y"(YBRZ
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M]/MV(Q5E"0_)/[AX$31U0<2^+KVJ4!B)1V\$0/Y] 2-BR !8&"33'[X'XSX
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M&!*2,WUII^B<(:[;%U:X*7'+4=<5(L1U^Q/$-.?NRA74U_KY+U!+ P04
M"  HD&A+V SR<"H$  "=)   #P   'AL+W=O<FMB;V]K+GAM;,6:2V_;.!"
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M"PC+IJKNXKX?YM'*[IN;MHW]YT+7_P%02P,$%     @ *)!H2V4-O+_] 0
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M8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  HD&A+Q0BFM.X    K @  $0
M            @ &9 0  9&]C4')O<',O8V]R92YX;6Q02P$"% ,4    "  H
MD&A+F5R<(Q &  "<)P  $P              @ &V @  >&PO=&AE;64O=&AE
M;64Q+GAM;%!+ 0(4 Q0    ( "B0:$L?\/<L5@(  *\'   8
M  "  ?<(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4    "  H
MD&A+F) >F\D#  #R$0  &               @ &#"P  >&PO=V]R:W-H965T
M<R]S:&5E=#(N>&UL4$L! A0#%     @ *)!H2V_TDB;E @  . P  !@
M         ( !@@\  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0
M   ( "B0:$NTJG[-XP,  !H1   8              "  9T2  !X;"]W;W)K
M<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  HD&A+'W&JBU(%  !>'
M&               @ &V%@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L!
M A0#%     @ *)!H2PA.E.PQ!0  RQL  !@              ( !/AP  'AL
M+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( "B0:$NB\;#]L0$
M -(#   8              "  :4A  !X;"]W;W)K<VAE971S+W-H965T-RYX
M;6Q02P$"% ,4    "  HD&A+"2TA%[0!  #2 P  &               @ &,
M(P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ *)!H2^0T
M.1VP 0  T@,  !@              ( !=B4  'AL+W=O<FMS:&5E=',O<VAE
M970Y+GAM;%!+ 0(4 Q0    ( "B0:$OZF4!<M0$  -(#   9
M  "  5PG  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @
M*)!H2PP.0XFR 0  T@,  !D              ( !2"D  'AL+W=O<FMS:&5E
M=',O<VAE970Q,2YX;6Q02P$"% ,4    "  HD&A+I=H\0;0!  #2 P  &0
M            @ $Q*P  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4
M Q0    ( "B0:$MRR\FBM $  -(#   9              "  1PM  !X;"]W
M;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @ *)!H2]-P!@&U 0
MT@,  !D              ( !!R\  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX
M;6Q02P$"% ,4    "  HD&A+GY*UAK(!  #2 P  &0              @ 'S
M,   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( "B0:$N0
M/T;@M $  -(#   9              "  =PR  !X;"]W;W)K<VAE971S+W-H
M965T,38N>&UL4$L! A0#%     @ *)!H2T<PTUFU 0  T@,  !D
M     ( !QS0  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( "B0:$O##KUBM@$  -(#   9              "
M 4$_  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ *)!H
M2SGP+J6X 0  T@,  !D              ( !+D$  'AL+W=O<FMS:&5E=',O
M<VAE970R,RYX;6Q02P$"% ,4    "  HD&A+#3%G<;8!  #2 P  &0
M        @ $=0P  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0
M   ( "B0:$M):E*QQ0$  #<$   9              "  0I%  !X;"]W;W)K
M<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ *)!H2RW,"M6X 0  T@,
M !D              ( !!D<  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q0
M2P$"% ,4    "  HD&A+M3\#4+8!  #2 P  &0              @ 'U2
M>&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( "B0:$NW,,'Q
MM@$  -(#   9              "  >)*  !X;"]W;W)K<VAE971S+W-H965T
M,C@N>&UL4$L! A0#%     @ *)!H2\"^ZB_4 0  G 0  !D
M ( !STP  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    "  H
MD&A+?V[W\;,!  #2 P  &0              @ ':3@  >&PO=V]R:W-H965T
M<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( "B0:$M7K)BD\ ,  !D3   9
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M970S-2YX;6Q02P$"% ,4    "  HD&A+IR)=WM8"  "0"P  &0
M    @ &K7P  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (
M "B0:$O@0IHST@$  (H$   9              "  ;AB  !X;"]W;W)K<VAE
M971S+W-H965T,S<N>&UL4$L! A0#%     @ *)!H2[_O1,)S @  *@D  !D
M             ( !P60  'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"
M% ,4    "  HD&A+0OV<7 @"  ",!0  &0              @ %K9P  >&PO
M=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( "B0:$M_Q )L6P(
M " (   9              "  :II  !X;"]W;W)K<VAE971S+W-H965T-# N
M>&UL4$L! A0#%     @ *)!H2TD(F800 P  2@T  !D              ( !
M/&P  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4    "  HD&A+
MX'H2G3("   /!P  &0              @ &#;P  >&PO=V]R:W-H965T<R]S
M:&5E=#0R+GAM;%!+ 0(4 Q0    ( "B0:$N#9UT0SP$  (P$   9
M      "  >QQ  !X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%
M  @ *)!H2X1V5L6<!   N!D  !D              ( !\G,  'AL+W=O<FMS
M:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  HD&A+=]#;Y^,!  #P!
M&0              @ '%>   >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+
M 0(4 Q0    ( "B0:$O9W"]K5@0  .,6   9              "  =]Z  !X
M;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ *)!H2S7*LFD=
M!   MQ0  !D              ( !;'\  'AL+W=O<FMS:&5E=',O<VAE970T
M-RYX;6Q02P$"% ,4    "  HD&A+U P*]PH#  #=#   &0
M@ ' @P  >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    ( "B0
M:$O^L%U4- (  #$'   9              "  0&'  !X;"]W;W)K<VAE971S
M+W-H965T-#DN>&UL4$L! A0#%     @ *)!H2V[&C7_1 0  / 0  !D
M         ( !;(D  'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4
M    "  HD&A+(.'[AJX#  "#$0  &0              @ %TBP  >&PO=V]R
M:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( "B0:$O5Q-B;@P(  $\(
M   9              "  5F/  !X;"]W;W)K<VAE971S+W-H965T-3(N>&UL
M4$L! A0#%     @ *)!H2Z5PG',I @  B08  !D              ( !$Y(
M 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    "  HD&A+!1(8
M]&H"   T"   &0              @ %SE   >&PO=V]R:W-H965T<R]S:&5E
M=#4T+GAM;%!+ 0(4 Q0    ( "B0:$O!:T,9:@(  *$(   9
M  "  127  !X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @
M*)!H2\B<(3:3 @  >0D  !D              ( !M9D  'AL+W=O<FMS:&5E
M=',O<VAE970U-BYX;6Q02P$"% ,4    "  HD&A+N[H1&,R#   ^$0( %
M            @ %_G   >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4
M"  HD&A+-IQG(I4"  #C#P  #0              @ %]( $ >&PO<W1Y;&5S
M+GAM;%!+ 0(4 Q0    ( "B0:$O8#/)P*@0  )TD   /              "
M 3TC 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  HD&A+90V\O_T!   -
M(@  &@              @ &4)P$ >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    "  HD&A+5=WD$-D!  "^(0  $P              @ ')
L*0$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     00!! +D1  #3*P$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>154</ContextCount>
  <ElementCount>263</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>62</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1001001 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002000 - Statement - Condensed Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfOperations</Role>
      <ShortName>Condensed Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Condensed Consolidated Statements of Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfPreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Condensed Consolidated Statements of Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1004000 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/CondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/DescriptionOfBusiness</Role>
      <ShortName>Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Strategic Alliance and Collaboration with Servier</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/StrategicAllianceAndCollaborationWithServier</Role>
      <ShortName>Strategic Alliance and Collaboration with Servier</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Reverse Merger</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/ReverseMerger</Role>
      <ShortName>Reverse Merger</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/AccruedLiabilities</Role>
      <ShortName>Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.miragentherapeutics.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Capital Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/CapitalStock</Role>
      <ShortName>Capital Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2135100 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2302302 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Reverse Merger (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/ReverseMergerTables</Role>
      <ShortName>Reverse Merger (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.miragentherapeutics.com/role/ReverseMerger</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.miragentherapeutics.com/role/PropertyAndEquipment</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/AccruedLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.miragentherapeutics.com/role/AccruedLiabilities</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Notes Payable (Tables)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.miragentherapeutics.com/role/NotesPayableTables</Role>
      <ShortName>Notes Payable (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.miragentherapeutics.com/role/NotesPayable</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.miragentherapeutics.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Capital Stock (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/CapitalStockTables</Role>
      <ShortName>Capital Stock (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.miragentherapeutics.com/role/CapitalStock</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.miragentherapeutics.com/role/Warrants</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.miragentherapeutics.com/role/ShareBasedCompensation</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.miragentherapeutics.com/role/NetLossPerShare</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2401401 - Disclosure - Description of Business - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/DescriptionOfBusinessNarrativeDetails</Role>
      <ShortName>Description of Business - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Summary of Significant Accounting Policies - Assets and Liabilities Measured on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Assets and Liabilities Measured on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Summary of Significant Accounting Policies - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesFairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/SummaryOfSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Strategic Alliance and Collaboration with Servier - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/StrategicAllianceAndCollaborationWithServierNarrativeDetails</Role>
      <ShortName>Strategic Alliance and Collaboration with Servier - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.miragentherapeutics.com/role/StrategicAllianceAndCollaborationWithServier</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Reverse Merger - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/ReverseMergerNarrativeDetails</Role>
      <ShortName>Reverse Merger - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Reverse Merger - Summary of Assets Acquired and Liabilities Assumed (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/ReverseMergerSummaryOfAssetsAcquiredAndLiabilitiesAssumedDetails</Role>
      <ShortName>Reverse Merger - Summary of Assets Acquired and Liabilities Assumed (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Property and Equipment - Components of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/PropertyAndEquipmentComponentsOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Components of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Property and Equipment - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/PropertyAndEquipmentNarrativeDetails</Role>
      <ShortName>Property and Equipment - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Accrued Liabilities - Components of Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/AccruedLiabilitiesComponentsOfAccruedLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities - Components of Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Notes Payable - Narrative (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.miragentherapeutics.com/role/NotesPayableNarrativeDetails</Role>
      <ShortName>Notes Payable - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Notes Payable - Composition of Notes Payable (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.miragentherapeutics.com/role/NotesPayableCompositionOfNotesPayableDetails</Role>
      <ShortName>Notes Payable - Composition of Notes Payable (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Notes Payable - Future Annual Minimum Principal Payments (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.miragentherapeutics.com/role/NotesPayableFutureAnnualMinimumPrincipalPaymentsDetails</Role>
      <ShortName>Notes Payable - Future Annual Minimum Principal Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Commitments and Contingencies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesNarrativeDetails</Role>
      <ShortName>Commitments and Contingencies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2408403 - Disclosure - Commitments and Contingencies - Future Minimum Rental Payments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/CommitmentsAndContingenciesFutureMinimumRentalPaymentsDetails</Role>
      <ShortName>Commitments and Contingencies - Future Minimum Rental Payments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Capital Stock - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/CapitalStockNarrativeDetails</Role>
      <ShortName>Capital Stock - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2409403 - Disclosure - Capital Stock - Summary of Series Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/CapitalStockSummaryOfSeriesPreferredStockDetails</Role>
      <ShortName>Capital Stock - Summary of Series Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Warrants - Stock Warrant Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/WarrantsStockWarrantActivityDetails</Role>
      <ShortName>Warrants - Stock Warrant Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Warrants - Stock Warrants Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/WarrantsStockWarrantsOutstandingDetails</Role>
      <ShortName>Warrants - Stock Warrants Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Warrants - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/WarrantsNarrativeDetails</Role>
      <ShortName>Warrants - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Share-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Share-Based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/ShareBasedCompensationStockOptionActivityDetails</Role>
      <ShortName>Share-Based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Share-Based Compensation - Fair Value Assumption for Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/ShareBasedCompensationFairValueAssumptionForStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Fair Value Assumption for Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Share-Based Compensation - Allocation of Share-based Compensation Expense on Statements of Operations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/ShareBasedCompensationAllocationOfShareBasedCompensationExpenseOnStatementsOfOperationsDetails</Role>
      <ShortName>Share-Based Compensation - Allocation of Share-based Compensation Expense on Statements of Operations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Net Loss Per Share - Summary of Potential Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/NetLossPerShareSummaryOfPotentialDilutiveSecuritiesDetails</Role>
      <ShortName>Net Loss Per Share - Summary of Potential Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="mgen-20170930.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2435401 - Disclosure - Subsequent Events - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.miragentherapeutics.com/role/SubsequentEventsNarrativeDetails</Role>
      <ShortName>Subsequent Events - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>mgen-20170930.xml</File>
    <File>mgen-20170930.xsd</File>
    <File>mgen-20170930_cal.xml</File>
    <File>mgen-20170930_def.xml</File>
    <File>mgen-20170930_lab.xml</File>
    <File>mgen-20170930_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>76
<FILENAME>0001590750-17-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001590750-17-000010-xbrl.zip
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MEO]ZE[_OWGY=N+8^&[7:7Q,!9T\,/\#[LJ'=>EG,\27#I=S4E:2>7=C'T_I
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M9_VOJ<O&?/AA.&)+3"_2$MWAP*]7_B(.="<QOB5K;]$8/4WO3P+T9NL _0_
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M#M0:\&^T446G.N;>H-I0C16^S;84&/1O/\Y"1HL-XL6$DW=?*@'&'6>8:"I
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M8A/8?/F1\\+I5<02KPD^/V(M;278F:W"]_MN&D\&/Z1;_0YX#6@]\0R/,I!
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MEV(@UA0E%' 'R1)!UQ%MF;R3+6OA>SM+2-ENKY<Z5=_U/Z6Q3VG,=#;QS7.
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M(G$UE;XE5'L@\J8?!^,\Y3=W['"@ O0]TTPA M8;I8'*THNFICZ1E,B]4%J
M;R_L)GGY/= +E O)F0>C3J0]Y>"SE+6BF-8+9!EB^Z$W!W __/X<[(%=FODD
MN8[ 9HP$Z=/<IS)>C^NE ]7,[L[@[8K; >H%/+,QA.B!00T/ELF@BDOGK*RW
MS6N^,XH;ZP2F_;2U/O6]+&PCP18$V2&)Q$Z '4C*PE@E13TY6^G460_*8X!>
M6X?#C9:IXA.\*(ZCM4*5?2\.9';CW.+]@9YT+J<0QSX$%I8+#4PBM402KD4:
MNU!$VRDA]<KC2CMM(PA[P+B6GA* 9#8$ G:CLBP$6^YWHXHU%\'L"N("I?>E
M92""2Y#X1###C50.D6)6@B&\[JA686P$85] UR_6P4X)Y<&*9&"8H1!+2<BH
M#?5<;&4LQ7;0WI0U1I/P:=JA62Z,J55E%SMJ5Y?BI@T>D4GG++A48%%R72ST
MP-206NZAUL>P#IR]P&ZJ0OXP_CSL=KJM_.%#JY?5=IV:$5#N;E(U4BRFV9 N
M8DP30X0$RU0Q8JRU@=(T, R#/"1XW;"P<T#X)N]^:XVRLI)B [:!:>2Q]H8B
MXBU!&I5#65E*G9XYMA^^9KTO[[/;V6C"07\#NDY;&7@R':/@(B! DG*NK$VC
MDX5;5WKTQ.@63VR8AKS:.0"_FG,&TE((R:BCR629^30:%&=CX\"QL:^F?P]]
MEX-SF(? 8V"$P;\J&1W<912C,I;6IW=B2<X.ZQTOM$AKT'0,P.G>.I#;3A5A
M !EY0SR*8'%V..]ZK0DSBAN:>G4Q"X!E&HB6KC7FD@5:'QF@]3GA_-B[#<<=
M0",C;DTD,>T7*FN695I@=4"I]G$PR>F!C])0B;ESS(JS&*@3TC)X5AM&HRV[
MF3P6M=@?1BO$TEJP#H#'IA9**7G:[$<]CQZN&;:Z["8,*FZC5O;'X"9/Z:G1
M0]IMD6;7I-J9^[N:B;I-L;)RABL,CHD%$RA:'F(1C5!.U-OGIMUS:W!9"=JA
M$-HTTTJ /<,D2#@-(H*X2,LDL*(1U6/+N%G^[XC0TMU-?N5D^=B[+VFGP735
M0O-ZSFV2F9YCZ5(IF8XF6.)!W!5)&Q1PX\[8!7RVA^S "!VWQ,L1[5.6EZ"
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M>3>PJ3?S^'63(..%U6Z+ED_XV!+]<RHMG,DV63H*'Y]+9%B1I&!U":7]J>(
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MY[A:X'?K/2Z\;7+BVX8QH]8D;+)B]X8(R1D01!9!7N(F$>:",#.+CB58>B]
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MZU+$/3(-LO.2_C'9L_.RSCSLTQ,#,HKU7?[F@HD0=\M9GHXT)L&^@R42<QY
ME/HFA#(;NB_W23Z37'B3H8?A-:KO@!)?(NP60:SEU=HE.U-5T3D$QHES(!@8
MYSR,$SF4(+.+L8J6L$A=X>"QBL#\>A,^=B!.HI3AWA^H!_:2Y)SH9S56=^X
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M^$/HD&)?(5I[B369K7#K_E<0287*@#P$;H2/H*>A3,E+??^"CC-7^)\OKQ/
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M=@79$W*Z=(%H(VY>&;UCA3JQ%#YX\(-G5TCJDY&_0<AU62'+[O+I#%6$.17
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MJ6=K.'R"MG=I#!(Z)DRD,K06>434/3;W060YQF1,R.(.&V.K"F $SJJ#<;.
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M2*_]Y^P'_AQX-8T&_6"\\]Y7P"-PM(.9>^,%-/)<X%0LEVZDF"LP2>^\74_
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MF5=_IG?&+YXF?]$&X0=H64&_9T7&/22+=K87$34'GB4'U@C@S\66-0#X:P<
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M81R4KGI9#?$-MA6Q7]BBV!OSPKAKQ_<-SV!KX0N3GU'6C"H8%CI#*Q=%(81
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M?5%EOL3C[,O64NU^)0; 7>IY_E"B=K 0J14C]-2@BOKL4B< 9EEXB,W;!IM
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M]DQI6[QE(FS?>!1.)'$.4IC3'!T,H*%XHADJI6<!M?!*(H\1!?%S+AUP7<_
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MT8P8)J(#Y&C9\= 6/DE[6_K<%C#$1"K@V62=P55%%#/5GB&8QK!&6YKWU=V
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M<C+Q?! 96)[UJ[NB:1K&6 3PPFA.+A8X-Y&FAKHTH[G>I\3'CS3SAIXG>!G
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MST/-0>AM#9CXPX!R\X^__!]02P,$%     @ *)!H2V-,_S4G8   R[($ !4
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MDGGL#2VT:6RUD*5"A35FS0/'.[\5'(TJG:$5<P_*EMMAGXTE>_9H0B'T4NA
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M%V2$(2-="B#K&J!X1MJEL0,U6R84 ZZ4+Z[+ TN]X J[<KY:P!'6@^F!$/V
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MF@65=5NRY&'DG[/NEI<^7A<L,&0A(,B1XE8/UD65WA)9ZV1S5:0W33,B"4>
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MM=B*3Q0.=0#A^'2>3G2=! E,@3,4(:(E09 B5Y[O$ -<<^]@;R9[1"+UAN/
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MOU=WA5!6[D>:3^>KDZGISK9-BH-? Q'&D!!A.3#Z 40L$&S,E-Y.NP9:8KJ
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MW2PFZW1FT[L\G<ZW5TK#SXMT*Y/E3-UF^7K^K^V_'YWC"0YU]8H$.L:<0C:
MA57XG"0L4WAIYZ!RKT@Y:<^V@5 =?,7ZD)[BVJEF"<=(4*<Q\$QJ[HDF I<S
M1<@VOXL37Z?I<;6Z'*F8)U"'SEMJ5I^+<#(4\TSL8_H]S5?I;VG^]8%"$5\Y
MFII_>K,*7\-JI:9!#*MRAF</NDXU2PPGR@(AD$#08:HA4OM%45FBZQ6PZ/N(
MZ\ $5OK^T=_J'W75ZRHA$&F I/0<6Q.LGK [[$-NE0E+4,RT[2>/O+H1[='#
MKE[0&O6AUX$9GSGH.M(BL<5U3V9AV%,$(!@C26T)2M"0FP>[1SO<ZEKZ61_
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M>98W?SY]B&=K6B+)W2Z0,4Z1 \P[*X3"6!M(8*TT"4:T59\X_;P :4[1-B7
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M)5EB^)8(1[:V4CK>2OSKTZ;*__ZW_P-02P,$%     @ *)!H2]"NN>_@MP
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M1J[;2W(CUO'MT2+7]7L<,TWC/&'A0O=78VL9 J"(O3#17N1$X*]95>?[N[;
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M=)V7?UWO#MG*]:GKNSZ&!!$6)4%*D^&Z1L82L5< EXK=<D(: ()UAQ#<-LC
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MIIN;G 3]=5WFW-;'==U55C!PW9#".$!NG$(,$^; P0QU4JD;!:6_W++@#'@
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M_I9.L6_?ZVNTJD=[NN-+]?T'&S$1T[7%A$-._T[?A1B #W+8;L-[)3C]TQ"
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M?[K%9UF:?Y+%9VES5!>?U7@:D+3U'/<XW>&+HY2D(4L8]6#$,2#JPA9/RMC
MY6A3*&PO4+_MCML"=2JD@Q,.4[[03O4F<(.I>H\KOC%<!F+,58,SQ@E<9CB/
M-.6Z(2FF'(MJB:=AS\PV'35MY_4DU0JS@U+75QBZ;Y;-=TMO$01QQ.* (TF
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ML ;3<]91'7.DQ%";)ZD.?:2ZSK5:FFI[,C4E'G&2L"CR$QRZH9<B/TQQ<\P
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MIU1>, VZ9Y8*:M*^?DDUSJ2FQHK+ S.Q.?JU$!.CIV?Q]=^6FX/H+T6"E"!
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MI6I$70J"MOB>0;2S9EHQPO-J<,NC^F^R+,4M54^BP7?]&KHAX3$S]A*&$"+
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MFWY&^/BX[Z6?-R1$"UWW(^^Q3#^FCWXD:,;\PRW;'^W[(MUY%+\5L\_%[-
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M4F -H8!'KU<BQIF065D)?HCC][8A[D0%50^L3G\MIZN/UF[H*3II7W\!8J.
M 818@P!A6$H+MSN\]UG/>7Z<8_6>X._6T\ORZP)2"&'!!:1,V%0(P^L:-\^9
MR2FU"'_(<_+6L&Z%-5?38E'>%1]&<2BG$&=?^P ,3D?\ADFKI(=8"E&?=WB(
M5!9W?IS3\H[@[LM46J4M5-.;=;)Z]^?]CHB%O=\'R['TE#%*!()"&:!A;09Z
MY466T?U#G8.W >_)FN=)+LOM7W>SHDFSH+T5#&/L'!0>JVCIL:W>))1DA>;^
M$.?7':#\P)&S)Q@]<XVL\Z05]2"Z-88:AZBEBJ-( +E.!RNX@;I1*MZ.;E+'
M7XJ;Y:2XNMU3S,17LR=\;%R)JY7^ _&0&Q_)S1U!RFA+&*SQ<Q)>6&:,CKCU
M] [V##/3OQZ*:B7=Q,0_S*M)>3-:%#=Z-$E!@!^^%,7B?(IH^_(TE2))48G1
M![FNYN6*GH?U3Y/F@4D#$;+,4:&P )HB1G&D! %>2XOA&=5./?Q=J8Y?_C"2
MG2HHB,"6&:&Y9M&VKB6B3EU:8I16)WG7P_93D'V=^1"HA-((#@$E$!'(!46D
MEE%8>&$/E4^=X,8)$(Z#\]4D0&"4:4F))L *C#VS3-5202\O[&EA"[/;( '"
M49"^O@0(G C#@5-,(R60]@P+^+"TFE4->#V4R9G@K 0(Q\&<22/=$HV:]Q.4
M)EQ+2!2BQ"EJ<+2CMRL.^)RZ00.ZRNZ&1IW!G$DCTQ*-FO<3O,' <Y_>4AHA
MTKTJP;5\!&35_QC0_74W-.H,YMX-YK=[7M/O_C@8B7%T'XA55,8_(.B8W"X.
M0RZL[F/;)O*I./;%#C6?%XMY@^.%[S\,@FD-H?7,62H)M"8B4TOC&;M4F_B$
MZ:Q:Q+%?5ICE+('3F!Q/O@\&0L6A5E)&[4> ,-K;C6S&&GQA9[2G3NR+_,B#
MLC?'>C3_DLZCXW_</Y?EU]%D=4*],*/9[%LY_?SOH\G>NH6-V@?E(8*$0PEQ
M' 83%&]76H0%9H4I#)5&)\__4]>[ X1[4T+C5?+F^?MB7,21Q^WX7;'8 +-/
M%^UI%ABA'EF/M)$6..Z%8>O]' *(/+\P8Z9=+K4(;']QP,7]J+S97)''A7"5
M;H6^@V5O1/#!UD%:+[G%CBGF+506,01JN0'!.>F!!NA:M4NH]O$]BWW4U"X*
MQD2U:K74DL716R0XM[4L5,B<C>SXF-_.R^^VK'PRD.SQU<%],5M\NYZ,HL33
MF[3CWJ_27!7[U<SN9@%[(CB,I!=$0T:PI&#+?V]83LGFP6Y8V39TBXCVQ9U'
MJN]=-1T?U"PO?A\D1X8:I@U%-.4O2CD@:]GBAGR1NU$V6]J LM^-Y^".$XBU
M6&#,HNC(,0XDD*@>?80HY\1WL%M-2Z[WD=CU%J==CCZ5DW*1+LBFZV/G+]4D
MSL@\:;?%MP:G-$V[" !9'!5D4HQ:: D-(/7VB@"".:D!!KCIM'BXUQ'"9^!8
M\[._W8V"X(A0JY!.#QX8-=@)54M)F<K*%3 \'K4_^;O9E8=TWR<XUZ-OJ_NS
MQF<WWS<(#'D5?04NF90"&ZR,XK5TJ9K7Q?+HY&G><723A6N/K)DMXVP\@V$_
M<5YN$Q>;$UY*J>/2(HQ9AA6K9>3>Y5A" ]S+NN%.*]#V19]WU:)HKG%>^#H0
MZ8W"GA+H$!?4:&;D5B[B<H)"!^A%=4"9?%#/9_$<9>D$A+B2PC#K+()6 $=5
M?>R-O,G*AC1 /ZL#JF1CVAM3JNGGE$C@,;?W<>6%SP,0SBE$A+)QQ_44"I3*
M:F\D RCG>&;8>U%']G ^QKT>[ST"I/D9WXN- I5 <ZFQQ0YJA3R4;KO<O*8Y
M>F?86U0W3&H-Z3/L6\TVK.  @T)[9I!1R!'GY8.QI@AO]/+K5>Y4G?OB1T+;
M6W#.[C>C^T)R=K<*SGB@%#&8..44B((R7<OIN,Z)YQI0JIG>*-0>U'U1ZF-Q
M=U_-1K-O:P3J(")UEPX7U&(Q*S\M%ZO7P-7UZ,#F=G1?@2(ML6&<6&&1\AQ"
MN/4@!,8YI](#RE;3&_VZGH#^XMM/N K9@R>$0C*/O:')\\!6"UD;D%ACEO-T
M:T"9;'JC66M(][EO5M/5L _&KS[Y-% (O10Z+@:L-<&":UB[KMBC+!4UP(/J
M-J;VA3TQ ]'>CJAO;E9/[E-:C/+FS=2,[LO%BR5P#K0(SD)+,;),F#@!2&F/
MZXT>(Y3U4'2 1P(=,*8=8/LBSOMB,4J%G=QH-HV;[5R-Q\N[5'ZGN$DEG\;E
MODWK<./ $"-:0,T(BV(#00RLM73:N7,>C [P7* #.K6.\?G,H*/,GP QHA(X
M9BW G"$O-:"U5(RXG == SP?Z( YV9@.)9(H(X(H2!$%(]H8Y@CQT4F0I(Z=
MPIR@G$JGQV?ZNZA3IC;P?F#84))MK3W++\4B53G\?K 7EGF+ L&0LXH(R &V
M3AO)5FG1''#IH7B3E=&Q]$=FWN)0>Q[-*TI9-,U-% B#6B*H;$YH^B"=G38G
M>7_FK>.0[3V10"N9M["SS@NI(BXJ7:A(:T@MHX@&U86RY\@);IQYZS@X>SM+
MR<R\I25A.BX=2;B  F%@J*JE4L1<:GJVTV?W<.:MXR#-S'5SALQ;R$>SG6('
MG02,&  A1[5\0( +2SJ0,\%9F;>.@SF31F?(O!7=>QW]-4XXC,8U ]!37<OG
M$<_1/ ,\EVN71IW!G$FC,V3>$E8"++$US"(J(4I7NMME8E7.\>X S^/:I5%G
M,/=N,+\]+?,6XEXQB;B#"#K*N$7@ 3N4E3]G@#JH;1/Y5!S/%$QQ/9I=S5:#
MOUG=?%T7LU5UXN8A%+MZ",@QS4$JE4VT)9Q+FO;HM?S<@8N[E3R= /M#)%H"
M^$P$6]>Z5LO%EVI6_JMXJ:9=PY8!QP4)D>32 !%5._;"U<:?Q]1?6%*"[@B5
M">Q9B;0NFGXLB=:M I#,:62U E8*BH37A-=R"@DN[(5-UP0Z"=2SDN=JN9@O
M1M.;<OKY6 8]:AJ(MUQ[B) AD'/-# *^EA@BD_.>8D!%-/NBT>G(GHE+;\OX
MGYMU7<_57!73\1'VTHO- T+"&,$MY%A9[@R*?Z@E-];E[&T##'+NCE-MH'N&
MD+\3S/ &K8.U2GA'??S]T*67CYQN-W;!9,X+]@'&+K?(JO;!/0.ICC"]][0*
MEA&H+;)8(:(X%ASR^A; >VESS@,&&)G<#8DR03T;>0Z:VSM:!.<MXAP9#:RG
MED!DX5;C0LUR;*0!U=[L@S0G 7HVPC0SL?<U"QISC)C"R$EE&$0<,?T@J<T)
MYI(_%G5.1W40(5M;:.97MRF5M)]4?PRB3N)V,,=%:3UK%IR@-AH+6NDX!8)%
MLY1"F0YB"(# JD;VV;"BL[075A./#=61J3*22^-:(JKYA=V#MS.Y^Z.RCD.T
MMTNFY:=Y>5-&ORM5G6\8E;6K3< \.OPN&D#8"1(-:B,4J64TQ%Y8W;)3)_@I
M3UJ"LS?*/(SRW>@N_O'C;#2=QY42)^Q@E-;AQ@%Z@X"#C %O+26.<JMJJ:VZ
MM+H?+<S^4SZU#?')<1/7L_)K7"*;@-?IY_W1$2]_':QR!BOEG%$*0 :8@: >
MJQ?DTNC0XN15;8/;GS=R;'A-PY:!8L"5\BG%!K#4"ZZPJ^75 EY81<0.R-0-
MT"=K&+6(?LC=:/:/(IIN<10'E<S.!L%!BI,'[HGGT@.1TKK7(Q9,Y%0"/_I2
M,4+[J7I]Y&@5X=.C];X4D]OWQ><RV>])F@-!>2]_'CPT'"%"-7$.&F.5!]OM
MEV#:;P[TUZ@J6D3WM83<)??0 N 1%,9[YAQ&M51(.YI3HF6(VTM+_D\NCGVQ
M(]6K&LV_7,^JK^5-<:.__3XO;MY,K^Z+1.WI9Q57R]?U:\O#YTG'=Q84,A99
M8[F,JU X)+&2-2I,PIP#U2%:PAFT>)I0MFNL>V3@F^FXNBO>5O-]JNF[[P*7
MS HIN=,.,>\-3>&P&UD0$Q=6 ;'+R7[.JY-A[B_7S'\NY^LT<1^K]\6XBN[?
MJO3>P\@_5NVIM2Y^7< <60@(<B1%=&.=BBC7R%HG<TSS 6ZK/1)X +/5USJP
M19SG<;F:__CG2;$BPO1&W571C?W7ZM_W\+I)\V#C]N0X6I7^(890P>EV?R+1
M&KHL17M>\E2=ST]O3D>ZX]6CU:7I7:IE>8B++S<(R# JH?988 XE]PCP[?[C
M:%:0V "UY*#8U\J,]&81C,>SU?+85$[=MYL_^33HN'2XP48(D_85[SA 6XFX
MSWD+-,#(^T%Q+',N^F*7'Y6S57SE WA7MW\?S6:CZ=[*@WO;!1&7$:914B2T
M8-XR#,#6P#%9Y_8#/(P;%._:G)B^2/C;ZO@YG4I]*,;+V0J(WZ>S8C1)09M_
M&Y73A*'[<SQ9IJ"J5?[^CU]&TVT0^IN[^RCV:@;V<+;-7Q. 5QYSK*&"QMEH
MCB"\1=(!G%.3H?G+ ;FF^+3XG *W/OY83#_C=/:U,"*L49YY88OU?Q\!N<E\
MVL#';]Y) %@*A@CTC%O"%.92UG<&F "5\QQF@ \7!L7FSF;I?%RMZQ!&:(OR
MZX& QB;-@\.2QL5I-"/2I#LIJ>MK:BP9ZZ?$:-]*MPMF'"1?-OCGH]WUK(AZ
M/27P74WFQOY6TYM'I;^/(F*3#@.#$&O!#5$,.V*1QDS4Z!A-^W'G?PAJ=C =
MYR-K+<7[XFLQW5M^X&#;8*1/+^"<@M(8+SBEW-8R:XPN[)W]6;B7!_GYM^+#
MI0P/M@W6(&<=5TH)Z[5P).J=6F:(1,ZAT@"=^[/NOJ=!?E::/:D>?"S3GC0/
M1&MB:=3= F/I&-1>UG< &%O7CYM]\63+0WUX 3VM!/($C;26.KEPEG,5Q3:\
M=N4P)S(GE/WX_;3S]/;]!F)T,P=G9N*;Z==BWE9HV9[.@N<4,*1MJL/NA,..
M1F^L-CL$R]F"!WAWV'UH67M8]_;F(DJAQO]<EG&:?$1L]>=U?OI][RUVMPI<
M1IM":>2U!@Y 01W8;BB.\ N+ANB2"$_?7K0&>E_DBF;GYE1T,^X(4]3-BV_7
MD]%T$3WME/3G/GVRAVO-.PF($ XT(=8[1#C7@(#:BR+$9-6W'N[928\,[&PJ
MSD;(E^Y^CN'B2^T#=PH @"2 %C-IF+.T7HP$^:S,J0,\/SDG_UJ ?WBF7BLF
M7D "4^ ,18AH21"DR-47D<0 EW../,#*;#V2L+,Y.#,3MV^$VW Z]G06$(A&
M"L*42B(=4XR"[:$ \=&(N2SUV+W3T1[6O6W#LVI<%#?S9,6F_%BILMO5[:/\
M1_NVX$-M@^)"0JH%T5'O*P^0(76 '.%&_QCO7EHAQ=/MMV7H^[;Z-@]=ZZ&;
M:K[W G=?LP"-)$)Y3"CG5%(OV/;(BCAD^GGR.1!7HQ.NM0?^>;5:@W(D1VN[
M!GV&:-!8ZZ/OQ1QS2CGO#-Y:P9I?V"Y[=BW8_I3T1=OWQ?UVK;VK%D6#N]U=
M30( -(7V2!]%]- 2QQ'=ZG^8E?NQN=-QP5JQ)>#/H1%72^#J/LWJW/U9S,;E
M?&]FVH-M0XJ,,!!A# D1E@.C'T#$ L'+NM(]DX9K _IST&V[4JYNWU:CZ5Q_
M<W?WD^I;4:PE^F,:9^Q+>9].+O<:@:?V&02CC"F-/>#6<TB!=7J#$77.Y9P"
M#C &^DST[')*AG<>T\HY3!!*,@>=DT :1"1TG-9'\Q08E_.HZOB$\.<Z&>R"
MF)W-09^7P=?%K*QNGD;W'+@+?KE10!PX;I@EDC%$K<?6;M>;LO#"SJ!;/.EK
M#=->PPBF-^D_Z0[PZVB2C%05U\-L]BU2?_62\%! P:'VT>QP464S!0C%C'L+
M.:D=* JERZE*<+3%=[^:GCCGL\5K8E7;(%\6P8CF1'JK'(/<<DUA7&RU[$3
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M#F]E6IB<F],!7NF?AX"]3],#50=2*W?S?+V:GJ]8[CIQW790S9(#OM0B(,*
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MJGM&;P$P$V&64#LAA$& :EQ;R5+AO">U [P0'H2)V,I4#,%8;(NA>SH+C$
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MIE+JG#.- >F*5N>WZ@7JUQSZ#1&CJ78OD$PYZYV'ECVH89-CF [(>>F"5!W
M>P8B78]F5[-5],_ZI=EU,5M)T8Q/NUH';C1S%FC*"&:8< UU[0)28G!.#/BK
M.']ME58MH=Q?WKSO2_>J\7AYMYRDX=OBMAR7^^(4#S<.T!C$/17(<.8PU!@1
MOU7.PN7L@Z_"E\[G5NL@#_NUG(Z^ >;(*DEU=!2 \ZZ.9*2,XQPGZU48VOF$
MR<&S+VY<SZIQ4=S,?40D&76CZ;A("4>W:G0/7PZV#8Y2G%+=$X,@ $8 3;;(
M&:(N)&]LEQQJ&^,S7"ZF8.HRSMGFV?&X*+\6-U?31R?@S>X9#_<3 %70&RJ(
M1M1&-0R5YQLL&/,XYU)A0 ]\N^1;EWB?'OX2!U5M;E2W;]S5<O&EFI7_*FX>
MC6A=EFK7N<&Q_00GK"""*J8XB7^"CN%:9S-OC,G@TX"2N79V>- QWN<(E%BF
M ]3XET>G(&^.5V4'NPD22@GBRO(022^,@E8EO!T32G/M<JK9#2B):T^:K&VX
MST"\Z]DZ1\>A8X9=30(!3&MFH%3,$X=(>M88);1*.:,LS'H%.J!4K#TQ*@?;
MWLZK1O,O:GJ3_I->O7^-HT\OU19U"<=#.8$:M0^  (&!%4ABCB'4<?G4A[Y,
M$9IC<@TITVJGAU8= -W[.^%JO$PO(:,<;KHH%]_>3&^KV=UWV2F/>!Z\ZT9Q
MSV_9\YRW<=O -*8N93CR7"D@'::$K1]C(T*Y;<3F?:MY7HS_\KGZ^NM-4::%
M3-(?DISDT?J-_Q36(WQ??"[3P*:+%#3T@F"[/@W:0J"(AUK(:$<9$NF(:CF$
M%EFICH:V*%N=UZI58(]3]<>1PT299Z/)F[B6_OS_BY>RS>S\-D ,D)6 $0PU
M<-Q3AOA6"GPIP7=]T",/V6[X48O\,?Z.';1X_$F(6M9%>97CF&C+H3),U6-6
MAN0\-QO<M5-7;,@ M%L27->IG.S+ 14[OPT(@FAI)-,6<\U-I+2&6QA$5B6;
MP=T8=4V+'&2[X8>*P[I)0_.3T4MQ$,^^"=K+.&@-"!(Z%8^@2(!ZU "@')MB
M<!="7?$A!]%N]80OY^/1Y#^*T<S'?WGIFG#/UX'): DY'9T<Z: 5"12YW?80
MRCDH'=Q%3]>Z(@_;/EBRUF;->?+H^V I Y2YZ,0B)ISW"!I<2Z,YS;D2'-P5
M33],.1W=;KABEK/9=S3>;WSL^CPB R&1F'G"D(F:$AIA-K)0367.?C.XRY>N
MF-(2N%WZL;Z<%#,3Q_2YFNWW8K_[,E#C*%'$<F4$A]0Y;%TM@8597LO@;DBZ
M]6%S<.WTA..XR-UF#8/UB'E(!0'66NU5=-!\+1\!/&<#&MY%2,>''^WAW/=Y
M];MBD:*RGMZH]9[!L@XFK ?2("GEKB8A/?0U6&K#(#1,"NCY.FFIY8RJ9D\=
M^I&R2:;;G6V"=<PH2S G'%,,B%3>UG)B9RXLXU;^=%?= 'OF)?MA>7<WFGV[
MNKVNXFI=E*.)+2?+E)7VH4;ZN?/3MKFZ!>=1@T85G1Y\Q3DQQ*WUJ54@3MQ)
M661;"E,8?RENENEN7,5YN'DV"^[/\609 4\QC*D$R;).I/J,B3L2U7;SBX(7
M"A-A(%<<.&>PU\;5B J0%9WZFO1(8V(]#8<XYVST%421*9K^]G('!U(@=/A;
M@X1$6V$TP01#Z*&BEM4X*V^R C:&Q_ISD?1IG:;!3.AY%TZC]+V'FB:/)7JG
MT4\5%"$(N#,(U!)C@RZLHL$@N-.(SR=/45^D_*XBX-4JD.M@ZHF=;0(5T:L5
M4$,1;6;M@&$:;62$'JNL(N.OA8:G3/E3?Z0E@#,R$FR/,>KBY?NS6NUL$*36
MCG.B%0,,>D&85[@>L98B)VQ[0($UG5&B573[>Q>>LB LRF@?V.+3X@&(@ZKE
M0,N (U@.$$Z94EQ#I8&#M;P,TYR#C@$%YG2N8-J%^60U<UWC?82FV=<FF/2&
M71*J'(QHF.C"R:UZU#HK#=*  G2Z538M OQ*7-*W>Q(PM?TK N+<6L !4U93
M(1$2[@%!RG-RP YP/[P,9_/4V7LE_-_Y1+35_@.0R F.(WB40X,M@5K4V!%B
M+BQ'7?^4:Y?S)TW:F2] 5DKB,NXV"$W9"SV,^ZP45$1?#^LU[B[NY_(B[C8:
M7'FV_\N"$\)*1  EG&-,55Q6KD96$79A2=CS"=;9'<>),]*[CJD6Q?QZ].WQ
M35SOJB5Y:;:<CR?5?-E(L;S<(/BX?[B45-L38C601,+-Z:9@5*%&^8+[D+")
M;MC1(EC,M5&*>>F,C[NG(X37,D:G)^?$:8 +/'>BJRY /><:34JG6I>\N;I]
M_(-SASZTM88)Q5C#A#H S&,?W:!-2C5DH6/VO&OXS30.<Q5B5S_6/NA>[&L6
ME)=,I^L8*V7<"[!3="NMT9=6<C=WRE]8S2TAVY<O^_V0?Y^.[JK9(N7&2; <
M1:07VH;H1U'IO/>:.Z"H=4+;6F9 8,X%5?/3%[EFT[3XG#(E?GS=I,I'N3]F
MK2=G72DF[A/SQ3PZD'OY]&*+0!F43DF "&?&8D$Q%;5\@I"<6G+-;R%>/8O:
MP/;DJX>WU?1SQ.PN2?4H;6G\XZQ8FPYI8)-H.JR>%14[,Z\?W5$P#B&/'+2$
M>4()=5IN)=3"Y=QA#?"2HB7:]()U7YKH)9?RI>RSCSX+A!-/TCT<E\:G*$2%
MX'9=.) 3I';\6^-J,9J\!M:T@.0Y.+%YH]:0&INO@U+228F\-AQ@Y"%C\F'7
M%2XG!JSYB^-7OBOEX]H77VI=V%"7O/1Y4!A3;+T$$D'( -!.Z:UDV.?<R!S]
M\OAK,?M4O2ZRM(#I.0]*_'*14)A.EZ/);^4T54.ZGI73<7F_W4+/_ERDK3,3
M976<4^ 5]EI;SPABFZ=WC&M)&NG&;M=Q&OAOH\7F%/U]<;^9@:O;[:2\+U)4
MQTW*V_GP?+G!FC^UZ\ 4@U1CYCE5E$( .,4U:ESJ1B=-K_[LI3%U=FB'GM#O
M>]]I(-:;:9+CXQ]5.QS==A<<L#X5^I(<D#0E%BM;(^-05BZ_ <;0G(^7IR(^
M7"[&W][$2CJNP^ 9E>E&)$X(,MC&Y4E=C8[76;E^!AB5>G8^GH#Y.1C9D&=I
M;2EM1*I+C1&G'E-O:DFHTOUFE3N79]\&>XY$\IRV][L45IL")R[%P+9,>ND<
MC]X.8UIP1O3F?IBM_)^A7$H>>E#]PM<! I=>5W@-"<!40DHTKF63$OX85Y"-
M)WCO;=$I@)[GYO' >^3G'P>/H@I+=1(0<\)@8;?1]E$JPR\LOC5K7O=RY 0P
MST.11D]W=S4)6$AC"&" ,V"U6A5*J"5,-?(NF2['3?%>MIR,Z,E7AQ_*23FN
MIO\^FDR*;WHT_8?Z' W2-);]+Y<.M0N(24Z8M@@#Y( '2M9/CYF"B%_@<4O>
M-%;=@7LR.:*S_/%+M9R/IC>^O%T4Q?2QV;>HGHTSU=P9?RFNIL5^]F1W')@7
M #*H, +8.LP]-?4.KI$'%T*OEME0G7$*>B=A;-<-";<=!X@TPI@I([PAFD L
MD*@1P%A>R'/P 9+PU"GH\^1DL7'D4\F  _;W2Y\'012D&@@M?2HW0($P-:!:
M8Y@3ES4@<G5A@;< Y[F(<M "?[E!L,!ZPBFD@$/%M)?;EVU,.\4;/848_G;8
MS@0?8,M)B)XCL.9CE33BX304.]L$C)A!F@OBHK3. "8DV<K(T(5Y;;D3O2>Z
M)@?6OJCS[Z-9F<;Z?K0XM!\]_31 BA"S4%"%A(<:2@=@+9$%/B?2?*!W0FWM
M19E0GH,<!_>@YQ\'[#A37&",.8+*V+AP="T5)/;"<FV>/JE[V'$2DGWQXWI6
MWJU&>7"W>?)E,-K05#'-*V:DT-P161^,Q;^(1F^_7R<SCIW0JDT@>\N.-1G-
MYU>WF\PZ5[/WY><OAZX;=K8)UF)CG$.$>4X<E]ISM=TYD<TQ8P?ZFJ"M?:8M
M3,_*FX,[SYY6@3N/).4FKC,I/+;I_+V6T]NLB/$!*IH6YKL)@T["]N2COA0_
M,/Z2UD&=J>M#,2N+N7Y?W!3%W?I!]#;9V_>YO?:?]>7W'%0<JDMZ7&-"I=2,
M$KG5XY#EQ$6]%GX=RX;JG#/0G^D\6:XF]&,Q_C(M_[D\[%V]U" (#H2#! E*
M4 K=YQ[6TAG!=<Z-^X#J+W;C8[4 Z/GHTL#?>KE)@%IIZJDUA$9!E8:VSB#'
MC%'@PI*#Y$[S0=:<A&I?O'DS'5=WA;J_GU51CSX?_$''K%D'05$J(-:48TN9
M(8A @VKI,:(75C\@GP15#RCWQ;%5*JLOU23.UMS]<YE*@"4SX,!^MJ=5\"+B
MIR#GT6=5QD>E[FOGUVA!+J1P;!>;6GNH]L4>/RIGB?"%_K9C\ =WNJ9=!(I)
MU/<,.Z\=TYH0#'V- %7^PHSQ5KA0]0)U7V2KG8AWU>)#L5A,BK38WDS-:/[E
MX$YXL&V@R@#NH+%&8<HBP@IL94:67]BA9?M4J+H%_#P1LF\;9-;>T2(P J5T
MTJF4H$I1B "I#V6,@C8G3<J RF)W'TY]*J+G88P?C0_GH][5)$@%(;!048:H
M%NGUO1%;"0&[,.\N>Y[W\N9D6#/.,K^+"%XF-7=UNXE?>TF%-&@5M$;:Q74D
M%*!0>68=VGHEZ<G@)<>$G4Z)]I$]CSI)3P,;*Y+T<< R57SD,&ZH5%H)(]FW
MVRJ4-L>.&7S<1MLJY 1 6U(>Z3>_F4;\BOGB:CKY5N<S::9$=K5.@4\ 2.64
M5HZXE%*,UT$+ED&8<V$V^,O65I5)2PB?1ZGHT;R<?XBS-;JYFCX.7X"-5<WN
M+N)F:Y% 2D)HB228H^@VU C O*0K@[_4:%L!M09S;\'-$8"K6Q/GITP&6#F)
M[F2]3E:A4XOK8E96-VYZLX=K1_02F!0$$L619!$(1(F2=0RP50#EN%F#/V[,
MIUMW2+>T$3Y)B!E',TXS]3G5;U@9][J:S:H_BI?HE--=H!I@X*WT/GD+#"BQ
MR<40I?4JJQ3HX-WW5K?*KB _:]A2[4P\U TQZ<'2C?Y6'WQM/CPZ**YYSX%K
MXB04C#!'#*":P^WYBB4$^ R*BLNEZ'G0/RM;W9]QT97SXGI6CHOM#[>B[#/[
M3NHO6$6D2,%"W@CE*8\>4^U:6PUM#C/E#\K,EC'O^])&36_6 [U:+N:+T?2F
MG'YN<%_S4K/@A51<"FVQ041;H"&O']M88W#6&R9P^?1J$=O>[YG5?+Z\6Q44
MG[L_[XOQ.D?SOB.R0TU#-"RD04X*B;B/"R=:M5M'2EF5%43\ QRZMXQO[XQZ
M,[V/]*]+?R2?IPF9GK<*J;*P9DQ&?\9I8Z-\I#XGM-31K OD"SZI;Q_:DSW/
M)T.XGE6?1I]6+G%U6V^_N]S,)FV#@L@"PPRC6#%)J;)^:S(J1+,RF%SPX7Q7
M #\0I?\$BF<N]=I6VD3.68KC@)Q9280A&*MU0A@' :2PT85U1X&-VSJ?J\??
M*\R/*MCZO%F(UC6-1$I5Z:G$VA E?2TML5G7)P.U%'*F?&?AU6QD>PN.W0[Y
M(;'OU>WCE*TG\*I95X$2A*"3B@CB.9=,"+9%A(JLK+H#M28ZX5HG:/>]<<3-
M[KZ8+;Y%CRU%Z-VG[?1L6T<]F.M)="(?CZC!+G*P;<#84X&LXA1XJZ3CV*\O
M&1R@SNM&)T<]RWU<U=]CN@E:0(2EP0Y1803WT;3!-1I(V@N+>6Z1'<\>UG<&
M^A!TP:ID\+38))M__O-S)^GN5F6XY!9*3AE@V%D/"1:; P9M$?5GK G^L WM
ME.)0/N^F703-TV8E-<><:X,I)TK4*%@I?SA5T9@5.TV'5@'O+VO+CD'K;PVR
M$C9H'0"PQG(.D91 ,B@]QG KM\IZWS5 HK5/AZ9;T\F0GYUJC;(:-F@=4CX+
MH8BE"I HL-,,T%IN M6%O<EIE0E-678RVGVQ;#O2@V^\GGP9&$3: 9@JLT1A
ME"&TCN^..X!Q%Z:H6IWAJDUD>[O26<ZFY;HDY(TO_TQ_.IPI<W>CH(#5'! @
M#/'.66TH1K64&L@<[3/ $Y@N^=,:R+U%T42':ADQ;ZY\=K0(R!L+J<?I/ EX
M0JW>'&Q&^>(DY>16&."-3Y<D:@?AW@*AB]%\]:KVS=W]K/JZ2IM^6!OM:;5*
M\N6=049PXIP1RKI-,D#MH,BJXC3 MQM=,JD]E,]N:K]M\$#Y<.-@'%$2 $JA
M-D(HX #GM=2$N N[;#B?3W<JXF?GV=]FU?PDCJT:!A11C-8B\(H+R;W'2-4Z
MVG&%+^SBM,WI;\JL4W#NBU5J/%[>+2>C17%CBSA9XW(UB?'/DV(UF],;=5?-
M%N6_5O^^4\8]_&OK5P3H&',*V0@65E'E2UBG[M7.0=5/:6:Y9NJT^#Q:1]&]
M7L*>:6+.KC#?%2==:L1F@6,DJ-,8>!:W'D\T$;B6%"&;DP3B>)>A\WJZYU"6
MQZ,\A%N^P=3<[?@ZSUM*L30DKG(# /=( VF1)A89CYN5(>TJ:.ZP ML;0G>X
M>8@4YR0J-L&D2"(#Q$PMO6:P41WB"["4CF?#LW?4K8,]!!UPYK#1;E<^ \Q8
M 2234D*M19R$.LP;1NW<J/Q9WU==.1$_#R$GUF-G!"32:$Z1M4*Q.B(::OSC
MK?K&3&A\S74BU'VO^??%UP3_;\7L\\-!8>_+7"_GT?B:STUU]ZF<KB2:-UCA
M^YH%R+$U7%/&+$>*.6K))I031XN.GW%QOS#LXT+ZFG40=&0UUTXJD6)*E4#*
MR!H!J,F%U5=OAPQ5#TB?=8T/QJCO8LT;;*VRFB$OO?>20V$WEWO*&"D&\3JD
M%D"-XUXQ+U<"Z&^/_M8\0J]95X' :,,B*7U:!!X+J)RI48E>[H45[FR'(#N#
M]#K!O*_3HQ<&?R! ;T>+8%-N2V:A)UH @C&2U-;R(0=SLM4,D%/=3?^._28/
M[G/2*?UQ5AP.QSO8-@A,B4;>. RI8H! 2-UVK7)VH6KKY)EOP*0<?$]^Y/RA
M_#P=3?:7SGK\30#> :X\8U@:92C0'/MZ7$Q>6IW/%N>I:@?1OK3'U1_3B.Z7
M\O[ %O3==\$)0Q@32#KOK,,2$;^Y(E>61FDN-7*@XXTG!^3>"7-P<WGR99#0
M 80HLNF!%6!:<L)J>3 V%[:5G#B7NQAQ$H8G;Q?7LXVC^MN;E4N[*LZWJ1:Q
M222T^=MH>G.U2O^R^?O^+2:WW\#B-@R\T4H(!"1PGK@MC@R#"XON/GGVJ_-A
MGFFB/*Y+TL1<>?Y]X!)8+[BV"'*B&+'0UENUU=0V.G-\/9M3*QQI"<N3Y_ZW
M]<E9\\G?V2!8@I1V2EAAK0<68E]'C"B+%.XWCN)US'Y;8/:6H"/.S"I\=Y,R
M<:71#M6NV]4F"$\0Q,1R $7<HXWBKK;+(_5ACJ<S0,+T9LNV!7C/*517PVQ:
MGOS1QR&E#4!*8J\,E-'#0X*16BICS87=\[0PNR^G/ST=TOZ"_QI5(]_W><"$
M&XT%%L893!F4CM3G219HFQ-O.D"RY$SMLZO^;#3[>TV6BIS/X^QL1-???E\7
MGBWFXUEYW^#<OVD7P7N/('+&,>FPQEQXH6H$",@ZI1W@*Z'>]K".\#\; ]^-
M[@[?">QI%:B**]50*(#11E)#O**UG/%/.:[5$/56Z]-_B%\G0]V&USU_,Y\O
MBYN/U<8?,-7=776$3W9"5R&:!U#3:"Y(2#B2($5L;*7$YL*N&5J9[QU^>T>0
MG_$6\VV#5X[[F@7#230 A$ "08>IAM&9W2Y++7.. @98D^J<U^.G8GY&=CVN
M2//OU:*<?JXK(,TW5W_[:E6=UF&PDF 4-PO '<)$>6UXO?:<9.#"[/YVB'*8
M?>TC?_)V^DS#/];-#S_<D7#^V"X"$4YI 0"CP#NLDN\M:ZDPSZHV/<"C[E;Y
MU#'6/>8L2=O\P]B;55K9URQ0CW$R132R&&,)TK%_+:GF/B<OP !/1#O14BWB
MV_<>^2AD\\.BN'\$2WI7\5 H\,TV1.9!_QX7,GQT]T&Z_]?>MS6WC23IOI]?
M4_?+RT;4==81GI;#W3,3^X2@)<AF#$5J2<IC[:\_520!T;)(@BR@ ,*:GG"K
M+=PR\ZNLK+S&=N'AH.6U9T(X0Q&MM3A"*<>% ?HY.MT_,\KA\K#@9/GO<FTF
MC]/U9':XU/+@M057UBK&<71)0QCG&CGYLM)H2@>* 9X VM\?6V!JC^KK<WF[
M^#J?_E]Y]^$NL&]ZOQFDJU:K\L4P5/.[C]/M2)%IN=I,,RKOCI?QM_RFF!OD
M,>)>(Z.$P59!4/G"G>4HY9@ZP%FVN91:1I'T6DKTY]/#PV3Y?'/?@+0Q5AL!
MH) )4@IRT0X@YRW9088#(7DCDV!\U49<$6NE%=8YH32D1'-9<06A9MW1K\_1
MD :0U&JC\WA^?=5&F'D$//,@$.E8G-3,846?PSYEO.L ,=6=^!M6&YW'[I%4
M&T$F'(TC. "5"FOC *YHMDR,5&U=+/GSJXW.XF^^:B.$D.;,2^2,CRWL *R2
MACCD"OX&<K]03@>KC<[CZ#5'^822@A#D*(HM7 T@'O**4N9T2J_E ?K ^]R6
M+N7Y-;H S&3U;==*YOMD%EL%9_((_/KBPEIM,070&DS#0K:(&5!S&_"1E7FW
M [P.'03)$KK*]?"TC,+;7OEI63Y.IG=QX/=\%=O[WT1'Q?9WN99)T^\I##34
M6L^)=4IKKS &K)(-%DDY:P/<'X:_>CH2W#4NJC\6\]LM._9^E\OS_-:["PZT
MQ $6&AJA/ "&5%EH'!*$\Q3#Y&Z$//@UTX:LKG)]9(W#*(6PX>%/(L,_5 E3
M)49R&/XKY2!Q?G"Y\P[,PP?]V2+I-0[3<X_63D(KUBHML&.20JHI%\Y747[N
M6+-1:OV'5LX:T][\<84&F &HF \<<19QPJHQ(8H#ST;6BJ =H"2$6"[D>VZ=
ML,GVTI-53!]\B%;M3TDKV=7"2Y_,F_O]#_I<;H8SF,5JO=I\\I?XR9\FSYNI
M2 T41]J#"X(0PDA1P:VF!C'/=#4 #D4+L#_5TI@PO4]8$RV3^.2"0,"-Q-)*
M!"TP$&!:#41 83V,;)Q.+H"][B"?54C#T$YJM@'+-@OZS2MV!_2;>5WWO;JY
MOWDLE]N-H.^\DL%J.8(1"<<R!6S8%@GC@%1F-/'<-IHEVK4!Y1X>9XOGLORS
M7'Z?WI:G$?)BT'\JE]/%E@G-$UA:?%\APSG%"DP!Y5 :P8BP56PCL'UL/1=R
M@?&@D=:?Z'(Y+S[,@ZHL:R7W<4?)B829(W<5"'..*%#4*>0Y(\"0*I)+I'4I
MR9T#A&C/6%ET)9>>\7<RL^;H?86$TD+C!2 &:2N()[+F'[? C@N#K4B]&9(N
MXF\N+'T. @OOBJ%*6WXO9XO-2)2=)7>R;4V#NPLJ<#!UL?>,6\H8%]#OVAYP
MRHP9F6YK"0.+KOF<"U]_*^?!_I_%Z5IW#]/Y-)H9<:1%4X0UNK^ EEK E0'0
M00 I%A94D77*J4R9D33 Z&TW&.N"T[E0UHX=\;%!DEG+;RJ\H[%AHK.0"&J5
M-[JVMZFE/$4[#A"YP[+\^I5EKK6Q(Z"\.^JT.0+Y9@\H -$:0>?#WB,%T'RC
M)7;4.\4;N3&N9Y_O#3NO9RAW(9QA.!S]9+K\YV3V5&Y"O9L^6GZQW%3+;QM0
MOWL4#SEQO():>0R#E*$/V[Y2D@NDPK\\!WH0'L4#*R9V&O^Z]1WKYU]<Z.H_
MD^5=<R]BXCL*"CSWTD,MM,-> ^L)WO)1@6!@I31.&:!*RP6Z@Y[#O.+*MO]N
M/C"\\H1_\*?K"B[C$%)"C52QF -@C5A%"[(L)<UH@-#K 0.O]]$$[N="TN6\
M>:%N?A?GWS9J\=G%ZS9Y&98&=8 L99:).."OYJRT(RL/O1!5KS5D_X+(?I!_
ML?).NH@.WE-PC[%V#L4R-Q*X[J "%8U"T)$UHNT7)H?.UHE"&8QN/<2[)DZC
M](<74'N-')1>"N^Q-5"\Z [H\<AZ^/5O#V0765:@?SE-V)?7A+UQ'%]%]\+M
MMOKB 9Y: )V\M. X[)V&$PV4%]AR%EOR[+ALM1F9VRDG+-]:$4.0X>"WA&,$
M_W,1#M.QA.'Y0'?7C&\O@-:,,&(Q!$PC"06&M.*[P2RE9'B(FTK/:V=0PKS*
M1?1YNOJW7Y9EU74RYQ)ZZ]V%)<&Z$%"H.$#&!EP8X"J><R12XLX#[($[E@74
M@BBO<OE4BL-.OT_OROE='SO0_KL+C#"&@B'-.8;A(.@PJ8^"E).1->H=R_)I
M092#63X'3X^["./?XN#;U8?Y-F;[KW+Z]5N@7'TO8S33_2B7M]-5^6DYO4U:
M2.U]1<$59\1PA@E7WB@&@S50R8% FK*DSNYE'+[OR^(W7E2]B748\?L_XMCH
MF$'V'J8_$#&U9C,XERLI%/*6>1)^@@QRI:&FC0I3WL/TP71SWF)I"7,2(THD
M MI5?$20C6P\6"[0=1:F/T]<V4R%*IUV.]@@DK:8;SC7<&3T6_<5 A-,%;6>
M>FP0DIL^BSM:#;4C@V8/&#DT3[H%:62+>?[\J2?C\F]>7T@KN:,LF =608.#
M^6U119M2H^N[W(Z<7P<M6^!L+M3LS0XZ&2'_Y=J"!T)\L"B58=9*RJ7A?D>3
M\5".K"U)HEP/3VVZB)NY$%)%\D]L8/N7%8!C(39E;CS:"(AH2RI**$KRR PQ
M(M#[?I7 _-PP.KDOO<H<@58SJZ'U7C$.N0=,@XH:P43*?+@!JIC+!'D #1=Q
M\.(^[%OM&-\=Z!;'^[&_=6TA-%"8R(!X#P0 R!,$J^\$V(VL<OA2(2W:96,K
MXH:LN;BK:PM+%=;: @0,,=!)\Z+K#-%@9%'CML5](1N'G:T.242HIMIBBSG1
M%,%:X0$E4LS)(<9!>S<;4K@__-C+<++5 ;.4"F(-@4;3."1!R(JS*.CI<>UL
M%Z(J1[;Z>8*XSFQU:+'F4&/"$;-(8$E@O?\C@T?6IZI?F#3.5C]/*!<;97\L
MYN498#IY3Q%,1XXDX(Y;A)BAX;]T;:=8-[*.&(, 4]M"R=8"*#+IA+E77U-@
M+'V@7@LLH'!:6HEM18,!20TKAIBST[NI=RGGLZ+G=*.HEZL*X;$#1!&'!#?8
M ,-I=82R0<V.K*KZ OF]A8"+>)<+ W^?_)@^/#V<1,%/UQ7(*Z"H#\I0.,.9
M",2\T"*;-8Z_,AR<*\5%>_S+A85_EJOU=/[UQ'ZR=U6!E D[*^>:(.*M4H+*
M:E>TU+"4L8YGIZS]#CO*Y;S/C*&39_Z?KBNPE]Y@X)TAC&,"'6=59HOUBHSL
M_'21%-]&PD7\Z]F-M%D&8:6$U70S/VU_G/&4@B+,%.38$<00PY1J7?/!2C"R
MBL(+,=#,Z=,"?X>#L[_^LV@!9_53XO@D);6C6F*'&8[%]576@ 4*IH3-!GA$
MSX6S2_F;'V=_6RSN5FI^M^\RV':36T5:5I/;2%NP 9X>'V?3<GDJ$3'IP07!
M6/AP/A$* D$@\M+6UB0@/J7A$!L>&ONWPK**:ZC@KD@Z([ISR8,+C5DX(CGK
M$8:&4F"9JA("+9=D9!D*N:"5B.@D&;7A:5\U]J_OKBR<UE ABQ!ESL&P@5E3
M;RG>)17,CP!'EPKT@/_\,J8/)KS=<\,@:CR72&'M+(/0.Q?C#3NN"652H,H'
M"-4![>>91#9XH.^J'&^>UJOU9'X7C/\_GBX[/EW^KL)3 (W6G"%A+1<, ^'J
MPR;B69W,5U(/VQB&;:V EH0W^ 6QI6JGHE;J:?UML8P-P;M8$(?>53@1>Z!Y
MQQ'%U! /+.853R%D(_,Z7.-R:$ETU[8<OD^FL[@#^\5R4QB?856\?F6A33CM
M4"((4!)A&0X[P1:H9&U@2BAJB'FLU[\X$B5X\2GR9#.\+P>:X6U3P3<_[F]X
MA\Z@;;^G<)#RP C/' .,8H"9L?66BE5*D&R(Z3OY$3X$L?50@VHFC]/U9+9=
MEG%<V?)[>1=6I7]:/RW+#ZO5TV1^M$G.V<\JE%. .T$P910Z:)V457Z>,XBF
MG'"'F#?0G[+N6C19+95+.IBZ'X_3[1#K;:N>4Z9)&^\HE":&24,<1!A(X"4!
MU4[F%'(I]9-##,CT;(OT(++!PW[SQRYN^SDVIUH%.F\CGKZ>;'?6]OLVXV6(
M-P A:("#WB-;2=<A"U(JTX?HS[S"Y="B^ 9_=MVG=;OX3[8_;^DUA<?$>$J5
MX=(;I@$ =3@D[+HFY8PJWA?",*0V>/PWZ6"X^:6=K,NZB6B'GO\SOZ1 Q"*"
MB(9&&<<E]596"4C.R:3Z*/F^BJY&L->YT/ZV7*PZ"1\??EOAF$=*0*VYT]1*
M+HFICG0>.Y64%0O>(VD#DU\_%=3_F0=-^&WZ& LQW9\WGRIG[\]#;AN-YS[G
M>845!E/,H1+" &6LQ* *K'@B2<IF  >=UY,=V3GDDTVG1QJBRZN\LT_+VM;;
M?O-/A'YZ6MY^"\R,=![O)7K1$PN@'>$\[';6,4W#\M:\VO.\9R2IHO(]J)M?
M0MFU[[$AYG\LYM_#6:;<'FM6?RW6D]G^[V/#X3\6Z_\IUR\CSIMHZ+;?66@1
M),DL=I@PB)&C#M4\%H@D-6MYC]X.4897OTZVVL,OEKN_BM<=<R3E_9!"(J$L
M%E1+9@P6)%B.L+89!4_J7OT>+;X:P;:0);%)()^<2B#_F=CU\SXA>]U4WC*A
M.GU?83@/NS3%6'(D-.3&UB41W@5YIRR$]UCST.0W"+QO%^[]3PLW!^[?>F]A
M#-&2"*0\HUQ!R,3+ 0QZF]3+]ST8/50YOJR#/L<([2UD%:C^/ET_OP\4>O/!
M!5):>HBT!<!J*6(?& 0$8M!*Z+UM5,/;D:_DJ@8*888X12(L60C"_XW30%9\
MC&MF7&5^N4#7V4"A\\25Z]!X62=EI2%4$#E$F**,6H\9KVA!2(ZL^4@/&#C:
M2?D\[@\F>'@%G90=LY8&-4&$D%@PSB !M99P:&2XOA!5.3HIGR>(?N* J9V4
M260OY3'VC[1S0"A?,YP"D!3/&Q[8^H5)XT[*YPEE,+JUYS)^X)R@4GJ)M=0(
M48EXO:]) 5)">T.,[/5N#V07V>"!_FMU]N?%;.87R_C+#I.0WGYA(3 3'$KK
MI'.2<*$E4!5WL08C.YOEA&-WY?R7R^\*5T</32Z,M8H)P8D7R!$L"<+UUFJ%
MS=I1^W&;$+&>+-?#7!DMP;/SYA?G"?5:%DK_B:P,<,@M, 9Q8@G5$!!:2QBP
ME(XP0[2HQK5,T@4ZB.S _>"D^U$N;Z>KXVU@SGY8815!AA$7- AS@ 49&5L;
MP 2E%/HW3X:26YC/RZ_1D_Q; ;UKB5V+P@^,O"^GL3J\7K8=*OPWWE8H#QF#
M@:M* 0RUX:(6(7(\J;-M\R2FWW@E]"[2:UDJ_1XB@*1(*:,]@T@(JS2'L.*I
M52:E,=C9*4[;0X2;OR^4C"*]PF7RJARPVDL_+:>W913)?4XO5<./*2CV A#(
MG(C=[P732%7[/*(>N?<#R/ \6-W(=F0KKO]E5B!)M3*(26*!5DY KD3%?^&L
M?O>$Y85Y/ROR3!@,9AD>C&DUJ85O;2FV]Q6%5AIHJJ'&BG!N+!:FMM.5QBDE
M66/:Z@:X$'L#P=4LQHK(WM?C61]28$H5I$(((C106 )/?"4-Y'S*_-Y+_8)_
MO:_,*X'#U2S.-YQ&?2W/,S^E<-IYA3AF-';05,19!&K;1>.48.[8W96#7YO=
M8F$PJW,TQTDN,+,0 H\\%90'L* JM!BDHK..)KXZGVCOJ[$7$ RC:&Z3!/E>
M(/>Z5HEIK+WF1&%NM")40&"Y0$HI+1SDC=9S/P5R^R'CJ@QR(^2_@EAU^*9_
M)U3&G7YX@2T2F%@@";<RV(H><51Q3DF1XK0>8-IE+IB=61+7NIRR60QO$+:O
MD?<)BVT<MQ!9K9X>MG^7A/3+7U1X@#VUW@#*"-9&2\E$Q4TB34HAR0#]5P-"
M?3:9Y5\!C5J][#K@A9]N[E_7]&_D<-YB:/F=X5QB-,8&&.4]!)(#J6HMX[E.
MV0T&V&FK]W71K_BR6[2!;>ORZ_0V4#2-XT34/! P"P!?;*<M_&NZ_K9AQ4N&
M3'8+]V;Y=1(8O.N[-%\M9M.[K1CF=Y_VN'!S[Z?S0,1T,OLS_$W9U-!MY?E%
MS""G3&HE$4' 4FOYSG_ '>"FQX80>P+]7NZ=V5[66A,-=\93"@*@YUY8K32S
M2G%AH:EX(532Y*L!6K"9\?/+Q*"NY#)D9?3'9+FEN._^-->AG*3'"!HE(6,8
M>^ D#SMDW(4THT(VFT3:M;%V",BK[3#TVP._WNO1M&K>MJ:MEQ56:N. <( $
MXY=Y;"D0%6<]]5FS8*Y%U35&XT$KK2?QY3K!?(X??**737U-0:42V!%.D*3.
MJD"+Y14-2-JQM6#H$02+=D20%48G>WOL754H1#SFDC/AO>%40NIES0EGDIIO
M#@]*%\CO+01<Q+M<&/C[=#Y]>'HXB8*?KBL8P(%N3C3%#B)EE(TU4AM:F"=)
MR61#Q<&Y4ERTQ[]L6)C\:(:%_>L*YYUV4F@M'+)4Q\:N-2V:L)1V4@-TS+:"
MA03^Y<)";$5T<[^W+9XP-]Z\OO!6>RXTYI0B&]C#I5$5;8%=*7.!!XB- 9D>
M;8@C6W?&7_@S>9LE)Q73F4\JD!<(<H\$X8A*RPS#NE;#5HUL&TO$Q.MNC9WR
M.A?V#BW4DU [?F.!G HG5428)$J$+=Y[5',5:9%2P3E 9'6&A8:^S(N8WC?$
MSM@+/C9H<-?F:PIGI$>.0 B@()1S3XVK.&E8IHX5O^.^W:,4+QZU<.B;/RW6
MX<_I9&;+[^5L\;A9J=-9N5HOYF45FGT#T>D/+9#Q<9P$-<P*Q[WB6(I:P2 V
MLHV]'] L>I)6=SC]7'Y]FD4D/+<'TR//+"@43$#".8*:(*FLPA6KN>9Z9.VO
MK@"E[0FK.Y":Q<-#3(F>S'9QEO:P>OK1A1<<B+"I8<T<-]HQSU#%!19LKG$9
M!E< V=9EEBWX4$X?OCP%"<:/_!RVA_G1H?1O75Y@#SEEP;B72EL"-(,&5I1Y
M)E*V^0'.Q.L5C2W*(1?"/DYOR_FJ7)T&UZLK"R'D=C"3\A8!9 5GU?F4<RQ2
M(J8#'#$W"%REB2 SI )CJA%@C<'UZSV%11(Q:AW@D""*+."N\E=PZY)2=P<X
MR6U(,$L61C[GT2JV=G _PI>N;N[U=!9>\75U,_]'8-C#XZS<)#W/-WDSJYOE
MI^7BZW)RPD]TT1,+'!0[1RCH<XJAL$8Q4.MX)6S*7LO?P7K &91#5-G"/+>W
MBZ? P<_E;3G]'KUD?Y3',AO?O+ZP3F)F 8+(0@RUH$H0+C"6"#KOD\J Q#L,
MWX[TM""([+G"3U]6Y?\^A5^[[_MGXNSYOZ\_I$%*[Z%;"@6415JCV(+84 4Q
MQ9OJ%8*Y AXU\A?EH;)12=2A>V)XB%OKL5%"8X@9L,A$.ADU!F&7=89"ANA#
MLKA?I\&VQ-B^U^Q@<OC;7,.:$QK.-D XK;",J<U<223#"5I*2%FCC)@L5)[,
ME7_C\B):')1)IPQ 87/A5-@==58:89*&4U_1RFTLY.,K]Q*>9BNB#9\ZO9M.
MEL]_3C;UPK$R^$2.V,%["@"-E$91+;0S5$ 7%%V@D06SE7I#QHV;,\7\!F;:
M8&HVX+Q\99QQ>'._9ZR>GH=Z\N:".TT<YE@ YK4'F##&-U0+:9 A*4WU!@JE
M1.F_QE/;++XX%*;6P4YXF"S_7:YO[@/7P]GW8%K6\1L*$(XW&'NBE >".<&P
M-_&+F;?6&9*U9<KW<OEET34L6A3BH@,.Y]RE]C7MZ1'@!^XH@/,.!+.;(*9E
M.#XSQ&"EGI%+:@4XP%A]ZSM4.DM[A,SI;>G0/07UC'BO!8O.9<8Y<+BB44&5
ME.(QT-TH2=*GD7,17WO"SLDDXC>O+XRCB%GIH!58"NDX=BZJ4BP0YAZ1T6/F
M7!D?1\U%7.T),1^;3+(^<$OA83AN4F8!18IC9(/%IW?\TMK@D74"ZG*+NI2G
M?9RA-N.%=OVZ5MLI=Q_F>^9>P]/4J<<4#C@*J S_8QS&65\Z_!>2Q"F$ 4F*
M_PU?*UT B"/'JI9YW0/J-MU8/Y7+#0G-$/;3+86U& 2:+$0,($8D(IN%2A#1
M CLTMFD4':(IA:^YD/-IN;@MR[N5#YR)>(_->S;]VQYVC32/0.CDO865,:ZI
MPI$3*2V 5!#A0#,UW(!P%DW!TO#WO70LM<W@'M11;#4S#0+;M0*,8>KR[N;\
M7?#T<PJ&J5*<.4R)D1Y&/T<T(XET/O"<YIE@FM.3U*'J:IW=^2.6#P^3Y7,@
M9_IU/KV?WD[FZUVV1!PSO)A-;Z<]MO[^]5,:1"X/WU1HY(4VPDJ%$..&,ZJV
MP_\<<;& L\?8Y3'^-TI&:/2 (HY+D@)Z987VG!DB@*XX8!T=V=&\#2B\7OU=
M\'F8RUZM5N4F4>OC=/)E.INNP]_]O9S$CHM!R05U][2,_G,]64U7?6<XM*TI
MO&% 0>@X15X98L(^L6TDZ3!WFC7J>M<-I7XR7<;.U65#\6P3[98_2>M4:D1K
M[RBH-(9@9+0F$&)'L;&BXB,D*&7HR77IF\: 6@Q#%+F,X)H^_5S_^-_3H+26
MM]^>/\:BVQ/QKF8/*%A@O /,.RN$PE@;2.".>B%!TJ#D 0*Q!]0<PFV;8LD.
MRAVK-AG+OY)Q,JQVUG,*R0WEC"#%#'<H&"A(TXH7 K*4D]F0(=H20 [AKP/6
M9X?AA_GCTWJU80H\&9,[<E=!7> 9ICS8O< X1P/9J**3H[%%<SO"P"&D)?.[
M3USABW"%*SJ),PH92YAVP K%(*M7*8 TI:WJ +WA_>'J,GYGQU6"U=$D@-SJ
M>XK ,(&5  @0'\_L0#A>\=)@/E;L]F\9]B"];*6"&])J2E]&533Q2IRZMS#8
M(^JE50PA3JAARM6["H3-)K%<X2Z>%R^O:PA;EDJV^NO)ZEL<,Q+^Y?[W:?I]
M,OMILWJAXP@B&S^C0%(A@"@R$N"@'"!EMMZ7L,<CFXO3(B9>%TYWQ/%\;2;J
M%7J9$FSV@ (2:B&CQ&(&$40.&^#JU2Q@"MY&NG>G:\).1).QAG_Y5-X=I^%X
MR.#T_042UF"D@I7. D^-U<BH>E%R/[)C=MN ^+5ZOW66#S/@5M/5(.#VC_GB
MRZI<;KH9; Z(<4SC_#;<M?G2L<7C+$)2TZ"P"*9(,$ -\KO!;@)CWF/5<8M"
M,Y/9;6S?&)-)%K.9W\ZT;W(0[NK=1>P7R8!4!H7ERYCAWE4#]438+T:FR=H
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M;OV2*KZTT]7C8C69_9(TWAQXESRN0 0;JC'2D/AP\H$4POK@$PS5)/_][^'
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M$330%[M?Q#^^3%;E?_V__P]02P$"% ,4    "  HD&A+2 "9V4DF 0#UL T
M$0              @ $     ;6=E;BTR,#$W,#DS,"YX;6Q02P$"% ,4
M"  HD&A+]MG5]0L2  "$QP  $0              @ %X)@$ ;6=E;BTR,#$W
M,#DS,"YX<V102P$"% ,4    "  HD&A+CUD*2V 9  !8"@$ %0
M    @ &R. $ ;6=E;BTR,#$W,#DS,%]C86PN>&UL4$L! A0#%     @ *)!H
M2V-,_S4G8   R[($ !4              ( !15(! &UG96XM,C Q-S Y,S!?
M9&5F+GAM;%!+ 0(4 Q0    ( "B0:$O0KKGOX+<  );%"0 5
M  "  9^R 0!M9V5N+3(P,3<P.3,P7VQA8BYX;6Q02P$"% ,4    "  ID&A+
M+9W>.LMZ  "&)08 %0              @ &R:@( ;6=E;BTR,#$W,#DS,%]P
<<F4N>&UL4$L%!@     &  8 B@$  +#E @    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
